Cancer

Cancer is a neoplastic disease caused by uncontrolled division of abnormal cells in a part of the body and their subsequent local invasion and systematic metastasis to other parts of the body. Oncogenic mutations, genome instability and inflammation initiate and expedite the acquisition of several hallmarks by cancer cells such as sustaining unlimited growth, resisting cell death, inducing angiogenesis, activating invasion and metastasis, reprogramming cellular metabolism, and evading immune checkpoints. Our large repertoire of cancer related small molecules are designed to facilitate both basic research on cancer biology and developing new strategies to treat cancer.

(+)-(3R,8S)-Falcarindiol

((3R,8S)-Falcarindiol; 3(R),8(S),9(Z)-Falcarindiol) Cat. No.: HY-N1976

(+)-(3R,8S)-Falcarindiol is a polyacetylene found in carrots, has **antimycobacterial** activity, with an IC_{50} of 6 μM and MIC of 24 μM against Mycobacterium tuberculosis H37Ra. Antineoplastic and anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

(+)-Apogossypol

(Apogossypol; NSC736630) Cat. No.: HY-13408

(+)-Apogossypol is a **pan-BCL-2** antagonist. (+)-Apogossypol binds to **Mcl-1**, **Bcl-2** and **Bcl-xL** with EC_{50}s of 2.6, 2.8 and 3.69 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

(+)-BAY-1251152

Cat. No.: HY-103019

(+)-BAY-1251152 is a **CDK9** inhibitor extracted from patent WO 2014076091 A1, example 1.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

(+)-Catechin hydrate

Cat. No.: HY-N0355

(+)-Catechin hydrate inhibits cyclooxygenase-1 (**COX-1**) with an IC_{50} of 1.4 μM.



Purity: 99.22%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg

(+)-Gallocatechin

Cat. No.: HY-N0521A

(+)-Gallocatechin is a polyphenol compound from green tea, possesses anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(+)-JQ-1

(JQ1) Cat. No.: HY-13030

(+)-JQ-1 is a **BET bromodomain** inhibitor, with IC_{50}s of 77 and 33 nM for the first and second bromodomain (**BRD4(1/2)**). (+)-JQ-1 also activates **autophagy**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

(+)-JQ1 PA

Cat. No.: HY-112789

(+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal **(BET)** inhibitor JQ1, with an IC_{50} of 10.4 nM.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(+)-Talarozole

Cat. No.: HY-14802C

(+)-Talarozole is a potent inhibitor of **retinoic acid** metabolism extracted from patent WO 1997049704 A1.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

(+)-Tetrabenazine

((+)-TBZ; (3R,11bR)-TBZ; (3R,11bR)-Tetrabenazine) Cat. No.: HY-B0590B

(+)-Tetrabenazine ((+)-TBZ; (3R,11bR)-TBZ; (3R,11bR)-Tetrabenazine) is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT-2), inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(+)-α-Tocopherol

(D-α-Tocopherol; α-Vitamin E) Cat. No.: HY-N0683

(+)-α-Tocopherol is a vitamin E derivative. vitamin E is a fat-soluble antioxidant.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 1 g

(-)-(S)-Equol

Cat. No.: HY-100583

(-)-(S)-Equol is a high affinity ligand for **estrogen receptor β** with a K_i of 0.73 nM.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

(-)-BAY-1251152

Cat. No.: HY-103019B

(-)-BAY-1251152 is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective **PTEF/CDK9** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

(-)-Catechin gallate

((-)-Catechin 3-gallate; (-)-Catechin 3-O-gallate)

Cat. No.: HY-N0356

(-)-Catechin gallate is a minor constituent in green tea catechins. (-)-Catechin gallate inhibits the activity of **COX-1** and **COX-2** enzymes.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

(-)-DHMEQ

(Dehydroxymethylepoxyquinomicin)

Cat. No.: HY-14645

(–)-DHMEQ is a potent **NF-κB** inhibitor.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

(-)-Epicatechin

((-)-Epicatechol; Epicatechin; epi-Catechin)

Cat. No.: HY-N0001

(-)-Epicatechin inhibits cyclooxygenase-1 (**COX-1**) with an IC_{50} of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB.



Purity: 99.00%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(-)-Epicatechin gallate

(ECG; Epicatechin gallate; (-)-Epicatechin 3-O-gallate)

Cat. No.: HY-N0002

Epicatechin gallate inhibits cyclooxygenase-1 (**COX-1**) with an IC_{50} of 7.5 μM.



Purity: 98.57%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

(-)-Epigallocatechin Gallate

(EGCG; Epigallocatechol Gallate)

Cat. No.: HY-13653

(-)-Epigallocatechin Gallate is a tea flavonoid with potent antioxidant, antiinflammatory, and anticarcinogenic properties. (-)-Epigallocatechin Gallate is reported to inhibit **EGFR** signaling and thereby exert anticancer effects.



Purity: 99.91%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 50 mg, 100 mg

(-)-Gallocatechin gallate

((-)-Gallocatechol gallate)

Cat. No.: HY-N0522

(-)-Gallocatechin gallate is the polyphenol isolated from tea, with cancer-preventive activities.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

(-)-Indolactam V

(Indolactam V)

Cat. No.: HY-12307

(-)-Indolactam V is a **PKC** activator, with K_is of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and K_ds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A),...



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

(-)-Menthol

Cat. No.: HY-75161

(-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (**TRPM8**), a Ca^{2+}-permeable nonselective cation channel, to increase $[Ca^{2+}]_i$. Antitumor activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

(-)-p-Bromotetramisole oxalate (L-p-Bromotetramisole oxalate; 6-Bromolevamisole oxalate; (-)-p-Bromolevamisole oxalate)

Cat. No.: HY-19695

(-)-p-Bromotetramisole Oxalate is a potent and non-specific alkaline phosphatase inhibitor.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

(-)-Talarozole

Cat. No.: HY-14802D

(-)-Talarozole is a potent inhibitor of **retinoic acid** metabolism extracted from patent WO 1997049704 A1.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

(1S,3R)-RSL3

Cat. No.: HY-100218A

(1S,3R)-RSL3 is a **glutathione peroxidase 4 (GPX4)** inhibitor with an EC_{50} of 10 μM in cellular assay.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(1S,3R,5R)-PIM447 dihydrochloride

((1S,3R,5R)-LGH447 dihydrochloride)

Cat. No.: HY-19322C

(1S,3R,5R)-PIM447 (dihydrochloride) an **PIM** inhibitor extracted from patent US 20100056576 A1, compound example 72, has IC_{50} values of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3.



Purity: 96.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

(2-Hydroxypropyl)-β-cyclodextrin (Hydroxypropyl betadex; Hydroxypropyl-β-cyclodextrin; HP-β-CD)

Cat. No.: HY-101103

(2-Hydroxypropyl)-β-cyclodextrin is a widely used drug delivery vehicle to improve the stability and bioavailability.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g, 10 g

(20S)-Protopanaxadiol

(20-Epiprotopanaxadiol; 20(S)-APPD)

Cat. No.: HY-N0797

(20S)-Protopanaxadiol (20-Epiprotopanaxadiol) is an aglycon metabolic derivative of the protopanaxadiol-type ginseng saponin; apoptosis inducer.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

(2R)-Octyl-α-hydroxyglutarate

((2R)-Octyl-2-HG)

Cat. No.: HY-103641

(2R)-Octyl-α-hydroxyglutarate ((2R)-Octyl-2-HG) is a modified form of D-isomer 2-Hydroxyglutarate.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

(2S)-Octyl-α-hydroxyglutarate

((2S)-Octyl-2-HG)

Cat. No.: HY-103641A

(2S)-Octyl-α-hydroxyglutarate ((2S)-Octyl-2-HG) is a modified form of S-isomer 2-Hydroxyglutarate.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

(Ac)Phe-Lys(Alloc)-PABC-PNP

Cat. No.: HY-20560

(Ac)Phe-Lys(Alloc)-PABC-PNP is a useful chemical linker in antibody drug conjugates.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(E)-2-Decenoic acid

(trans-2-Decenoic acid)

Cat. No.: HY-13211

(E)-2-Decenoic acid is an interesting fatty acid isolated from royal jelly secretions of honey bees.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

(E)-AG 99

((E)-Tyrphostin 46; (E)-Tyrphostin AG 99) Cat. No.: HY-100962

(E)-AG 99 ((E)-Tyrphostin 46; (E)-Tyrphostin AG 99) is a potent **EGFR** inhibitor.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(E)-Daporinad

(FK866; APO866) Cat. No.: HY-50876

(E)-Daporinad (FK866) is an effective inhibitor of nicotinamide phosphoribosyltransferase (**NMPRTase**) with an IC_{50} of 0.09 nM.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(E)-Necrosulfonamide

Cat. No.: HY-100573

(E)-Necrosulfonamide is a **necroptosis** inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein **(MLKL)** to block the necrosome formation.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(E)-[6]-Dehydroparadol

Cat. No.: HY-77293

(E)--Dehydroparadol, extracted from patent US 9272994, compound M15, shows growth inhibition and induction of apoptosis against human cancer cells with IC_{50} values of 43.02 μM in HCT-116 cell and 41.59 μM in H-1299 cell, respectively.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg

(R)-(-)-Gossypol

(AT-101; R-(-)-gossypol acetic acid) Cat. No.: HY-15464

(R)-(-)-Gossypol (AT-101) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to **Bcl-2**, **Mcl-1** and **Bcl-xL** proteins with K_is of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 10 mg, 50 mg

(R)-(-)-Gossypol acetic acid (AT-101 (acetic acid);

(-)-Gossypol acetic acid; (R)-Gossypol acetic acid) Cat. No.: HY-15464A

(R)-(-)-Gossypol acetic acid (AT-101 (acetic acid)) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to **Bcl-2**, **Mcl-1** and **Bcl-xL** proteins with K_is of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.



Purity: 97.40%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg

(R)-(-)-JQ1 Enantiomer

Cat. No.: HY-13030A

(R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (R)-(-)-JQ1 Enantiomer has no effect.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(R)-BAY1238097

Cat. No.: HY-112316A

(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(R)-Equol

((+)-Equol) Cat. No.: HY-108414

(R)-Equol is an agonist of both **ERα** and **ERβ** with K_is of 27.4 and 15.4 nM, respectively.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

(R)-Filanesib

((R)-ARRY-520) Cat. No.: HY-15187A

(R)-Filanesib ((R)-ARRY-520) is the R-enantiomer of ARRY-520. (R)-Filanesib ((R)-ARRY-520) is a synthetic **kinesin spindle protein (KSP)** inhibitor with IC_{50} of 6 nM.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(R)-GNE-140

Cat. No.: HY-100742A

(R)-GNE-140 is a potent lactate dehydrogenase A (**LDHA**) inhibitor, with **IC_{50}**s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

(R)-Nedisertib

((R)-M3814)

Cat. No.: HY-101570A

(R)-Nedisertib ((R)-M3814) is a less active R-enantiomer of Nedisertib, with an **IC_{50}** in the range of 7-30 nM for **DNA-PK**.



Purity: 92.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

(rac)-Antineoplaston A10

Cat. No.: HY-128553A

(rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a **Ras** inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(rac)-BAY1238097

Cat. No.: HY-112316B

(rac)-BAY1238097 is a **BET** inhibitor, with an **IC_{50}** of 1.02 μM for BRD4. Used in cancer research.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(S)-10-Hydroxycamptothecin

(10-HCPT; 10-Hydroxycamptothecin)

Cat. No.: HY-N0095

(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

(S)-GNE-140

Cat. No.: HY-100742B

(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit **Lactate dehydrogenase A** (**LDHA**).



Purity: 97.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

(S)-Gossypol acetic acid

((S)-(+)-Gossypol acetic acid)

Cat. No.: HY-15464D

(S)-Gossypol is the isomer of a natural product Gossypol. (S)-Gossypol binds to the BH3-binding groove of **Bcl-xL** and **Bcl-2** proteins with high affinity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

(S)-JQ-35

(TEN-010)

Cat. No.: HY-117286

(S)-JQ-35 (TEN-010) is an inhibitor of the Bromodomain and Extra-Terminal **(BET)** family bromodomain-containing proteins with potential antineoplastic activity.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(Z)-2-decenoic acid

(cis-2-Decenoic acid)

Cat. No.: HY-13212

(Z)-2-decenoic acid(cis-2-Decenoic acid) is an unsaturated short chain fatty acid that is secreted by P. aeruginosa and induces a dispersion response in biofilms formed by gram-negative and gram-positive bacteria, as well as by the yeast C. albicans.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

(Z)-SMI-4a

Cat. No.: HY-16576A

(Z)-SMI-4a is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM for Pim-1 compared to an IC50 of 100 nM for Pim-2 and with little or no activity against a panel of 50 other kinases tested.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

(±)-BAY-1251152

Cat. No.: HY-103019A

(±)-BAY-1251152 is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective **PTEF/CDK9** inhibitor.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

(±)-Equol

Cat. No.: HY-100583A

(±)-Equol is the racemate of equol. Equol is a metabolite of the soy isoflavones, daidzin and daidzein.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

(±)-Zanubrutinib

((±)-BGB-3111)

Cat. No.: HY-101474

(±)-Zanubrutinib is a potent, selective and orally available Bruton's tyrosine kinase (**Btk**) inhibitor.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

1,4-Chrysenequinone

(Chrysene-1,4-dione)

Cat. No.: HY-111441

1,4-Chrysenequinone, a polycyclic aromatic quinone, acts as an activator of aryl hydrocarbon receptor (**AhR**).



Purity: >93.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

1-Acetyl-3-o-toluyl-5-fluorouracil

(A-OT-Fu)

Cat. No.: HY-U00130

1-Acetyl-3-o-toluyl-5-fluorouracil is a potent an antineoplastic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

1-Aminobenzotriazole

(ABT; 3-Aminobenzotriazole)

Cat. No.: HY-103389

1-Aminobenzotriazole is a nonspecific and irreversible inhibitor of **cytochrome P450** (**P450**).



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

1-Ethynylnaphthalene

Cat. No.: HY-111430

1-Ethynylnaphthalene is a selective inhibitor of cytochrome **P450 1B1**.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

1-Naphthyl PP1

(1-NA-PP 1)

Cat. No.: HY-13941

1-Naphthyl PP1(1-NA-PP 1) is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively).



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1-Naphthyl PP1 hydrochloride

(1-NA-PP 1 hydrochloride)

Cat. No.: HY-13941B

1-Naphthyl PP1(1-NA-PP1) hydrochloride is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively).



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1-NM-PP1

(PP1 Analog II)

Cat. No.: HY-13942

1-NM-PP1, a cell-permeable PP1 analog, is a potent **Src family kinases** inhibitor with IC_{50}s of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

1-beta-D-Arabinofuranosyluracil

(Uracil 1-β-D-arabinofuranoside)

Cat. No.: HY-N6652

1-beta-D-Arabinofuranosyluracil (Uracil 1-β-D-arabinofuranoside) isolated from the Caribbean sponge Tectitethya crypta, is a methoxyadenosine derivative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

10,11-Dehydrocurvularin

Cat. No.: HY-N6679

10,11-Dehydrocurvularin is an antibiotic and a strong activator of the **heat shock response**, a conserved evolutionary mechanism that maintains protein homeostasis via the overexpression of heat shock factor 1 (HSF1) and various chaperones including heat shock protein 90...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

10-Deacetyl-7-xylosyl paclitaxel (10-Deacetyl-7-xylosyltaxol; 10-Deacetylpaclitaxel 7-Xyloside; ...)

Cat. No.: HY-20584

10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

10-Deacetylbaccatin III

Cat. No.: HY-16565

10-Deacetylbaccatin-III is an intermediate for taxol analog preparations. IC50 value: Target: Taxols have exhibit antitumor agents. Several of these taxols can be synthesized from 10-Deacetylbaccatin-III.



Purity: 95.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

10-Oxo Docetaxel

(Docetaxel Impurity 1)

Cat. No.: HY-16674

10-Oxo Docetaxel (Docetaxel Impurity 1) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

10058-F4

Cat. No.: HY-12702

10058-F4 is a **c-Myc** inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

10074-G5

Cat. No.: HY-100996

10074-G5 is an inhibitor of **c-Myc-Max** dimerization with an IC_{50} of 146 μM.



Purity: 97.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

15-Acetyl-deoxynivalenol

Cat. No.: HY-N6683

15-Acetyl-deoxynivalenol is a highly toxic trichothecene found in cereals, and a metabolite of deoxynivalenol, exhibits toxicity to HepG2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

18β-Glycyrrhetinic acid

Cat. No.: HY-N0180

18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhizae Radix and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties.

Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

1A-116

Cat. No.: HY-104064

1A-116 is a specific **Rac1** inhibitor.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

1alpha-Hydroxy VD4

(1α-Hydroxy vitamin D4)

Cat. No.: HY-13249

1alpha-Hydroxy VD4 , a 1alpha(OH)D derivative, can effectively induce the differentiation of monoblastic leukaemia U937, P39/TSU and P31/FUJ cells.



Purity: 97.87%
Clinical Data: No Development Reported
Size: 1 mg

2'-Deoxyinosine

Cat. No.: HY-W008638

2′-deoxyadenosine inhibits the growth of human colon-carcinoma cell lines and is found to be associated with purine nucleoside phosphorylase (PNP) deficiency.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2,2'-Anhydrouridine

(2,2'-Cyclouridine; O2,2'-Cyclouridine)

Cat. No.: HY-W012313

2,2'-Anhydrouridine is used for anticancer and antiviral research.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2,4-Pyrimidinediamine with linker

Cat. No.: HY-18625

2,4-Pyrimidinediamine with linker is a patent compound in WO2013055780A1, Page 71; multikinase inhibitor and has a -NH2 terminal linker for further synthesis.



Purity: 96.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

2-(4-Methoxyphenyl)acetic acid

(4-Methoxyphenylacetic acid)

Cat. No.: HY-W004206

2-(4-Methoxyphenyl)acetic acid is a plasma metabolite, with high sensitivity and specificity value as a biomarker for discriminating between NSCLC and healthy controls.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 g

2-Aminobenzenesulfonamide

(Orthanilamide)

Cat. No.: HY-B2147

2-Aminobenzenesulfonamide is a **carbonic anhydrase IX** inhibitor.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2-D08

Cat. No.: HY-114166

2-D08 is a cell permeable, mechanistically unique inhibitor of protein **SUMOylation**. 2-D08 also inhibits **Axl** with an IC_{50} of 0.49 nM.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

2-Deoxy-D-glucose

(2-Deoxy-D-arabino-hexose; D-Arabino-2-deoxyhexose)

Cat. No.: HY-13966

2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on **hexokinase**.



Purity: >99.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 g, 5 g

2-HBA

Cat. No.: HY-103667

2-HBA is a potent inducer of **NAD(P)H:quinone acceptor oxidoreductase 1** (**NQO1**) which can also activate **caspase-3** and **caspase-10**.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

2-Keto Crizotinib

(PF-06260182)

Cat. No.: HY-13320

2-Keto Crizotinib (PF-06260182) is an active lactam metabolite of crizotinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)

Cat. No.: HY-N1393

2-Methoxybenzoic acid (NSC 3778) is used as an internal standard of salicylic acid and its putative biosynthetic precursors in cucumber leaves. Another known use is in the synthesis of Benextramine.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

2-Methoxyestradiol (2-ME2; NSC-659853)

Cat. No.: HY-12033

2-Methoxyestradiol is an **angiogenesis** inhibitor and **apoptosis** inducer with potent antineoplastic activity. 2-Methoxyestradiol also destablize **microtubules**.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

20(R)-Ginsenoside Rg3 (20(R)-Propanaxadiol)

Cat. No.: HY-N1376

20(R)-ginsenoside Rg3 (20(R)-Propanaxadiol), one of the active compounds present in ginseng root, has a potent angiosuppressive and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

20(R)-Ginsenoside Rh2

Cat. No.: HY-N1401

20(R)-Ginsenoside Rh2, a **matrix metalloproteinase (MMP)** inhibitor, acts as a cell antiproliferator. It has anticancer effects via blocking cell proliferation and causing G1 phase arrest.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

20(S)-Hydroxycholesterol (20α-Hydroxycholesterol)

Cat. No.: HY-12316

20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the **oncoprotein smoothened (Smo)** that activates the hedgehog (Hh) signaling pathway with an EC_{50} of 3 μM in a gene transcription reporter assay using NIH3T3 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

20-HEDE (WIT 002)

Cat. No.: HY-101527

20-HEDE (WIT 002) is an antagonist of 20-hydroxyeicosatetraenoic acid (**20-HETE**).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

23-Hydroxybetulinic acid (Anemosapogenin)

Cat. No.: HY-N0566

23-hydroxybetulinic acid is one of the bioactive components responsible for its anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

24R-Calcipotriol (PRI 2202; Impurity D of Calcipotriol)

Cat. No.: HY-15266

24R-Calcipotriol(PRI 2202) is an impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.



Purity: 95.64%
Clinical Data: No Development Reported
Size: 1 mg

27-Hydroxycholesterol

Cat. No.: HY-N2371

27-Hydroxycholesterol is a selective **estrogen receptor** modulator and an agonist of the **liver X receptor**.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

2OH-BNPP1

Cat. No.: HY-102081

2OH-BNPP1 is an inhibitor of **BUB1 kinase**, a Ser/Thr kinase, used for the treatment of cancer.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

3'-Fluoro-3'-deoxythymidine

(Alovudine) Cat. No.: HY-B1516

3'-Fluoro-3'-deoxythymidine (Alovudine) is a marker of DNA synthesis that is less susceptible to inflammatory changes than ^{18}F-Fluorodeoxyglucose (FDG) and thus is a better biomarker in pancreatic cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3,3',5-Triiodo-L-thyronine

(T3; L-3,3',5-Triiodothyronine; Liothyronine) Cat. No.: HY-A0070A

3,3',5-Triiodo-L-thyronine (Liothyronine) is a potent agonist of thyroid hormone receptors **TRα** and **TRβ** with K_is of 2.3 nM.



Purity: 98.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

3,3',5-Triiodo-L-thyronine sodium (T3 Sodium salt; Sodium L-3,3',5-triiodothyronine; Liothyronine sodium)

Cat. No.: HY-A0070

3,3',5-Triiodo-L-thyronine sodium is an active form of thyroid hormone, which binds to **β1 thyroid hormone receptor** (**TRβ1**), and activates its activity.



Purity: 98.16%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

3,3'-Diindolylmethane

(DIM; Arundine; HB 236) Cat. No.: HY-15758

3,3'-Diindolylmethane is a strong, pure **androgen receptor** (AR) antagonist.



Purity: 98.74%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

3,4-Dimethoxycinnamic acid

(O-Methylferulic acid) Cat. No.: HY-N1778

3,4-Dimethoxycinnamic acid (O-Methylferulic acid) is a monomer extracted and purified from Securidaca inappendiculata Hassk. 3,4-Dimethoxycinnamic acid exerts anti-apoptotic effects on L-02 cells via the ROS-mediated signaling pathway. Anti-apoptotic effects.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3,6-DMAD hydrochloride

Cat. No.: HY-U00460

3,6-DMAD hydrochloride is a inhibitor of the **IRE1α-XBP1** pathway of the unfolded protein response.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg

3-(Methylthio)propionic acid

(3-Methylsulfanylpropionic acid) Cat. No.: HY-101401

3-(Methylthio)propionic acid is an intermediate in the methionine metabolism.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3-Aminobenzamide

(PARP-IN-1) Cat. No.: HY-12022

3-Aminobenzamide is a potent inhibitor of **PARP** with IC_{50} of appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 200 mg, 500 mg

3-arylisoquinolinamine derivative

Cat. No.: HY-32364

3-arylisoquinolinamine derivative is a 3-arylisoquinolinamine derivative with antitumor activity.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

3-Bromopyruvic acid

(Bromopyruvic acid; Hexokinase II Inhibitor II, 3-BP) Cat. No.: HY-19992

3-Bromopyruvic acid is a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g, 5 g, 10 g, 25 g

3-Deazaneplanocin A

(DZNep; 3-Deazaneplanocin) Cat. No.: HY-10442

3-Deazaneplanocin A (DZNep) is a potent **histone methyltransferase EZH2** inhibitor.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

3-Deazaneplanocin A hydrochloride (DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride) Cat. No.: HY-12186

3-Deazaneplanocin A hydrochloride is a potent **histone methyltransferase EZH2** inhibitor.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

3-Hydroxycapric acid

Cat. No.: HY-113057

3-Hydroxycapric acid is an inhibitor for mitotic progression.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

3-Isomangostin

Cat. No.: HY-N6845

3-Isomangostin, extracted from Garciniamangostana.L. shell, is a potent MutT homologue 1 (**MTH1**) inhibitor with an IC_{50} value of 52 nM. 3-isomangostin would be an attractive chemical tool for the development of anticancer agents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Methyladenine

(3-MA) Cat. No.: HY-19312

3-Methyladenine is a **PI3K** inhibitor.
3-Methyladenine is a widely used inhibitor of **autophagy** via its inhibitory effect on class III PI3K.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

3-Methylcytidine

Cat. No.: HY-111645

3-Methylcytidine, a urinary nucleoside, can be used as a biomarker of four different types of cancer: lung cancer, gastric cancer, colon cancer, and breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

3-Methyltoxoflavin

Cat. No.: HY-111117

3-Methyltoxoflavin is a potent **Protein disulfide isomerase (PDI)** inhibitor, with an IC_{50} of 170 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

360A

Cat. No.: HY-15595

360A is a selective stabilizer of **G-quadruplex**, and also inhibits **telomerase** activity with an IC_{50} of 300 nM for telomerase in TRAP-G4 assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

360A iodide

(360 A iodide) Cat. No.: HY-15595A

360A iodide is a selective stabilizer of **G-quadruplex**, and also inhibits **telomerase** activity with an IC_{50} of 300 nM for telomerase in TRAP-G4 assay.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

3BDO

Cat. No.: HY-U00434

3BDO is a new **mTOR** activator which can also inhibit **autophagy**.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

3CAI

Cat. No.: HY-16666

3CAI is a potent and specific **AKT1** and **AKT2** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

3PO

Cat. No.: HY-19824

3PO is a novel small-molecule inhibitor of the PFKFB3 isozyme, 3PO markedly attenuates the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50, 1.4-24 μM) IC50 value Target: PFKFB3 isozyme in vitro: 3PO inhibits recombinant PFKFB3...



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

3α-Aminocholestane

Cat. No.: HY-19776

3α-Aminocholestane is a selective **SH2 domain-containing inositol-5'-phosphatase 1** (**SHIP1**) inhibitor with an IC_{50} of ~2.5 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

4'-Demethylepipodophyllotoxin

(4'-O-demethylepipodophyllotoxin; 4'-DMEP)

Cat. No.: HY-17435

4'-Demethylepipodophyllotoxin(4'-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

4'-Methylchrysoeriol

Cat. No.: HY-112734

4'-Methylchrysoeriol is a potent inhibitor of **Cytochrome P450** enzymes, with an IC_{50} of 19 nM for human P450 1B1-dependent EROD.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

4(3H)-Quinazolinone

Cat. No.: HY-W018800

4(3H)-Quinazolinone is a building block in chemical synthesis. Biologically active nitrogen heterocyclic compounds. Possesses a wide spectrum of biological properties like antibacterial, antifungal, anticonvulsant, anti-inflammatory, anti-HIV, anticancerous and analgesic activities.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

4,4'-Dimethoxybenzil

(p-Anisil)

Cat. No.: HY-103610

4,4'-Dimethoxybenzil is a human intestinal carboxyl esterase (**hiCE**) inhibitor with K_i of 70 nM.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

4-Hydroxybenzyl alcohol

Cat. No.: HY-Y0892

4-Hydroxybenzyl alcohol is a phenolic compound widely distributed in various kinds of plants. Anti-inflammatory, anti-oxidant, anti-nociceptive activity. Neuroprotective effect. Inhibitor of tumor angiogenesis and growth.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

4-Hydroxytamoxifen

((Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen)

Cat. No.: HY-16950

4-Hydroxytamoxifen is a selective estrogen receptor modulator (**SERM**).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

4-IBP

Cat. No.: HY-100155

4-IBP is a selective σ1 agonist with a high level of affinity for the σ1 receptor (Ki = 1.7 nM) and a moderate affinity for the σ2 receptor (Ki = 25.2 nM) .



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

4-Methylumbelliferone

(Hymecromone; 4-MU)

Cat. No.: HY-N0187

4-Methylumbelliferone is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

4-O-Methyl honokiol

Cat. No.: HY-U00450

4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a **PPARγ** agonist, and inhibtis **NF-κB** activity, used for cancer and inflammation research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

42-(2-Tetrazolyl)rapamycin

Cat. No.: HY-12424A

42-(2-Tetrazolyl)rapamycin is a prodrug compound of a rapamycin analog extracted from patent US 20080171763 A1, Example 1. Rapamycin is a specific mTOR inhibitor.



Purity: 95.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 2 mg, 5 mg, 10 mg

4E1RCat

Cat. No.: HY-14427

4E1RCat is an inhibitor of cap-dependent translation, and inhibits **eIF4E:eIF4GI** interaction, with an **IC_{50}** an of 4 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

4EGI-1

Cat. No.: HY-19831

4EGI-1 is an inhibitor of **eIF4E/eIF4G** interaction, with a **K_d** of 25 μM against eIF4E binding.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

5'-N-Ethylcarboxamidoadenosine

(NECA)

Cat. No.: HY-103173

5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective **adenosine receptor** agonist.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

5,15-Diacetyl-3-benzoyllathyrol

(Euphorbia factor L3)

Cat. No.: HY-N0562

5,15-Diacetyl-3-benzoyllathyrol is one of the lathyrane diterpenoids, that has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

5-(N,N-Hexamethylene)-amiloride

(Hexamethylene amiloride; HMA)

Cat. No.: HY-128067

5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent **Na^+/H^+ exchanger** inhibitor, which decreases the intracellular pH (pH_i) and induces apoptosis in leukemic cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-Azacytidine

(Ladakamycin; 5-AzaC; Azacitidine)

Cat. No.: HY-10586

5-Azacytidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping **DNA methyltransferases**.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

5-Fluorouracil

(5-FU)

Cat. No.: HY-90006

5-Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting **thymidylate synthetase** thus depleting intracellular dTTP pools.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g

5-Hydroxy-7-acetoxyflavone

Cat. No.: HY-N2487

5-Hydroxy-7-acetoxyflavone, an active natural flavone derivative found in various plant sources, modulates several biological activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-Hydroxyindole-3-acetic acid

Cat. No.: HY-W008253

5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

5-IAF

(5-Iodoacetamidofluorescein)

Cat. No.: HY-D0807

5-IAF is an idoacetamide derivate of fluoresceine.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

5-Iodo-indirubin-3'-monoxime

Cat. No.: HY-111930

5-Iodo-indirubin-3'-monoxime is a potent **GSK-3β**, **CDK5/P25** and **CDK1/cyclin B** inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC_{50}s of 9, 20 and 25 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

5-Iodotubercidin

(NSC 113939; 5-ITu)

Cat. No.: HY-15424

5-Iodotubercidin is a potent **adenosine kinase** inhibitor with IC_{50} of 26 nM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 25 mg, 50 mg

5α-Pregnane-3β,6α-diol-20-one

Cat. No.: HY-109564

5α-Pregnane-3β,6α-diol-20-one is a mitogenic metabolite of progesterone, and it can be produced in starved androgen-responsive prostate cancer cells.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

6-Aminochrysene

(6-Chrysenamine)

Cat. No.: HY-108315

6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as a chemotherapeutic agent in the treatment of splenomegaly, myeloid leukemia, and breast cancer.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

6-Biopterin

(L-Biopterin)

Cat. No.: HY-102015

6-Biopterin (L-Biopterin), a pterin derivative, is a **NO synthase** cofactor.

Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

6-Bromo-2-hydroxy-3-methoxybenzaldehyde

(NSC95682)

Cat. No.: HY-107371

6-Bromo-2-hydroxy-3-methoxybenzaldehyde (NSC95682) is an **IRE-1α** inhibitor with an IC_{50} of 0.08 μM, extracted from patent WO 2008154484 A1, IRE-lα inhibitor compound 3-5.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

6-Chloropurine

(6-Chloro-9H-purine)

Cat. No.: HY-Y0247

6-Chloropurine is a building block in chemical synthesis. Intermediate in the preparation of 9-alkylpurines and 6-rnercaptopurine. Antitumor activities.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

6-Maleimidohexanoic acid N-hydroxysuccinimide ester

(EMCS) Cat. No.: HY-78961

6-Maleimidohexanoic acid N-hydroxysuccinimide ester(ECMS) is a useful protective group in antibody drug conjugates.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

6-Mercaptopurine

(Mercaptopurine; 6-MP) Cat. No.: HY-13677

6-Mercaptopurine is a purine analogue which acts as an antagonist of the **endogenous purines** and has been widely used as antileukemic agent and immunosuppressive drug.



Purity: >96.0%
Clinical Data: Launched
Size: 50 mg, 100 mg, 500 mg

6-Mercaptopurine hydrate

(Mercaptopurine hydrate; 6-MP hydrate) Cat. No.: HY-13677A

6-Mercaptopurine hydrate (Mercaptopurine hydrate) is a purine analogue which acts as an antagonist of the **endogenous purines** and has been widely used as antileukemic agent and immunosuppressive drug.



Purity: 98.74%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)-

Cat. No.: HY-21210

6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)- is an useful linker for antibody-drug-conjugations (ADCs), extracted from [Bioorg Chem. 2012 Apr-Jun;41-42:1-5.] compound 1i.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

6-Thio-2'-Deoxyguanosine

(6-thio-dG; β-TGdR) Cat. No.: HY-18762

6-Thio-2'-Deoxyguanosine is a nucleoside analogue that can be incorporated into de novo-synthesized telomeres by telomerase.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

6-Thioguanine

(Thioguanine2-Amino-6-purinethiol) Cat. No.: HY-13765

6-Thioguanine (Thioguanine) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (**PLpros**) and also potently inhibits **USP2** activity, with **IC_{50}**s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

666-15

Cat. No.: HY-101120

666-15 is a potent and selective **CREB** inhibitor with an **IC_{50}** of 81 nM.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

6H05

Cat. No.: HY-12408

6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C). IC50 value: Target: K-Ras G12C 6H05 gives the greatest degree of modification, which allosterically modifies the oncogenic G12C mutant of highly homologous protein H-Ras without affecting wild-type K-Ras .



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

6H05 TFA

Cat. No.: HY-12408A

6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C). IC50 value: Target: K-Ras G12C 6H05 gives the greatest degree of modification, which allosterically modifies the oncogenic G12C mutant of highly homologous protein H-Ras without affecting wild-type K-Ras .



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

7-Epi-10-oxo-docetaxel

(Docetaxel Impurity 2) Cat. No.: HY-16675

7-Epi-10-oxo-docetaxel (Docetaxel Impurity 2) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-Epi-docetaxel

(4-epi-Docetaxel; 7-Epidocetaxel; 7-Epitaxotere)

Cat. No.: HY-16676

7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 10 mg

7-epi-Taxol

(7-epi-Paclitaxel)

Cat. No.: HY-N0227

7-epi-Taxol is an active metabolite of taxol, with activity comparable to that of taxol against cell replication, promoting **microtubule** bundle formation and against microtubule depolymerization.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

7-Hydroxy-4-chromone

(7-Hydroxychromone)

Cat. No.: HY-N6596

7-Hydroxychromone is a **Src kinase** inhibitor with an IC_{50} of <300 μM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

7-Methoxyisoflavone

Cat. No.: HY-N6631

7-Methoxyisoflavone is an isoflavone derivative and also an activator of adenosine monophosphate-activated protein kinase (**AMPK**).



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

7-xylosyltaxol

(7-Xylosylpaclitaxel; Taxol-7-xyloside)

Cat. No.: HY-77574

7-xylosyltaxol(Taxol-7-xyloside) is a taxol (Paclitaxel) derivative; Paclitaxel binds to tubulin and inhibits the disassembly of microtubules.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

740 Y-P

(740YPDGFR; PDGFR 740Y-P)

Cat. No.: HY-P0175

740 Y-P (PDGFR 740Y-P) is a potent and cell permeable **PI3K** activator.

Purity: 96.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7ACC1

(DEAC; Coumarin D 1421; D 1421)

Cat. No.: HY-D0067

7ACC1(DEAC; Coumarin D 1421; D 1421) selectively interfere with lactate fluxes in the lactate-rich tumor microenvironment; inhibits lactate influx but not efflux in tumor cells expressing MCT1 and MCT4 transporters.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg

7ACC2

Cat. No.: HY-D0713

7ACC2 is a new potent MCT inhibitor with IC50 of 11 nM for inhibition of [14C]-lactate influx; new antitumor treatment targeting lactate transport in cancer cells.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

8,9-Epoxy-3-isobutyryloxy-10-(2-methylbutanoyl)thymo l

Cat. No.: HY-N6844

8,9-Epoxy-3-isobutyryloxy-10-(2-methylbutanoyl)thy mol is a chemical composition of essential oils from Telekia speciosa.
8,9-Epoxy-3-isobutyryloxy-10-(2-methylbutanoyl)thymol also shows marked antipro-liferative activity against human cancer cell lines in vitro .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

8-Azaguanine

Cat. No.: HY-B1468

8-Azaguanine is a purine analogue which shows antineoplastic activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

8-Bromo-cAMP sodium salt

(8-Br-Camp sodium salt) Cat. No.: HY-12306

8-Bromo-cAMP sodium salt (8-Br-Camp sodium salt), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (**PKA**).



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

8-Hydroxy-2'-deoxyguanosine

Cat. No.: HY-W011540

8-Hydroxy-2'-deoxyguanosine is a critical biomarker of oxidative stress and carcinogenesis.



Purity: 95.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

9-amino-CPT

(9-amino-20(S)-camptothecin) Cat. No.: HY-100309

9-Aminocamptothecin is a **topoisomerase I** inhibitor with potent anticancer activity.



Purity: 98.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

9-Dihydro-13-acetylbaccatin III

(9-DHAB III; 13-Acetyl-9-dihydrobaccatin III) Cat. No.: HY-77434

9-Dihydro-13-acetylbaccatin III (9-DHAB III) is an intermediate for taxol analog preparations.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 100 mg

A 1070722

Cat. No.: HY-107531

A 1070722 is a potent and selective **glycogen synthase kinase 3 (GSK-3)** inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

A 419259

(RK-20449) Cat. No.: HY-15764

A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, designed to enhance selectivity towards the Src family with IC_{50} of 9 nM, <3 nM and <3 nM for **Src**, **Lck** and **Lyn**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

A 419259 trihydrochloride

(RK 20449 trihydrochloride) Cat. No.: HY-15764A

A 419259 trihydrochloride is a **Src family kinases** inhibitor with IC_{50}s of 9 nM, 3 nM and 3 nM for **Src**, **Lck** and **Lyn**, respectively.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A 77-01

Cat. No.: HY-78349

A 77-01 is a potent inhibitor of TGF-β type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

A 83-01

Cat. No.: HY-10432

A 83-01 is a potent inhibitor of **TGF-β type I receptor ALK5 kinase**, type I activin/nodal receptor **ALK4** and type I nodal receptor **ALK7**, with IC_{50}s of 12, 45 and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

A 83-01 sodium salt

Cat. No.: HY-10432A

A 83-01 sodium salt is a potent inhibitor of **TGF-β type I receptor ALK5 kinase**, type I activin/nodal receptor **ALK4** and type I nodal receptor **ALK7**, with IC_{50}s of 12, 45 and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

A-1155463

Cat. No.: HY-19725

A-1155463 is a highly potent and selective **BCL-X_L** inhibitor with an **EC_{50}** of 70 nM in Molt-4 cell.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

A-1210477

Cat. No.: HY-12468

A-1210477 is a potent and selective inhibitor of **MCL-1** with a **K_i** of 0.45 nM.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

A-1331852

Cat. No.: HY-19741

A-1331852 is an orally available **BCL-XL** selective inhibitor with a **K_i** of less than 10 pM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

A-196

Cat. No.: HY-100201

A-196 is a potent and selective chemical inhibitor of SUV420H1 and SUV420H2 that inhibits the di- and trimethylation of H4K20me in multiple cell lines. Target: A-196 is a selective chemical probe for SUV420H1/H2.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

A-366

Cat. No.: HY-12583

A-366 is a potent **histone methyltransferase G9a** inhibitor with an **IC_{50}** of 3.3 nM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A-385358

Cat. No.: HY-16014

A-385358 is a selective inhibitor of **Bcl-X_L** with **K_i**s of 0.80 and 67 nM for **Bcl-X_L** and **Bcl-2**, respectively.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

A-395

Cat. No.: HY-101512

A-395 is a novel antagonist of **Polycomb repressive complex 2 (PRC2)** protein–protein interactions that potently inhibits the trimeric PRC2 complex (EZH2–EED–SUZ12) with an **IC_{50}** of 18 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

A-443654

Cat. No.: HY-10425

A-443654 is a potent **Akt1/2/3** inhbitor, with a **K_i** of 160 pM for Akt1.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

A-484954

Cat. No.: HY-110096

A-484954 is a highly selective eukaryotic elongationfactor-2 **(eEF2)** inhibitor, with an **IC_{50}** of 280 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

A-485

Cat. No.: HY-107455

A-485 is a potent and selective catalytic inhibitor of **p300/CBP** with **IC_{50}**s of 9.8nM and 2.6nM for **p300** and **CBP** histone acetyltransferase (HAT), respectively.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

A-674563

Cat. No.: HY-13254

A-674563 is a potent and selective **Akt1** inhibitor with a K_i of 11 nM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

A-674563 hydrochloride

Cat. No.: HY-13254A

A-674563 hydrochloride is a potent and selective **Akt1** inhibitor with K_i of 11 nM.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

A-802715

Cat. No.: HY-U00142

A802715 is a methylxanthine derivative. A802715 has a TD_{50} (toxic dose of 50%) of 0.9-1.1 mM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

A-804598

Cat. No.: HY-100483

A-804598 is a CNS penetrant, competitive and selective **P2X7** receptor antagonist with IC_{50}s of 9 nM, 10 nM and 11 nM for mouse, rat and human **P2X7** receptors, respectively.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

A-966492

Cat. No.: HY-10614

A-966492 is a novel and potent inhibitor of **PARP1** and <
b>PARP2 with K_i of
1 nM and 1.5 nM, respectively.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A1874

Cat. No.: HY-114305

A1874 is a nutlin-based and **BRD4-degrading PROTAC** with a DC_{50} of 32 nM (induce BRD4 degradation in cells). Effective in inhibiting many cancer cell lines proliferation.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

A2A receptor antagonist 1

Cat. No.: HY-102024

A2A receptor antagonist 1 is an antagonist of both **adenosine A_{2A} receptor** and **A_1 receptor** with K_is of 4 and 264 nM, respectively.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

A2B receptor antagonist 1

Cat. No.: HY-U00321

A2B receptor antagonist 1 is a potent **A2B adenosine receptor** antagonist extracted from patent WO 2009157938 A1 EXAMPLE 9B.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

A66

Cat. No.: HY-13261

A66 is a highly specific and selective **p110α** inhibitor with an IC_{50} of 32 nM.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

A939572

Cat. No.: HY-50709

A939572 is a potent, and orally bioavailable **stearoyl-CoA desaturase1 (SCD1)** inhibitor with IC_{50} values of <4 nM and 37 nM for **mSCD1** and **hSCD1**, respectively.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

AB-680

Cat. No.: HY-125286

AB-680 is highly potent, reversible and selective small molecule inhibitor of **CD73** (an ecto-nucleotidase), with a K_i of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Abarelix

(R3827; PPI 149)

Cat. No.: HY-13534

Abarelix is a potent **gonadotrophin-releasing hormone (GnRH)** antagonist, used for prostate cancer treatment.



Purity: 98.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Abarelix Acetate

(PPI 149 (Acetate); R 3827 (Acetate))

Cat. No.: HY-13534A

Abarelix Acetate is a potent **gonadotrophin-releasing hormone (GnRH)** antagonist, used for prostate cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ABBV-744

Cat. No.: HY-112090

ABBV-744 is a highly **BDII-selective BET bromodomain** inhibitor, used in the research of inflammatory diseases, cancer, and AIDS.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Abemaciclib

(LY2835219)

Cat. No.: HY-16297A

Abemaciclib (LY2835219) is a selective **CDK4/6** inhibitor with IC_{50} values of 2 nM and 10 nM for CDK4 and CDK6, respectively.



Purity: 99.69%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Abemaciclib Metabolites M2

Cat. No.: HY-128669

Abemaciclib Metabolites M2 is a metabolite of abemaciclib, acts as a potent **CDK4** and **CDK6** inhibitor, with IC_{50}s in the range of 1-3 nM. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abemaciclib methanesulfonate

(LY2835219 (methanesulfonate))

Cat. No.: HY-16297

Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective **CDK4/6** inhibitor with IC_{50}s of 2 nM and 10 nM for CDK4 and CDK6, respectively.



Purity: 99.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Abexinostat

(CRA 024781; PCI-24781)

Cat. No.: HY-10990

Abexinostat (CRA 024781) is a novel pan-**HDAC** inhibitor mostly targeting HDAC1 with K_i of 7 nM.



Purity: 98.61%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

Abiraterone

(CB-7598)

Cat. No.: HY-70013

Abiraterone is a potent and irreversible **CYP17A1** inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC_{50}s of 2.5 nM and 15 nM, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Abiraterone acetate

(CB7630)

Cat. No.: HY-75054

Abiraterone acetate is an oral, potent, selective, and irreversible inhibitor of **CYP17A1** with antiandrogen activity. Abiraterone acetate is a prodrug form of Abiraterone (CB7598).



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Abiraterone metabolite 1

(3β-OH-5α-Abi)

Cat. No.: HY-103687

Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal drug, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Abl Cytosolic Substrate

Cat. No.: HY-P1785

Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl). Abl Protein Tyrosine Kinase (Abl) is a truncated form of the v-Abl Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus.

EAIYAAPFAKKK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ABL127

Cat. No.: HY-108317

ABL127 is a selective and covalent inhibitor of **protein methylesterase 1** (**PME-1**) with IC_{50}s of 6.4 nM and 4.2 nM in HEK293T and MDA-MB-231 cells, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

ABT-737

Cat. No.: HY-50907

ABT-737 is a selective and BH3 mimetic **Bcl-xL**, **Bcl-2** and **Bcl-w** inhibitor with EC_{50}s of 78.7 nM, 30.3 nM and 197.8 nM, respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

ABT-751

(E7010)

Cat. No.: HY-13270

ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively.



Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ac-DEVD-AFC

Cat. No.: HY-P1005

Ac-DEVD-AFC is a fluorogenic substrate (λ_{ex}=400 nm, λ_{em}=530 nm).



Purity: 98.53%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Ac-DEVD-AMC

Cat. No.: HY-P1003

Ac-DEVD-AMC is the **Caspase-3 substrate**.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac-DEVD-CHO

Cat. No.: HY-P1001

Ac-DEVD-CHO is a specific **Caspase-3** inhibitor with a K_i value of 230 pM.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac-Gly-BoroPro

Cat. No.: HY-101801

Ac-Gly-BoroPro is a selective **FAP** inhibitor with a K_i of 23 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AC710

Cat. No.: HY-13493

AC710 is a potent **PDGFR** inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AC710 Mesylate

Cat. No.: HY-13493A

AC710 Mesylate is a potent **PDGFR** inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Acalabrutinib

(ACP-196)

Cat. No.: HY-17600

Acalabrutinib is a novel, potent, and highly selective **BTK** inhibitor, with an **IC_{50}** of 3 nM and **EC_{50}** of 8 nM in in vitro assay.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Acalisib

(GS-9820; CAL-120)

Cat. No.: HY-12644

Acalisib is a potent and selective **PI3Kδ** inhibitor with an **IC_{50}** of 12.7 nM.



Purity: 99.98%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ACBI1

Cat. No.: HY-128359

ACBI1 is a potent **PROTAC** degrader of BAF ATPase subunits **SMARCA2** and **SMARCA4**, also degrades the polybromo-associated BAF (PBAF) complex member **PBRM1**, with **DC_{50}**s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acefylline

(Theophyllineacetic acid; Theophylline-7-acetic acid)

Cat. No.: HY-B1505

Acefylline is an **adenosine receptor** antagonist.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Acelarin

(NUC-1031)

Cat. No.: HY-100885

Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.



Purity: 99.68%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Acetylene-linker-Val-Cit-PABC-MMAE

(LCB14-0602)

Cat. No.: HY-19812

Acetylene-linker-Val-Cit-PABC-MMAE consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE), Acetylene-linker-Val-Cit-PABC-MMAE is an antibody drug conjugate.



Purity: 95.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Aclacinomycin A hydrochloride

(Aclarubicin hydrochloride)

Cat. No.: HY-N2306A

Aclacinomycin A hydrochloride (Aclarubicin hydrochloride), a fluorescent molecule and the first described non-peptidic inhibitor showing discrete specificity for the CTRL (chymotrypsin-like) activity of the **20S proteasome**.



Purity: 98.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AcLys-PABC-VC-Aur0101

Cat. No.: HY-111554

AcLys-PABC-VC-Aur0101 is a cleavable **anti-CXCR4 drug-linker conjugates for ADC**.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Acolbifene

(EM652; Sch-57068)

Cat. No.: HY-16023A

Acolbifene (EM652) is a fourth-generation selective **estrogen receptor** antagonist with a LC_{50} value of 22±3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Acriflavine

Cat. No.: HY-100575

Acriflavine is a fluorescent dye for labeling high molecular weight RNA. It is also a topical antiseptic.



Purity: 98.62%
Clinical Data: Launched
Size: 100 mg

ACTB-1003

Cat. No.: HY-16025

ACTB-1003 is an oral kinase inhibitor with IC_{50}s of 6, 2 and 4 nM for **FGFR1**, **VEGFR2** and **Tie-2**.



Purity: 97.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

ACTH (1-17) TFA

(α1-17-ACTH (TFA))

Cat. No.: HY-P1545A

ACTH (1-17) TFA, an adrenocorticotropin analogue, is a potent **human melanocortin 1 (MC1) receptor** agonist with a K_i of 0.21 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ACTH 1-17

(α1-17-ACTH)

Cat. No.: HY-P1545

ACTH (1-17), an adrenocorticotropin analogue, is a potent **human melanocortin 1 (MC1) receptor** agonist with a K_i of 0.21 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Actinomycin D

(Dactinomycin; Actinomycin IV)

Cat. No.: HY-17559

Actinomycin D inhibits **DNA repair** with an IC_{50} of 0.42 μM.



Purity: 99.89%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg

ACY-1083

Cat. No.: HY-111791

ACY-1083 is a selective and brain-penetrating **HDAC6** inhibitor with an IC_{50} of 3 nM and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ACY-738

Cat. No.: HY-19327

ACY-738 is a potent, selective and orally-bioavailable **HDAC6** inhibitor, with an IC_{50} of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC_{50}s of 94, 128, and 218 nM.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AD80

Cat. No.: HY-101963

AD80, a multikinase inhibitor, inhibits **RET**, **RAF**,**SRC**and **S6K**, with greatly reduced mTOR activity.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Adarotene

(ST1926)

Cat. No.: HY-14808

Adarotene is an effective apoptosis inducer, which surprisingly produces DNA damage and exhibites a potent antiproliferative activity on a large panel of human tumor cells.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Adavosertib

(AZD1775; MK-1775)

Cat. No.: HY-10993

Adavosertib (AZD-1775; MK-1775) is a potent **Wee1** inhibitor with an IC_{50} of 5.2 nM.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ADDA 5 hydrochloride

Cat. No.: HY-U00448

ADDA 5 hydrochloride is a partial non-competitive inhibitor of **cytochrome c oxidase (CcO)**, with IC_{50}s of 18.93 μM and 31.82 μM for purified CcO from human glioma and bovine heart, respectively.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Adenine

(6-Aminopurine; Vitamin B4)

Cat. No.: HY-B0152

Adenine is a purine derivative and a nucleobase with a variety of roles in biochemistry.

Purity: 98.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g

ADH-1

Cat. No.: HY-13541

ADH-1, an **N-cadherin** antagonist, inhibits N-cadherin mediated cell adhesion.



Purity: 99.93%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

ADH-1 trifluoroacetate

Cat. No.: HY-13541A

ADH-1 trifluoroacetate is an **N-cadherin** antagonist, which inhibits N-cadherin mediated cell adhesion.



Purity: >95.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Adjudin

(AF-2364)

Cat. No.: HY-18996

Adjudin is an extensively studied male contraceptive with a superior **mitochondria**-inhibitory effect. Adjudin is also a potent **Cl⁻ channel** blocker.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Adrenomedullin (AM) (1-52), human

(Human adrenomedullin-(1-52)-NH2)

Cat. No.: HY-P1455

Adrenomedullin (AM) (1-52), human is a 52-amino acid peptide, which affects cell proliferation and angiogenesis in cancer.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Adrenomedullin (AM) (1-52), human TFA

(Human adrenomedullin-(1-52)-NH2 (TFA))

Cat. No.: HY-P1455A

Adrenomedullin (AM) (1-52), human (TFA) affects cell proliferation and angiogenesis in cancer.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Adrenorphin

(Metorphamide)

Cat. No.: HY-P1087

Adrenorphin is a opioid octapeptide, acting as a potent agonist of **μ-opioid receptor**, with K_i of 12 nM.



Purity: 95.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AEE788

(NVP-AEE 788)

Cat. No.: HY-10045

AEE788 is an inhibitor of the **EGFR** and **ErbB2** with IC_{50} values of 2 and 6 nM, respectively.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AES-135

Cat. No.: HY-114483

AES-135 is a potent **HDAC** inhibitor, inhibits **HDAC3**, **HDAC6**, **HDAC11** with IC_{50}s of 654, 190, and 636 nM, respectively. Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

AF-353

(Ro-4)

Cat. No.: HY-14483

AF-353 (Ro-4) is a potent, selective and orally bioavailable **P2X3/P2X2/3 receptor** antagonist, with a **pIC_{50}** of 8.0 for both human and rat P2X3, and with a **pIC_{50}** of 7.3 for human P2X2/3.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Afatinib

(BIBW 2992)

Cat. No.: HY-10261

Afatinib (BIBW 2992) is an irreversible **EGFR** family inhibitor with **IC_{50}**s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Afatinib dimaleate

(BIBW 2992MA2)

Cat. No.: HY-10261A

Afatinib dimaleate is an irreversible **EGFR** family inhibitor with **IC_{50}**s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.31%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Aflatoxin B1

Cat. No.: HY-N6615

Aflatoxin B1 (AFB1) is a Class 1A carcinogen, which is a secondary metabolite of Aspergillus flavus and A. parasiticus. Aflatoxin B1 (AFB1) mainly induces the transversion of G-->T in the third position of codon 249 of the p53 tumor suppressor gene, resulting in mutation.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Aflatoxin B2

Cat. No.: HY-N6696

Aflatoxin B2 is a major naturally produced aflatoxin. Aflatoxin B2 is a mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aflatoxin G1

Cat. No.: HY-N6697

Aflatoxin G1 is one type of aflatoxins occuring in nature. It is produced by molds, such as Aspergillus flavus and Aspergillus parasiticus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aflatoxin G2

Cat. No.: HY-N6698

Aflatoxin G2 is a major naturally produced aflatoxin. Aflatoxin G2 is a mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aflatoxin M1

Cat. No.: HY-N6699

Aflatoxin M1 is a major metabolite of Aflatoxin B1. Aflatoxin M1 is a mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aflatoxin M2

Cat. No.: HY-N6700

Aflatoxin M2 is a major metabolite of Aflatoxin B1. Aflatoxin M2 is a mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AFP464

Cat. No.: HY-16031

AFP464, is an active **HIF-1α** inhibitor with an **IC_{50}** of 0.25 μM, also is a potent **aryl hydrocarbon receptor (AhR)** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Afuresertib

(GSK2110183C) Cat. No.: HY-15727

Afuresertib is a potent and ATP-competitive specific **Akt** inhibitor.



Purity: 98.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Afuresertib hydrochloride

(GSK 2110183B) Cat. No.: HY-15727A

Afuresertib hydrochloride is a potent and ATP-competitive specific **Akt** inhibitor.



Purity: 96.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG 555

(Tyrphostin AG 555) Cat. No.: HY-15336

AG 555 is an **EGFR** tyrosine kinase inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG-1478

(Tyrphostin AG-1478; NSC 693255) Cat. No.: HY-13524

AG-1478 is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AG-490

(Tyrphostin AG 490) Cat. No.: HY-12000

AG-490 is a tyrosine kinase inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

AG1024

(Tyrphostin AG 1024) Cat. No.: HY-10253

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, less potent to IR with IC50 of 57 μM.



Purity: 97.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AG14361

Cat. No.: HY-12032

AG14361 is a potent **PARP-1** inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC_{50}s are 29 nM and 14 nM, respectively.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Agerafenib

(CEP-32496; RXDX-105) Cat. No.: HY-15200

Agerafenib (CEP-32496; RXDX-105) is a highly potent and orally efficacious inhibitor of **$BRAF^{V600E}$** with a K_d of 14 nM.



Purity: 99.20%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Agerafenib hydrochloride

(CEP-32496 (hydrochloride); RXDX-105 hydrochloride) Cat. No.: HY-15199

Agerafenib hydrochloride is a highly potent and orally efficacious inhibitor of **$BRAF^{V600E}$** with a K_d of 14 nM.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

AGI-24512

Cat. No.: HY-112130

AGI-24512 is a methionine adenosyltransferase 2A (**MATA2**) inhibitors useful for treatment of cancer. AGI-24512 blocks growth of MTAP-deleted cancer cells in vitro.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AGI-25696

Cat. No.: HY-112129

AGI-25696 is a methionine adenosyltransferase 2A (**MATA2**) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AGI-5198

(IDH-C35)

Cat. No.: HY-18082

AGI-5198 is a potent and selective mutant **IDH1**^{R132H} inhibitor with an **IC**$_{50}$ of 0.07 μM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AGI-6780

Cat. No.: HY-15734

AGI-6780 that potentially and selectively inhibits the tumor-associated mutant **IDH2**^{R140Q} with **IC**$_{50}$ of 23±1.7 nM. AGI-6780 is less potent against **IDH2**^{WT} with **IC**$_{50}$ of 190±8.1 nM.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AGK2

Cat. No.: HY-100578

AGK2 is a selective **SIRT2** inhibitor with **IC**$_{50}$ of 3.5 μM. AGK2 can also inhibit **SIRT1** and **SIRT3** with **IC**$_{50}$ of 30 and 91 μM, respectively.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

AGN 193109

Cat. No.: HY-U00449

AGN 193109 is a retinoid analog, and acts as a specific and highly effective antagonist of **retinoic acid receptors (RARs)**, with **K**$_d$s of 2 nM, 2 nM, and 3 nM for **RARα**, **RARβ**, and **RARγ**, respectively.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

AGN 194078

Cat. No.: HY-100273

AGN 194078 is a selective **RARα** agonist with a **K**$_d$ and **EC**$_{50}$ of 3 and 112 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AGN 194310

(VTP-194310)

Cat. No.: HY-16681

AGN 194310(VTP-194310) is a potent and selective pan-RARs agonist with Kd values of 3/2/5 nM for RARα/β/γ respectively.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

AGN 195183

Cat. No.: HY-16684

AGN 195183 is a potent and selective agonist of RARα(Kd=3 nM) with improved binding selectivity relative to AGN 193836; no activity on RARβ/γ. IC50 value: 3 nM (Kd); 200 nM (EC80, RAR Trans.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AGN 196996

Cat. No.: HY-16682

AGN 196996 is a potent and selective RARα antagonist with Ki value of 2 nM; little binding affinity for RARβ(Ki=1087 nM) and RARγ(Ki=8523 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AGN 205327

Cat. No.: HY-16685

AGN 205327 is a potent synthetic RARs agonist with EC50 of 3766/734/32 nM for RARα/β/γ respectively; no inhibition on RXR.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AGN 205728

Cat. No.: HY-16683

AGN 205728 is a potent and selective RARγ antagonist with Ki/IC95 values of 3 nM/ 0.6 nM; no inhibiton on RARα and RARβ.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AHR antagonist 1

Cat. No.: HY-111449

AHR antagonist 1 is an **aryl hydrocarbon receptor (AHR)** antagonist extracted from patent WO2017202816A1, example 23, has an IC_{50} of 39.9 nM in human cell line.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

AI-10-49

Cat. No.: HY-16786

AI-10-49 is a protein-protein interaction inhibitor that selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1 with a FRET IC50 of 0.26 uM.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AICAR

(Acadesine; AICA Riboside)

Cat. No.: HY-13417

AICAR is a cell-permeable AMP-activated protein kinase (**AMPK**) activator.



Purity: 99.92%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

AICAR phosphate

(Acadesine phosphate; AICA Riboside phosphate)

Cat. No.: HY-13417A

AICAR phosphate is an activator of AMP-activated protein kinase (**AMPK**).



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Ailanthone

(Δ13-Dehydrochaparrinone)

Cat. No.: HY-N1943

Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length **androgen receptor (AR)** (IC_{50}=69nM) and constitutively active truncated AR splice variants (AR_{1-651} IC_{50}=309nM).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AIM-100

Cat. No.: HY-15290

AIM-100 is a small molecule inhibitor of Ack1 with an IC50 of 24 nM.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AKBA

(Acetyl-11-keto-β-boswellic acid)

Cat. No.: HY-N0892

Acetyl-11-Keto-β-Boswellic Acid (AKBA) is an active triterpenoid compound from the extract of Boswellia serrate; a novel Nrf2 activator.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AKT inhibitor VIII

(AKTi-1/2)

Cat. No.: HY-10355

AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit **Akt1**, **Akt2**, and **Akt3** activity with IC_{50}s of 58 nM, 210 nM, and 2119 nM, respectively.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AKT Kinase Inhibitor

Cat. No.: HY-10249A

AKT Kinase Inhibitor is an **Akt** kinase inhibitor.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AKT-IN-1

Cat. No.: HY-18296

AKT-IN-1 is an allosteric **AKT** inhibitor with an **IC_{50}** of 1.042 μM.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AKT-IN-2

Cat. No.: HY-112148

AKT-IN-2 is a potent, selective and orally bioavailable **AKT** inhibitor with an **IC_{50}** of 5 nM for **AKT1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Akt1 and Akt2-IN-1

Cat. No.: HY-50862

Akt1 and Akt2-IN-1 is an allosteric inhibitor of **Akt1** (**IC_{50}**=3.5 nM) and **Akt2** (IC_{50}=42 nM), with potent and balanced activity.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Alantolactone

((+)-Alantolactone; Alant camphor; Inula camphor) Cat. No.: HY-N0038

Alantolactone is a selective **STAT3** inhibitor, with potent anticancer activity.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Alda-1

Cat. No.: HY-18936

Alda-1 is a potent **ALDH2** agonist, which activates wild-type ALDH2 and restores near wild-type activity to ALDH2*2.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Aldoxorubicin

(INNO-206; DOXO-EMCH) Cat. No.: HY-16261

Aldoxorubicin (INNO-206) is an albumin-binding prodrug of doxorubicin, which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.



Purity: 92.43%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Alectinib

(CH5424802; RO5424802; AF802) Cat. No.: HY-13011

Alectinib (CH5424802; RO5424802; AF802) is a potent, selective, and orally available **ALK** inhibitor with an **IC_{50}** of 1.9 nM.



Purity: 99.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Alectinib Hydrochloride (CH5424802 (Hydrochloride); RO5424802 (Hydrochloride); AF-802 (Hydrochloride))

Cat. No.: HY-13011A

Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available **ALK** inhibitor with **IC_{50}** of 1.9 nM, the dissociation constant (**K_D**) value for ALK in an ATP-competitive manner is 2.4 nM using...



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Alendronate sodium hydrate

(Alendronate; MK 217; G-704650 Adronat) Cat. No.: HY-11101

Alendronate (sodium hydrate) is a farnesyl diphosphate synthase inhibitor with **IC_{50}** of 460 nM.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Alisertib

(MLN 8237) Cat. No.: HY-10971

Alisertib (MLN 8237) is an orally active and selective **Aurora A kinase** inhibitor (**IC_{50}**=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation.



Purity: 99.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Alizapride hydrochloride

Cat. No.: HY-A0125A

Alizapride hydrochloride is a **dopamine receptor** antagonist with prokinetic and antiemetic effects which can also be used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

ALK inhibitor 1

Cat. No.: HY-15357

ALK inhibitor 1 is a novel and selective inhibitor for the ALK kinase.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ALK inhibitor 2

Cat. No.: HY-15358

ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ALK-IN-1

Cat. No.: HY-13464

ALK-IN-1 is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ALK-IN-6

Cat. No.: HY-128596

ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of **anaplastic lymphoma kinase (ALK)**, with IC_{50} values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

ALK2-IN-2

Cat. No.: HY-112815

ALK2-IN-2 is a potent and selective inhibitor of **activin receptor-like kinase 2 (ALK2)** with an IC_{50} of 9 nM, and over 700-fold selectivity against ALK3.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Allantoin

(5-Ureidohydantoin)

Cat. No.: HY-N0543

Allantoin is a skin conditioning agent that promotes healthy skin, stimulates new and healthy tissue growth.

Purity: 98.36%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Allitinib

(AST-1306; ALS 1306)

Cat. No.: HY-15375

Allitinib (AST1306) is a selective, irreversible **EGFR** and **ErbB2** inhibitor with IC_{50}s of 0.5 and 3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Allitinib tosylate

(AST-1306 (TsOH))

Cat. No.: HY-13427

Allitinib tosylate (AST-1306 TsOH) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ALLO-2

Cat. No.: HY-117407

ALLO-2 is a potent drug-resistant **Smoothened (Smo)** mutant antagonist that inhibits Smo agonist Hh-Ag1.5-induced luciferase expression in TM3-Gli-Luc cells with IC_{50} of 6 nM.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Alobresib
(GS-5829) Cat. No.: HY-109050

Alobresib (GS-5829) is a **BET bromodomain** inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aloe emodin
(Rhabarberone; 3-Hydroxymethylchrysazine) Cat. No.: HY-N0189

Aloe emodin is a hydroxyanthraquinone present in Aloe vera leaves, has a specific in vitro and in vivo antitumor activity. IC50 value: Target: in vitro: aloe-emodin treatment led to the dissociation of heat shock protein 90 (HSP90) and ER α and increased ER α ubiquitination.



Purity: 97.70%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

Alofanib
(RPT835) Cat. No.: HY-17601

Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (**FGFR2**). Anticancer and antiangiogenic activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Aloin
(Aloin-A; Barbaloin-A) Cat. No.: HY-N0123

Aloin(Aloin-A; Barbaloin-A) is a natural antitumor anthraquinone glycoside with iron chelating and non-atherogenic activities. IC50 value: Target: in vitro: Aloin significantly inhibited HUVECs proliferation, migration and tube formation in vitro.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Alpelisib
(BYL-719) Cat. No.: HY-15244

Alpelisib (BYL-719) is a potent and selective **PI3Kα** inhibitor with **IC_{50}**s of 5 nM, 250 nM, 290 nM and 1200 nM for **p110α**, **p110γ**, **p110δ**, and **p110β**, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

alpha-Amanitin
(α-Amanitin; α-Amatoxin) Cat. No.: HY-19610

alpha-Amanitin is the principal toxin of several deadly poisonous mushrooms, exerting its toxic function by inhibiting **RNA-polymerase II**.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 1 mg, 2 mg, 5 mg

alpha-Bisabolol
Cat. No.: HY-121222

alpha-Bisabolol is a nontoxic sesquiterpene alcohol present in natural essential oil, with anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

alpha-Mangostin
(α-Mangostin) Cat. No.: HY-N0328

Alpha-mangostin is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (**IDH1-R132H**) with a **K_i** of 2.85 μM.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Alprenolol
((RS)-Alprenolol; dl-Alprenolol) Cat. No.: HY-B1517

Alprenolol is a non-selective beta blocker as well as 5-HT1A receptor antagonist.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Alprenolol hydrochloride
((RS)-Alprenolol hydrochloride; dl-Alprenolol hydrochloride) Cat. No.: HY-B1517A

Alprenolol (hydrochloride) is a non-selective beta blocker as well as 5-HT1A receptor antagonist.



Purity: 98.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Alsterpaullone

(9-Nitropaullone; NSC 705701) Cat. No.: HY-108359

Alsterpaullone (9-Nitropaullone;NSC 705701) is a potent **cyclin-dependent kinases (CDK)** inhibitor, with IC_{50}s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Altiratinib

(DCC-2701) Cat. No.: HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC_{50}s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for **MET**, **TIE2**, **VEGFR2**, **FLT3**, **Trk1**, **Trk2**, and **Trk3** respectively.



Purity: 95.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Altretamine

(ENT-50852; RB-1515; WR-95704) Cat. No.: HY-B0181

Altretamine is an **alkylating** antineoplastic agent.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Altretamine hydrochloride (ENT-50852 hydrochloride; RB-1515 hydrochloride; WR-95704 hydrochloride)

Cat. No.: HY-B0181A

Altretamine hydrochloride is an **alkylating** antineoplastic agent.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg

Alvespimycin

(17-DMAG; NSC 707545) Cat. No.: HY-10389

Alvespimycin is a potent inhibitor of **Hsp90**, binding to Hsp90 with an EC_{50} of 62 ± 29 nM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg

Alvespimycin hydrochloride

(17-DMAG hydrochloride; KOS-1022; BMS 826476) Cat. No.: HY-12024

Alvespimycin hydrochloride is a potent inhibitor of **Hsp90**, binding to Hsp90 with an EC_{50} of 62±29 nM.



Purity: 99.32%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 25 mg, 100 mg, 200 mg

ALW-II-41-27

(Eph receptor tyrosine kinase inhibitor) Cat. No.: HY-18007

ALW-II-41-27 is a **Eph** family tyrosine kinase inhibitor with an IC_{50} of 11 nM for Eph2.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AM-8735

Cat. No.: HY-12734

AM-8735 is a potent and selective **MDM2** inhibitor with an IC_{50} of 25 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AM580

(CD336; NSC608001; Ro 40-6055) Cat. No.: HY-10475

AM580 is a selective **RARα** agonist with IC_{50} and EC_{50} of 8 nM and 0.36 nM, respectively.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Amcasertib

(BBI503) Cat. No.: HY-17602

Amcasertib is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases.



Purity: 98.58%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

AMG 232

Cat. No.: HY-12296

AMG 232 is a potent, selective and orally available inhibitor of **p53-MDM2** interaction, with an IC_{50} of 0.6 nM. AMG 232 binds to MDM2 with a K_d of 0.045 nM.



Purity: 99.90%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

AMG 487

Cat. No.: HY-15319

AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 **(CXCR3)** which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC_{50}s of 8.0 and 8.2 nM, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG 900

Cat. No.: HY-13253

AMG 900 is a potent and highly selective **pan-Aurora** kinases inhibitor with IC_{50} of 5 nM, 4 nM and 1 nM for **Aurora A**, **B** and **C**, respectively.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG 925

Cat. No.: HY-15889

AMG 925 is a potent, selective, and orally available **FLT3/CDK4** dual inhibitor with IC_{50}s of 2±1 nM and 3±1 nM, respectively.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

AMG 925 HCl

Cat. No.: HY-15889A

AMG 925 HCl is a potent, selective, and orally available **FLT3/CDK4** dual inhibitor with IC_{50}s of 2±1 nM and 3±1 nM, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

AMG-176

Cat. No.: HY-101565

AMG-176 is a potent, selective and orally bioavailable MCL-1 inhibitor, with a K_i of 0.13 nM.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMG-208

Cat. No.: HY-12035

AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM. IC50 value: 9.3 nM Target: c-Met in vitro: AMG-208 shows the potent inhibition of kinase c-Met activity with IC50 of 9 nM in a cell-free assay.



Purity: 99.34%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG-337

Cat. No.: HY-18696

AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.



Purity: 99.26%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

AMG-510

Cat. No.: HY-114277

AMG-510 is a potent **KRAS G12C** covalent inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG-510 racemate

Cat. No.: HY-114277A

AMG-510 racemate is the racemate of AMG-510. AMG-510 is a potent **KRAS G12C** covalent inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AMG319

Cat. No.: HY-12948

AMG319 is a potent and selective **PI3Kδ** kinase inhibitor with **IC_{50}** of 18 nM.



Purity: 98.40%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMI-1

Cat. No.: HY-18962

AMI-1 is a potent, cell-permeable compound which inhibits protein arginine N-methyltransferases (PRMTs), including human PRMT1 (IC50 = 8.8μM) and yeast-Hmt1p (IC50 = 3.0μM), by blocking peptide-substrate binding.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Amifostine

(WR2721)

Cat. No.: HY-B0639

Amifostine is a broad-spectrum cytoprotection agent against the DNA damaging effects of ionizing radiation and chemotherapy drug.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Aminomalonic acid

Cat. No.: HY-112052

Aminomalonic acid is an amino endogenous metabolite, acts as a strong inhibitor of **L-asparagine synthetase** from Leukemia 5178Y/AR (K_i= 0.0023 M) and mouse pancreas (K_i= 0.0015 M) in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminooxyacetic acid hemihydrochloride

(Carboxymethoxylamine Hemihydrochloride)

Cat. No.: HY-107994

Aminooxyacetic acid hemihydrochloride is a **malate-aspartate shuttle** (**MAS**) inhibitor which also inhibits the GABA degradating enzyme **GABA-T**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

Amiselimod hydrochloride

(MT-1303 hydrochloride)

Cat. No.: HY-16734A

Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.



Purity: 99.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Amisulpride

(DAN 2163)

Cat. No.: HY-14545

Amisulpride is a **dopamine D_2/D_3 receptor** antagonist with K_is of 2.8 and 3.2 nM for human **dopamine D_2** and **D_3**, respectively.



Purity: >98.0%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Amonafide

(AS1413)

Cat. No.: HY-10982

Amonafide is a **topoisomerase II** inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.



Purity: 99.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AmPEG6C2-Aur0131

Cat. No.: HY-111555

AmPEG6C2-Aur0131 is a non-cleavable **anti-CXCR4 drug-linker conjugates for ADC**.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Amphethinile

(Amphetinile; CRC 82-07)

Cat. No.: HY-100190

Amphethinile is an **anti-tubulin** agent. The affinity constant for the association (K_a) of Amphethinile with tubulin is 1.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Amrubicin

(SM-5887; AMR) Cat. No.: HY-B0067

Amrubicin (SM-5887) is a DNA **topoisomerase II** inhibitor, used for the research of cancer.



Purity: >98.0%
Clinical Data: Launched
Size: 1 mg, 5 mg

Amrubicin hydrochloride

(SM-5887 (hydrochloride); AMR (hydrochloride)) Cat. No.: HY-B0067A

Amrubicin (hydrochloride) (SM-5887 (hydrochloride)) is a DNA **topoisomerase II** inhibitor, used for the research of cancer.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Amsacrine

(m-AMSA; acridinyl anisidide) Cat. No.: HY-13551

Amsacrine (m-AMSA) is an inhibitor of **topoisomerase II**, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Amsacrine hydrochloride

(m-AMSA hydrochloride; acridinyl anisidide hydrochloride) Cat. No.: HY-13551A

Amsacrine hydrochloride (mAMSA hydrochloride) is an inhibitor of **topoisomerase II**, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Amuvatinib

(MP470; HPK 56) Cat. No.: HY-10206

Amuvatinib (MP470) is a multi-targeted receptor tyrosine kinases inhibitor, which inhibits **c-Kit (D816V)**, **c-Kit (D816H)**, **c-Kit (V560G)**, **c-Kit (V654A)**, **PDGFRα (D842V)**, and **PDGFRα (V561D)** with IC_{50}s of 950 nM, 10 nM, 34 nM, 127 nM, 81 nM, and 40 nM, respectively. Antineoplastic activity.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride) Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is a multi-targeted receptor tyrosine kinases inhibitor, which inhibits **c-Kit (D816V)**, **c-Kit (D816H)**, **c-Kit (V560G)**, **c-Kit (V654A)**, **PDGFRα (D842V)**, and **PDGFRα (V561D)** with IC_{50}s of 950 nM, 10 nM, 34 nM, 127 nM, 81 nM, and 40...



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

AMXT-1501 tetrahydrochloride

Cat. No.: HY-124617A

AMXT-1501 tetrahydrochloride is a novel inhibitor of the polyamine transport system. AMXT1501 blocks tumor growth in immunocompetent mice but not in athymic nude mice lacking T cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Amygdalin

Cat. No.: HY-N0190

Amygdalin is a plant glucoside isolated from the stones of rosaceous fruits, such as apricots, peaches, almond, cherries, and plums.



Purity: 98.03%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

amyloid P-IN-1

Cat. No.: HY-19771

amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Anacardic Acid

(Hydroginkgolic acid) Cat. No.: HY-N2020

Anacardic Acid, extracted from cashew nut shell liquid, is a **histone acetyltransferase** inhibitor, inhibits HAT activity of p300 and PCAF, with IC_{50}s of 8.5 μM and 5 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Anamorelin

(RC-1291; ONO-7643) Cat. No.: HY-14734

Anamorelin is a novel **ghrelin receptor** agonist with EC_{50} value of 0.74 nM in the FLIPR assay.



Purity: 99.91%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Anamorelin Fumarate

(ONO-7643 Fumarate; RC1291 Fumarate) Cat. No.: HY-14734B

Anamorelin Fumarate is a novel **ghrelin receptor** agonist with EC_{50} value of 0.74 nM in the FLIPR assay.



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Anamorelin hydrochloride

(RC-1291 hydrochloride; ONO-7643 hydrochloride) Cat. No.: HY-14734A

Anamorelin hydrochloride is a novel **ghrelin receptor** agonist with EC_{50} value of 0.74 nM in the FLIPR assay.



Purity: 99.80%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Anastrozole

(ZD1033) Cat. No.: HY-14274

Anastrozole is a potent, highly selective **aromatase** inhibitor, which inhibits human placental aromatase with an IC_{50} of 15 nM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Ancitabine hydrochloride (Cyclocytidine hydrochloride; Cyclo-CMP hydrochloride; Cyclo-C)

Cat. No.: HY-N0093

Ancitabine (hydrochloride) is an important antileukemia drugs.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg, 1 g

Andarine

(GTx-007; S-4) Cat. No.: HY-12023

Andarine (S-4) is an investigational selective androgen receptor modulator (SARM) and an active partial agonist.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Androgen receptor modulators 1

Cat. No.: HY-101781

Androgen receptor modulators 1 is a **selective androgen receptor modulator (SARM)**. Androgen receptor modulators 1 has strong agonistic activities with an EC_{50} of 4.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Andrographolide

(Andrographis) Cat. No.: HY-N0191

Andrographolide is a **NF-κB** inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on **p50** in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation.



Purity: 97.46%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Androstanolone acetate

Cat. No.: HY-111847

Androstanolone acetate is an androgen ligand, which targets androgen receptor (AR). Androstanolone acetate binds to **cIAP1** ligand Bestatin via a linker to form **PROTACs**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Anethole trithione

Cat. No.: HY-B1223

Anethole trithione is a drug used in the treatment of dry mouth being studied in the treatment of cancer.



Purity: >99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Angiogenin (108-122) TFA

Cat. No.: HY-P1516A

Angiogenin (108-122) TFA is an angiogenin peptide.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Angiogenin 108-122

Cat. No.: HY-P1516

Angiogenin (108-122) is an angiogenin peptide.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Angiotensin II 5-valine

(Valine angiotensin II; 5-L-Valine angiotensin II)

Cat. No.: HY-P0108

Angiotensin II 5-valine is an agonist of **angiotensin receptor**.



Purity: 95.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Anisomycin

(Flagecidin; Wuningmeisu C)

Cat. No.: HY-18982

Anisomycin is a potent **protein synthesis** inhibitor which interferes with protein and **DNA synthesis** by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a JNK activator, which increases phospho-JNK.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ansamitocin P 3'

(Antibiotic C 15003P3'; Maytansinol butyrate)

Cat. No.: HY-19839

Ansamitocin P 3' exhibits antitumour activity, is an antibody drug conjugate cytotoxin. The more information please refer to Ansamitocin P-3 (HY-15739).



Purity: 87.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ansamitocin P-3

(Antibiotic C 15003P3; Maytansinol isobutyrate)

Cat. No.: HY-15739

Ansamitocin P-3 is a **microtubule** inhibitor. Ansamitocin P-3 is a macrocyclic antitumor antibiotic.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Antennapedia Peptide

Cat. No.: HY-P0307

Antennapedia Peptide is a 16 amino acid peptide, originally derived from the 60 amino acid long homeodomain of the Drosophila transcription factor Antennapedia and is a member of the family of Cell-penetrating peptides.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Antennapedia Peptide(TFA)

Cat. No.: HY-P0307A

Antennapedia Peptide is a 16 amino acid peptide, originally derived from the 60 amino acid long homeodomain of the Drosophila transcription factor Antennapedia and is a member of the family of Cell-penetrating peptides.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Anticancer agent 3

Cat. No.: HY-128689

Anticancer agent 3 (Compound 4) is a anti-cancer agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Antineoplaston A10

Cat. No.: HY-128553

Antineoplaston A10, a naturally occurring substance in human body, is a **Ras** inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Antioxidant peptide A

Cat. No.: HY-P1512

Antioxidant peptide A is a short peptide, which contains alternative aromatic or sulfur-containing amino acid. The side chains of Antioxidant peptide A are believed to contribute to strong radical scavenging activities of peptides in the cancer cell.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Antitumor Compound 1

Cat. No.: HY-15961

Antitumor Compound 1 is a potent compound which comprises a new imidazopyridine having excellent antitumor activity as an active ingredient.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Antitumor Compound 2

Cat. No.: HY-U00414

Antitumor Compound 2, a butenylphenyl phosphate derivative, is a drug for mammary cancer and anovulatory sterility.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

AP-III-a4

(ENOblock)

Cat. No.: HY-15858

ENOblock(AP-III-a4) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AP-III-a4 hydrochloride

(ENOblock hydrochloride)

Cat. No.: HY-15858A

ENOblock Hcl(AP-III-a4 Hcl) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AP1867

Cat. No.: HY-114434

AP1867 is a synthetic $FKBP12^{F36V}$-directed ligand.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Apabetalone

(RVX-208; RVX000222)

Cat. No.: HY-16652

Apabetalone (RVX-208) is an inhibitor of **BET** transcriptional regulators with selectivity for the second bromodomain. The IC_{50}s are 87±10 μM and 0.51±0.041 μM for **BD1** and **BD2**, respectively.



Purity: 99.33%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Apalutamide

(ARN-509)

Cat. No.: HY-16060

Apalutamide (ARN-509) is a potent and competitive **androgen receptor** (**AR**) antagonist, binding AR with an IC_{50} of 16 nM.



Purity: 99.69%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Apatinib

(YN968D1)

Cat. No.: HY-13342

Apatinib is a highly selective **VEGFR2** inhibitor with an IC_{50} of 1 nM. Apatinib also potently suppresses the activities of Ret, c-Kit and c-Src with IC_{50}s of 13, 429 and 530 nM, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

APG-115

(AA-115)

Cat. No.: HY-101518

APG-115 (AA-115) is an orally active **MDM2** protein inhibitor binding to MDM2 protein with IC_{50} and K_i values of 3.8 nM and 1 nM, respectively. APG-115 blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and **apoptosis** in a p53-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Apicidin

(OSI 2040)

Cat. No.: HY-N6735

Apicidin (OSI 2040) is a fungal metabolite, acts as a **histone deacetylase (HDAC)** inhibitor, with antiparasitic activity and a broad spectrum antiproliferative activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apigenin-7-glucuronide

(Apigenin 7-O-glucuronide)

Cat. No.: HY-N1454

Apigenin-7-glucuronide could inhibit Matrix Metalloproteinases **(MMP)** activities, with IC_{50}s of 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Apitolisib

(GDC-0980; GNE 390; RG 7422)

Cat. No.: HY-13246

Apitolisib (GDC-0980) is a selective, potent, orally bioavailable Class I **PI3** kinase and **mTOR kinase** (**TORC1/2**) inhibitor with IC_{50}s of 5 nM/27 nM/7 nM/14 nM for **PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ**, and with a K_i of 17 nM for **mTOR**.



Purity: 99.13%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Apocynin

(Acetovanillone)

Cat. No.: HY-N0088

Apocynin is a selective **NADPH-oxidase** inhibitor with an IC_{50} of 10 μM.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 g, 5 g

Apoptozole

(Apoptosis Activator VII)

Cat. No.: HY-15098

Apoptozole is an inhibitor of the ATPase domain of **Hsc70** and **Hsp70**, with K_ds of 0.21 and 0.14 μM, respectively, and can induce apoptosis.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

APS-2-79

Cat. No.: HY-100627

APS-2-79 behaves as a kinase suppressor of Ras (**KSR**)-dependent antagonist of RAF-mediated **MEK** phosphorylation. APS-2-79 binds directly to **KSR2** within the KSR2-MEK1 complex with an IC_{50} of 120±23 nM for KSR2.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

APS-2-79 hydrochloride

Cat. No.: HY-100627A

APS-2-79 hydrochloride behaves as a kinase suppressor of Ras (**KSR**)-dependent antagonist of RAF-mediated **MEK** phosphorylation. APS-2-79 binds directly to **KSR2** within the KSR2-MEK1 complex with an IC_{50} of 120±23 nM for KSR2.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

APTO-253

(LOR-253; LT-253)

Cat. No.: HY-16291

APTO-253 is an inducer of **Kruppel-like factor 4 (KLF4)**, and also stabilizes **Gquadruplex**, with anti-proliferative activity.



Purity: 96.80%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

APY29

Cat. No.: HY-17537

APY29 is an allosteric modulator of **IRE1α** which inhibits IRE1α autophosphorylation with IC_{50} of 280 nM and activates IRE1α RNase activity.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ar-Turmerone

((+)-ar-Turmerone)

Cat. No.: HY-N6703

ar-Turmerone ((+)-ar-Turmerone) is a major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities. ar-turmerone ((+)-ar-Turmerone) activates apoptotic protein in human lymphoma U937 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arctigenin

((-)-Arctigenin)

Cat. No.: HY-N0035

Arctigenin is a lignan found in certain plants of the Asteraceae; it has shown antiviral and anticancer effects in glass; it is the aglycone of arctiin. IC50 value: Target: anticancer agent Arctiin and its aglucone, arctigenin from the fruits of Arctium lappa L.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Arctiin

(Arctii; NSC 315527; Arctigenin-4-glucoside)

Cat. No.: HY-N0034

Arctiin(NSC 315527), a plant lignan that can be extracted from the Arctium lappa (burdock) seeds, is a possible environmental endocrine disruptor compounds and have been shown to influence sex hormone metabolism as well as protein synthesis, steroid biosynthesis.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Arenobufagin

Cat. No.: HY-N0876

Arenobufagin is a natural bufadienolide from toad venom; has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Arginase inhibitor 1

Cat. No.: HY-15775

Arginase inhibitor 1 is a potent inhibitor of human **arginases I** and **II** with IC_{50}s of 223 and 509 nM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Arglabin

((+)-Arglabin)

Cat. No.: HY-16059

Arglabin is a sesquiterpene gamma-lactone is isolated from Artemisia glabella; anticancer natural compound.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Aristeromycin

Cat. No.: HY-112639

Aristeromycin, an adenosine analog, is an antibiotic and a potent **S-adenosylhomocysteine hydrolase (AHCY)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Aristolochic acid A

(Aristolochic acid I; TR 1736)

Cat. No.: HY-N0510

Aristolochic acid A (Aristolochic acid I) is the main component of plant extract Aristolochic acids, which are found in various herbal plants of genus Aristolochia and Asarum. AAI significantly reduces both activator protein 1 (AP-1) and **NF-κB** activities.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg

Aristolochic acid D

Cat. No.: HY-N1465

Aristolochic acid D is an aristolochic acid derivative isolated from stems of Aristolochia indica. Aristolochic acid is nephrotoxin and carcinogen.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARN-3236

Cat. No.: HY-120856

ARN-3236 is an oral active and selective inhibitor of **salt-inducible kinase 2 (SIK2)**, with IC_{50}s of <1 nM, 21.63 nM and 6.63 nM for SIK2, SIK1 and SIK3, respectively. Has anti-cancer activity.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Arnicolide D

Cat. No.: HY-N6843

Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the **caspase** signaling pathway and inhibits the **PI3K/AKT/mTOR** and **STAT3** signaling pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ArnicolideC

Cat. No.: HY-N6842

ArnicolideC is a sesquiterpene lactone isolated Centipeda minima. ArnicolideC exertes a cytotoxic effect on the panel of Nasopharyngeal carcinoma (NPC) cells, significantly inhibiting cell growth in a dose- and time- dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARQ 531

Cat. No.: HY-112215

ARQ 531 is a reversible non-covalent inhibitor of Bruton's Tyrosine Kinase (**BTK**), with IC_{50}s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARRY-380 analog

Cat. No.: HY-10531

ARRY-380 analog is the analog of ARRY-380, ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.



Purity: 96.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ARS-1323

Cat. No.: HY-U00416

ARS-1323 is a novel inhibitor of **mutant K-ras G12C** extracted from patent WO 2015054572 A1.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

ARS-1323-alkyne

Cat. No.: HY-128522

ARS-1323-alkyne, a **switch-II pocket (S-IIP)** inhibitor, is a conformational specific chemical reporter of $KRAS^{G12C}$ nucleotide state in living cells.



Purity: >98%
Clinical Data:
Size: 100 mg, 250 mg, 500 mg

ARS-1620

Cat. No.: HY-U00418

ARS-1620 is an atropisomeric selective $KRAS^{G12C}$ inhibitor with desirable pharmacokinetics.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

ARS-1630

Cat. No.: HY-U00417

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of **mutant K-ras G12C** extracted from patent WO 2015054572 A1.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARS-853

Cat. No.: HY-19706

ARS-853 is a selective, covalent $KRAS^{G12C}$ inhibitor with an IC_{50} of 2.5 μM.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Artesunate

Cat. No.: HY-N0193

Artesunate is an inhibitor of both **STAT-3** and **exported protein 1** (**EXP1**).



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

ARV-771

Cat. No.: HY-100972

ARV-771 is a potent bromodomain and extra-terminal (**BET**) proteins degrader based on PROTAC technology with K_d values of 4.7, 7.6, 7.6 nM against BRD2, BRD3 and BRD4, respectively.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ARV-825

Cat. No.: HY-16954

ARV-825 is a **BRD4** degrader based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with K_ds of 90 and 28 nM, respectively.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Arzoxifene hydrochloride

(LY 353381 HCl; SERM 3)

Cat. No.: HY-13556A

Arzoxifene hydrocloride is a selective **estrogen receptor** modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AS-252424

Cat. No.: HY-13532

AS-252424 is a potent and selective **PI3Kγ** inhibitor with an IC_{50} of 30±10 nM.



Purity: 97.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AS-605240

Cat. No.: HY-10109

AS-605240 is a specific and orally active inhibitor of the **PI3Kγ**, with an IC_{50} of 8 nM, and a K_i of 7.8 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

AS601245

Cat. No.: HY-11010

AS601245 is a **JNK** Inhibitor with IC_{50}s of 150, 220, and 70 nM for three JNK human isoforms (**hJNK1**, **hJNK2**, and **hJNK3**), respectively.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Asciminib

(ABL001)

Cat. No.: HY-104010

Asciminib (ABL001) is a potent and selective allosteric **Bcr-Abl** inhibitor; inhibits Ba/F3 cells grown with an IC_{50} of 0.25 nM.



Purity: 98.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ASP-9521

Cat. No.: HY-19903

ASP-9521 is a potent, selective and orally available **AKR1C3** inhibitor with an IC_{50} of 11 nM for human AKR1C3.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

ASP3026

Cat. No.: HY-13326

ASP3026 is a novel and selective inhibitor for ALK (anaplastic lymphoma kinase) with IC50 of 3.5 nM.



Purity: 99.76%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ASP5878

Cat. No.: HY-19983

ASP5878 is an oral active inhibitor of **FGFR 1, 2, 3, and 4**, with IC_{50} values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AST 487

(NVP-AST 487)

Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AST2818 mesylate

Cat. No.: HY-112870A

AST2818 mesylate is an **EGFR** inhibitor.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Astaxanthin

Cat. No.: HY-B2163

Astaxanthin, a red dietary carotenoid isolated from Haematococcus pluvialis, is an inhibitor of **PPARγ** and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity.



Purity: >98.0%
Clinical Data: Launched
Size: 5 mg, 10 mg

Astragaloside A

(Astramembrannin I; Astragalin A)

Cat. No.: HY-N0099

Astragaloside A is one of the major active constituents of Astragalus membranaceus in Traditional Chinese Medicine; has been widely used to treat ischemic diseases.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Astragaloside IV

Cat. No.: HY-N0431

Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of **ERK1/2** and **JNK**, and downregulates matrix metalloproteases **(MMP)-2, (MMP)-9** in MDA-MB-231 breast cancer cells.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ASTX660

Cat. No.: HY-109565

ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (**cIAP**) and X-linked inhibitor of apoptosis protein (**XIAP**).



Purity: 98.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

AT13148

Cat. No.: HY-16071

AT13148 is an orally active and ATP-competitive, multi-**AGC kinase** inhibitor with **IC_{50}**s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.



Purity: 99.54%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT6

Cat. No.: HY-112375

AT6 is a PROTAC AT1 analogue, which is a highly selective bromodomain (Brd4) degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

AT7519

Cat. No.: HY-50940

AT7519 as a potent inhibitor of **CDKs**, with **IC_{50}**s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.



Purity: 98.15%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT7519 Hydrochloride

Cat. No.: HY-50943

AT7519 Hydrochloride is a potent inhibitor of **CDKs**, with **IC_{50}**s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT7519 trifluoroacetate

Cat. No.: HY-50940A

AT7519 trifluoroacetate as a potent inhibitor of **CDKs**, with **IC_{50}**s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.



Purity: 98.16%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT7867

Cat. No.: HY-12059

AT7867 is a potent ATP-competitive inhibitor of **Akt1/Akt2/Akt3** and **p70S6K/PKA** with IC_{50}s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT7867 dihydrochloride

Cat. No.: HY-12059A

AT7867 dihydrochloride is a potent ATP-competitive inhibitor of **Akt1/Akt2/Akt3** and **p70S6K/PKA** with IC_{50}s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT9283

Cat. No.: HY-50514

AT9283 is a multitargeted kinase inhibitor which potently inhibits **aurora kinase A/B**, **JAK2/3** (IC_{50}=1.2 nM, 1.1 nM).



Purity: 99.13%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Atezolizumab

(MPDL3280A)

Cat. No.: HY-P9904

Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (**PD-L1**), used for cancer research.

Purity: 98.98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg

ATM Inhibitor-1

Cat. No.: HY-112614

ATM Inhibitor-1 is a highly potent, selective and orally active **ATM** inhibitor, with an IC_{50} of 0.7 nM, shows weak activity against mTOR (IC_{50}, 21 μM), DNAPK (IC_{50}, 2.8 μM), PI3Kα (IC_{50}, 3.8 μM), PI3Kβ (IC_{50}, 10.3 μM), PI3Kγ (IC_{50}, 3 μM) and PI3Kδ (IC_{50}, 0.73 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

ATM-3507

Cat. No.: HY-100948

ATM-3507 is a potent **tropomyosin** inhibitor with IC_{50}s from 3.83-6.84 μM in human melanoma cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

ATN-161

Cat. No.: HY-13535

ATN-161 is a novel **integrin α5β1** antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

ATN-161 trifluoroacetate salt

(ATN-161 TFA salt)

Cat. No.: HY-13535A

ATN-161 trifluoroacetate salt is a novel **integrin α5β1** antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.



Purity: >95.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

ATR inhibitor 1

Cat. No.: HY-111451

ATR inhibitor 1 is a **ATR** inhibitor extracted from patent WO2015187451A1, compound I-l, has a K_i value below 1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atractylenolide I

Cat. No.: HY-N0201

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Atractylenolide II

(Asterolide) Cat. No.: HY-N0202

Atractylenolide II is a sesquiterpene compound isolated from the dried rhizome of Atractylodes macrocephala (Baizhu in Chinese); anti-proliferative activity.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Atractylenolide III

(ICodonolactone; 8β-Hydroxyasterolide) Cat. No.: HY-N0203

Atractylenolide III is a major component of Atractylodes rhizome can induce apoptosis of the lung carcinoma cells.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Atrasentan

(ABT-627; (+)-A 127722; A-147627) Cat. No.: HY-15403

Atrasentan is an **endothelin receptor** antagonist with IC_{50} of 0.0551 nM for ET_A.



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg

Atrasentan hydrochloride (ABT-627 (hydrochloride); (+)-A 127722 (hydrochloride); A-147627 (hydrochloride))

Cat. No.: HY-15403A

Atrasentan (hydrochloride) is an **endothelin receptor** antagonist with IC_{50} of 0.0551 nM for ET_A.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Atrimustine

(Bestrabucil; KM2210) Cat. No.: HY-101604

Atrimustine is a conjugate of chlorambucil and β-estradiol benzoate with the antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Atuveciclib

(BAY-1143572) Cat. No.: HY-12871B

Atuveciclib (BAY-1143572) is a potent and highly selective, oral **PTEFb/CDK9** inhibitor. Atuveciclib (BAY-1143572) inhibits **CDK9/CycT1** with an IC_{50} of 13 nM.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Atuveciclib Racemate

(BAY-1143572 Racemate) Cat. No.: HY-12871

Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral **P-TEFb/CDK9** inhibitor which supresses **CDK9/CycT1** with an IC_{50} of 13 nM.



Purity: 98.48%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Atuveciclib S-Enantiomer

(BAY-1143572 S-Enantiomer) Cat. No.: HY-12871C

Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective **CDK9** inhibitor, which inhibits **CDK9/CycT1** with an IC_{50} of 16 nM.



Purity: 97.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AU1235

Cat. No.: HY-101867

AU1235 is an **adamantyl urea** inhibitor of **Mycobacterium tuberculosis**.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Auristatin E

Cat. No.: HY-15582

Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Auristatin F

Cat. No.: HY-15583

Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates.



Purity: 97.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Aurora A inhibitor I

Cat. No.: HY-70061

Aurora A inhibitor I is a potent and highly selective **Aurora A** inhibitor with with an **IC_{50}** of 3.4 nM.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Aurora B inhibitor 1

Cat. No.: HY-U00304

Aurora B inhibitor 1 is an **Aurora B** (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a **K_i** value of <0.010 uM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Aurora inhibitor 1

Cat. No.: HY-111506

Aurora inhibitor 1 is a potent **Aurora** inhibitor with an **IC_{50}** of ≤ 4 nM and ≤13 nM for **Aurora A** and **Aurora B** kinase, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Aurothioglucose

(Gold thioglucose)

Cat. No.: HY-A0068

Aurothioglucose (Gold thioglucose) is a well known active-site inhibitor of TrxR1, inhibited TrxR1 activity in HeLa cell cytosol but had no effect on the viability of the cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AUT1

Cat. No.: HY-117639

AUT1 is a **Kv3 potassium channel** modulator, with **pEC_{50}**s of 5.33 and 5.31 for human recombinant Kv3.1b and Kv3.2a, respectively, exhibits 10-fold lower potency at human recombinant Kv3.3 channel (**pEC_{50}**, 4.5).



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Autogramin-1

Cat. No.: HY-128339

Autogramin-1 potently inhibits **autophagy** induced by either starvation (IC_{50}=0.17 μM) or mTORC1 inhibition (Rapamycin; IC_{50}=0.44 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Autogramin-2

Cat. No.: HY-128340

Autogramin-2 potently inhibits **autophagy** induced by either starvation (IC_{50}=0.27 μM) or mTORC1 inhibition (Rapamycin; IC_{50}=0.14 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Autophinib

Cat. No.: HY-101920

Autophinib is a potent **autophagy** inhibitor, which can inhibit autophagy induced by starvation or rapamycin by targeting the lipid kinase VPS34 with **IC_{50}**s of 90, 40 and 19 nM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

AUZ 454

(K03861)

Cat. No.: HY-15004

AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

AV-412
(MP412) Cat. No.: HY-10346

AV-412 (MP412) is an **EGFR** inhibitor with **IC_{50}**s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$, $EGFR^{L858R/T790M}$ and ErbB2, respectively.



Purity: 99.26%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AV-412 free base
(MP-412 free base) Cat. No.: HY-10346A

AV-412 free base (MP-412 free base) is an **EGFR** inhibitor with **IC_{50}**s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$, $EGFR^{L858R/T790M}$ and ErbB2, respectively.



Purity: 98.49%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Avadomide
(CC 122) Cat. No.: HY-100507

Avadomide (CC122) is a novel agent for DLBCL with antitumor and immunomodulatory activity. Avadomide (CC122) binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL.



Purity: 99.53%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Avagacestat
(BMS-708163) Cat. No.: HY-50845

Avagacestat (BMS-708163) is a potent inhibitor of **γ-secretase**, with **IC_{50}**s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with **IC_{50}** of 0.84 nM and shows weak inhibition of CYP2C19, with IC_{50} of...



Purity: 99.93%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Avapritinib
(BLU-285) Cat. No.: HY-101561

Avapritinib is a potent and selective exon 17 mutant **KIT kinase** inhibitor with **IC_{50}** of 0.27 nM for **KIT D816V**.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Avasimibe
(CI-1011; PD-148515) Cat. No.: HY-13215

Avasimibe is an oral inhibitor of **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** with **IC_{50}**s of 24 and 9.2 μM for ACAT1 and ACAT2, respectively.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Avelumab (Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C)
Cat. No.: HY-108730

Avelumab is a fully human IgG1 anti-**PD-L1** monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

Avelumab

Purity: >99.0%
Clinical Data: Launched
Size: 1 mg, 5 mg, 20 mg

Aviptadil (Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine))
Cat. No.: HY-P0012

Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction.

HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH_2

Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Avitinib maleate
Cat. No.: HY-19816A

Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (**EGFR**) inhibitor with an **IC_{50}** of 7.68 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AVN-944
(VX-944) Cat. No.: HY-13560

AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AX-15836

Cat. No.: HY-101846

AX-15836 is a potent and selective **ERK5** inhibitor with an IC_{50} of 8 nM.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Axitinib

(AG-013736)

Cat. No.: HY-10065

Axitinib is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 0.1, 0.2, 0.1-0.3, 1.6 nM for **VEGFR1**, **VEGFR2**, **VEGFR3** and **PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

AZ 628

Cat. No.: HY-11004

AZ 628 is a **pan-Raf** kinase inhibitor with IC_{50}s of 105, 34 and 29 nM for **B-Raf**, **B-RafV600E**, and **c-Raf-1**, respectively.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AZ PFKFB3 26

Cat. No.: HY-101971

AZ PFKFB3 26 is a potent and selective inhibitor of the metabolic kinase **PFKFB3** with an IC_{50} of 23 nM. AZ PFKFB3 26 inhibits PFKFB1 and PFKFB2 with IC_{50}s of 2.06 and 0.384 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AZ-23

(AZ23; AZ 23)

Cat. No.: HY-15590

AZ-23 is an ATP-competitive and orally bioavailable **Trk kinase A/B/C** inhibitor with IC_{50}s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ-3

Cat. No.: HY-112442

AZ-3 is a potent and selective **JAK1** inhibitor with an IC_{50} of 34 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AZ-5104

Cat. No.: HY-B0793

AZ-5104 is an active, demethylated metabolite of AZD 9291. AZ-5104 is an **EGFR** inhibitor with IC_{50}s of 1, 6, 1, 25 and 7 nM for $EGFR^{L858R/T790M}$, $EGFR^{L858R}$, $EGFR^{L861Q}$, EGFR and ErbB4, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AZ1495

Cat. No.: HY-111101

AZ1495 (compound 28) is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 **(IRAK4)**, with IC_{50} values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Shows activity in treatment of mutant $MYD88^{L265P}$ diffuse large B-cell lymphoma (DLBCL).



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ191

Cat. No.: HY-12277

AZ191 is a potent inhibitor that selectively inhibits **DYRK1B** with IC_{50} of 17 nM.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ20

Cat. No.: HY-15557

AZ20 is a potent and selective inhibitor of **ATR** with an IC_{50} of 5 nM, and has 8-fold selectivity against **mTOR** (IC_{50}=38 nM).



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ304

Cat. No.: HY-117273

AZ304 is an ATP-competitive dual **BRAF** kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC_{50}s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC_{50}, 6 nM), CSF1R (IC_{50}, 35 nM).



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ3146

Cat. No.: HY-14710

AZ3146 is a reasonably potent and selective **Mps1** inhibitor with IC_{50} of 35 nM for $Mps1^{Cat}$.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

AZ32

Cat. No.: HY-112305

AZ32 is an orally bioavailable and blood-brain barrier-penetrating **ATM** inhibitor with an IC_{50} of <6.2 nM for ATM enzyme, and an IC_{50} of 0.31 μM for ATM in cell.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ505

Cat. No.: HY-15226

AZ505 is a potent and selective **SMYD2** inhibitor with IC_{50} of 0.12 μM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ505 ditrifluoroacetate

Cat. No.: HY-15226A

AZ505 ditrifluoroacetate is a potent and selective **SMYD2** inhibitor with IC_{50} of 0.12 μM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ6102

Cat. No.: HY-12975

AZ6102 is a potent dual **TNKS1** and **TNKS2** inhibitor, with IC_{50}s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC_{50}s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ7550

Cat. No.: HY-B0794

AZ7550 is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg

AZ7550 hydrochloride

Cat. No.: HY-B0794A

AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AZ7550 Mesylate

(AZ7550 trimesylate salt)

Cat. No.: HY-B0794B

AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AZ82

Cat. No.: HY-12241

AZ82 is a selective **kinesin-like protein KIFC1 (HSET/KIFC1)** inhibitor, with a K_i of 43 nM and an IC_{50} of 300 nM for KIFC1.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

AZ876

Cat. No.: HY-18282

AZ876 is a novel high-affinity LXR agonist.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

AZ960

Cat. No.: HY-10411

AZ960 is a potent and specific inhibitor of the **JAK2** kinase with a K_i of 0.45 nM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 2 mg, 5 mg, 10 mg, 50 mg

Azaserine

(CI-337; O-Diazoacetyl-L-serine; P-165)

Cat. No.: HY-B0919

Azazerine (CI-337) is a competitive inhibitor of glutamine amidotransferase, a key enzyme responsible for glutamine metabolism.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

AZD 6482

(KIN 193)

Cat. No.: HY-10344

AZD 6482 is a potent and selective **p110β** inhibitor with IC_{50} of 0.69 nM.

Purity: 99.26%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZD-0364

Cat. No.: HY-111483

AZD-0364 is a potent and selective **ERK2** inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC_{50} of 0.6 nM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AZD-1480

Cat. No.: HY-10193

AZD-1480 is an ATP-competitive inhibitor of **JAK1** and **JAK2** with IC_{50}s of 1.3 and <0.4nM, respectively.



Purity: 99.37%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AZD-2461

Cat. No.: HY-13536

AZD-2461 is a potent **PARP** inhibitor, with IC_{50}s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.



Purity: 98.39%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD-3463

(ALK/IGF1R inhibitor)

Cat. No.: HY-15609

AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib. IC50 Value: Target: ALK/IGF1R.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD-5069

Cat. No.: HY-19855

AZD-5069 is a potent **CXCR2 chemokine receptor** antagonist, used for caner treatment.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD-5438

Cat. No.: HY-10012

AZD-5438 is a potent inhibitor of **CDK1/2/9** with IC_{50} of 16 nM/6 nM/20 nM in cell-free assays. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6.



Purity: 99.84%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

AZD-5991

Cat. No.: HY-101533

AZD-5991 is a potent and selective **Mcl-1** inhibitor with an IC_{50} of 0.7 nM in FRET assay and a K_d of 0.17 nM in surface plasmon resonance (SPR) assay.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZD-5991 Racemate

Cat. No.: HY-101533A

AZD-5991 Racemate is the racemate of AZD-5991. AZD-5991 Racemate is a **Mcl-1** inhibitor with an IC_{50} of <3 nM in FRET assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AZD-5991 S-enantiomer

Cat. No.: HY-101533B

AZD-5991 S-enantiomer is the less active enantiomer of AZD-5991. AZD-5991 S-enantiomer is a **Mcl-1** inhibitor with an IC_{50} of 6.3 μM in FRET assay and a K_d of 0.98 μM in surface plasmon resonance (SPR) assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AZD-7648

Cat. No.: HY-111783

AZD-7648 is a potent and selective **DNA-PK** inhibitor. Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AZD-7762

Cat. No.: HY-10992

AZD-7762 is a potent ATP-competitive checkpoint kinase (**Chk**) inhibitor in with an IC_{50} of 5 nM for Chk1.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD-8055

Cat. No.: HY-10422

AZD-8055 is a novel ATP-competitive inhibitor of **mTOR** kinase with an IC_{50} of 0.8 nM. AZD-8055 inhibits both **mTORC1** and **mTORC2**.



Purity: 98.60%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

AZD-8835

Cat. No.: HY-12869

AZD8835 is a potent and selective inhibitor of **PI3Kα** and **PI3Kδ** with IC_{50}s of 6.2 and 5.7 nM, respectively.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD0156

Cat. No.: HY-100016

AZD0156 is an oral, potent and selective **ATM** inhibitor with an IC_{50} of 0.58 nM.



Purity: 99.82%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD1152

(Barasertib)

Cat. No.: HY-10127

AZD1152 is a pro-drug of Barasertib-hQPA, which is a highly selective **Aurora B** inhibitor with IC_{50} of 0.37 nM in a cell-free assay.



Purity: 98.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZD1208

Cat. No.: HY-15604

AZD1208 is a novel, orally bioavailable, highly selective **PIM** kinases inhibitor.



Purity: 99.67%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AZD1390

Cat. No.: HY-109566

AZD1390 is an **ATM** inhibitor.



Purity: 99.81%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

AZD2932

Cat. No.: HY-18179

AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with IC_{50}s of 8, 4, 7 and 9 nM in cell assay, respectively.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD3229

Cat. No.: HY-112802

AZD3229 is a potent pan-**KIT** mutant inhibitor for the treatment of gastrointestinal stromal tumors.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD3229 Tosylate

Cat. No.: HY-112802A

AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD3514

Cat. No.: HY-16079

AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression.



Purity: 98.77%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD3759

Cat. No.: HY-18750

AZD3759 is a potent, oral active, central nervous system-penetrant, **EGFR** inhibitor. At K_m ATP concentrations, the IC_{50}s are 0.3, 0.2, and 0.2 nM for $EGFR^{wt}$, $EGFR^{L858R}$, and $EGFR^{exon\ 19Del}$, respectively.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD3839 free base

Cat. No.: HY-13438

AZD3839 (free base) is a potent and selective BACE1 inhibitor with IC50 of 23.6 uM, about 14-fold selectivity over BACE2, also a β-secretase enzyme inhibitor.



Purity: 99.99%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AZD3965

Cat. No.: HY-12750

AZD3965 is a selective **MCT1** inhibitor with a K_i of 1.6 nM, showing 6-fold selectivity over MCT2.



Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD4320

Cat. No.: HY-112416

AZD4320 is a novel BH3-mimicking dual **BCL2/BCLxL** inhibitor with IC_{50}s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

AZD4547

Cat. No.: HY-13330

AZD4547 is a potent inhibitor of the **FGFR** family with IC_{50}s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 99.80%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AZD4573

Cat. No.: HY-112088

AZD4573 is a **CDK9** inhibitor with an IC_{50} of <3 nM extracted from patent US 20160376287 A1, example 14.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD4635

(HTL1071)

Cat. No.: HY-101980

AZD4635 is a novel **adenosine 2A receptor** (**A2AR**) inhibitor with a K_i of 1.7 nM.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD5153 6-Hydroxy-2-naphthoic acid

(AZD-5153 HNT salt)

Cat. No.: HY-100653A

AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available **BET/BRD4** bromodomain inhibitor; disrupts BRD4 with an IC_{50} of 1.7 nM.



Purity: 98.05%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD5582

Cat. No.: HY-12600

AZD5582 is an antagonist of the inhibitor of **apoptosis proteins (IAPs)**, which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC_{50}s of 15, 21, and 15 nM respectively.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZD7507

Cat. No.: HY-117244

AZD7507 is a potent and orally active **CSF-1R** inhibitor, with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD8186

Cat. No.: HY-12330

AZD8186 is a **PI3K** inhibitor, which potently inhibits PI3Kβ (IC_{50}=4 nM) and PI3Kδ ($IC50_{50}$=12 nM) with selectivity over PI3Kα (IC_{50}=35 nM) and PI3Kγ (IC_{50}=675 nM).



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD8330

(ARRY-424704; ARRY-704)

Cat. No.: HY-12058

AZD8330 (ARRY-424704) is a potent, uncompetitive **MEK1/MEK2** inhibitor, with an IC_{50} of 7 nM.



Purity: 98.75%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD9496

Cat. No.: HY-12870

AZD9496 is a potent and selective estrogen receptor (**ERα**) antagonist with an IC_{50} of 0.28 nM.



Purity: 99.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD9496 maleate

Cat. No.: HY-12870A

AZD9496 maleate is a potent and selective estrogen receptor (**ERα**)antagonist with IC_{50} of 0.28 nM.



Purity: >95.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Azetidine-2-carboxylic acid

Cat. No.: HY-75308

Azetidine-2-carboxylic acid is a non proteinogenic amino acid homologue of proline. Found in common beets. Azetidine-2-carboxylic acid can be misincorporated into proteins in place of proline in many species, including humans. Toxic and teratogenic agent.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

AZM475271

(M475271) Cat. No.: HY-13561

AZM475271 is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Azoxymethane

(AOM) Cat. No.: HY-111375

Azoxymethane is a colon carcinogen which leads to the formation of DNA adducts.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

B I09

Cat. No.: HY-107400

B I09 is an **IRE-1** RNase inhibitor, with an IC_{50} of 1230 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

b-AP15

(NSC 687852) Cat. No.: HY-13989

b-AP15 is a specific inhibitor of the **deubiquitinating** enzymes **UCHL5** and **Usp14**.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

B-Raf IN 1

Cat. No.: HY-18227

B-Raf IN 1 is a potent and selective **B-Raf** kinase inhibitor with an IC_{50} of 24 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

B-Raf inhibitor 1

Cat. No.: HY-14177

B-Raf inhibitor 1 is a potent **Raf** kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for $B\text{-}Raf^{WT}$, $B\text{-}Raf^{V600E}$, and C-Raf, respectively.



Purity: 97.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

B-Raf inhibitor 1 dihydrochloride

Cat. No.: HY-14177A

B-Raf inhibitor 1 dihydrochloride is a potent **Raf** kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for $B\text{-}Raf^{WT}$, $B\text{-}Raf^{V600E}$, and C-Raf, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

B220

Cat. No.: HY-100272

B220 is an antiviral agent which can inhibit the growth of **HSV-1**, **HSV-2** and **human cytomegalovirus** (**CMV**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bafetinib

(INNO-406; NS-187) Cat. No.: HY-50868

Bafetinib is a **Lyn and Bcr-Abl** tyrosine kinase inhibitor with potential antineoplastic activity.



Purity: 99.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bafilomycin A1

((-)-Bafilomycin A1) Cat. No.: HY-100558

Bafilomycin A1, a macrolide antibiotic isolated from the Streptomyces species, is a specific inhibitor of **vacuolar-type H+ ATPase (V-ATPase)**. Bafilomycin A1 inhibits **autophagy**.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 µg

BAI1

Cat. No.: HY-103269

BAI1 is a direct allosteric inhibitor of **BAX**.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Baicalein

(5,6,7-Trihydroxyflavone)

Cat. No.: HY-N0196

Baicalein (5,6,7-Trihydroxyflavone) is a **xanthine oxidase** inhibitor with an IC_{50} value of 3.12 mM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Bak BH3

Cat. No.: HY-P0300

Bak BH3 is derived from the BH3 domain of Bak, can antagonize the function of **Bcl-xL** in cells.

GQVGRQLAIIGDDINR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bakuchiol

((S)-(+)-Bakuchiol)

Cat. No.: HY-N0235

Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L; has anti-tumor effects.



Purity: 99.25%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Balamapimod

(MKI 833)

Cat. No.: HY-14947

Balamapimod (MKI 833) is a reversible **Ras/Raf/MEK** inhibitor with potential anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BAM7

Cat. No.: HY-15341

BAM7 is a direct and selective activator of proapoptotic **BAX** with an IC_{50} of 3.3 μM.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

BAMB-4

(ITPKA-IN-C14)

Cat. No.: HY-16694

BAMB-4(ITPKA-IN-C14) is a new membrane-permeable inhibitor against inositol-1,4,5-trisphosphate-3-kinase A((ITPKA) with IC50 of 37 uM in ADP-Glo Assay.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Banoxantrone D12

(AQ4N D12)

Cat. No.: HY-13562S

Banoxantrone D12 (AQ4N D12) is the deuterium labeled banoxantrone. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent **topoisomerase II** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Banoxantrone D12 dihydrochloride

(AQ4N D12 dihydrochloride)

Cat. No.: HY-13562AS

Banoxantrone D12 dihydrochloride (AQ4N D12 dihydrochloride) is the deuterium labeled banoxantrone dihydrochloride. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent **topoisomerase II** inhibitor.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Banoxantrone dihydrochloride

(AQ4N dihydrochloride)

Cat. No.: HY-13562A

Banoxantrone dihydrochloride is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent **topoisomerase II** inhibitor.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Baohuoside I

(Icariin-II; Icariside-II) Cat. No.: HY-N0011

Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of **CXCR4**, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Barasertib-HQPA

(AZD2811; INH-34; AZD1152-HQPA) Cat. No.: HY-10126

Barasertib-HQPA (AZD2811) is a highly selective **Aurora B** inhibitor with an IC_{50} of 0.37 nM in a cell-free assay, and shows 3700-fold selectivity for Aurora B over Aurora A.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bardoxolone

(CDDO; RTA 401) Cat. No.: HY-14909

Bardoxolone is a novel nuclear regulator factor (**Nrf-2**) activator.



Purity: 99.14%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bardoxolone methyl

(NSC 713200; RTA 402; CDDO Methyl ester) Cat. No.: HY-13324

Bardoxolone methyl (NSC 713200; RTA 402; CDDO Methyl ester) is a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities, acting as an activator of the **Nrf2** pathway and an inhibitor of the **NF-κB** pathway.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Batimastat

(BB94) Cat. No.: HY-13564

Batimastat is a potent broad spectrum **MMP** inhibitor with IC_{50} of 3, 4, 4, 6, and 20 nM for **MMP-1**, **MMP-2**, **MMP-9**, **MMP-7** and **MMP-3**, respectively.



Purity: 95.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Batimastat sodium salt

(BB-94 sodium salt) Cat. No.: HY-13564A

Batimastat sodium salt is a potent broad spectrum **MMP** inhibitor with IC_{50} of 3, 4, 4, 6, and 20 nM for **MMP-1**, **MMP-2**, **MMP-9**, **MMP-7** and **MMP-3**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bavachalcone

(Broussochalcone B) Cat. No.: HY-N0231

Bavachalcone is a major bioactive compounds isolated from Psoralea corylifolia L.; has been widely used as traditional Chinese medicine; antibiotic or anticancer agent.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Bavachin

(Corylifolin) Cat. No.: HY-N0233

Bavachin, a flavonoid first isolated from seeds of P. corylifolia, acts as a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC_{50}s of 320 and 680 nM, respectively.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Bax activator-1

Cat. No.: HY-122760

Bax activator-1 (compound 106) is a **Bax** activator that induces Bax-dependent tumor cell apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Bax inhibitor peptide V5

(BIP-V5; BAX Inhibiting Peptide V5) Cat. No.: HY-P0081

Bax inhibitor peptide V5 is a **Bax**-mediated apoptosis inhibitor, used for cancer treatment.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

BAY 11-7082

(BAY 11-7821) Cat. No.: HY-13453

BAY 11-7082 is a **NF-κB** inhibitor which decreases NF-κB by inhibiting TNF-α-induced phosphorylation of IκB-α. BAY 11-7082 inhibits ubiquitin-specific protease **USP7** and **USP21** with IC_{50}s of 0.19 μM and 0.96 μM, respectively.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY 11-7085

(BAY 11-7083) Cat. No.: HY-10257

BAY 11-7085 is an inhibitor of **NF-κB** activation and phosphorylation of **IκBα**; it stabilizes IκBα with an IC_{50} of 10 μM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bay 59-3074

Cat. No.: HY-100488

Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively . Orally active CB1 agonist in vivo.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY 87-2243

Cat. No.: HY-15836

BAY 87-2243 is a highly potent and selective hypoxia-inducible factor-1 (**HIF-1**) inhibitor.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY-1436032

Cat. No.: HY-100020

BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (**IDH1**) inhibitor.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-1816032

Cat. No.: HY-103020

BAY-1816032 is a potent and oral available **BUB1 (budding uninhibited by benzimidazoles 1) kinase** inhibitor with an IC_{50} of 7 nM.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-1895344

Cat. No.: HY-101566

BAY-1895344 is a potent, orally available and selective **ATR** inhibitor, with IC_{50} of 7 nM. Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-1895344 hydrochloride

Cat. No.: HY-101566A

BAY-1895344 hydrochloride is a potent, orally available and selective **ATR** inhibitor, with IC_{50} of 7 nM. Anti-tumor activity.



Purity: 99.04%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-2402234

Cat. No.: HY-112645

BAY-2402234 is a selective dihydroorotate dehydrogenase **(DHODH)** inhibitor for the treatment of myeloid malignancies.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-293

Cat. No.: HY-114398

BAY-293 is a potent **SOS1** inhibitors that block **RAS** activation via disruption of the **RAS-SOS1** interaction with an IC_{50} of 21 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY-299

Cat. No.: HY-107424

BAY-299 is a very potent, dual inhibitor with IC_{50}s of 67 nM for **BRPF2 bromodomains (BD)**, 8 nM for **TAF1 BD2**, and 106 nM for **TAF1L BD2**.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-320

Cat. No.: HY-104000

BAY-320 is a **Bub1** inhibitor, with an IC_{50} of 680 nM for human Bub1 in the presence of 2 mM ATP.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BAY-524

Cat. No.: HY-104001

BAY-524 is a **Bub1** inhibitor, with an IC_{50} of 450 nM for human Bub1 in the presence of 2 mM ATP.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BAY-598

Cat. No.: HY-19546

BAY-598 is selective small molecule inhibitor of **SMYD2** .



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-8002

Cat. No.: HY-122312

BAY-8002 is a potent, selective, orally active inhibitor of **monocarboxylate transporter 1 (MCT1)**, with an IC_{50} of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4. Anti-tumor activity.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY-876

Cat. No.: HY-100017

BAY-876 is an oral and selective **GLUT1** inhibitor with an IC_{50} of 2 nM. BAY-876 shows good metabolic stability in vitro and high oral bioavailability in vivo.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BAY1125976

Cat. No.: HY-100018

BAY1125976 is a selective allosteric **Akt1/Akt2** inhibitor; inhibits Akt1 and Akt2 activity with IC_{50} values of 5.2 nM and 18 nM at 10 μM ATP, respectively.



Purity: 99.63%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BAY1217389

Cat. No.: HY-12859

BAY 1217389 is a potent, and selective inhibitor of the monopolar spindle 1 (**MPS1**) kinase with an IC_{50} value less than 10 nM.



Purity: 99.94%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

BAY1238097

Cat. No.: HY-112316

BAY1238097 is a potent and selective inhibitor of **BET binding to histones** and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC_{50} <100 nM).



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY885

Cat. No.: HY-112082

BAY885 is a novel **ERK5** inhibitor.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bazedoxifene

(TSE-424) Cat. No.: HY-A0031

Bazedoxifene (TSE-424) is a selective estrogen receptor modulator (SERM) currently in development for osteoporosis prevention and treatment.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg

Bazedoxifene acetate

(TSE-424 (acetate)) Cat. No.: HY-A0036

Bazedoxifene acetate is a third generation **selective estrogen receptor modulator (SERM)** with IC_{50}s of 26 and 99 nM for ERα and ERβ, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BBT594

(NVP-BBT594) Cat. No.: HY-18840

BBT594 is a potent **receptor tyrosine kinase RET inhibitor**, used for cancer treatment.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BCI-121

Cat. No.: HY-21972

BCI-121 is a **SMYD3** inhibitor that impairs the proliferation of cancer cell.



Purity: 97.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BCMA72-80

Cat. No.: HY-P1700

BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.

YLMFLLRKI

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCR-ABL-IN-1

Cat. No.: HY-100314

BCR-ABL-IN-1 is an inhibitor of **BCR-ABL** tyrosine kinase, with a pIC_{50} of 6.46, and may be used in the research of chronic myelogenous leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BCR-ABL-IN-2

Cat. No.: HY-18819

BCR-ABL-IN-2 is an inhibitor of **BCR-ABL1** tyrosine kinase, with IC_{50}s of 57 nM, 773 nm for $ABL1^{native}$ and $ABL1^{T315I}$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BCRP-IN-1

Cat. No.: HY-100390

BCRP-IN-1 is a breast cancer resistance protein (**BCRP**) inhibitor with an IC_{50} of 0.6 μM on BCRP efflux transporter.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BCTC

Cat. No.: HY-19960

BCTC is a potent and specific inhibitor of transient receptor potential cation channel subfamily M member 8 (TRPM8) in prostate cancer (PCa) DU145 cells.



Purity: 97.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BDP5290

Cat. No.: HY-12437

BDP5290 is a potent inhibitor of both **ROCK** and **MRCK** with IC_{50}s of 5 nM, 50 nM, 10 nM and 100 nM for **ROCK1**, **ROCK2**, **MRCKα** and **MRCKβ**, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BDP9066

Cat. No.: HY-111424

BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinases **MRCK** inhibitor with an IC_{50} of 64 nM for MRCKβ in SCC12 cells, K_i values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Beaucage reagent

Cat. No.: HY-100951

Beaucage reagent is found to be potent in causing DNA cleavage.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 1 g

BEBT-908

(PI3Kα inhibitor 1)

Cat. No.: HY-19763

BEBT-908 is a selective **PI3Kα** inhibitor extracted from patent US/20120088764A1, Compound 243, has an IC_{50}<0.1 μM, PI3Kα inhibitor 1 also inhibits HDAC (0.1 μM≤IC_{50}≤1 μM) .



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BEC hydrochloride

Cat. No.: HY-19548A

BEC hydrochloride is a slow-binding and competitive Arginase II inhibitor with Ki of 0.31 μM (ph 7.5). target: Arginase II ; In vitro: BEC hydrochloride causes significant enhancement of NO-dependent smooth muscle relaxation in this tissue.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Belinostat

(PXD101; PX105684)

Cat. No.: HY-10225

Belinostat is a potent **HDAC** inhibitor with an IC_{50} of 27 nM in HeLa cell extracts.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Belizatinib

(TSR-011)

Cat. No.: HY-17603

Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC_{50} of 0.7nM for wild-type recombinant ALK kinase.



Purity: 99.32%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Belotecan hydrochloride

(CKD-602)

Cat. No.: HY-13566A

Belotecan hydrochloride (CKD-602 hydrochloride), a **Topoisomerase I** inhibitor, is a synthetic and water-soluble camptothecin derivative.



Purity: 98.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Belvarafenib

Cat. No.: HY-109080

Belvarafenib is a potent and pan **RAF** (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC_{50}s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF^{V600E} and C-RAF respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Belvarafenib TFA

Cat. No.: HY-109080A

Belvarafenib (TFA) is a potent and pan **RAF** (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC_{50}s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF^{V600E} and C-RAF respectively.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Bemcentinib

(R428; BGB324)

Cat. No.: HY-15150

Bemcentinib (R428) is a potent and selective inhibitor of **Axl** with an IC_{50} of 14 nM.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bendamustine hydrochloride

(SDX-105; EP-3101) Cat. No.: HY-B0077

Bendamustine hydrochloride is a **DNA cross-linking** agent that causes DNA breaks, with alkylating and antimetabolite properties.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 100 mg, 200 mg, 500 mg

Benin

(Butocin; Butocine) Cat. No.: HY-U00073

Benin is a potent cytostatic drug that can be used for the treatment of generalized carcinoma of the breast.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 10 mg, 20 mg

Bentamapimod

(AS 602801) Cat. No.: HY-14761

Bentamapimod (AS 602801) is an ATP-competitive **JNK** inhibitor with **IC_{50}** of 80 nM, 90 nM, and 230 nM for **JNK1**, **JNK2**, and **JNK3**, respectively.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Benzenebutyric acid

(4-Phenylbutyric acid) Cat. No.: HY-A0281

Benzenebutyric acid is an inhibitor of **HDAC** and endoplasmic reticulum **(ER)** stress, used in cancer and infection research.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 g

Benzo[a]pyrene

(3,4-Benzopyrene) Cat. No.: HY-107377

Benzo[a]pyrene shows **lung carcinogenicity** in animal models, and it is frequently used in chemoprevention studies.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Berbamine dihydrochloride

Cat. No.: HY-N0714A

Berbamine dihydrochloride is an inhibitor of **NF-κB** activity with remarkable anti-myeloma efficacy.



Purity: 95.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg, 500 mg

Berberine chloride

(Natural Yellow 18 (chloride)) Cat. No.: HY-18258

Berberine chloride is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an **antibiotic**. Berberine chloride induces reactive oxygen species (**ROS**) generation and inhibits **DNA topoisomerase**. Antineoplastic properties.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Berberine chloride hydrate

(Natural Yellow 18 (chloride hydrate)) Cat. No.: HY-17577

Berberine chloride hydrate is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an **antibiotic**. Berberine chloride hydrate induces reactive oxygen species (**ROS**) generation and inhibits **DNA topoisomerase**. Antineoplastic properties.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 g

Bergamottin

(5-Geranoxypsoralen; Bergamotine; Bergaptin) Cat. No.: HY-N2194

Bergamottin is a potent and competitive **CYP1A1** inhibitor with a **K_i** of 10.703 nM.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Bergapten

(5-Methoxypsoralen) Cat. No.: HY-N0370

Bergapten is a natural anti-inflammatory and anti-tumor agent isolated from bergamot essential oil, other citrus essential oils and grapefruit juice. Bergapten is inhibitory towards mouse and human **CYP** isoforms.



Purity: 99.96%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 g, 5 g

Bergaptol

(5-Hydroxypsoralen; 4-Hydroxybergapten) Cat. No.: HY-76316

Bergaptol a hydroxylated psoralen that acts as a potent inhibitors of debenzylation activity of CYP3A4 enzyme with an IC50 value of 24.92 uM. Recent studies suggest that it may have antiproliferative and anticancer properties.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Berzosertib

(VE-822; VX-970) Cat. No.: HY-13902

Berzosertib (VE-822) is an **ATR** inhibitor with a K_i value of less than 0.2 nM. It also inhibits **ATM** with a K_i of 34 nM.



Purity: 99.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Bestatin

(Ubenimex) Cat. No.: HY-B0134

Bestatin is a natural, broad-spectrum, and competitive **aminopeptidase** inhibitor.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bestatin hydrochloride

(Ubenimex hydrochloride) Cat. No.: HY-B0134A

Bestatin hydrochloride is an inhibitor of **CD13 (Aminopeptidase N)/APN** and **leukotriene A4 hydrolase**, used for cancer treatment.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Bestatin trifluoroacetate

(Ubenimex trifluoroacetate) Cat. No.: HY-B0134B

Bestatin trifluoroacetate is an inhibitor of **CD13 (Aminopeptidase N)/APN** and **leukotriene A4 hydrolase**, used for cancer treatment.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

BET bromodomain inhibitor

Cat. No.: HY-103036

BET bromodomain inhibitor is a potent **BET** inhibitor extracted from patent WO/2015/153871A2, compound example 11.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BET-BAY 002

Cat. No.: HY-12421

BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BET-IN-2

Cat. No.: HY-102044

BET-IN-2 is a **BET** inhibitor with an IC_{50} of 52 nM for BRD4-BD1.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BET-IN-4

Cat. No.: HY-111916

BET-IN-4 is a potent **BET** bromodomain protein (**BRD4**) inhibitor, with an IC_{50} of ≤ 1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

beta-lactamase-IN-1

Cat. No.: HY-19773

beta-lactamase-IN-1 targets Neisseria gonorrhoeae infection which comprises administering to a subject in need thereof novel Tricyclic nitrogen containing compounds and corresponding pharmaceutical compositions as described herein.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

BETd-246

Cat. No.: HY-115568

BETd-246 is a second-generation **BET bromodomain (BRD)** inhibitor, exhibiting superior selectivity, potency and antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BETd-260

(ZBC 260)

Cat. No.: HY-101519

BETd-260 is a potent **BET** degrader based on **PROTAC** technology, with as low as 30 pM against **BRD4** protein in RS4;11 leukemia cell line.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Betulin

(Trochol)

Cat. No.: HY-N0083

Betulin (Trochol), is a sterol regulatory element-binding protein (**SREBP**) inhibitor with an IC_{50} of 14.5 μM in K562 cell line.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 200 mg

Betulinic acid

(Lupatic acid; Betulic acid)

Cat. No.: HY-10529

Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic **topoisomerase I** inhibitor, with an IC_{50} of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties.



Purity: 98.18%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Bevacizumab

(Anti-Human VEGF, Humanized Antibody)

Cat. No.: HY-P9906

Bevacizumab, a humanized monoclonal antibody, specifically binds to all **VEGF-A** isoforms with high affinity.

Purity: >99.0%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Bexarotene

(LGD1069)

Cat. No.: HY-14171

Bexarotene (LGD1069) is a selective **retinoid X receptors (RXR)** agonist for the treatment of cutaneous T-cell lymphoma.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

BFH772

Cat. No.: HY-100419

BFH772 is a potent oral **VEGFR2** inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC_{50} value of 3 nM.



Purity: 98.03%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BG45

Cat. No.: HY-18712

BG45 is an HDAC class I inhibitor with selectivity for HDAC3 (IC50 = 289 nM). It inhibits HDAC1, HDAC2, and HDAC6 with greatly reduced potency (IC50s = 2, 2.2, and >20 μM, respectively).



Purity: 99.71 %
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BGB-102

(JNJ-26483327)

Cat. No.: HY-15732

BGB-102 is a potent multi-kinase inhibitor against **EGFR**, **HER2**, and **HER4** with IC_{50}s of 9.6 nM, 18 nM and 40.3 nM, respectively.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 20 mg

BGT226

(NVP-BGT226)

Cat. No.: HY-13334A

BGT226 (NVP-BGT226) is a **PI3K** (with IC_{50}s of 4 nM, 63 nM and 38 nM for **PI3Kα**, **PI3Kβ** and **PI3Kγ**)/**mTOR** dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

BGT226 maleate

(NVP-BGT226 (maleate))

Cat. No.: HY-13334

BGT226 maleate (NVP-BGT226 maleate) is a **PI3K** (with IC_{50}s of 4 nM, 63 nM and 38 nM for **PI3Kα**, **PI3Kβ** and **PI3Kγ**) /**mTOR** dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BH3I-1

(BHI1; BH 3I1)

Cat. No.: HY-100383

BH3I-1 is a **Bcl-2 family** antagonist, which inhibits the binding of the **Bak** BH3 peptide to **Bcl-xL** with a K_i of 2.4±0.2 μM in FP assay. BH3I-1 has a K_d of 5.3 μM against the **p53/MDM2** pair.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

BHPI

Cat. No.: HY-12825

BHPI is a potent inhibitor of nuclear estrogen–ERα-regulated gene expression; elicits sustained ERα-dependent activation of the endoplasmic reticulum (ER) stress sensor, the unfolded protein response (UPR), and persistent inhibition of protein synthesis.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BI 2536

Cat. No.: HY-50698

BI 2536 is a dual **PLK1** and **BRD4** inhibitor with IC_{50}s of 0.83 and 25 nM, respectively. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-0252

Cat. No.: HY-100765

BI-0252 is an orally active, selective **MDM2-p53** inhibitor with an IC_{50} of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BI-1347

Cat. No.: HY-120350

BI-1347 is a potent **CDK8** inhibitor extracted from patent WO2017202719A1, product I-003, has an IC_{50} of 1.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-3663

Cat. No.: HY-111546

BI-3663 is a highly selective **PTK2/FAK PROTAC**, with VHL and cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC_{50} of 18 nM. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

BI-3802

Cat. No.: HY-108705

BI-3802 is a highly potent **BCL6** degrader, inhibiting the BTB domain of BCL6, with an IC_{50} of ≤3 nM; BI-3802 has antitumor activity.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-3812

Cat. No.: HY-111381

BI-3812 is potent and efficacious **BCL6** inhibitor, inhibiting the BTB domain of BCL6, with an IC_{50} of ≤3 nM; BI-3812 has antitumor activity.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-4464

Cat. No.: HY-124625

BI-4464 is a highly selective ATP competitive inhibitor of **PTK2/FAK**, with an IC_{50} of 17 nM. A PTK2 ligand for PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-7273

Cat. No.: HY-100351

BI-7273 is a selective, and cell-permeable **BRD9** inhibitor, with an IC_{50} and a K_d of 19 and 0.75 nM; also shows high effect on BRD7, with an IC_{50} and a K_d of 117 nM and 0.3 nM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BI-847325

Cat. No.: HY-18955

BI-847325 is an ATP competitive dual inhibitor of **MEK** and aurora kinases (**AK**) with IC_{50} values of 4 and 15 nM for human MEK2 and AK-C, respectively.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-882370

Cat. No.: HY-107779

BI-882370 is a potent and selective **RAF** kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BI-9564

Cat. No.: HY-100352

BI-9564 is a selective, and cell-permeable **BRD9 BD** inhibitor, with K_d of 5.9 nM for BRD9, and IC_{50} of > 100 μM for BET family.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

BI-D1870

Cat. No.: HY-10510

BI-D1870 is an ATP-competitive inhibitor of **RSK** isoforms, with IC_{50}s of 31 nM/24 nM/18 nM/15 nM for RSK1/SK2/SK3/SK4, respectively.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

BI8622

Cat. No.: HY-120929

BI8622 is a specific inhibitor of the ubiquitin ligase **HUWE1** with an IC_{50} of 3.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BI8626

Cat. No.: HY-120204

BI8626 is a specific inhibitor of the ubiquitin ligase **HUWE1** with an IC_{50} of 0.9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BIBF 1202

Cat. No.: HY-15992

BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits **VEGFR2** kinase with an IC_{50} of 62 nM.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

BIBF0775

Cat. No.: HY-13783

BIBF0775 is a potent and selective **transforming growth factor β (TGFβ) type I receptor (Alk5)** inhibitor with an IC_{50} of 34 nM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BIBR 1532

Cat. No.: HY-17353

BIBR 1532 is a potent, selective and non-competitive **telomerase** inhibitor with IC_{50} of 100 nM in a cell-free assay.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bicalutamide

Cat. No.: HY-14249

Bicalutamide is a non-steroidal **androgen receptor** inhibitor.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

BIIB021

(CNF2024)

Cat. No.: HY-10212

BIIB021 is an orally available, fully synthetic inhibitor of **HSP90** with K_i and EC_{50} of 1.7 nM and 38 nM, respectively.



Purity: 99.93%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Bimiralisib

(PQR309)

Cat. No.: HY-12868

Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I **PI3K/mTOR** inhibitor with IC_{50}s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ**, **PI3Kγ** and **mTOR**, respectively. Bimiralisib is an **mTORC1** and **mTORC2** inhibitor.



Purity: 98.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Binimetinib

(MEK162; ARRY-162; ARRY-438162)

Cat. No.: HY-15202

Binimetinib (MEK162) is an oral and selective **MEK1/2** inhibitor. Binimetinib (MEK162) inhibits **MEK** with an IC_{50} of 12 nM.



Purity: 98.61%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Biotin-BS

Cat. No.: HY-111879

Biotin-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and biotin, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Biotin-VAD-FMK

Cat. No.: HY-100894

Biotin-VAD-FMK is a cell permeable, irreversible biotin-labeled **caspase** inhibitor, used to identify active caspases in cell lysates.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bioymifi

(DR5 Activator)

Cat. No.: HY-18377

Bioymifi(DR5 Activator) is the first novel and potent small-molecule activator of the TRAIL receptor DR5 in human cancer cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Birabresib

(OTX-015; MK-8628)

Cat. No.: HY-15743

Birabresib (OTX-015) is a potent **bromodomain (BRD2/3/4)** inhibitor with IC_{50}s ranging from 92 to 112 nM.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Biricodar

(VX-710)

Cat. No.: HY-13574A

Biricodar (VX-710) is a modulator of **P-glycoprotein** and **MRP-1**; shows effective chemosensitizing activity in multidrug resistant cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Birinapant

(TL32711)

Cat. No.: HY-16591

Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for **XIAP** and **cIAP1** with K_ds of 45 nM and less than 1 nM, respectively.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bis-PEG4-acid

Cat. No.: HY-119429

Bis-PEG4-acid is a PEG **PROTAC linker**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Bisantrene

(CL216942)

Cat. No.: HY-100875

Bisantrene is a highly effective antitumor drug, targets eukaryotic type **II topoisomerases**.



Purity: 95.44%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Bisdemethoxycurcumin

(Curcumin III; Didemethoxycurcumin)

Cat. No.: HY-N0007

Bisdemethoxycurcumin(Curcumin III; Didemethoxycurcumin) is a natural derivative of curcumin with anti-inflammatory and anti-cancer activities.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bithionol

Cat. No.: HY-17592

Bithionol is a clinically approved anti-parasitic drug; has been shown to inhibit solid tumor growth in several preclinical cancer models.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Bithionol sulfoxide

Cat. No.: HY-17592A

Bithionol sulfoxide(Bitin-S) is a clinically approved anti-parasitic drug; has been shown to inhibit solid tumor growth in several preclinical cancer models.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

BIX-01338 hydrate

(BIX01338 hydrate; BIX 01338 hydrate)

Cat. No.: HY-12991A

BIX-01338 hydrate is a **histone lysine methyltransferase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BIX02188

Cat. No.: HY-12055

BIX02188 is a potent **MEK5**-selective inhibitor with an IC_{50} of 4.3 nM. BIX02188 inhibits **ERK5** catalytic activity, with an IC_{50} of 810 nM.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BIX02189

Cat. No.: HY-12056

BIX02189 is a potent and selective **MEK5** inhibitor with an IC_{50} of 1.5 nM. BIX02189 also inhibits **ERK5** catalytic activity with an IC_{50} of 59 nM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bleomycin sulfate

Cat. No.: HY-17565

Bleomycin sulfate is a **DNA synthesis** inhibitor with potent antitumor activity.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

BLM-IN-1

Cat. No.: HY-111756

BLM-IN-1 (compound 29) is an effective **Bloom syndrome protein (BLM)** inhibitor, with a strong BLM binding K_D of 1.81 μM and an IC_{50} of 0.95 μM for BLM. Induces DNA damage response, as well as apoptosis and proliferation arrest in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BLU9931

Cat. No.: HY-12823

BLU9931 is a potent, selective, and irreversible **FGFR4** inhibitor with an IC_{50} of 3 nM.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BLZ945

Cat. No.: HY-12768

BLZ945 is a potent, selective and brain-penetrant **CSF-1R** inhibitor with an IC_{50} of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.



Purity: 99.56%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BM 957

Cat. No.: HY-18106

BM 957 is a potent Bcl-2 and Bcl-xL inhibitor, with K_i**s** of 1.2, <1 nM and IC_{50}**s** of 5.4, 6.0 nM respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BMf-BH3

Cat. No.: HY-P1733

BMf-BH3 belongs to the Bcl-2 apoptosis mediator family. BH3-only protein, Bmf is a key molecule for histone deacetylase (HDAC) inhibitors mediated enhancing effect on ionizing radiation-induced cell death.

LQHRAEVQIARKLQCIADQFHRLHT

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMH-21

Cat. No.: HY-12484

BMH-21 is a small molecule DNA intercalator that binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription; does not cause phosphorylation of H2AX.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

BML-190

(Indomethacin morpholinylamide; IMMA)

Cat. No.: HY-15420

BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

BML-210

Cat. No.: HY-19350

BML-210 is a novel HDAC inhibitor, and its mechanism of action has not been characterized.



Purity: 96.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BML-277

(Chk2 Inhibitor II)

Cat. No.: HY-13946

BML-277 is a selective checkpoint kinase 2 (**Chk2**) inhibitor with an IC_{50} of 15 nM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

BML-284

Cat. No.: HY-19987

BML-284 is selective and cell-permeable **Wnt** signaling activator.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

BMS 777607

(BMS 817378)

Cat. No.: HY-12076

BMS 777607 is a **Met-related** inhibitor for **c-Met**, **Axl**, **Ron** and **Tyro3** with IC_{50}s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all...



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-1

(PD-1/PD-L1 inhibitor 1)

Cat. No.: HY-19991

BMS-1 is an inhibitor of the **PD-1/PD-L1** protein/protein interaction (IC_{50} between 6 and 100 nM).



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-202

Cat. No.: HY-19745

BMS-202 is an inhibitor of the **PD-1/PD-L1** protein/protein interaction with an **IC_{50}** of 18 nM.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-214662

Cat. No.: HY-16111

BMS-214662 is a potent and selective **farnesyl transferase** inhibitor with potent antitumor activity with an **IC_{50}** of 1.35 nM.



Purity: 99.69%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-265246

Cat. No.: HY-15275

BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.



Purity: 97.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-3

Cat. No.: HY-18304

BMS-3 is a potent **LIMK** inhibitor with **IC_{50}**s of 5 nM and 6 nM for **LIMK1** and **LIMK2**, respectively.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-345541 free base

Cat. No.: HY-10519

BMS-345541 free base is a selective inhibitor of the catalytic subunits of **IKK** (**IKK-2 IC_{50}**=0.3 μM, **IKK-1 IC_{50}**=4 μM). BMS-345541 binds at an allosteric site of IKK.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 50 mg

BMS-345541 hydrochloride

Cat. No.: HY-10518

BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of **IKK** (**IKK-2 IC_{50}**=0.3 μM, **IKK-1 IC_{50}**=4 μM). BMS-345541 binds at an allosteric site of IKK.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BMS-5

(LIMKi 3)

Cat. No.: HY-18305

BMS-5 (LIMKi 3) is a potent **LIMK** inhibitor with **IC_{50}**s of 7 nM and 8 nM for **LIMK1** and **LIMK2**, respectively.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-536924

Cat. No.: HY-10262

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BMS-599626

(AC480)

Cat. No.: HY-10251

AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc.



Purity: >98%
Clinical Data: Phase 1
Size: 10 mg, 50 mg

BMS-599626 Hydrochloride

(AC480 (Hydrochloride))

Cat. No.: HY-12010

BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc.



Purity: 99.82%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 50 mg, 100 mg

BMS-690514

Cat. No.: HY-10333

BMS-690514 is a potent and orally active inhibitor of **EGFR** and **VEGFR**; has IC_{50}s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.



Purity: 99.37%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

BMS-754807

Cat. No.: HY-10200

BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor **(IGF-1R)**/insulin receptor family kinases **(IR)** with IC_{50} of 1.8 and 1.7 nM, respectively and K_i of <2 nM for both, and also shows potent activities against Met, RON, TrkA, TrkB, AurA,...



Purity: 99.18%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-794833

Cat. No.: HY-10497

BMS-794833 is a **VEGFR2** and **Met** inhibitor extracted from patent WO2009094417, compound example 1; has IC_{50}s of 15 and 1.7 nM, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-833923

(XL-139)

Cat. No.: HY-13809

BMS-833923 (XL-139) is an orally bioavailable small-molecule inhibitor of Smoothened with potential antineoplastic activity; inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM.



Purity: 96.57%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

BMS-906024

Cat. No.: HY-15670

BMS-906024 is an oral and selective **gamma secretase** inhibitor (GSI) that is a small molecule **Notch** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

BMS-911543

Cat. No.: HY-15270

BMS-911543 is a selective **JAK2** inhibitor, with IC_{50}s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC_{50}, 75, 360, 66 nM, respectively).



Purity: 98.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-983970

Cat. No.: HY-12419

BMS-983970 is an oral pan-Notch inhibitor for the treatment of cancer.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-986020

(AM152)

Cat. No.: HY-100619

BMS-986020 is an LPA1 antagonist. target: LPA1
BMS-986020 is in Phase 2 clinical development for treating idiopathic pulmonary fibrosis.



Purity: 99.53%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-986158

Cat. No.: HY-101567

BMS-986158 is an inhibitor of the bromodomain and extra-terminal (**BET**) proteins.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-986195

Cat. No.: HY-112161

BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton's tyrosine kinase **(BTK)**, with an IC_{50} of <1 nM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

BMX-IN-1

(BMX kinase inhibitor)

Cat. No.: HY-80002

BMX-IN-1 is a selective, irreversible inhibitor of **bone marrow tyrosine kinase on chromosome X (BMX)** that targets Cys^{496} in the BMX ATP binding domain with an IC_{50} of 8 nM, also targets the related Bruton's tyrosine kinase **(BTK)** with an IC_{50} value of 10.4 nM, but is more...



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BN82002

Cat. No.: HY-112776

BN82002 is a synthetic inhibitor of **CDC25** phophatases, with IC_{50}**s** of 2.4-6.3 μM for recombinant CDC25 phosphatases.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BNC105

Cat. No.: HY-16114

BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bobcat339 hydrochloride

Cat. No.: HY-111558A

Bobcat339 hydrochloride is a cytosine-based **TET enzyme** inhibitor with IC_{50} of 33 μM (**TET1**) and 73 μM (**TET2**). It is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BOC-D-FMK

Cat. No.: HY-13229

Boc-D-FMK is a cell-permeable, irreversible and broad spectrum **caspase** inhibitor; inhibits apoptosis stimulated by TNF-α with an IC_{50} of 39 μM.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Bortezomib (PS-341; Brotezamide; DPBA; LDP 341; MG 341; Radiciol; NSC 681239)

Cat. No.: HY-10227

Bortezomib (PS-341) is a cell-permeable, reversible, and selective **proteasome** inhibitor, and potently inhibits **20S proteasome** (K_i=0.6 nM) by targeting a threonine residue. Bortezomib (PS-341) disrupts the cell cycle, induces apoptosis, and inhibits **NF-κB**.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Borussertib

Cat. No.: HY-122913

Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase **Akt**, with an IC_{50} of 0.8 nM and a K_i of 2.2 nM for Akt^{wt}.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BOS-172722

Cat. No.: HY-112162

BOS-172722 is an inhibitor of monopolar spindle 1 **(MPS1)** checkpoint with an IC_{50} of 2 nM.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bosutinib

(SKI-606)

Cat. No.: HY-10158

Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

BP-1-102

Cat. No.: HY-100493

BP-1-102 is an orally available, small-molecule inhibitor of transcription factor **Stat3**, with an IC_{50} of 6.8 μM.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BPK-29

Cat. No.: HY-122054

BPK-29 is a covalent small molecule that disrupts NR0B1 complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

BPR1J-097

Cat. No.: HY-13537

BPR1J-097 is a novel potent **FLT3** inhibitor with an IC_{50} of 11nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BPR1J-097 Hydrochloride

Cat. No.: HY-13537A

BPR1J-097 Hydrochloride is a novel and potent **FLT3** inhibitor with an IC_{50} of 11nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BPR1K871

Cat. No.: HY-100865

BPR1K871 is a potent and selective dual **FLT3/AURKA** inhibitor with IC_{50}s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

BPTES

Cat. No.: HY-12683

BPTES is an allosteric and selective **glutaminase** inhibitor with an IC_{50} of 0.16 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BPTU

(BMS-646786)

Cat. No.: HY-13831

BPTU is a novel **P2Y1** allosteric antagonist.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BQU57

Cat. No.: HY-12875

BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. The IC50 for BQU57 of 2.0 μM in H2122 and 1.3 μM in H358.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BR351

Cat. No.: HY-114396

BR351 is a brain penetrant **MMP** inhibitor with IC_{50}s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BR351 precursor

Cat. No.: HY-43586

BR351 precursor is a precursor of BR351. BR351 is a brain penetrant **MMP** inhibitor with IC_{50}s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BRAF inhibitor

Cat. No.: HY-10247

BRAF inhibitor is a **B-Raf** inhibitor extracted from patent WO/2011103196 A1, Compound P-0850.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Bragsin1

Cat. No.: HY-111549

Bragsin1 is a potent, selective and noncompetitive inhibitor of the **ArfGEF BRAG2**, inhibits Arf GTPase activation, with an IC_{50} of 3 μM. Bragsin1 binds to PH domain of BRAG2, and is a noncompetitive interfacial inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Bragsin2

Cat. No.: HY-111550

Bragsin2 is a potent, selective and noncompetitive nucleotide exchange factor **BRAG2** inhibitor, with an IC_{50} of 3 μM. Bragsin2 binds at the interface between the PH domain of BRAG2 and the lipid bilayer, leads BRAG2 unable to activate lipidated Arf GTPase.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Branaplam

(LMI070; NVS-SM1)

Cat. No.: HY-19620

Branaplam (LMI070) is a highly potent, selective and orally active small molecule **SMN2 splicing** modulator.



Purity: 99.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brassinolide

(Brassin lactone)

Cat. No.: HY-N0273

Brassinolide is a predominant plant growth modulator that regulate plant cell elongation.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

BRCA1-IN-1

Cat. No.: HY-100863

BRCA1-IN-1 is a novel small-molecule-like **BRCA1** inhibitor with IC_{50} and K_i of 0.53 μM and 0.71 μM, respecrively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

BRCA1-IN-2

Cat. No.: HY-100862

BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for **BRCA1** with an IC_{50} of 0.31 μM and a K_d of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 $(BRCT)_2$/protein interactions.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

BRD 4354

Cat. No.: HY-112719

BRD 4354 is a moderately potent inhibitor of **HDAC5** and **HDAC9**, with IC_{50}**s** of 0.85 and 1.88 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BRD 4354 ditrifluoroacetate

Cat. No.: HY-112719B

BRD 4354 (ditrifluoroacetate) is a moderately potent inhibitor of **HDAC5** and **HDAC9**, with IC_{50}**s** of 0.85 and 1.88 μM, respectively.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BRD4 degrader AT1

Cat. No.: HY-111433

BRD4 degrader AT1 is a highly selective **Brd4** degrader based on **PROTAC** technology, with a K_d of 44 nM for $Brd4^{BD2}$ in cells.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BRD4 Inhibitor-10

Cat. No.: HY-117491

BRD4 Inhibitor-10 is a potent **BRD4-BD1** inhibitor extracted from patent WO2015022332A1, Compound II-25, has an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

BRD4770

Cat. No.: HY-16705

BRD4770 is a novel G9a(EHMT2) inhibitor with EC50 of 5 uM (trimethylated H3K9 in PANC-1 cell).



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

BRD7-IN-1

Cat. No.: HY-111905

BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a **PROTAC** VZ185 (VZ185 against BRD7/9 with DC_{50}s of 4.5 and 1.8 nM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BRD7-IN-1 free base

Cat. No.: HY-111905A

BRD7-IN-1 free base, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a **PROTAC** VZ185 (VZ185 against BRD7/9 with DC_{50}s of 4.5 and 1.8 nM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD73954

Cat. No.: HY-18700

BRD73954 ia a potent and selective HDAC inhibitor with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BRD9539

Cat. No.: HY-15647

BRD9539 inhibits G9a activity with an IC50 of 6.3 μM, inhibits PRC2 activity with a similar IC50.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Brefeldin A

(BFA; Cyanein; Decumbin)

Cat. No.: HY-16592

Brefeldin A is a specific inhibitor of **protein trafficking** which blocks the protein transport from the endoplasmic reticulum to the Golgi complex.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brequinar

(DUP785; NSC 368390)

Cat. No.: HY-108325

Brequinar (DUP785) is a potent inhibitor of **dihydroorotate dehydrogenase**, with potent activities against a broad spectrum of viruses.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Brevilin A

Cat. No.: HY-N2959

Brevilin A is a sesquiterpene lactone isolated from Centipeda minima with anti-tumor activity. Brevilin A is a selective inhibitor of **JAK-STAT** signal pathway by attenuating the JAKs activity and blocking STAT3 signaling (IC_{50} = 10.6 μM) in Cancer Cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Briciclib

(ON 014185)

Cat. No.: HY-16366

Briciclib is a water soluble derivative of ON 013100, and has the potential in targeting **eIF4E** for solid cancers.



Purity: 99.58%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Brigatinib

(AP-26113) Cat. No.: HY-12857

Brigatinib is a highly potent and selective **ALK** inhibitor, with an **IC_{50}** of 0.6 nM.



Purity: 99.98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Brilanestrant

(ARN-810; GDC-0810) Cat. No.: HY-12864

Brilanestrant (ARN-810) is an orally bioavailable **selective estrogen receptor degrader (SERD)** with **IC_{50}** of 0.7 nM.



Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brivanib

(BMS-540215) Cat. No.: HY-10337

Brivanib is an ATP-competitive inhibitor against **VEGFR2** with **IC_{50}** of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brivanib alaninate

(BMS-582664) Cat. No.: HY-10336

Brivanib alaninate is an ATP-competitive inhibitor against **VEGFR2** with an **IC_{50}** of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BRM/BRG1 ATP Inhibitor-1

Cat. No.: HY-119374

BRM/BRG1 ATP Inhibitor-1 is an allosteric dual **brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2)** and **brahma related gene 1 (BRG1)/SMARCA4** ATPase activity inhibitor, both **IC_{50}**s are below 0.005 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Bromosporine

Cat. No.: HY-15815

Bromosporine is a broad spectrum inhibitor for bromodomains with IC50 of 0.41 μM, 0.29 μM, 0.122 μM and 0.017 μM for BRD2, BRD4, BRD9 and CECR2, respectively.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Bruceantin

((-)-Bruceantin; NCI165563; NSC165563) Cat. No.: HY-N0840

Bruceantin(NSC165563) is first isolated from Brucea antidysenterica, a tree used in Ethiopia for the treatment of cancer, and activity was observed against B16 melanoma, colon 38, and L1210 and P388 leukemia in mice.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Brusatol

(NSC 172924; (+)-Brusatol) Cat. No.: HY-19543

Brusatol (NSC 172924), isolated from the Brucea javanica plant, inhibits **Nrf2**.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

BS-181

Cat. No.: HY-13266

BS-181 is a highly selective **CDK7** inhibitor with an **IC_{50}** of 21 nM, showing 40-fold selective over CDK1, 2, 4, 5, 6, or 9.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BS-181 hydrochloride

Cat. No.: HY-13266A

BS-181 hydrochloride is a highly selective **CDK7** inhibitor with **IC_{50}** of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

BSc5371

Cat. No.: HY-111545

BSc5371 is a potent and irreversible **FLT3** inhibitor, with K_ds of 1.3, 0.83, 1.5, 5.8 and 2.3 nM for mutant FLT3(D835H), FLT3(ITD, D835V), FLT3(ITD, F691L), FLT3-ITD and wild type FLT3wt, respectively. BSc5371 is cytotoxic to FLT3-dependent cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

BSJ-03-123

Cat. No.: HY-111556

BSJ-03-123 is a potent and novel **CDK6**-selective small-molecule degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BTB-1

Cat. No.: HY-101770

BTB-1 is a potent, selective and reversible mitotic motor protein **Kif18A** inhibitor with an IC_{50} of 1.69 μM.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BTB06584

Cat. No.: HY-15877

BTB06584 is an IF1-dependent selective inhibitor of the mitochondrial F1Fo-ATPase. Target: ATPase in vitro: BTB06584 inhibits F1Fo-ATPase activity with no effect on ΔΨm or O2 consumption.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BTK IN-1

Cat. No.: HY-101941

BTK IN-1 is a potent **BTK** inhibitor, with an IC_{50} of <100 nM.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Btk inhibitor 1

Cat. No.: HY-13036

Btk inhibitor 1 is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor. IC50 value: Target: Btk From PCT Int. Appl. (2012), WO 2012158843 A2 20121122.



Purity: 97.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Btk inhibitor 1 hydrochloride

Cat. No.: HY-13036C

Btk inhibitor 1 Hcl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Btk inhibitor 1 R enantiomer

Cat. No.: HY-13036A

Btk inhibitor 1 R enantiomer is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor. IC50 value: Target: Btk From PCT Int. Appl. (2012), WO 2012158843 A2 20121122.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Btk inhibitor 1 R enantiomer hydrochloride

Cat. No.: HY-13036B

Btk inhibitor 1R enantiomer Hcl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BTR-1

Cat. No.: HY-111617

BTR-1 is an active anti-cancer agent, causes S phase arrest, and affects DNA replication in leukemic cells. BTR-1 activates **apoptosis** and induces cell death.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BTS

(N-Benzyl-p-toluenesulfonamide; N-Tosylbenzylamine)

Cat. No.: HY-16690

BTS is a potent inhibitor of Ca2+-stimulated myosin S1 ATPase (IC50 ~ 5 μM) and reversibly blocks the gliding motility.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

BTZ043

Cat. No.: HY-13579

BTZ043 is an inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), with MICs of of 2.3 nM and 9.2 nM for M. tuberculosis H37Rv and Mycobacterium smegmatis, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bufalin

Cat. No.: HY-N0877

Bufalin is an active component isolated from Chan Su, acts as a potent **Na^+/K^+-ATPase** inhibitor, binds to the subunit α1, α2 and α3, with K_d of 42.5, 45 and 40 nM, respectively. Anti-cancer activity.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Bufotalin

Cat. No.: HY-N0878

Bufotalin is a cardiotoxic bufanolide steroid, cardiac glycoside analogue, secreted by a number of toad species; a novel anti-osteoblastoma agent. IC50 value: Target: in vitro: bufotalin induced osteoblastoma cell death and apoptosis in dose- and time-dependent manners.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Buparlisib

(NVP-BKM120; BKM120)

Cat. No.: HY-70063

Buparlisib (NVP-BKM120) is a pan-class I **PI3K** inhibitor, with IC_{50}s of 52, 166, 116 and 262 nM for **p110α**, **p110β**, **p110δ** and **p110γ**, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Buparlisib Hydrochloride

(BKM120 (Hydrochloride); NVP-BKM120 (Hydrochloride))

Cat. No.: HY-15180

Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I **PI3K** inhibitor, with IC_{50} of 52 nM/166 nM/116 nM/262 nM for **p110α/p110β/p110δ/p110γ**, respectively.



Purity: 98.01%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Buserelin Acetate

Cat. No.: HY-13581A

Buserelin (INN) Acetate is a gonadotropin-releasing hormone agonist (GnRH agonist).



Purity: 99.98%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Busulfan

Cat. No.: HY-B0245

Busulfan is a potent **alkylator** with selective immunosuppressive effect on bone marrow.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g

Butein

(2′,3,4,4′-tetrahydroxy Chalcone)

Cat. No.: HY-16558

Butein, a plant polyphenol isolated from Rhus verniciflua, inhibit the activation of protein tyrosine kinase and EGFR. target: EGFR In vitro: 1) Butein inhibited the activation of AKT, extracellular signal-regulated kinase (ERKs) and p38 kinases in the presence of cisplatin.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BV6

Cat. No.: HY-16701

BV6 is an antagonist of **cIAP1** and **XIAP**, members of the inhibitors of apoptosis (IAP) family.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BVT948

Cat. No.: HY-100625

BVT948 is a **protein tyrosine phosphatase** (**PTP**) inhibitor which can also inhibit several **cytochrome P450** (**P450**) isoforms and lysine methyltransferase **SETD8** (**KMT5A**).



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

BX-912

Cat. No.: HY-11005

BX-912 is a potent **PDK1** inhibitors with an IC_{50} of 12 nM.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 50 mg, 100 mg

BX517

Cat. No.: HY-13842

BX517 is a potent and selective inhibitor of **PDK1** with IC_{50} of 6 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BX795

Cat. No.: HY-10514

BX795 is a potent and selective dual inhibitor of **TBK1/PDK1** with IC_{50}s of 6 nM/6 nM, respectively, and has >50 fold selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

BzNH-BS

Cat. No.: HY-111878

BzNH-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and benzoyl-amide, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

c(phg-isoD-G-R-(NMe)k)

Cat. No.: HY-111413

c(phg-isoD-G-R-(NMe)k) is a selective **α5β1 integrin** ligand with an IC_{50} of 2.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

C-11

Cat. No.: HY-100861

C-11 is a tubulysin-based **antibody–drug conjugates (ADCs)**, displays cytotoxicity for carcinoma cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

c-Fms-IN-7

Cat. No.: HY-111948

c-Fms-IN-7 is a **cFMS** inhibitor extracted from patent WO2011079076A1, example159, has an IC_{50} of 18.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

c-Fms-IN-9

Cat. No.: HY-128680

c-Fms-IN-9 is a **c-FMS** inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (**uFMS**) and **uKIT** with IC_{50}s of <0.01 μM and 0.1-1 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

c-Kit-IN-1

Cat. No.: HY-15240

c-Kit-IN-1 is a potent inhibitor of **c-Kit** and **c-Met** with IC_{50}s of <200 nM.



Purity: 98.46%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

c-Kit-IN-2

Cat. No.: HY-128602

c-Kit-IN-2 is a **c-KIT** inhibitor with an IC_{50} of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI_{50}s of 3, 1, and 2 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

c-Met inhibitor 1

Cat. No.: HY-15735

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

c-met-IN-1

Cat. No.: HY-101031

c-met-IN-1 (compound 16) is a potent and selective **c-Met** inhibitor, with IC_{50} of 1.1 nM, with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

c-Met-IN-2

Cat. No.: HY-101773

c-Met-IN-2 is a potent, selective and orally available **c-Met** inhibitor, with an IC_{50} of 0.6 nM, with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

c-Myc Peptide Trifluoroacetate

Cat. No.: HY-P0312

c-Myc Peptide Trifluoroacetate is a synthetic peptide corresponding to the C-terminal amino acids (410-419) of human c-myc protein, and participates in regulation of growth-related gene transcription.

EQKLISEEDL



Purity: 98.18%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

C-Phycocyanin

(C-PC)

Cat. No.: HY-D1025

C-phycocyanin (C-PC) is a water-soluble protein pigment which is also widely used as an excellent nutrient supplement for human beings.

C-Phycocyanin

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

C188-9

Cat. No.: HY-112288

C188-9 is a **Stat3** inhibitor, with a K_d of 4.7 nM.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C527

Cat. No.: HY-12988

C527 is a is a pan **DUB enzyme** inhibitor, with a high potency for the **USP1/UAF1** complex (IC_{50}=0.88 μM).



Purity: 98.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C646

Cat. No.: HY-13823

C646 is a selective and competitive **histone acetyltransferase p300** inhibitor with K_i of 400 nM, and is less potent for other acetyltransferases.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

C75

Cat. No.: HY-12364

C75 is a synthetic fatty-acid synthase (**FASN**) inhibitor; inhibits prostate cancer cells PC3 with an IC_{50} of 35 μM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

C75 trans

((±)-C75) Cat. No.: HY-12364A

C75 trans is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (**FASN**) inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CA-074

Cat. No.: HY-103350

CA-074 is a potent inhibitor of **cathepsin B** with a K_i of 2 to 5 nM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

CA-4948

Cat. No.: HY-109585

CA-4948 is a selective and potent **IRAK4** inhibitor.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

CA-5f

Cat. No.: HY-112698

CA-5f is a potent late-stage **macroautophagy/autophagy** inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein both in A549 cells and HUVECs. Anti-tumor activity.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cabazitaxel

(XRP6258; RPR-116258A; taxoid XRP6258) Cat. No.: HY-15459

Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cabozantinib

(XL184; BMS-907351) Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cabozantinib S-malate

(XL184 (S-malate); BMS-907351 (S-malate)) Cat. No.: HY-12044

Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

CaCCinh-A01

Cat. No.: HY-100611

CaCCinh-A01 is an inhibitor of both **TMEM16A** and **calcium-activated chloride channel** (**CaCC**) with IC_{50}s of 2.1 and 10 μM, respectively.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CADD522

Cat. No.: HY-107999

CADD522 is a potent inhibitor of runt-related transcription factor-2 (**RUNX2**)-**DNA** binding with an IC_{50} of 10 nM. CADD522 exhibits antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Caffeic acid phenethyl ester

Cat. No.: HY-N0274

Caffeic acid phenethyl ester is a **NF-κB** inhibitor.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 100 mg

CAL-130

Cat. No.: HY-16122A

CAL-130 is a **PI3Kδ** and **PI3Kγ** inhibitor with IC_{50}s of 1.3 and 6.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CAL-130 Hydrochloride

Cat. No.: HY-16122B

CAL-130 is a **PI3Kδ** and **PI3Kγ** inhibitor with IC_{50}s of 1.3 and 6.1 nM, respectively.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CAL-130 Racemate

Cat. No.: HY-16122

CAL-130 Racemate is the racemate of CAL-130.
CAL-130 Racemate is a **PI3Kδ** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Calcein-AM

(Calcein acetoxymethyl ester)

Cat. No.: HY-D0041

Calcein-AM is cell-permeable fluorescent dye used to determine the cell viability.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 100 μg

Calcimycin

(A23187)

Cat. No.: HY-N6687

Calcimycin (A23187) is an antibiotic and a unique divalent cation ionophore (like calcium and magnesium). It induces Ca^{2+}-dependent cell death by increasing intracellular calcium concentration. Calcimycin inhibits the growth of Gram-positive bacteria and some fungi.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Calcitonin salmon

(Salmon calcitonin)

Cat. No.: HY-P0090

Calcitonin salmon, a calcium regulating hormone, is a dual-action **amylin** and **calcitonin receptor** agonist, could stimulate bone formation and inhibit bone resorption.

Purity: 98.09%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Calcitriol

(1,25-Dihydroxyvitamin D3)

Cat. No.: HY-10002

Calcitriol is the most active metabolite of vitamin D and also a **vitamin D receptor** (**VDR**) agonist.



Purity: 99.81%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Calcium N5-methyltetrahydrofolate

(NSC173328)

Cat. No.: HY-17557

Calcium N5-methyltetrahydrofolate(NSC173328) is the calcium salt of levomefolic acid, which has been proposed for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Calf thymus DNA

(DNA from calf thymus, Thymonucleic acid)

Cat. No.: HY-109517

Calf thymus DNA is high quality double-stranded template DNA isolated from the thymus of male and female calves.

Calf thymus DNA

Purity: >98%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Calicheamicin

(Calicheamicin γ1)

Cat. No.: HY-19609

Calicheamicin is a cytotoxic agent that causes double-strand DNA breaks.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Calmidazolium chloride

(R 24571) Cat. No.: HY-103319

Calmidazolium chloride (R 24571) is a **calmodulin (CaMK)** antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC_{50}s of 0.15 and 0.35 μM, respectively.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Calycosin

(Cyclosin) Cat. No.: HY-N0519

Calycosin (Cyclosin) is a natural active compound with anti-oxidative and anti-inflammation activity.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Calyculin A

((-)-Calyculin A) Cat. No.: HY-18983

Calyculin A is a potent and cell-permeable protein phosphatase 1 (**PP1**) and protein phosphatase 2A (**PP2A**) inhibitor with IC_{50}s of 2 nM and 0.5-1 nM.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 0.5 mM * 50 μL , 0.5 mM * 200 μL , 0.5 mM * 20 μL ,

Cambinol

Cat. No.: HY-100732

Cambinol is a **SIRT1** and **SIRT2** inhibitor with IC_{50} values of 56 and 59 μM, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Campathecin

(Camptothecin; (S)-(+)-Camptothecin; CPT) Cat. No.: HY-16560

Campathecin is a potent DNA enzyme **topoisomerase I** inhibitor, with an IC_{50} of 679 nM.



Purity: 98.26%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Campesterol

((24R)-5-Ergosten-3β-ol) Cat. No.: HY-N1459

Campesterol is a plant sterol with cholesterol lowering and anticarcinogenic effects.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg

Camphor

((±)-Camphor) Cat. No.: HY-N0808

Camphor ((±)-Camphor) is a topical anti-infective and anti-pruritic and internally as a stimulant and carminative. However, Camphor is poisonous when ingested. Antiviral, antitussive, and anticancer activities. Camphor is a **TRPV3** agonist.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Cancer-Targeting Compound 1

Cat. No.: HY-U00300

Cancer-Targeting Compound 1 is used in the research of hormone-related cancer, extracted from patent WO 2008021331 A2.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Canertinib

(CI-1033; PD-183805) Cat. No.: HY-10367

Canertinib (CI-1033;PD-183805) is a potent and irreversible **EGFR** inhibitor; inhibits cellular **EGFR** and **ErbB2** autophosphorylation with IC_{50}s of 7.4 and 9 nM.



Purity: 99.10%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Canertinib dihydrochloride

(CI-1033 dihydrochloride; PD-183805 dihydrochloride) Cat. No.: HY-10367A

Canertinib dihydrochloride (CI-1033;PD-183805) is a potent and irreversible **EGFR** inhibitor; inhibits cellular **EGFR** and **ErbB2** autophosphorylation with IC_{50}s of 7.4 and 9 nM.



Purity: 98.51%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Canthaxanthin

(E 161g; all-trans-Canthaxanthin)

Cat. No.: HY-B1960

Canthaxanthin is a red-orange carotenoid with various biological activities, such as antioxidant, antitumor properties.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Capecitabine

Cat. No.: HY-B0016

Capecitabine is an oral prodrug that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g

Capivasertib

(AZD5363)

Cat. No.: HY-15431

Capivasertib (AZD5363) is a potent **pan-AKT** kinase inhibitor with IC_{50} of 3, 7 and 7 nM for **Akt1**,**Akt2** and **Akt3**, respectively.



Purity: 99.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Capmatinib

(INCB28060; INC-280)

Cat. No.: HY-13404

Capmatinib (INCB28060) is a potent and selective **c-MET** kinase inhibitor. Capmatinib (INCB28060) inhibits c-MET kinase activity with an average IC_{50} of 0.13 nM.



Purity: 99.84%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Capsaicin

((E)-Capsaicin; 8-Methyl-N-vanillyl-trans-6-nonenamide)

Cat. No.: HY-10448

Capsaicin is a **TRPV1** agonist with an EC_{50} of 0.29 μM in HEK293 cells.



Purity: 98.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Capsazepine

Cat. No.: HY-15640

Capsazepine is a synthetic analogue of the sensory neurone excitotoxin, and an antagonist of **TRPV1 receptor** with an IC_{50} of 562 nM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Capzimin

Cat. No.: HY-110404

Capzimin is a potent and moderately specific proteasome isopeptidase **Rpn11** inhibitor.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Carboplatin

(NSC 241240)

Cat. No.: HY-17393

Carboplatin (NSC 241240) is a **DNA synthesis** inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.



Purity: 99.93%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Carboxyamidotriazole

(L 651582; CAI)

Cat. No.: HY-16126

Carboxyamidotriazole (L 651582) is a blocker of non-voltage dependent **calcium channel**. Carboxyamidotriazole (L 651582) is a non-cytotoxic anti-tumor drug, which also shows anti-inflammatory activity.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Carboxypeptidase G2 (CPG2) Inhibitor

(CPG2 Inhibitor)

Cat. No.: HY-70003

Carboxypeptidase G2 (CPG2) Inhibitor is a novel Carboxypeptidase G2 (CPG2) Inhibitor, Antitumor agents.



Purity: 97.53%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Carcinoembryonic Antigen CEA

Cat. No.: HY-P0277

Carcinoembryonic Antigen (CEA) is a tumor marker in lung cancer.

YLSGANLNL

Purity: 98.55%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Carfilzomib

(PR-171)

Cat. No.: HY-10455

Carfilzomib is an irreversible **proteasome** inhibitor with an **IC_{50}** of 5 nM in ANBL-6 and RPMI 8226 cells.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Carglumic Acid

(N-Carbamyl-L-glutamic acid)

Cat. No.: HY-B0711

Carglumic acid (N-Carbamyl-L-glutamic acid), a functional analogue of N-acetylglutamate (NAG) and a **carbamoyl phosphate synthetase 1** (**CPS1**) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g

CARM1-IN-1

Cat. No.: HY-12759

CARM1-IN-1 is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CARM1-IN-1 hydrochloride

Cat. No.: HY-12759A

CARM1-IN-1 hydrochloride is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Carmofur

(HCFU)

Cat. No.: HY-B0182

Carmofur is a derivative of fluorouracil, an antimetabolite used as an antineoplastic agent.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Carmustine

Cat. No.: HY-13585

Carmustine is an antitumor chemotherapeutic agent, which works by **akylating DNA and RNA**.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Carnosic acid

Cat. No.: HY-N0644

Carnosic acid has demonstrated inhibition of oxidative stress and inflammation, suppression of cell proliferation, and antibacterial activity.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Carnosol

Cat. No.: HY-N0643

Carnosol is a potent Ribosomal S6 Kinase **(RSK2)** inhibitor that could be useful for treating gastric cancer, with an **IC_{50}** of ~5.5 μM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

CASIN

Cat. No.: HY-12874

CASIN is a selective GTPase Cdc42 inhibitor with IC50 of 2 uM.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Castanospermine

Cat. No.: HY-N2022

Castanospermine inhibits all forms of α- and β-glucosidases, especially glucosidase I (required for glucoprotein processing by transfer of mannose and glucose from asparagine-linked lipids). targetα- and β-glucosidases.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Catechin

((+)-Catechin; Cianidanol; Catechuic acid)

Cat. No.: HY-N0898

Catechin inhibits cyclooxygenase-1 (**COX-1**) with an IC_{50} of 1.4 μM.



Purity: >99.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cathepsin Inhibitor 2

Cat. No.: HY-U00377

Cathepsin Inhibitor 2 is a potent **Cathepsin S** inhibitor extracted from patent WO2009123623A1, has a K_i of <20 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CAY10471 Racemate

(TM30089 Racemate)

Cat. No.: HY-13706

CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective **prostaglandin D2 receptor CRTH2** antagonist, with a K_i of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (K_i, >10000 nM) or PGD2 receptor DP (K_i, 1200 nM).



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

CAY10505

Cat. No.: HY-13530

CAY10505 is a potent and selective **PI3Kγ** inhibitor with an IC_{50} of 30 nM in neurons.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

CAY10566

Cat. No.: HY-15823

CAY10566 is a **stearoyl-CoA desaturase1** (**SCD1**) inhibitor.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

CAY10603

(BML-281)

Cat. No.: HY-18613

CAY10603 (BML-281) is a potent and selective **HDAC6** inhibitor, with an IC_{50} of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC_{50}s of 271, 252, 0.42, 6851, 90.7 nM.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CB 300919

Cat. No.: HY-14375

CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC_{50} value of 2 nM in human CH1 ovarian tumor xenograft.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CB-1158

(INCB01158)

Cat. No.: HY-101979

CB-1158 is a potent and orally bioavailable inhibitor of **arginase**, with IC_{50}s of 86 and 296 nM for recombinant human arginase 1 and 2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

CB-1158 dihydrochloride

(INCB01158 (dihydrochloride))

Cat. No.: HY-101979A

CB-1158 dihydrochloride (INCB01158 dihydrochloride) is a potent and orally bioavailable inhibitor of **arginase**, with IC_{50}s of 86 and 296 nM for recombinant human arginase 1 and 2, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

CB-5083

Cat. No.: HY-12861

CB-5083 is a potent, selective and orally bioavailable **p97** inhibitor with an IC_{50} value of 11 nM.



Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CB-6644

Cat. No.: HY-114429

CB-6644 is a selective inhibitor of **RUVBL1/2** complex with anti-cancer activity. CB-6644 blocks the ATPase activity of RUVBL1/2 with an IC_{50} of 15 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CB30865

(ZM 242421)

Cat. No.: HY-14373

CB30865(ZM 242421) is a potent inhibitor of Nampt , an enzyme present in the NAD biosynthetic pathway.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CBB1003

Cat. No.: HY-15774

CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CBB1003 hydrochloride

Cat. No.: HY-15774A

CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CBB1007

Cat. No.: HY-15313

CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CBB1007 hydrochloride

Cat. No.: HY-15313B

CBB1007 Hcl is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CBB1007 trihydrochloride

Cat. No.: HY-15313C

CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).



Purity: 96.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CBL0137 hydrochloride

(Curaxin-137 hydrochloride; CBL-C137 hydrochloride)

Cat. No.: HY-18935A

CBL0137 hydrochloride is an inhibitor of the histone chaperone, **FACT**. CBL0137 hydrochloride can also activate **p53** and inhibits **NF-κB** with EC_{50}s of 0.37 and 0.47 μM, respectively.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

CBP-IN-1

Cat. No.: HY-111784

CBP-IN-1 is a potent **p300/CBP** bromodomain inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CBP/EP300-IN-1

Cat. No.: HY-111420

CBP/EP300-IN-1 is a **CBP/EP300** bromodomain inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CBR-5884

Cat. No.: HY-100012

CBR-5884 is an active, selective inhibitor of **phosphoglycerate dehydrogenase (PHGDH)** with an IC_{50} of 33 μM. CBR-5884 inhibits de novo **serine synthesis** in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CBS9106

(SL-801)

Cat. No.: HY-108716

CBS9106 (SL-801) is a reversible oral **CRM1** inhibitor with CRM1 degrading and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CC-115

Cat. No.: HY-16962

CC-115 is a potent and dual **DNA-PK** and **mTOR** kinase inhibitor with IC_{50}s of 13 nM and 21 nM, respectively. CC-115 blocks both **mTORC1** and **mTORC2** signaling.



Purity: 96.64%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CC-115 hydrochloride

Cat. No.: HY-16962A

CC-115 hydrochloride is a potent and dual **DNA-PK** and **mTOR** kinase inhibitor with IC_{50}s of 13 nM and 21 nM, respectively. CC-115 blocks both **mTORC1** and **mTORC2** signaling.



Purity: 97.22%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CC-223

Cat. No.: HY-16956

CC-223 is a potent inhibitor of **mTOR** kinase, with an IC_{50} value for mTOR kinase of 16 nM. CC-223 inhibits both **mTORC1** and **mTORC2**.



Purity: 99.43%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CC-401

Cat. No.: HY-13022A

CC-401 is a potent inhibitor of all three forms of **JNK** with K_i of 25 to 50 nM.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg

CC-401 hydrochloride

(CC401 HCl)

Cat. No.: HY-13022

CC-401 hydrochloride is a potent inhibitor of all three forms of **JNK** with K_i of 25 to 50 nM.



Purity: 99.96%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CC-671

Cat. No.: HY-108709

CC-671 is a dual **TTK protein kinase/CDC2-like kinase** (**CLK2**) inhibitor with IC_{50}s of 0.005 and 0.006 μM for TTK and CLK2, respectively.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CC-885

Cat. No.: HY-101488

CC-885 is a cereblon (**CRBN**) modulator with potent anti-tumour activity.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CC-90003

Cat. No.: HY-112570

CC-90003 is an irreversible and selective inhibitor of **ERK 1/2** with antitumor activity.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CC0651

Cat. No.: HY-15301

CC0651 is an allosteric inhibitor of the human **Cdc34 ubiquitin-conjugating enzyme**. CC0651 potently (IC_{50}=1.72 μM) inhibits the ubiquitination of $p27^{Kip1}$, as confirmed by dose-response analysis.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

CCB02

Cat. No.: HY-114302

CCB02 is a selective **CPAP-tubulin interaction** inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC_{50} of 689 nM, and shows potent anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CCCP (Carbonyl cyanide 3-chlorophenylhydrazone; Carbonyl Cyanide m-Chlorophenylhydrazone)

Cat. No.: HY-100941

CCCP is an oxidative phosphorylation uncoupler.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

CCF642

Cat. No.: HY-100430

CCF642 is a novel PDI-inhibiting compound with antimyeloma activity. The IC50 is 2.9 μmol/L. In vitro: CCF642 inhibit PDI reductase activity about 100-fold more potently than the structurally distinct established inhibitors PACMA 31 and LOC14.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCG-1423

Cat. No.: HY-13991

CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

CCG-63802

Cat. No.: HY-70074

CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CCG-63808

Cat. No.: HY-70075

CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins.



Purity: 97.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

CCG215022

Cat. No.: HY-18991

CCG215022 is a G protein-coupled receptor kinases (**GRK**s) inhibitor with IC_{50}s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for **GRK2**, **GRK5** and **GRK1**, respectively.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CCI-006

Cat. No.: HY-114410

CCI-006 is a selective inhibitor and chemosensitizer of MLL-rearranged leukemia cells, by inhibits mitochondrial respiration resulting in insurmountable mitochondrial depolarization and a pro-apoptotic unfolded protein response (UPR) in a subset of MLL-r leukemia cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CCR6 inhibitor 1

Cat. No.: HY-112701

CCR6 inhibitor 1 is a potent and selective **CCR6** inhibitor, with IC_{50}s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC_{50}, > 30000 nM), and CCR7 (IC_{50}, 9400 nM). CCR6 inhibitor 1 markedly blocks ERK phosphorylation.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCT 137690

Cat. No.: HY-10804

CCT 137690 is a potent and orally available **aurora** kinase inhibitor with IC_{50}s of 15, 25, and 19 nM for aurora A, B and C, respectively.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCT-251921

Cat. No.: HY-19984

CCT-251921 is a potent, selective, and orally bioavailable **CDK8** inhibitor with an IC_{50} of 2.3 nM.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCT007093

Cat. No.: HY-15880

CCT 007093 is an effective PPM1D inhibitor that selectively reduces viability of human tumour cell lines. IC50 value: Target: PPM1D As expected of a specific inhibitor, the toxicity of CCT007093 to PPM1D overexpressing cell lines after inhibitor treatment is P38 dependent .



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CCT020312

Cat. No.: HY-119240

CCT020312 is a selective **EIF2AK3/PERK** activator. CCT020312 elicits EIF2A phosphorylation in cells.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCT128930

Cat. No.: HY-13260

CCT128930 is a potent and selective inhibitor of **Akt2** (IC_{50} 6 nM) with 28-fold selectivity over the closely related PKA kinase (IC_{50} 168 nM), as well as 20-fold selectivity over p70S6K (IC_{50} 120 nM).



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCT129202

Cat. No.: HY-12049

CCT129202 is an **aurora** kinase inhibitor with IC_{50}s of 42, 198, and 227 nM for aurora A, B and C, respectively.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CCT196969

Cat. No.: HY-12846

CCT196969 is a pan-Raf inhibitor, which inhibits **B-Raf**, **BRaf^{V600E}** and **CRAF** with IC_{50}s of 0.1, 0.04, and 0.01 μM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCT241533

Cat. No.: HY-14715

CCT241533 is a potent and selective ATP competitive inhibitor of **CHK2** with an IC_{50} of 3 nM and K_i of 1.16 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CCT241533 hydrochloride

Cat. No.: HY-14715B

CCT241533 hydrochloride is a potent and selective **CHK2** inhibitor with an IC_{50} of 3 nM and a K_i of 1.16 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCT241736

Cat. No.: HY-18161

CCT241736 is a potent and orally bioavailable dual **FLT3** and **Aurora kinase** inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC_{50}, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCT244747

Cat. No.: HY-18175

CCT244747 is a potent, orally bioavailable and highly selective **CHK1** inhibitor, with an IC_{50} of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC_{50} of 29 nM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

CCT245737

Cat. No.: HY-18958

CCT245737 is a orally active and seletive **Chk1** inhibitor, with an IC_{50} of 1.3 nM.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCT251236

Cat. No.: HY-101026

CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC_{50} of 19 nM for inhibition of HSF1-mediated **HSP72** induction.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CCT251455

Cat. No.: HY-12603

CCT251455 is a potent and selective mitotic kinase monopolar spindle 1 (**MPS1**) inhibitor with an IC_{50} of 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CCT251545

Cat. No.: HY-12681

CCT251545 is an orally bioavailable and potent inhibitor of **WNT** signaling with an IC_{50} of 5 nM in 7dF3 cells.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CD437

(AHPN)

Cat. No.: HY-100532

CD437 is a selective **Retinoic Acid Receptor γ (RARγ)** agonist.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CD73-IN-1

Cat. No.: HY-103695

CD73-IN-1 is an inhibitor of **CD73** which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Cdc7-IN-1

Cat. No.: HY-101523

Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of **Cdc7 kinase**, with an IC_{50} value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CDC801

Cat. No.: HY-U00179

CDC801 is a potent and orally active phosphodiesterase 4 (**PDE4**) and tumor necrosis factor-α (**TNF-α**) inhibitor with IC_{50} of 1.1 μM and 2.5 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

CDDO-EA

(CDDO ethyl amide; TP319; RTA 405) Cat. No.: HY-12213

CDDO-EA is an NF-E2 related factor 2/antioxidant response element (**Nrf2/ARE**) activator.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CDDO-Im

(RTA-403; TP-235; CDDO-Imidazolide) Cat. No.: HY-15725

CDDO-Im (CDDO-imidazolide) is an activator of **Nrf2** and **PPAR**, with K_is of 232 and 344 nM for PPARα and PPARγ.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CDK-IN-2

(CDK inhibitor II) Cat. No.: HY-13033

CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM, extracted from reference 1, example 4. IC50 Value: <8 nM Target: CDK9 In vitro: In vivo:.



Purity: 97.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

CDK2

Cat. No.: HY-P0235

CDK2 is a member of the eukaryotic S/T protein kinase family and its function is to catalyze the phosphoryl transfer of ATP γ-phosphate to serine or threonine hydroxyl (denoted as S_0/T_0) in a protein substrate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK2-IN-4

Cat. No.: HY-117535

CDK2-IN-4 is a potent and selective **CDK2** inhibitor with an **IC_{50}** of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (**IC_{50}**=86 uM).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CDK4/6-IN-2

Cat. No.: HY-114339

CDK4/6-IN-2 is a potent **CDK4** and **CDK6** inhibitor extracted from patent US20180000819A1, Compound 1, has **IC_{50}**s of 2.7 and 16 nM for CDK4 and CDK6, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CDK4/6/1 Inhibitor

Cat. No.: HY-112280

CDK4/6/1 Inhibitor is a **CDK4/6** inhibitor with **IC_{50}**s of 3 and 1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CDK8-IN-1

Cat. No.: HY-103492

CDK8-IN-1 is a potent and selective **CDK8** inhibitor with an **IC_{50}** of 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CDK8-IN-3

Cat. No.: HY-111463

CDK8-IN-3 is an inhibitor of **CDK8** extracted from patent WO2016041618A1, compound example 1.7.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CDK8-IN-4

Cat. No.: HY-111465

CDK8-IN-4 is an inhibitor of **CDK8** extracted from patent WO2014090692A1, compound example 16, with an **IC_{50}** of 0.2 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CDK8/19-IN-1

Cat. No.: HY-111427

CDK8/19-IN-1 is a potent, selective and oral bioavailable **CDK8/19** dual inhibitor, with IC_{50}s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CDK9 Antagonist-1

Cat. No.: HY-112811

CDK9 Antagonist-1 (compounds 11c) is a potent and selective **CDK9** degrader based on PROTAC, with an IC_{50} of 17 μM in MCF-7 cell lines. Natural product Wogonin binds ubiquitin E3 ligase cereblon (CRBN) via a linker to form PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CDK9-IN-8

Cat. No.: HY-102039

CDK9-IN-8 is a highly effective and selective **CDK9** inhibitor with an IC_{50} of 12 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CDKI-73

Cat. No.: HY-12445

CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM; shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM).



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CE-245677

Cat. No.: HY-112423

CE-245677 is a potent reversible inhibitor of **Tie2** and **TrkA/B** kinases with a cellular IC_{50}s of 4.7 and 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Ceanothic acid

(Emmolic acid)

Cat. No.: HY-N3558

Ceanothic acid (Emmolic acid) is a ring-A homologue of betulinic acid. Ceanothic acid inhibits OVCAR-3, HeLa, and FS-5 cells with the cell survival of 68%, 65%, and 81%, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cecropin A

Cat. No.: HY-P1539

Cecropin A is a linear 37-residue antimicrobial polypeptide, with anticancer and anti-inflammatory activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cecropin A TFA

Cat. No.: HY-P1539A

Cecropin A TFA is a linear 37-residue antimicrobial polypeptide isolated from Hyalaphora cecropia pupae. Cecropin A TFA exhibits anti-bacterial, anti-inflammatory and anti-cancer activity.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cecropin B

Cat. No.: HY-P0092

Cecropin B has high level of antimicrobial activity and is considered as a valuable peptide antibiotic.

Purity: 98.12%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

Cedazuridine

(E7727)

Cat. No.: HY-109081

Cedazuridine (E7727) is a **Cytidine Deaminase (CDA)** inhibitor with an IC_{50} value of 0.4 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Cediranib
(AZD2171)

Cat. No.: HY-10205

Cediranib (AZD2171) is a highly potent, orally available **VEGFR** tyrosine kinase inhibitor with IC_{50}s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.



Purity: 99.58%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cediranib maleate
(AZD-2171 maleate)

Cat. No.: HY-13049

Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available **VEGFR** inhibitor with IC_{50}s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.



Purity: 96.67%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CeMMEC1

Cat. No.: HY-111445

CeMMEC1 is an inhibitor of **BRD4**, and also has high affinity for **TAF1**, with an IC_{50} of 0.9 μM for TAF1, and a K_d of 1.8 μM for TAF1 (2).



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CeMMEC13

Cat. No.: HY-101088

CeMMEC13 is a potent inhibitor of **TAF1 (2)** bromodomain, with an IC_{50} of 2.1 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Centrinone
(LCR-263)

Cat. No.: HY-18682

Centrinone (LCR-263) is a selective and reversible inhibitor of polo-like kinase 4 (**PIK4**) with a K_i of 0.16 nM.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Centrinone-B
(LCR-323)

Cat. No.: HY-18683

Centrinone-B (LCR-323) is a potent and highly selective **PLK4** inhibitor, with a K_i of 0.59 nM.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CEP-28122

Cat. No.: HY-18030

CEP-28122 is a highly potent and selective orally active ALK inhibitor with IC50 of 1.9 ± 0.5 nM in an enzyme-based TRF assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CEP-28122 mesylate salt

Cat. No.: HY-18030A

CEP-28122 mesylate salt is a highly potent and selective orally active ALK inhibitor with IC50 of 1.9 ± 0.5 nM in an enzyme-based TRF assay.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CEP-33779

Cat. No.: HY-15343

CEP-33779 is a novel, selective, and orally bioavailable inhibitor of **JAK2** with an IC_{50} of 1.8±0.6 nM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CEP-37440

Cat. No.: HY-15841

CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).



Purity: 99.87%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CEP-40783

(RXDX-106)

Cat. No.: HY-100946

CEP-40783 is a potent, selective and orally available inhibitor of **AXL** and **c-Met** with IC_{50} values of 7 nM and 12 nM, respectively.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cephalomannine

Cat. No.: HY-77554

Cephalomannine is a taxol derivative with antitumor, antiproliferative properties.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cephalotaxlen

((-)-Cephalotaxine; ZINC19795976)

Cat. No.: HY-N0838

Cephalotaxine is an antiviral as well as antitumor agent.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ceralasertib

(AZD6738)

Cat. No.: HY-19323

Ceralasertib (AZD6738) is a potent inhibitor of **ATR** kinase with an IC_{50} of 1 nM.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cercosporamide

((-)-Cercosporamide)

Cat. No.: HY-16982

Cercosporamide is a highly potent, ATP-competitive **Pkc1** kinase inhibitor, with an IC_{50} of <50 nM and a K_i of <7 nM. Cercosporamide is a unique **Mnk** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg

Cercosporin

Cat. No.: HY-N6743

Cercosporin is produced by a plant pathogen, Cercosporakikuchii, and the elsinochromes, pigments of the elsinoe family of fungi.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cerdulatinib

(PRT062070; PRT2070)

Cat. No.: HY-15999

Cerdulatinib (PRT062070) is a dual **JAK** and **SYK** inhibitor with IC_{50}s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.



Purity: 99.00%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ceritinib

(LDK378)

Cat. No.: HY-15656

Ceritinib (LDK378) is a potent and specific **ALK** inhibitor with an IC_{50} of 0.2 nM.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ceritinib dihydrochloride

(LDK378 (dihydrochloride))

Cat. No.: HY-15656A

Ceritinib dihydrochloride (LDK378 dihydrochloride) is potent inhibitor against ALK with IC_{50} of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cetuximab

(C225)

Cat. No.: HY-P9905

Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (**EGFR**), with a K_d of 0.201 nM for soluble EGFR by SPR. Cetuximab has potent antitumor activity.

Cetuximab

Purity: 99.70%
Clinical Data: Launched
Size: 1 mg, 5 mg

Cevipabulin

(TTI-237) Cat. No.: HY-14949

Cevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [^{3}H] vinblastine to tubulin, with an **IC_{50}** of 18-40 nM for cytotoxicity in human tumor cell line.



Purity: 99.03%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cevipabulin fumarate

(TTI-237 fumarate) Cat. No.: HY-14949C

Cevipabulin fumarate (TTI-237 fumarate) is an oral, microtubule-active, antitumor compound and inhibits the binding of [^{3}H] vinblastine to tubulin, with an **IC_{50}** of 18-40 nM for cytotoxicity in human tumor cell line.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CF53

Cat. No.: HY-112610

CF53 is a highly potent, selective and orally active inhibitor of **BET** protein, with a **K_i** of <1 nM, **K_d** of 2.2 nM and an **IC_{50}** of 2 nM for BRD4 BD1.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CFI-400945 free base

Cat. No.: HY-12300

CFI-400945 free base is a potent, selective and orally bioavailable **PLK4** inhibitor with a **K_i** and an **IC_{50}** of 0.26 nM and 2.8 nM, respectively.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CFI-400945 fumarate

Cat. No.: HY-12300B

CFI-400945 fumarate is a potent, selective and orally bioavailable **PLK4** inhibitor with a **K_i** and an **IC_{50}** of 0.26 nM and 2.8 nM, respectively.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CFI-402257

Cat. No.: HY-101340

CFI-402257 is a highly selective and orally bioavailable **TTK/Mps1** inhibitor with an **IC_{50}** of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity.



Purity: 99.52%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CFI-402257 hydrochloride

Cat. No.: HY-101340A

CFI-402257 hydrochloride is a highly selective and orally bioavailable **TTK/Mps1** inhibitor with an **IC_{50}** of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CFMTI

Cat. No.: HY-100402

CFMTI is a potent and selective metabotropic glutamate receptor (mGluR) 1 allosteric antagonist with IC50 of 2.6 nM. The selectivity of CFMTI to mGluR1 over mGluR5 was >2000-fold.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

CG-200745

Cat. No.: HY-16138

CG-200745 is a potent **HDAC** inhibitor, with **IC_{50}**s of <3 μM for sensitive non-small cell lung cancer (NSCLC) cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CG-806

Cat. No.: HY-112646

CG-806 is a pan **FLT3/BTK** Multi-Kinase inhibitor.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CGK733

Cat. No.: HY-15520

CGK733 is a potent **ATM/ATR** inhibitor, used for the research of cancer.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CGP 57380

Cat. No.: HY-10520

CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of **Mnk1** with IC_{50} of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CGP37157

Cat. No.: HY-15754

CGP37157 is a potent, selective inhibitor of **Na^+/Ca^{2+} exchanger**, inhibiting the Na^+-induced Ca^{2+}-release from guinea-pig heart mitochondria, with an IC_{50} of 0.8 μM.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CGP60474

Cat. No.: HY-11009

CGP60474 is a potent **VEGFR-2** inhibitor, with an IC_{50} of 84 nM, and also an ATP-competitive **PKC** inhibitor.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CH-223191

Cat. No.: HY-12684

CH-223191 is a potent and specific antagonist of **aryl hydrocarbon receptor (AhR)**. CH-223191 blocks the binding of TCDD to AhR with an IC_{50} of 0.03 μM.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

CH5132799

Cat. No.: HY-15466

CH5132799 is a selective class I **PI3K** inhibitor. CH5132799 inhibits class I PI3Ks, particularly PI3Kα, with an IC_{50} of 14 nM.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CH5183284

(Debio 1347)

Cat. No.: HY-19957

CH5183284 is an orally available and selective **FGFR** inhibitor with IC_{50}s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

CH7057288

Cat. No.: HY-107362

CH7057288 is a potent and selective **TRK** inhibitor.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Chaetocin

Cat. No.: HY-N2019

Chaetocin is a specific inhibitor of the histone methyltransferase (**HMT**) SU(VAR)3-9 with an IC_{50} of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (**TrxR**) with an IC_{50} of 4 μM.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

CHDI-390576

Cat. No.: HY-119939

CHDI-390576, a potent, cell permeable and CNS penetrant **class IIa histonedeacetylase (HDAC)** inhibitor with IC_{50}s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold...



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CHIR-124

Cat. No.: HY-13263

CHIR-124 is a potent and selective **Chk1** inhibitor with IC_{50} of 0.3 nM, and also potently targets **PDGFR** and **FLT3** with IC_{50}s of 6.6 nM and 5.8 nM.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHIR-99021

(CT99021)

Cat. No.: HY-10182

CHIR-99021 is a **GSK-3α/β** inhibitor with an IC_{50} of 10 and 6.7 nMshowing 500-fold selectivity over its closest homologs CDC2 and ERK2, as well as other protein kinases.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHIR-99021 monohydrochloride

(CT99021 monohydrochloride)

Cat. No.: HY-10182A

CHIR-99021 monohydrochloride is a **GSK-3α/β** inhibitor with IC_{50} of 10 nM/6.7 nM; > 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CHIR-99021 trihydrochloride

(CT99021 trihydrochloride)

Cat. No.: HY-10182B

CHIR-99021 trihydrochloride is a **GSK-3α/β** inhibitor with IC_{50} of 10 nM/6.7 nM; > 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases.



Purity: 97.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Chitosan

(Deacetylated chitin; Poly(D-glucosamine))

Cat. No.: HY-B2144

Chitosan is a natural polycationic linear polysaccharide derived from chitin.



Purity: 95.00%
Clinical Data: Phase 4
Size: 10 g

Chitosan oligosaccharide COS

Cat. No.: HY-112108

Chitosan oligosaccharide (COS) is an oligomer of β-(14)-linked D-glucosamine. Chitosan oligosaccharide (COS) activates **AMPK** and inhibits inflammatory signaling pathways including **NF-κB** and **MAPK** pathways.

Purity: >91.0%
Clinical Data: No Development Reported
Size: 1 g, 5 g

CHK-IN-1

Cat. No.: HY-U00345

CHK-IN-1 is an inhibitor of **CHK1** and **CHK2**, with anti-proliferative activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

CHK1-IN-2

Cat. No.: HY-111369

CHK1-IN-2 is a checkpoint kinase 1 **(CHK1)** inhibitor, with an IC_{50} of 6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CHK1-IN-3

Cat. No.: HY-128601

CHK1-IN-3 is a **Checkpoint Kinase 1 (CHK1)** inhibitor with an IC_{50} of 0.4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Chlorambucil

(CB-1348; WR-139013)

Cat. No.: HY-13593

Chlorambucil is an **alkylating** agent with antitumor activity.



Purity: 98.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Chlormethine hydrochloride
(Mechlorethamine hydrochloride)

Cat. No.: HY-B1253

Chlormethine hydrochloride is a vesicant and necrotizing irritant destructive to mucous membranes. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Chloropyramine hydrochloride

Cat. No.: HY-B1305

Chloropyramine hydrochloride is a **histamine receptor H1** antagonist which can also inhibit the biochemical function of **VEGFR-3** and **FAK**.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Chlorotoxin

Cat. No.: HY-P0173A

Chlorotoxin is a 36 amino-acid peptide from the venom of the Israeli scorpion Leiurus quinquestriatus with anticancer activity. Chlorotoxin is a **chloride channel** blocker.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg, 1 mg

Chlorotoxin(linear)

Cat. No.: HY-P0173

Chlorotoxin(linear) is a linear 36 amino-acid peptide which can be used in Chlorotoxin related research.

Purity: 97.35%
Clinical Data: Phase 1
Size: 500 μg, 1 mg, 5 mg, 10 mg, 25 mg

CHMFL-ABL-039

Cat. No.: HY-126143

CHMFL-ABL-039 is a type II native **ABL** kinase and drug-resistant V299L mutant **BCR-ABL** inhibitor with the IC_{50}s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CHMFL-ABL-121

Cat. No.: HY-119370

CHMFL-ABL-121 is a highly potent type II **ABL kinase** inhibitor with IC_{50}s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CHMFL-ABL/KIT-155
(CHMFL-ABL-KIT-155)

Cat. No.: HY-101034

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active **type II ABL/c-KIT** dual kinase inhibitor (IC_{50}s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC_{50}=81 nM), CSF1R (IC_{50}=227 nM), DDR1 (IC_{50}=116 nM),...



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CHMFL-BMX-078
(CHMFL-BMX 078)

Cat. No.: HY-101267

CHMFL-BMX-078 is a highly potent and selective type II irreversible **BMX** kinase inhibitor with an IC_{50} of 11 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

CHMFL-BTK-01

Cat. No.: HY-101521

CHMFL-BTK-01 (compound 9) is a highly selective irreversible **BTK** inhibitor, with an IC_{50} of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CHMFL-EGFR-202

Cat. No.: HY-101522

CHMFL-EGFR-202 is a potent, irreversible inhibitor of **epidermal growth factor receptor (EGFR) mutant kinase**, with IC_{50}s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CHMFL-KIT-033

Cat. No.: HY-128589

CHMFL-KIT-033 is a potent and selective inhibitor of **c-KIT T670I mutant** for gastrointestinal stromal tumors (GISTs), with an IC_{50} of 0.045 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CHMFL-PI3KD-317

Cat. No.: HY-112608

CHMFL-PI3KD-317 is a highly potent, selective and orally active **PI3Kδ** inhibitor, with an IC_{50} of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC_{50}, 62.6 nM), PI3Kβ (IC_{50}, 284 nM), PI3Kγ (IC_{50}, 202.7 nM),...



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Cholecalciferol

(Vitamin D3; Colecalciferol)

Cat. No.: HY-15398

Cholecalciferol(Vitamin D3) is a naturally occuring form of vitamin D; Reported that upon metabolic activation, Cholecalciferol induces cell differentiation and prevents proliferation of cancer cells.



Purity: >98.0%
Clinical Data: Launched
Size: 100 mg, 1 g, 5 g

Cholesterol myristate

(Cholesteryl myristate; Cholesteryl tetradecanoate)

Cat. No.: HY-N2338

Cholesterol myristate is a natural steroid present in traditional Chinese medicine. Cholesterol myristate binds to several ion channels such as the **nicotinic acetylcholine receptor**, **GABAA receptor**, and the inward-rectifier **potassium ion channel**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 250 mg

CHR-6494

Cat. No.: HY-15217

CHR-6494 is a potent inhibitor of **haspin**, inhibiting histone H3T3 phosphorylation, with an IC_{50} of 2 nM.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chrysin

(5,7-Dihydroxyflavone)

Cat. No.: HY-14589

Chrysin is one of the most well known **estrogen** blockers.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

Chrysophanol

(Chrysophanic acid)

Cat. No.: HY-13595

Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of **EGFR** and suppresses activation of **AKT** and **mTOR/p70S6K**.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

CHS-828

(GMX1778)

Cat. No.: HY-10079

CHS-828 (GMX1778) is a competitive inhibitor of **nicotinamide phosphoribosyltransferase (NAMPT)**, with an IC_{50} less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ChX710

Cat. No.: HY-112951

ChX710 could prime the type I interferon response to cytosolic DNA, which induces the ISRE promoter sequence, specific cellular Interferon-Stimulated Genes (ISGs), and the phosphorylation of Interferon Regulatory Factor (IRF) 3.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CHZ868

Cat. No.: HY-18960

CHZ868 is a type II **JAK2** inhibitor with an IC_{50} of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CI-1040

(PD 184352)

Cat. No.: HY-50295

CI-1040 (PD184352) is an orally active, highly specific, small-molecule inhibitor of **MEK** with an IC_{50} of 17 nM for MEK1.



Purity: 98.54%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

CID 2011756

Cat. No.: HY-13454

CID 2011756 is an ATP competitive **PKD** inhibitor, with an IC_{50} of 3.2 μM for PKD1 in cell free assay, and also shows cellular pan-PKD inhibitory activity against PKD2 and PKD3 (IC_{50}, 0.6 and 0.7 μM, respectively). CID 2011756 also has antitumor activity.



Purity: 95.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CID-2858522

Cat. No.: HY-15530

CID-2858522 is a highly potent and selective antigen receptor-mediated **NF-κB** activation inhibitor with an IC_{50} of 70 nM.



Purity: 96.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CID5721353

Cat. No.: HY-100502

CID5721353 is an inhibitor of **BCL6** with an IC_{50} value of 212 μM, which corresponds to a K_i of 147 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CID755673

Cat. No.: HY-12239

CID755673 is a potent **PKD** inhibitor with IC_{50}s of 182 nM, 280 nM and 227 nM for **PKD1**, **PKD2** and **PKD3**, respectively.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CIL56

Cat. No.: HY-112063

CIL56 is a potent and selective **ferroptosis** inhibitor. Ferroptosis is an iron-dependent form of regulated cell death (RCD).



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cilengitide

(EMD 121974)

Cat. No.: HY-16141

Cilengitide is a potent and selective **integrin** inhibitor for $\alpha_v\beta_3$ and $\alpha_v\beta_5$ receptor, with IC_{50}s of 4 and 79 nM, respectively.



Purity: 99.06%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ciliobrevin A

(HPI-4)

Cat. No.: HY-100790

Ciliobrevin A is a **hedgehog** (**Hh**) signaling pathway inhibitor with median inhibitory concentration (IC_{50}) less than 10 μM.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cimetidine

(SKF-92334)

Cat. No.: HY-14289

Cimetidine is a histamine-2 (H2) receptor antagonist.



Purity: >98.0%
Clinical Data: Launched
Size: 1 g, 5 g, 10 g

Cinchonine

((8R,9S)-Cinchonine; LA40221)

Cat. No.: HY-Y0152

Cinchonine is a natural compound present in Cinchona bark. Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Cinnamic acid

(3-Phenylacrylic acid; β-Phenylacrylic acid)

Cat. No.: HY-N0610A

Cinnamic acid has potential use in cancer intervention, with **IC_{50}s** of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

Cinobufagin

(Cinobufagine)

Cat. No.: HY-N0421

Cinobufagin, a kind of Chinese materia medica with antitumor effect, is widely used in clinical practice, especially in anti-liver cancer. IC50 value: Target: In vitro: Cinobufagin inhibited proliferation of cancer cells at doses of 0.1, 1, or 10 μM after 2–4 days of culture.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cinobufotalin

Cat. No.: HY-N0880

Cinobufotalin is one of the bufadienolides prepared from toad venom; has anticancer activity. IC50 value: Target: in vitro: Cinobufotalin(CB) caused significant DNA fragmentation, decrease of MMP, and an increase in the intracellular Ca(2+) ion and ROS production.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cintirorgon

(LYC-55716)

Cat. No.: HY-104037

Cintirorgon (LYC-55716) is novel oral RAR-related orphan receptor γ (**RORγ**) agonist.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Cipemastat

(Ro 32-3555)

Cat. No.: HY-19677

Cipemastat is a potent, competitive inhibitor of human **collagenases** 1, 2 and 3 with **K_is** of 3.0, 4.4 and 3.4 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Ciprofibrate

(Win35833)

Cat. No.: HY-B0664

Ciprofibrate is a peroxisome proliferator-activated receptor agonist.



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

cis-Pralsetinib

(cis-Blu667)

Cat. No.: HY-112301A

cis-Pralsetinib (cis-Blu667) is a highly potent and selective inhibitor of **rearranged during transfection (RET)**, with **IC_{50}** values ranging from 0.3 to 0.4 nM for WT RET and four enzyme variants (V804L, V804M, M918T, CCDC6-RET), and with broad, robust and anti-tumor activity against...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cisplatin

(CDDP; cis-Diaminodichloroplatinum)

Cat. No.: HY-17394

Cisplatin is a antineoplastic chemotherapy drug which works by cross-linking with **DNA** and causing DNA damage in cancer cells.



Purity: >99.0%
Clinical Data: Launched
Size: 100 mg, 500 mg

Citarinostat

(ACY241)

Cat. No.: HY-15994

Citarinostat is a HDAC6 specific inhibitor, with IC50 of 4 nM and 76 nM for HDAC6 and HDAC3, respectively. IC50 value: 4 nM (HDAC6), 76 nM (HDAC3) Target: HDAC The detailed information please refer to WO2015061684A1 and 2015054197A1.



Purity: 99.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Citric acid

Cat. No.: HY-N1428

Citric acid is a weak organic tricarboxylic acid found in citrus fruits. Citric acid is a natural preservative and food tartness enhancer.

Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

CK-636

(CK-0944636)

Cat. No.: HY-15892

CK-636 is a cell permeable inhibitor of **Arp2/3 complex**, that could inhibit actin polymerization, with IC_{50} values of 4 μM, 24 μM and 32 μM for human, fission yeast and bovine, respectively.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

CK-869

Cat. No.: HY-16927

CK-869 is an Actin-Related Protein 2/3 **(ARP2/3)** complex inhibitor, with an IC_{50} of 7 μM.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CL-387785

(EKI-785; WAY-EKI 785)

Cat. No.: HY-10325

CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of **EGFR** with IC_{50} of 370 pM.



Purity: 97.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CL-82198

Cat. No.: HY-100359

CL-82198 is a selective inhibitor of MMP-13. In vitro: In the presence of 10 and 20 μM of the specific MMP-13 inhibitor, CL-82198, migration of the LS174 cells was significantly reduced by 55 and 52%, respectively. .



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CLIP 86-100

Cat. No.: HY-P1826

CLIP (86-100) is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP).

PVSKMRMATPLLMQA

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clofarabine

Cat. No.: HY-A0005

Clofarabine(Clolar; Clofarex) inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. IC50 Value: 65 nM Target: in vitro: Clofarabine is a second generation purine nucleoside analog with antineoplastic activity.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Clofilium tosylate

Cat. No.: HY-33350

Clofilium tosylate, a **potassium channel** blocker, induces apoptosis of human promyelocytic leukemia (HL-60) cells via Bcl-2-insensitive activation of caspase-3. Antiarrhythmic agent.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CM-579

Cat. No.: HY-117421

CM-579 is a first-in-class reversible, dual inhibitor of **G9a** and **DNMT**, with IC_{50} values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CM-579 trihydrochloride

Cat. No.: HY-117421A

CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of **G9a** and **DNMT**, with IC_{50} values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CMD178

Cat. No.: HY-P1453

CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling. CMD178 also is an inhibitor of STAT5 and inhibit T_{reg} cell development.

RFKF[Y(OBn)]

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMK

Cat. No.: HY-52101

CMK is a **RSK2 kinase** inhibitor which exhibits similar potency but less chemical stability compared with FMK.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

CMPD 7

Cat. No.: HY-112261

CMPD 7 is a potent and selective **CDK12** inhibitor with an **IC_{50}** of 491 nM in enzymatic assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CMPD1

Cat. No.: HY-108643

CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated **MK2 phosphorylation** inhibitor with apparent **K_i (K_i^{app})** of 330nM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

CNDAC

Cat. No.: HY-16445A

CNDAC is a major metabolite of oral drug sapacitabine, and a nucleoside analog.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

CNX-1351

Cat. No.: HY-16596

CNX-1351 is a potent and isoform-selective targeted covalent **PI3Kα** inhibitor with **IC_{50}** of 6.8 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CNX-2006

Cat. No.: HY-13897

CNX-2006 is a mutant-selective and irreversible **EGFR** inhibitor with an **IC_{50}** below 20 nM for $EGFR^{T790M}$.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CNX-774

Cat. No.: HY-13943

CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cobimetinib

(GDC-0973; XL518)

Cat. No.: HY-13064

Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral **MEK1** inhibitor with an **IC_{50}** of 4.2 nM for **MEK1**.



Purity: 99.38%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cobimetinib hemifumarate

(GDC-0973 hemifumarate; XL-518 hemifumarate)

Cat. No.: HY-13064A

Cobimetinib hemifumarate is a novel selective **MEK1** inhibitor, and the **IC_{50}** value against MEK1 is 4.2 nM.



Purity: 99.27%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cobimetinib R-enantiomer

(GDC-0973 R-enantiomer; XL-518 R-enantiomer)

Cat. No.: HY-13079

Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Cobimetinib racemate

(GDC-0973 (racemate); XL518 (racemate))

Cat. No.: HY-13078

Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the less active racemate of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor.



Purity: 99.09%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Coelenterazine

Cat. No.: HY-18743

Coelenterazine is a luminescent enzyme substrate for apoaequorin and Renilla luciferase.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg, 10 mg, 25 mg

Coenzyme Q10

(Ubiquinone-10; CoQ10)

Cat. No.: HY-N0111

Coenzyme Q10 is an essential cofactor of the electron transport chain and a potent antioxidant agent.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 100 mg, 200 mg, 500 mg, 1 g, 5 g

COH000

Cat. No.: HY-114304

COH000 is an allosteric, covalent and irreversible inhibitor of **ubiquitin-like 1-activating enzyme (SUMO-activating enzyme) (E1)**, with an IC_{50} of 0.2 µM for SUMOylation in vitro.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

COH29

(RNR Inhibitor COH29)

Cat. No.: HY-19931

COH29 is a potent ribonucleotide reductase (**RNR**) inhibitor with anticancer activity. COH29 inhibits α and β subunit of RNR with IC_{50}s of 16 µM.



Purity: 98.04%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Colchicine

Cat. No.: HY-16569

Colchicine is a **tubulin** inhibitor and a **microtubule** disrupting agent. Colchicine inhibits microtubule polymerization with an IC_{50} of 3 nM.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Collagen proline hydroxylase inhibitor

Cat. No.: HY-15183

Collagen proline hydroxylase inhibitor is a collagen proline hydroxylase inhibitor; useful for antifibroproliferative agents.



Purity: 95.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Collagen proline hydroxylase inhibitor-1

Cat. No.: HY-15182

Collagen proline hydroxylase inhibitor-1 is an antifibroproliferative agents.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Columbianadin

Cat. No.: HY-N0362

Columbianadin, a natural coumarin from, is known to have various biological activities including anti-inflammatory and anti-cancer effects.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Combretastatin A4

(CRC 87-09)

Cat. No.: HY-N2146

Combretastatin A4 is a **microtubule**-targeting agent that binds **β-tubulin** with K_d of 0.4 µM.



Purity: 99.41%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Complanatuside

Cat. No.: HY-N1444

Complanatuside is a flavonoid found in the traditional Chinese medicine Semen Astragali Complanati.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Compound 401

Cat. No.: HY-19341

Compound 401 is a synthetic inhibitor of **DNA-PK** (IC_{50} = 0.28 μM) that also targets mTOR but not PI3K in vitro.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Compound E

(Compound E (secretase inhibitor)DuPont E)

Cat. No.: HY-14176

Compound E is a **γ-secretase** inhibitor. Compound E bloks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC_{50}s of 0.24, 0.37, 0.32 nM, respectively.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Concanamycin A

(Antibiotic X 4357B; Concanamycin; X 4357B)

Cat. No.: HY-N1724

Concanamycin A (Antibiotic X 4357B) is a macrolide antibiotic and a specific **vacuolar type H⁺-ATPase (V-ATPase)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Conteltinib

(CT-707)

Cat. No.: HY-109084

Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib (CT-707) exerts significant inhibitory effect on **FAK** with an IC_{50} of 1.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Copanlisib

(BAY 80-6946)

Cat. No.: HY-15346

Copanlisib (BAY 80-6946) is a selective and ATP-competitive class-I **PI3K** inhibitor, with IC_{50}s of 0.5, 0.7, 3.7 and 6.4 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ** and **PI3Kγ**, respectively.



Purity: 98.91%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Coptisine

(Coptisin)

Cat. No.: HY-N0430

Coptisine is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive **IDO** inhibitor with a K_i value of 5.8 μM and an IC_{50} value of 6.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Coptisine chloride

Cat. No.: HY-N0736

Coptisine chloride is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive **IDO** inhibitor with a K_i value of 5.8 μM and an IC_{50} value of 6.3 μM.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cordycepin

(3'-Deoxyadenosine)

Cat. No.: HY-N0262

Cordycepin, which is a nucleoside derivative isolated from Cordyceps, inhibits IL-1β-induced **MMP-1** and **MMP-3** expression in rheumatoid arthritis synovial fibroblasts (RASFs) in a dose-dependent manner.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Corin

Cat. No.: HY-111048

Corin is a dual inhibitor of histone lysine specific demethylase **(LSD1)** and histone deacetylase **(HDAC)**, with a K_i**(inact)** of 110 nM for LSD1 and an IC_{50} of 147 nM for HDAC1.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Corosolic acid

(Colosolic acid; Corsolic acid; Glucosol) Cat. No.: HY-N0280

Corosolic acid isolated from the fruit of Cratoegus pinnatifida var. psilosa, was reported to have anticancer activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cortisone acetate

(Cortisone 21-acetate) Cat. No.: HY-17461A

Cortisone acetate (17-hydroxy-11-dehydrocorticosterone), a 21-carbon steroid hormone, is one of the main hormones released by the adrenal gland in response to stress.



Purity: 99.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Corylin

Cat. No.: HY-N0236

Corylin is a major bioactive compound isolated from Psoralea corylifolia L; antibiotic or anticancer compound.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Corynoxine

Cat. No.: HY-N0901

Corynoxine is an enantiomer of Corynoxine B; induces autophagy in different neuronal cell lines, including N2a and SHSY-5Y cells.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Corynoxine B

Cat. No.: HY-N0901A

Corynoxine B is an oxindole alkaloid isolated from Uncaria rhynchophylla (Miq.) Jacks (Gouteng in Chinese); a Beclin-1-dependent autophagy inducer.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Costunolide

((+)-Costunolide; Costus lactone) Cat. No.: HY-N0036

Costunolide, a sesquiterpene lactone, exhibits anti-inflammatory and anti-oxidant properties and mediates apoptosis.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cot inhibitor-1

Cat. No.: HY-32015

Cot inhibitor-1 is a COT/Tpl2 inhibitor.



Purity: 95.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cot inhibitor-2

Cat. No.: HY-32018

Cot inhibitor-2 is a COT/Tpl2 inhibitor.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

COTI-2

Cat. No.: HY-19896

COTI-2 is a small molecule candidate anti-cancer drug which can convert mutant **p53** to wild-type conformation.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Coumarin

Cat. No.: HY-N0709

Coumarin is the primary bioactive ingredient in Radix Glehniae, named Beishashen in China, which possesses many pharmacological activities, including anticancer, anti-inflammation and antivirus activities.



Purity: 99.91%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Coumestrol

Cat. No.: HY-N2335

Coumestrol, a phytoestrogen present in soybean products, exhibits activities against cancers, neurological disorders, and autoimmune diseases. It suppresses proliferation of ES2 cells with an IC_{50} of 50 μM.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CP-466722

Cat. No.: HY-11002

CP-466722 is a rapidly reversible inhibitor of **ATM**, with an IC_{50} of 4.1 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CP-547632

Cat. No.: HY-13302

CP-547632 is a potent inhibitor of the **VEGFR2** and **FGF2** kinases with IC_{50}s of 11 and 9 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CP-673451

Cat. No.: HY-12050

CP-673451 is a potent and selective inhibitor of **PDGFR** with IC_{50}s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CP-724714

Cat. No.: HY-14674

CP-724,714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc. Phase 2.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CP21R7

(CP21)

Cat. No.: HY-100207

CP21R7 is potent **GSK-3β** inhibitor, with an IC_{50} of 1.8 nM; CP21R7 also shows inhibitory activitiy against **PKCα**, with an IC_{50} of 1900 nM.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CPI-169

(CPI 169 R-enantiomer)

Cat. No.: HY-15956A

CPI-169 is a novel and potent **EZH2** inhibitor, with IC_{50}s of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.



Purity: 96.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CPI-169 racemate

Cat. No.: HY-15956

CPI-169 racemate is the racemate of CPI-169. CPI-169 is a novel and potent **EZH2** inhibitor.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CPI-203

Cat. No.: HY-15846

CPI-203 is a novel potent, selective and cell permeable inhibitor of **BET bromodomain**, with an IC_{50} value of appr 37 nM (BRD4 α-screen assay).



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

CPI-360

Cat. No.: HY-15955

CPI-360 is a potent, selective EZH2inhibitor with IC50 of 0.5 nM and 2.5 nM nM for wt EZH2 and Y641N EZH2, respectively.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CPI-444

(V81444; ciforadenant)

Cat. No.: HY-101978

CPI-444 is a potent and selective inhibitor of **A2A receptor** (**A2AR**) induces antitumor responses.



Purity: 99.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CPI-455

Cat. No.: HY-100421

CPI-455 is a specific **KDM5** inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CPI-637

Cat. No.: HY-100482

CPI-637 is a potent and selective CBP/EP300 bromodomains inhibitor with IC50 of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CPUY074020

Cat. No.: HY-100757

CPUY074020 is a potent **G9a** inhibitor with an **IC_{50}** of 2.18 μM, and possesses anti-proliferative activity .



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CRA-026440

Cat. No.: HY-19754

CRA-026440 is a potent, broad-spectrum **HDAC** inhibitor. The **K_i** values against recombinant HDAC isoenzymes **HDAC1**, **HDAC2**, **HDAC3**, **HDAC6**, **HDAC8**, and **HDAC10** are 4, 14, 11, 15, 7, and 20 nM respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Crenigacestat

(LY3039478)

Cat. No.: HY-12449

Crenigacestat (LY3039478) is a novel and potent Notch inhibitor.



Purity: 98.62%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Crenolanib

(CP-868596)

Cat. No.: HY-13223

Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases **FLT3** and **PDGFRα/β** with **K_d**s of 0.74 nM and 2.1 nM/3.2 nM, respectively.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

cRIPGBM

Cat. No.: HY-125466

cRIPGBM, a proapoptotic derivative of RIPGBM, a cell type-selective inducer of **apoptosis** in GBM cancer stem cells (CSCs) by binding to receptor-interacting protein kinase 2 **(RIPK2)**, with an **EC_{50}** of 68 nM in GBM-1 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Crizotinib

(PF-02341066)

Cat. No.: HY-50878

Crizotinib is a potent inhibitor of **c-Met** and **ALK** with an **IC_{50}** of 11 nM and 24 nM in cell-based assays, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib hydrochloride

(PF-02341066 hydrochloride)

Cat. No.: HY-50878A

Crizotinib hydrochloride is a potent inhibitor of **c-Met** and **ALK** with **IC_{50}**s of 11 nM and 24 nM in cell-based assays, respectively.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crolibulin

(EPC2407)

Cat. No.: HY-13603

Crolibulin is a small molecule **tubulin polymerization** inhibitor.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CRT0066101 dihydrochloride

Cat. No.: HY-15698A

CRT0066101 dihydrochloride is a potent and specific **PKD** inhibitor with IC_{50} values of 1, 2.5 and 2 nM for PKD1, 2, and 3 respectively.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Cryptotanshinone

(Cryptotanshinon; Tanshinone c)

Cat. No.: HY-N0174

Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits **STAT3** with an IC_{50} of 4.6 μM.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CSF1R-IN-1

Cat. No.: HY-101774

CSF1R-IN-1 is a **CSF1R** inhibitor with an with an IC_{50} of 0.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CSF1R-IN-2

Cat. No.: HY-111787

CSF1R-IN-2 (compound 5) is an oral-active inhibitor of **SRC**, **MET** and **c-FMS**, with IC_{50} values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CSN5i-3

Cat. No.: HY-112134

CSN5i-3 is a potent, selective and orally available inhibitor of CSN5; inhibits CSN-catalysed Cul1 deneddylation with an IC_{50} value of 5.8nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CT-721

Cat. No.: HY-108704

CT-721 is a potent and time-dependent **Bcr-Abl kinase** inhibitor with an IC_{50} of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

CT7001 hydrochloride

(ICEC0942 hydrochloride)

Cat. No.: HY-103712A

CT7001 hydrochloride is a selective **CDK7** inhibitor, with IC_{50}s of 41 nM and 578 nM for **CDK7/CycH/MAT1** and **CDK2/cycE1**, respectively.

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CTPB

Cat. No.: HY-124960

CTPB is a good activator of **p300 histone acetyl transferase** (**HAT**) enzyme.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CTS-1027

(Ro 1130830; RS 130830)

Cat. No.: HY-10398

CTS-1027 is a potent small molecule inhibitor of **MMPs**, with IC_{50}s of 0.3 nM, 0.5 nM for **MMP2**, **MMP13**, respectively, and has > 1,000 fold selectivity over MMP1.



Purity: 98.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CTTHWGFTLC, CYCLIC

Cat. No.: HY-P1789

CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for **matrix metalloproteinases MMP-2** and **MMP-9**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CTX1

Cat. No.: HY-U00442

CTX1 is a novel small molecule **p53** activator.



Purity: >96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

CU-CPT17e

Cat. No.: HY-101929

CU-CPT17e is a multi-**Toll-like receptor** (**TLR**) agonist that activates **TLR3**, **TLR8**, and **TLR9**.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CU-CPT22

Cat. No.: HY-108471

CU-CPT22 is a toll-like receptor 1 and 2 (**TLR1/2**) inhibitor with an **IC_{50}** of 0.58 μM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Cucurbitacin B

Cat. No.: HY-N0416

Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids; could repress cancer cell progression.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Cucurbitacin E

(α-Elaterin; α-Elaterine)

Cat. No.: HY-N0417

Cucurbitacin E is a natural compound which from the climbing stem of Cucumic melo L. Cucurbitacin E significantly suppresses the activity of the **cyclin B1/CDC2** complex.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cucurbitacin I

(Elatericin B; JSI-124; NSC-521777)

Cat. No.: HY-N1405

Cucurbitacin I is a natural selective inhibitor of **JAK2/STAT3**, with potent anti-cancer activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

CUDC-101

Cat. No.: HY-10223

CUDC-101 is a potent inhibitor of **HDAC**, **EGFR**, and **HER2** with **IC_{50}**s of 4.4, 2.4, and 15.7 nM, respectively.



Purity: 99.59%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CUDC-427

(GDC-0917)

Cat. No.: HY-15835

CUDC-427 is a potent second-generation pan-selective **IAP** antagonist, used for treatment of various cancers.



Purity: 99.23%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Curcumenol

((+)-Curcumenol)

Cat. No.: HY-N2259

Curcumenol ((+)-Curcumenol) is a potent **CYP3A4** inhibitor with an **IC_{50}** of 12.6 μM, which is one of constituents in the plants of medicinally important genus of Curcuma zedoaria, with neuroprotection, anti-inflammatory, anti-tumor and hepatoprotective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Curcumin

(Turmeric yellow; Natural Yellow 3; Diferuloylmethane) **Cat. No.:** HY-N0005

Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities.



Purity: 99.66%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Curcumol

((-)-Curcumol) **Cat. No.:** HY-N0104

Curcumol is a sesquiterpene originally isolated from curcuma rhizomes; shows anticancer activities both in vitro and in vivo.



Purity: 99.58%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

CVT-313

(Cdk2 Inhibitor III) **Cat. No.:** HY-15339

CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of **CDK2** with **IC_{50}** of 0.5 μM.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CW-069

Cat. No.: HY-15857

CW-069 is an allosteric inhibitor of **microtubule motor protein HSET** with an **IC_{50}** of 75 μM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CWHM-12

Cat. No.: HY-18644

CWHM-12 is a potent inhibitor of **αV integrins** with **IC_{50}**s of 0.2, 0.8, 1.5, and 1.8 nM for **αvβ8**, **αvβ3**, **αvβ6**, and **αvβ1**.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CX-5461

Cat. No.: HY-13323

CX-5461 is a potent and oral **rRNA synthesis** inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with **IC_{50}**s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively.



Purity: 98.47%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

CX-5461 dihydrochloride

Cat. No.: HY-13323A

CX-5461 dihydrochloride is a potent and orally bioavailable inhibitor of Pol I-mediated **rRNA synthesis**, with **IC_{50}**s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (**IC_{50}** ≥25 μM).



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CX-6258

Cat. No.: HY-18095

CX-6258 is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CX-6258 hydrochloride hydrate

Cat. No.: HY-18095A

CX-6258 hydrochloride hydrate is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cyanidin Chloride

(IdB 1027) **Cat. No.:** HY-N0499

Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CYC-116

Cat. No.: HY-10558

CYC-116 is a potent **aurora A** and **aurora B** inhibitor with K_is of 8 and 9 nM, respectively.



Purity: 98.17%
Clinical Data: Phase 1
Size: 10 mg, 50 mg, 100 mg

CYC065

Cat. No.: HY-101212

CYC065 is a second-generation, orally available ATP-competitive inhibitor of **CDK2/CDK 9** kinases.



Purity: 98.58%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Cyclic somatostatin

(SRIF-14; Somatostatin-14)

Cat. No.: HY-P0084

Cyclic somatostatin is a growth hormone-release inhibiting factor used in the treatment of severe, acute hemorrhages of gastroduodenal ulcers.

Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Cyclic-di-GMP

(c-di-GMP; cyclic diguanylate; 5GP-5GP)

Cat. No.: HY-107780

Cyclic-di-GMP is a **STING** agonist and a ubiquitous second messenger that regulates biofilm formation, motility, and virulence in diverse bacterial species.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Cyclo(-RGDfK)

Cat. No.: HY-P0023

Cyclo(-RGDfK) is a potent and selective inhibitor of the $\alpha_v\beta_3$ integrin, with an IC_{50} of 0.94 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA

Cat. No.: HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of **integrin αvβ3**, with antitumor activity.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclo(RGDyK) trifluoroacetate

Cat. No.: HY-100563

Cyclo(RGDyK) trifluoroacetate is a potent and selective **$\alpha_V\beta_3$ integrin** inhibitor with an IC_{50} of 20 nM.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cyclopamine

(11-Deoxojervine)

Cat. No.: HY-17024

Cyclopamine is a **Hedgehog** (**Hh**) pathway antagonist with an IC_{50} of 46 nM in the Hh cell assay.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Cyclophosphamide

Cat. No.: HY-17420

Cyclophosphamide is a synthetic **alkylating** agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.



Purity: >98.0%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Cyclophosphamide hydrate

(Cyclophosphamide monohydrate)

Cat. No.: HY-17420A

Cyclophosphamide hydrate is a synthetic **alkylating** agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.



Purity: >98.0%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Cynaropicrin

Cat. No.: HY-N2350

Cynaropicrin is a sesquiterpene lactone which can inhibit **tumor necrosis factor** (**TNF-α**) release with **IC_{50}**s of 8.24 and 3.18 μM for murine and human macrophage cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CYP17-IN-1

Cat. No.: HY-101516

CYP17-IN-1 (compound 9c) is a potent and orally active **CYP17** inhibitor against rat and human CYP17 with **IC_{50}**s of 15.8 and 20.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Cys-mcMMAD

Cat. No.: HY-15750

Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. IC50 Value: N/A Target: tubulin; ADCs For comparison purposes, the ADC A1 -mc-MMAD and/or A1 -vc-MMAD were used. The linker payload,.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Cytarabine (Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C)

Cat. No.: HY-13605

Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits **DNA polymerase**. Cytarabine inhibits **DNA synthesis** with an **IC_{50}** of 16 nM.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Cytarabine hydrochloride (Cytosine β-D-arabinofuranoside hydrochloride; Cytosine Arabinoside hydrochloride; ...)

Cat. No.: HY-13605A

Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits **DNA polymerase**. Cytarabine inhibits **DNA synthesis** with an **IC_{50}** of 16 nM.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg

Cytidine

(Cytosine β-D-riboside; Cytosine-1-β-D-ribofuranoside)

Cat. No.: HY-B0158

Cytidine is a nucleoside molecule that is formed when cytosine is attached to a ribose ring, cytidine is a component of RNA.

Purity: 98.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g

Cytochalasin B

(Phomin)

Cat. No.: HY-16928

Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of **actin** filaments, disrupting the formation of actin polymers, with **K_d** value of 1.4-2.2 nM for F-actin.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Cytochalasin E

Cat. No.: HY-N6772

Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. Cytochalasin E is a potent actin depolymerization agent, and it binds and caps the barbed end of actin filaments to prevent actin elongation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cytosporone B

(Csn-B; Dothiorelone G)

Cat. No.: HY-N2148

Cytosporone B (Csn-B; Dothiorelone G) is a naturally occurring nuclear orphan receptor **Nur77/NR4A1** agonist with an **EC_{50}** of 0.278 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

CZ415

Cat. No.: HY-100222

CZ415 is a potent and highly selective **mTOR** inhibitor with a **pIC_{50}** of 8.07. CZ415 inhibits **mTORC1** and **mTORC2** protein complex.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CZC-8004

(CZC-00008004) Cat. No.: HY-111138

CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including **ABL** kinase.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

D,L-Buthionine-(S,R)-sulfoximine

(Butionine sulfoximine) Cat. No.: HY-106376

D,L-Buthionine-(S,R)-sulfoximine is a potent inhibitor of **glutamylcysteine synthetase biosynthesis**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

D-3263

Cat. No.: HY-16162

D-3263 is an agonist of transient receptor potential melastatin member 8 (**TRPM8**) with potential antineoplastic activity.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 20 mg

D-3263 hydrochloride

Cat. No.: HY-16162A

D-3263 hydrochloride is an enteric-coated, orally bioavailable (transient receptor potential melastatin member 8) **TRPM8** agonist.



Purity: 98.01%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

D-64131

Cat. No.: HY-15482

D-64131 is a novel inhibitor of Tubulin polymerization that competitively binds with [(3)H]colchicine to αβ-Tubulin.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

D-alpha-Hydroxyglutaric acid disodium salt

(Disodium (R)-2-hydroxyglutarate) Cat. No.: HY-100542

D-alpha-Hydroxyglutaric acid disodium salt is a weak competitive α-Ketoglutarate(**α-KG**)-dependent dioxygenase inhibitor with K_i of 10.87±1.85 mM. K_i for L-Hydroxyglutaric acid (L-2-HG) is 0.628±0.036 mM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

D-Erythro-dihydrosphingosine

Cat. No.: HY-W019838

D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase $A_2\alpha$ (**cPLA$_2$α**) activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

D-erythro-Sphingosine (Erythrosphingosine; erythro-C18-Sphingosine; trans-4-Sphingenine)

Cat. No.: HY-101047

D-erythro-Sphingosine is a very potent activator of **p32-kinase** with an **EC_{50}** of 8 μM. D-erythro-Sphingosine inhibits protein kinase C (**PKC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

D-Lin-MC3-DMA

Cat. No.: HY-112251

D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

D4-abiraterone

(Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite) Cat. No.: HY-109619

D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of **CYP17A1**, 3b-hydroxysteroid dehydrogenase (**3βHSD**) and steroid-5a-reductase (**SRD5A**) and also an antagonist of **androgen receptor**.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

D4476

(Casein Kinase I Inhibitor) Cat. No.: HY-10324

D4476 is a potent, selective and cell-permeable inhibitor of casein kinase 1(**CK1**) with an **IC_{50}** value of 0.3 μM in vitro.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

D609

Cat. No.: HY-70072

D609 is a selective competitive inhibitor of **phosphatidyl choline-specific phospholipase C (PC-PLC)**, with **K_i** of 6.4 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

D8-MMAD (Demethyldolastatin 10 D8; Monomethylauristatin D D8; Monomethyl Dolastatin 10 D8)

Cat. No.: HY-15581S

D8-MMAD is a deuterated form of MMAD, which is a **microtubule** disrupting agent.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

D8-MMAE

(D8-Monomethyl auristatin E) Cat. No.: HY-15162A

D8-MMAE is a deuterated labeled MMAE, a potent **mitotic** inhibitor.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

D8-MMAF

(Monomethylauristatin F D8) Cat. No.: HY-15579S

D8-MMAF is a deuterated form of MMAF, which is a **microtubule** disrupting agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

D8-MMAF hydrochloride

Cat. No.: HY-15579AS

D8-MMAF hydrochloride is a deuterated form of MMAF hydrochloride, which is a **microtubule** disrupting agent.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Dabrafenib

(GSK2118436A; GSK2118436) Cat. No.: HY-14660

Dabrafenib is an ATP-competitive inhibitor of **Raf** with **IC_{50}**s of 5 nM and 0.6 nM for **C-Raf** and **B-Raf^{V600E}**, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dabrafenib Mesylate

(GSK2118436 Mesylate; GSK 2118436B) Cat. No.: HY-14660A

Dabrafenib Mesylate is a potent and selective **Raf kinase** inhibitor with **IC_{50}**s of 0.6 and 5.0 nM for Raf^{V600E} and c-Raf, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg

Dacarbazine

(Imidazole Carboxamide) Cat. No.: HY-B0078

Dacarbazine(DTIC-Dome; DTIC) is an antineoplastic agent. It has significant activity against melanomas.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 1 g

Dacinostat

(NVP-LAQ824; LAQ824) Cat. No.: HY-13606

Dacinostat is a potent **HDAC** inhibitor, with an **IC_{50}** of 32 nM; Dacinostat also inhibits **HDAC1** with an **IC_{50}** of 9 nM, and used in cancer research.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Dacomitinib

(PF-00299804; PF-299804) Cat. No.: HY-13272

Dacomitinib is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: 99.83%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dactolisib

(BEZ235; NVP-BEZ235) Cat. No.: HY-50673

Dactolisib (BEZ235) is a dual pan-class I **PI3K** and **mTOR** kinase inhibitor with IC_{50}s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for **p110α/p110γ/p110δ/p110β** and **mTOR**, respectively. Dactolisib (BEZ235) inhibits both **mTORC1** and **mTORC2**.



Purity: 99.13%
Clinical Data: Phase 2
Size: 50 mg, 100 mg, 200 mg, 500 mg

Dactolisib Tosylate

(BEZ235 (Tosylate); NVP-BEZ 235 (Tosylate)) Cat. No.: HY-15174

Dactolisib (BEZ235) Tosylate is a dual **PI3K** and **mTOR** kinase inhibitor with IC_{50} values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib (BEZ235) Tosylate inhibits **mTORC1** and **mTORC2**.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

DAMGO

Cat. No.: HY-P0210

DAMGO is a **μ-opioid receptor** (**μ-OPR**) selective agonist.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Daminozide

Cat. No.: HY-13643

Daminozide(DMASA; DIMG; B 995), a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g, 5 g

Danusertib

(PHA-739358) Cat. No.: HY-10179

Danusertib is a pyrrolo-pyrazole and **aurora kinase** inhibitor with IC_{50} of 13, 79, and 61 nM for Aurora A, B, and C, respectively.



Purity: 99.44%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Darolutamide

(ODM-201; BAY-1841788) Cat. No.: HY-16985

Darolutamide (ODM-201;BAY-1841788) is a potent androgen receptor (**AR**) antagonist with an IC_{50} of 26 nM in in vitro assay.



Purity: 97.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DASA-58

Cat. No.: HY-19330

DASA-58 is a potent activator of pyruvate kinase M2 (**PKM2**) with an AC_{90} of 680 nM, and an AC_{50} of 38 nM.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dasatinib

(BMS-354825) Cat. No.: HY-10181

Dasatinib (BMS-354825) is a dual **Bcr-Abl** and **Src** family tyrosine kinase inhibitor with IC_{50}s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-Kit^{D816V}, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Dasatinib hydrochloride

(BMS 354825 hydrochloride) Cat. No.: HY-10181A

Dasatinib hydrochloride is a potent and dual Abl^{WT}/**Src** inhibitor IC_{50} of 0.6 nM/0.8 nM respectively; also inhibits **c-**Kit^{WT}/**c-**Kit^{D816V} with IC_{50} of 79 nM/37 nM.



Purity: 98.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Datelliptium chloride

Cat. No.: HY-U00337

Datelliptium chloride is a DNA-intercalating agent derived from ellipticine, with anti-tumor activities.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Daucosterol

(Eleutheroside A; β-Sitosterol β-D-glucoside) Cat. No.: HY-N0410

Daucosterol is a natural sterolin.



Purity: 81.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Daun02

Cat. No.: HY-13061

Daun02 is a prodrug of the **topoisomerase** inhibitor Daunorubicin.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Daunorubicin

(RP 13057; Daunomycin; Rubidomycin) Cat. No.: HY-13062A

Daunorubicin (RP 13057) is a **topoisomerase II** inhibitor with potent antineoplastic activities. Daunorubicin (RP 13057) inhibits **DNA and RNA synthesis** in sensitive and resistant Ehrlich ascites tumor cells.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg

Daunorubicin Hydrochloride (RP 13057 (Hydrochloride); Daunomycin (Hydrochloride); Rubidomycin (Hydrochloride))

Cat. No.: HY-13062

Daunorubicin Hydrochloride (RP 13057 Hydrochloride) is a **topoisomerase II** inhibitor with potent antineoplastic activities.



Purity: 99.27%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Daurisoline

((R,R)-Daurisoline) Cat. No.: HY-N0221

Daurisoline is a **hERG** inhibitor and also an **autophagy** blocker.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

DB07268

Cat. No.: HY-15737

DB07268 is a potent and selective **JNK1** inhibitor with an IC_{50} value of 9 nM.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DBCO-(PEG)3-VC-PAB-MMAE

Cat. No.: HY-111012

DBCO-(PEG)3-VC-PAB-MMAE is made by MMAE conjugated to DBCO-(PEG)3-vc-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

DBeQ

(JRF 12) Cat. No.: HY-15945

DBeQ is a selective, potent, reversible, and ATP-competitive **p97** inhibitor, with an IC_{50} value of 1.5 μM and 1.6 μM for p97(wt) and p97(C522A), respectively; DBeQ also inhibits **Vps4** with an IC_{50} of 11.5 μM.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

dBET1

Cat. No.: HY-101838

dBET1 is a potent **BRD4** protein degrader based on **PROTAC** technology with an EC_{50} of 430 nM.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

dBET57

Cat. No.: HY-123844

dBET57 is a potent and selective heterobifunctional degrader of **BRD4** based on the **PROTAC** technology, with a $DC_{50/5h}$ of 500 nM for $BRD4_{BD1}$, and is inactive on $BRD4_{BD2}$.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

dBET6

Cat. No.: HY-112588

dBET6 is a highly potent, selective and cell-permeable degrader of **BET** based on **PROTAC**, with an IC_{50} of 14 nM, and has antitumor activity.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DC-05

Cat. No.: HY-12746

DC-05 is a DNA methyltransferase 1 (**DNMT1**) inhibitor, with an IC_{50} and a K_d of 10.3 μM and 1.09 μM, respectively.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

DC1

Cat. No.: HY-112899

DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DC1-SMe

Cat. No.: HY-112898

DC1-Sme is an antibody conjugate of phosphate prodrug of cytotoxic DNA alkylators for the targeted treatment of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DC661

Cat. No.: HY-111621

DC661 is a potent palmitoyl-protein thioesterase 1 (**PPT1**) inhibitor, inhibits **autophagy**, and acts as an anti-lysosomal agent. Anti-cancer activity.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DC_517

Cat. No.: HY-12747

DC_517 is a DNA methyltransferase 1 (**DNMT1**) inhibitor, with an IC_{50} and a K_d of 1.7 μM and 0.91 μM, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

DC_C66

Cat. No.: HY-100855

DC_C66 is a cell-permeable, selective **coactivator associated arginine methyltransferase 1 (CARM1)** inhibitor with an IC_{50} of 1.8 μM. DC_C66 has a good selectivity for CARM1 against PRMT1 (IC_{50}=21 μM), PRMT6 (IC_{50}= 47μM), and PRMT5.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

DDP-38003 dihydrochloride

Cat. No.: HY-19612A

DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (**KDM1A/LSD1**) with an IC_{50} of 84 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

DDP-38003 trihydrochloride

Cat. No.: HY-19612B

DDP-38003 trihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (**KDM1A/LSD1**) with an IC_{50} of 84 nM.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

DDR Inhibitor

Cat. No.: HY-W018931

DDR Inhibitor is a potent **discoidin domain receptor (DDR)** inhibitor, with an IC_{50} of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.



Purity: 97.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

DDR1-IN-1

Cat. No.: HY-13979

DDR1-IN-1 is a potent and selective **DDR1 receptor tyrosine kinase** inhibitor with an IC_{50} of 105 nM; 4-fold less potent for DDR2 (IC_{50} = 413 nM).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DDR1-IN-1 dihydrochloride

Cat. No.: HY-13979A

DDR1-IN-1 dihydrochloride is a potent and selective **DDR1 receptor tyrosine kinase** inhibitor with an IC_{50} of 105 nM; 4-fold less potent for DDR2 (IC_{50} = 413 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDR1-IN-3

Cat. No.: HY-100695

DDR1-IN-3 is a selective Discoidin Domain Receptor 1 **(DDR1)** inhibitor, with an IC_{50} value of 9.4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Debio 0932

(CUDC-305)

Cat. No.: HY-13469

Debio 0932 is an orally active **HSP90** inhibitor, with IC_{50}s of 100 and 103 nM for HSP90α and HSP90β, respectively.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Decoyinine

(Angustmycin A)

Cat. No.: HY-101835

Decoyinine is a selective inhibitor of GMP synthetase (**GMPS**).



Purity: 99.96%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Decursin

((+)-Decursin)

Cat. No.: HY-18981

Decursin is an anticancer agent, with potential anti-inflammatory activity.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Defactinib

(VS-6063; PF-04554878)

Cat. No.: HY-12289

Defactinib (VS-6063; PF-04554878) is a novel **FAK** inhibitor with potential antiangiogenic and antineoplastic activities.



Purity: 99.74%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Defactinib hydrochloride

(VS-6063 hydrochloride; PF 04554878 hydrochloride)

Cat. No.: HY-12289A

Defactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel **FAK** inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.



Purity: 99.11%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Deforolimus

(AP23573; MK-8669; Ridaforolimus)

Cat. No.: HY-50908

Deforolimus (AP23573; MK-8669) is a potent and selective **mTOR** inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC_{50} of 0.2 nM in HT-1080 cells.



Purity: 98.46%
Clinical Data: Phase 3
Size: 10 mg, 50 mg

Degarelix

Cat. No.: HY-16168A

Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (**GnRHR**) antagonist.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Degrasyn

(WP1130)

Cat. No.: HY-13264

Degrasyn (WP1130) is a cell-permeable **deubiquitinase (DUB)** inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. Degrasyn has been shown to downregulate the antiapoptotic proteins **Bcr-Abl** and **JAK2**.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Deguelin

((-)-Deguelin; (-)-cis-Deguelin)

Cat. No.: HY-13425

Deguelin, a naturally occurring rotenoid, is a potent **PI3K/AKT** inhibitor.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Dehydroaltenusin

Cat. No.: HY-100513A

Dehydroaltenusin is a small molecule selective inhibitor of eukaryotic **DNA polymerase α**, a type of antibiotic produced by a fungus with an IC_{50} value of 0.68 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydrocorydaline

(13-Methylpalmatine)

Cat. No.: HY-N0674

Dehydrocorydaline (13-Methylpalmatine) is an alkaloid isolated from traditional Chinese herb Corydalis yanhusuo W.T. Wang. Dehydrocorydaline regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Dehydrocorydaline chloride

(13-Methylpalmatine chloride)

Cat. No.: HY-N0674A

Dehydrocorydaline chloride is an alkaloidal that has anti-inflammatory and anti-cancer activities. Dehydrocorydaline chloride can elevate **p38 MAPK** activation.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

DEL-22379

Cat. No.: HY-18932

DEL-22379 is an **ERK dimerization** Inhibitor. DEL-22379 readily binds to ERK2 with a K_d estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. **ERK2 dimerization** is progressively inhibited with an IC_{50} of ~0.5 μM.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Delamanid

(OPC-67683)

Cat. No.: HY-10846

Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids, cruciala component of the cell wall of the Mycobacterium tuberculosis complex.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Delanzomib

(CEP-18770)

Cat. No.: HY-10454

Delanzomib(CEP-18770) is a novel orally-active inhibitor of the chymotrypsin-like activity of the proteasome that down-modulates the nuclear factor-kappaB (NF-kappaB) activity.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Deltarasin

Cat. No.: HY-15747

Deltarasin is an inhibitor of **KRAS-PDEδ** interaction with K_d of 38 nM for binding to purified PDEδ.



Purity: 95.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Deltarasin hydrochloride

Cat. No.: HY-15747A

Deltarasin hydrochloride is an inhibitor of **KRAS-PDEδ**interaction with K_d of 38 nM for binding to purified PDEδ.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Deltasonamide 2

Cat. No.: HY-122641A

Deltasonamide 2 is a **PDEδ** inhibitor with a K_d of ~385 pM and an EC_{50} of 1.24 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Deltasonamide 2 TFA

Cat. No.: HY-122641B

Deltasonamide 2 TFA is a **PDEδ** inhibitor with a K_d of ~385 pM and an EC_{50} of 1.24 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Deltonin

Cat. No.: HY-N2283

Deltonin, a steroidal saponin, isolated from Dioscorea zingiberensis Wright, with antitumor activity; Deltonin inhibits **ERK1/2** and **AKT** activation.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg

Dendrophenol

Cat. No.: HY-N6031

Dendrophenol, isolated from the stem of Dendrobium loddigesii Rolfe, act as a **NF-κB** inhibitor. Antineoplastic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Deoxyandrographolide

Cat. No.: HY-N0857

Deoxyandrographolide is a natural compound extracted from A. paniculata; potently inhibit the growth of liver (HepG2 and SK-Hep1) and bile duct (HuCCA-1 and RMCCA-1) cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Deoxycytidine triphosphate

(dCTP)

Cat. No.: HY-101400

Deoxycytidine triphosphate (dCTP), a nucleoside triphosphate, is a raw material in DNA synthesis. Deoxycytidine triphosphate has many applications, such as real-time PCR, cDNA synthesis, and DNA sequencing.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Derazantinib

(ARQ-087)

Cat. No.: HY-19981

Derazantinib (ARQ-087) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against **FGFR1-3** chondrocytes with IC_{50}s of 4.5, 1.8, and 4.5 nM, respectively.



Purity: 99.06%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Deruxtecan

Cat. No.: HY-13631E

Deruxtecan, a toxin and linker moiety of DS-8201, is a drug-linker conjugate for antibody-drug conjugate (ADC) extracted from patent WO2017002776A1, compound 1.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Desacetylcinobufotalin

(Deacetylcinobufotalin)

Cat. No.: HY-N0882

Desacetylcinobufotalin is a natural compound; apoptosis inducer and shows the marked inhibition effect to HepG2 cells and the IC50 value is 0.0279μmol/ml.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Desmethyl Erlotinib

(OSI-420; CP-473420)

Cat. No.: HY-13256

Desmethyl Erlotinib (OSI-420) is an active metabolite of erlotinib, which is a potent EGFR tyrosin kinase inhibitor.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Destruxin A

Cat. No.: HY-N6689

Destruxin A (DA) is a cyclo-peptidic mycotoxin from the entomopathogenic fungus Metarhizium anisopliae, with insecticidal, anti-viral and antiproliferative activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Destruxin B

Cat. No.: HY-N6690

Destruxin B, isolated from entomopathogenic fungus Metarhizium anisopliae, is one of the cyclodepsipeptides with insecticidal and anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Devimistat

(CPI-613)

Cat. No.: HY-15453

Devimistat (CPI-613) is a lipoic acid analog that inhibits **pyruvate dehydrogenase (PDH)** and **α-ketoglutarate dehydrogenase**, disrupts mitochondrial metabolism and shows strong antitumor activity.



Purity: 99.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DFMTI

(MK5435)

Cat. No.: HY-100404

DFMTI can completely block the rmGlu1 L757V glutamate response.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

DG172 dihydrochloride

Cat. No.: HY-19737A

DG172 dihydrochloride is a selective **PPARβ/δ** antagonist, with an IC_{50} of 27 nM.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DHMEQ racemate

(rel-DHMEQ)

Cat. No.: HY-14645B

DHMEQ racemate is a **NF-κB** inhibitor. DHMEQ racemate is less active than (-)-DHMEQ.



Purity: >98%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg

Diazepinomicin

(ECO-4601; TLN-4601; BU 4664L)

Cat. No.: HY-N6674

Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Dibutyl phthalate

Cat. No.: HY-Y0304

Dibutyl phthalate is a commonly used plasticizer commonly found in some food packaging materials, personal care products, and the coating of oral medications. May cause toxicity and adverse neurobehavioral effects.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Dicoumarol

(Dicumarol)

Cat. No.: HY-N0645

Dicoumarol is an inhibitor of both **NAD(P)H:quinone oxidoreductase 1** (**NQO1**) and **PDK1** with IC_{50}s of 0.37 and 19.42 μM, respectively.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Didox

(NSC-324360)

Cat. No.: HY-19387

Didox (NSC-324360) is a synthetic **ribonucleotide reductase** (**RR**) inhibitor.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Diethyl-pythiDC

Cat. No.: HY-103068

Diethyl-pythiDC is an inhibitor of collagen prolyl 4-hydroxylases (CP4Hs).



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Digitonin

Cat. No.: HY-N4000

Digitonin, a glycoside obtained from Digitalis purpurea, could increase cell permeability by binding to cholesterol molecules and reduce tumor growth.



Purity: >50.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

Dihydroartemisinin

(Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol)

Cat. No.: HY-N0176

Dihydroartemisinin is a potent **anti-malaria** agent.



Purity: 99.03%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Dihydrocoumarin

(Hydrocoumarin; Chroman-2-one)

Cat. No.: HY-N1926

Dihydrocoumarin is a compound found in Melilotus officinalis. Dihydrocoumarin is a **yeast Sir2p** inhibitor. Dihydrocoumarin also inhibits **human SIRT1** and **SIRT2** with IC_{50}s of 208 μM and 295 μM, respectively.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Dihydroisotanshinone I

Cat. No.: HY-B1919

Dihydroisotanshinone I is a bioactive compound present in a widely used traditional Chinese medicine named danshen.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Dihydromyricetin

(Ampeloptin; Ampelopsin)

Cat. No.: HY-N0112

Dihydromyricetin is a potent inhibitor with an IC_{50} of 48 μM on **dihydropyrimidinase**. Dihydromyricetin can activate autophagy through inhibiting **mTOR** signaling. Dihydromyricetin suppresses the formation of mTOR complexes (**mTORC1/2**).



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DIM-C-pPhCO2Me

Cat. No.: HY-112056

DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. Antineoplastic activity.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DIM-C-pPhOCH3

Cat. No.: HY-111492

DIM-C-pPhOCH$_3$ is a **Nur77** agonist. Nerve growth factor-induced Bα (NGFI-Bα, Nur77) is an orphan nuclear receptor.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Dimesna

(BNP-7787)

Cat. No.: HY-B1022

Dimesna is an protective agent used to decrease urotoxicity.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Dimethylcurcumin

(ASC-J9; GO-Y025)

Cat. No.: HY-15194

Dimethylcurcumin (ASC-J9) is an **androgen receptor** degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.



Purity: 98.06%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Dimethylenastron

Cat. No.: HY-19944

Dimethylenastron is a potent **kinesin Eg5** inhibitor, with an IC_{50} of 200 nM.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dimethylfraxetin

(6,7,8-Trimethoxycoumarin; Fraxetin dimethyl ether)

Cat. No.: HY-N0085

Dimethylfraxetin is a **Carbonic anhydrase** inhibitor, with a K_i value of 0.0097 μM.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Dinaciclib

(SCH 727965)

Cat. No.: HY-10492

Dinaciclib is a potent inhibitor of **CDK**, with IC_{50}s of 1, 1, 3, and 4 nM for **CDK2**, **CDK5**, **CDK1**, and **CDK9**, respectively.



Purity: 99.73%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dioscin

(Collettiside III; CCRIS 4123)

Cat. No.: HY-N0124

Dioscin(CCRIS 4123; Collettiside III) is a natural steroid saponin derived from several plants, showing potent anti-cancer effect against a variety of tumor cell lines.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Diosmetin

Cat. No.: HY-N0125

Diosmetin is a natural flavonoid which inhibits human **CYP1A** enzyme activity with an IC_{50} of 40 μM in HepG2 cell.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Diosmin

Cat. No.: HY-N0178

Diosmin is a flavonoid found in a variety of citrus fruits and also an agonist of the **aryl hydrocarbon receptor** (**AhR**).



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

DIQ3

Cat. No.: HY-111761

DIQ3 is a potent anti-cancer agent, nontoxic to normal human cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Disitertide

(P144)

Cat. No.: HY-P0118

Disitertide is an inhibitor of **TGF-β1**.

TSLDASIIWAMMQN

Purity: 98.12%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg

DK419

Cat. No.: HY-112799

DK419 is a potent and orally active **Wnt/β-catenin** signaling inhibitor, with an IC_{50} of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

DKM 2-93

Cat. No.: HY-101836

DKM 2-93 is a relatively selective inhibitor of **UBA5** with an IC_{50} of 430 μM.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

DL-Serine

Cat. No.: HY-Y0507

DL-Serine is a mixture of D-Serine and L-Serine.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

DM4

Cat. No.: HY-12454

DM4 is is an **antitubulin** agent that inhibit cell division. DM4 can be used in the preparation of antibody drug conjugate.



Purity: 98.28%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

DMA

Cat. No.: HY-15621

DMA is a fluorescent compound (λ_{ex}=340 nm, λ_{em}=478 nm).



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DMA trihydrochloride

Cat. No.: HY-15621A

DMA trihydrochloride is a fluorescent compound (λ_{ex}=340 nm, λ_{em}=478 nm).



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DMAPT

(Dimethylamino Parthenolide)

Cat. No.: HY-16172

DMAPT (Dimethylamino Parthenolide), a water soluble analogue of Parthenolide (PTL), is an oral active **NF-κB** inhibitor, with a LD_{50} of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

DMAT

(Casein kinase II Inhibitor; CK2 Inhibitor)

Cat. No.: HY-15535

DMAT is a potent and specific **CK2** inhibitor with an IC_{50} value of 130 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

dMCL1-2

Cat. No.: HY-128360

dMCL1-2 is a potent and selective degrader of myeloid cell leukemia 1 (MCL1) based on PROTAC, which binds to MCL1 with a K_D of 30 nM. dMCL1-2 activats the cellular apoptosis machinery by degradation of MCL1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DMCM hydrochloride

Cat. No.: HY-100369A

DMCM (hydrochloride) is Benzodiazepine inverse agonist that displays anxiogenic and potent convulsant activity. The reference for administration is ranging 0.4 from 0.8 mg/kg .



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DMH-1

Cat. No.: HY-12273

DMH-1 is a potent and selective **BMP** inhibitor with IC_{50}s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

DMOG
(Dimethyloxallyl Glycine)

Cat. No.: HY-15893

DMOG (Dimethyloxallyl Glycine) is a cell-permeable and competitive inhibitor of **HIF-1α prolyl hydroxylase (HIF-PH)**.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

DMU2105

Cat. No.: HY-101284

DMU2105 is a potent and specific **CYP1B1** inhibitor, with IC_{50}s of 10 nM and 742 nM for CYP1B1 and CYP1A1, respectively.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DMU2139

Cat. No.: HY-101285

DMU2139 is a potent and specific **CYP1B1** inhibitor, with IC_{50}s of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DNQX
(FG 9041)

Cat. No.: HY-15067

DNQX (FG 9041) is a AMPA receptor antagonists.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg, 200 mg

Docetaxel
(RP-56976)

Cat. No.: HY-B0011

Docetaxel is an antineoplastic drug by inhibiting **microtubule** depolymerization, and attenuating of the effects of **bcl-2** and **bcl-xL** gene expression.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

Docetaxel Trihydrate
(RP-56976 (Trihydrate))

Cat. No.: HY-B0011A

Docetaxel Trihydrate is a semi-synthetic taxane analogue, acts as a **microtubule** stabilizer.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg

Dofequidar

Cat. No.: HY-17013

Dofequidar(MS-209) is a novel quinoline compound, which can reverse P-glycoprotein (P-gp)-mediated MDR.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Dofequidar fumarate
(MS-209)

Cat. No.: HY-17013A

Dofequidar fumarate(MS-209 fumarate), an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both.



Purity: 99.99%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dolastatin 10
(DLS 10; NSC 376128)

Cat. No.: HY-15580

Angiotensin II human is a vasoconstrictor that acts on the **AT1** and the **AT2** receptor.



Purity: 99.83%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Domatinostat
(4SC-202 (free base))

Cat. No.: HY-16012A

Domatinostat (4SC-202 free base) is a selective class I **HDAC** inhibitor with IC_{50} of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against **Lysine specific demethylase 1 (LSD1)**.



Purity: 98.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Domatinostat tosylate

(4SC-202) Cat. No.: HY-16012

Domatinostat tosylate (4SC-202) is a selective class I **HDAC** inhibitor with IC_{50} of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against **Lysine specific demethylase 1 (LSD1)**.



Purity: 98.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dorsomorphin

(BML-275; Compound C) Cat. No.: HY-13418A

Dorsomorphin (BML-275; Compound C) is a potent and selective **AMPK** inhibitor, that is competitive with ATP, with K_i=109 nM in the absence of AMP. Dorsomorphin inhibits BMP pathway by targeting the type I receptors **ALK2**, **ALK3**, and **ALK6**.



Purity: 99.65%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Dorsomorphin dihydrochloride

(BML-275 dihydrochloride; Compound C dihydrochloride) Cat. No.: HY-13418

Dorsomorphin dihydrochloride (BML-275 dihydrochloride; Compound C dihydrochloride) is a potent, selective and ATP-competitive **AMPK** inhibitor, with a K_i of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors **ALK2**, **ALK3**, and **ALK6**.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dot1L-IN-1

Cat. No.: HY-101520

Dot1L-IN-1 is a highly potent, selective and structurally novel **Dot1L** inhibitor with a K_i of 2 pM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Dovitinib

(CHIR-258; TKI258) Cat. No.: HY-50905

Dovitinib is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.31%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate) Cat. No.: HY-10207

Dovitinib(CHIR-258; TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (**FGFR3**) with an IC_{50} of 5 nM.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Doxifluridine

(Ro 21-9738; 5-Fluoro-5'-deoxyuridine; 5'-DFUR) Cat. No.: HY-B0021

Doxifluridine is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g

Doxorubicin

(Hydroxydaunorubicin) Cat. No.: HY-15142A

Doxorubicin is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of **topoisomerase-II**-mediated DNA repair.



Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg

Doxorubicin hydrochloride

(Hydroxydaunorubicin (hydrochloride)) Cat. No.: HY-15142

Doxorubicin hydrochloride is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of **topoisomerase-II**-mediated DNA repair.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Dp44mT

Cat. No.: HY-18973

Dp44mT is an **iron chelator** with selective anticancer activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

DPBQ

Cat. No.: HY-U00441

DPBQ is a **p53** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

DPH

Cat. No.: HY-12070

DPH is a potent cell permeable **c-Abl** activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation. .

Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

DprE1-IN-2

Cat. No.: HY-100531

DprE1-IN-2 is a potent DprE1 inhibitor.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Droxinostat

(NS 41080)

Cat. No.: HY-13267

Droxinostat(NS41080) is a selective inhibitor of HDAC3, HDAC6, and HDAC8 with IC50 of 16.9, 2.47 and 1.46 μM, respectively; > 8-fold selective against HDAC3 and no inhibition to HDAC1, 2, 4, 5, 7, 9, and 10.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DS21360717

Cat. No.: HY-128576

DS21360717 is a potent and orally active **FER** tyrosine kinase inhibitor, with an IC_{50} of 0.49 nM. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

DT-061

Cat. No.: HY-112929

DT-061 is an orally bioavailable activator of **protein phosphatase 2A (PP2A)** and could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

dTRIM24

Cat. No.: HY-111519

dTRIM24 is a selective bifunctional degrader of **TRIM24** based on **PROTAC**.

Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dubermatinib

(TP-0903)

Cat. No.: HY-12963

Dubermatinib (TP-0903) is a potent and selective **Axl** receptor tyrosine kinase inhibitor with an IC_{50} value of 27 nM.



Purity: 99.53%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DUBs-IN-1

Cat. No.: HY-50736

DUBs-IN-1 is an active inhibitor of **ubiquitin-specific proteases (USPs)**, with an IC_{50} of 0.24 μM for USP8.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DUBs-IN-2

Cat. No.: HY-50737A

DUBs-IN-2 is a potent **deubiquitinase** inhibitor with an IC_{50} of 0.28 μM for USP8.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DUBs-IN-3

Cat. No.: HY-50737

DUBs-IN-3 is a potent **deubiquitinase (USP)** enzyme inhibitor extracted from reference compound 22c with an IC_{50} of 0.56 μM for USP8.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Duocarmycin TM

Cat. No.: HY-107769

Duocarmycin TM is an exceptionally potent antitumor antibiotic.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DUPA

Cat. No.: HY-111606

DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in drug conjugate to selectively deliver cytotoxic drugs to prostate cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

DUPA(OtBu)-OH

Cat. No.: HY-103591

DUPA(OtBu)-OH is a **DUPA** precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Durvalumab

(MEDI 4736)

Cat. No.: HY-P9919

Durvalumab (MEDI 4736) is an humanized anti-**PD-L1** monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of **PD-L1** to both **PD-1** and **CD80**, with IC_{50}s of 0.1 and 0.04 nM, respectively.

Durvalumab

Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg

Dutasteride

(GG 745; GI 198745)

Cat. No.: HY-13613

Dutasteride (GG745) is a potent inhibitor of both 5 alpha-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Duvelisib

(IPI-145; INK1197)

Cat. No.: HY-17044

Duvelisib is a selectivite **p100δ** inhibitor with IC_{50} of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.



Purity: 99.91%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Duvelisib R enantiomer

(IPI-145 R enantiomer; INK1197 R enantiomer)

Cat. No.: HY-17044A

Duvelisib R enantiomer is a **PI3K** inhibitor, which is the less active enantiomer of Duvelisib.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DW14800

Cat. No.: HY-128579

DW14800 is a protein arginine methyltransferase 5 (**PRMT5**) inhibitor, with an IC_{50} of 17 nM. DW14800 reduces H4R3me2s levels and enhances the transcription of HNF4α, but does not alter PRMT5 expression. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Dxd

(Exatecan derivative for ADC)

Cat. No.: HY-13631D

Dxd is a potent **DNA topoisomerase I** inhibitor, with an IC_{50} of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

DY131

(GSK 9089)

Cat. No.: HY-15483

DY131(GSK 9089) is a novel selective agonist of ERRβ and ERRγ; displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

E-7386

Cat. No.: HY-111386

E-7386 is an orally active **CBP/beta-catenin** modulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

E260

Cat. No.: HY-112097

E260 is a **Fer/FerT** kinase inhibitor.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

E3 ligase Ligand 1

Cat. No.: HY-42424

E3 ligase Ligand 1 is a **Ligand for E3 Ligase** extracted from patent WO/2017/030814A1 compound example 202, used in **PROTAC** technology.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand 1 dihydrochloride

Cat. No.: HY-42424A

E3 ligase Ligand 1 dihydrochloride is a **Hippel-Landau (VHL) E3 ligase**-binding moiety based on **PROTAC** technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand 10

Cat. No.: HY-128807

E3 ligase Ligand 10 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 10 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 ligase Ligand 11

Cat. No.: HY-128809

E3 ligase Ligand 13 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 13 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 ligase Ligand 12

Cat. No.: HY-128808

E3 ligase Ligand 12 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 12 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 ligase Ligand 13

Cat. No.: HY-128810

E3 ligase Ligand 13 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 13 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 ligase Ligand 14

Cat. No.: HY-128811

E3 ligase Ligand 14 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 14 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 ligase Ligand 1A

Cat. No.: HY-112078

E3 ligase Ligand 1A is a ligand of E3 ligase, used in **PROTAC** technology; E3 ligase Ligand 1A can be used in the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand 2

Cat. No.: HY-103596

E3 ligase Ligand 2 is a **ligand for E3 ligase** used in **PROTAC** technology.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand 5

Cat. No.: HY-U00425

E3 ligase Ligand 5 is a ligand of E3 ligase, extracted from patent US 20160058872A1, Paragraph 0515. E3 ligase Ligand 5 can be used in **PROTAC** technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

E3 ligase Ligand 8

Cat. No.: HY-43961

E3 ligase Ligand 8 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 8 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 ligase Ligand 9

Cat. No.: HY-128806

E3 ligase Ligand 9 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 9 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 Ligase Ligand-Linker Conjugates 1

Cat. No.: HY-21930

E3 Ligase Ligand-Linker Conjugate 1 incorporates a ligand for the E3 ubiquitin ligase, and a **PROTAC** linker, which bring together target protein and ubiquitinating machinery.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 10

Cat. No.: HY-103607

E3 ligase Ligand-Linker Conjugates 10 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 11

Cat. No.: HY-103608

E3 Ligase Ligand-Linker Conjugate 11 is a synthesized compound which incorporates a ligand for the E3 ubiquitin ligase and a **PROTAC** linker to bring together target protein and ubiquitinating machinery.



Purity: 96.30%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 12

Cat. No.: HY-103598

E3 ligase Ligand-Linker Conjugates 12 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 97.19%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 13

Cat. No.: HY-103599

E3 ligase Ligand-Linker Conjugates 13 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 97.99%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 14

Cat. No.: HY-103611

E3 ligase Ligand-Linker Conjugates 14 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 Ligase Ligand-Linker Conjugates 14 free base

Cat. No.: HY-107440

E3 Ligase Ligand-Linker Conjugates 14 free base is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 15

Cat. No.: HY-103612

E3 ligase Ligand-Linker Conjugates 15 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 Ligase Ligand-Linker Conjugates 19

Cat. No.: HY-107438

E3 Ligase Ligand-Linker Conjugates 19 is a degron-linker. The **PROTAC** linker is bound lo at least one targeting ligand.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 Ligase Ligand-Linker Conjugates 2

Cat. No.: HY-41549

E3 Ligase Ligand-Linker Conjugates 2 incorporates a ligand for the E3 ubiquitin ligase, and a **PROTAC** linker, which bring together target protein and ubiquitinating machinery.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 Ligase Ligand-Linker Conjugates 20

Cat. No.: HY-107439

E3 Ligase Ligand-Linker Conjugates 20 is a degron-linker (refer to Compound DL7-TL). The **PROTAC** linker is bound lo at least one targeting ligand.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 Ligase Ligand-Linker Conjugates 22

Cat. No.: HY-112599

E3 Ligase Ligand-Linker Conjugates 22 incorporates an **E3** ligase ligand and a linker, can be used for the treatment of **EZH2**-mediated cancer.

Purity: 95.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

E3 Ligase Ligand-Linker Conjugates 23 TFA

Cat. No.: HY-112600A

E3 Ligase Ligand-Linker Conjugates 23 (TFA) is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.



Purity: 96.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

E3 Ligase Ligand-Linker Conjugates 24 TFA

(E3 Ligase Ligand-Linker Conjugates 24 trifluoroacetate)

Cat. No.: HY-112617A

E3 Ligase Ligand-Linker Conjugates 24 (TFA) incorporates an E3 ligase ligand and a linker, can be an immunomodulater for the treatment of cancer.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 28

Cat. No.: HY-114176

E3 ligase Ligand-Linker Conjugates 28 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.



Purity: 95.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 29

Cat. No.: HY-111824

E3 ligase Ligand-Linker Conjugates 29 is a compound binding to **BRD4**, used to inhibit BRD4 based on **PROTAC**.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

E3 ligase Ligand-Linker Conjugates 3

Cat. No.: HY-103600

E3 ligase Ligand-Linker Conjugates 3 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 30

Cat. No.: HY-128716

E3 ligase Ligand-Linker Conjugates 30 incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 30 can be used to design PROTAC MDM2 degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E3 ligase Ligand-Linker Conjugates 31

Cat. No.: HY-122725

E3 ligase Ligand-Linker Conjugates 31 is a Ligand with linker of BETd-260 for **E3 Ligase** used in **PROTAC**. BETd-260 is a potent BET degrader based on PROTAC technology, with an IC_{50} of 51 pM against BRD4 protein in RS4;11 leukemia cell line.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 32 hydrochloride

Cat. No.: HY-115446A

E3 ligase Ligand-Linker Conjugates 32 hydrochloride is a Ligand with linker of **BET** for E3 Ligase used in **PROTAC**, with IC_{50} values of 0.98 nM and 13.7 nM in RS4;11 and MOLM-13 cells, respectively.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

E3 ligase Ligand-Linker Conjugates 33

Cat. No.: HY-128812

E3 ligase Ligand-Linker Conjugates 33 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 33 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 33 Hydrochloride

Cat. No.: HY-128812A

E3 ligase Ligand-Linker Conjugates 33 Hydrochloride incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 33 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 34

Cat. No.: HY-128813

E3 ligase Ligand-Linker Conjugates 34 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 34 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 34 Hydrochloride

Cat. No.: HY-128813A

E3 ligase Ligand-Linker Conjugates 34 Hydrochloride incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 34 Hydrochloride can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 35 Hydrochlride

Cat. No.: HY-128814

E3 ligase Ligand-Linker Conjugates 35 Hydrochlride incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 35 Hydrochlride can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 36

Cat. No.: HY-128815

E3 ligase Ligand-Linker Conjugates 36 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 36 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 37

Cat. No.: HY-128816

E3 ligase Ligand-Linker Conjugates 37 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 37 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 37 Hydrochloride

Cat. No.: HY-128816A

E3 ligase Ligand-Linker Conjugates 37 Hydrochloride incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 37 Hydrochloride can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 38

Cat. No.: HY-128817

E3 ligase Ligand-Linker Conjugates 38 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 38 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 39

Cat. No.: HY-128818

E3 ligase Ligand-Linker Conjugates 39 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 39 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 40

Cat. No.: HY-128819

E3 ligase Ligand-Linker Conjugates 40 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 40 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 41

Cat. No.: HY-128820

E3 ligase Ligand-Linker Conjugates 41 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 41 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 42

Cat. No.: HY-128821

E3 ligase Ligand-Linker Conjugates 42 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 42 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 43

Cat. No.: HY-128822

E3 ligase Ligand-Linker Conjugates 43 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 43 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 44

Cat. No.: HY-128823

E3 ligase Ligand-Linker Conjugates 44 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 44 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 45

Cat. No.: HY-128824

E3 ligase Ligand-Linker Conjugates 45 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 45 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 46

Cat. No.: HY-128825

E3 ligase Ligand-Linker Conjugates 46 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 46 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 47

Cat. No.: HY-128826

E3 ligase Ligand-Linker Conjugates 47 incorporates a cIAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 47 can be used to design PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 5

Cat. No.: HY-103602

E3 ligase Ligand-Linker Conjugates 5 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 5 Free Base

Cat. No.: HY-103602A

E3 ligase Ligand-Linker Conjugates 5 Free Base is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 6

Cat. No.: HY-103603

E3 ligase Ligand-Linker Conjugates 6 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 6 Free Base

Cat. No.: HY-103603A

E3 ligase Ligand-Linker Conjugates 6 Free Base is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 7

Cat. No.: HY-103604

E3 ligase Ligand-Linker Conjugates 7 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 7 Free Base

Cat. No.: HY-103604A

E3 ligase Ligand-Linker Conjugates 7 Free Base is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 8

Cat. No.: HY-103605

E3 ligase Ligand-Linker Conjugates 8 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.



Purity: 95.04%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E3 ligase Ligand-Linker Conjugates 9

Cat. No.: HY-103606

E3 ligase Ligand-Linker Conjugates 9 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in **PROTAC** technology.

Purity: 96.46%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

E7046

Cat. No.: HY-103088

E7046 is an orally bioavailable and specific **EP4** antagonist, with IC_{50} of 13.5 nM and K_i of 23.14 nM, exhibiting anti-tumor activities.



Purity: 99.60%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

E7449

Cat. No.: HY-12418

E7449 is a potent **PARP1** and **PARP2** inhibitor and also inhibits **TNKS1** and **TNKS2**, with IC_{50}s of 2.0, 1.0, 50 and 50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using ^{32}P-NAD$^+$ as substrate.



Purity: >99.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

E7820

(ER68203-00)

Cat. No.: HY-14571

E7820 is an angiogenesis inhibitor by suppressing **integrin a2**, a cell adhesion molecule expressed on endothelial cells.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

EAI045

Cat. No.: HY-100213

EAI045 is an allosteric inhibitor of mutant **EGFR** with IC_{50}s of 1.9, 0.019, 0.19 and 0.002 μM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$ and $EGFR^{L858R/T790M}$ at 10 μM ATP, respectively.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

EBI-1051

Cat. No.: HY-111368

EBI-1051 is a highly potent and orally efficacious **MEK** inhibitor with an IC_{50} of 3.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

EBI-2511

Cat. No.: HY-111418

EBI-2511 is a highly potent and orally active **EZH2** inhibitor, with an IC_{50} of 6 nM in Pfeffiera cell lines, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EC-17 disodium salt

Cat. No.: HY-13615A

EC-17 (disodium salt) is a **folate receptor alpha (FRα)** targeting contrast agent with fluorescent properties in the visible light spectrum. The peak excitation and emission wavelengths of EC-17 are 470/520nm.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

EC0489

Cat. No.: HY-114306

EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor. Small molecule-drug conjugate (SMDC).

{Ggu}-QEQEQC

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

EC330

Cat. No.: HY-100949

EC330 is a leukemia inhibitory factor (**LIF**) inhibitor.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

eCF506

Cat. No.: HY-112096

eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase **Src** with an IC_{50} of less than 0.5 nM.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ecteinascidin 770

(Ecteinascidine 770; Et-770)

Cat. No.: HY-101191

Ecteinascidin 770 (ET-770) is a 1,2,3,4-tetrahydroisoquinoline alkaloid with potent anti-cancer activities; inhibits U373MG cells with an IC_{50} of 4.83 nM.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Ecteinascidin-Analog-1

Cat. No.: HY-12395

Ecteinascidin-Analog-1 is a useful intermediate for chemical sythesis of Ecteinascidin analogues; Ecteinascidins is a family of tetrahydroisoquinoline alkaloids with wide range of antitumor and antimicrobial activities.



Purity: >90.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

EDO-S101

(Tinostamustine)

Cat. No.: HY-101780

EDO-S101 is a pan **HDAC** inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC_{50} values of 9, 9 and 25 nM, respectively.



Purity: 98.09%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Edotecarin

(J 107088; PF 804950)

Cat. No.: HY-13618

Edotecarin is a potent inhibitor of **topoisomerase I** that can induces single-strand DNA cleavage, with IC_{50} of 50 nM.



Purity: 98.39%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg

EED inhibitor-1

Cat. No.: HY-103663

EED inhibitor-1 is an embryonic ectoderm development (**EED**) inhibitor extracted from patent US20160176882 A1, compound example 2; has IC_{50}s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

EED226

Cat. No.: HY-101117

EED226 is a potent, selective, and orally bioavailable embryonic ectoderm development (**EED**) inhibitor with an IC_{50} of 22 nM.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EF-5

Cat. No.: HY-U00118

EF-5 (EF5; 2-Nitroimidazole) is a hypoxia labeling agent used to identify hypoxia in cells.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Efaproxiral

(RSR13)

Cat. No.: HY-13619

Efaproxiral is a **haemoglobin (Hb)** synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy .



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg

Efaproxiral sodium

(RSR13 sodium)

Cat. No.: HY-13619A

Efaproxiral sodium is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg

EG00229

Cat. No.: HY-10799

EG00229 is the first small molecule inhibitors of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 uM(125I-VEGF binding to PAE/NRP1 cells).



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EG01377

Cat. No.: HY-112151

EG01377 is a **neuropilin-1 (NRP1)** antagonist, with a K_d of 1.32 μM for NRP1-b1, and IC_{50}s of both 609 nM for NRP1-a1 and NRP1-b1, but shows no effect on NRP2; EG01377 has antiangiogenic, antimigratory, and antitumor effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Eg5 Inhibitor V, trans-24

Cat. No.: HY-112915

Eg5 Inhibitor V, trans-24 is a potent and specific **kinesin Eg5** inhibitor with an IC_{50} of 0.65 μM, and can be used in the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

EGFR-IN-2

Cat. No.: HY-100520

EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation **EGFR** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

EGFR-IN-3

Cat. No.: HY-19815

EGFR-IN-3 is an epidermal growth factor receptor **(EGFR)** inhibitor.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-5

Cat. No.: HY-111415

EGFR-IN-5 is a **EGFR** inhibitor with IC_{50}s of 10.4, 1.1, 34, 7.2 nM for EGFR, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, and $EGFR^{L858R/T790M/C797S}$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

EGFRvIII peptide PEPvIII

Cat. No.: HY-P1828

EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy.

LEEKKGNYVVTDHC

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EHMT2-IN-1

Cat. No.: HY-111778

EHMT2-IN-1 is a potent **EHMT** inhibitor, with IC_{50}s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disorder or cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

EHMT2-IN-2

Cat. No.: HY-111904

EHMT2-IN-2 is a potent **EHMT** inhibitor, with IC_{50}s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disease or cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

EHop-016

Cat. No.: HY-12810

EHop-016 is a novel potent and selective inhibitor of Rac GTPase; inhibits Rac1 activity in MDA-MB-435 cells with an IC50 of 1.1 uM.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

EI1

(KB-145943)

Cat. No.: HY-15573

EI1 (KB-145943) is a potent and selective **EZH2** inhibitor with **IC_{50}** of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

eIF4A3-IN-1

Cat. No.: HY-101513

eIF4A3-IN-1 (compound 53a) is a selective **eukaryotic initiation factor 4A3 (eIF4A3)** inhibitor (**IC_{50}**=0.26 μM; **K_d**=0.043 μM), which binds to a non-ATP binding site of eIF4A3 and shows significant cellular nonsense-mediated RNA decay (NMD) inhibition at 10 and 3 μM and can be as...



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

eIF4A3-IN-2

Cat. No.: HY-101785

eIF4A3-IN-2 is a highly selective and noncompetitive **eukaryotic initiation factor 4A-3 (eIF4A3)** inhibitor with an **IC_{50}** of 110 nM.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EIPA

(L593754; MH 12-43; Ethylisopropylamiloride)

Cat. No.: HY-101840

EIPA is a **TRPP3 channel** inhibitor with an **IC_{50}** of 10.5 μM. EIPA also inhibits **Na^+/H^+-exchanger (NHE)** and **macropinocytosis**.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

EIPA hydrochloride (L593754 hydrochloride; MH 12-43 hydrochloride; Ethylisopropylamiloride hydrochloride)

Cat. No.: HY-101840A

EIPA hydrochloride (L593754 hydrochloride) is a **TRPP3 channel** inhibitor with an **IC_{50}** of 10.5 μM. EIPA also inhibits **Na^+/H^+-exchanger (NHE)** and **macropinocytosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

EL-102

Cat. No.: HY-16187

EL102 is a inhibitor of HIF1α , Which can inhibit tubulin polymerisation and decreased microtubule stability.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Elacestrant

(RAD1901)

Cat. No.: HY-19822

Elacestrant (RAD1901) is a selective and orally available estrogen receptor (**ER**) degrader with **IC_{50}** values of 48 and 870 nM for ERα and ERβ, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Elacestrant dihydrochloride

(RAD1901 dihydrochloride)

Cat. No.: HY-19822A

Elacestrant dihydrochloride (RAD1901 dihydrochloride) is a selective and orally available estrogen receptor (**ERR**) degrader with **IC_{50}** values of 48 and 870 nM for ERα and ERβ, respectively.



Purity: 98.93%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Elacestrant S enantiomer

(RAD1901 S enantiomer;)

Cat. No.: HY-19822D

Elacestrant S enantiomer is an low activity enantiomer of elacestrant. Elacestrant (RAD1901) is a selective and orally available estrogen receptor (**ERR**) degrader with **IC_{50}** values of 48 and 870 nM for ERα and ERβ, respectively.



Purity: >98%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Elacestrant S enantiomer dihydrochloride (RAD1901 S enantiomer dihydrochloride; ...)

Cat. No.: HY-19822B

Elacestrant S enantiomer dihydrochloride is an low activity enantiomer of elacestrant dihydrochloride.



Purity: 94.83%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Elacridar

(GF120918; GW0918; GG918; GW120918)

Cat. No.: HY-50879

Elacridar is a potent **P-glycoprotein (Pgp)** and **BCRP** inhibitor.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Elacridar hydrochloride

(GF120918A)

Cat. No.: HY-50880

Elacridar hydrochloride (GF120918A) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Elacytarabine

(CP 4055)

Cat. No.: HY-14941

Elacytarabine (CP 4055) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine (CP 4055) is an antineoplastic drug with cytotoxicity in solid tumors.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Elagolix

(NBI-56418)

Cat. No.: HY-14789

Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).



Purity: 98.06%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Elaiophylin

(Azalomycin B; Gopalamicin; Efomycin E)

Cat. No.: HY-15184

Elaiophylin (Azalomycin B; Gopalamicin; Efomycin E) is an **autophagy** inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Elesclomol

(STA-4783)

Cat. No.: HY-12040

Elesclomol is an **oxidative stress** inducer that induces cancer cell apoptosis.



Purity: 99.80%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ellagic acid

Cat. No.: HY-B0183

Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive **CK2** inhibitor, with an IC_{50} of 40 nM and a K_i of 20 nM.



Purity: 99.92%
Clinical Data: Phase 2
Size: 1 g, 5 g

Ellipticine

(NSC 71795)

Cat. No.: HY-15753

Ellipticine (NSC 71795) is a potent antineoplastic agent; inhibits **DNA topoisomerase II** activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Ellipticine hydrochloride

(NSC 71795 (hydrochloride))

Cat. No.: HY-15753A

Ellipticine (NSC 71795) hydrochloride is a potent antineoplastic agent; inhibits **DNA topoisomerase II** activities.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ELN-441958

Cat. No.: HY-15043

ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ELR510444

Cat. No.: HY-16191

ELR510444 is a novel microtubule disruptor; inhibits MDA-MB-231 cell proliferation with IC50 of 30.9 nM; not a substrate for the P-glycoprotein drug transporter and retains activity in βIII-tubulin-overexpressing cell lines.



Purity: 95.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Eltanexor Z-isomer

(KPT-8602 (Z-isomer))

Cat. No.: HY-100423A

Eltanexor Z-isomer (KPT-8602 Z-isomer) is the less active isomer of KPT-8602. KPT-8602 is a potent **CRM1** inhibitor. IC50 In Vitro: Eltanexor Z-isomer exhibits different inhibitory effects on Z138, MM15, 3T3 cell lines, with IC_{50}s of 100 nM-50 μM, < 100 nM, > 30 μM, respectively.



Purity: 95.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Embelin

(Embelic acid; Emberine; NSC 91874)

Cat. No.: HY-17473

Embelin is a cell-permeable benzoquinone compound that exhibits antitumor properties. Specifically antagonizes XIAP-mediated inhibition of caspase-9 activation by directly targeting the Smac and caspase-9 binding domain BIR3 (IC50 = 4.1 uM in a competitive binding assay with Smac peptide).



Purity: 98.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

EMD534085

Cat. No.: HY-15000

EMD534085 is a potent and selective inhibitor of the mitotic **kinesin-5** with an IC_{50} of 8 nM.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Emeramide

(BDTH2)

Cat. No.: HY-16739

Emeramide is a novel lipid-soluble, thiol-redox antioxidant and heavy metal chelator.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

EML4-ALK kinase inhibitor 1

Cat. No.: HY-111752

EML4-ALK kinase inhibitor 1 is a potent oral active inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase **(EML4-ALK)**, with an IC_{50} of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

EML741

Cat. No.: HY-111544

EML741 is a histone lysine methyltransferase **G9a/GLP** inhibitor, with an IC_{50} of 23 nM, K_d of 1.13 μM for G9a. EML741 also inhibits DNMT1 (IC_{50}, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Emodin

(Frangula emodin)

Cat. No.: HY-14393

Emodin is a broad-spectrum anticancer agent. Emodin inhibits **casein kinase** II (CKII) activity with IC_{50} of 2 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Empesertib

(BAY 1161909)

Cat. No.: HY-12858

Empesertib (BAY 1161909) is a potent **Mps1** inhibitor, with an IC_{50} of < 1 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Emricasan

(PF 03491390; IDN-6556)

Cat. No.: HY-10396

Emricasan (PF 03491390) is an irreversible **pan-caspase** inhibitor.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EMT inhibitor-1

Cat. No.: HY-101275

EMT inhibitor-1 is an inhibitor of of **Hippo**, **TGF-β**, and **Wnt** signaling pathways with antitumor activities.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Enasidenib

(AG-221)

Cat. No.: HY-18690

Enasidenib is an oral, potent, reversible, selective inhibitor of the **IDH2** mutant enzymes, with IC_{50}s of 100 and 400 nM against $IDH2^{R140Q}$ and $IDH2^{R172K}$, respectively.



Purity: 99.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Enasidenib mesylate

(AG-221 mesylate)

Cat. No.: HY-18690A

Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the **IDH2** mutant enzymes.



Purity: 99.25%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Encequidar mesylate

(HM30181 (mesylate); HM30181A (mesylate))

Cat. No.: HY-13646A

Encequidar (mesylate) (HM30181 (mesylate)) is a competitive and potent **P-glycoprotein** inhibitor.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Encorafenib

(LGX818)

Cat. No.: HY-15605

Encorafenib (LGX818) is a highly potent **BRAF** inhibitor with selective anti-proliferative and apoptotic activity in cells expressing $BRAF^{V600E}$ (EC_{50}=4 nM).



Purity: 99.63%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Endoxifen

Cat. No.: HY-18719E

Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to **estrogen receptor** that also inhibits aromatase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Endoxifen E-isomer

(E-Endoxifen)

Cat. No.: HY-18719D

Endoxifen E-isomer is the E-isomer of (Z)-Endoxifen. (Z)-Endoxifen, an active metabolite generated via actions of CYP3A4/5 and CYP2D6, is a more potent selective **estrogen receptor** modulator (**SERM**) than Tamoxifen.



Purity: 97.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Endoxifen E-isomer hydrochloride

(E-Endoxifen hydrochloride)

Cat. No.: HY-18719C

Endoxifen (E-isomer hydrochloride) is a tamoxifen metabolite and potent Selective Estrogen Response Modifier (SERM).



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Endoxifen hydrochloride

Cat. No.: HY-18719B

Endoxifen hydrochloride, the active metabolite of Tamoxifen, is a potent antiestrogen that targets **estrogen receptor**.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Endoxifen Z-isomer

Cat. No.: HY-18719

Endoxifen Z-isomer is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Endoxifen Z-isomer hydrochloride

Cat. No.: HY-18719A

Endoxifen Z-isomer hydrochloride is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα).



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Eniluracil

(5-Ethynyluracil; GW776C85)

Cat. No.: HY-10533

Eniluracil (5-Ethynyluracil), a uracil analogue and a mechanism-based irreversible inhibitor of **dihydropyrimidine dehydrogenase (DPD)**, increases the oral bioavailability of 5-fluorouracil (5-FU) to 100%, facilitating uniform absorption and predictable toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ENMD-119

(ENMD 1198; IRC 110160)

Cat. No.: HY-16196

ENMD-119 is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity, and is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.23%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Enniatin A1

Cat. No.: HY-N6704

Enniatin A1 isolated from Fusarium mycotoxins is a cyclic hexadepsipeptide consisting of alternating D-α-hydroxyisovaleric acids and N-methyl-L-amino acids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enniatin B

Cat. No.: HY-N3806

Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (**ACAT**) activity with an IC_{50} of 113 μM in an enzyme assay using rat liver microsomes. Enniatins B decreases the activation of **ERK** (p44/p42).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enniatin B1

Cat. No.: HY-N3807

Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (**ACAT**) activity with an IC_{50} of 73 μM in an enzyme assay using rat liver microsomes. Enniatin B1 crosss the blood-brain barrier.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enniatin complex

Cat. No.: HY-N6706

Enniatin complex is a mixture of cyclohexadepsipeptides isolated largely from Fusarium species of fungi, and has ionophoric, antibiotic, and in vitro hypolipidaemic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ensartinib

(X-396)

Cat. No.: HY-103714

Ensartinib (X-396) is a potent and dual **ALK/MET** inhibitor with IC_{50}s of <0.4 nM and 0.74 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Ensartinib hydrochloride

(X-396 hydrochloride) Cat. No.: HY-103714A

Ensartinib hydrochloride (X-396 hydrochloride) is a potent and dual **ALK/MET** inhibitor with **IC_{50}**s of <0.4 nM and 0.74 nM, respectively.



Purity: 98.51%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg

Entasobulin

Cat. No.: HY-16777

Entasobulin is a **β-tubulin** polymerization inhibitor with potential anticancer activity.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Entinostat

(MS-275; SNDX-275) Cat. No.: HY-12163

Entinostat is an oral and selective class I **HDAC** inhibitor, with **IC_{50}**s of 243 nM, 453 nM, and 248 nM for **HDAC1**, **HDAC2**, and **HDAC3**, respectively.



Purity: 99.65%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Entospletinib

(GS-9973) Cat. No.: HY-15968

Entospletinib (GS-9973) is an orally bioavailable, selective **Syk** inhibitor with an **IC_{50}** of 7.7 nM.



Purity: 99.23%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Entrectinib

(NMS-E628; RXDX-101) Cat. No.: HY-12678

Entrectinib is a potent and orally available **Trk**, **ROS1**, and **ALK** inhibitor; inhibits TrkA, TrkB, TrkC, ROS1 and ALK with **IC_{50}** values of 1, 3, 5, 12 and 7 nM, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Enzalutamide

(MDV3100) Cat. No.: HY-70002

Enzalutamide (MDV3100) is an **androgen receptor (AR)** antagonist with an **IC_{50}** of 36 nM in LNCaP prostate cells.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Enzastaurin

(LY317615) Cat. No.: HY-10342

Enzastaurin is a potent and selective **PKCβ** inhibitor with an **IC_{50}** of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε.



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

EOAI3402143

Cat. No.: HY-111408

EOAI3402143 is a **deubiquitinase** (**DUB**) inhibitor, which inhibits dose-dependently inhibits **Usp9x/Usp24** and **Usp5**.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EPAC 5376753

Cat. No.: HY-111446

EPAC 5376753 is an allosterically inhibitor of **Epac** which inhibits Epac1 with an **IC_{50}** of 4 μM in Swiss 3T3 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Epertinib

(S-22611) Cat. No.: HY-107367

Epertinib is a potent, oral, reversible, and selective tyrosine kinase inhibitor of **EGFR**, **HER2** and **HER4**, with **IC_{50}**s of 1.48 nM, 7.15 nM and 2.49 nM, respectively; Epertinib shows potent antitumor activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg

Epibrassinolide

(24-Epibrassinolide; B1105; BP55) Cat. No.: HY-N0848

Epibrassinolide is a natural brassinosteroid (BR) derivative, is a plant regulator with a similar structure to mammalian steroids. Epibrassinolide is a potential **apoptotic inducer** in various cancer cells without affecting the non-tumor cell growth.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg

Epimedin A1

(Hexandraside F) Cat. No.: HY-N0258

Epimedin A1 is a flavonoid extracted from Herba Epimedii which is one of commonly used Chinese medicines.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Epirubicin

Cat. No.: HY-13624

Epirubicin is a semisynthetic L-arabino derivative of doxorubicin, and an antineoplastic agent by inhibiting **Topoisomerase**.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg

Epirubicin hydrochloride

(4'-Epidoxorubicin hydrochloride) Cat. No.: HY-13624A

Epirubicin (hydrochloride) is a semisynthetic L-arabino derivative of doxorubicin, and an antineoplastic agent by inhibiting **Topoisomerase**.



Purity: 98.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Episilvestrol

Cat. No.: HY-15359

Episilvestrol is a derivative of silvestrol, isolated from the fruits and twigs of Aglaia silvestris, and is a specific **eIF4A**-targeting translation inhibitor, with antitumor activity.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Epothilone A

(Epo A) Cat. No.: HY-13503

Epothilone A is a competitive inhibitor of the binding of [^{3}H] paclitaxel to **tubulin** polymers, with a K_i of 0.6-1.4 μM.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Epothilone B

(EPO 906; Patupilone) Cat. No.: HY-17029

Epothilone B is a **microtubule** stabilizer with a K_i of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.



Purity: 99.88%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Epothilone D

(KOS 862) Cat. No.: HY-15278

Epothilone D (KOS 862) is a potent **microtubule** stabilizer.



Purity: 99.93%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Epoxomicin

(BU-4061T) Cat. No.: HY-13821

Epoxomicin is a cell-permeable and irreversible **proteasome** inhibitor, primarily the chymotrypsin-like activity.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 μg, 1 mg, 5 mg, 10 mg, 20 mg

Epristeride

(ONO-9302; SKF105657) Cat. No.: HY-107385

Epristeride is a novel **5α-reductase** inhibor.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Epsilon-momfluorothrin

Cat. No.: HY-111634

Epsilon-momfluorothrin is a type I synthetic pyrethroid insecticide, activates **constitutive androstane receptor (CAR)**, and induces hepatocellular tumors in rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

EPZ004777

Cat. No.: HY-15227

EPZ004777 is a potent, selective **DOT1L** inhibitor with an IC_{50} of 0.4 nM.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EPZ004777 hydrochloride

Cat. No.: HY-15227A

EPZ004777 hydrochloride is a potent, selective **DOT1L** inhibitor with IC_{50} of 0.4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EPZ005687

Cat. No.: HY-15555

EPZ005687 is a potent and selective inhibitor of **EZH2** with K_i of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EPZ011989

Cat. No.: HY-16986

EPZ011989 is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EPZ011989 trifluoroacetate

(EPZ-011989 trifluoroacetate)

Cat. No.: HY-16986A

EPZ011989 trifluoroacetate is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

EPZ015666

(GSK3235025)

Cat. No.: HY-12727

EPZ015666 (GSK3235025) is an orally available inhibitor of **PRMT5** with an IC_{50} of 22 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EPZ015866

(GSK591; GSK3203591)

Cat. No.: HY-100235

EPZ015866 is a potent and selective inhibitor of **protein methyltransferase 5 (PRMT5)** with an IC_{50} of 22 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EPZ020411

Cat. No.: HY-12970

EPZ020411 is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has 10 fold selectivity for PRMT6 over PRMT1 and PRMT8.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

EPZ020411 hydrochloride

Cat. No.: HY-12970A

EPZ020411 hydrochloride is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has 10 fold selectivity for PRMT6 over PRMT1 and PRMT8. IC50 value: 10 nM Target: PRMT6 in vitro: EPZ020411 inhibits methylation of PRMT6 substrates in cells.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

EPZ031686

Cat. No.: HY-19324

EPZ031686 is an orally available **SMYD3** inhibitor with an IC_{50} of 3 nM in cell-free assay.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ER-000444793

Cat. No.: HY-100852

ER-000444793 is a potent inhibitor of mitochondrial permeability transition pore (**mPTP**) opening. ER-000444793 inhibits mPTP with an IC_{50} of 2.8μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Erastin

Cat. No.: HY-15763

Erastin is a **ferroptosis** inducer. Erastin binds and inhibits voltage-dependent anion channels (**VDAC2/VDAC3**).



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

ERD-308

Cat. No.: HY-128600

ERD-308 is a highly potent PROTAC degrader of **estrogen receptor (ER)** for ER positive breast cancer treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Erdafitinib

(JNJ-42756493)

Cat. No.: HY-18708

Erdafitinib (JNJ-42756493) is a potent and orally available **FGFR** family inhibitor; inhibits FGFR1/2/3/4 with IC_{50}s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.



Purity: 99.29%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Erianin

Cat. No.: HY-N0517

Erianin, often used as an antipyretic and analgesic agent, could inhibit IDO-induced tumor angiogenesis.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Eribulin

(B1939; E7389; ER-086526)

Cat. No.: HY-13442

Eribulin (E7389) is a **microtubule** targeting agent that is used in the treatment of metastatic breast cancer. Eribulin (E7389) inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.



Purity: >98%
Clinical Data: Launched
Size: 1 mg

Eribulin mesylate

(B1939 mesylate; E7389 mesylate; ER-086526 mesylate)

Cat. No.: HY-13442A

Eribulin mesylate (E7389 mesylate) is a **microtubule** targeting agent that is used in the treatment of metastatic breast cancer. Eribulin mesylate (E7389 mesylate) inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.



Purity: 98.97%
Clinical Data: Launched
Size: 500 μg, 1 mg

Erismodegib

(LDE225; NVP-LDE 225)

Cat. No.: HY-16582A

Erismodegib (LDE225) is a potent and selective **Smoothened (Smo)** antagonist with IC_{50}s of 1.3 nM and 2.5 nM for mouse and human Smo, respectively.



Purity: 99.68%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Erismodegib diphosphate

(LDE225 diphosphate; NVP-LDE 225 diphosphate)

Cat. No.: HY-16582

Erismodegib diphosphate (LDE225 diphosphate) is a potent and selective **Smo** antagonist with IC_{50} of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively.



Purity: 99.83%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ERK-IN-1

Cat. No.: HY-114491

ERK-IN-1 (compound B) is a **RAF** and **ERK1/2** inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

ERK1/2 inhibitor 1

Cat. No.: HY-112287

ERK1/2 inhibitor 1 is a potent, orally bioavailable **ERK1/2** inhibitor, showing 60% inhibition at 1 nM and an IC_{50} of 3.0 nM against ERK1 and ERK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

ERK2 IN-1

Cat. No.: HY-112300

ERK2 IN-1 is a selective **ERK2** inhibitor with an IC_{50} of 7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

ERK5-IN-1

Cat. No.: HY-14403

ERK5-IN-1 is a potent **ERK5** inhibitor with an IC_{50} of 87±7 nM. ERK5-IN-1 also inhibits **LRRK2**[G2019S] with an IC_{50} of 26 nM.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ERK5-IN-2

Cat. No.: HY-128341

ERK5-IN-2 is an orally active, sub-micromolar, selective **ERK5** inhibitor with IC_{50}s of 0.82 μM, 3 μM for **ERK5** and **ERK5 MEF2D**, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Erlotinib

(CP-358774; NSC 718781; OSI-774)

Cat. No.: HY-50896

Erlotinib is a medication for the treatment of non-small cell lung cancer. It inhibits purified **EGFR** kinase with an IC_{50} of 2 nM.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Erlotinib Hydrochloride (CP-358774 (Hydrochloride); NSC 718781 (Hydrochloride); OSI-774 (Hydrochloride))

Cat. No.: HY-12008

Erlotinib Hydrochloride inhibits purified **EGFR** kinase with an IC_{50} of 2 nM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Erlotinib mesylate (CP-358774 (mesylate); NSC 718781 (mesylate); OSI-774 (mesylate))

Cat. No.: HY-12008A

Erlotinib mesylate inhibits purified **EGFR** kinase with an IC_{50} of 2 nM.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg

ERRγ Inverse Agonist 1

Cat. No.: HY-114411

ERRγ Inverse Agonist 1 (Compound 12) is a potent, selective and orally bioavailable **Estrogen-related Receptor grammar (ERRγ)** inverse agonist, with an IC_{50} of 40 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

ERα ligand 1

Cat. No.: HY-111845

ERα ligand 1 is an estrogen ligand, which targets estrogen receptor α (ERα). ERα ligand 1 binds to **cIAP1** ligand Bestatin via a linker to form **PROTACs**.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

ESI-09

Cat. No.: HY-16704

ESI-09 is a novel noncyclic nucleotide **EPAC** antagonist with IC_{50} values of 3.2 and 1.4 μM for EPAC1 and EPAC2, respectively.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Estradiol 3-sulfamate

(BLE 00084; E2MATE; ES-J 995)

Cat. No.: HY-U00112

Estradiol 3-sulfamate (BLE 00084; E2MATE; ES-J 995) is a potent, long-acting, and orally active **steroid sulfatase** inhibitor; inhibits estrone sulfatase with an IC_{50} of 251 nM and a K_i of 133 nM.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Estramustine phosphate sodium

Cat. No.: HY-13627

Estramustine phosphate sodium is an antimicrotubule chemotherapy agent; arrests prostate cancer cells in the G2/M phase of the cell cycle.



Purity: 98.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Estriol

(Oestriol)

Cat. No.: HY-B0412

Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.

Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

ETC-159

(ETC-1922159)

Cat. No.: HY-18988

ETC-159 is a potent, orally available **PORCN** inhibitor. It inhibits β-catenin reporter activity with an IC_{50} of 2.9 nM.



Purity: 98.67%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ETC-206

Cat. No.: HY-112424

ETC-206 is a selective **MNK1** and **MNK2** inhibitor with IC_{50}s of 64 nM and 86 nM, respectively.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ethoxyquin

Cat. No.: HY-B1425

Ethoxyquin is an antioxidant which has been used in animal feed for many years and also an inhibitor of **heat shock protein 90** (**Hsp90**).



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

Ethynylcytidine

(ECyD; TAS-106; 3'-C-Ethynylcytidine)

Cat. No.: HY-16200

Ethynylcytidine is a new **nucleoside antimetabolite**.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Etoposide

(VP-16; VP-16-213)

Cat. No.: HY-13629

Etoposide (VP-16; VP-16-213), a chemotherapy medication used for the treatments of a number of types of cancer, inhibits **DNA synthesis** by forming a complex with topoisomerase II and DNA. Etoposide arrests cell cycle in G2 and induces apoptosis.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

ETP-46321

Cat. No.: HY-12340

ETP-46321 is a potent and orally bioavailable **PI3Kα** and **PI3Kδ** inhibitor with K_{iapp}s of 2.3 and 14.2 nM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ETP-46464

Cat. No.: HY-15521

ETP-46464 is an effective **mTOR** and **ATR** inhibitor with IC_{50}s of 0.6 and 14 nM, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Eupatorin

Cat. No.: HY-N2374

Eupatorin, a naturally occurring flavone, arrests cells at the G2-M phase of the cell cycle and induces apoptotic cell death involving activation of multiple caspases, mitochondrial release of cytochrome c and poly(ADP-ribose) polymerase cleavage.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Everolimus

(RAD001; SDZ-RAD)

Cat. No.: HY-10218

Everolimus (RAD001) is a potent **mTOR** inhibitor that binds to FKBP-12 to generate an immunosuppressive complex.



Purity: 98.79%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Evobrutinib

(M2951; MSC2364447C)

Cat. No.: HY-101215

Evobrutinib is an inhibitor of Bruton's tyrosin kinase (**Btk**) inhibitor extracted from patent US20140162983 example 0174.



Purity: 98.17%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Evodiamine

((+)-Evodiamine; d-Evodiamine)

Cat. No.: HY-N0114

Evodiamine is an alkaloid isolated from the fruit of Evodia rutaecarpa Bentham with diverse biological activities including anti-inflammatory, anti-obesity, and antitumor.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Evofosfamide

(TH-302)

Cat. No.: HY-10535

Evofosfamide (TH-302) is a **hypoxia**-activated prodrug with IC_{50} of 10 μM and 1000 μM in hypoxia (N_2) and normoxia (21% O_2), respectively.



Purity: 98.13%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Exatecan

(DX-8951)

Cat. No.: HY-13631

Exatecan is a water soluble **topoisomerase I** inhibitor, with an IC_{50} of 2.2 μM (0.975 μg/mL), and can be used in cancer research.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg

Exatecan Mesylate

(DX8951f)

Cat. No.: HY-13631A

Exatecan Mesylate is a water soluble **topoisomerase I** inhibitor, with an IC_{50} of 2.2 μM (0.975 μg/mL), and can be used in cancer research.



Purity: 99.12%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg, 500 mg

Exemestane

(FCE 24304; EXE)

Cat. No.: HY-13632

Exemestane(FCE 24304) is an aromatase inhibitor, inhibits human placental and rat ovarian aromatase with IC50 of 30 nM and 40 nM, respectively.



Purity: 97.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ezatiostat

(TER199(free base); TLK199)

Cat. No.: HY-13634A

Ezatiostat (TER199 free base; TLK199) is a glutathione analog inhibitor of **glutathione S-transferase P1-1 (GSTP1-1)**.



Purity: >96.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ezatiostat hydrochloride

(TER199; TLK199 (hydrochloride))

Cat. No.: HY-13634

Ezatiostat hydrochloride (TER199;TLK199 hydrochloride) is a glutathione analog inhibitor of **glutathione S-transferase P1-1 (GSTP1-1)**.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

EZM 2302

Cat. No.: HY-111109

EZM 2302 is an inhibitor of coactivator-associated arginine methyltransferase 1 (**CARM1**) with an IC_{50} of 6nM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ezutromid

(SMT C1100; BMN 195; VOX-C1100)

Cat. No.: HY-17614

Ezutromid is a novel Small utrophin's translation modulator with EC50 of 0.4 uM . In vitro: 1) SMT C1100 induces increased levels of utrophin RNA in human muscle cells.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

F-1

Cat. No.: HY-112801

F-1 is a potent **ALK** and **ROS1** dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC_{50}s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK^{WT}, $ROS1^{WT}$, ALK^{L1196M} and ALK^{G1202R}, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

F1063-0967

Cat. No.: HY-101510

F1063-0967 is a **Dual-specificity phosphatase 26** (**DUSP26**) inhibitor with an IC_{50} of 11.62 μM.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

F16

Cat. No.: HY-100395

F16 is a small molecule that selectively inhibits proliferation of mammary epithelial, neu-overexpressing cells, as well as a variety of mouse mammary tumor and human breast cancer cell lines.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

FAAH inhibitor 1

Cat. No.: HY-10862

FAAH inhibitor 1 is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 18±8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Fadrozole

Cat. No.: HY-14247A

Fadrozole is a potent, selective and nonsteroidal inhibitor of **aromatase** with an IC_{50} of 6.4 nM.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fadrozole hydrochloride

(CGS 16949A)

Cat. No.: HY-14247

Fadrozole hydrochloride is a potent, selective and nonsteroidal inhibitor of **aromatase** with an IC_{50} of 6.4 nM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FAK inhibitor 2

Cat. No.: HY-128580

FAK inhibitor 2 is a potent **focal adhesion kinase (FAK)** inhibitor with an IC_{50} of 0.07 nM, with antitumor and anti-angiogenesis activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Falnidamol

(BIBX 1382)

Cat. No.: HY-10322

Falnidamol (BIBX 1382) is a potent, selective inhibitor of EGFR tyrosine kinase (IC_{50} = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC_{50} = 3.4 μM) and a range of other related tyrosine kinases (IC_{50} > 10 μM).



Purity: 98.07%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

FAPI-2

Cat. No.: HY-128642

FAPI-2 is a **fibroblast activation protein (FAP)** inhibitor for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FAPI-4

Cat. No.: HY-128643

FAPI-4 is a **fibroblast activation protein (FAP)** inhibitor used in cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FAS-IN-1 Tosylate

Cat. No.: HY-12648A

FAS-IN-1 Tosylate is a potent inhibitor of fatty acid synthase (**FAS**) extracted from patent WO 2012064642 A1, compound 29; has an IC_{50} of 10 nM.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

FASN inhibitor 1

Cat. No.: HY-U00436

FASN inhibitor 1 is a **fatty acid synthase** (**FASN**) inhibitor extracted from patent US20170119786A1, compound 242A.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FASN-IN-1

Cat. No.: HY-111777

FASN-IN-1 is a **fatty acid synthase (FASN)** inhibitor extracted from patent WO2015134790A1, compound 56.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fasudil

(HA-1077; AT877)

Cat. No.: HY-10341A

Fasudil (HA-1077; AT877), a potent inhibitor of **ROCK** with a K_i of 0.33 μM for ROCK1, which is also a potent **Ca^{2+} channel** antagonist and vasodilator.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Fasudil Hydrochloride

(HA-1077 (Hydrochloride); AT-877 (Hydrochloride))

Cat. No.: HY-10341

Fasudil Hydrochloride (HA-1077 Hydrochloride; AT-877 Hydrochloride), a potent inhibitor of **ROCK** with a K_i of 0.33 μM for ROCK1, which is also a potent **Ca^{2+} channel** antagonist and vasodilator.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Fatostatin

(125B11)

Cat. No.: HY-14452

Fatostatin (125B11) is an inhibitor of SREBP that directly binds SCAP and blocks its ER-to-Golgi transport with IC_{50} of 2.5 and 10 μM in mammalian cells.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FB23-2

Cat. No.: HY-127103

FB23-2 is a potent and selective inhibitor of mRNA N^6-methyladenosine (m^6A) demethylase **FTO**, with an IC_{50} of 2.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FCCP

(Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) Cat. No.: HY-100410

FCCP is an uncoupler of oxidative phosphorylation in mitochondria.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

FD 12-9

(Ac12Az9) Cat. No.: HY-128685

FD 12-9 is a flavonoid dimer, acts as a dual inhibitor of **P-gp** and **BCRP**, with EC_{50}s of 285 nM and 0.9 nM, respectively. Anti-glioblastoma activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FDI-6

Cat. No.: HY-112721

FDI-6 is an inhibitor of **FOXM1**. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Fedratinib

(TG-101348; SAR 302503) Cat. No.: HY-10409

Fedratinib (TG-101348) is a selective inhibitor of **JAK2** with an IC_{50} of 3 nM, showing 35- and 334-fold selectivity over JAK1 and JAK3, respectively.



Purity: 98.62%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fenebrutinib

(GDC-0853) Cat. No.: HY-19834

Fenebrutinib (GDC-0853) is a potent, selective, and noncovalent bruton's tyrosine kinase (**Btk**) inhibitor with a K_i of 0.91 nM.



Purity: 99.50%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fenretinide

(4-HPR) Cat. No.: HY-15373

Fenretinide is a synthetic retinoid deriverative, binding to the retinoic acid receptors (**RAR**) at concentrations necessary to induce cell death.



Purity: 99.41%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ferrostatin-1

Cat. No.: HY-100579

Ferrostatin-1 is a potent inhibitor of **ferroptosis** with an EC_{50} of 60 nM.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Ferulic acid

(Coniferic acid) Cat. No.: HY-N0060

Ferulic acid is a novel fibroblast growth factor receptor 1 (**FGFR1**) inhibitor with IC_{50}s of 3.78 and 12.5 μM for **FGFR1** and **FGFR2**, respectively.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

Fevipiprant

(NVP-QAW039; QAW039) Cat. No.: HY-16768

Fevipiprant(QAW039) is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood.



Purity: 98.73%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

FGFR1/DDR2 inhibitor 1

Cat. No.: HY-114311

FGFR1/DDR2 inhibitor 1 (compound 11k) is an inhibitor of **fibroblast growth factor receptor 1 (FGFR1)** and **discoindin domain receptor 2 (DDR2)**, with IC_{50} values of 31.1 nM, 108.4 nM and 3.2 nM for FGFR1, KG-1, and DDR2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FGTI-2734

Cat. No.: HY-128350

FGTI-2734 is a RAS C-terminal mimetic dual **farnesyl transferase (FT)** and **geranylgeranyl transferase-1 (GGT)** inhibitor with IC_{50}s of 250 nM and 520 nM for **FT** and **GGT**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FH535

Cat. No.: HY-15721

FH535 is an inhibitor of **Wnt/β-catenin** and **PPAR**, with anti-tumor activities.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Fibronectin CS1 Peptide

Cat. No.: HY-P1816

The connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FIIN-2

Cat. No.: HY-18602

FIIN-2 is an irreversible inhibitor of **FGFR** with an IC_{50} of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

FIIN-3

Cat. No.: HY-18603

FIIN-3 is an irreversible inhibitor of **FGFR** with an IC_{50} of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Filanesib

(ARRY-520)

Cat. No.: HY-15187

Filanesib (ARRY-520) is a synthetic **kinesin spindle protein (KSP)** inhibitor with IC_{50} of 6 nM.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Filgotinib

(GLPG0634)

Cat. No.: HY-18300

Filgotinib (GLPG0634) is a selective **JAK1** inhibitor with IC_{50} of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.



Purity: 99.64%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fimepinostat

(CUDC-907)

Cat. No.: HY-13522

Fimepinostat (CUDC-907) potently inhibits class I **PI3K**s as well as classes I and II **HDAC** enzymes with an IC_{50} of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Finasteride

(MK-906)

Cat. No.: HY-13635

Finasteride is an orally active testosterone 5-alpha-reductase inhibitor (Ki= 10 nM).



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

Finasteride acetate

(MK-906 acetate)

Cat. No.: HY-13635A

Finasteride (acetate) is an orally active testosterone 5-alpha-reductase inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg

Fisetin

Cat. No.: HY-N0182

Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Fisogatinib

(BLU-554)

Cat. No.: HY-100492

Fisogatinib (BLU-554) is a potent fibroblast growth factor receptor 4 (**FGFR4**) inhibitor.



Purity: 99.84%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

FITM

Cat. No.: HY-101845

FITM is a negative allosteric modulator of **mGlu1** receptor with a K_i of 2.5 nM.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FL-411

(BRD4-IN-1)

Cat. No.: HY-111102

FL-411 is a potent and selective **BRD4** inhibitor with an IC_{50} of 0.43±0.09 μM for **BRD4(1)**.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Flavopiridol

(L868275; HMR-1275; Alvocidib)

Cat. No.: HY-10005

Flavopiridol is a broad spectrum and competitive inhibitor of **CDKs**, inhibiting CDK1, CDK2, CDK4 with IC_{50}s of 30, 170, 100 nM, respectively.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Flavopiridol Hydrochloride (HL 275; NSC 649890; MDL 107826A; FLAVOPIRIDOL HCL; Alvocidib Hydrochloride)

Cat. No.: HY-10006

Flavopiridol Hydrochloride is a broad inhibitor of **CDK**, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC_{50}s of 30, 170, 100 nM, respectively.



Purity: 99.00%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FLI-06

Cat. No.: HY-15860

FLI-06 is an inhibitor of **Notch** signaling with an EC_{50} of 2.3 μM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

FLLL32

Cat. No.: HY-100544

FLLL32, a synthetic analog of curcumina, is a **JAK2/STAT3** dual inhibitor with anti-tumor activity.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Floxuridine

(5-Fluorouracil 2'-deoxyriboside)

Cat. No.: HY-B0097

Floxuridine (5-fluorodeoxyuridine) is an oncology drug that belongs to the class known as antimetabolites with an GI50 of 5.1 μM for the inhibition of PEPT1.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

FLT3-IN-1

Cat. No.: HY-109584

FLT3-IN-1 is a potent **FLT3** inhibitor extracted from patent WO2015056683A1, compound example A.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3-IN-1 Succinate

Cat. No.: HY-109584A

FLT3-IN-1 Succinate is a potent **FLT3** inhibitor extracted from patent WO2015056683A1, compound example A.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3-IN-2

Cat. No.: HY-18744

FLT3-IN-2 is a FLT3 inhibitor with IC50 of 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FLT3-IN-3

Cat. No.: HY-112145

FLT3-IN-3 is a potent **FLT3** inhibitor with IC_{50}s of 13 and 8 nM for **FLT3 WT** and **FLT3 D835Y**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FLT3-IN-4

Cat. No.: HY-128571

FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (**FLT3**; IC_{50}=7 nM) inhibitor for treating acute myelogenous leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FLT3-IN-6

Cat. No.: HY-128572

FLT3-IN-6 is a potent and selective inhibitor of **FLT3-ITD** (FLT3 mutation) with an IC_{50} of 1.336 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Fludarabine

(F-ara-A; NSC 118218)

Cat. No.: HY-B0069

Fludarabine (NSC 118218) is a **DNA synthesis** inhibitor, which also inhibits phosphorylation of **STAT1**.



Purity: 99.28%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Fludarabine phosphate

(NSC 118218 (phosphate))

Cat. No.: HY-B0028

Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Fluensulfone

(MCW-2)

Cat. No.: HY-107771

Fluensulfone is a new nematicide for chemical control of plant parasitic nematodes.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg

Flumatinib

(HHGV678)

Cat. No.: HY-13904

Flumatinib (HHGV678) is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Flumatinib mesylate

(HHGV678 mesylate)

Cat. No.: HY-13905

Flumatinib mesylate (HH-GV-678 mesylate), a derivative of imatinib, is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.



Purity: >95.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 500 mg

Flutamide

(SCH 13521)

Cat. No.: HY-B0022

Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer.



Purity: 99.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g

FMF-04-159-2

Cat. No.: HY-127104

FMF-04-159-2 is a covalent **CDK14** inhibitor. FMF-04-159-2 inhibits CDK14 and CDK2 with IC_{50}s of 39.6 nM and 256 nM in NanoBRET assay, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FMK

Cat. No.: HY-52101A

FMK is a an irreversible **RSK2** kinase inhibitor, that covalently modifies the C-terminal kinase domain of RSK.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

FMK 9a

Cat. No.: HY-100522

FMK 9a is an **autophagin-1** inhibitor with IC_{50} values of 80 and 73 μM in FRET and LRA assay.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FMK-MEA

Cat. No.: HY-52101C

FMK-MEA is a potent and selective **p90 Ribosomal S6 Kinase (RSK)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Fmoc-1,6-diaminohexane

Cat. No.: HY-103664

Fmoc-1,6-diaminohexane is an analog of Osw-1 which can be used to treat Alzheimer's disease and cancer, extracted from patent US 20140135279 A1.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg

Fmoc-Phe-Lys(Boc)-PAB-PNP

Cat. No.: HY-114430

Fmoc-Phe-Lys(Boc)-PAB-PNP is an **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.67%
Clinical Data: No Development Reported
Size: 50 mg

Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH

(Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH; ...)

Cat. No.: HY-104004

Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH is a drug for cancer.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fmoc-Thr[GalNAc(Ac)3-α-D]-OH

(Fmoc-Thr(Ac_3AcNH-α-Gal)-OH)

Cat. No.: HY-P0232

AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.



Purity: 97.72%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Fmoc-Val-Cit-PAB

Cat. No.: HY-19318

Fmoc-Val-Cit-PAB is a linker for antibody-drug-conjugation (ADC).



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 500 mg

Fmoc-Val-Cit-PAB-MMAE

Cat. No.: HY-19811

Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), Fmoc-Val-Cit-PAB-MMAE is an antibody drug conjugate.



Purity: 95.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Fmoc-Val-Cit-PAB-PNP

Cat. No.: HY-41189

Fmoc-Val-Cit-PAB-PNP is a peptide prodrug linker, is a linker for antibody-drug-conjugation (ADC).



Purity: 96.13%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

FN-1501

Cat. No.: HY-111361

FN-1501 is a potent inhibitor of **FLT3** and **CDK**, with **IC_{50}**s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Folinic acid

(leucovorin)

Cat. No.: HY-17556

Folinic acid is an adjuvant used in cancer chemotherapy involving the drug methotrexate. Target: Antifolate Folinic acid is a 5-formyl derivative of tetrahydrofolic acid. It is readily converted to other reduced folic acid derivatives (e.g.



Purity: >98%
Clinical Data: Launched
Size: 100 mg

Folinic acid Calcium

(Leucovorin Calcium; Calcium Folinate)

Cat. No.: HY-13664

Leucovorin Calcium is a reduced folic acid. IC50 Value: 30 μM for zcSHMT and70 μM for zmSHMT Target: Antifolate in vitro: Increasing concentrations of leucovorin (N5-CHO-THF) inhibit both zcSHMT and hcSHMT activities substantially, yet to a lesser extent than zmSHMT.



Purity: 99.73%
Clinical Data: Launched
Size: 100 mg, 500 mg

Folinic acid calcium salt pentahydrate

(Leucovorin calcium salt pentahydrate)

Cat. No.: HY-B0080

Folinic acid (calcium salt pentahydrate) is a reduced folic acid, which is used in combination with other chemotherapy drugs.



Purity: 99.73%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Foretinib

(XL880; GSK1363089; GSK089; EXEL-2880)

Cat. No.: HY-10338

Foretinib is a multi-target tyrosine kinase inhibitor with **IC_{50}**s of 0.4 nM and 0.9 nM for **Met** and **KDR**.



Purity: 99.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Formononetin

(Biochanin B; Flavosil; Formononetol)

Cat. No.: HY-N0183

Formononetin (Formononetol; Flavosil) is a bioactive component extracted from the red clover; inhibits the proliferation of DU-145/PC-3 cells in a dose-dependent manner.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Forodesine

(BCX-1777 freebase; Immucillin-H)

Cat. No.: HY-16210

Forodesine(BCX-1777 freebase; Immucillin-H) is an orally bioavailable PNP inhibitor with picomolar potency; induces apoptosis, mainly in T cells.



Purity: >98%
Clinical Data: Launched
Size: 2500 μg, 5 mg, 10 mg

Forodesine hydrochloride

(BCX-1777; Immucillin-H hydrochloride)

Cat. No.: HY-16209

Forodesine hydrochloride is a potent and oral **purine nucleoside phosphorylase (PNP)** inhibitor with **IC_{50}**s ranging from 0.48 to 1.57 nM.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1000 μg, 2500 μg, 5 mg, 10 mg

Fosbretabulin disodium

(CA 4DP; CA 4P; Combretastatin A4 disodium phosphate) Cat. No.: HY-17449

Fosbretabulin disodium(CA 4DP; CA 4P) is a microtubule destabilizing drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.



Purity: 99.47%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Fosteabine

(Cytarabine ocfosfate; YNK 01) Cat. No.: HY-106349

Fosteabine is an oral and prodrug analogue of cytarabine which is resistant to deoxycytidine deaminase.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Fotemustine

(S10036) Cat. No.: HY-B0733

Fotemustine is a **DNA-alkylating** agent, with antitumor activity.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg

FPH2

(BRD-9424) Cat. No.: HY-12281

FPH2 induces of functional proliferation of primary human hepatocytes and may lead to the development of new therapeutics for liver diseases.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FR 180204

Cat. No.: HY-12275

FR 180204 is an ATP-competitive, selective **ERK** inhibitor with K_i of 0.31 μM and 0.14 μM for ERK1 and ERK2, respectively.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

FRAX1036

Cat. No.: HY-19538

FRAX1036 is a **PAK** inhibitor with K_is of 23.3 nM, 72.4 nM, and 2.4 μM for PAK1, PAK2 and PAK4, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

FRAX486

Cat. No.: HY-15542B

FRAX486 is a p21-activated kinase (**PAK**) inhibitor with IC_{50}s of 14, 33 and 39 nM for PAK1, PAK2 and PAK3, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FRAX597

Cat. No.: HY-15542A

FRAX597 is a potent group I p21-activated Kinases (**PAK**s) inhibitor with IC_{50} of 8, 13 and 19 nM for **PAK1**, **2** and **3**.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fruquintinib

(HMPL-013) Cat. No.: HY-19912

Fruquintinib (HMPL-013) is a highly potent and selective **VEGFR 1/2/3** inhibitor with IC_{50}s of 33, 0.35, and 35 nM, respectively.



Purity: 99.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FT-1518

Cat. No.: HY-107363

FT-1518 is a new generation selective, potent and oral bioavailable **mTORC1** and **mTORC2** inhibitor, and exhibits antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

FT113

Cat. No.: HY-111551

FT113 is a potent and orally active **fatty acid synthase (FASN)** inhibitor, with an IC_{50} of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC_{50}, 90 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FT671

Cat. No.: HY-107985

FT671 is a potent, non-covalent and selective **USP7** inhibitor with an IC_{50} of 52 nM and binds to the USP7 catalytic domain with a K_d of 65 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

FT827

Cat. No.: HY-111350

FT827 is a selective and covalent ubiquitin-specific protease 7 (**USP7**) inhibitor with an IC_{50} of 52 nM.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FTI 276

Cat. No.: HY-15873

FTI-276 is a **protein farnesyl transferase (PFT)** inhibitor with IC_{50}s of 0.9 and 0.5 nM for Plasmodium falciparum and human.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FTI 276 TFA

Cat. No.: HY-15873A

FTI-276 is a **protein farnesyl transferase (PFT)** inhibitor with IC_{50}s of 0.9 nM and 0.5 nM for Plasmodium falciparum and human, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FTI-277

Cat. No.: HY-15872

FTI-277 is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

FTI-277 hydrochloride

Cat. No.: HY-15872A

FTI-277 Hcl is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FUBP1–IN-1

Cat. No.: HY-100758

FUBP1–IN-1 is a potent **FUSE binding protein 1 (FUBP1)** inhibitor which interferes with the binding of FUBP1 to its single stranded target DNA FUSE sequence , with an IC_{50} value of 11.0 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Fucoxanthin

(all-trans-Fucoxanthin)

Cat. No.: HY-N2302

Fucoxanthin is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.

Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fulvestrant

(ICI 182780; ZD 9238; ZM 182780)

Cat. No.: HY-13636

Fulvestrant is a potent **Estrogen Receptor** antagonist with an IC_{50} of 9.4 nM.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Fulvestrant R enantiomer (ICI 182780 R enantiomer; ZD 9238 R enantiomer; ZM 182780 R enantiomer)

Cat. No.: HY-13636B

Fulvestrant R enantiomer is the R enantiomer of Fulvestrant. Fulvestrant is a selective estrogen receptor (ER) antagonist which can be used to treat breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Fulvestrant S enantiomer (ICI 182780 S enantiomer; ZD 9238 S enantiomer; ZM 182780 S enantiomer)

Cat. No.: HY-13636A

Fulvestrant S enantiomer is the S enantiomer of Fulvestrant. Fulvestrant is a selective estrogen receptor (ER) antagonist which can be used to treat breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Fumarate hydratase-IN-1

Cat. No.: HY-100004

Fumarate hydratase-IN-1, an enzyme of the TCA cycle. Inhibition of fumarate hydratase-IN-1 can contribute to tumorigenicity in some cells. The use of a photoaffinity labeling strategy identified fumarate hydratase as the principal pharmacological target.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Fumaric acid

Cat. No.: HY-W015883

Fumaric acid, associated with fumarase deficiency, is identified as an oncometabolite or an endogenous, cancer causing metabolite.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 g

Fumitremorgin C (12α-Fumitremorgin C)

Cat. No.: HY-N2143

Fumitremorgin C is a potent and selective **ABCG2/BRCP** inhibitor.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 μg, 1 mg

Furafylline

Cat. No.: HY-107204

Furafylline is a potent and selective inhibitor of **human cytochrome P450IA2** with an IC_{50} of 0.07 μM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Futibatinib (TAS-120)

Cat. No.: HY-100818

Futibatinib (TAS-120) is a potent **FGFR** inhibitor, used for antitumor treatment.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

FX-11 (LDHA Inhibitor FX11)

Cat. No.: HY-16214

FX-11 is a potent **LDH-A** inhibitor with an IC_{50} of 23.3 μM for HeLa cella K_i value of 8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

FX1

Cat. No.: HY-102027

FX1 is a potent and specific **BCL6** inhibitor, with an IC_{50} of around 35 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

G-1

Cat. No.: HY-107216

G-1 is a nonsteroidal, high-affinity and selective agonist of **GPR30** with a K_i of 11 nM.



Purity: 99.20%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

G-5555

Cat. No.: HY-19635

G-5555 is a potent p21-activated kinase 1 (**PAK1**) inhibitor with K_is of 3.7 nM and 11 nM for PAK1 and PAK2, respectively.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

G-5555 hydrochloride

Cat. No.: HY-19635A

G-5555 hydrochloride is a potent and selective p21-activated kinase 1 (**PAK1**) inhibitor with a K_i of 3.7 nM.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

G-749

Cat. No.: HY-12333

G-749 is a novel FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC50s of 0.4/0.6/3.5/7.5 nM for Wt Flt3/D835Y/MV4-11/Molm-14 respectively.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

G007-LK

Cat. No.: HY-12438

G007-LK is a potent and selective inhibitor of **TNKS1** and **TNKS2**, with IC_{50}s of 46 nM and 25 nM, respectively.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

G15

Cat. No.: HY-103449

G15 is a high affinity and selective **G-protein-coupled estrogen receptor (GPER/GPR30)** antagonist with a K_i of 20 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

G280-9

Cat. No.: HY-P1794

G280-9 is a 9 amino acid native epitope peptide. G280-9 is a relevant target expressed on melanoma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

G3-C12

Cat. No.: HY-P1592

G3-C12 is a galectin-3 binding peptide, with K_d of 88 nM, and shows anticancer activity.

ANTPCGPYTHDCPVKR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

G3-C12 TFA

Cat. No.: HY-P1592A

G3-C12 (TFA) is a galectin-3 binding peptide, with K_d of 88 nM, and shows anticancer activity.

ANTPCGPYTHDCPVKR

Purity: 99.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gadoxetate Disodium

(Gd-EOB-DTPA (Disodium); ZK 139834)

Cat. No.: HY-16219

Gadoxetate Disodium (Gd-EOB-DTPA Disodium; ZK 139834) is a contrast agent in magnetic resonance imaging (MRI) of the hepatobiliary system, which accumulates in normal, functioning hepatocytes.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Galangin

(Norizalpinin; 3,5,7-Trihydroxyflavone)

Cat. No.: HY-N0382

Galangin is an agonist/antagonist of the arylhydrocarbon receptor, and also shows inhibition of **CYP1A1** activity.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Galeterone

(TOK-001; VN-124-1) Cat. No.: HY-70006

Galeterone (TOK-001) is a multifunctional antiandrogen and **CYP17** inhibitor (IC_{50}=47 nM) in castration resistant prostate cancer (CRPC).



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Gallic acid

(3,4,5-Trihydroxybenzoic acid) Cat. No.: HY-N0523

Gallic acid is an antioxidant which can inhibit both **COX-2**.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Galunisertib

(LY2157299) Cat. No.: HY-13226

Galunisertib (LY2157299) is a oral and selective **TGF-β receptor type I (TGF-βRI) kinase** inhibitor with an IC_{50} of 56 nM.



Purity: 99.89%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Gamabufotalin

(Gamabufagin) Cat. No.: HY-N0883

Gamabufotalin (Gamabufagin), a major bufadienolide of Chansu, has been used for cancer therapy due to its desirable metabolic stability and less adverse effect.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gambogic Acid

(Beta-Guttiferrin) Cat. No.: HY-N0087

Gambogic acid is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic acid inhibits **Bcl-X_L**, **Bcl-2**, **Bcl-W**, **Bcl-B**, **Bfl-1** and **Mcl-1** with IC_{50}s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM.



Purity: 95.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gamitrinib TPP

Cat. No.: HY-102007

Gamitrinib TPP is a **GA mitochondrial matrix** inhibitor. Gamitrinib TPP is offered as the hexafluorophosphate salt (Cat# HY-102007A).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gamitrinib TPP hexafluorophosphate

Cat. No.: HY-102007A

Gamitrinib TPP hexafluorophosphate is a **Gamitrinib (GA) mitochondrial matrix** inhibitor.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Gandotinib

(LY2784544) Cat. No.: HY-13034

Gandotinib (LY2784544) is a potent **JAK2** inhibitor with IC_{50} of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC_{50} of 4, 25, 32, 44, and 95 nM.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ganetespib

(STA-9090) Cat. No.: HY-15205

Ganetespib is a heat shock protein 90 (**HSP90**) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ganoderic acid A

Cat. No.: HY-N1447

Ganoderic acid can Inhibitt of the JAK-STAT3 signaling pathway, also inhibit proliferation, viability, ROS. In vitro: A lower doses of Ganoderic acid enhance HLA class II-mediated antigen presentation and CD4+ T cell recognition of lymphoma.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

GANT 58

(NSC 75503)

Cat. No.: HY-13282

GANT 58 is a potent **Gli** antagonist that inhibits GLI1-induced transcription with IC_{50} of 5 μM.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GANT 61

(NSC 136476)

Cat. No.: HY-13901

GANT 61 is an inhibitor of **Gli1** and **Gli2** targeting the Hedgehog/GLI pathway.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gardiquimod trifluoroacetate

Cat. No.: HY-103697A

Gardiquimod trifluoroacetate is a specific **TLR7** agonist which can also inhibit **HIV-1 reverse transcriptase**.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gastrin-Releasing Peptide, human

Cat. No.: HY-P0238

Gastrin-Releasing Peptide, human (GRP) belongs to the bombesin-like peptide family, and is not a classical hypothalamic-hypophyseal regulatory hormone since it plays only a perfunctory role in the mediation of pituitary hormone release.

Purity: 98.16%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

GB-110

Cat. No.: HY-120528

GB-110 is a potent, orally active, and nonpeptidic **protease activated receptor 2 (PAR2)** agonist. GB-110 selectively induces PAR2-mediated intracellular Ca^{2+} release in HT29 cells with an EC_{50} of 0.28 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

GB1107

Cat. No.: HY-114409

GB1107 is a potent, selective, orally active inhibitor of **Galectin-3 (Gal-3)** with a K_d of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Gboxin

Cat. No.: HY-111651

Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Gboxin inhibits the activity of F_0F_1 **ATP synthase**. Antitumour activity.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GC7 Sulfate

Cat. No.: HY-108314A

GC7 Sulfate is a **deoxyhypusine synthase** (**DHPS**) inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

GCN2-IN-1

(A-92)

Cat. No.: HY-100877

GCN2-IN-1 is a potent general control nonderepressible 2 kinase (**GCN2**) inhibitor with IC_{50}s of <0.3 μM in the enzyme and cell assay.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GCN2iB

Cat. No.: HY-112654

GCN2iB is an ATP-competitive inhibitor of a serine/threonine-protein kinase **general control nonderepressible 2 (GCN2)**, with an IC_{50} of 2.4 nM.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GDC-0077

(RG6114)

Cat. No.: HY-101562

GDC-0077 is an orally available **PI3K** inhibitor with potential antineoplastic activity. GDC-0077 is extracted from patent WO 2017001645 A1, formula I.



Purity: 99.07%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GDC-0084

(RG7666)

Cat. No.: HY-19962

GDC-0084 is a brain penetrant inhibitor of **PI3K** and **mTOR**, with K_is of 2 nM, 46 nM, 3 nM, 10 nM and 70 nM for PI3Kα PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively.



Purity: 99.28%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GDC-0152

Cat. No.: HY-13638

GDC-0152 is a potent inhibitor of **IAPs** which binds to the **XIAP** BIR3 domain, the BIR domain of **ML-IAP**, and the BIR3 domains of **cIAP1** and **cIAP2** with K_i values of 28, 14, 17, and 43 nM, respectively.



Purity: 98.73%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

GDC-0326

Cat. No.: HY-101272

GDC-0326 is a potent and selective **PI3Kα** inhibitor with a K_i of 0.2 nM.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GDC-0339

Cat. No.: HY-16976

GDC-0339 is a Pim kinase inhibitor with IC50 of 43.6 nM for BaF3 PIM1. IC50 value: 43.6 nM (for BaF3 PIM1), 0.04 nM (Ki, for PIM1 LC-3K) Target: Pim.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

GDC-0349

Cat. No.: HY-15248

GDC-0349 is a potent and selective ATP-competitive **mTOR** inhibitor with a K_i of 3.8 nM. GDC-0349 inhibits of both **mTORC1** and **mTORC2** complexes.



Purity: 98.20%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GDC-0575

(ARRY-575, RG7741)

Cat. No.: HY-112167

GDC-0575 (ARRY-575, RG7741) is a highly-selective oral small-molecule **Chk1** inhibitor with an IC_{50} of 1.2nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GDC-0575 dihydrochloride

(ARRY-575 dihydrochloride; RG7741 dihydrochloride)

Cat. No.: HY-112167A

GDC-0575 dihydrochloride is an orally bioavailable **CHK1** inhibitor, with an IC_{50} of 1.2 nM, and has antitumor activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GDC-0623

(RG 7421; MEK inhibitor 1)

Cat. No.: HY-15610

GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of **MEK1** (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC_{50}=42 nM) versus A375 ($BRAF^{V600E}$, EC_{50}=7 nM).



Purity: 99.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GDC-0879

Cat. No.: HY-50864

GDC-0879 is a potent and selective **B-Raf** inhibitor with an IC_{50} of 0.13 nM.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

GDC-0927

(SRN-927)

Cat. No.: HY-111484

GDC-0927 (SRN-927) is a novel, potent, non-steroidal, orally bioavailable, selective **estrogen receptor** antagonist.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

GDC-0927 Racemate

(SRN-927 Racemate)

Cat. No.: HY-111484A

GDC-0927 Racemate (SRN-927 Racemate) is a degrader of **estrogen receptor**, potently inhibits **ER-α** activity, with an IC_{50} of 0.2 nM, and is used in the research of ER-related diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

GDP366

Cat. No.: HY-U00177

GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GeA-69

Cat. No.: HY-108708

GeA-69 is a selective, highly cell permeable allosteric inhibitor of **poly-adenosine-diphosphate-ribose polymerase 14 (PARP14)** targeting macrodomain 2, with a K_d of 2.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Gedatolisib

(PKI-587; PF-05212384)

Cat. No.: HY-10681

Gedatolisib (PKI-587) is a highly potent dual inhibitor of **PI3Kα**, **PI3Kγ**, and **mTOR** with IC_{50}s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. PKI-587 is equally effective in both complexes of mTOR, **mTORC1** and **mTORC2**.



Purity: 99.11%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gefitinib

(ZD1839)

Cat. No.: HY-50895

Gefitinib (ZD1839) is a **EGFR tyrosine kinase** inhibitor, with IC_{50} of 2-37 nM in NR6wtEGFR cells.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Gefitinib hydrochloride

(ZD-1839 hydrochloride)

Cat. No.: HY-50895A

Gefitinib hydrochloride is an inhibitor that specifically binds and inhibits the **EGFR tyrosine kinase**, with the IC_{50} value of 2-37 nM in NR6wtEGFR cells.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Gefitinib-based PROTAC 3

Cat. No.: HY-123921

Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces **EGFR** degradation with DC_{50}s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Geldanamycin

Cat. No.: HY-15230

Geldanamycin is a **Hsp90** inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gemcitabine

(NSC 613327; LY188011)

Cat. No.: HY-17026

Gemcitabine (NSC 613327;LY188011) is a **DNA synthesis** inhibitor which inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC_{50}s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g

Gemcitabine elaidate

(CP-4126; CO-101; Gemcitabine 5'-elaidate) Cat. No.: HY-13538

Gemcitabine elaidate(CP-4126; CO-101) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.



Purity: 99.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gemcitabine Hydrochloride

(LY 188011 hydrochloride) Cat. No.: HY-B0003

Gemcitabine (Hydrochloride) is a **DNA synthesis** inhibitor with IC_{50}s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g

Geniposidic acid

Cat. No.: HY-N0010

Geniposidic acid is an effective anticancer and radioprotection agent.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Genistein

(NPI 031L) Cat. No.: HY-14596

Genistein, a soy isoflavone, is a multiple **tyrosine kinases** inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.



Purity: 99.68%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Genistin (Genistine; Genistoside; Genistein 7-O-β-D-glucopyranoside)

Cat. No.: HY-N0595

Genistin is the major isoflavonoid of soybeans and soy products.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Genz-644282

Cat. No.: HY-16228

Genz-644282 is a non-camptothecin **topoisomerase I** inhibitor, used for cancer research.



Purity: 98.03%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Geraniin

Cat. No.: HY-N0472

Geraniin is a **TNF-α** releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC_{50} of 43 μM.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gestonorone Capronate

(Gestonorone caproate) Cat. No.: HY-U00091

Gestonorone Capronate is a progestin for the treatment of benign prostatic hypertrophy and endometrial cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

GF 15

Cat. No.: HY-12797

GF 15 is a potent inhibitor of centrosomal clustering in tumor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

GGTI-2418

Cat. No.: HY-16231

GGTI-2418 is a highly potent, competitive, and selective **geranylgeranyltransferase I** (**GGTase I**) inhibitor. GGTI-2418 inhibits **GGTase I** and FTase activities with IC_{50}s of 9.5 nM and 53 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GGTI298

Cat. No.: HY-100876

GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC_{50} values of 3 and > 20 μM in vivo, respectively.



Purity: >96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

GGTI298 Trifluoroacetate

Cat. No.: HY-15871

GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (**GGTase I**) inhibitor, which can inhibit **Rap1A** with IC_{50} of 3 μM; little effect on **Ha-Ras** with IC_{50} of >20 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

GI254023X

(GI4023; SRI028594)

Cat. No.: HY-19956

GI254023X is a potent **MMP9** and **ADAM10** inhibitor with IC_{50}s of 2.5 and 5.3 nM, respectively.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Gigantol

Cat. No.: HY-N2523

Gigantol is a bibenzyl compound derived from several medicinal orchids. Giganto shows promising therapeutic potential against cancer cells. Gigantol is a novel inhibitor of the **Wnt/β-catenin** pathway.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gilteritinib

(ASP2215)

Cat. No.: HY-12432

Gilteritinib is a potent **FLT3/AXL** inhibitor with IC_{50}s of 0.29 nM/0.73 nM, respectively.



Purity: 99.55%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib hemifumarate

(ASP2215 hemifumarate)

Cat. No.: HY-12432A

Gilteritinib hemifumarate is a potent **FLT3/AXL** inhibitor with IC_{50} of 0.29 nM/0.73 nM, respectively.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gimeracil

(Gimestat)

Cat. No.: HY-17469

Gimeracil(Gimestat) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood; inhibits homologous recombination.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg, 500 mg

Ginkgolic Acid (Ginkgolic acid (15:1); Ginkgolic acid I; Romanicardic acid)

Cat. No.: HY-N0077

Ginkgolic Acid is a natural compound that inhibits **SUMOylation** with an IC_{50} of 3.0 μM in in vitro assay.

Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside F1

(20(S)-Ginsenoside F1)

Cat. No.: HY-N0598

Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of **CYP3A4** activity and weaker inhibition of CYP2D6 activity.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ginsenoside Ra3

Cat. No.: HY-N4259

Ginsenoside Ra3, isolated from Panax ginseng, possesses anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rb3

(Gypenoside IV) Cat. No.: HY-N0041

Ginsenoside Rb3 is extracted from steamed Panax notoginseng. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced **NF-κB** transcriptional activity with an IC_{50} of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of **COX-2** and **iNOS** mRNA.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ginsenoside Rc

(Panaxoside Rc) Cat. No.: HY-N0042

Ginsenoside Rc, one of major Ginsenosides from Panax ginseng, enhances GABA receptor$_A$ ($GABA_A$)-mediated ion channel currents (I_{GABA}). Ginsenoside Rc inhibits the expression of **TNF-α** and **IL-1β**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rf

(Panaxoside Rf) Cat. No.: HY-N0601

Ginsenoside Rf is a trace component of ginseng root. Ginsenoside Rf inhibits **N-type Ca^{2+} channel**.



Purity: 94.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rg3

(20(S)-Ginsenoside-Rg3; Rg3; S-Ginsenoside Rg3) Cat. No.: HY-N0603

Ginsenoside Rg3 is the main component of Red ginseng. Ginsenoside Rg3 inhibits **Na^+** and **hKv1.4** channel with IC_{50}s of 32.2±4.5 and 32.6±2.2 μM, respectively. Ginsenoside Rg3 also inhibits **Aβ** levels, **NF-κB** activity, and **COX-2** expression.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ginsenoside Rg5

Cat. No.: HY-N0908

Ginsenoside Rg5 is the main component of Red ginseng. Ginsenoside blocks binding of **IGF-1** to its receptor with an IC_{50} of ~90 nM. Ginsenoside Rg5 also inhibits the mRNA expression of **COX-2** via suppression of the DNA binding activities of **NF-κB p65**.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rg6

Cat. No.: HY-N0907

Ginsenoside Rg6 is the component isolated from notoginseng. Ginsenoside Rg6 inhibits TNF-α-induced **NF-κB** transcriptional activity with an IC_{50} of 29.34±2.22 μM in HepG2 cells. Ginsenoside Rg6 also exhibits **apoptosis**-inducing effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ginsenoside Rh2

(20(S)-Ginsenoside Rh2; 20(S)-Rh2; Ginsenoside-Rh2) Cat. No.: HY-N0605

Ginsenoside Rh2 is isolated from the root of Ginseng. Ginsenoside Rh2 induces the activation of **caspase-8** and **caspase-9**. Ginsenoside Rh2 induces cancer cell **apoptosis** in a multi-path manner.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rh4

Cat. No.: HY-N0905

Ginsenoside Rh4 is a rare saponin obtained from Panax notoginseng. Ginsenoside Rh4 activates **Bax**, **caspase 3**, **caspase 8**, and **caspase 9**. Ginsenoside Rh4 also induces **autophagy**.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Givinostat

(ITF-2357) Cat. No.: HY-14842

Givinostat (ITF-2357) is a **HDAC** inhibitor with an IC_{50} of 198 and 157 nM for **HDAC1** and **HDAC3**, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Givinostat hydrochloride

(ITF-2357 hydrochloride) Cat. No.: HY-14842A

Givinostat hydrochloride (ITF-2357 hydrochloride) is a **HDAC** inhibitor with an IC_{50} of 198 and 157 nM for **HDAC1** and **HDAC3**, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Givinostat hydrochloride monohydrate

(ITF-2357 hydrochloride monohydrate)

Cat. No.: HY-14842B

Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a **HDAC** inhibitor with an IC_{50} of 198 and 157 nM for **HDAC1** and **HDAC3**, respectively.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GK921

Cat. No.: HY-12337

GK921 is a transglutaminase 2 (**TGase**) inhibitor with an IC_{50} of 7.71 μM for human recombinant TGase 2.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GKI-1

Cat. No.: HY-100521

GKI-1 is a **Greatwall (GWL) kinase** inhibitor with IC_{50}s of 4.9 and 2.5 μM against $hGWL^{FL}$ and hGWL-KinDom, respectively. GKI-1 robustly inhibits **ROCK1** with an IC_{50} of 11 μM, but only weakly affected PKA.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Glabridin

Cat. No.: HY-N0393

Glabridin is a natural isoflavan from Glycyrrhiza glabra, binds to and activates **PPARγ**, with an EC_{50} of 6115 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Glasdegib

(PF-04449913)

Cat. No.: HY-16391

Glasdegib (PF-04449913) is a potent and orally bioavailable smoothened inhibitor. Glasdegib (PF-04449913) binds to human **SMO** (amino acids 181-787) with an IC_{50} of 4 nM.



Purity: 99.31%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Glaucocalyxin B

Cat. No.: HY-N2113

Glaucocalyxin B is an ent kaurane diterpenoid isolated from the Chinese traditional medicine Rabdosia japonica with anticancer and antitumor activity; decreases the growth of HL-60 cells with an IC_{50} of approximately 5.86 μM at 24 h.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Glesatinib hydrochloride

(MGCD265 hydrochloride)

Cat. No.: HY-19642A

Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GLPG0187

Cat. No.: HY-100506

GLPG0187 is a broad spectrum **integrin** receptor antagonist with antitumor activity; inhibits $\alpha_V\beta_1$-integrin with an IC_{50} of 1.3 nM.



Purity: 98.08%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GLPG0634 analog

Cat. No.: HY-13961

GLPG0634 (analog) (compound176)is a pan JAK inhibitor with IC50s of 50-200 nM for JAK1/JAK2/JAK3; more information can be found in the reference patents.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Glucoraphanin

Cat. No.: HY-N4068

Glucoraphanin, a natural glucosinolate found in cruciferous vegetable, is a stable precursor of the Nrf2 inducer sulforaphane, which possesses antioxidant, anti-inflammatory, and anti-carcinogenic effects.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Glucose-conjugated MGMT inhibitor

(O6BTG-C8-βGlu) Cat. No.: HY-13057

Glucose-conjugated MGMT inhibitor is a potent O^6-methylguanine-DNAmethyl-transferase (**MGMT**) inhibitor, with IC_{50}s of 32 nM in vitro (cell extracts) and 10 nM in HeLa S3 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GLUFOSFAMIDE

(D 19575; Glucosylifosfamide mustard) Cat. No.: HY-16232

Glufosfamide is a novel alkylating agent in which the active metabolite of isophosphoramide mustard is glycosidically linked to **β-D-glucose**.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Glumetinib

(SCC244) Cat. No.: HY-116000

Glumetinib (SCC244) is a potent and highly selective **c-Met kinase** inhibitor with an IC_{50} of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Glutaminase C-IN-1

(Compound 968) Cat. No.: HY-12682

Glutaminase C-IN-1 (968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Glutaminase-IN-1

Cat. No.: HY-114334

Glutaminase-IN-1, a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (**KGA**), with an IC_{50} of 1 nM. Glutaminase-IN-1 shows improved cellular uptake and antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Glycerol

(Glycerin) Cat. No.: HY-B1659

Glycerol is a clear, colourless, viscous, sweet-tasting liquid. Glycerol is used in sample preparation and gel formation for polyacrylamide gel electrophoresis.

Purity: >99.0%
Clinical Data: Launched
Size: 100 mL

Glycochenodeoxycholic acid

(Chenodeoxycholylglycine) Cat. No.: HY-N2334

Glycochenodeoxycholic acid is a bile salt formed in the liver from chenodeoxycholate and glycine; used to induce hepatocyte apoptosis in research.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Glycocholic acid

Cat. No.: HY-N1423

Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Glycodeoxycholic acid monohydrate

Cat. No.: HY-N1427A

Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Glycyrrhizic acid

(Glycyrrhizin) Cat. No.: HY-N0184

Glycyrrhizic acid is a triterpenoid saponinl, acting as a direct **HMGB1** antagonist, with anti-tumor, anti-diabetic activities.



Purity: >98.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Glyoxalase I inhibitor

Cat. No.: HY-15167

Glyoxalase I inhibitor is a potent Glyoxalase I inhibitor, candidate for anticancer agents.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Glyoxalase I inhibitor free base

Cat. No.: HY-15167A

Glyoxalase I inhibitor (free base) is a potent Glyoxalase I **(GLO1)** inhibitor, candidate for anticancer agents.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

GlyRS-IN-1

Cat. No.: HY-108940

GlyRS-IN-1 is a **glycyl-tRNA synthase** (**GlyRS**) inhibitor extracted from patent WO 2017066459 A1. GlyRS-IN-1 can also inhibit the growth of bacteria.



Purity: 97.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

GN44028

Cat. No.: HY-110266

GN44028 is a **hypoxia inducible factor (HIF)-1** inhibitor, with an IC_{50} of 14 nM. GN44028 inhibits hypoxia-induced HIF-1α transcriptional activity without suppressing HIF-1α mRNA expression, HIF-1α protein accumulation, or HIF-1α/HIF-1β heterodimerization.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

GNA002

Cat. No.: HY-101508

GNA002 is a potentially and specifically strong **EZH2** (Enhancer of zeste homolog 2) inhibitor with an IC_{50} of 1.1 μM. GNA002 can covalently bind with specific cysteine residue of EZH2 to trigger its ubiquitination and subsequent degradation by the protein quality control E3 ligase, CHIP.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 250 mg, 500 mg

GNE 220

Cat. No.: HY-U00428

GNE-220 is a potent and selective inhibitor of **MAP4K4** with an IC_{50} of 7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

GNE 220 Hydrochloride

Cat. No.: HY-U00428A

GNE 220 (Hydrochloride) is a potent and selective inhibitor of **MAP4K4**, with an IC_{50} of 7 nM.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

GNE-049

Cat. No.: HY-108435

GNE-049 is a highly potent and selective **CBP** inhibitor with an IC_{50} of 1.1 nM in TR-FRET assay. GNE-049 also inhibits **BRET** and **BRD4(1)** with IC_{50}s of 12 nM and 4200 nM, respectively.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-140 racemate

Cat. No.: HY-100742

GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. (R)-GNE-140 is a potent **lactate dehydrogenase A (LDHA)** inhibitor.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GNE-207

Cat. No.: HY-120028

GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of **CBP**, with an IC_{50} of 1 nM, exhibits a selectively index of >2500-fold against BRD4 (1). GNE-207 shows excellent CBP potency, with an EC_{50} of 18 nM for MYC expression in MV-4-11 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

GNE-272

Cat. No.: HY-100726

GNE-272 is a potent and selective in vivo probe for the bromodomains of **CBP/EP300** with IC_{50} values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GNE-317

Cat. No.: HY-12763

GNE-317 is a **PI3K/mTOR** inhibitor, is able to cross the blood-brain barrier (BBB).



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-3511

Cat. No.: HY-12947

GNE-3511 is a **dual leucine zipper kinase (DLK)** inhibitor with a K_i of 0.5 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GNE-477

Cat. No.: HY-11042

GNE-477 is a potent and efficacious dual **PI3K** (IC_{50}=4 nM)/**mTOR**(K_i=21 nM) inhibitor.



Purity: 95.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

GNE-493

Cat. No.: HY-10811

GNE-493 is a potent, selective, and orally available dual **pan-PI3-kinase/mTOR** inhibitor with IC_{50}s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.



Purity: 95.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GNE-495

Cat. No.: HY-100343

GNE-495 is a potent and selective **MAP4K4** inhibitor with an IC_{50} of 3.7 nM.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GNE-617 hydrochloride

Cat. No.: HY-15766A

GNE-617 hydrochloride is a specific **NAMPT** inhibitor that inhibits the biochemical activity of NAMPT with an IC_{50} of 5 nM and exhibits efficacy in xenograft models of cancer.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GNE-6640

Cat. No.: HY-112937

GNE-6640 is a selective and non-covalent inhibitor of ubiquitin epecific peptidase 7 **(USP7)**, with IC_{50} values of 0.75 μM, 0.43 μM, 20.3 μM and 0.23 μM for full length USP7, USP7 catalytic domain, full length USP43 and Ub-MDM2, respectively.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GNE-6776

Cat. No.: HY-107986

GNE-6776 is a selective **USP7** inhibitor.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-781

Cat. No.: HY-108696

GNE-781 is a highly potent and selective **CBP** inhibitor with an IC_{50} of 0.94 nM in TR-FRET assay. GNE-781 also inhibits **BRET** and **BRD4(1)** with IC_{50}s of 6.2 nM and 5100 nM, respectively.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-955

Cat. No.: HY-101783

GNE-955 is a potent and orally active pan **Pim kinase** inhibitor with K_is of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

GNE684

Cat. No.: HY-128585

GNE684 is a potent inhibitor of **potent receptor interacting protein 1 (RIP1)**, with mean K_i^{app} values of 21 nM, 189 nM and 691 nM for human mouse and rat RIP1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

GNF-2

Cat. No.: HY-11007

GNF-2 is a highly selective non-ATP competitive inhibitor of oncogenic Bcr-Abl activity (IC50 = 0.14 μM). IC50 value: 0.14 uM Target: Bcr-Abl in vitro: Ba/F3 cells harboring native or T315I mutated Bcr-Abl constructs were treated with GNF-2 and AKIs.



Purity: 94.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GNF-5

Cat. No.: HY-15738

GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GNF-5837

Cat. No.: HY-13491

GNF-5837 is a potent pan-Trk inhibitor which display antiproliferative effects in cellular Ba/F3 assays (IC50 values are 7, 9 and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively).



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GNF-6231

Cat. No.: HY-100408

GNF-6231 is a potent, selective, and orally bioavailable Porcupine inhibitor that blocks Wnt signaling.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GNF-7

Cat. No.: HY-10943

GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM, respectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Go 6983

(Gö 6983; Goe 6983)

Cat. No.: HY-13689

Go 6983 is a pan-PKC inhibitor against for **PKCα**, **PKCβ**, **PKCγ**, **PKCδ** and **PKCζ** with IC_{50} of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.



Purity: 97.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GOAT-IN-1

Cat. No.: HY-103479

GOAT-IN-1 is an inhibitor of **ghrelin O-acyltransferase (GOAT)**, which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence,...



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Golgicide A

Cat. No.: HY-100540

Golgicide A is a potent, highly specific, and reversible inhibitor of the cis-Golgi ADP-ribosylation factor guanine nucleotide exchange factors (ArfGEF), GBF1.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg

Golvatinib

(E-7050) Cat. No.: HY-13068

Golvatinib (E-7050) is a potent dual inhibitor of both **c-Met** and **VEGFR2** kinases with IC_{50}s of 14 and 16 nM, respectively.



Purity: 99.29%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gossypol

(BL 193) Cat. No.: HY-13407

Gossypol, a natural product isolated from cottonseeds and roots, binds to **Bcl-xL** protein and **Bcl-2** protein with K_is of 0.5-0.6 μM and 0.2-0.3 mM, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 100 mg, 200 mg, 500 mg

Gossypol acetic acid

((±)-Gossypol-acetic acid; BL 193 (acetic acid)) Cat. No.: HY-17510

Gossypol acetic acid ((±)-Gossypol-acetic acid), a natural product isolated from cottonseeds and roots, binds to **Bcl-xL** protein and **Bcl-2** protein with K_is of 0.5-0.6 μM and 0.2-0.3 mM, respectively.



Purity: 99.41%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 200 mg, 500 mg

Gp100 619-627

Cat. No.: HY-P1796

Gp100 (619-627) is amino acids 619 to 627 fragment of human melanoma antigen glycoprotein 100 (gp100). Gp100 has been a widely studied target for melanoma immunotherapy.

RLMKQDFSV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GPR35 agonist 1

Cat. No.: HY-101033

GPR35 agonist 1 (compound 50) is a potent and specific **G protein-coupled receptor-35 (GPR35)** agonist with an EC_{50} of 5.8 nM, displays good druggability.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Gracillin

Cat. No.: HY-N0706

Gracillin is a kind of steroidal saponin isolated from the root bark of wild yam Dioscorea nipponica with antitumor agent. Gracillin could induce cell cycle arrest, oxidative stress, and apoptosis in HL60 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gramine

(Donaxine) Cat. No.: HY-N0166

Gramine (Donaxine) is a natural alkaloid isolated from giant reed, acts as an active **adiponectin receptor (AdipoR)** agonist, with IC_{50}s of 3.2 and 4.2 μM for AdipoR2 and AdipoR1, respectively. Gramine is also a human and mouse **β2-Adrenergic receptor (β2-AR)** agonist.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

GRGDSP

Cat. No.: HY-P0290

GRGDSP, a synthetic linear RGD peptide, is an **integrin** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GRGDSP TFA

Cat. No.: HY-P0290A

GRGDSP (TFA) is an **integrin** inhibitor.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

GRGDSPC

Cat. No.: HY-P1559

GRGDSPC, a 7-amino acid peptide, is a thiolated cell adhesion peptide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Grp94 Inhibitor-1

Cat. No.: HY-112910

Grp94 Inhibitor-1 is a potent, selective **Grp94** inhibitor with an **IC_{50}** value of 2 nM, and over 1000-fold selectivity to Grp94 against Hsp90α.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

GS-444217

Cat. No.: HY-100844

GS-444217 is a potent and selective ATP-competitive inhibitor of apoptosis signal-regulating kinase 1 (**ASK1**) with an **IC_{50}** of 2.87 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GS-626510

Cat. No.: HY-114416

GS-626510 is a potent, and orally bioavailable **BET family bromodomains** inhibitor, with **K_d** values of 0.59-3.2 nM for BRD2/3/4, with **IC_{50}** values of 83 nM and 78 nM foe BD1 and BD2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

GSK 2830371

Cat. No.: HY-15832

GSK 2830371 is a highly selective **Wip1 phosphatase** inhibitor with **IC_{50}** of 6 nM.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GSK 3 Inhibitor IX

(6-Bromoindirubin-3'-oxime; BIO; MLS 2052)

Cat. No.: HY-10580

GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of **GSK-3α/β** and **CDK1-cyclinB** complex with **IC_{50}**s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK 4027

Cat. No.: HY-101027

GSK 4027 is a chemical probe for the **PCAF/GCN5 bromodomain** with an **pIC_{50}** of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK 525768A

Cat. No.: HY-13032A

GSK 525768A is the inactive enantiomer of GSK525762A. GSK 525768A has no activity towards BET.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK 650394

Cat. No.: HY-15192

GSK 650394 is a novel **SGK** inhibitor with **IC_{50}** of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK'481

(GSK481)

Cat. No.: HY-100131

GSK'481 can inhibit RIP1 WT S166 phosphorylation in human vs mouse plasmids overexpressed in HEK293T cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK-1070916

(GSK-1070916A)

Cat. No.: HY-70044

GSK-1070916 is a potent and selective ATP-competitive inhibitor of **aurora B** and **aurora C** with **K_i**s of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.



Purity: 99.55%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GSK-4716

Cat. No.: HY-33353

GSK-4716 is a selective **ERRβ/γ** agonist.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GSK-5959

Cat. No.: HY-18665

GSK-5959 is a potent, selective and cell permeable BRPF1 bromodomain inhibitor with IC50 ~ 80 nM. Exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK-690693

Cat. No.: HY-10249

GSK-690693 is an ATP-competitive **pan-Akt** inhibitor with **IC_{50}**s of 2, 13, 9 nM for Akt1, Akt2 and Akt3, respectively.



Purity: 97.52%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK-923295

Cat. No.: HY-10299

GSK-923295 is a special, allosteric inhibitor of **centromere-associated protein-E (CENP-E)** kinesin motor ATPase activity, with **K_i** of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.



Purity: >99.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK-J1

Cat. No.: HY-15648

GSK-J1 is a potent inhibitor of **H3K27me3/me2-demethylases JMJD3/KDM6B** and **UTX/KDM6A**, with **IC_{50}** of 60 nM towards KDM6B. .



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

GSK-J1 lithium salt

Cat. No.: HY-15648D

GSK-J1 lithium salt is a potent inhibitor of **H3K27me3/me2-demethylases JMJD3/KDM6B** and **UTX/KDM6A**, with **IC_{50}** of 60 nM towards KDM6B.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

GSK-J2

Cat. No.: HY-15648A

GSK-J2 is an isomer of GSK-J1 that does not have any specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

GSK-J4

Cat. No.: HY-15648B

GSK-J4 is a potent **H3K27me3 histone lysine demethylase (KDM)** inhibitor, with **IC_{50}**s of 8.6 μM and 6.6 μM against KDM6B and KDM6A, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

GSK-LSD1 Dihydrochloride

Cat. No.: HY-100546A

GSK-LSD1 Dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (**LSD1**) inhibitor with an **IC_{50}** of 16 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GSK1016790A

Cat. No.: HY-19608

GSK1016790A is a potent transient receptor potential vanilloid 4 (**TRPV4**) activator.



Purity: 97.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK1059615

Cat. No.: HY-12036

GSK1059615 is a dual inhibitor of **PI3Kα/β/δ/γ** (reversible) and **mTOR** with IC_{50} of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.



Purity: 98.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK126

(GSK2816126A)

Cat. No.: HY-13470

GSK126 (GSK2816126A) is a potent, highly selective inhibitor of **EZH2 methyltransferase** with an IC_{50} of 9.9 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GSK1324726A

(I-BET726)

Cat. No.: HY-13960

GSK1324726A is a novel, potent, and selective inhibitor of **BET** proteins with high affinity to **BRD2** (IC_{50}=41 nM), **BRD3** (IC_{50}=31 nM), and **BRD4** (IC_{50}=22 nM).



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK1838705A

Cat. No.: HY-13020

GSK1838705A is a potent and reversible **IGF-IR** and the **insulin receptor** inhibitor with IC_{50}s of 2.0 and 1.6 nM, respectively. It also inhibits **ALK** with an IC_{50} of 0.5 nM.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK1904529A

Cat. No.: HY-10524

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GSK1940029

(SCD inhibitor 1)

Cat. No.: HY-19762

GSK1940029 is a stearoyl-coa desaturase (**SCD**) extracted from patent WO/2009060053 A1, compound example 16.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK2110183

Cat. No.: HY-15966

GSK2110183 is an orally bioavailable, selective, ATP-competitive and potent **pan-Akt** kinase inhibitor with K_is of 0.08/2/2.6 nM for **Akt1/Akt2/Akt3** respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

GSK2110183 hydrochloride

Cat. No.: HY-15966A

GSK2110183 hydrochloride is an orally bioavailable, selective, ATP-competitive and potent **pan-Akt** kinase inhibitor with K_is of 0.08/2/2.6 nM for **Akt1/Akt2/Akt3** respectively.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2194069

Cat. No.: HY-12325

GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ± 4.1 nM in an assay detecting released CoA.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2256098

Cat. No.: HY-100498

GSK2256098 is a selective **FAK** kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.



Purity: 99.35%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK2334470

Cat. No.: HY-14981

GSK2334470 is a highly specific and potent inhibitor of **PDK1** with an IC_{50} of 10 nM.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GSK2606414

Cat. No.: HY-18072

GSK2606414 is a cell-permeable and orally available **protein kinase R-like endoplasmic reticulum (ER) kinase (PERK)** inhibitor with an IC_{50} of 0.4 nM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GSK2636771

Cat. No.: HY-15245

GSK2636771 is a potent, selective and oral inhibitor of **PI3Kβ** with a K_i of 0.89 nM and an IC_{50} of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2643943A

Cat. No.: HY-111458

GSK2643943A is a deubiquitylating enzyme **(DUB)** inhibitor, with an IC_{50} of 160 nM for USP20/Ub-Rho.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK2656157

Cat. No.: HY-13820

GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (**PERK**) with an IC_{50} of 0.9 nM.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GSK2795039

Cat. No.: HY-18950

GSK2795039 is a **NADPH oxidase 2** inhibitor with a mean pIC_{50} of 6 in different cell-free assays.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK2801

Cat. No.: HY-15658

GSK2801 is a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd=136 nM) and BAZ2B(Kd=257 nM) bromodomains.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK2837808A

Cat. No.: HY-100681

GSK2837808A is a potent and selective **lactate dehydrogenase A (LDHA)** inhibitor with IC_{50}s of 1.9 and 14 nM for LDHA and LDHB, respectively.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK2850163

Cat. No.: HY-U00459

GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha (**IRE1α**) which can inhibit **IRE1α kinase activity** and **RNase activity** with IC_{50}s of 20 and 200 nM, respectively.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

GSK2850163 hydrochloride

Cat. No.: HY-U00459B

GSK2850163 hydrochloride is a novel inhibitor of inositol-requiring enzyme-1 alpha (**IRE1α**) which can inhibit **IRE1α kinase activity** and **RNase activity** with IC_{50}s of 20 and 200 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

GSK2879552

Cat. No.: HY-18632

GSK2879552 is an orally available, irreversible inhibitor of **lysine specific demethylase 1 (LSD1)**, with potential antineoplastic activity.



Purity: 99.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK3145095

Cat. No.: HY-111946

GSK3145095 is a **RIP1 kinase** inhibitor with an IC_{50} of 6.3 nM .



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

GSK3186899

(DDD-853651)

Cat. No.: HY-112622

GSK3186899 is an inhibitor of cdc-2-related kinase 12 (**CRK12**), with an EC_{50} of 1.4 μM for L. donovani in an intra-macrophage assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

GSK3326595

(EPZ015938)

Cat. No.: HY-101563

GSK3326595 is a potent, selective, reversible inhibitor of **protein arginine methyltransferase 5 (PRMT5)** with an IC_{50} of 6.2 nM.



Purity: 99.24%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GSK3368715

(EPZ019997)

Cat. No.: HY-128717

GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive **type I protein arginine methyltransferases (PRMTs)** inhibitor (IC_{50}=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

GSK3368715 dihydrochloride

(EPZ019997 (dihydrochloride))

Cat. No.: HY-128717A

GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive **type I protein arginine methyltransferases (PRMTs)** inhibitor (IC_{50}=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK343

Cat. No.: HY-13500

GSK343 is a highly potent and selective **EZH2** inhibitor with an IC_{50} of 4 nM.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK3787

Cat. No.: HY-15577

GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (**PPARδ**) antagonist with pIC_{50} of 6.6.



Purity: 96.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

GSK4028

Cat. No.: HY-101027A

GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC_{50} of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK429286A

Cat. No.: HY-11000

GSK429286A is a selective inhibitor of **ROCK1** with an IC_{50} value of 14 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK461364

(GSK461364A) Cat. No.: HY-50877

GSK461364 is a selective, reversible and ATP-competitive **Polo-like kinase 1 (PLK1)** inhibitor with a K_i value of 2.2 nM.



Purity: 99.82%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GSK467

Cat. No.: HY-116761

GSK467 is a cell penetrant and selective **KDM5B (JARID1B or PLU1)** inhibitor with a K_i of 10 nM, shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK484

(GTPL8577; AOB6992) Cat. No.: HY-100514

GSK484 is a peptidylarginine deiminase 4 (**PAD4**) inhibitor. GSK484 demonstrates high affinity binding to PAD4 with IC_{50}s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK503

Cat. No.: HY-12856

GSK503 is a potent and specific inhibitor of **EZH2** methyltransferase with K_i^{app} values of 3 to 27 nM.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK547

(GSK'547) Cat. No.: HY-114492

GSK547 (GSK'547) is a highly selective and potent inhibitor of **receptor-interacting serine/threonine protein kinase 1 (RIP1)**, inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

GSK6853

Cat. No.: HY-100220

GSK6853 is a potent and selective inhibitor of the BRPF1 bromodomain. shows excellent BRPF1 potency (pKd 9.5) and greater than 1600-fold selectivity over all other bromodomains tested.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK8612

Cat. No.: HY-111941

GSK8612 is a highly selective and potent **Tank-binding Kinase-1 (TBK1)** inhibitor, with a **pIC$_{50}$** of 6.8 for recombinant TBK1.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GSK864

Cat. No.: HY-19540

GSK864 is an isocitrate dehydrogenase 1 (**IDH1**) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC_{50} values of 8.8, 15.2 and 16.6 nM.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK9311

Cat. No.: HY-100729

GSK9311 is a potent inhibitor of the **BRPF** bromodomain with **pIC$_{50}$** values of 6.0 and 4.3 for BRPF1 and BRPF2, respectively.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSTO-IN-2

Cat. No.: HY-112534

GSTO-IN-2 is a **glutathione S-transferase** inhibitor with IC_{50}s of 3.6, 16.3, and 1.4 μM for GSTA2, GSTM1, and GSTP1-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSTO1-IN-1

Cat. No.: HY-111530

GSTO1-IN-1 is a potent **glutathione S-transferase omega 1** (**GSTO1**) inhibitor with an IC_{50} of 31 nM.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Guadecitabine

(SGI-110)

Cat. No.: HY-13542

Guadecitabine (SGI-110) is a **DNA methyltransferases** (**DNMT**) inhibitor.



Purity: 98.00%
Clinical Data: Phase 3
Size: 5 mg, 10 mg

Guadecitabine sodium

(SGI-110 sodium; S-110 sodium)

Cat. No.: HY-15229

Guadecitabine sodium (SGI-110 sodium; S-110 sodium) is a dinucleotide consisting of 5-Aza-CdR followed by a deoxyguanosine which shows to be an effective **DNA methylation inhibitor**.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Guaiol

(Champacol; Guaiac alcohol)

Cat. No.: HY-N3980

Guaiol is a sesquiterpene alcohol that has been found in several traditional Chinese medicinal plants and has antiproliferative, pro-autophagic, insect repellent, and insecticidal biological activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Guanine

Cat. No.: HY-Y1055

Guanine is one of the fundamental components of nucleic acids (**DNA** and **RNA**). Guanine is a purine derivative, consisting of a fused pyrimidine-imidazole ring system with conjugated double bonds.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 g

Gusacitinib

(ASN-002)

Cat. No.: HY-103018

Gusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (**SYK**) and janus kinase (**JAK**) with IC_{50} values of 5-46 nM.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gusperimus trihydrochloride

(Spanidin; NKT-01; BMS181173)

Cat. No.: HY-13644A

Gusperimus trihydrochloride (Spanidin) is a derivative of the antitumor antibiotic spergualin with immunosuppressant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

GW 441756

Cat. No.: HY-18314

GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM; little activity to c-Raf1 and CDK2.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

GW 5074

Cat. No.: HY-10542

GW 5074 is a potent and selective **c-Raf** inhibitor with IC_{50} of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GW 6471

Cat. No.: HY-15372

GW 6471 is a potent **PPARα** antagonist.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GW284543
(UNC10225170)

Cat. No.: HY-114189

GW284543 (UNC10225170) is a selective **MEK5** inhibitor. GW284543 (UNC10225170) reduces pERK5, and decreases endogenous MYC protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GW7604

Cat. No.: HY-117153

GW7604 is an antiestrogen. GW7604 is the metabolite of GW5638, which is a high affinity estrogen receptor (ER) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

GW788388

Cat. No.: HY-10326

GW788388 is a potent and selective inhibitor of **ALK5** with IC_{50} of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GW843682X
(GW843682)

Cat. No.: HY-11003

GW843682X is a selective, ATP-competitive inhibitor of **PLK1** and **PLK3**, with IC_{50}s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against 30 other kinases.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GW9662

Cat. No.: HY-16578

GW9662 is a potent and selective **PPARγ** antagonist with an IC_{50} of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GZD824
(HQP1351)

Cat. No.: HY-15666

GZD824 (HQP1351) is an orally bioavailable **Bcr-Abl** inhibitor for Bcr-Abl (WT) and Bcr-Abl (T315I) with IC_{50}s of 0.34 nM and 0.68 nM, respectively.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GZD856

Cat. No.: HY-101489

GZD856 is a novel and orally bioavailable **PDGFRα/β** inhibitor with IC_{50}s of 68.6 and 136.6 nM, respectively. Anti-lung cancer activities. Also a **Bcr-Abl**^{T315I} inhibitor with IC_{50}s of 19.9 and 15.4nM for Bcr-Abl and T315I mutant.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

H2N-PEG2-CH2COOH

Cat. No.: HY-W006524

H2N-PEG2-CH2COOH belongs to a polyethylene glycol (PEG) linker covalently bound to E3 Ligase binding group (E3LB) and protein binding group (PB).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

H3B-5942

Cat. No.: HY-112611

H3B-5942 is a selective, irreversible and orally active **estrogen receptor** covalent antagonist, inactivates both wild-type and mutant **ERα** by targeting Cys530, with K_is of 1 nM and 0.41 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

H3B-6545

Cat. No.: HY-112596

H3B-6545 is an oral, selective **estrogen receptor** covalent antagonist (**SERCA**).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

H3B-6545 Hydrochloride

Cat. No.: HY-112596A

H3B-6545 Hydrochloride is an oral, selective **estrogen receptor** covalent antagonist (**SERCA**).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

HA-100

Cat. No.: HY-100984

HA-100 is an inhibitor of cGMP-dependent protein kinase (**PKG**), cAMP-dependent protein kinase (**PKA**), Protein kinase C (**PKC**) and **MLC-kinase** with IC_{50}s of 4, 8, 12 and 240 μM, respectively.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HA130

Cat. No.: HY-19329

HA130 is a selective **autotaxin (ATX)** inhibitor with an IC_{50} of 28 nM.



Purity: 98.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HA14-1

Cat. No.: HY-12011

HA14-1 is a **Bcl-2/Bcl-X_L** antagonist. HA14-1 binds the designated pocket on Bcl-2 with the IC_{50} of ≈9 μM in competing with the Bcl-2 binding of Flu-BakBH3, and inhibits its function.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

HA15

Cat. No.: HY-100437

HA15 is a potent and specific inhibitor of ER chaperone **BiP/GRP78/HSPA5**, inhibits the ATPase activity of BiP, with anti-cancerous activity.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HaloPROTAC 2

Cat. No.: HY-112495

HaloPROTAC 2, a chloroalkane-containing **PROTAC**, induces degradation of HaloTag fusion proteins.

Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

HAMNO

(NSC111847)

Cat. No.: HY-111285

HAMNO is a novel protein interaction inhibitor of **replication protein A** (**RPA**).



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Harmine

(Telepathine)

Cat. No.: HY-N0737A

Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase ((**DYRK**)) inhibitor with anticancer and anti-inflammatory activities.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Harringtonine

Cat. No.: HY-N0862

Harringtonine is a natural Cephalotaxus alkaloid that inhibits **protein synthesis**.



Purity: 99.91%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

HAT-IN-1

Cat. No.: HY-103669

HAT-IN-1 is an inhibitor of **HAT**, used in the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

HBX 19818

Cat. No.: HY-17540

HBX 19818 is a specific inhibitor of **ubiquitin-specific protease 7 (USP7)**, with an IC_{50} of 28.1 μM.



Purity: 96.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HC-067047

Cat. No.: HY-100208

HC-067047 is a potent and selective **TRPV4** antagonist with IC_{50}s of 48 nM, 133 nM, and 17 nM for human, rat, and mouse TRPV4.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HDAC-IN-3

Cat. No.: HY-19772

HDAC-IN-3 is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2008040934 A1.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

HDAC-IN-4

(CXD101)

Cat. No.: HY-100748

HDAC-IN-4 is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2007045844 A1 20070426.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

HDAC-IN-5

Cat. No.: HY-18362

HDAC-IN-5 is a histone deacetylase **(HDAC)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

HDAC-IN-7

(Chidamide impurity)

Cat. No.: HY-13592

HDAC-IN-7 (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.



Purity: 96.09%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 50 mg

HDAC6-IN-1

Cat. No.: HY-18947

HDAC6-IN-1 is a potent and selective inhibitor for **HDAC6** with an IC_{50} of 17 nM and shows 25-fold and 200-fold selectivity relative to **HDAC1** (IC_{50}=422 nM) and **HDAC8** (IC_{50}=3398 nM), respectively.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

HDAC8-IN-1

Cat. No.: HY-111342

HDAC8-IN-1 is a **HDAC8** inhibitor with an IC_{50} of 27.2 nM.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HDACs/mTOR Inhibitor 1

Cat. No.: HY-114414

HDACs/mTOR Inhibitor 1 is a dual **Histone Deacetylases (HDACs)** and **mammalian target of Rapamycin (mTOR)** target inhibitor for treating hematologic malignancies, with IC_{50}**s** of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hederagenin

Cat. No.: HY-N0256

Hederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κB.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Heparan Sulfate

Cat. No.: HY-101916

Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Hepsulfam

(NCI 329680; ZINC01574758)

Cat. No.: HY-U00095

Hepsulfam (NCI 329680; ZINC01574758) is a anticancer agent that shows excellent antileukemic activity with an median IC_{50} of 0.91 μg/mL in a panel of different tumors.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

HER2/neu (654-662) GP2

Cat. No.: HY-P1855

HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Herniarin

(7-Methoxycoumarin; Methyl umbelliferyl ether)

Cat. No.: HY-N1366

Herniarin is a natural coumarin occurs in some flowering plants, with antitumor effect.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Hesperadin

Cat. No.: HY-12054

Hesperadin is an ATP-competitive inhibitor of **aurora B** kinase with an IC_{50} of 250 nM.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hesperidin

(Hesperetin 7-rutinoside)

Cat. No.: HY-15337

Hesperidin (HP) is a bioflavonoid that plays a role in plant defense and is abundant in citrus species, such as grapefruit, lemon and orange.



Purity: 97.00%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Hesperin

Cat. No.: HY-101371

Hesperin is a bioactive ingredient present in Japanese horseradish (wasabi) and has been shown to be an **Nrf2** activator.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hexadimethrine bromide

(1,5-Dimethyl-1,5-diazaundecamethylene polymethobromide)

Cat. No.: HY-112735

Hexadimethrine bromide is a cationic polymer discovered to enhance retroviral transduction.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Hexahydrocurcumin

Cat. No.: HY-N0929

Hexahydrocurcumin is a natural compound which posesses anticancer and anti-inflammatory activities; selective COX-2 inhibitor.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Hexaminolevulinate hydrochloride (Hexyl 5-aminolevulinate hydrochloride; P-1206; ...)

Cat. No.: HY-16045

Hexaminolevulinate hydrochloride is a fluorescent agent, has approved for cystoscopic detection of papillary bladder cancer.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

HG-14-10-04

Cat. No.: HY-15801

HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HG6-64-1

(HMSL 10017-101-1)

Cat. No.: HY-12291

HG6-64-1 is a potent and selective **B-Raf** inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a IC_{50} of 0.09 μM on B-raf V600E transformed Ba/F3 cells.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HhAntag

Cat. No.: HY-15412

HhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway; antitumor agent.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HI-TOPK-032

Cat. No.: HY-101550

HI-TOPK-032 is a potent and specific **TOPK** inhibitor.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Hinokitiol

(β-Thujaplicin)

Cat. No.: HY-B2230

Hinokitiol is a component of essential oils isolated from Chymacyparis obtusa, reduces **Nrf2** expression, and decreases **DNMT1** and UHRF1 mRNA and protein expression, with anti-infective, anti-oxidative, and anti-tumor activities.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Hispidulin

(Dinatin)

Cat. No.: HY-N1950

Hispidulin is a natural flavone with a broad spectrum of biological activities. Hispidulin is a Pim-1 inhibitor with an IC_{50} of 2.71 μM.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Histone Acetyltransferase Inhibitor II

Cat. No.: HY-100734

Histone Acetyltransferase Inhibitor II is a potent and cell permeable **p300** inhibitor, with an IC_{50} of 5 μM; Histone Acetyltransferase Inhibitor II can be used in cancer research.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HJB97

Cat. No.: HY-112429

HJB97 is a high-affinity **BET** inhibitor with K_is of 0.9±0.2 nM (**BRD2 BD1**), 0.27±0.09 nM (**BRD2 BD2**), 0.18±0.01 nM (**BRD3 BD1**), 0.21±0.03 nM (**BRD3 BD2**), 0.5±0.2 nM (**BRD4 BD1**), 1.0±0.1 nM (**BRD4 BD2**), respectively.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HJC0152 hydrochloride

Cat. No.: HY-100602

HJC0152 hydrochloride is a **signal transducers and activators of transcription 3** (**STAT3**) inhibitor.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HJC0350

Cat. No.: HY-15702

HJC0350 is a potent and specific **EPAC2** antagonist with an IC_{50} of 0.3 μM.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

HLCL-61 hydrochloride

Cat. No.: HY-100025A

HLCL-61 hydrochloride is a first-in-class inhibitor of **protein arginine methyltransferase 5 (PRMT5)**.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

HLM006474

Cat. No.: HY-16667

HLM006474 is a pan **E2F** inhibitor, which inhibits E2F4 DNA-binding with an IC_{50} of 29.8 μM in A375 cells.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HLY78

Cat. No.: HY-122816

HLY78 is an activator of the **Wnt/β-catenin** signaling pathway, which targets the DIX domain of Axin and potentiates the Axin-LRP6 association to promote Wnt signaling transduction.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HMN-154

Cat. No.: HY-103001

HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC_{50} values of 0.0026 and 0.003 μg/mL, respectively.



Purity: 97.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

HMN-176

Cat. No.: HY-13647

HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (**plk1**), without significant effect on tubulin polymerization. .



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

HMN-214

(IVX-214)

Cat. No.: HY-12045

HMN-214, an orally bioavailable prodrug of HMN-176, is an inhibitor of polo-like kinase-1 (**plk1**), with antitumor activity.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HO-1-IN-1

Cat. No.: HY-111798

HO-1-IN-1 (Compound 2) is a heme oxygenase 1 (**HO-1**) inhibitor with an IC_{50} of 250 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HO-1-IN-1 hydrochloride

Cat. No.: HY-111798A

HO-1-IN-1 hydrochloride (Compound 2) is a heme oxygenase 1 (**HO-1**) inhibitor with an IC_{50} of 250 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HO-3867

Cat. No.: HY-100453

HO-3867 is a selective and potent **STAT3** inhibitor and shows good antitumor activity.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Hoechst 33258

(bisBenzimide H 33258; H 33258)

Cat. No.: HY-15558

Hoechst 33258 is a fluorescent dye that emits blue fluorescence when bound to dsDNA.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Hoechst 33258 analog 2

Cat. No.: HY-15624

Hoechst stains are part of a family of blue fluorescent dyes used to stain DNA. IC50 Value: Target: These Bis-benzimides were originally developed by Hoechst AG, which numbered all their compounds so that the dye Hoechst 33342 is the 33342nd compound made by the company.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Hoechst 33258 trihydrochloride (bisBenzimide H 33258 trihydrochloride; H 33258 trihydrochloride)

Cat. No.: HY-15558A

Hoechst 33258 trihydrochloride is a fluorescent dyes, which can be used as a cell dye for DNA.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Homo-PROTAC cereblon degrader 1

Cat. No.: HY-111594

Homo-PROTAC cereblon degrader 1 (compound 15a) is a highly potent and efficient **cereblon (CRBN)** degrader with only minimal effects on IKZF1 and IKZF3.



Purity: 99.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Homo-PROTAC pVHL30 degrader 1

Cat. No.: HY-111593

Homo-PROTAC pVHL30 degrader 1 is a potent **pVHL30** degrader based on **PROTAC**.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Homoharringtonine (Omacetaxine mepesuccinate; HHT)

Cat. No.: HY-14944

Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting **translation elongation**.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Honokiol (NSC 293100)

Cat. No.: HY-N0003

Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of **Akt** and enhances the phosphorylation of **ERK1/ERK2**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

HPOB

Cat. No.: HY-19747

HPOB is a highly potent and selective inhibitor of histone deacetylase 6 (HDAC6) with IC50 of 56 nM, >30 fold less potent against other HDACs. target: HDAC6 IC 50: 56nM In vitro: HPOB causes growth inhibition of normal and transformed cells but does not induce cell death.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HPPH (Photochlor)

Cat. No.: HY-13722

HPPH (Photochlor) is a second generation photosensitizer, which acts as a photodynamic therapy (PDT) agent.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HPV16-E711-20 epitope

Cat. No.: HY-P1881

HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro.

YMLDLQPETT

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HS-10296 hydrochloride

Cat. No.: HY-112823B

HS-10296 hydrochloride is an orally available and third-Generation inhibitor of epidermal growth factor receptor **(EGFR)**-activating mutations and **T790M**-resistant mutation with limited activity against wild-type EGFR.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HS-1371

Cat. No.: HY-114349

HS-1371 is a potent and ATP-competitive **receptor-interacting protein kinase 3 (RIP3)** inhibitor with an **IC_{50}** of 20.8nM.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HS-173

Cat. No.: HY-15868

HS-173 is a novel **PI3K** inhibitor, that is used for cancer treatment.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

HS79

Cat. No.: HY-112522

HS-79 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-79 is able to inhibit the incorporation of tritiated acetate into lipids with an IC_{50} of 1.57 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

HS80

Cat. No.: HY-112522A

HS-80 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-80 is able to inhibit the incorporation of tritiated acetate into lipids with an IC_{50} of 7.13 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

HSF1A

Cat. No.: HY-103000

HSF1A is a cell-permeable activator of heat shock transcription factor 1 (**HSF1**).



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

HSP70-IN-1

Cat. No.: HY-12622

HSP70-IN-1 is a heat shock protein (**HSP**) inhibitor; inhibits the growth of Kasumi-1 cells with an **IC_{50}** of 2.3 μM.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Hsp90-Cdc37-IN-1

Cat. No.: HY-111414

Hsp90-Cdc37-IN-1 is an **Hsp90-Cdc37** interaction disruptors that inhibit cell migration and reverse drug resistance, with an **IC_{50}** of 140 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

HSV-TK substrate

Cat. No.: HY-126218

HSV-TK substrate is a substrate for HSV-TK, and induces multi-log cytotoxicity in HSV-TK-expressing and bystander cells. HSV-TK substrate shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HTH-01-015

Cat. No.: HY-12334

HTH-01-015 is a selective **NUAK1/ARK5** inhibitor (**IC_{50}** is 100 nM). HTH-01-015 inhibits NUAK1 with >100-fold higher potency than NUAK2 (IC50 of >10 μM).



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HUHS015

Cat. No.: HY-100199

HUHS015 is a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Human Papillomavirus (HPV) E7 protein 49-57

Cat. No.: HY-P1907

Human Papillomavirus (HPV) E7 protein (49-57) is the H-2^{d}-restricted human papillomavirus (HPV) $E7_{49-57}$ epitope (short peptide spanning the 49th to 57th amino acid residues in the E7 protein).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

hVEGF-IN-1

Cat. No.: HY-101931

hVEGF-IN-1 represses human **VEGF-A** translation and shows antitumor activity.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Hyaluronic acid

Cat. No.: HY-B0633A

Hyaluronic acid is a biopolymer composed of repeating units of disaccharides with various applications.



Purity: >98%
Clinical Data: Phase 4
Size: 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Hyaluronic acid sodium salt

(Sodium hyaluronate)

Cat. No.: HY-B0633

Hyaluronic acid sodium salt is a biopolymer composed of repeating units of disaccharides with various applications.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Hydroxychloroquine sulfate

(HCQ sulfate)

Cat. No.: HY-B1370

Hydroxychloroquine sulfate is a synthetic **antimalarial** drug which can also inhibit **Toll-like receptor 7/9** (**TLR7/9**) signaling.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Hydroxysafflor yellow A

(Safflomin A; HSYA)

Cat. No.: HY-N0567

Hydroxysafflor yellow A is a flavonoid derived and isolated from traditional Chinese medicine Carthamus tinctorius L., possesses anti-tumor activity.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Hydroxytyrosol

(DOPET; 3,4-Dihydroxyphenethyl alcohol; 3-Hydroxytyrosol)

Cat. No.: HY-N0570

Hydroxytyrosol (DOPET) is a phenolic compound drawn from the olive tree and its leaves with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxyurea

(Hydroxycarbamide)

Cat. No.: HY-B0313

Hydroxyurea is a cell apoptosis inducer that inhibit**DNA** synthesis through inhibition of **ribonucleotide reductase**.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g

Hypocrellin A

Cat. No.: HY-N2575

Hypocrellin A, a naturally occurring **PKC** inhibitor, has many biological and pharmacological properties, such as antitumour, antiviral, antibacterial, and antileishmanial activities. Hypocrellin A is a promising photosensitizer for anticancer photodynamic therapy (PDT).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

I-191

Cat. No.: HY-117793

I-191 is a potent **protease-activated receptor 2 (PAR2)** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

I-BET151

(GSK1210151A)

Cat. No.: HY-13235

I-BET151 is a **BET bromodomain** inhibitor which inhibits **BRD4**, **BRD2**, and **BRD3** with **pIC$_{50}$** of 6.1, 6.3, and 6.6, respectively.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

I-BRD9

Cat. No.: HY-18975

I-BRD9 is the first selective cellular chemical probe for BRD9 (pIC50=7.3).



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

I-CBP112

Cat. No.: HY-19541

I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the **CBP/p300** bromodomains, enhances acetylation by p300.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

IACS-10759

Cat. No.: HY-112037

IACS-10759 is a potent inhibitor of complex I of oxidative phosphorylation (**OXPHOS**).



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IACS-10759 Hydrochloride

Cat. No.: HY-112037A

IACS-10759 Hydrochloride is a potent inhibitor of complex I of oxidative phosphorylation (**OXPHOS**).



Purity: 98.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IACS-8968

(IDO/TDO Inhibitor)

Cat. No.: HY-112164

IACS-8968 is a dual **IDO** and **TDO** inhibitor, with **pIC$_{50}$s** of 6.43 for IDO and <5 for TDO, respectively.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

IACS-8968 R-enantiomer

(IDO/TDO Inhibitor (R-enantiomer))

Cat. No.: HY-112164A

IACS-8968 (R-enantiomer) is the R-enantiomer of IACS-8968. IACS-8968 is a dual **IDO** and **TDO** inhibitor, with **pIC$_{50}$s** of 6.43 for IDO and <5 for TDO, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

IACS-8968 S-enantiomer

(IDO/TDO Inhibitor (S-enantiomer))

Cat. No.: HY-112164B

IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual **IDO** and **TDO** inhibitor, with **pIC$_{50}$s** of 6.43 for IDO and <5 for TDO, respectively.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

IACS-9571

(ASIS-P040)

Cat. No.: HY-102000

IACS-9571 is a potent and selective inhibitor of **TRIM24** and **BRPF1**, with **IC$_{50}$** of 8 nM for TRIM24, and **K$_d$**s of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

IACS-9571 Hydrochloride

(ASIS-P040 Hydrochloride)

Cat. No.: HY-102000B

IACS-9571 Hydrochloride is a potent and selective inhibitor of **TRIM24** and **BRPF1**, with an **IC$_{50}$** of 8 nM for TRIM24, and **K$_d$**s of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

IAXO-102

Cat. No.: HY-125171

IAXO-102 is a **TLR4** antagonist, inhibits MAPK and p65 NF-kB phosphorylation involved in down regulation of the expression of TLR4 and TLR4 dependent proinflammatory protein. IAXO-102 prevents experimental abdominal aortic aneurysm development.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Iberin

(NSC 321801)

Cat. No.: HY-101413

Iberin, a sulfoxide analogue of sulforaphane, is a naturally occurring member of isothiocyanate family. It inhibits cell survival with an IC_{50} of 2.3 μM in HL60 cell.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg

IBR2

Cat. No.: HY-103710

IBR2 is a specific **RAD51** inhibitor.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ibrutinib

(PCI-32765)

Cat. No.: HY-10997

Ibrutinib (PCI-32765) is a selective, irreversible **Btk** inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Ibrutinib Racemate

(PCI-32765 (Racemate))

Cat. No.: HY-10997A

Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible **Btk** inhibitor with IC_{50} value of 0.5 nM.



Purity: 94.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ibrutinib-biotin

Cat. No.: HY-100342

Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC_{50} of 0.755-1.02 nM for **BTK**.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IC-87114

Cat. No.: HY-10110

IC-87114 is a potent and selective **PI3Kδ** inhibitor with IC_{50} of 0.5 μM.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IC261

Cat. No.: HY-12774

IC261 is a selective, ATP-competitive **CK1** inhibitor, with IC_{50}s of 1 μM, 1 μM, 16 μM for **Ckiδ**, **Ckiε** and Ckiα1, respectively.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Icaritin

(Anhydroicaritin)

Cat. No.: HY-N0678

Icaritin(Anhydroicaritin) is a component of Epimedium flavonoid isolated from Herba Epimedii; enhances osteoblastic differentiation of mesenchymal stem cells (MSCs) while it inhibits adipogenic differentiation of MSCs by inhibiting PPAR-g pathway.



Purity: 98.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

ICG-001

Cat. No.: HY-14428

ICG-001 is an inhibitor of **β-catenin/TCF** mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC_{50} of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Icilin

(AG-3-5) Cat. No.: HY-11062

Icilin(AG 3-5) is a synthetic super-agonist of TRPM8 ion channel.



Purity: >96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Icotinib

(BPI-2009) Cat. No.: HY-15164A

Icotinib (BPI-2009) is a potent and specific **EGFR** inhibitor with an IC_{50} of 5 nM; also inhibits mutant $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{T790M}$ and $EGFR^{L861Q}$.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Icotinib Hydrochloride

(BPI-2009H) Cat. No.: HY-15164

Icotinib Hydrochloride (BPI-2009) is a potent and specific **EGFR** inhibitor with an IC_{50} of 5 nM; also inhibits mutant $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{T790M}$ and $EGFR^{L861Q}$.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

iCRT 14

Cat. No.: HY-16665

iCRT 14 is a novel potent inhibitor of **β-catenin-responsive transcription (CRT)**, with IC_{50} of 40.3 nM against Wnt responsive STF16 luciferase.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

iCRT3

Cat. No.: HY-103705

iCRT3 is an inhibitor of both **Wnt** and **β-catenin-responsive transcription**.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ID-8

Cat. No.: HY-15838

ID-8 is a DYRK inhibitor, and sustains embryonic stem cell self-renewal in long-term culture.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Idarubicin hydrochloride

(4-Demethoxydaunorubicin hydrochloride) Cat. No.: HY-17381

Idarubicin hydrochloride is an anthracycline antileukemic drug. It inhibits the **topoisomerase II** interfering with the replication of DNA and RNA transcription.



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Idasanutlin

(RG7388) Cat. No.: HY-15676

Idasanutlin (RG7388) is a potent and selective **MDM2** antagonist, inhibiting p53-MDM2 binding, with an IC_{50} of 6 nM.



Purity: 99.88%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Idelalisib

(CAL-101; GS-1101) Cat. No.: HY-13026

Idelalisib (CAL-101) is a highly selective and orally bioavailable **p110δ** inhibitor with an IC_{50} of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

IDF-11774

Cat. No.: HY-111387

IDF-11774 is a novel **hypoxia-inducible factor α (HIFα)-1** inhibitor with an IC_{50} of 3.65μM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

IDH-305

Cat. No.: HY-104036

IDH-305 is an orally available, mutant-selective and brain-penetrant **IDH1** inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC_{50}= 27 nM ($IDH1^{R132H}$), 28 nM ($IDH1^{R132C}$), 6.14 μM ($IDH1^{WT}$)).



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

IDH1 Inhibitor 1

Cat. No.: HY-112601

IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-penetrant and selective mutant **IDH1** inhibitor with IC_{50}s of 0.021 μM, 0.045 μM, and 2.52 μM for $IDH1^{R132H}$, $IDH1^{R132C}$, and $IDH1^{WT}$, respectively. Anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

IDH1 Inhibitor 3

Cat. No.: HY-107977

IDH1 Inhibitor 3 (compound 6f) is a mutant **isocitric dehydrogenase 1 (IDH1)** inhibitor, with an IC_{50} of 45 nM for $IDH1^{R132H}$.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO-IN-1

Cat. No.: HY-79531

IDO-IN-1 is a potent indoleamine 2,3-dioxygenase (**IDO**) inhibitor with an IC_{50} of 59 nM.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

IDO-IN-11

Cat. No.: HY-111234

IDO-IN-11 is an indoleamine-2,3-dioxygenase (**IDO**) inhibitor with IC_{50}s of 0.18 μM (Kinase) and 0.014 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 13.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

IDO-IN-12

Cat. No.: HY-115122

IDO-IN-12 is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor extracted from patent WO 2017181849 A1.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

IDO-IN-2

Cat. No.: HY-100771

IDO-IN-2 is an **IDO** inhibitor extracted from patent WO/2015031295 A1, compound example 1, has IC_{50} values of 0.068 μM in HeLa cell and 0.16 μM in HEK293 cell.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

IDO-IN-3

Cat. No.: HY-16987

IDO-IN-3 is a potent indoleamine 2,3-dioxygenase (**IDO**) inhibitor with an IC_{50} of 290 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

IDO-IN-4

Cat. No.: HY-18769

IDO-IN-4 is an indoleamine 2,3-dioxygenase 1 (**IDO-1**) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

IDO-IN-5
(NLG-1489)

Cat. No.: HY-18770

IDO-IN-5 (NLG-1489) is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor extracted from patent WO WO2012142237A1, compound 1489, has an IC_{50} of 1-10 μM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

IDO-IN-6

(NLG-1486) Cat. No.: HY-18770A

IDO-IN-6 (NLG-1486) is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor extracted from patent WO WO2012142237A1, Compound 1486, has an IC_{50} of <1 μM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

IDO-IN-7

(NLG-919 analogue; GDC-0919 analogue) Cat. No.: HY-13983

IDO-IN-7 (NLG-919 analogue) is a a potent **IDO1** inhibitor with an IC_{50} of 38 nM.



Purity: 99.92%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

IDO-IN-8

(NLG-1487) Cat. No.: HY-18770C

IDO-IN-8 (NLG-1487) is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor extracted from patent WO WO2012142237A1, compound 1487, has an IC_{50} of 1-10 μM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

IDO-IN-9

Cat. No.: HY-110387

IDO-IN-9 is an indoleamine-2,3-dioxygenase (**IDO**) inhibitor with IC_{50}s of 0.011 μM (Kinase) and 0.0018 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 6.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

IDO/TDO-IN-1

Cat. No.: HY-128355

IDO/TDO-IN-1 (compound 25) is a highly potent and orally active dual **indoleamine-2,3-dioxygenase (IDO)** and **tryptophan 2,3-dioxygenase (TDO)** inhibitor with IC_{50}s of 9.7 and 47 nM, respectively .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1 and HDAC1 Inhibitor

Cat. No.: HY-112147

IDO1 and HDAC1 Inhibitor (Compound 10) is a dual **IDO1** and **HDAC1** inhibitor with IC_{50}s of 69.0 nM and 66.5 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

IDO5L

Cat. No.: HY-15683

IDO5L is a potent indoleamine 2,3-dioxygenase (**IDO**) inhibitor with an IC_{50} of 67 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Idoxifene

(CB7432) Cat. No.: HY-U00178

Idoxifene (CB7432) is a novel tissue-specific selective **estrogen receptor** modulator (**SERM**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Ifosfamide

Cat. No.: HY-17419

Ifosfamide is an **alkylating** chemotherapeutic agent with activity against a wide range of tumors.



Purity: >98.0%
Clinical Data: Launched
Size: 200 mg, 500 mg

IIIM-290

Cat. No.: HY-111356

IIIM-290 is a potent and oral **CDK** inhibitor with IC_{50}s of 90 and 94 nM for CDK2/A and CDK9/T1.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 251 mg, 500 mg

IITZ-01

Cat. No.: HY-112897

IITZ-01 is a potent lysosomotropic **autophagy** inhibitor with single-agent antitumor activity, with an IC_{50} of 2.62 μM for PI3Kγ.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ikarisoside F

(Ikarisoside-F; Icarisoside-F)

Cat. No.: HY-N0861

Ikarisoside F is a flavonol glycoside from Vancouveria hexandra; could bind to AdoHcy hydrolase.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

IKKγ NBD Inhibitory Peptide

Cat. No.: HY-P1847

IKKγ NBD Inhibitory Peptide is a NEMO-binding domain peptide (NBD peptide) corresponding to the NEMO amino-terminal alpha-helical region, which is shown to block TNF-alpha-induced NF-kB activation.

DRQIKIWFQNRRMKWKKTALDWSWLQTE

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ilginatinib

(NS-018)

Cat. No.: HY-19631A

Ilginatinib (NS-018) is a highly active and orally bioavailable **JAK2** inhibitor, with an IC_{50} of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC_{50}, 33 nM), JAK3 (IC_{50}, 39 nM), and Tyk2 (IC_{50}, 22 nM).



Purity: 95.88%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ilginatinib hydrochloride

(NS-018 hydrochloride)

Cat. No.: HY-19631B

Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable **JAK2** inhibitor, with an IC_{50} of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC_{50}, 33 nM), JAK3 (IC_{50}, 39 nM), and Tyk2 (IC_{50}, 22 nM).



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ilginatinib maleate

(NS-018 (maleate))

Cat. No.: HY-19631

Ilginatinib (maleate) (NS-018 (maleate)) is a highly active and orally bioavailable **JAK2** inhibitor, with an IC_{50} of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC_{50}, 33 nM), JAK3 (IC_{50}, 39 nM), and Tyk2 (IC_{50}, 22 nM).



Purity: 97.04%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ILK-IN-2

Cat. No.: HY-18676B

ILK-IN-2 is a ILK inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Ilomastat

(GM6001; Galardin)

Cat. No.: HY-15768

Ilomastat (GM6001) is a potent and broad spectrum matrix metalloprotease (**MMP**) inhibitor, inhibits MMPs (IC_{50}s, 1.5 nM for MMP-1; 1.1 nM for MMP-2; 1.9 nM for MMP-3; 0.5 nM for MMP-9), with a K_i of 0.4 nM for human skin fibroblast collagenase (MMP-1).



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ilorasertib

(ABT-348)

Cat. No.: HY-16018

Ilorasertib (ABT-348) is an ATP-competitive multitargeted kinase inhibitor with IC_{50}s for inhibiting binding Aurora B (7 nM), C (1 nM), and A (120 nM), and also inhibits RET tyrosine kinase, PDGFRβ, and Flt1 with IC_{50}s of 7 nM, 3 nM and 32 nM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

IM-12

Cat. No.: HY-12292

IM-12 is an inhibitor of **GSK-3β**, with an IC_{50} of 53 nM, and also enhances Wnt signalling.



Purity: 96.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Imatinib

(STI571; CGP-57148B) Cat. No.: HY-15463

Imatinib (STI571) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (IC_{50}=100 nM) tyrosine kinases.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib Mesylate

(STI571 (Mesylate); CGP-57148B (Mesylate)) Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (IC_{50}=100 nM) tyrosine kinases.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

IMD-0354

(IKK2 Inhibitor V) Cat. No.: HY-10172

IMD-0354 is a selective **IKKβ** inhibitor which inhibits NF-κB activity. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC_{50} of 1.2±0.3 uM.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IMD-0560

Cat. No.: HY-105661

IMD-0560 is a novel **IκB kinase β** inhibitor.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Imexon

(BM 06002) Cat. No.: HY-15385

Imexon (BM 06002) is an iminopyrrolidone aziridine with anti-cancer activity.



Purity: >98.0%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 20 mg

Imidazole ketone erastin

(IKE) Cat. No.: HY-114481

Imidazole ketone erastin (IKE) is a potent, selective, and metabolically stable inhibitor of the cystine-glutamate antiporter, **system X_c^-** and an activator of **ferroptosis**.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Imisopasem manganese

(M40403) Cat. No.: HY-13336

Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide **MnSOD**.



Purity: >98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Importazole

Cat. No.: HY-101091

Importazole is a small molecule inhibitor of the nuclear transport receptor **importin-β**.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Impurity B of Calcitriol

(1β,25-Dihydroxyvitamin-D3; 1-Epicalcitriol) Cat. No.: HY-13292

Impurity B of Calcitriol, Calcitriol(1,25-Dihydroxyvitamin D3; Rocaltrol) is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).



Purity: 97.25%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Impurity C of Calcitriol

Cat. No.: HY-13293

Impurity C of Calcitriol, Calcitriol(1,25-Dihydroxyvitamin D3; Rocaltrol) is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).



Purity: 99.98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Impurity F of Calcipotriol

Cat. No.: HY-15265

Impurity F of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors. IC50 value: Target: Vitamin D3 analog that displays minimal effects on calcium homeostasis.



Purity: 97.12%
Clinical Data: No Development Reported
Size: 1 mg

IMR-1

Cat. No.: HY-100431

IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μmol/L.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

IMR-1A

Cat. No.: HY-100431A

IMR-1A is the metabolite of IMR-1. IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μmol/L.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Inauhzin

(INZ)

Cat. No.: HY-15869

Inauhzin is a dual **SirT1/IMPDH2** inhibitor, and acts as an activator **p53**, used in the research of cancer.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

INCB-057643

Cat. No.: HY-111485

INCB-057643 is a novel, orally bioavailable **BET** inhibitor.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

INCB053914 phosphate

Cat. No.: HY-101870B

INCB053914 phosphate is an inhibitor of **Pim** extracted from patent WO 2017044730 A1, compound 1; has an IC_{50} of less than 35 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

INCB054329

Cat. No.: HY-112504

INCB054329 is a potent **BET** inhibitor.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Incyclinide

(CMT-3; COL-3)

Cat. No.: HY-13648

Incyclinide (CMT-3, COL-3) is a matrix metalloproteinase (**MMP**) inhibitor, thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.



Purity: 98.26%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Indirubin

(Couroupitine B; Indigo red; Indigopurpurin)

Cat. No.: HY-N0117

Indirubin (Couroupitine B) is a purple 3,2-bisindole and a stable isomer of indigo isolated from Indigo naturalis (Apiaceae); anti-inflammatory and anticancer activities.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 250 mg

Indirubin Derivative E804

Cat. No.: HY-18785

E 804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (**IGF1R**), with an IC_{50} of 0.65 μM for IGF1R.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Indirubin-3'-monoxime

(Indirubin-3'-oxime)

Cat. No.: HY-19807



Indirubin-3'-monoxime is a potent **GSK-3β** inhibitor, and weakly inhibits **5-Lipoxygenase**, with IC_{50}s of 22 nM and 7.8-10 μM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC_{50}s of 100 and 180 nM.

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Indirubin-3'-monoxime-5-sulphonic acid

Cat. No.: HY-111931



Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of **CDK1**, **CDK5**, and **GSK-3β** with IC_{50}s of 5 nM, 7 nM, and 80 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Indirubin-5-sulfonate

Cat. No.: HY-111932



Indirubin-5-sulfonate is a **cyclin-dependent kinase (CDK)** inhibitor, with IC_{50} values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively. Indirubin-5-sulfonate also shows inhibitory activity against **GSK-3β**.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Indisulam

(E 7070)

Cat. No.: HY-13650



Indisulam (E 7070) is a **carbonic anhydrase** inhibitor and a G1-targeting agent. Indisulam causes a blockade in the G1/S transition through inhibition of the activation of both cyclin-dependent kinase 2 (CDK2) and cyclin E.

Purity: 98.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Indole-3-carbinol

(I3C; 3-Indolemethanol)

Cat. No.: HY-N0170



Indole-3-carbinol (I3C) inhibits **NF-κB** activity and also is an **Aryl hydrocarbon receptor** (**AhR**) agonist, and an inhibitor of **WWP1** (WW domain-containing ubiquitin E3 ligase 1).

Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 200 mg, 1 g

Indotecan

(LMP-400; NSC-724998)

Cat. No.: HY-18351



Indotecan (LMP-400) is a potent **topoisomerase 1(Top1)** inhibitor with IC_{50} values of 300, 1200, 560 nM for P388, HCT116, MCF-7 cell lines, respectively.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Indoximod

(NLG-8189; 1-Methyl-D-tryptophan)

Cat. No.: HY-16724



Indoximod (D-1MT, NLG8189) is an indoleamine 2,3-dioxygenase (**IDO**) pathway inhibitor with a K_i of 19 μM.

Purity: 98.98%
Clinical Data: Phase 3
Size: 250 mg

Infigratinib

(BGJ-398; NVP-BGJ398)

Cat. No.: HY-13311



Infigratinib (BGJ-398) is a potent inhibitor of the **FGFR** family with IC_{50}s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.

Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Infigratinib phosphate

(BGJ-398 phosphate; NVP-BGJ398 (phosphate))

Cat. No.: HY-13311A



Infigratinib phosphate (BGJ-398 phosphate) is a potent inhibitor of the **FGFR** family with IC_{50} of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.

Purity: 97.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ingenol

((-)-Ingenol)

Cat. No.: HY-N0865



Ingenol is a **PKC** activator, with a K_i of 30 μM, with antitumor activity.

Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ingenol Mebutate

(Ingenol 3-angelate; PEP005) Cat. No.: HY-B0719

Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent **PKC** modulator, with K_is of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.



Purity: 98.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

INH1

(IBT13131) Cat. No.: HY-16660

INH1 is a small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

INH14

Cat. No.: HY-114454

INH14 is a cell permeable inhibitor of **IKKα/IKKβ**, with IC_{50}s of 8.97 and 3.59 μM, respectively. INH14 inhibits the IKKα/β-dependent **TLR** inflammatory response. INH14 also inhibits downstream of TAK1/TAB1 and NF-kB pathways. Anti-inflammatory and anti-cancer activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

INH154

Cat. No.: HY-117154

INH154 is a highly potent inhibitor for Nek2 and Hec1 binding **(INH)**, with IC_{50}**s** of 200 nM and 120 nM for INH in Hela and MB468 cells.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

INH6

Cat. No.: HY-100541

INH6 is a potent **Nek2/Hec1** inhibitor; inhibits the growth of HeLa cells with an IC_{50} of 2.4 μM.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Iniparib

(BSI-201; NSC-746045; IND-71677) Cat. No.: HY-12015

Iniparib (BSI-201) is an irreversible inhibitor of **PARP1**, used in the research of triple negative breast cancer.



Purity: 99.65%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Inolitazone

(Efatutazone; CS-7017; RS5444) Cat. No.: HY-14792

Inolitazone a novel high-affinity **PPARγ** agonist that is dependent upon PPARγ for its biological activity with IC_{50} of 0.8 nM for growth inhibition.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg

Inolitazone dihydrochloride (Efatutazone (dihydrochloride); CS-7017 (dihydrochloride); RS5444 (dihydrochloride))

Cat. No.: HY-14792B

Inolitazone dihydrochloride is a novel high-affinity **PPARγ** agonist that is dependent upon PPARγ for its biological activity with IC_{50} of 0.8 nM for growth inhibition.



Purity: 99.21%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg

inS3-54A18

Cat. No.: HY-103128

inS3-54A18 is a potent **STAT3** inhibitor, with anti-cancer properties.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

INT-767

Cat. No.: HY-12434

INT-767 is a dual **farnesoid X receptor (FXR)/TGR5** agonist with mean EC_{50}s of 30 and 630 nM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Integrin Antagonists 27

Cat. No.: HY-18668

Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Intoplicine

Cat. No.: HY-101647

Intoplicine is a **DNA topoisomerase I** and **II** inhibitor.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg

Inulicin

(1-O-Acetylbritannilactone)

Cat. No.: HY-N0896

Inulicin (1-O-Acetylbritannilactone) is an active compound isolated from Inula Britannica L. Inulicin (1-O-Acetylbritannilactone) inhibits VEGF-mediated activation of **Src** and **FAK**.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ionomycin

(SQ23377)

Cat. No.: HY-13434

Ionomycin (SQ23377) is a **Calcium ionophore** and an antibiotic produced by **Streptomyces conglobatus**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 14.1 mM*500 μL , 14.1 mM*100 μL ,

IOX1

Cat. No.: HY-12304

IOX1 is the most potent broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases; IC50 for KDM4A/KDM3A is 0.6/0.1 uM.



Purity: 97.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IOX2

Cat. No.: HY-15468

IOX2 is a specific prolyl hydroxylase-2 (**PHD2**) inhibitor with IC_{50} of 22 nM.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IPA-3

Cat. No.: HY-15663

IPA-3 is a selective non-ATP competitive **PAK1** inhibitor with IC_{50} of 2.5 μM, and shows no inhibition to group II PAKs (PAKs 4-6).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ipatasertib

(GDC-0068; RG7440)

Cat. No.: HY-15186

Ipatasertib (GDC-0068) is a highly selective and ATP-competitive **pan-Akt** inhibitor with IC_{50}s of 5, 18 and 8 nM for **Akt1**, **Akt2** and **Akt3**, respectively.



Purity: 98.89%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ipatasertib dihydrochloride

(GDC-0068 (dihydrochloride); RG-7440 dihydrochloride)

Cat. No.: HY-15186A

Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective pan-**Akt** inhibitor targeting **Akt1/2/3** with IC_{50} of 5/18/8 nM, 620-fold selectivity over PKA.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

IPI549

Cat. No.: HY-100716

IPI549 is a potent and selective **PI3Kγ** inhibitor with an IC_{50} of 16 nM.



Purity: 99.34%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ipilimumab

(MDX-010; BMS-734016) Cat. No.: HY-P9901

Ipilimumab is a fully human monoclonal IgG1κ antibody against the cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune-inhibitory molecule expressed in activated T cells and in suppressor T regulatory cells.

Ipilimumab

Purity: 99.88%
Clinical Data: Launched
Size: 1 mg, 5 mg

IQ 1

Cat. No.: HY-10593

IQ 1 has many functions such as decreasing Wnt-stimulated phosphorylation, maintaining the pluripotency of murine ESCs, preventing PP2A/Nkd interaction and so on. IQ 1 maintains the pluripotency of murine ESCs in long-term culture in a Wnt-dependent manner.

Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

IQ-1S free acid

Cat. No.: HY-100233

IQ-1S free acid is a prospective inhibitor of **NF-κB**/activating protein 1 (**AP-1**) activity with an IC_{50} of 2.3±0.41 μM. IQ-1S free acid has binding affinity (K_d values) in the nanomolar range for all three **JNKs** with K_ds of 100 nM, 240 nM, and 360 nM for **JNK3**, **JNK1**, and **JNK2**, respectively.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

iRGD peptide

(c(CRGDKGPDC)) Cat. No.: HY-P0122

iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to **av integrins**, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Irinotecan

((+)-Irinotecan; CPT-11) Cat. No.: HY-16562

Irinotecan is a water soluble **topoisomerase I** inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Irinotecan hydrochloride

(CPT-11 hydrochloride; Camptothecin 11 hydrochloride) Cat. No.: HY-16562A

Irinotecan hydrochloride is a water soluble **topoisomerase I** inhibitor mainly used to treat colon cancer and rectal cancer.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Irinotecan hydrochloride trihydrate

Cat. No.: HY-16568

Irinotecan hydrochloride trihydrate is a water soluble **topoisomerase I** inhibitor with antitumor activity.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Iristectorin A

Cat. No.: HY-N6820

Iristectorin A, a natural product from Iris tectorum, has anti-cancer activities in breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iristectorin B

Cat. No.: HY-N6819

Iristectorin B is an isoflavone from Iris tectorum, has anti-cancer activities in breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Irosustat

(STX64; BN83495; 667-Coumate) Cat. No.: HY-14586

Irosustat is a potent **steroid sulfatase** inhibitor, with an IC_{50} of 8 nM, and exhibits anti-breast cancer activity.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ISA-2011B

Cat. No.: HY-16937

ISA-2011B is a **PIP5Kα** inhibitor with promising anticancer effects .



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Isatin

(Indoline-2,3-dione)

Cat. No.: HY-Y0265

Isatin (Indoline-2,3-dione) is a potent inhibitor of **monoamine oxidase (MAO)** with an IC_{50} of 3 μM. Also binds to central benzodiazepine receptors (IC_{50} against clonazepam, 123 μM).



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Isoalantolactone

((+)-Isoalantolactone; Isohelenin)

Cat. No.: HY-N0780

Isoalantolactone is an **apoptosis** inducer, which also acts as an alkylating agent.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Isobavachalcone

(Corylifolinin; Isobacachalcone)

Cat. No.: HY-13065

Isobavachalcone(Corylifolinin) is a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. IC50 value: Target: Isobavachalcone inhibits platelet aggregation. Inhibitor of Epstein-Barr virus early antigen (EBV-EA) induction.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Isocryptotanshinone

Cat. No.: HY-N6651

Isocryptotanshinone is a potent signal transducer and activator of transcription 3 (**STAT3**) and protein tyrosine phosphatase 1B **PTP1B** inhibitor, with an IC_{50} of 56.1 μM for PTP1B.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Isoeugenol acetate

Cat. No.: HY-N6805

Isoeugenol acetate, an essential oil constituent of nutmeg, clove, and cinnamon, shows excellent inhibitory effects against some metabolic enzymes such as acetylcholinesterase (AChE) enzymes (IC_{50}=77 nM; K_i=16 nM), α-glycosidase (IC_{50}=19.25 nM; K_i=21 nM), and α-amylase (IC_{50}=411.5...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isoginkgetin

Cat. No.: HY-N2117

Isoginkgetin is a MMP-9 inhibitor, also a Pre-mRNA Splicing Inhibitor with IC 50 of 30 uM. target : MMP-9 , Pre-mRNA Splicing IC 50: 30 u M (Pre-mRNA Splicing) In vitro: Isoginkgetin inhibits HT1080 tumor cell invasion substantially.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Isoliquiritigenin

(GU17; ISL; Isoliquiritigen)

Cat. No.: HY-N0102

Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza glabra, which inhibits **aldose reductase** with an IC_{50} of 320 nM.



Purity: 98.24%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Isoorientin

(Homoorientin)

Cat. No.: HY-N0767

Isoorientin is a potent inhibitor of **COX-2** with an IC_{50} value of 39 μM.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Isorhamnetin

(3'-Methylquercetin)

Cat. No.: HY-N0776

Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of **MEK1** and **PI3K**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Isosilybin

(Isosilybinin) Cat. No.: HY-N0779

Isosilybin (Isosilybinin) is a flavonoid from milk thistle; inhibits **CYP3A4** induction with an IC_{50} of 74 μM.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Isotretinoin

(13-cis-Retinoic acid) Cat. No.: HY-15127

Isotretinoin(13-cis-Retinoic acid) is a medication used for the treatment of severe acne. It was first developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.

Purity: 94.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Ispinesib

(SB-715992) Cat. No.: HY-50759

Ispinesib is a specific inhibitor of **kinesin spindle protein (KSP)**, with a $K_{i\ app}$ of 1.7 nM.



Purity: 98.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg

Itacitinib

(INCB039110) Cat. No.: HY-16997

Itacitinib is a potent and selective inhibitor of **JAK1**, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.



Purity: 99.87%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Itacitinib adipate

Cat. No.: HY-16997A

Itacitinib adipate is a selective **JAK1** inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ITSA-1

Cat. No.: HY-100508

ITSA-1 is membrane permeable and specifically suppresses TSA inhibition of HDAC (histone deacetylase), but not other HDAC inhibitors.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Ivosidenib

(AG-120) Cat. No.: HY-18767

Ivosidenib (AG-120) is a mutant isocitrate dehydrogenase 1 (**IDH1**) inhibitor with an IC_{50} of 12 nM for mouse $IDH1^{R132H}$.



Purity: 99.24%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IWP L6

(Porcn Inhibitor III) Cat. No.: HY-15825

IWP L6 is a Porcn inhibitor with EC50 of 0.5 nM. IC50 Value: 0.5 nM(EC50) Target: Porcupine in vitro: IWP-L6 effectively suppressed the phosphorylation of dishevelled 2 (Dvl2) in HEK293 cells, a biochemical event associated with many Wnt-dependent cellular responses.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

IWP-2

Cat. No.: HY-13912

IWP-2 is an inhibitor of **Wnt** processing and secretion with IC_{50} of 27 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

IWP-4

Cat. No.: HY-12879

IWP-4 is a small molecule **Wnt** inhibitor with an IC_{50} of 25 nM.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

IWP-O1

Cat. No.: HY-100853

IWP-O1 is a highly potent **Porcupine (Porcn)** inhibitor, with an EC_{50} of 80 pM in L-Wnt-STF cells, suppressing the phosphorylation of Dvl2/3 and LRP6 in HeLa cells. IWP-O1 functions by preventing the secretion of **Wnt** proteins.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IWR-1

(endo-IWR 1; IWR-1-endo)

Cat. No.: HY-12238

IWR-1 is a **tankyrase** inhibitor which inhibits Wnt/β-catenin signaling pathway.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ixabepilone

(Azaepothilone B; BMS 247550; BMS 247550-1)

Cat. No.: HY-10222

Ixabepilone is an orally bioavailable **microtubule** inhibitor, which binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arrests cells in the G2-M phase of the cell cycle and induces tumor cell apoptosis.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ixazomib

(MLN2238)

Cat. No.: HY-10453

Ixazomib (MLN2238) is a selective, potent, and reversible **proteasome** inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC_{50} of 3.4 nM (K_i of 0.93 nM).



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Ixazomib citrate

(MLN9708)

Cat. No.: HY-10452

Ixazomib citrate (MLN9708) is a reversible inhibitor of the chymotrypsin-like proteolytic β5 site of the **20S proteasome** with an IC_{50} of 3.4 nM and a K_i of 0.93 nM.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IZCZ-3

Cat. No.: HY-111411

IZCZ-3 is a potent **c-MYC transcription** inhibitor with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

J22352

Cat. No.: HY-126147

J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective **HDAC6** inhibitor with an IC_{50} value of 4.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Jaceosidin

Cat. No.: HY-N0831

Jaceosidin is a flavonoid isolated from Artemisia vestita, induces apoptosis in cancer cells, activates **Bax** and down-regulates Mcl-1 and c-FLIP expression.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Jagged-1 (188-204) TFA

Cat. No.: HY-P1846A

Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.

CDDYYYGFGCNKFCRPR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Jagged-1 188-204

Cat. No.: HY-P1846

Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.

CDDYYYGFGCNKFCRPR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK/HDAC-IN-1

Cat. No.: HY-126141

JAK/HDAC-IN-1 is a potent **JAK2/HDAC** dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC_{50}s of 4 and 2 nM for JAK2 and HDAC, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

JAK1-IN-3

Cat. No.: HY-107361

JAK1-IN-3 is a selective **JAK1** inhibitor, with an IC_{50} of 73 nM, weakly inhibits JAK2, and shows little inhibition on JAK3 (IC_{50}, >14.7, >30 μM, respectively).



Purity: 99.32%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JAK1-IN-4

Cat. No.: HY-116505

JAK1-IN-4 is a potent and selective **JAK1** inhibitor, with IC_{50}s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC_{50}, 227 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

JAK3-IN-1

Cat. No.: HY-19544

JAK3-IN-1 is a potent JAK3 inhibitor with IC50 of 4.8 nM, also inhibits JAK1 (IC50 = 896 nM) and JAK2 (IC50 = 1050 nM). IC50 value: 4.8 nM Target: JAK3 in vitro: JAK3-IN-1 provides a set of useful tools to pharmacologically interrogate JAK3-dependent biology.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JAK3-IN-7

Cat. No.: HY-U00390

JAK3-IN-7 is a potent and selective **JAK3** inhibitor extracted from patent WO2011013785A1, has an IC_{50} of <0.01 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

JANEX-1

(WHI-P131; Jak3 inhibitor I)

Cat. No.: HY-15508

JANEX-1 is a potent and specific **JAK3** inhibitor (estimated K_i=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC_{50} of 78 μM), does not inhibit JAK1 and JAK2.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Jervine

(11-Ketocyclopamine)

Cat. No.: HY-N0836

Jervine(11-Ketocyclopamine) is a naturally occuring steroidal alkaloid that causes cyclopia by blocking sonic hedgehog(Shh) signaling; Jervine is an inhibitor of Smo. IC50 value: Target: sonic hedgehog is derived from the Veratrum plant species.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

JG-98

Cat. No.: HY-117282

JG-98, an allosteric **heat shock protein 70 (Hsp70)** inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

JH-RE-06

Cat. No.: HY-126214

JH-RE-06, a potent **REV1-REV7** interface inhibitor (IC_{50}=0.78 μM; K_d=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JH-VIII-157-02

Cat. No.: HY-112140

JH-VIII-157-02 is a structural analogue of alectinib, acts as an **ALK** inhibitor, and shows an IC_{50} of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JH-XI-10-02

Cat. No.: HY-111518

JH-XI-10-02 is a potent and selective degrader of **CDK8**, with an IC_{50} of 159 nM, based on **PROTAC**. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

JI051

Cat. No.: HY-117113

JI051 is a stabilizer for the **Hes1-PHB2** interaction, interacts with a cancer-associated protein chaperone prohibitin 2 (**PHB2**), induces cell-cycle arrest by inhibiting the **Notch** downstream effector gene Hes1. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JIB-04

Cat. No.: HY-13953

JIB-04 is a pan-selective **Jumonji histone demethylase** inihibitor with IC_{50}s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

JK184

Cat. No.: HY-13307

JK184 is a potent **Hedgehog (Hh)** pathway inhibitor with IC_{50} of 30 nM in mammalian cells.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JMS-17-2

Cat. No.: HY-123918

JMS-17-2 is a potent and selective **CX3CR1** antagonist with an IC_{50} of 0.32 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

JND3229

Cat. No.: HY-119944

JND3229 is a new highly potent $EGFR^{C797S}$ reversible inhibitor with IC_{50} value of 5.8 nM, and also potently suppressed $EGFR^{L858R/T790M}$ and $EGFR^{WT}$ with IC_{50} values of 30.5 and 6.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

JNJ-38877605

Cat. No.: HY-50683

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.



Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-38877618

Cat. No.: HY-111050

JNJ-38877618 is a potent, highly selective, orally bioavailable **Met** kinase inhibitor with IC_{50}s of 2 and 3 nM for wild type and mutant Met, respectively.

Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-47117096 hydrochloride

(MELK-T1 hydrochloride)

Cat. No.: HY-12420

JNJ-47117096 hydrochloride is potent and selective **MELK** inhibitor, with an IC_{50} of 23 nM, also effectively inhibits **Flt3**, with an IC_{50} of 18 nM.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNJ-64619178

Cat. No.: HY-101564

JNJ-64619178 is a selective, orally active and pseudo-irreversible **PRMT5** inhibitor with an IC_{50} of 0.14 nM. JNJ-64619178 has potent activity In lung cancer.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-7706621

Cat. No.: HY-10329

JNJ-7706621 is a potent **aurora kinase** inhibitor, and also inhibits **CDK1** and **CDK2**, with IC_{50}s of 9, 3, 11, and 15 nM for CDK1, CDK2, Aurora-A and Aurora-B, respectively.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

JNJ0966

Cat. No.: HY-103482

JNJ0966 is a highly selective **MMP-9 zymogen** inhibitor with an IC_{50} of 440 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNK Inhibitor VIII

(TCS JNK 6o)

Cat. No.: HY-107598

JNK Inhibitor VIII (TCS JNK 6o) is a **c-Jun N-terminal kinases (JNK-1, -2, and -3)** inhibitor with K_i values of 2 nM, 4 nM, 52 nM, respectively, and has IC_{50} values of 45 nM and 160 nM for JNK-1 and -2, respectively.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNK-IN-7

(JNK inhibitor)

Cat. No.: HY-15617

JNK-IN-7 is a potent **JNK** inhibitor with IC_{50} of 1.5, 2 and 0.7 nM for **JNK1**, **JNK2** and **JNK3**, respectively.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNK-IN-8

Cat. No.: HY-13319

JNK-IN-8 is a potent **JNK** inhibitor with IC_{50}s of 4.7 nM, 18.7 nM, and 1 nM for **JNK1**, **JNK2**, and **JNK3**, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JPH203

(KYT-0353)

Cat. No.: HY-100868

JPH203 is a potent and selective L-type amino acid transporter 1 (**LAT-1**) inhibitor.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JPH203 Dihydrochloride

Cat. No.: HY-U00445

JPH203 Dihydrochloride is a tyrosine analog, acts as a selective inhibitor of L-type amino acid transporter 1 (**LAT1**), and is used in cancer research.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JQ-1 carboxylic acid

Cat. No.: HY-78695

JQ-1 carboxylic acid is a highly potent, selective and cell-permeable **BRD4** inhibitor with IC_{50}s of 77 nM and 33 nM for BRD4(1) and BRD4(2), respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

JQEZ5

Cat. No.: HY-100846

JQEZ5 is a novel and potent **EZH2** inhibitor.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

JR-AB2-011

Cat. No.: HY-122022

JR-AB2-011 is a selective **mTORC2** inhibitor with an IC_{50} value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (K_i: 0.19 μM). JR-AB2-011 has anti-glioblastoma multiforme (GBM) properties.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JSH-150

Cat. No.: HY-X0150

JSH-150 is a highly selective and potent **CDK9** inhibitor with an IC_{50} of 1 nM.



Purity: 92.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

JSH-23

Cat. No.: HY-13982

JSH-23 is an **NF-κB** inhibitor which inhibits NF-κB transcriptional activity with an IC_{50} of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

JT010

Cat. No.: HY-111132

JT010 is a potent agonist of **TRPA1** with an EC_{50} of 0.65 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Juglanin

Cat. No.: HY-N3442

Juglanin is a **JNK** activator.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

JW 55

Cat. No.: HY-13968

JW 55 is a potent and selective **β-catenin** signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC_{50}s of 1.9 μM and 830 nM respectively.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

JW74

Cat. No.: HY-19739

JW74 antagonizes LiCl-induced activation of the canonical **Wnt** signaling with an IC_{50} of 420 nM.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

K-252c

Cat. No.: HY-N6736

K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable **PKC** inhibitor, with an IC_{50} of 2.45 μM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K-756

Cat. No.: HY-U00422

K-756 is a direct and selective **tankyrase** (**TNKS**) inhibitor, which inhibits the ADP-ribosylation activity of **TNKS1** and **TNKS2** with IC_{50}s of 31 and 36 nM, respectively.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

K-80003

(TX-803)

Cat. No.: HY-U00458

K-80003 is a potent inhibitor of tRXRα-dependent **Akt** activation and cancer cell growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

K-Ras G12C-IN-1

Cat. No.: HY-18604

K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1. IC50 value: Target: K-ras G12C inhibitor.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

K-Ras G12C-IN-2

Cat. No.: HY-18605

K-Ras G12C-IN-2 is a novel and irreversible inhibitor of **G12C mutant K-Ras** protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

K-Ras G12C-IN-3

Cat. No.: HY-18606

K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

K-Ras(G12C) inhibitor 12

Cat. No.: HY-18707

K-Ras(G12C) inhibitor 12 is a K-Ras(G12C) inhibitor, the half-maximum effective concentration (EC50) for K-Ras(G12C) inhibitor 12 in H1792 cells is 0.32 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

K-Ras-IN-1

Cat. No.: HY-18674

K-Ras-IN-1 is a K-Ras inhibitor, by binding to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure.(the detailed information refer to the reference).



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

K145

Cat. No.: HY-15779

K145 is a selective SphK2 inhibitor with an IC50 of 4.30±0.06 μM , while no inhibition of SphK1 at concentrations up to 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

K145 hydrochloride

Cat. No.: HY-15779A

K145 is a selective SphK2 inhibitor with an IC50 of 4.30±0.06 μM , while no inhibition of SphK1 at concentrations up to 10 μM.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

K858 Racemic

Cat. No.: HY-19966

K858 Racemic is an ATP-uncompetitive inhibitor of **kinesin Eg5** with an IC_{50} of 1.3 μM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kaempferitrin

(Lespedin; Lespenephryl)

Cat. No.: HY-N0628

Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates **insulin** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Kaempferol

(Robigenin; Kempferol)

Cat. No.: HY-14590

Kaempferol inhibits **estrogen receptor α** expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Kallikrein Inhibitor

Cat. No.: HY-P0237

Kallikrein Inhibitor is a synthetic peptide. The synthetic kallikrein inhibitor can attenuate breast cancer cell invasion.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

KAN0438757

Cat. No.: HY-112808

KAN0438757 is a potent and selective inhibitor of the metabolic kinase **PFKFB3** with an IC_{50} of 0.19 μM .



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Karenitecin

(Cositecan; BNP 1350)

Cat. No.: HY-14812

Karenitecin (Cositecan) is a **topoisomerase I** inhibitor, with potent anti-cancer activity.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

kb NB 142-70

Cat. No.: HY-15528

kb NB 142-70 is a potent **PKD** inhibitor, with IC_{50}s of 28.3, 58.7 and 53.2 nM for PKD1, PKD2, and PKD3, respectively. kb NB 142-70 also has antitumor activity.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

KB SRC 4

Cat. No.: HY-108488

KB SRC 4 is a potent, and highly selective **c-Src** inhibitor, with a K_i of 44 nM and a K_d of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

kb-NB77-78

Cat. No.: HY-16698

kb-NB77-78 is an analogue of CID797718, but shows no PKD inhibitory activity.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

KC7F2

Cat. No.: HY-18777

KC7F2 is a potent **hypoxia inducible factor-1 (HIF-1)** pathway inhibitor with an IC_{50} of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KDM2A/7A-IN-1

Cat. No.: HY-108706

KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of **histone lysine demethylases KDM2A/7A**, with an IC_{50} of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone...



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

KDM4-IN-2

Cat. No.: HY-128343

KDM4-IN-2 (Compound 19a) is a potent and selective **KDM4/KDM5** dual inhibitor with K_is of 4 and 7 nM for KDM4A and KDM5B, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM4D-IN-1

Cat. No.: HY-101928

KDM4D-IN-1 is a new **histone lysine demethylase 4D** (**KDM4D**) inhibitor with an IC_{50} value of 0.41±0.03 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KDM5-IN-1

Cat. No.: HY-100422

KDM5-IN-1 is a potent, selective and orally bioavailable **KDM5** inhibitor with an IC_{50} of 15.1 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KDM5A-IN-1

Cat. No.: HY-100014

KDM5A-IN-1 is an inhibitor histone demethylases.
Target: Histone Demethylase.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KDOAM-25

Cat. No.: HY-102047

KDOAM-25 is a potent and selective **KDM5** inhibitor with **IC_{50}**s of 71, 19, 69, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Kenpaullone

(9-Bromopaullone; NSC-664704)

Cat. No.: HY-12302

Kenpaullone is a potent inhibitor of **CDK1/cyclin B** and **GSK-3β**, with **IC_{50}**s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with **IC_{50}**s of 0.68 μM, 7.5 μM, 0.85 μM, respectively.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride; ...)

Cat. No.: HY-16271

Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

KH-CB19

Cat. No.: HY-12828

KH-CB19 is a potent and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4).



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Ki16425

(Debio 0719)

Cat. No.: HY-13285

Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, **LPA1** and **LPA3** with **K_i**s of 0.34 μM and 0.93 μM, respectively.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ki8751

Cat. No.: HY-12038

Ki8751 is a potent **VEGFR2** inhibitor with an **IC_{50}** of 0.9 nM.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Kif15-IN-1

Cat. No.: HY-15948

Kif15-IN-1 is an inhibitor of the mitotic **Kinesin family member 15 (Kif15)**, and is used for the research of cellular proliferative diseases.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kif15-IN-2

Cat. No.: HY-15949

Kif15-IN-2 is an inhibitor of the mitotic **kinesin Kif15**, and is used for the research of cellular proliferative diseases.



Purity: 96.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kinase inhibitor-1

Cat. No.: HY-43533

Kinase inhibitor-1 (Compound 5) is a kinase inhibitor.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Kinetin riboside

(N6-Furfuryladenosine)

Cat. No.: HY-101055

Kinetin riboside, a cytokinin analog, can induce **apoptosis** in cancer cells. It inhibits the proliferation of HCT-15 cells with an IC_{50} of 2.5 μM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

KIRA6

Cat. No.: HY-19708

KIRA6 allosterically inhibits **IRE1α RNase kinase** activity with an IC_{50} of 0.6 μM.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Kisspeptin-10 Trifluoroacetate

Cat. No.: HY-P0254A

Kisspeptin-10 Trifluoroacetate is the trifluoroacetate salt form of Kisspeptin-10. Kisspeptin-10, the minimal kisspeptin sequence with biological activity, is a potent endogenous ligand for **GPR54**.

Purity: 99.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KJ Pyr 9

Cat. No.: HY-19735

KJ Pyr 9 is an inhibitor of **MYC** with a K_d of 6.5 nM in in vitro assay.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KN-93

Cat. No.: HY-15465

KN-93 is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (**CaMKII**) with a K_i of 370 nM.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

KN-93 hydrochloride

Cat. No.: HY-15465A

KN-93 hydrochloride is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (**CaMKII**) with a K_i of 370 nM.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

KN-93 phosphate

Cat. No.: HY-15465B

KN-93 phosphate is a novel membrane-permeant synthetic inhibitor of purified neuronal **CaMK-II**, with K_i of 370 nM.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

KNK437

(Heat Shock Protein Inhibitor I)

Cat. No.: HY-100110

KNK437 is a **HSP** inhibitor, and inhibits the induction of HSP105, HSP70, and HSP40.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Ko 143

Cat. No.: HY-10010

Ko 143 is a potent and selective ATP-binding cassette sub-family G member 2 (**ABCG2**) inhibitor.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KO-947

Cat. No.: HY-112181

KO-947 is a potent and selective inhibitor of **ERK1/2** kinases with potential clinical utility in MAPK pathway dysregulated tumors.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Kobe0065

Cat. No.: HY-15716

Kobe0065 is a novel and effective inhibitor of **Ras-Raf interaction**, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 46±13 μM.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

kobe2602

Cat. No.: HY-15717

kobe2602 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 149 ± 55 μM.



Purity: 89.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 250 mg

Koumine

Cat. No.: HY-N1440

Koumine is an alkaloid separated from Gelsemium elegans, shows potent anti-tumor activity. Koumine up-regulates the Bax/Bcl-2 ratio and caspase-3 expression in human breast cancer cells.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

KRas G12C inhibitor 1

Cat. No.: HY-112491

KRas G12C inhibitor 1 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

KRas G12C inhibitor 2

Cat. No.: HY-112492

KRas G12C inhibitor 2 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

KRas G12C inhibitor 3

Cat. No.: HY-112493

KRas G12C inhibitor 3 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

KRas G12C inhibitor 4

Cat. No.: HY-112494

KRas G12C inhibitor 1 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

KRAS G12C inhibitor 5

Cat. No.: HY-114168

KRAS G12C inhibitor 5 is a **KRas G12C** inhibitor extracted from patent WO2017201161A1, Compound example 147.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

KRCA-0008

Cat. No.: HY-12331

KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.



Purity: 96.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

KRIBB11

Cat. No.: HY-100872

KRIBB11 is an inhibitor of **Heat shock factor 1 (HSF1)**, with IC_{50} of 1.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRN-633

Cat. No.: HY-12060

KRN-633 is a potent **VEGFR** inhibitor with IC_{50}s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KS176

Cat. No.: HY-19753

KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter (IC50 values are 0.59 and 1.39 μM in Pheo A and Hoechst 33342 assays respectively). Displays no inhibitory activity against P-gp or MRP1.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KSI-3716

Cat. No.: HY-12703

KSI-3716 is a **c-Myc** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

KU 59403

Cat. No.: HY-18650

KU 59403 is a potent **ATM** inhibitor, with an IC_{50} of 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

KU-0063794

Cat. No.: HY-50710

KU-0063794 is a potent and specific **mTOR** inhibitor, inhibiting both the **mTORC1** and **mTORC2** complexes with IC_{50}s of 10 nM.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KU-55933

Cat. No.: HY-12016

KU-55933 is a potent **ATM** inhibitor with an IC_{50} and K_i of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KU-57788

(NU7441)

Cat. No.: HY-11006

KU-57788 is a potent and selective inhibitor of **DNA-PK** with an IC_{50} of 13 nM, with selectivity over a range of kinases including mTOR, PI 3-K, ATM and ATR.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KU-60019

Cat. No.: HY-12061

KU-60019 is an improved **ATM** kinase-specific inhibitor with IC_{50} of 6.3 nM.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kuwanon E

Cat. No.: HY-N3514

Kuwanon E is a flavonoid isolated from Morus alba, cytotoxic to human monocytic leukemic cell lines, and reduces the level of IL-1β.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL**^{T315I} and **Aurora kinase** with IC_{50}s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KW-2478

Cat. No.: HY-13468

KW-2478 is an inhibitor of **Hsp90α**, with an IC_{50} of 3.8 nM, and has antitumor activity against various human hematological tumor cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KY02111

Cat. No.: HY-13815

KY02111 is a small molecule which can promote differentiation of hPSCs to cardiomyocytes.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

KY1220

Cat. No.: HY-102028

KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the **Wnt/β-catenin** pathway; with an IC_{50} of 2.1 μM in HEK293 reporter cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KYA1797K

Cat. No.: HY-101090

KYA1797K is a potent and selective **Wnt/β-catenin** inhibitor with an IC_{50} of 0.75 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-2-Hydroxyglutaric acid

Cat. No.: HY-113039

L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

L-4-Oxalysine hydrochloride

Cat. No.: HY-U00097

L-4-Oxalysine hydrochloride is a natural product isolated from the culture media of Streptomyces roseovirdofuscus in China which has shown antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

L-45

(L-Moses)

Cat. No.: HY-101125

L-45 is the first potent, selective, and cell-active p300/CBP-associated factor (**PCAF**) bromodomain (**Brd**) inhibitor with a K_d of 126±15 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

L-45 dihydrochloride

(L-Moses dihydrochloride)

Cat. No.: HY-101125A

L-45 dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (**PCAF**) bromodomain (**Brd**) inhibitor with a K_d of 126±15 nM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

L-771688

Cat. No.: HY-U00237

L-771688 is a highly selective **α1A-Adrenoceptor** antagonist with a K_i of 0.43±0.02 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

L-778123 hydrochloride

(L-778,123 hydrochloride)

Cat. No.: HY-16273A

L-778123 hydrochloride is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

L-779450

Cat. No.: HY-12787

L-779450 is a potent and selective **B-Raf** kinase inhibitor with a K_d of 2.4 nM.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

L-Ascorbic acid sodium salt ((+)-Sodium L-ascorbate; Vitamin C sodium salt; Sodium L-ascorbate)

Cat. No.: HY-B0166A

L-Ascorbic acid sodium salt is a more bioavailable form of vitamin C that is an antioxidant agent.



Purity: >98.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 1 g

L-Asparaginase

(L-ASNase)

Cat. No.: HY-P1923

L-Asparaginase (L-ASNase), a hydrolase that catalyzes the conversion of L-asparagine, used in acute lymphoblastic leukemia treatment. L-Asparaginase depletes L-asparagine from plasma resulting in inhibition of RNA and DNA synthesis with the subsequent blastic cell apoptosis.

L-Asparaginase

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

L-Buthionine-(S,R)-sulfoximine

(L-Buthionine sulfoximine)

Cat. No.: HY-106376A

L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of **g-glutamylcysteine synthetase** and depletes cellular glutathione levels.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

L-Canavanine sulfate

Cat. No.: HY-B1581A

L-Canavanine sulfate is a selective inhibitor of inducible **NO synthase**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

L-Eflornithine

(L-DFMO; L-RMI71782; L-α-difluoromethylornithine)

Cat. No.: HY-B0744C

L-Eflornithine (L-DFMO) is an enantiomer of Eflornithine. L-Eflornithine is an irreversible **ornithine decarboxylase** (**ODC**) inhibitor with a K_D of 1.3±0.3 μM, and a K_{inact} of 0.15±0.03 min^{-1}.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

L-Eflornithine monohydrochloride (L-DFMO (monohydrochloride); ; L-RMI71782 (monohydrochloride); ...)

Cat. No.: HY-B0744D

L-Eflornithine monohydrochloride (L-DFMO monohydrochloride) is an enantiomer of Eflornithine. L-Eflornithine is an irreversible **ornithine decarboxylase** (**ODC**) inhibitor with a K_D of 1.3±0.3 μM, and a K_{inact} of 0.15±0.03 min^{-1}.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

L-Glutathione reduced

(GSH; γ-L-Glutamyl-L-cysteinyl-glycine)

Cat. No.: HY-D0187

L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 g, 5 g

L-Kynurenine

Cat. No.: HY-104026

L-Kynurenine is a metabolite of the amino acid L-tryptophan. L-Kynurenine is an **aryl hydrocarbon receptor** agonist.

Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

L-NAME hydrochloride

(NG-Nitroarginine methyl ester hydrochloride)

Cat. No.: HY-18729A

L-NAME hydrochloride inhibits **NOS** with an IC_{50} of 70 μM. L-NAME is a precursor to **NOS** inhibitor L-NOARG which has an IC_{50} value of 1.4 μM.



Purity: >98.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

L-Serine ((-)-Serine; (S)-2-Amino-3-hydroxypropanoic acid; (S)-Serine)

Cat. No.: HY-N0650

L-Serine, one of the so-called non-essential amino acids, plays a central role in cellular proliferation.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

L189

Cat. No.: HY-15588

L189 is a novel human DNA ligase inhibitor, inhibits hLigI/III/IV with IC50 of 5/9/5 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

L67 (DNA Ligase Inhibitor)

Cat. No.: HY-15586

L67 is a novel, competitive human DNA ligase inhibitor, inhibits DNA ligases I and III with IC50 of 10 μM and 10 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

L755507

Cat. No.: HY-19334

L755507 is a potent, selective agonist of β_3-AR with an IC_{50} of 35 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Lactoferrin (17-41) TFA

Cat. No.: HY-P1791A

Lactoferrin (17-41) TFA, known as lactoferricin B (LfcinB), corresponds to residues 17-41 of bovine lactoferrin, has antimicrobial and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lactoferrin 17-41

Cat. No.: HY-P1791

Lactoferrin 17-41, known as lactoferricin B (LfcinB), corresponds to residues 17-41 of bovine lactoferrin, has antimicrobial and antitumor activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib (GW572016)

Cat. No.: HY-50898

Lapatinib (GW572016) is a potent **EGFR** and **ErbB2** inhibitor with IC_{50}s of 10.2 and 9.8 nM, respectively.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Lapatinib ditosylate (GW-572016 ditosylate)

Cat. No.: HY-50898A

Lapatinib ditosylate is a potent **EGFR** and **ErbB2** inhibitor with IC_{50} of 10.2 and 9.8 nM, respectively.



Purity: 98.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Larotrectinib (LOXO-101; ARRY-470)

Cat. No.: HY-12866

Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase **(TRK)** family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).



Purity: 98.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Larotrectinib sulfate (LOXO-101 (sulfate); ARRY-470 (sulfate))

Cat. No.: HY-12866A

Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase **(TRK)** family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).



Purity: 99.10%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lasmiditan hydrochloride

(LY 573144 hydrochloride; COL-144 hydrochloride) Cat. No.: HY-14861A

Lasmiditan hydrochloride is a high-affinity, highly selective 5-HT1F receptor agonist (Ki=2.1 nM), compared with Ki of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively.



Purity: 99.91%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Lathyrol

Cat. No.: HY-N0561

Lathyrol is a natural product, and is used for cancer treatment.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Lavendustin A

(RG-14355) Cat. No.: HY-18963

Lavendustin A (RG-14355), isolated from Streptomyces Griseolavendus, is a potent, specific and ATP-competitive inhibitor of **tyrosine kinase**, with an IC_{50} of 11 ng/mL for EGFR-associated tyrosine kinase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Lazertinib

(YH25448; GNS-1480) Cat. No.: HY-109061

Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation **EGFR** tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LB-60-OF61

Cat. No.: HY-101280

LB-60-OF61 is a **NAMPT** inhibitor and is a cytotoxic compound with a selectivity towards MYC overexpressing cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LCL161

Cat. No.: HY-15518

LCL161 is a **IAP** inhibitor which inhibits **XIAP** in HEK293 cell and **cIAP1** in MDA-MB-231 cell with IC_{50}s of 35 and 0.4 nM, respectively.



Purity: 99.17%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LCL521

Cat. No.: HY-103593

LCL521 is an **acid ceramidase** (**ACDase**) inhibitor. LCL521 also inhibits the lysosomal **acid sphingomyelinase** (**ASMase**).



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LCL521 dihydrochloride

(1,3DMG-B13 dihydrochloride) Cat. No.: HY-103593A

LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride) is an **acid ceramidase** (**ACDase**) inhibitor. LCL521 also inhibits the lysosomal **acid sphingomyelinase** (**ASMase**).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

LDC000067

(LDC067) Cat. No.: HY-15878

LDC000067 is a highly specific **CDK9** inhibitor with an IC_{50} value of 44±10 nM in vitro.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

LDH-IN-1

Cat. No.: HY-111108

LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase **(LDH)** with IC_{50}s of 32 and 27 nM for LDHA and LDHB, respectively.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LDN-192960

Cat. No.: HY-13455

LDN-192960 is a potent **Haspin** (**Haploid Germ Cell-Specific Nuclear Protein Kinase**) inhibitor with an IC_{50} of 0.010 μM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg

LDN-212854

Cat. No.: HY-15897

LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors; possesses a bias towards ALK2(IC50=1.3 nM) versus ALK1 and ALK3 compared to other inhibitors.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LDN-214117

Cat. No.: HY-16712

LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM; > 100 fold selectivity for ALK5; also inhibits BMP6(IC50=100 nM).



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LDN193189

(DM-3189)

Cat. No.: HY-12071

LDN193189 is a **BMP** signaling inhibitor, inhibiting **ALK1**, **ALK2**, **ALK3** and **ALK6** with IC_{50}s of 0.8, 0.8, 5.3, 16.7 nM, respectively.



Purity: 95.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

LDN193189 Hydrochloride

Cat. No.: HY-12071A

LDN193189 Hydrochloride is a **BMP** signaling inhibitor, inhibiting **ALK1**, **ALK2**, **ALK3** and **ALK6** with IC_{50}s of 0.8, 0.8, 5.3, 16.7 nM, respectively.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lecirelin

Cat. No.: HY-P0051

Lecirelin is a synthetic GnRH (gonadotropin releasing hormone) analogue which shows a great efficacy in the treatment of bovine ovarian follicular cysts.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Leflunomide

(HWA486; RS-34821; SU101)

Cat. No.: HY-B0083

Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase, and acts as a disease-modifying antirheumatic drug.



Purity: 98.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Lenalidomide

(CC-5013)

Cat. No.: HY-A0003

Lenalidomide interacts with E3 ligase cereblon, links casein kinase 1A1 (CKIα) to the human E3 ligase cereblon, and induces CKIa degradation.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Lenalidomide hemihydrate

(CC-5013 hemihydrate)

Cat. No.: HY-A0003B

Lenalidomide interacts with E3 ligase cereblon, links casein kinase 1A1 (CKIα) to the human E3 ligase cereblon, and induces CKIa degradation.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Lenalidomide hydrochloride

(CC-5013 hydrochloride)

Cat. No.: HY-A0003A

Lenalidomide hydrochloride interacts with E3 ligase cereblon, links casein kinase 1A1 (CKIα) to the human E3 ligase cereblon, and induces CKIa degradation.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg, 1 g

Lenampicillin hydrochloride

(KBT 1585 hydrochloride) Cat. No.: HY-100500

Lenampicillin (hydrochloride) is the efficient prodrug of ampicillin (ABPC) in terms of the enhancement of absorption and decrease of side effects.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Lenvatinib

(E7080) Cat. No.: HY-10981

Lenvatinib is an oral, multi-targeted tyrosine kinase inhibitor with **IC_{50}**s of 4 and 5.2 nM for **VEGFR2(KDR)** and **VEGFR3(Flt-4)**, respectively. Lenvatinib is less potent against VEGFR1/Flt-1 and shows approximately 10-fold selectivity for VEGFR2/3 over FGFR1, PDGFRα/β.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Leptomycin B

(CI 940; LMB) Cat. No.: HY-16909

Leptomycin B (CI 940; LMB) is a potent inhibitor of the nuclear export of proteins. Leptomycin B inactivates **CRM1/exportin 1** by covalent modification at a cysteine residue. Leptomycin B is a potent antifungal antibiotic blocking the eukaryotic cell cycle.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 0.046 mM * 200 μL ,

LEQ506

(NVP-LEQ506) Cat. No.: HY-18636

LEQ506 is a second-generation inhibitor of **smoothened** (**Smo**) with **IC_{50}**s of 2 and 4 nM in human and mouse, respectively.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Lerociclib

(G1T38) Cat. No.: HY-112272

Lerociclib (G1T38) is a potent and selective inhibitor of **CDK4/6**, with **IC_{50}**s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Lerociclib dihydrochloride

(G1T38 dihydrochloride) Cat. No.: HY-112272A

Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of **CDK4/CDK6**, with **IC_{50}**s of 1 nM and 2 nM for **CDK4/CyclinD1** and **CDK6/CyclinD3**, respectively.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lestaurtinib

(CEP-701; KT-5555) Cat. No.: HY-50867

Lestaurtinib (CEP-701;KT-5555) is a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits **JAK2**, **FLT3** and **TrkA** with **IC_{50}**s of 0.9, 3 and less than 25 nM, respectively.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Letrozole

(CGS 20267) Cat. No.: HY-14248

Letrozole is an **aromatase** inhibitor with an **IC_{50}** of 1-13 nM.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Leu-AMS

Cat. No.: HY-108900

Leu-AMS is a potent inhibitor of **leucyl-tRNA synthetase** (**LRS**) with an **IC_{50}** of 22.34 nM and inhibits the growth of bacteria.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Levoleucovorin Calcium

(Calcium levofolinate; CL307782) Cat. No.: HY-13667

Levoleucovorin calcium is the calcium salt of Levoleucovorin, which is the enantiomerically active form of folinic acid.



Purity: 95.24%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

Levomefolate calcium

Cat. No.: HY-17383

Levomefolate calcium is an artificial form of folate. IC50 Value: Target: Antifolate The calcium salt of L-5-methyltetrahydrofolic acid which belongs to the group of folate vitamins (Vitamin B9, Folacin).



Purity: 95.17%
Clinical Data: Launched
Size: 10 mg, 50 mg

Levomefolic acid

(5-MTHF)

Cat. No.: HY-14781

Levomefolic acid (5-MTHF) is the natural, active form of folic acid used at the cellular level for DNA reproduction, the cysteine cycle and the regulation of homocysteine among other functions.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lexibulin

(CYT-997)

Cat. No.: HY-10498

Lexibulin(CYT-997) is a potent tubulin polymerisation inhibitor with IC50 of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo.



Purity: 99.46%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lexibulin dihydrochloride

(CYT-997 dihydrochloride)

Cat. No.: HY-10498A

Lexibulin 2Hcl (CYT-997 2Hcl) is a potent tubulin polymerisation inhibitor with IC50 of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

LF3

Cat. No.: HY-101486

LF3 is an antagonist of the **β-Catenin/TCF4** interaction with antitumor activity; has an IC_{50} of 1.65 μM.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LFM-A13

Cat. No.: HY-18009

LFM-A13 is a potent **BTK**, **JAK2**, **PLK** inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC_{50}s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LG-100064

Cat. No.: HY-104070

LG-100064 is a **retinoid-X-receptor (RXR)** agonist, with EC_{50}s of 330 nM, 200 nM, and 260 nM for RXRα, RXRβ and RXRγ; LG-100064 can be used in the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

LGK974

(WNT974)

Cat. No.: HY-17545

LGK974 (WNT974) is a potent and specific **Porcupine** (**PORCN**) inhibitor with an IC_{50} of 0.1 nM.



Purity: 99.74%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LGnRH-III, lamprey

Cat. No.: HY-P1808

LGnRH-III, lamprey, an isoform of GnRH isolated from the sea lamprey, is a weak **GnRH** agonist with antitumor activities.

{pGLP}-HWSHDWKPG-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LH846

Cat. No.: HY-15704

LH846 is a selective inhibitor of **CKIδ**, with an IC_{50} of 290 nM, and less potently inhibits CKIα and CKIε, with IC_{50}s of 2.5 μM and 1.3 μM, respectively.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LHC-165

Cat. No.: HY-111786

LHC-165 is a **TLR7** agonist. Has potential to treat solid tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Licochalcone A

(Licochalcone-A)

Cat. No.: HY-N0372

Licochalcone A, a flavonoid isolated from the famous Chinese medicinal herb Glycyrrhiza uralensis Fisch, presents obvious anti-cancer effects. The IC50 value is 0.97 μM for UGT1A1.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Licochalcone D

Cat. No.: HY-N4187

Licochalcone D, a flavonoid compound mainly existing in the root of Glycyrrhiza inflate, is a potent inhibitor of **NF-kappaB (NF-κB) p65**. Licochalcone D possesses antioxidant, anti-inflammatory, anti-cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Licoflavone C

Cat. No.: HY-N4183

Licoflavone C is a prenyl-flavone extracted from Genista ephedroides, reduces the genotoxicity of cancer drugs in human peripheral lymphocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lificiguat

(YC-1)

Cat. No.: HY-14927

Lificiguat binds to the β subunit of **soluble guanylyl cyclase**(**sGC**) with K_d of 0.6-1.1 μM in the presence of CO.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Lifirafenib

(BGB-283)

Cat. No.: HY-18957

Lifirafenib (BGB-283) is a novel and potent **Raf** Kinase and **EGFR** inhibitor with IC_{50} values of 23 and 29 nM for recombinant $BRaf^{V600E}$ and EGFR, respectively.



Purity: 98.00%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Limonene

Cat. No.: HY-N0544

Limonene is a monoterpene in citrus peel oil. A popular disinfectant and food preservative. Antimicrobial activities. Anti-proliferative activities. Antioxidant and anti-inflammatory effect.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Linalool

Cat. No.: HY-N0368

Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of **Nmethyl d-aspartate (NMDA) receptor**, with anti-tumor, anti-cardiotoxicity activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linaprazan

(AZD0865)

Cat. No.: HY-100412

Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase by K+-competitive binding. (IC50: 1.0 ± 0.2 μM) It is a acid-suppressing agents with rapid onset of action and potent acid inhibition. In vitro: Linaprazan can inhibit the final step in acid secretion.



Purity: 98.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Linifanib

(ABT-869; AL-39324)

Cat. No.: HY-50751

Linifanib (ABT-869) is a multi-targeted inhibitor of **VEGF** and **PDGFR** receptor family with IC_{50}s of 3, 4, 66, 4 nM for KDR, Flt-1, PDGFRβ and FLT3, respectively.



Purity: 99.60%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Linrodostat

(BMS-986205; ONO-7701) Cat. No.: HY-101560

Linrodostat (BMS-986205; ONO-7701) is a selective **indoleamine 2,3-dioxygenase 1** (**IDO1**) inhibitor.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Linsitinib

(OSI-906) Cat. No.: HY-10191

Linsitinib (OSI-906) is a dual inhibitor of the **IGF-1 receptor** and **insulin receptor** with IC_{50}s of 35 and 75 nM, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lipofermata

Cat. No.: HY-116788

Lipofermata is a **fatty acid transport proteins (FATP)** inhibitor that abrogates lipid transport into melanoma cells and reduces melanoma growth and invasion.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Liquiritigenin

(4',7-Dihydroxyflavanone) Cat. No.: HY-N0377

Liquiritigenin, a flavanone isolated from Glycyrrhiza uralensis, is a highly selective estrogen receptor β (**ERβ**) agonist with an EC_{50} of 36.5 nM for activation of the ERE tk-Luc.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Liquiritin

Cat. No.: HY-N0376

Liquiritin is a flavonoid isolated from Glycyrrhiza, acts as an antioxidant and has neuroprotective, anti-cancer and anti-inflammatory activity.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Litronesib

(LY-2523355; KF-89617) Cat. No.: HY-14846

Litronesib is a selective mitosis-specific **kinesin Eg5** inhibitor, with antitumor activity.



Purity: 99.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LJH685

Cat. No.: HY-19712

LJH685 is a potent, specific and selective **RSK** inhibitor, inhibits RSK1, 2, and 3 biochemical activities with IC_{50}s of 6, 5, 4 nM, respectively.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LJI308

Cat. No.: HY-19713

LJI308 is a new and potent pan-RSK inhibitor, with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LLY-283

Cat. No.: HY-107777

LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (**PRMT5**) inhibitor, with an IC_{50} of 22 nM and a K_d of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

LLY-507

Cat. No.: HY-19313

LLY-507 is a potent and selective inhibitor of protein-lysine methyltransferase **SMYD2** with an IC_{50} of 15 nM.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

LM985

Cat. No.: HY-U00379

LM985 is one of a series of compounds based on the flavone ring structure, with anti-tumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

LMK-235

Cat. No.: HY-18998

LMK-235 is a potent and selective **HDAC4/5** inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with **IC_{50}**s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

LMP7-IN-1

Cat. No.: HY-111790

LMP7-IN-1 is an inhibitor of **immunoproteasome (LMP7)**, may used in the research of inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

LMP744

(MJ-III65; NSC706744)

Cat. No.: HY-U00248

LMP744 (MJ-III65) is a DNA intercalator and **Topoisomerase I (Top1)** inhibitor with antitumor activity.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 50 mg

LMP744 hydrochloride

(MJ-III65 hydrochloride; NSC706744 hydrochloride)

Cat. No.: HY-U00248A

LMP744 hydrochloride (MJ-III65 hydrochloride) is a DNA intercalator and **Topoisomerase I (Top1)** inhibitor with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

LNK754

Cat. No.: HY-U00401

LNK754 is a **farnesyltransferase** inhibitor, used for the treatment of cancer and Alzheimer's disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

LOM612

Cat. No.: HY-101035

LOM612 is a potent activator of **FOXO** nuclear translocation, with an **EC_{50}** value of 1.5 μM in cells.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lomeguatrib

(PaTrin-2)

Cat. No.: HY-13668

Lomeguatrib is a O^6-methylguanine-DNA methyltransferase (**MGMT**) inhibitor, with **IC_{50}**s of 9 nM in cell-free assay and 6nM in MCF-7 cells.



Purity: 97.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Lomustine

(CCNU; NSC 79037)

Cat. No.: HY-13669

Lomustine (CCNU) is a **DNA alkylating** agent, with antitumor activity.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Lonafarnib

(Sch66336)

Cat. No.: HY-15136

Lonafarnib is an orally bioavailable farnesyl protein transferase (**FPTase**) inhibitor for H-ras, K-ras and N-ras with **IC_{50}** of 1.9 nM, 5.2 nM and 2.8 nM, respectively.



Purity: 98.67%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Lonidamine

(DICA; Diclondazolic Acid; AF1890)

Cat. No.: HY-B0486

Lonidamine, a antitumor agent, is a **hexokinase**, **mitochondrial pyruvate carrier** (K_i 2.5 μM in isolated rat liver mitochondria) and **plasma membrane monocarboxylate transporters** inhibitor, which also inhibits mitochondrial complex II.



Purity: 95.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lorlatinib

(PF-06463922)

Cat. No.: HY-12215

Lorlatinib (PF-06463922) is a potent, dual **ALK/ROS1** inhibitor, with K_is of 0.02 nM, 0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK-L1196M, respectively.



Purity: 99.83%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lp-PLA2 -IN-1

Cat. No.: HY-19757

Lp-PLA2 -IN-1 inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

LPA2 antagonist 1

Cat. No.: HY-18075

LPA2 antagonist 1 is a **LPA2** antagonist with an IC_{50} of 17 nM.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LRE1

Cat. No.: HY-100524

LRE1 is a specific and allosteric inhibitor of soluble **adenylyl cyclase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

LSD1-IN-5

Cat. No.: HY-100859

LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (**LSD1**), with an IC_{50} of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

LSD1-IN-6

Cat. No.: HY-100860

LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (**LSD1**), with an IC_{50} of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

LSKL, Inhibitor of Thrombospondin TSP-1

Cat. No.: HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of **TGF-β** and prevents the progression of hepatic damage and fibrosis.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

LSN 3213128

Cat. No.: HY-107981

LSN 3213128 is a selective, nonclassical, orally bioavailable antifolate with potent and specific inhibitory activity for aminoimidazole-4-carboxamide ribonucleotide formyltransferase (**AICARFT**), with IC_{50} of 16 nM for AICARFT enzyme inhibiton and 19 nM in...



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

LSZ-102

Cat. No.: HY-111486

LSZ-102 is a potent, orally bioavailable selective **estrogen receptor** degrader with an IC_{50} of 0.2 nM.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LTURM34

Cat. No.: HY-101667

LTURM34 is a specific **DNA-PK** inhibitor with an IC_{50} of 0.034 μM.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LTV-1

Cat. No.: HY-18667

LTV-1 is a highly potent, cell-permeable and reversible inhibitor of lymphoid tyrosine phosphatase (LYP) (IC50 = 508 nM). IC50 value: 508 nM Target: LYP in vitro: LTV-1 inhibits LYP in a dose-dependent manner at low- and sub-micromolar concentrations in T cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LTX-315

(K-K-W-W-K-K-W-Dip-K-NH2)

Cat. No.: HY-19894

LTX-315 is an oncolytic peptide with potent anticancer activity; inhibits MRC-5, A20 and AT84 with IC_{50}s of 34.3, 8.3 and 11 μM, respectively.



Purity: 98.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Lucanthone

Cat. No.: HY-B2098

Lucanthone is an endonuclease inhibitor of Apurinic endonuclease-1 (**APE-1**).



Purity: 98.47%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Lucidin

(NSC 30546)

Cat. No.: HY-15733

Lucidin (NSC 30546) is a natural component of Rubia tinctorum L. lucidin is mutagenic in bacteria and mammalian cells.



Purity: >96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Luciferase

Cat. No.: HY-P1004

Luciferase from Vibrio fischeri has also been used in a study to investigate the sensitivity of dark mutants of various strains of luminescent bacteria to reactive oxygen species.

Luciferase

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Lucitanib

(E-3810)

Cat. No.: HY-15391

Lucitanib (E-3810) is a novel dual inhibitor of **VEGFR** and **FGFR**, potently and selectively inhibits **VEGFR1**, **VEGFR2**, **VEGFR3**, **FGFR1** and **FGFR2** with IC_{50}s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.



Purity: 98.24%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Luminespib

(NVP-AUY922; AUY922; VER-52296)

Cat. No.: HY-10215

Luminespib (NVP-AUY922) is a potent **HSP90** inhibitor with IC_{50}s of 7.8 and 21 nM for HSP90α and HSP90β, respectively.



Purity: 99.14%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 100 mg, 200 mg

Lupeol

(Fagarasterol)

Cat. No.: HY-N0790

Lupeol is a novel **androgen receptor** inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Lurbinectedin

(PM01183)

Cat. No.: HY-16293

Lurbinectedin (PM01183) is a new **DNA** minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC_{50} values of 1.25 and 1.16 nM, respectively.



Purity: 96.81%
Clinical Data: Launched
Size: 1 mg, 2 mg

Luteolin

(Luteolol; Digitoflavone; Luteoline) **Cat. No.:** HY-N0162

Luteolin (Luteolol) is a falconoid compound, which exhibits anticancer properties.



Purity: 98.14%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

LV-320

Cat. No.: HY-112711

LV-320 is a potent **ATG4B** inhibitor with an IC_{50} of 24.5μM.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LW6

(HIF-1α inhibitor; LW8) **Cat. No.:** HY-13671

LW6 is a novel **HIF-1** inhibitor with an IC_{50} of 4.4 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LXH254

Cat. No.: HY-112089

LXH254 is a potent **CRAF** inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent **BRAF** inhibitor.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

LXS196

Cat. No.: HY-101569

LXS196 is a potent, selective and orally active protein kinase C (**PKC**) inhibitor, with IC_{50} values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. It can be used for the treatment of uveal melanoma.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

LY 222306

Cat. No.: HY-14522

LY 222306 is a glycinamide ribonucleotide formyltransferase **(GARFT)** inhibitor with a K_i of 0.77 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

LY 254155

Cat. No.: HY-14523

LY 254155, an antifolate, inhibits **hGARFT** and binds to **mFBP** with K_is of 2.1±0.2 and 1.7±0.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

LY 303511

Cat. No.: HY-15643

LY303511 is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances **TRAIL** sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks **K**$^+$ currents (IC_{50}=64.6±9.1 μM) in MIN6 insulinoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

LY 303511 hydrochloride

Cat. No.: HY-15643A

LY 303511 hydrochloride is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances **TRAIL** sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks **K**$^+$ currents (IC_{50}=64.6±9.1 μM) in MIN6 insulinoma cells.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LY-2584702 free base

Cat. No.: HY-12493

LY-2584702 free base is a selective ATP competitive inhibitor of **p70S6K** with an IC_{50} of 4 nM. In **S6K1** enzyme assay, the IC_{50} of LY-2584702 is 2 nM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

LY-2584702 hydrochloride

Cat. No.: HY-12493B

LY-2584702 hydrochloride is a selective ATP competitive inhibitor of **p70S6K** with an IC_{50} of 4 nM. In **S6K1** enzyme assay, the IC_{50} of LY-2584702 is 2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

LY-2584702 tosylate salt

Cat. No.: HY-12493A

LY-2584702 tosylate salt is a selective ATP competitive inhibitor of **p70S6K** with an IC_{50} of 4 nM. In **S6K1** enzyme assay, the IC_{50} of LY-2584702 is 2 nM.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY-3381916

Cat. No.: HY-111540

LY-3381916 is a potent, selective and brain penetrated inhibitor of **IDO1** activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

LY-364947

(HTS466284)

Cat. No.: HY-13462

LY-364947 is a potent ATP-competitive inhibitor of **TGFβR-I** with IC_{50} of 59 nM, and exhibits 7-fold selectivity over TGFβR-II.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LY2090314

Cat. No.: HY-16294

LY2090314 is a potent inhibitor of **glycogen synthase kinase-3 (GSK-3)** with IC_{50} values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.



Purity: 99.75%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY2109761

Cat. No.: HY-12075

LY2109761 is an orally active, selective **TGF-β receptor type I/II** inhibitor with K_is of 38 nM and 300 nM, respectively.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

LY2334737

Cat. No.: HY-13672

LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.



Purity: 98.29%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY2365109 hydrochloride

Cat. No.: HY-100416A

LY2365109 is a potent and selective GlyT1 inhibitors with IC50 value of 15.8 nM. target: GlyT1 IC 50: 15.8 nM In vivo: The reference for LY2365109 is 0.3 or 30 mg/kg by PO.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY2409881

Cat. No.: HY-B0788

LY2409881 is a selective IκB kinase β (**IKK2**) inhibitor with an IC_{50} of 30 nM.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

LY2409881 trihydrochloride

Cat. No.: HY-B0788A

LY2409881 trihydrochloride is a selective IκB kinase β (**IKK2**) inhibitor with an IC_{50} of 30 nM.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY2452473

Cat. No.: HY-114530

LY2452473 is an orally bioavailable, selective **androgen receptor** modulator (SARM).



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY2510924

Cat. No.: HY-12488

LY2510924 is a potent and selective **CXCR4** antagonist that blocks SDF-1 binding to CXCR4 with an IC_{50} of 0.079 nM.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY2857785

Cat. No.: HY-12293

LY2857785 is a type I reversible and competitive ATP kinase inhibitor against **CDK9** (IC_{50} 11 nM) and other transcription kinases **CDK8** (IC_{50} 16 nM), and **CDK7** (IC_{50} 246 nM).



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

LY2874455

Cat. No.: HY-13304

LY2874455 is a **pan-FGFR** inhibitor with IC_{50}s of 2.8, 2.6, 6.4, 6 nM for **FGFR1**, **FGFR2**, **FGFR3**, **FGFR4**, respectively.



Purity: 98.02%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY294002

(NSC 697286; SF 1101)

Cat. No.: HY-10108

LY294002 is a broad-spectrum inhibitor of **PI3K** with IC_{50}s of 0.5, 0.57, and 0.97 μM for **PI3Kα**, **PI3Kδ** and **PI3Kβ**, respectively. LY294002 also inhibits **CK2** with an IC_{50} of 98 nM.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

LY3009120

(DP-4978)

Cat. No.: HY-12558

LY3009120 is a pan **RAF** inhibitor which inhibits $BRAF^{V600E}$, $BRAF^{WT}$ and $CRAF^{WT}$ with IC_{50}s of 5.8, 9.1 and 15 nM, respectively.



Purity: 98.66%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY3023414

Cat. No.: HY-12513

LY3023414 potently and selectively inhibits **class I PI3K** isoforms, **DNA-PK**, and **mTORC1/2** with IC_{50}s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. LY3023414 potently inhibits **mTORC1/2** at low nanomolar concentrations.



Purity: 99.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY309887

Cat. No.: HY-10818

LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (**GARFT**), with a K_i of 6.5 nM, and has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

LY3177833

Cat. No.: HY-100023

LY3177833 is an **CDC7** and **pMCM2** inhibitor extracted from patent US 20140275131and patent WO 2014143601 A1 compound example 4; has IC_{50} values of 3.3 nM and 290 nM, respectively.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY3200882

Cat. No.: HY-103021

LY3200882 is a novel and highly selective inhibitor of **TGF-β receptor type 1** (**TGFβRI**).



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY3214996

Cat. No.: HY-101494

LY3214996 is a highly selective inhibitor of **ERK1** and **ERK2**, with IC_{50} of 5 nM for both enzymes in biochemical assays.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

LY3295668

(AK-01)

Cat. No.: HY-114258

LY3295668 is a potent, orally active and highly specific **Aurora-A kinase** inhibitor, with K_i values of 0.8 nM and 1038 nM for AurA and AurB, respectively.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lycopodine

Cat. No.: HY-114372

Lycopodine, a pharmacologically important bioactive component derived from Lycopodium clavatumspores, triggers apoptosis by modulating **5-lipoxygenase**, and depolarizing mitochondrial membrane potential in refractory prostate cancer cells without modulating...



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Lycorine hydrochloride

Cat. No.: HY-N0289

Lycorine (hydrochloride) is VE-cadherin inhibitor,and has IC50 of 1.2μM in Hey1B cell.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

LYN-1604

(LYN1604; LYN 1604)

Cat. No.: HY-101923

LYN-1604 is a potent UNC-51-like kinase 1 (**ULK1**) agonist with an EC_{50} of 18.94 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LYN-1604 hydrochloride

Cat. No.: HY-101923A

LYN-1604 hydrochloride is a potent **ULK1** activator with an EC_{50} of 18.94 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lyn-IN-1

Cat. No.: HY-12039

Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor, extracted from patent WO2014169128A1.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lys01 trihydrochloride

(Lys05)

Cat. No.: HY-12855A

Lys01 trihydrochloride (Lys05) is a novel **lysosomal autophagy** inhibitor with IC_{50} values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

M-110

Cat. No.: HY-12830

M-110 is a novel and highly selective inhibitor of PIM kinases; inhibits the proliferation of prostate cancer cell lines with IC50s of 0.6 to 0.9 uM, with no activity on normal human peripheral blood mononuclear cells up to 40 uM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

M1001

Cat. No.: HY-111547

M1001 is a weak agonist of **HIF-2α**, directly binds to the HIF-2α PAS-B domain, with a K_d of 667 nM. M1001 enhances the stabilities of HIF-2α-ARNT complex.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

M344

(D 237; MS 344)

Cat. No.: HY-13506

M344 (D 237) is an inhibitor of **histone deacetylase** (IC_{50}=100 nM) and an inducer of terminal cell fifferentiation.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

M443

Cat. No.: HY-112274

M443 is an irreversible and specific inhibitor of **MRK**, with an IC_{50}<125 nM.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MA242

Cat. No.: HY-112816

MA242 is a dual inhibitor of **murine double minute 2 (MDM2)** and **nuclear factor of activated T cells 1 (NFAT1)** for Pancreatic Cancer Therapy.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Macozinone

(PBTZ169)

Cat. No.: HY-12903

Macozinone (PBTZ169) inhibits decaprenylphosphoryl-β-d-ribose 2′-oxidase (DprE1).



Purity: 99.13%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Macropa-NCS

Cat. No.: HY-111605

Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070. A promising therapeutic radionuclide applied in the treatment of soft-tissue metastases.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Macropa-NH2

Cat. No.: HY-111895

Macropa-NH2 is the precursor of Macropa-NCS. Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Macropa-NH2 hydrochloride

Cat. No.: HY-111895A

Macropa-NH2 hydrochloride is the precursor of Macropa-NCS. Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Madrasin

(DDD00107587)

Cat. No.: HY-100236

Madrasin is a potent and cell penetrant splicing inhibitor that interferes with the early stages of spliceosome assembly.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MAGE-A3 195-203

Cat. No.: HY-P1842

MAGE-A3 (195-203) is a human leukocyte antigen (HLA) -A24 molecules epitope encoded by melanoma antigen gene (MAGE).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Magnolol

Cat. No.: HY-N0163

Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both **RXRα** and **PPARγ**, with EC_{50} values of 10.4 μM and 17.7 μM, respectively.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MAL-di-EG-Val-Cit-PAB-MMAE

Cat. No.: HY-100567

MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent **tubulin** inhibitor (MMAE), MAL-di-EG-Val-Cit-PAB-MMAE is an antibody drug conjugate.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

MAL-di-EG-Val-Cit-PAB-MMAF

Cat. No.: HY-128711

MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F). MAL-di-EG-Val-Cit-PAB-MMAF is an antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Malotilate

(NKK 105)

Cat. No.: HY-A0060

Malotilate is a liver protein metabolism improved compound, which selectively inhibit the 5-lipoxygenase.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MALT1 inhibitor MI-2

Cat. No.: HY-12276

MALT1 inhibitor MI-2 is a **MALT1** inhibitor (IC_{50}=5.84 μM).



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mangiferin

Cat. No.: HY-N0290

Mangiferin is a **Nrf2** activator. Mangiferin suppresses nuclear translocation of the **NF-κB** subunits **p65** and **p50**.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Manumycin A

Cat. No.: HY-N6796

Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein **farnesyltransferase (FTase)** with respect to farnesylpyrophosphate (K_i=1.2 μM), and as a noncompetitive inhibitor with respect to the **Ras** protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mardepodect hydrochloride

(PF-2545920 (hydrochloride))

Cat. No.: HY-50098A

Mardepodect hydrochloride (PF-2545920 hydrochloride) hydrochloride is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE.



Purity: 95.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Marimastat

(BB2516; TA2516)

Cat. No.: HY-12169

Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of **MMPs**, with potent activity against MMP-9 (IC_{50}=3 nM), MMP-1 (IC_{50}=5 nM), MMP-2 (IC_{50}=6 nM), MMP-14 (IC_{50}=9 nM) and MMP-7 (IC_{50}=13 nM), used in the treatment of cancer.



Purity: >98.00%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Maritoclax

(Marinopyrrole A)

Cat. No.: HY-15613

Maritoclax (Marinopyrrole A) is a novel and specific **Mcl-1** inhibitor with an IC_{50} value of 10.1 μM, and shows >8 fold selectivity than BCL-xl (IC_{50} > 80 μM).



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MARK4 inhibitor 1

Cat. No.: HY-114317

MARK4 inhibitor 1 is a potent **microtubule affinity-regulating kinase 4 (MARK4)** inhibitor, with an IC_{50} of 1.54 μM. MARK4 inhibitor 1 inhibits cancer cell proliferation, metastasis and induces apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Masitinib

(AB1010) Cat. No.: HY-10209

Masitinib is an orally available **Kit** inhibitor with an IC_{50} of 200 nM. It also inhibits **PDGFRα/β** with an IC_{50} of 540 nM/800 nM nM.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate) Cat. No.: HY-10209A

Masitinib mesylate is a novel inhibitor for **Kit** and **PDGFRα/β** with IC_{50} of 200 nM and 540 nM/800 nM, and has weak inhibition to ABL and c-Fms.



Purity: 99.31%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

MAT2A inhibitor 1

Cat. No.: HY-112131

MAT2A inhibitor 1 is a methionine adenosyltransferase 2A (**MATA2**) inhibitor extracted from patent US20180079753, compound example 196 (4).



Purity: 99.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

MAT2A inhibitor 2

Cat. No.: HY-112569

MAT2A inhibitor 2 is a methionine adenosyltransferase 2A **(MAT2A)** inhibitor.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Matrine

(Matridin-15-one; Vegard; α-Matrine) Cat. No.: HY-N0164

Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor and u-receptor agonist.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Maytansinol

(Ansamitocin P-0) Cat. No.: HY-19474

Maytansinol inhibits microtubule assembly and induces microtubule disassembly in vitro. Target: Microtubule/Tubulin in vitro: Maytansinol disrupts the mitotic spindle and prevents mitotic exit in Drosophila.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MB-7133

Cat. No.: HY-16311

MB-7133 is a **DNA synthesis** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

MBC-11

Cat. No.: HY-107093

MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). Has potential to treat tumor-induced bone disease (TIBD).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

MBC-11 trisodium salt

Cat. No.: HY-107093A

MBC-11 trisodium salt is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. Has potential to treat tumor-induced bone disease (TIBD).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

MBM-17

Cat. No.: HY-101030

MBM-17 (compound 42c) is a potent **NIMA-related kinase 2 (Nek2)** inhibitor with an IC_{50} of 3 nM. It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

MBM-55

Cat. No.: HY-101029

MBM-55 (compound 42g) is a potent **NIMA-related kinase 2 (Nek2)** inhibitor with an IC_{50} of 1 nM. MBM-55 shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC_{50}=5.4 nM) and DYRK1a (IC_{50}=6.5 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

MBQ-167

Cat. No.: HY-112842

MBQ-167 is a dual **Rac/Cdc42** inhibitor, with IC_{50}s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MC 1046

(Impurity A of Calcipotriol)

Cat. No.: HY-15264

MC 1046(Impurity A of Calcipotriol) is an impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors. IC50 value: Target: Vitamin D3 analog that displays minimal effects on calcium homeostasis.



Purity: 91.48%
Clinical Data: No Development Reported
Size: 1 mg

MC-DOXHZN

(Doxorubicin(6-maleimidocaproyl)hydrazone)

Cat. No.: HY-16261A

MC-DOXHZN is an albumin-binding prodrug of Doxorubicin, with acid-sensitive properties.



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

MC-DOXHZN hydrochloride

(Doxorubicin(6-maleimidocaproyl)hydrazone hydrochloride)

Cat. No.: HY-16261B

MC-DOXHZN hydrochloride is an albumin-binding prodrug of Doxorubicin, with acid-sensitive properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Mc-MMAD

Cat. No.: HY-15740

Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate; Mc-MMAD is a protective group (maleimidocaproyl) -conjugated MMAD. IC50 Value: Target: tubulin; ADCs For comparison purposes, the ADC A1 -mc-MMAD and/or A1 -vc-MMAD were used.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Mc-MMAE

(Maleimidocaproyl-monomethylauristatin E)

Cat. No.: HY-15741

Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent **tubulin** inhibitor, is a toxin payload in antibody drug conjugate (**ADC**).



Purity: 97.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

MC-Val-Cit-PAB

Cat. No.: HY-78738

MC-Val-Cit-PAB is a cathepsin cleavable **ADC linker** that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 1 g

Mc-Val-Cit-PABC-PNP

Cat. No.: HY-20336

Mc-Val-Cit-PABC-PNP is a cathepsin cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 200 mg

MC1568

Cat. No.: HY-16914

MC1568 is a selective class II (IIa) histone deacetylas (**HDAC II**) inhibitor, used for cancer research.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MC180295

((rel)-MC180295)

Cat. No.: HY-119940

MC180295 ((rel)-MC180295) is a potent and selective **CDK9-Cyclin T1** inhibitor, with an IC_{50} of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MC3482

Cat. No.: HY-112587

MC3482 is a specific sirtuin5 (**SIRT5**) inhibitor.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MCB-613

Cat. No.: HY-19625

MCB-613 is a potent, pan steroid receptor coactivator (SRC) stimulator. Target: SRC in vitro: MCB-613 exerts the greatest activation of SRC-1 in the primary screen, is confirmed to be a strong activator of all three SRCs.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCI826

Cat. No.: HY-U00247

MCI826 is a **P-glycoprotein** (**P-gp**) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Mcl1-IN-1

Cat. No.: HY-16669

Mcl1-IN-1 is an inhibitor of myeloid cell factor 1 (**Mcl-1**) (IC_{50}=2.4 μM).



Purity: 96.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mcl1-IN-11

Cat. No.: HY-100762

Mcl1-IN-11 (Compound G) is a selective **Mcl-1** inhibitor, less potent at Bcl-2, with K_is of 0.06 and 4.2 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Mcl1-IN-12

Cat. No.: HY-100763

Mcl1-IN-12 (Compound F) is a selective **Mcl-1** inhibitor, less potent at Bcl-2, with K_is of 0.29 and 3.1 μM, respectively. Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Mcl1-IN-2

Cat. No.: HY-12826

Mcl1-IN-2 is an inhibitor of myeloid cell factor 1 (**Mcl-1**).



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mcl1-IN-3

Cat. No.: HY-111468

Mcl1-IN-3 is an inhibitor of **Mcl1** extracted from patent WO2015153959A2, compound example 57; has an IC_{50} and K_i of 0.67 and 0.13 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Mcl1-IN-4

Cat. No.: HY-111467

Mcl1-IN-4 is an inhibitor of **Mcl1** with an IC_{50} of 0.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Mcl1-IN-9

Cat. No.: HY-128607

Mcl1-IN-9 is a potent **myeloid cell leukemia-1 (Mcl-1)** Inhibitor with an IC_{50} of 446 nM in reengineered BCR-ABL+ B-ALL cells and a K_i of 0.03 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

McMMAF

(Maleimidocaproyl monomethylauristatin F)

Cat. No.: HY-15578

Mc-MMAF is a protective group-conjugated MMAF. MMAF is a more potent drug than Monomethyl auristatin E (MMAE), but is charged and relatively membrane-impermeable, is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

MD2-TLR4-IN-1

Cat. No.: HY-128598

MD2-TLR4-IN-1 (compound 22m) is an inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex, inhibiting lipopolysaccharides (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with...



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Mdivi-1

(Mitochondrial division inhibitor 1)

Cat. No.: HY-15886

Mdivi-1 is a selective dynamin-related protein 1 (**Drp1**) inhibitor. Mdivi-1 is a mitochondrial division/**mitophagy** inhibitor.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MDK83190

Cat. No.: HY-18633

MDK83190 is a potent apoptosis activator; increases procaspase-9 processing and subsequent caspase-3 activation.



Purity: 97.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

mDPR-Val-Cit-PAB-MMAE

Cat. No.: HY-19813

mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ME0328

Cat. No.: HY-100225

ME0328 is a potent and selective **ARTD3/PARP3** inhibitor with an IC_{50} of 0.89±0.28 μM.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Meisoindigo

(Dian III; N-Methylisoindigotin; Natura-α)

Cat. No.: HY-13680

Meisoindigo(Natura-α; N-Methylisoindigotin; Dian III), a derivative of Indigo naturalis, might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML).



Purity: 96.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MEK inhibitor

Cat. No.: HY-12202

MEK inhibitor is a potent **MEK** inhibitor with antitumor potency.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MEK-IN-1

Cat. No.: HY-U00312

MEK-IN-1 is a **MEK** inhibitor extracted from patent WO2008076415A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Melittin

Cat. No.: HY-P0233

Melittin is a **PLA_2** activator, stimulates the activity of the low molecular weight PLA_2, while it does not the increase activity of the high molecular weight PLA_2.

Purity: 96.73%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MELK-8a hydrochloride

Cat. No.: HY-100368A

MELK-8a hydrochloride is a novel maternal embryonic leucine zipper kinase (**MELK**) inhibitor with an **IC_{50}** of 2 nM.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

MELK-IN-1

Cat. No.: HY-101515

MELK-IN-1 is a potent inhibitor of **maternal embryonic leucine zipper kinase (MELK)** with an **IC_{50}** and a **K_i** of 3 nM and 0.39 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Melphalan

(L-PAM)

Cat. No.: HY-17575

Melphalan is an effective **DNA alkylating** agent, with potent antitumor activity.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Menin-MLL inhibitor MI-2

Cat. No.: HY-15222

Menin-MLL inhibitor MI-2 is a **Menin-MLL** interaction inhibitor with **IC_{50}** of 446±28 nM.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Merestinib

(LY2801653)

Cat. No.: HY-15514

Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of **MET** tyrosine kinase with a dissociation constant (K_i) of 2 nM.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride

(LY2801653 (dihydrochloride))

Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a type-II ATP competitive, slow-off inhibitor of **MET** tyrosine kinase with a dissociation constant (K_i) of 2 nM.



Purity: 99.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mertansine

(DM1; Maytansinoid DM1)

Cat. No.: HY-19792

Mertansine (DM1) is a **microtubulin** inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.



Purity: 98.74%
Clinical Data: Phase 2
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mesna

(Sodium 2-mercaptoethanesulfonate; Mesnum)

Cat. No.: HY-13679

2-mercaptoethane sulfonate (Mesna), is a synthetic small molecule, widely used as a systemic protective agent against chemotherapy toxicity, but is primarily used to reduce hemorrhagic cystitis induced by cyclophosphamide.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 g, 10 g

meta-iodoHoechst 33258

Cat. No.: HY-15622

Hoechst stains are part of a family of blue fluorescent dyes used to stain DNA. IC50 Value: Target: These Bis-benzimides were originally developed by Hoechst AG, which numbered all their compounds so that the dye Hoechst 33342 is the 33342nd compound made by the company.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Metformin hydrochloride

(1,1-Dimethylbiguanide hydrochloride) Cat. No.: HY-17471A

Metformin (hydrochloride) is an FDA approved first-line drug for the treatment of type 2 diabetes. Metformin decreases hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory-chain complex 1.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 g, 50 g

MethADP

(Adenosine 5'-(α,β-methylene)diphosphate) Cat. No.: HY-112502

MethADP is a specific **CD73** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

MethADP sodium salt

Cat. No.: HY-112502B

MethADP (sodium salt) is a specific **CD73** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Methionine

(MRX-1024; D-Methionine) Cat. No.: HY-13694

Methionine (MRX-1024) is an effective chemoprotective agent which can also inhibit the neuronal activity through **$GABA_A$** receptor activation.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

Methotrexate

(Amethopterin; CL14377; WR19039) Cat. No.: HY-14519

Methotrexate is a **folate** antagonist, with median **IC_{50}** of 78 nM in in vitro assay.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Methuosis inducer 1

Cat. No.: HY-112440

Methuosis inducer 1 is a potent **methuosis** inducer. Anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Methyl 3,4-dihydroxybenzoate

(Protocatechuic acid methyl ester; Methyl protocatechuate) Cat. No.: HY-Z0548

Methyl 3,4-dihydroxybenzoate (Protocatechuic acid methyl ester;Methyl protocatechuate) is a major metabolite of antioxidant polyphenols found in green tea. Antioxidant and anti-inflammatory effect.



Purity: 97.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Methyl gallate

(Gallincin; NSC 363001) Cat. No.: HY-N2010

Methyl gallate is a plant phenolic with antioxidant, anticancer, and anti-inflammatory activities. Methyl gallate also shows **bacterial** inhibition activity.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 g

Methyl protodioscin

(NSC-698790; Smilax saponin B) Cat. No.: HY-N0863

Methyl protodioscin(NSC-698790) is a furostanol bisglycoside with antitumor properties; shows to reduce proliferation, cause cell cycle arrest.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Methyl-β-cyclodextrin

(Methyl-beta-cyclodextrin) Cat. No.: HY-101461

Methyl-β-cyclodextrin, a cyclic heptasaccharide, is an effective agent for the depletion of cholesterol from cells; also inhibits PEL cell growth with an **IC_{50}** of 3.33-4.23 mM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 g, 5 g, 10 g, 25 g, 50 g

Methylmalonate (Isosuccinic acid; Methylmalonic acid; Methylpropanedioic acid)

Cat. No.: HY-103395

Methylmalonate is an indicator of Vitamin B-12 deficiency in cancer.



Purity: >97.0%
Clinical Data:
Size: 10 mM × 1 mL, 1 g

Methylnitronitrosoguanidine (MNNG)

Cat. No.: HY-128612

Methylnitronitrosoguanidine (MNNG) is an **alkylating** agent with toxic and mutagenic effects.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Methylprednisolone succinate (Methylprednisolone hydrogen succinate)

Cat. No.: HY-B1900

Methylprednisolone succinate is a synthetic glucocorticoid and widely used as an anti-inflammatory agent.



Purity: 99.14%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Methylproamine

Cat. No.: HY-15620

Methylproamine is a DNA-binding radioprotector which, on the basis of published pulse radiolysis studies, acts by repair of transient radiation-induced oxidative species on DNA.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Mevastatin (Compactin; ML236B)

Cat. No.: HY-17408

Mevastatin (Compactin; ML236B) inhibits HMGCR (HMG-CoA reductase) (Ki for acid form is 1 nM) which in turn inhibits isoprenoid biosynthesis and therefore blocks protein isoprenylation and reduces plasma cholesterol levels in humans.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

MF-094

Cat. No.: HY-112438

MF-094 is a potent and selective **USP30** inhibitor with an IC_{50} of 120 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MG 149 (Tip60 HAT inhibitor)

Cat. No.: HY-15887

MG149 is a selective and potent Tip60 inhibitor with IC50 of 74 uM, similar potentcy for MOF(IC50= 47 uM); little potent for PCAF and p300(IC50 >200 uM).



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MG-101 (Calpain inhibitor I; Ac-LLnL-CHO; ALLN)

Cat. No.: HY-18964

MG-101 is a potent inhibitor of **cysteine proteases** which inhibits calpain I, calpain II, cathepsin B and cathepsin L with K_is of 190, 220, 150 and 500 pM, respectively.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MG-132

Cat. No.: HY-13259

MG-132 is a peptide aldehyde and a potent, reversible, and cell-permeable **proteasome** inhibitor with an IC_{50} of 100 nM, and effectively blocks the proteolytic activity of the 26S proteasome complex.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

MGCD-265 analog

Cat. No.: HY-10991

MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively.



Purity: 96.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

MHY1485

Cat. No.: HY-B0795

MHY1485 is a cell-permeable **mTOR** activator. MHY1485 has an inhibitory effect on the autophagic process by inhibition of fusion between autophagosomes and lysosomes.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

MI-136

Cat. No.: HY-19319

MI-136 inhibits DHT-induced expression of androgen receptor (AR) target genes.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MI-3

(Menin-MLL inhibitor 3)

Cat. No.: HY-15223

MI-3 is a Menin-MLL interaction inhibitor with IC50 value of 648 ± 25 nM. IC50 value: 648 ± 25 nM Target: Menin-MLL in vitro: The menin-MLL inhibitors very effectively blocked proliferation of MLL-AF9 and MLL-ENL transduced BMC, with GI50 values of about 5 μM for MI-2 and MI-3.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MI-463

Cat. No.: HY-19809

MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the **menin-mLL** interaction.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

MI-503

Cat. No.: HY-16925

MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the **menin-mLL** interaction.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

MI-538

Cat. No.: HY-19810

MI-538 is an inhibitor of the interaction between **menin** and **MLL** fusion proteins with an $\mathbf{IC_{50}}$ of 21 nM.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MI-773

Cat. No.: HY-17493

MI-773 is a new small molecule inhibitor of the **MDM2-p53** interaction, binds to **MDM2** with high affinity ($\mathbf{K_i}$=0.88 nM) and blocks the p53-MDM2 interaction.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Microtubule inhibitor 1

Cat. No.: HY-114313

Microtubule inhibitor 1 is an antitumor agent with **microtubule polymerization** inhibitory activity, with an $\mathbf{IC_{50}}$ value of 9-16 nM in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Midostaurin

(PKC412; CGP 41251)

Cat. No.: HY-10230

Midostaurin (PKC412; CGP 41251) is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with $\mathbf{IC_{50}}$ ranging from 16-500 nM.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Mifamurtide (CGP-19835; MTP-PE; MTP-cephalin; CGP19835; L-MTP-PE; MLV19835)

Cat. No.: HY-13682

Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.



Purity: >99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

MIK665

(S-64315)

Cat. No.: HY-112218

MIK665 (S-64315) is a special **Mcl-1** inhibitor extracted from patent WO2016207225A1, compound Preparation 13, has an IC_{50} of 1.81 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Milademetan

(DS-3032)

Cat. No.: HY-101266

Mliademetan is a specific **MDM2** inhibitor, a pharmaceutical composition for use in treating acute myeloid leukemia (AML).



Purity: 92.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Milciclib

(PHA-848125)

Cat. No.: HY-10424

Milciclib (PHA-848125) is a potent, dual inhibitor of **CDK** and **Tropomyosin receptor kinase (TRK)**, with IC_{50}s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.



Purity: 98.61%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MIM1

(Inhibitor of Mcl-1)

Cat. No.: HY-16695

MIM-1 is an inhibitor of myeloid cell factor 1 (**Mcl-1**).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Mini Gastrin I, human

Cat. No.: HY-P1593

Mini Gastrin I, human is a shorter version of human gastrin 1, consists of amino acids 5-17 of the parent peptide, and binds with the **CCK2i4svR**.

LEEEEEAYGWMDF-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Minnelide

Cat. No.: HY-124584

Minnelide is a prodrug of triptolide that shows potent **antitumor** activity in a number of tumor types, particularly in pancreatic cancer. Minnelide causes **apoptotic**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Miquelianin

(Quercetin 3-O-glucuronide; Quercetin 3-glucuronide)

Cat. No.: HY-13930

Miquelianin (Quercetin 3-O-glucuronide) is a metabolite of quercetin and a type of natural flavonoid.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

MIR96-IN-1

Cat. No.: HY-15843

MIR96-IN-1 selectively inhibits biogenesis of microRNA-96, upregulating a protein target (FOXO1) and inducing apoptosis in cancer cells.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Miransertib

(ARQ-092)

Cat. No.: HY-19719

Miransertib (ARQ-092) is an orally bioavailable, selective, and potent allosteric **Akt** inhibitor with IC_{50}s of 2.7 nM, 14 nM and 8.1 nM for **Akt1**, **Akt2**, **Akt3**, respectively.



Purity: 99.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Mirin

Cat. No.: HY-19959

Mirin is a small-molecule inhibitor of MRN (Mre11, Rad50, and Nbs1) complex.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Miriplatin

(SM-11355) Cat. No.: HY-16325A

Miriplatin is a chemotherapy agent which belongs to the class of **alkylating** agents.



Purity: >98.0%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Miriplatin hydrate

(SM-11355 (hydrate)) Cat. No.: HY-16325

Miriplatin hydrate (SM-11355 hydrate) is a chemotherapy agent which belongs to the class of **alkylating** agents.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Mirk-IN-1

(Dyrk1B/A-IN-1) Cat. No.: HY-12838

Mirk-IN-1 is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68±48 nM and 22±8 nM respectively. IC50 value: 68±48/22±8 nM (Dyrk1B/Dyrk1A) Target: Dyrk inhibitor Mirk-IN-1 had an EC50 of 1.9 ±0.2 mmol/L on SW620 cells.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Mitapivat

Cat. No.: HY-12689

Mitapivat is a **pyruvate kinase isoenzyme M2** (**PKM2**) activator.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mitomycin C

(Ametycine) Cat. No.: HY-13316

Mitomycin C is an antitumor drug and antibiotic that shows extraordinary ability to inhibit **DNA synthesis**. Mitomycin C is a DNA cross-linking agent, which induces DNA damaging.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Mitotane

(2,4'-DDD; o,p'-DDD) Cat. No.: HY-13690

Mitotane(2,4'-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Mitoxantrone

(mitozantrone) Cat. No.: HY-13502

Mitoxantrone is a **topoisomerase II** inhibitor; also inhibits protein kinase C (**PKC**) activity with an IC_{50} of 8.5 μM.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Mitoxantrone dihydrochloride

(mitozantrone dihydrochloride) Cat. No.: HY-13502A

Mitoxantrone dihydrochloride is a **topoisomerase II** inhibitor; also inhibits protein kinase C (**PKC**) activity with an IC_{50} of 8.5 μM.



Purity: 97.02%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Mivebresib

(ABBV-075) Cat. No.: HY-100015

Mivebresib is a potent and orally available bromodomain and extraterminal domain (**BET**) bromodomain inhibitor. Mivebresib binds to BRD4 with a K_i of 1.5 nM.



Purity: 99.69%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK 2206 dihydrochloride

Cat. No.: HY-10358

MK-2206 dihydrochloride is an orally active allosteric **AKT** inhibitor with IC_{50}s of 5 nM, 12 nM, and 65 nM for **AKT1**, **AKT2**, and **AKT3**, respectively.



Purity: 99.47%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

MK-1064

Cat. No.: HY-19914

MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-2461

Cat. No.: HY-50703

MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

MK-4101

Cat. No.: HY-100036

MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

MK-5108

(VX-689)

Cat. No.: HY-13252

MK-5108 is a highly potent and specific inhibitor of **Aurora A kinase** with an IC_{50} value of 0.064 nM.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-6892

Cat. No.: HY-10680

MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor **GPR109A**. K_i and GTPγS EC_{50} of MK-6892 on the Human GPR109A is 4 nM and 16 nM, respectively.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-8033

Cat. No.: HY-13299

MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-8033 hydrochloride

Cat. No.: HY-13299A

MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg

MK-8353

(SCH900353)

Cat. No.: HY-111407

MK-8353 (SCH900353) is a potent, selective and orally available **ERK1/2** inhibitor, with IC_{50}s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

MK-8745

Cat. No.: HY-13819

MK-8745 is an **aurora A** kinase inhibitor with an IC_{50} of 0.6 nM.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MK-886

(L 663536)

Cat. No.: HY-14166

MK886 is a **5-lipoxygenase-activating protein** inhibitor and a **leukotriene biosynthesis** inhibitor (IC_{50}=2.5 nM).



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK2-IN-1

Cat. No.: HY-12834

MK2-IN-1 is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

MKC3946

Cat. No.: HY-19710

MKC3946 is a potent and soluble **IRE1α** inhibitor, used for cancer research.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

MKC8866

Cat. No.: HY-104040

MKC8866, a salicylaldehyde analog, is a potent, selective **IRE1 RNase** inhibitor with an IC_{50} of 0.29μM in human vitro.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MKC9989

Cat. No.: HY-12399

MKC9989 is a **Hydroxy aryl aldehydes** (**HAA**) inhibitor and also inhibits **IRE1α** with an IC_{50} of 0.23 to 44 μM.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

MKT-077

(FJ-776)

Cat. No.: HY-15096

MKT-077 is a rhodacyanine dye and also a heat shock protein 70 (**Hsp70**) inhibitor which exhibits significant antitumor activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ML-098

(CID-7345532)

Cat. No.: HY-19800

ML-098 (CID-7345532) is an activator of the GTP-binding protein **Rab7** with an EC_{50} of 77.6 nM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

ML-18

Cat. No.: HY-101844

ML-18 is a non-peptide bombesin receptor subtype-3 (**BRS-3**) antagonist with an IC_{50} of 4.8 μM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML-323

Cat. No.: HY-17543

ML-323 is a reversible, potent **USP1-UAF1** inhibitor with IC_{50} of 76 nM in a Ub-Rho assay. The measured inhibition constants of ML-323 for the free enzyme (K_i) is 68 nM.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML-7 hydrochloride

Cat. No.: HY-15417

ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits **MLCK** (IC_{50}=300 nM) and TRPC6 channel (IC_{50}>10 μM).



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ML-792

Cat. No.: HY-108702

ML-792 is a specific small ubiquitin-like modifier (SUMO)-activating enzyme (**SAE**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

ML132

(NCGC 00185682)

Cat. No.: HY-12412

ML132 (NCGC 00185682) is a potent and selective **caspase 1** inhibitor with an IC_{50} of 0.316 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

ML141

(CID-2950007)

Cat. No.: HY-12755

ML141(CID-2950007) is a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase(IC50=200 nM) with low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML167

(CID44968231; NCGC00188654)

Cat. No.: HY-15951

ML167 is a highly selective Cdc2-like kinase 4 (**Clk4**) inhibitor with IC_{50} of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B.



Purity: 98.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ML204 hydrochloride

Cat. No.: HY-12949A

ML204 hydrochloride is a novel, potent, selective TRPC4 channel inhibitor with IC50 of 0.96 uM. exhibit 19-fold selectivity against TRPC6 channels in similar fluorescent assays. target: ML204 IC50: 0.96 uM In vitro: ML204 inhibited TRPC4β-mediated intracellular Ca2+ rise.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML216

(CID-49852229)

Cat. No.: HY-12342

ML216(CID-49852229) is a potent inhibitor of the DNA unwinding activity of BLM helicase; showing similar IC50s of 3.0 and 0.97 μM for full length BLM and BLM636–1298 respectively.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

ML228

(CID-46742353)

Cat. No.: HY-12754

ML228(CID-46742353) is an activator of the Hypoxia Inducible Factor (HIF) pathway; potently activate HIF in vitro as well as its downstream target VEGF.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML230

(CID44640177; SID 88095709)

Cat. No.: HY-111678

ML230 (CID44640177; SID 88095709) is a selective inhibitor of **ATP-binding cassette (ABC) transporter ABCG2**, and 36-fold selective for ABCG2 over ABCB1 with EC_{50}s values of 0.13 μM and 4.65 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg

ML239

Cat. No.: HY-19971

ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC_{50} of 1.16 μM.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML240

Cat. No.: HY-19795

ML240 is a potent **p97** inhibitor, inhibiting p97 ATPase with IC_{50} value of 100 nM.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML241 hydrochloride

Cat. No.: HY-19797A

ML241 hydrochloride is a potent **p97** inhibitor, inhibiting p97 ATPase with IC_{50} value of 100 nM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML264

Cat. No.: HY-19994

ML264 is an antitumor agent that potently and selectively inhibits Krüppel-like factor five (**KLF5**) expression.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML281

Cat. No.: HY-13495

ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM. ML281 showed a 550-fold selectivity over AurB and greater than 700-fold selectivity over PKA.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

ML311

Cat. No.: HY-101778

ML311 is a potent and selective inhibitor of the **Mcl-1/Bim** interaction.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML324

Cat. No.: HY-12725

ML324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ML327

Cat. No.: HY-103038

ML327 is a blocker of **MYC** which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML347

(LDN 193719)

Cat. No.: HY-12274

ML347(DN193719) is a highly selective ALK1/ALK2 inhibitor with IC50s of 46/32 nM; shows >300-fold selectivity for ALK2 vs. ALK3.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ML348

(GNF-Pf-1127)

Cat. No.: HY-100736

ML348 is a selective and reversible **lysophospholipase 1 (LYPLA1)** inhibitor with an IC_{50} of 210 nM, and barely inhibits LYPLA2.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML349

Cat. No.: HY-100737

ML349 is a potent and specific **acyl protein thioesterase 2** (**APT-2**) inhibitor with a K_i of 120 nM. ML349 is also an inhibitor of **LYPLA2** with an IC_{50} of 144 nM.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

ML364

Cat. No.: HY-100900

ML364 is an inhibitor of **ubiquitin specific peptidase 2 (USP2)**, and can be used for the research of breast cancer, extracted from patent WO 2016134026 A1, compound Figure 10G.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML367

Cat. No.: HY-122198

ML367 is a potent inhibitor of ATPase family AAA domain-containing protein 5 (**ATAD5**) stabilization, acts as a probe molecule that has low micromolar inhibitory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML385

Cat. No.: HY-100523

ML385 is a specific nuclear factor erythroid 2-related factor 2 (**NRF2**) inhibitor with an IC_{50} of 1.9 μM.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

ML390

Cat. No.: HY-100688

ML390 exerts its potent differentiation effect on multiple leukemia models. ML390 will offer insight into the mechanism of overcoming differentiation arrest, and will translate into a starting point for a much-needed new and potent treatment for patients with acute myeloid leukemia.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

MLN0905

(PLK1 Inhibitor)

Cat. No.: HY-15155

MLN0905 is a potent **PLK1** inhibitor, with an IC_{50} of 2 nM.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MLN120B

(ML120B)

Cat. No.: HY-15473

MLN120B is a specific, ATP competitive **IKKβ** inhibitor with an IC_{50} of 60 nM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MLN8054

Cat. No.: HY-10180

MLN8054 is a potent, selective and orally available **aurora A** kinase inhibitor with an IC_{50} of 4 nM.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MM-102

(HMTase Inhibitor IX)

Cat. No.: HY-12220

MM-102 is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide.



Purity: >98%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 50 mg

MM-102 TFA

(HMTase Inhibitor IX (TFA))

Cat. No.: HY-12220A

MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

MM-589

Cat. No.: HY-100869

MM-589 is a potent inhibitor of **WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL)** protein-protein interaction. MM-589 binds to WDR5 with an IC_{50} of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC_{50} of 12.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

MM-589 TFA

Cat. No.: HY-100869A

MM-589 TFA is a potent inhibitor of **WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL)** protein-protein interaction. MM-589 binds to WDR5 with an IC_{50} of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC_{50} of 12.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MMAD (Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10)

Cat. No.: HY-15581

MMAD is a potent **tubulin** inhibitor, is a toxin payload in antibody drug conjugates (**ADCs**).



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MMAF

(Monomethylauristatin F)

Cat. No.: HY-15579

MMAF (Monomethylauristatin F) is an antitubulin agent that inhibit cell division; inhibits H3397 cell growth with an **IC_{50}** of 105 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg

MMAF Hydrochloride

(Monomethylauristatin F Hydrochloride)

Cat. No.: HY-15579A

MMAF hydrochloride is an antitubulin agent that inhibit cell division; inhibits H3397 cell growth with an **IC_{50}** of 105 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

MMAF-OMe

(Monomethyl auristatin F methyl ester)

Cat. No.: HY-79256

MMAF-Ome belongs to ADC, and inhibits several tumor cell lines with **IC_{50}**s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively.



Purity: 96.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

MMP3 inhibitor 1

Cat. No.: HY-114418

MMP3 inhibitor 1 is a potent and highly selective **MMP-3** inhibitor with an **IC_{50}** of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

MN-64

Cat. No.: HY-19351

MN-64 is a potent **tankyrase 1** inhibitor, with **IC_{50}**s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for **TNKS1**, TNKS2, ARTD1 and ARTD2, respectively.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MNS

(NSC 170724; 5-(2-Nitrovinyl)benzodioxole)

Cat. No.: HY-78263

MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases. target: src, syk. IC50:29.3 (src), 2.5 uM (syk); In vitro: no direct effects on protein kinase C, Ca2+ mobilization, Ca2+-dependent enzymes, PKC activation.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Mocetinostat

(MGCD0103)

Cat. No.: HY-12164

Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective **HDAC (Class I/IV)** inhibitor with **IC_{50}**s of 0.15, 0.29, 1.66 and 0.59 μM for **HDAC1**, **HDAC2**, **HDAC3** and **HDAC11**, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Mogrol

Cat. No.: HY-N2312

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the **ERK1/2** and **STAT3** pathways, or reducing **CREB** activation and activating **AMPK** signaling.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Mogroside I A1

Cat. No.: HY-N6854

Mogroside I A1, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mogroside I E1

Cat. No.: HY-N6853

Mogroside I E1, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mogroside IIA1

Cat. No.: HY-N6855

Mogroside IIA1, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mogroside IIe

Cat. No.: HY-N6814

Mogroside IIe, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Molibresib

(GSK 525762A; I-BET 762)

Cat. No.: HY-13032

Molibresib (GSK 525762A; I-BET 762) is a **BET bromodomain** inhibitor with **IC_{50}** of 32.5-42.5 nM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Molibresib besylate

(GSK 525762C; I-BET 762 besylate)

Cat. No.: HY-13032B

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is a **BET bromodomain** inhibitor with **IC_{50}** of 32.5-42.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Momelotinib

(CYT387)

Cat. No.: HY-10961

Momelotinib (CYT387) is an ATP-competitive inhibitor of **JAK1/JAK2** with **IC_{50}**a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.



Purity: 98.11%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Momelotinib Mesylate

(CYT387 (Mesylate))

Cat. No.: HY-10963

Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of **JAK1/JAK2** with **IC_{50}** of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Momelotinib sulfate

(CYT387 (sulfate salt))

Cat. No.: HY-10962

Momelotinib sulfate (CYT387 sulfate) is an ATP-competitive inhibitor of **JAK1/JAK2** with **IC_{50}** of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC_{50}=155 nM).



Purity: >96.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Monastrol

((±)-Monastrol)

Cat. No.: HY-101071A

Monastrol is a potent and cell-permeable inhibitor of the mitotic **kinesin Eg5** with an **IC_{50}** value of 14 μM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Monepantel

(AAD1566)

Cat. No.: HY-14774

Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (**nAChR**) subunits.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Monomethyl auristatin E

(MMAE; SGD-1010)

Cat. No.: HY-15162

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent **mitotic** inhibitor by inhibiting tubulin polymerization.



Purity: 99.94%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg

Morusin

(Mulberrochromene)

Cat. No.: HY-N0622

Morusin is a prenylated flavonoid isolated from M. australis with various biological activities, such as antitumor, antioxidant, and anti-bacteria property. Morusin could inhibit **NF-κB** and **STAT3** activity.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Motesanib

(AMG 706;)

Cat. No.: HY-10228

Motesanib is a potent ATP-competitive inhibitor of **VEGFR1/2/3< /b> with IC_{50}s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.** .



Purity: 99.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Motesanib Diphosphate

(AMG 706 (Diphosphate))

Cat. No.: HY-10229

Motesanib Diphosphate is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with IC_{50}s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.



Purity: 99.64%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Motixafortide

(BKT140 (4-fluorobenzoyl); BL-8040; TF14016)

Cat. No.: HY-P0171

Motixafortide (BKT140 4-fluorobenzoyl) is a novel **CXCR4** antagonist with an IC_{50} vakue of 1 nM.



Purity: 99.19%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 25 mg

Motolimod

(VTX-2337; VTX-378)

Cat. No.: HY-13773

Motolimod is a selective **Toll-like receptor 8 (TLR8)** agonist, with an EC_{50} of approximately 100 nM.



Purity: 98.83%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

MOZ-IN-2

Cat. No.: HY-102059

MOZ-IN-2 is an inhibitor of protein **MOZ**, a member of histone acetyltransferases, with an IC_{50} of 125 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Mozavaptan

(OPC-31260; OPC31260I)

Cat. No.: HY-18346

Mozavaptan (OPC31260) is a orally effective, nonpeptide **vasopressin** V2 receptor antagonist with an IC_{50} of 14 nM.



Purity: 98.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MP-A08

Cat. No.: HY-19794

MP-A08 is a highly selective ATP competitive SK inhibitor that targets both SK1 and SK2 with Kivalues of 6.9 ± 0.8 μM and 27 ± 3 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

MP7

(PDK1 inhibitor)

Cat. No.: HY-14440

MP7 is a phosphoinositide-dependent kinase-1 (**PDK1**) inhibitor.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MPI-0479605

Cat. No.: HY-12660

MPI-0479605 is a potent and selective ATP-competitive inhibitor of **Mps1**, with an IC_{50} of 1.8 nM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Mps1-IN-1

Cat. No.: HY-13298

Mps1-IN-1 is a potent, selective and ATP-competitive **Mps1** kinase inhibitor, with an IC_{50} and a K_d of 367 nM and 27 nM.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mps1-IN-2

Cat. No.: HY-13994

Mps1-IN-2 is a potent, selective and ATP-competitive dual **Mps1/Plk1** inhibitor, with an IC_{50} and a K_d of 145 nM and 12 nM for Mps1 and a K_d of 61 nM for Plk1.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mps1-IN-3

Cat. No.: HY-12401

Mps1-IN-3 is a potent and selective **MPS1** kinase inhibitor, with an IC_{50} of 50 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MPT0B392

Cat. No.: HY-101287

MPT0B392, an orally active quinoline derivative, induces **c-Jun N-terminal kinase** (JNK) activation, leading to **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

MRE3008F20

Cat. No.: HY-103178

MRE3008F20 is a highly potent and selective antagonist of **adenosine A3 receptor (AA3R)**, inhibits agonist-induced cAMP elevation in resting T lymphocytes with an IC_{50} of 5 nM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg

MRK-016

Cat. No.: HY-100370

MRK-016 is a selective, orally bioavailable inverse agonist of **$GABA_A$ α5 receptor**, with an EC_{50} of 3 nM for $GABA_A$ α5, and K_is of 0.83, 0.85, 0.77and 1.4nM for human$GABA_A$α1β3γ2, $GABA_A$α2β3γ2, $GABA_A$α3β3γ2, and $GABA_A$α5β3γ2, respectively; MRK-016 also readily penetrates...



Purity: 98.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MRT-83

Cat. No.: HY-18287

MRT-83 is a potent antagonist of **Smo**, with an IC_{50} in the nanomolar range. MRT-83 also blocks Hedgehog (Hh) signaling.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MRT68921

Cat. No.: HY-100006

MRT68921 is a potent inhibitor of **ULK1** and **ULK2**, with IC_{50} values of 2.9 nM and 1.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MRT68921 dihydrochloride

Cat. No.: HY-100006A

MRT68921 dihydrochloride is the most potent inhibitor of **ULK1** and **ULK2**, with IC_{50} values of 2.9 nM and 1.1 nM, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

MRTX-1257

Cat. No.: HY-114436

MRTX-1257 is a selective, irreversible, covalent and oral active **KRAS G12C** inhibitor, with an IC_{50} of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

MRX-2843

(UNC2371) Cat. No.: HY-101549

MRX-2843 is an orally available small-molecule inhibitor of both **MERTK** and **FLT3**.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

MS-444

(BE-34776) Cat. No.: HY-100685

MS-444 inhibits the activity of purified smooth muscle myosin light chain kinase (**MLCK**) with an IC_{50} value of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

MS023

Cat. No.: HY-19615

MS023 is a potent, selective, and cell-active inhibitor of human **type I protein arginine methyltransferases (PRMTs)** inhibitor, with IC_{50}s of 30, 119, 83, 4 and 5 nM for **PRMT1**, **PRMT3**, **PRMT4**, **PRMT6**, and **PRMT8**, respectively.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS023 dihydrochloride

Cat. No.: HY-19615B

MS023 dihydrochloride is a potent, selective, and cell-active inhibitor of human **type I protein arginine methyltransferases (PRMTs)** inhibitor, with IC_{50}s of 30, 119, 83, 4 and 5 nM for **PRMT1**, **PRMT3**, **PRMT4**, **PRMT6**, and **PRMT8**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS049

Cat. No.: HY-100360

MS 049 is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC 50 of 34 nM and 43 nM respectively. target: PRMT4, PRMT6; IC 50: 34 nM (PRMT4), 43 nM (PRMT6); In vitro: MS 049 reduces the H3R2me2a mark in HEK293 cells in a concentration dependent manner.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS402

Cat. No.: HY-120000

MS402 is a **BD1**-selective **BET BrD** inhibitor with K_is of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for **BRD4(BD1)**, **BRD4(BD2)**, **BRD3(BD1)**, **BRD3(BD2)**, **BRD2(BD1)** and **BRD2(BD2)**, respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

MS4077

Cat. No.: HY-112156

MS4077 is an anaplastic lymphoma kinase (**ALK**) **PROTAC** (degrader) with a K_d of 37 nM for binding affinity to ALK.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

MS4078

Cat. No.: HY-112155

MS4078 is an anaplastic lymphoma kinase (**ALK**) **PROTAC** (degrader) with a K_d of 19 nM for binding affinity to ALK.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

MS436

Cat. No.: HY-13959

MS436 is a new class of **bromodomain** inhibitor, exhibits potent affinity of an estimated K_i=30-50 nM for the BRD4 BrD1 and a 10-fold selectivity over the BrD2.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MSC2530818

Cat. No.: HY-101611

MSC2530818 is a potent, selective and orally available **CDK8** inhibitor with an IC_{50} of 2.6 nM for CDK8.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MSX-122

Cat. No.: HY-13696

MSX-122 is a orally active partial antagonist of **CXCR4**, inhibiting **CXCR4/CXCL12** actions, with an IC_{50} of 10 nM. MSX-122 has anti-inflammatory and anti-metastatic activity.



Purity: 98.29%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MT-4

Cat. No.: HY-128595

MT-4 blocks the **TG2/FN complex** at the interface between cancer cells and the tumor niche. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

MT-802

Cat. No.: HY-122562

MT-802 is a potent **BTK** degrader based on **PROTAC** technology, with a DC_{50} of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MT-DADMe-ImmA

(Methylthio-DADMe-Immucillin A; MTDIA)

Cat. No.: HY-101496

MT-DADMe-ImmA is an inhibitor of human 5'-methylthioadenosine phosphorylase (**MTAP**) with a K_i of 90 pM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

mTOR inhibitor-1

Cat. No.: HY-112914

mTOR inhibitor-1 is a novel **mTOR pathway** inhibitor which can suppress cells proliferation and inducing autophagy.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

mTOR inhibitor-2

Cat. No.: HY-111370

mTOR inhibitor-2 is a highlt potent, selective and oral **mTOR** inhibitor with an IC_{50} of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

mTOR inhibitor-3

Cat. No.: HY-18353

mTOR inhibitor-3 is a remarkably selective **mTOR** inhibitor with a K_i of 1.5 nM. mTOR inhibitor-3 suppresses **mTORC1** and **mTORC2** in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

mTRP-2 180-188

Cat. No.: HY-P1827

mTRP-2 (180-188) is a murine tyrosinase-related protein 2 (TRP-2) -derived peptide, corresponding to residues 180-188. TRP-2 (180-188) is identified as the major reactive epitope within TRP-2 recognized by anti-B16 CTLs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MTX-211

Cat. No.: HY-107364

MTX-211 is a dual inhibitor of **EGFR** and **PI3K**, used for the treatment of cancer and other diseases.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Mubritinib

(TAK-165)

Cat. No.: HY-13501

Mubritinib (TAK-165) is a potent and selective **EGFR2/HER2** inhibitor with an IC_{50} of 6 nM.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MUC5AC motif peptide

Cat. No.: HY-P0280

MUC5AC motif peptide is a 16-amino acid fragment of mucin 5.

GTTPSPVPTTSTTSAP

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mutant EGFR inhibitor

Cat. No.: HY-13984

Mutant EGFR inhibitor is a potent and selective mutant **EGFR** inhibitor extracted from patent WO 2013014448 A1; inhibits $EGFR^{L858R}$, $EGFR^{Exon\ 19\ deletion}$ and $EGFR^{T790M}$.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mutant IDH1 inhibitor

Cat. No.: HY-13972

Mutant IDH1 inhibitor is a potent mutant **IDH1 R132H** inhibitor with **IC_{50}** of < 72 nM.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mutant IDH1-IN-1

Cat. No.: HY-12475

Mutant IDH1-IN-1 is a mutant-selective **IDH1** inhibitor with with **IC_{50}**s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mutant IDH1-IN-2

Cat. No.: HY-18717

Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.



Purity: 97.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mutant IDH1-IN-4

Cat. No.: HY-114459

Mutant IDH1-IN-4 (compound 434) is an inhibitor of **mutant Isocitrate dehydrogenase 1 (IDH 1)**, with **IC_{50}** values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Mutated EGFR-IN-1

Cat. No.: HY-78869

Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MX69

Cat. No.: HY-100892

MX69 is an inhibitor of **MDM2/XIAP**, used for cancer treatment.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Mycophenolate Mofetil

(RS 61443; TM-MMF)

Cat. No.: HY-B0199

Mycophenolate Mofetil is a non-competitive, selective and reversible inhibitor of **inosine monophosphate dehydrogenase (IMPDH)** with **IC_{50}**s of 39 nM and 27 nM, respectively.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Mycro 3

Cat. No.: HY-100669

Mycro 3 is potent and selective for **c-Myc** in whole cell assays.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Myricetin
(Cannabiscetin) Cat. No.: HY-15097

Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

MZ 1
Cat. No.: HY-107425

MZ 1 is a **BRD4** protein degrader based on **PROTAC** technology.



Purity: 98.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

MZP-54
Cat. No.: HY-112376

MZP-54 is a selective degrader of **BRD3/4** based on **PROTAC** technology, with a K_d of 4 nM for $Brd4^{BD2}$.

Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

MZP-55
Cat. No.: HY-112377

MZP-55 is a selective degrader of **BRD3/4** based on **PROTAC** technology, with a K_d of 8 nM for $Brd4^{BD2}$.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

M89
Cat. No.: HY-128347

M-89 is a highly potent and specific **menin** inhibitor, with a K_d of 1.4 nM for binding to menin. M-89 inhibits the **menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction** and has potential to treat MLL leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-(5-Aminopentyl)acetamide
(Monoacetylcadaverine) Cat. No.: HY-101403

N-(5-Aminopentyl)acetamide is the acetylated form of the polyamine cadaverine.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

N-Acetyl-Calicheamicin
(N-Acetyl-Calicheamicin γ; N-Acetyl-γ-calicheamicin) Cat. No.: HY-19791

N-Acetyl-Calicheamicin is a potent enediyne antitumor antibiotic.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride
Cat. No.: HY-112716

N-alpha-Tosyl-L-lysine chloromethyl ketone (TLCK), a trypsin like protease inhibitor, sensitizes HeLa cells to Fas-mediated cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

N-Benzoyl-(2R,3S)-3-phenylisoserine
Cat. No.: HY-N2380

N-Benzoyl-(2R,3S)-3-phenylisoserine is a Taxol C-13 Side Chain and crucial for the strong antitumor activity of Taxol.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

N-Bis(2-hydroxypropyl)nitrosamine (DHPN; Di(2-hydroxypropyl)nitrosamine; Diisopropanolnitrosamine)
Cat. No.: HY-112085

N-Bis(2-hydroxypropyl)nitrosamine is an agent with carcinogenic activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

N-deacetylated BMS-202

Cat. No.: HY-19745A

N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the **PD-l/PD-Ll** interaction, mainly used for cancer treatment.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-Desethyl Sunitinib

(SU-11662)

Cat. No.: HY-10873

N-Desethyl Sunitinib is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive **VEGFR**, **PDGFRβ** and **KIT** inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

N-desmethyl Enzalutamide

(N-desmethyl MDV 3100)

Cat. No.: HY-70002A

N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. Enzalutamide is an **androgen-receptor (AR)** antagonist with IC_{50} of 36 nM in LNCaP cells.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

N-ε-propargyloxycarbonyl-L-lysine hydrochloride

(H-L-Lys(Poc)-OH (hydrochloride))

Cat. No.: HY-128676

N-ε-propargyloxycarbonyl-L-lysine hydrochloride is a modified amino acid (L-lysine) for cancer therapy development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N2,N2-Dimethylguanosine

Cat. No.: HY-113137

N2,N2-Dimethylguanosine is an urinary nucleoside, a primary degradation product of tRNA.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

N3-PEG3-vc-PAB-MMAE

Cat. No.: HY-100874

N3-PEG3-vc-PAB-MMAE is a **drug-linker conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide N3-PEG3-vc-PAB.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

N33-TEG-COOH (N3-TEG-COOH; 14-Azido-3,6,9,12-tetraoxatetradecanoic acid)

Cat. No.: HY-108370

N33-TEG-COOH is a **PROTAC** linker containing four polyethylene glycol (PEG) units.



Purity: >96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

N3PT

(N3-pyridyl thiamine)

Cat. No.: HY-16339

N3PT(N3-pyridyl thiamine) is a potent and selective transketolase(TK) inhibitor (IC50= 22 nM for Apo-TK) both in vitro and in vivo.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NAcM-OPT

Cat. No.: HY-111505

NAcM-OPT is an orally bioavailable cullin neddylation 1 (**DCN1**) inhibitor, which potently inhibits the DCN1-UBE2M interaction.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

NADPH tetrasodium salt

Cat. No.: HY-F0003

NADPH tetrasodium salt is a cofactor, used to donate electrons and a hydrogens to reactions catalyzed by some enzymes.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Naltrindole hydrochloride

Cat. No.: HY-101177

Naltrindole hydrochloride is a highly potent and selective non-peptide **δ opioid** receptor antagonist with a K_i of 0.02 nM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

NAMI-A

Cat. No.: HY-19376

NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration. In vitro: NAMI-A can significantly affect tumor cells with metastatic ability.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Namitecan

(ST-1968)

Cat. No.: HY-14821

Namitecan is a potent **topoisomerase I** inhibitor, with antitumor property.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Namodenoson

(CF-102; 2-Cl-IB-MECA)

Cat. No.: HY-12365

Namodenoson (CF-102) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NAMPT inhibitor-linker 1

Cat. No.: HY-112615

NAMPT inhibitor-linker 1 is a drug-linker conjugates for **ADC**, composed of an **NAMPT** inhibitor as a payload, and a linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

NAMPT inhibitor-linker 2

Cat. No.: HY-112616

NAMPT inhibitor-linker 2 is a drug-linker conjugates for **ADC**, composed of an **NAMPT** inhibitor as a payload, and a linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Nampt-IN-1

(LSN3154567)

Cat. No.: HY-12971

Nampt-IN-1 (LSN3154567) is a potent and selective **NAMPT** inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC_{50} of 3.1 nM.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nampt-IN-3

Cat. No.: HY-108701

Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (**NAMPT**) and **HDAC** with IC_{50}s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell **apoptosis** and **autophagy** and ultimately leads to cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Nanatinostat

(CHR-3996)

Cat. No.: HY-13432

Nanatinostat (CHR-3996) is a potent, class I selective and orally active **histone deacetylase (HDAC)** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Napabucasin

Cat. No.: HY-13919

Napabucasin is a **STAT3** inhibitor which blocks stem cell activity in cancer cells.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Naquotinib

(ASP8273)

Cat. No.: HY-19729

Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible **EGFR** inhibitor; with IC_{50}s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg

Naquotinib mesylate

(ASP8273 (mesylate))

Cat. No.: HY-19803

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible **EGFR** inhibitor; with IC_{50}s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.



Purity: 98.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Narciclasine

(Lycoricidinol)

Cat. No.: HY-16563

Narciclasine is a plant growth modulator. Narciclasine modulates the Rho/Rho kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity as well as inducing actin stress fiber formation in a RhoA-dependent manner.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Naringenin

Cat. No.: HY-N0100

Naringenin is the predominant flavanone in grapefruit; displays strong anti-inflammatory and antioxidant activities.



Purity: 98.72%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Naringin Dihydrochalcone

(Naringin DC)

Cat. No.: HY-N0119

Naringin Dihydrochalcone is an artificial sweetener derived from naringin. Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Nastorazepide

(Z-360)

Cat. No.: HY-17617

Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NAV-2729

Cat. No.: HY-112473

NAV-2729 is a dual **Arf1**/**Arf6** activation inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Navitoclax

(ABT-263)

Cat. No.: HY-10087

Navitoclax (ABT-263) is a potent and oral **Bcl-2 family protein** inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-x_L, Bcl-2 and Bcl-w, with a K_i of less than 1 nM.



Purity: 99.97%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Navoximod

(GDC-0919; NLG-919)

Cat. No.: HY-18770B

Navoximod (GDC-0919; NLG-919) is a potent **IDO** (indoleamine-(2,3)-dioxygenase) pathway inhibitor with K_i/EC_{50} of 7 nM/75 nM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Nazartinib

(EGF816)

Cat. No.: HY-12872

Nazartinib (EGF816) is a novel, covalent mutant-selective **EGFR** inhibitor, with K_i and K_{inact} of 31 nM and 0.222 min^{-1} on EGFR(L858R/790M) mutant, respectively.



Purity: 99.57%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nazartinib mesylate

(EGF816 (mesylate)) Cat. No.: HY-12872A

Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective **EGFR** inhibitor, with K_i and K_{inact} of 31 nM and 0.222 min^{-1} on EGFR(L858R/790M) mutant, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

NCB-0846

Cat. No.: HY-100830

NCB-0846 is an orally available **TNIK** inhibitor with an IC_{50} of 21nM.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NCGC00244536

(KDM4B Inhibitor B3) Cat. No.: HY-101799

NCGC00244536 is a potent **KDM4B** inhibitor with an IC_{50} of 10 nM.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NCGC00247743

Cat. No.: HY-112308

NCGC00247743 is a histone lysine demethylase **KDM4** inhibitor.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

NCI172112

(NSC172112; NSC268497) Cat. No.: HY-U00155

NCI172112 is a classical bifunctional alkylating agent synthesized in an effort to develop antitumor agents effective against CNS tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

NCT-501

Cat. No.: HY-18768

NCT-501 is a potent and selective theophylline-based inhibitor of **aldehyde dehydrogenase 1A1 (ALDH1A1)**, inhibits hALDH1A1 with IC_{50} of 40 nM, typically shows better selectivity over other ALDH isozymes and other dehydrogenases (hALDH1B1, hALDH3A1, and...



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NCT-502

Cat. No.: HY-117240

NCT-502 is a human phosphoglycerate dehydrogenase (**PHGDH**) inhibitor, cytotoxic to PHGDH-dependent cancer cells, and reduces glucose-derived serine production, with an IC_{50} of 3.7 μM against PHGDH.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NCT-503

Cat. No.: HY-101966

NCT-503 is a phosphoglycerate dehydrogenase (**PHGDH**) inhibitor with an IC_{50} of 2.5 μM.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NCT-505

Cat. No.: HY-112277

NCT-505 is a potent and selective **aldehyde dehydrogenase (ALDH1A1)** inhibitor, with an IC_{50} of 7 nM, and weakly inhibits hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 (IC_{50}s, >57, 22.8, 20.1, >57 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

NCT-506

Cat. No.: HY-112278

NCT-506 is an orally bioavailable aldehyde dehydrogenase 1A1 (**ALDH1A1**) inhibitors with an IC_{50} of 7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

ND-646

Cat. No.: HY-101842

ND-646 is an orally bioavailable and steric inhibitor of acetyl-CoA carboxylase (**ACC**) with IC_{50}s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Necrostatin 2

Cat. No.: HY-14622

Necrostatin 2 is a potent **necroptosis** inhibitor. EC_{50} for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with **TNF-α** is 0.05 μM. Necrostatin 2 is also a **RIPK1** inhibitor.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Necrostatin 2 racemate

(Necrostatin-2 racemate)

Cat. No.: HY-14622A

Necrostatin 2 racemate is a potent necroptosis inhibitor, acts as a RIPK1 inhibitor lacking the IDO-targeting effect.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Necrostatin 2 S enantiomer

Cat. No.: HY-14622B

Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin 2. Necrostatin 2 is a potent necroptosis inhibitor, acts as a RIPK1 inhibitor lacking the IDO-targeting effect.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Necrostatin-1

(Nec-1)

Cat. No.: HY-15760

Necrostatin-1 (Nec-1) is a potent, selective and cell-permeable **necroptosis** inhibitor with an EC_{50} of 490 nM in Jurkat cells. Necrostatin-1 acts by inhibiting (**RIP1**) kinase domain in the necroptosis pathway.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

NecroX-5

Cat. No.: HY-104015

NecroX-5 is a derivative of the NecroX, reduces intracellular **calcium** concentration, and possesses anti-inflammatory and anti-cancer activity.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nedaplatin

(NSC 375101D)

Cat. No.: HY-13700

Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Nedisertib

(M3814)

Cat. No.: HY-101570

Nedisertib (M3814) is a potent and selective inhibitor of **DNA-dependent Protein Kinase** (**DNA-PK**), with an IC_{50} of <3 nM.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nelarabine

(506U78; GW 506U78; Nelzarabine)

Cat. No.: HY-13701

Nelarabine (Arranon, 506U78) is a purine nucleoside analog and DNA synthesis inhibitor with IC50 from 0.067-2.15 μM in tumor cells. Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nelotanserin

(APD125)

Cat. No.: HY-10559

Nelotanserin is a potent **5-HT_{2A}** inverse agonist, a moderately potent **5-HT_{2C}** partial inverse agonist and a weak **5-HT_{2B}** inverse agonist, with IC_{50}s of 1.7, 79, 791 nM in IP accumulation assays, respectively.



Purity: 99.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Nemiralisib

(GSK2269557 (free base))

Cat. No.: HY-19535A

Nemiralisib (GSK2269557 free base) is a potent and highly selective **PI3Kδ** inhibitor with a **pK_i** of 9.9.



Purity: 99.50%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nemorubicin

(Methoxymorpholinyldoxorubicin; PNU 152243; PNU-152243A)

Cat. No.: HY-15794

Nemorubicin is a derivative of doxorubicin, and has antitumor activity.



Purity: 97.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Neoseptin 3

Cat. No.: HY-U00435

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (**mTLR4/MD-2**) agonist with an **EC_{50}** of 18.5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Neratinib

(HKI-272)

Cat. No.: HY-32721

Neratinib is an orally available, irreversible **tyrosine kinase** inhibitor with **IC_{50}**s of 59 nM and 92 nM for HER2 and EGFR, respectively.



Purity: 98.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Nesiritide

(Brain Natriuretic Peptide-32 human; BNP-32)

Cat. No.: HY-P0003

Nesiritide is an agonist of natriuretic peptide receptors (NPRs), with **K_d** values of 7.3 and 13 pM for NPR-A and NPR-C, respectively.

Purity: 98.28%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Neurotensin

Cat. No.: HY-P0234

Neurotensin, a gut tridecapeptide, acts as a potent cellular mitogen for various colorectal and pancreatic cancers which possess high-affinity **neurotensin receptors** (**NTR**).

Pyr-LYENKPRRPYIL

Purity: 97.32%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Nevanimibe

(PD-132301; ATR-101)

Cat. No.: HY-100399

Nevanimibe (PD-132301; ATR101) is a selective and potent acyl-coenzyme A:cholesterol O-acyltransferase 1 (**ACAT1**) inhibitor with an **EC_{50}** of 9 nM. Nevanimibe (PD-132301; ATR101) inhibits ACAT2 with an EC_{50} of 368 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Nevanimibe hydrochloride

(PD-132301 hydrochloride; ATR101 hydrochloride)

Cat. No.: HY-100399A

Nevanimibe hydrochloride (PD-132301 hydrochloride; ATR101 hydrochloride) is a selective and potent acyl-coenzyme A:cholesterol O-acyltransferase 1 (**ACAT1**) inhibitor with an **EC_{50}** of 9 nM.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nexturastat A

Cat. No.: HY-16699

Nexturastat A is a potent and selective HDAC6 inhibitor with IC50 of 5 nM; no inhibition on other HDAC forms.



Purity: 97.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NG 52

(Compound 52)

Cat. No.: HY-15154

NG 52 (Compound 52) is a potent, cell-permeable, reversible, selective, and ATP-compatible inhibitor of the cell cycle-regulating kinase, Cdc28p (IC50 = 7 μM), and the related Pho85p kinase (IC50 = 2 μM).



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NG25

Cat. No.: HY-15434

NG25 is a potent dual **TAK1** and **MAP4K2** inhibitor, with IC_{50}s of 149 nM and 21.7 nM, respectively.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

NGI-1

(ML414)

Cat. No.: HY-117383

NGI-1 is a cell permeable inhibitor.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NGR peptide Trifluoroacetate

Cat. No.: HY-P1043A

NGR peptide Trifluoroacetate containing the asparagine-glycine-arginine (NGR) motif is recognized by **CD13/aminopeptidase N** (**APN**) **receptor** isoforms that are selectively overexpressed in tumor neovasculature.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

NH125

Cat. No.: HY-100576

NH125 is a potent and selective inhibitor of eukaryotic elongation factor 2 kinase **(eEF-2K/CaMKIII)**, also could induce eEF2 phosphorylation, with an IC_{50} of 60 nM for eEF-2K.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NI-42

Cat. No.: HY-101121

NI-42 (compound 13-d), a structurally orthogonal chemical probe for the BRPFs, is a biased, potent inhibitor of the **BRD of the BRPFs** (IC_{50}s of BRPF1/2/3=7.9/48/260 nM; K_ds of BRPF1/2/3=40/210/ 940 nM) with excellent selectivity over nonclass IV BRD proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

NI-57

Cat. No.: HY-19537

NI-57 is an inhibitor of bromodomain and plant homeodomain finger-containing (**BRPF**) famlily of proteins, with IC_{50}s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NIC3

Cat. No.: HY-128577

NIC3 is a selective nucleus accumbens-associated protein-1 (**NAC1**) inhibitor, binds to the conserved Leu-90 of NAC1, prevents its homodimerization, and leads to proteasomal NAC1 degradation. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Nicaraven

Cat. No.: HY-100592

Nicaraven is a novel chemically synthesized hydroxyl radical-specific scavenger.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Nifuroxazide

Cat. No.: HY-B1436

Nifuroxazide is an effective inhibitor of **STAT3**, also exerts potent anti-tumor and anti-metastasis activity.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Nifurtimox

Cat. No.: HY-W040073

Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of **lactate dehydrogenase** (**LDH**).



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Nigericin sodium salt

(Sodium Nigericin) Cat. No.: HY-100381

Nigericin sodium salt is an antibiotic from Streptomyces hygroscopicus that works by acting as an H^+, K^+, and Pb^{2+} ionophore.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nilotinib

(AMN107) Cat. No.: HY-10159

Nilotinib is an orally available **Bcr-Abl** tyrosine kinase inhibitor with antineoplastic activity.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Nilotinib monohydrochloride monohydrate

(AMN107 (monohydrochloride monohydrate)) Cat. No.: HY-10159A

Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against **BCR-ABL**, and is active against many BCR-ABL mutants.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Nilutamide

(Nilandron; RU 23908) Cat. No.: HY-13702

Nilutamide (Nilandron) is a non-steroidal anti-androgen drug proposed in the treatment of metastatic prostatic carcinoma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nimbolide

Cat. No.: HY-116035

Nimbolide is a triterpene derived from the leaves and flowers of neem (Azadirachta indica L). Nimbolide induces apoptosis through inactivation of **NF-κB**. Nimbolide inhibits **CDK4/CDK6** kinase activity. Nimbolide suppresses the NF-κB, Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nimustine hydrochloride

(ACNU) Cat. No.: HY-13703A

Nimustine hydrochloride (ACNU) is a DNA cross-linking and DNA alkylating agent, which induces DNA replication blocking lesions and DNA double-strand breaks and inhibits **DNA synthesis**, commonly used in chemotherapy for glioblastomas.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ningetinib

Cat. No.: HY-107145A

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with IC_{50}s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ningetinib Tosylate

Cat. No.: HY-107145

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with IC_{50}s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nintedanib

(BIBF 1120) Cat. No.: HY-50904

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Nintedanib esylate

(BIBF 1120 (esylate)) Cat. No.: HY-11106

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Niraparib

(MK-4827) Cat. No.: HY-10619

Niraparib (MK-4827) is a highly potent **PARP1** and **PARP2** inhibitor with IC_{50}s of 3.8 and 2.1 nM, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Niraparib hydrochloride

(MK-4827 (hydrochloride)) Cat. No.: HY-10619A

Niraparib hydrochloride (MK-4827 hydrochloride) is an excellent **PARP1** and **PARP2** inhibitor with IC_{50} of 3.8 and 2.1 nM, respectively.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Niraparib R-enantiomer

(MK 4827 (R-enantiomer)) Cat. No.: HY-10619D

Niraparib R-enantiomer (MK-4827 R-enantiomer) is an excellent **PARP1** inhibitor with IC_{50} of 2.4 nM.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Niraparib tosylate

(MK-4827 (tosylate)) Cat. No.: HY-10619B

Niraparib tosylate (MK-4827 tosylate) is an excellent **PARP1** and **PARP2** inhibitor with an IC_{50} of 3.8 and 2.1 nM, respectively.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nitracrine

Cat. No.: HY-U00279

Nitracrine is an antitumor drug that has been used clinically for several years.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Nitromifene

(CI628) Cat. No.: HY-100266

Nitromifene is an antagonist of **estrogen receptor** (**ER**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nivolumab

(BMS-936558; ONO-4538; MDX-1106) Cat. No.: HY-P9903

Nivolumab is a programmed death receptor-1 (**PD-1**) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.

Purity: 98.56%
Clinical Data: Launched
Size: 1 mg, 5 mg

NK-252

Cat. No.: HY-19734

NK-252 is a potential **Nrf2** activator, which exhibits a great **Nrf2**-activating potential.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NKL 22

Cat. No.: HY-100384

NKL 22 is a HDAC inhibitor. The value of IC 50 is 78 uM NKL 22 increase frataxin protein concentrations NKL 22 inhibitors increase FXN mRNA in FRDA lymphocytes. HDAC inhibitors act directly on FXN.



Purity: 97.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NKP-1339

(IT-139; KP-1339) Cat. No.: HY-16350

NKP-1339(IT-139) is a ruthenium(iii) coordination anticancer compound based on target to transferrin.



Purity: 95.92%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NMDI14

Cat. No.: HY-111374

NMDI14 is a nonsense mediated RNA decay (**NMD**) inhibitor.



Purity: 95.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NMS-1286937

(NMS-P937)

Cat. No.: HY-15828

NMS-1286937 is a potent, selective and orally available **PLK1** inhibitor, with an IC_{50} of 2 nM.



Purity: 99.70%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NMS-859

Cat. No.: HY-15714

NMS-859 is a potent, covalent **VCP (p97)** inhibitor, with IC_{50}s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.



Purity: 97.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NMS-873

Cat. No.: HY-15713

NMS-873 is a potent, selective allosteric **VCP/p97** inhibitor with IC_{50} value of 30 nM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NMS-P118

Cat. No.: HY-18954

NMS-P118 is a potent, orally available, and highly selective **PARP-1** Inhibitor for cancer therapy.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NMS-P515

Cat. No.: HY-128599

NMS-P515 is a potent, orally active and stereospecific **PARP-1** inhibitor, with a K_d of 16 nM and an IC_{50} of 27 nM (in Hela cells). Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

NMS-P715

Cat. No.: HY-12382

NMS-P715 is a selective, ATP-competitive inhibitor of **MPS1**, with an IC_{50} of 182 nM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NMS-P715 analog

Cat. No.: HY-14712

NMS-P715 analog is an inhibitor of **MPS1**, with an IC_{50} of 84 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Nobiletin

Cat. No.: HY-N0155

Nobiletin is a citrus flavonoid with anti-inflammatory, anti-cancer, cholesterol lowering, memory protection activities.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nocodazole

(Oncodazole; R17934)

Cat. No.: HY-13520

Nocodazole is a rapidly-reversible inhibitor of **microtubule**. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits **Bcr-Abl**, activates **CRISPR/Cas9**.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Nolatrexed dihydrochloride

(AG 337; Thymitaq) Cat. No.: HY-108474

Nolatrexed dihydrochloride (AG 337) is a non-competitive lipophilic inhibitor of **thymidylate synthase**, interacts at the folate cofactor binding site of the enzyme, with a K_i of 11 nM for human thymidylate synthase.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

nor-NOHA acetate

(Nω-hydroxy-nor-Arginine acetate) Cat. No.: HY-112885A

nor-NOHA acetate is a specific and reversible **arginase** inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Anti-leukemic activity, effective in endothelial dysfunction, immunosuppression and metabolism.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nordihydroguaiaretic acid

(NDGA) Cat. No.: HY-N0198

Nordihydroguaiaretic acid is a **5-lipoxygenase** (**5LOX**) (**IC_{50}**=8±3 μM) and tyrosine kinase inhibitor.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 500 mg

Noscapine

((S,R)-Noscapine) Cat. No.: HY-13716

Noscapine is an orally administrable drug used worldwide for cough suppression, primarily mediated by its σ-receptor agonist activity, and possess anticancer activity.



Purity: 97.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Notch inhibitor 1

Cat. No.: HY-12860

Notch inhibitor 1 is a potent **Notch** inhibitor, with **IC_{50}**s of 7.8 and 8.5 nM for Notch 1 and Notch 3, respectively. Used in the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

NP-12

Cat. No.: HY-P1812

NP-12 is a peptide antagonist of the **PD-1** signaling pathway, which acts as an immunomodulatory agent for cancer therapy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NP-12 TFA

Cat. No.: HY-P1812A

NP-12 (TFA) is a peptide antagonist of the **PD-1 signaling pathway**, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NPB

Cat. No.: HY-119368

NPB is a specific and potent inhibitor of **BAD phosphorylation at Ser99**, with an **IC_{50}** of 0.41 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

NPS-1034

Cat. No.: HY-100509

NPS-1034 is a dual inhibitor of **AXL** and **MET** with **IC_{50}**s of 10.3 and 48 nM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NQDI-1

Cat. No.: HY-19566

NQDI-1 inhibits apoptosis signal-regulating kinase 1 (**ASK1**) with a K_i of 500 nM and an **IC_{50}** of 3 μM.



Purity: 95.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NQO1 substrate

Cat. No.: HY-114315

NQO1 substrate acts as an efficient NQO1 substrate and may be a new option for the treatment of NQO1-overexpresssing drug-resistant NSCLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

NRC-2694

Cat. No.: HY-19909

NRC-2694 is an epidermal growth factor receptor (**EGFR**) antagonist with anti-cancer and anti-proliferative properties.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Nrf2-IN-1

Cat. No.: HY-101025

Nrf2-IN-1 (Compound 4f) is an inhibitor of **nuclear factor-erythroid 2-related factor 2 (Nrf2)**, acts as a promising agent in acute myeloid leukemia (AML) therapy.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

NRX-252262

Cat. No.: HY-111760

NRX-252262 is a potent enhancer of the interaction between **β-Catenin**, and its cognate **E3 ligase**, $SCF^{\beta\text{-}TrCP}$, induces mutant β-catenin degradation, with an EC_{50} of 3.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

NSC 185058

Cat. No.: HY-125169

NSC 185058 is an inhibitor of **ATG4B**, a major **cysteine protease**. NSC185058 markedly attenuates **autophagic** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

NSC 228155

Cat. No.: HY-101084

NSC 228155 is an activator of **EGFR**, binds to the extracellular region of **EGFR** and enhance tyrosine phosphorylation of EGFR.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC 23766

Cat. No.: HY-15723

NSC 23766 is a specific inhibitor of the binding and activation of **Rac GTPase**, used for cancer treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

NSC 23766 trihydrochloride

Cat. No.: HY-15723A

NSC 23766 trihydrochloride is an inhibitor of **Rac1** activation.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NSC 405020

Cat. No.: HY-15827

NSC-405020 is a novel small molecule inhibitor of MT1-MMP that specifically targets PEX domain rather than the catalytic domain of MT1-MMP with IC50 >100 μM and does not inhibit the catalytic activity of MT1-MMP or MMP-2.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

NSC 42834

(JAK2 Inhibitor V; Z3)

Cat. No.: HY-15480

NSC 42834 a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.



Purity: 95.5%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

NSC 601980

Cat. No.: HY-B1714A

NSC601980 shows antitumor activity in the yeast screening experiment, which can inhibit cell proliferation in the COLO 205 and HT29 with Log GI 50 of -6.6 and -6.9 respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NSC 663284

(DA-3003-1)

Cat. No.: HY-100034

NSC 663284 is a **Cdc25 dual specificity phosphatases** inhibitor with an IC_{50} of 0.21 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC 74859

(S3I-201)

Cat. No.: HY-15146

NSC 74859 is a selective **Stat3** inhibitor with an IC_{50} of 86±33 μM.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC 95397

Cat. No.: HY-108543

NSC 95397 is a potent, selective **Cdc25** dual specificity phosphatase inhibitor (K_i=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC_{50}=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC139021

(ERGi-USU)

Cat. No.: HY-112158

NSC139021 (ERGi-USU) is a highly selective inhibitor for the growth of **ERG-positive** cancer cells with IC_{50}s ranging from 30 to 400 nM.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

NSC16168

Cat. No.: HY-100690

NSC16168 is a specific inhibitor of **ERCC1-XPF**, with an IC_{50} value of 0.42 μM. NSC16168 inhibits DNA repair and potentiates CDDP efficacy in cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC23005 sodium

Cat. No.: HY-100791

NSC23005 sodium is a novel and effective **p18** inhibitor (ED_{50}=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

NSC232003

Cat. No.: HY-103236

NSC232003 is a highly potent and cell-permeable **UHRF1** inhibitor, which inhibits DNA methylation in vitro and disrupts DNMT1/UHRF1 interactions at a cellular level.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NSC23925

Cat. No.: HY-19626

NSC23925 is a novel, selective and effective **P-glycoprotein** (**Pgp**) inhibitor.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

NSC305787

Cat. No.: HY-18931

NSC305787 is an inhibitor of **ezrin** with a K_d of 5.85 μM, inhibits the phosphorylation of ezrin caused by PKCI with an IC_{50} of 8.3 μM, has antitumor activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC305787 hydrochloride

Cat. No.: HY-18931A

NSC305787 hydrochloride is an inhibitor of **ezrin** with a K_d of 5.85 μM, inhibits the phosphorylation of ezrin caused by PKCI with an IC_{50} of 8.3 μM, has antitumor activity.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC319726

(ZMC1)

Cat. No.: HY-18634

NSC319726 (ZMC1) is a mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NSC348884

Cat. No.: HY-13915

NSC348884 is a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis, inhibits cell proliferation at an IC50 of 1.7-4.0 μM in distinct cancer cell lines.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC5844

(RE-640)

Cat. No.: HY-100033

NSC5844 is a 4-aminoquinoline derivative, with antitumor and antimalarial activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

NSC59984

Cat. No.: HY-19726

NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway. The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC632839

Cat. No.: HY-100708

NSC632839 is a nonselective isopeptidase inhibitor, which inhibits **USP2**, **USP7**, and **SENP2** with EC_{50}s of 45±4 μM, 37±1 μM, and 9.8±1.8 μM, respectively.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC781406

Cat. No.: HY-100470

NSC781406 is a highly potent **PI3K** and **mTOR** inhibitor with an IC_{50} of 2 nM for PI3Kα.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NU 7026

(DNA-PK Inhibitor II; LY293646)

Cat. No.: HY-15719

NU 7026 is a novel specific **DNA-PK** inhibitor with IC_{50} of 0.23±0.01 μM, also inhibits **PI3K** with IC_{50} of 13±3 μM.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NU2058

(O6-(Cyclohexylmethyl)guanine)

Cat. No.: HY-19316

NU2058 is a guanine-based CDK inhibitor with IC50 of 17 μM and 26 μM for CDK2 and CDK1.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NU6140

Cat. No.: HY-107419

NU6140 is a selective **CDK2-cyclin A** inhibitor (IC_{50}, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs. NU6140 also potently inhibits **Aurora A** and **Aurora B**, with IC_{50}s of 67 and 35 nM, respectively. Enhances the apoptotic effect, with anti-cancer activity.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg

NU6300

Cat. No.: HY-18930

NU6300 is the first covalent ATP-competitive CDK2 inhibitor. IC50 value: Target: CDK2 in vitro: NU6300 is a covalent CDK2 inhibitor that illustrates the potential of using vinyl sulfones to mediate irreversible inhibition. NU6300 blocks the inhibitor binding site.



Purity: 97.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nuclear pore complex protein Nup98 315-360

Cat. No.: HY-P1730

Nuclear pore complex protein Nup98 (315-360) is the 315-360 fragment part of the nuclear pore complex (NPC) protein.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Nutlin 3

Cat. No.: HY-50696

Nutlin 3 is a commercial available **p53-MDM2** inhibitor, with K_i of 90 nM.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nutlin 3a

(Nutlin-3a chiral)

Cat. No.: HY-10029

Nutlin 3a is an active enantiomer of Nutlin-3, acts as a murine double minute (**MDM2**) antagonist that inhibits **MDM2-p53** interactions and stabilizes the p53 protein, and thereby induces cell cycle arrest and apoptosis.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Nutlin 3b

(Nutlin-3b)

Cat. No.: HY-15335

Nutlin-3b is a **p53/MDM2** inhibitor with an IC_{50} of 13.6 μM. Nutlin-3b is 150 times less potent in binding to MDM2 than Nutlin-3a.



Purity: 96.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NVP 231

Cat. No.: HY-13945

NVP-231 is a potent, specific, and reversible CerK inhibitor(IC50=12±2 nM) that competitively inhibits binding of ceramide to CerK.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-2

Cat. No.: HY-12214A

NVP-2 is a **CDK9** inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-ACC789

(ACC-789; ZK202650)

Cat. No.: HY-19624

NVP-ACC789 is an inhibitor of human **VEGFR-1**, **VEGFR-2** (mouse **VEGFR-2**), **VEGFR-3** and **PDGFR-β** with IC_{50}s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

NVP-ADW742

(ADW742; GSK 552602A; ADW)

Cat. No.: HY-10252

NVP-ADW742(ADW742; GSK 552602A) is an selective IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-AEW541

(AEW541)

Cat. No.: HY-50866

NVP-AEW541 is a potent inhibitor of **IGF-1R** with IC_{50} of 0.15 μM, also inhibits **InsR**, with IC_{50} of 0.14 μM.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BAG956

(BAG 956) Cat. No.: HY-13333

NVP-BAG956 is an ATP-competitive **PI3K** inhibitor with **IC50**s of 34, 56, 112 and 444 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

NVP-BHG712 isomer

Cat. No.: HY-13258

NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BSK805

(BSK 805) Cat. No.: HY-14722

NVP-BSK805 is an ATP-competitive **JAK2** inhibitor, with **IC_{50}**s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NVP-BSK805 dihydrochloride

(BSK805 dihydrochloride) Cat. No.: HY-14722A

NVP-BSK805 dihydrochloride is an ATP-competitive **JAK2** inhibitor, with **IC_{50}**s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BVU972

Cat. No.: HY-15456

NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM). Antitumor agents.



Purity: 97.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NVP-CGM097

(CGM097) Cat. No.: HY-15954

NVP-CGM097 is a potent and selective **MDM2** inhibitor with **IC_{50}** of 1.7±0.1 nM for **hMDM2**.



Purity: 98.32%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-CGM097 sulfate

(CGM097 sulfate) Cat. No.: HY-15954B

NVP-CGM097 sulfate is a potent and selective **MDM2** inhibitor with **IC_{50}** of 1.7±0.1 nM for **hMDM2**.



Purity: 98.83%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-HSP990

(HSP-990) Cat. No.: HY-15190

NVP-HSP990 is a potent and selective **Hsp90** inhibitor, with **IC_{50}** values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NVP-LCQ195

(LCQ-195; AT9311) Cat. No.: HY-15241

NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

NVP-QAV-572

Cat. No.: HY-16355

NVP-QAV-572 is a **PI3K** inhibitor extracted from patent US7998990B2, Compound Example 8, has an **IC_{50}** of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NVP-TAE 226

(TAE226) Cat. No.: HY-13203

NVP-TAE 226 is a dual tyrosine kinase inhibitor of **FAK** (IC_{50}=5.5 nM) and **IGF-IR** (mean IC_{50}=0.14 μM).



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-TAE 684

(TAE 684) Cat. No.: HY-10192

NVP-TAE 684 is a highly potent and selective **ALK** inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC_{50} values between 2 and 10 nM.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-TNKS656

(TNKS656) Cat. No.: HY-13990

NVP-TNKS656 is a highly potent, selective, and orally active **TNKS2** inhibitor with IC_{50} of 6 nM, and is > 300 fold selectivity against **PARP1** and **PARP2**.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NVS-PAK1-1

Cat. No.: HY-100519

NVS-PAK1-1 is a potent and selective allosteric **PAK1** inhibitor with an IC_{50} of 5 nM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NVX-207

Cat. No.: HY-101597

NVX-207 is a derivative of betulinic acid with anti-cancer activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NXT629

Cat. No.: HY-114263

NXT629 is a potent, selective, and competitive **PPAR-α** antagonist, with an IC_{50} of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC_{50}s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NY-BR-1 p904 A2

Cat. No.: HY-P1914

NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Obatoclax

(Obatoclax Mesylate; GX15-070) Cat. No.: HY-10969

Obatoclax is an inhibitor of the **BCL-2** family proteins. It binds to **BCL-2** with a K_i of 220 nM.



Purity: 99.20%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Obinutuzumab

(GA101; Anti-Human CD20 type II, Humanized Antibody) Cat. No.: HY-P9910

Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Obinutuzumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ochratoxin B

Cat. No.: HY-N6786

Ochratoxin B, a secondary metabolite of Aspergillus ochraceus, is the nonchlorinated analogue of the mycotoxin Ochratoxin A. Ochratoxin B has been shown to reduce the toxic effects of Ochratoxin A, and it is one of the most potent renal carcinogens in rodents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ODM-203

Cat. No.: HY-119367

ODM-203 is a potent **FGFR** and **VEGFR** families inhibitor with IC_{50}s of 11, 16, 6, 35 nM towards recombinant FGFR1, FGFR2, FGFR3 and FGFR4 as well as 26, 9, 5 nM towards VEGFR1, VEGFR2 and VEGFR3, respectively. ODM-203 exhibits strong anti-tumor activity and induces anti-tumor immunity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

ODM-204

Cat. No.: HY-111421

ODM-204 is novel nonsteroidal dual inhibitor of both **androgen receptor** and **CYP17A1 enzyme**, with IC_{50}s of 80 nM and 22 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

OF-1

Cat. No.: HY-12518

OF-1 is a selective BRPF1B and BRPF2 bromodomain inhibitor with Kd values of 100 nM/500 nM for BRPF1B/BRPF2; 39-fold selectivity over BRD4.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

OICR-0547

Cat. No.: HY-16994

OICR-0547 is a closely related derivative of OICR-9429. OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction, while OICR-0547 cannot bind to WDR5.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

OICR-9429

Cat. No.: HY-16993

OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction with IC50 of 5 uM. inhibit proliferation and induce differentiation .



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olaparib

(AZD2281; KU0059436)

Cat. No.: HY-10162

Olaparib (AZD2281;KU0059436) is a potent and oral **PARP** inhibitor with IC_{50}s of 5 and 1 nM for **PARP1** and **PARP2**, respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Oleandrin

Cat. No.: HY-13719

Oleandrin inhibits the **Na^+, K^+-ATPase** activity with an IC_{50} of 620 nM.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Oleanolic Acid

(Oleanic acid; Caryophyllin)

Cat. No.: HY-N0156

Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg, 500 mg

Oleanonic acid

(3-Oxooleanolic acid)

Cat. No.: HY-N1487

Oleanolic acid is a triterpenoid, inhibits infection by HIV-1 in in vitro infected PBMC, naturally infected PBMC and monocyte/macrophages with EC50 of 22.7 mM, 24.6 mM and 57.4 mM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Oligomycin A

(MCH 32)

Cat. No.: HY-16589

Oligomycin A, created by Streptomyces, acts as a mitochondrial **F_0F_1-ATPase** inhibitor, with a K_i of 1 μM; Oligomycin A shows anti-fungal activity.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Olmutinib

(HM61713, BI 1482694) Cat. No.: HY-19730

Olmutinib (HM61713; BI-1482694) is an irreversible **EGFR** tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Oltipraz

(RP 35972; NSC 347901) Cat. No.: HY-12519

Oltipraz has an inhibitory effect on HIF-1α activation in a time-dependent manner, completely abrogating HIF-1α induction at ≥10 μM concentrations, the IC50 of Oltipraz for HIF-1α inhibition is 10 μM.

Purity: 99.82%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Olutasidenib

(FT-2102) Cat. No.: HY-114226

Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase 1 **(IDH1)** that could be used in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ombrabulin

(AVE8062; AC7700) Cat. No.: HY-14797

Ombrabulin (AVE8062) is a derivative of CA-4 phosphate, which is known to exhibit antivascular effects through selective disruption of the **tubulin** cytoskeleton of endothelial cells.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 20 mg

Ombrabulin hydrochloride

(AVE8062 (hydrochloride); AC7700 (hydrochloride)) Cat. No.: HY-18256

Ombrabulin hydrochloride is a derivative of CA-4 phosphate, which is known to exhibit antivascular effects through selective disruption of the **tubulin** cytoskeleton of endothelial cells.



Purity: 99.57%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Omipalisib

(GSK2126458; GSK458) Cat. No.: HY-10297

Omipalisib (GSK2126458) is a highly selective and potent inhibitor of **PI3K** with K_is of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively.



Purity: 99.31%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ON 146040

Cat. No.: HY-12338

ON 146040 is a potent **PI3Kα** and **PI3Kδ** (IC_{50}≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits **Abl1** (IC_{50}<150 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ON-013100

Cat. No.: HY-112822

ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit **Cyclin D1** expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ON123300

Cat. No.: HY-12624

ON123300 is a potent inhibitor of CDK4, with an IC50 of 3.8 nM, with little inhibitory activity against CDKs 1,2,5 and 8.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Onalespib

(AT13387) Cat. No.: HY-14463

Onalespib (AT13387) is a potent inhibitor of **Hsp90**, with a K_d of 0.71 nM.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ONC212

Cat. No.: HY-111343

ONC212, a fluorinated-ONC201 analogue, is a promising anti-cancer drug and also a selective agonist of **GPR132**.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Oncrasin-1

Cat. No.: HY-16662

Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations; also led to abnormal aggregation of PKCι in nucleus of sensitive cells but not in resistant cells.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ONO-4059 analog

Cat. No.: HY-18951

ONO-4059 analog is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ONO-AE3-208

(AE 3-208)

Cat. No.: HY-50901

ONO-AE3-208 is an **EP4** antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.

Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Opaganib

(ABC294640)

Cat. No.: HY-16015

Opaganib (ABC294640) is a selective, competitive sphingosine kinase 2 (**SK2**) inhibitor with K_i of 9.8 μM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ophiobolin A

Cat. No.: HY-N6781

Ophiobolin A, a fungal metabolite and a phytotoxin, is a potent and irreversibly inhibitor of **calmodulin-activated cyclic nucleotide phosphodiesterase**, with an IC_{50} value of 9 μM. Ophiobolin A antimicrobial and anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oprozomib

(ONX 0912; PR-047)

Cat. No.: HY-12113

Oprozomib (ONX 0912; PR047) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.



Purity: 99.60%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Orantinib

(SU6668; TSU-68)

Cat. No.: HY-10517

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for **Flt-1**, **PDGFRβ** and **FGFR1**, respectively.



Purity: 99.02%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ORIC-101

Cat. No.: HY-112710

ORIC-101 is a highly potent and selective **glucocorticoid receptor** antagonist, with an EC_{50} of 5.6 nM. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Oridonin

(NSC-250682; Isodonol)

Cat. No.: HY-N0004

Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of **AKT**, with IC_{50}s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Orotic acid

(6-Carboxyuracil; Vitamin B13) Cat. No.: HY-N0157

Orotic acid (OA) is an intermediate in pyrimidine metabolism.



Purity: 95.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Oroxylin A

(Baicalein 6-methyl ether; 6-Methoxybaicalein) Cat. No.: HY-N0560

Oroxylin A is a natural active flavonoid with strong anticancer effects. IC50 value: Target: In vitro: Oroxylin A suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells .



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Orteronel

(TAK-700) Cat. No.: HY-10505

Orteronel is a highly selective inhibitor of human **17,20-lyase** with **IC_{50}** of 38 nM, and exhibits >1000-fold selectivity over other CYPs such as 11-hydroxylase and CYP3A4.



Purity: 99.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ORY-1001(trans)

Cat. No.: HY-12782T

ORY-1001 trans is a selective irreversible lysine (K)-specific demethylase 1A (**KDM1A/LSD1**) inhibitor.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Osajin

(CID 95168; NSC 21565) Cat. No.: HY-N3125

Osajin is the major bioactive isoflavone present in the fruit of Maclura pomifera with antitumor, antioxidant and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

OSI-027

Cat. No.: HY-10423

OSI-027 is an ATP-competitive **mTOR** kinase activity inhibitor with an **IC_{50}** of 4 nM. OSI-027 targets both **mTORC1** and **mTORC2** with **IC_{50}**s of 22 nM and 65 nM, respectively.



Purity: 98.60%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

OSI-930

Cat. No.: HY-10204

OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl.



Purity: 97.23%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Osilodrostat

(LCI699) Cat. No.: HY-16276

Osilodrostat (LCI699) is a potent inhibitor of human **11β-hydroxylase** and **aldosterone synthase** with **IC_{50}** values of 2.5 and 0.7 nM, respectively.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Osimertinib

(AZD-9291; Mereletinib) Cat. No.: HY-15772

Osimertinib (AZD-9291) is an irreversible and mutant selective **EGFR** inhibitor with **IC_{50}**s of 12 and 1 nM against $EGFR^{L858R}$ and $EGFR^{L858R/T790M}$, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib dimesylate

(AZD-9291 (dimesylate); Mereletinib (dimesylate)) Cat. No.: HY-79077

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective **EGFR** inhibitor with **IC_{50}**s of 12 and 1 nM against $EGFR^{L858R}$ and $EGFR^{L858R/T790M}$, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Osimertinib mesylate

(AZD-9291 mesylate; Mereletinib mesylate) Cat. No.: HY-15772A

Osimertinib mesylate (AZD-9291 mesylate) is an irreversible and mutant selective **EGFR** inhibitor with **IC_{50}**s of 12 and 1 nM against $EGFR^{L858R}$ and $EGFR^{L858R/T790M}$, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

OSIP-486823

(OSIP 486823; OSIP486823; CP248) Cat. No.: HY-U00004

OSIP-486823 is a novel **microtubule**-interfering agent with distinct biological effects on both protein kinase G (PKG) and microtubules.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Ospemifene

(FC-1271a) Cat. No.: HY-B0723

Ospemifene is a selective estrogen for the prevention of postmenopausal osteoporosis with IC50 values of 827nM and 1633nM for ERα and ERβ, respectively.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

OSS_128167

Cat. No.: HY-107454

OSS_128167 is a selective **SIRT6** inhibitor with **IC_{50}**s of 89, 1578 and 751 μM for **SIRT6**, **SIRT1** and **SIRT2**, respectively.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Osthole

(NSC 31868; Osthol; Ostol) Cat. No.: HY-N0054

Osthole is a natural antihistamine alternative. Osthole may be a potential inhibitor of **histamine H_1 receptor** activity.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 1 g, 5 g

OSU-T315

Cat. No.: HY-18676

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase **(ILK)** inhibitor with an IC_{50} of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain).



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

OTS-964

Cat. No.: HY-12467

OTS-964 is a potent **T-lymphokine-activated killer cell-originated protein kinase (TOPK)** inhibitor (**IC_{50}**=28 nM), which inhibits TOPK kinase activity with high affinity and selectivity.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

OTS186935

Cat. No.: HY-122181

OTS186935 is a protein methyltransferase **SUV39H2** inhibitor with an **IC_{50}** of 6.49 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

OTS514

Cat. No.: HY-18621

OTS514 is a highly potent **TOPK** inhibitor, which inhibits TOPK kinase activity with a median inhibitory concentration (**IC_{50}**) value of 2.6 nM.



Purity: 95.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

OTSSP167

Cat. No.: HY-15512

OTSSP167 is a highly potent **MELK** inhibitor with **IC_{50}** value of 0.41 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

OTSSP167 hydrochloride

Cat. No.: HY-15512A

OTSSP167 (hydrochloride) is a highly potent **MELK** inhibitor with **IC_{50}** value of 0.41 nM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

OTX008

(Calixarene 0118; PTX008)

Cat. No.: HY-19756

OTX008 is a selective inhibitor of **galectin-1**.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Oxaliplatin

Cat. No.: HY-17371

Oxaliplatin is a **DNA synthesis** inhibitor. It causes DNA crosslinking damage, prevents DNA replication and transcription and causes cell death.



Purity: 99.86%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg

Oxamflatin

(Metacept-3)

Cat. No.: HY-102033

Oxamflatin (Metacept-3) is a potent **HDAC** inhibitor with an **IC_{50}** of 15.7 nM.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Oxidopamine hydrobromide

(6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide)

Cat. No.: HY-B1081A

Oxidopamine (hydrobromide), an antagonist of the **neurotransmitter dopamine**, is a widely used neurotoxin that selectively destroys dopaminergic neurons.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Oxindole

(Indolin-2-one)

Cat. No.: HY-Y0061

Oxindole (Indolin-2-one) is an aromatic heterocyclic building block. 2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Oxyphenisatine

(Oxyphenisatin)

Cat. No.: HY-B2102

Oxyphenisatine (Oxyphenisatin) is a laxative. Oxyphenisatin acetate is the pro-drug of oxyphenisatin with anticancer activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Oxythiamine

(Hydroxythiamin)

Cat. No.: HY-107430

Oxythiamine, an antimetabolite and a **vitamin B1** antagonist, is a well-known **thiamine** antagonist and inhibitor of **transketolase**.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

P 22077

Cat. No.: HY-13865

P 22077 is a cell-permeable **ubiquitin-specific protease 7 (USP7)** inhibitor with an **EC_{50}** of 8.01 μM. It also inhibits USP47 with an **EC_{50}** of 8.74 μM.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

p-Coumaric acid

(trans-4-Hydroxycinnamic acid)

Cat. No.: HY-N0351

p-Coumaric acid is the abundant isomer of cinnamic acid which has antitumor and anti-mutagenic activities.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 1 g

P-gp inhibitor 1

Cat. No.: HY-101791

P-gp inhibitor 1 is a novel inhibitor reversing **P-glycoprotein**-mediated multidrug resistance.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

P-gp modulator 1

Cat. No.: HY-112912

P-gp modulator 1 is a high affinity, orally available modulator of **P-glycoprotein (Pgp)**, can reverse the Pgp-mediated multidrug resistance ((MDR).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

P005091

(P5091)

Cat. No.: HY-15667

P005091 is a selective and potent inhibitor of **ubiquitin-specific protease 7 (USP7)** with an EC_{50} of 4.2 μM.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

p32 Inhibitor M36

(M36)

Cat. No.: HY-124718

p32 inhibitor M36 (M36) is a **p32** mitochondrial protein inhibitor, which binds directly to p32 and inhibits p32 association with LyP-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

p38 MAPK-IN-1

Cat. No.: HY-12839

p38 MAPK-IN-1 is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM, shows sustained levels, low clearance and good bioavailability.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

p53 17-26

Cat. No.: HY-P1755

p53 (17-26) is amino acids 17 to 26 fragment of p53. p53 (17-26) is mdm-2-binding domain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

p53 and MDM2 proteins-interaction-inhibitor chiral

Cat. No.: HY-70027

p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.



Purity: 97.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 100 mg

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride

Cat. No.: HY-70027A

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 100 mg

p53 and MDM2 proteins-interaction-inhibitor racemic

Cat. No.: HY-70028

p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 100 mg

PAC

Cat. No.: HY-112100

PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PAC-1

(Procaspase activating compound 1)

Cat. No.: HY-13523

PAC-1 is an activator of **procaspase-3** induces apoptosis in cancer cells with **EC_{50}** of 2.08 μM.



Purity: 95.98%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

Pachymic acid

(3-O-Acetyltumulosic acid)

Cat. No.: HY-N0371

Pachymic acid is a lanostrane-type triterpenoid from P. cocos. Pachymic acid inhibits **Akt** and **ERK** signaling pathways.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Paclitaxel

(Taxol)

Cat. No.: HY-B0015

Paclitaxel (Taxol), a naturally occurring antineoplastic agent, stabilizes **tubulin polymerization**, resulting in arrest at the G2/M phase of the cell cycle and apoptotic cell death.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Pacritinib

(SB1518)

Cat. No.: HY-16379

Pacritinib is a potent inhibitor of both wild-type **JAK2** (IC_{50}=23 nM) and **$JAK2^{V617F}$** mutant (IC_{50}=19 nM). Pacritinib also inhibits **FLT3** (IC_{50}=22 nM) and its mutant **$FLT3^{D835Y}$** (IC_{50}=6 nM).



Purity: 99.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PAK-IN-1

Cat. No.: HY-12632

PAK-IN-1 is a **PAK** inhibitor that displays group II selectivity. PAK-IN-1 inhibits PAK4, PAK5 and PAK6 with **IC_{50}**s of 7.5, 36, 126 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Palbociclib

(PD 0332991)

Cat. No.: HY-50767

Palbociclib (PD 0332991) is a selective **CDK4** and **CDK6** inhibitor with **IC_{50}**s of 11 and 16 nM, respectively. Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer.



Purity: 99.96%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Palbociclib hydrochloride

(PD 0332991 hydrochloride)

Cat. No.: HY-50767A

Palbociclib hydrochloride is a highly selective **CDK4/6** inhibitor with **IC_{50}**s of 11 nM and 16 nM, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Palbociclib isethionate

(PD 0332991 isethionate)

Cat. No.: HY-A0065

Palbociclib isethionate is a highly selective inhibitor of **CDK4/6** with **IC_{50}**s of 11 nM/16 nM, respectively. .



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Palifosfamide

(Isophosphoramide mustard; IPM; ZIO-201)

Cat. No.: HY-14798

Palifosfamide is a novel DNA alkylator and the active metabolite of ifosfamide, with antitumor activity.



Purity: >95.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Palomid 529

(P529)

Cat. No.: HY-14581

Palomid 529 is a potent inhibitor of **mTORC1** and **mTORC2** complexes.



Purity: 99.42%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pamapimod

(Ro4402257; R1503)

Cat. No.: HY-10405

Pamapimod is a novel p38 mitogen-activated protein kinase inhibitor. Pamapimod inhibited p38α and p38β enzymatic activity, with IC50 values of 0.014 ± 0.002 and 0.48 ± 0.04 μM, respectively. Pamapimod is p38 inhibitor with IC50 of 0.06μM in THP-1 cell.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Pamidronic acid

Cat. No.: HY-B0012

Pamidronic acid is a drug used to treat a broad spectrum of bone absorption diseases.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Pamiparib

(BGB-290)

Cat. No.: HY-104044

Pamiparib is a **PARP** inhibitor which can be used for the treatment of various cancers including the solid tumor, extracted from patent WO 2013097225 A1.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pan-RAS-IN-1

Cat. No.: HY-101295

Pan-RAS-IN-1 is a **pan-Ras** inhibitor that disrupts the interaction of Ras proteins and their effectors.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Panaxadiol

(20(R)-Panaxadiol)

Cat. No.: HY-N0596

Panaxadiol is a novel antitumor agent extracted from the Chinese medical herb Panax ginseng.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Panobinostat

(LBH589; NVP-LBH589)

Cat. No.: HY-10224

Panobinostat is a non-selective histone deacetylase (**HDAC**) inhibitor.



Purity: 98.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Paradol

([6]-Gingerone; [6]-Paradol)

Cat. No.: HY-14617

Paradol is a pungent phenolic substance found in ginger and other Zingiberaceae plants. Paradol is an effective inhibitor of tumor promotion in mouse skin carcinogenesis, binds to **cyclooxygenase (COX)-2** active site.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PARP-2-IN-1

Cat. No.: HY-102035

PARP-2-IN-1 is a potent and selective **PARP-2** inhibitor with an IC_{50} of 11.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Parsaclisib

(INCB050465)

Cat. No.: HY-109068

Parsaclisib is a potent and selective **PI3Kδ** inhibitor, with an IC_{50} of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Parthenolide

((-)-Parthenolide)

Cat. No.: HY-N0141

Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting **NF-κB** activation; also inhibits **HDAC1** protein without affecting other class I/II HDACs.



Purity: 99.88%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Pazopanib

(GW786034) Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with **IC_{50}**s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride)) Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an **IC_{50}** of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

PBIT

Cat. No.: HY-101451

PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1(**JARID1**) enzymes. PBIT inhibits **JARID1B** (**KDM5B** or **PLU1**) histone demethylase an **IC_{50}** of about 3 μM . PBIT also inhibits **JARID1A** and **JARID1C** with **IC5** s of 6 and 4.9 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg

PBOX 6

Cat. No.: HY-U00446

PBOX 6 is a pyrrolo-1,5-benzoxazepine (PBOX) compound, acts as a **microtubule**-depolymerizing agent and an apoptotic agent.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PCI-27483

Cat. No.: HY-16382

PCI-27483 is a **FVIIa/tissue factor** inhibitor, with antitumour effects.



Purity: 95.29%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

PCI-34051

Cat. No.: HY-15224

PCI-34051 is a potent and selective **HDAC8** inhibitor with **IC_{50}** of 10 nM, with >200-fold selectivity over the other HDAC isoforms.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PD 169316

Cat. No.: HY-10578

PD 169316 is a potent, cell-permeable and selective **p38 MAP kinase** inhibitor, with **IC_{50}** of 89 nM.

Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PD-1-IN-17

Cat. No.: HY-101097

PD-1-IN-17 is a programmed cell death- 1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PD-1-IN-17 TFA

Cat. No.: HY-101097A

PD-1-IN-17 TFA is a programmed cell death- 1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

PD-1-IN-20

Cat. No.: HY-101093B

PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PD-1-IN-22

Cat. No.: HY-128605

PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC_{50} of 92.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PD-166866

Cat. No.: HY-101296

PD166866 is a selective **FGFR1** tyrosine kinase inhibitor with an IC_{50} of 52.4 nM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD0166285

Cat. No.: HY-13925

PD0166285 is a **WEE1** inhibitor and a weak **Myt1** inhibitor with IC_{50}s of 24 and 72 nM, respectively.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD0325901

(PD325901)

Cat. No.: HY-10254

PD0325901 is a selective and cell permeable **MEK** inhibitor with an IC_{50} of 0.33 nM.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD150606

Cat. No.: HY-100529

PD 150606 is a selective, cell-permeable non-peptide **calpain** inhibitor with K_i values of 0.21 μM and 0.37 μM for μ- and m-calpains respectively, which is neuroprotective.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD153035

(SU-5271; AG1517; ZM 252868)

Cat. No.: HY-14346

PD153035 (SU-5271; AG1517; ZM 252868) is a potent **EGFR** inhibitor with K_i and IC_{50} of 6 and 25 pM, respectively.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PD153035 Hydrochloride

(SU-5271 (Hydrochloride); AG1517 (Hydrochloride); ZM 252868 (Hydrochloride))

Cat. No.: HY-12013

PD153035 Hydrochloride (SU-5271 Hydrochloride) is a potent **EGFR** inhibitor with K_i and IC_{50} of 6 and 25 pM, respectively.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PD158780

Cat. No.: HY-18609

PD158780 is a potent **EGFR** family inhibitor with IC_{50}s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PD168393

Cat. No.: HY-13896

PD168393 is an potent, cell-permeable, irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773, inactive against insulin, PDGFR, FGFR and PKC.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

PD173074

Cat. No.: HY-10321

PD173074 is a potent **FGFR1** inhibitor with an IC_{50} of 25 nM and also inhibits **VEGFR2** with an IC_{50} of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

PD173955

Cat. No.: HY-10395

PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PD176252

Cat. No.: HY-103286

PD176252 is a potent antagonist of neuromedin-B preferring (BB_1) and gastrin-releasing peptide-preferring (BB_2) receptor with K_is of 0.17 nM and 1 nM for human BB_1 and BB_2 receptors, and 0.66 nM, 16 nM for Rat BB_1 and BB_2 receptors, respectively; PD176252 is also...



Purity: >99.0%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg

PD318088

Cat. No.: HY-12062

PD318088 is an allosteric **MEK** inhibitor.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PD98059

Cat. No.: HY-12028

PD98059 is a potent, selective and cell-permeable **MEK1** and **MEK2** inhibitor with IC_{50}s of 4 μM and 50 μM respectively.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PDD 00017273

Cat. No.: HY-108360

PDD 00017273 is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (**PARG**), with an IC_{50} of 26 nM, and a K_D of 1.45 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PDGFRα kinase inhibitor 1

Cat. No.: HY-111507

PDGFRα kinase inhibitor 1 is a highly selective type II **PDGFRα** kinase inhibitor with IC_{50}s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Pelitinib

(EKB-569; WAY-EKB 569)

Cat. No.: HY-32718

Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: 98.18%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pelitrexol

(AG 2037)

Cat. No.: HY-14530

Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase (**GARFT**).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Pembrolizumab

(MK-3475; Lambrolizumab)

Cat. No.: HY-P9902

Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (**PD-1**) receptor, used in cancer immunotherapy.

Pembrolizumab

Purity: 98.56%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pemetrexed

(LY231514)

Cat. No.: HY-10820

Pemetrexed is a novel **antifolate**, the K_i values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (**TS**), dihydrofolate reductase (**DHFR**), and glycinamide ribonucleotide formyltransferase (**GARFT**), respectively.



Purity: 99.30%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Pemetrexed disodium

(LY231514 disodium) Cat. No.: HY-10820A

Pemetrexed disodium is a novel **antifolate** that inhibits the folatedependent enzymes **thymidylate synthase**, **dihydrofolate reductase**, and **glycinamide ribonucleotide formyltransferase** with K_is of 1.3, 7.2, and 65 nM, respectively.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Pemetrexed disodium hemipenta hydrate

(LY231514 (disodium hemipenta hydrate)) Cat. No.: HY-13781

Pemetrexed disodium hemipenta hydrate is a novel **antifolate**, the K_i values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (**TS**), dihydrofolate reductase (**DHFR**), and glycinamide ribonucleotide formyltransferase (**GARFT**), respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Pemigatinib

Cat. No.: HY-109099

Pemigatinib is a selective **FGFR** inhibitor in development for the treatment of patients with cholangiocarcinoma.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Penicillic acid

Cat. No.: HY-N6777

Penicillic acid is a polyketide mycotoxin produced by several species of Aspergillus and Penicillium, which exhibits cytotoxicity in rat alveolar macrophages (AM) in vitro. Penicillic acid inhibits Fas ligand-induced apoptosis by blocking self-processing of caspase-8.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Penitrem A

Cat. No.: HY-N6776

Penitrem A is an indole diterpene neurotoxic alkaloid produced by Penicillium, acts as a selective **BK channel** antagonist with antiproliferative and anti-invasive activities against multiple malignancies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pentagastrin

(ICI-50123) Cat. No.: HY-A0261

Pentagastrin is a synthetic polypeptide that has effects like gastrin when given parenterally, which can cause the secretion and synthesis of salivary proteins.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pentostatin

(CI-825; Deoxycoformycin) Cat. No.: HY-A0006

Pentostatin is an irreversible inhibitor of **adenosine deaminase** with K_i of 2.5 pM.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Peretinoin

(NIK333) Cat. No.: HY-100008

Peretinoin is an oral acyclic retinoid retinoid with a vitamin A-like structure that targets retinoid nuclear receptors. Peretinoin reduces the **mRNA** level of **sphingosine kinase 1 (SPHK1)** in vitro by downregulating a transcription factor, Sp1.



Purity: 98.38%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Perhexiline maleate

Cat. No.: HY-B1334A

Perhexiline maleate is a potent **carnitine palmitoyltransferase 1 (CPT 1)** inhibitor with IC_{50}s of 77 and 148 μM for rat heart and liver CPT 1, respectively.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Perifosine

(KRX-0401; NSC 639966; D21266) Cat. No.: HY-50909

Perifosine is an oral **Akt** inhibitor which inhibits proliferation of different tumor cell lines with IC_{50}s of 0.6-8.9 μM.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pertuzumab

Cat. No.: HY-P9912

Pertuzumab, a humanized monoclonal antibody, is a **HER2** dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

Pertuzumab

Purity: 99.10%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pevonedistat

(MLN4924)

Cat. No.: HY-70062

Pevonedistat (MLN4924) is a potent and selective **NEDD8-activating enzyme** (**NAE**) inhibitor with an IC_{50} of 4.7 nM.



Purity: 98.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Pevonedistat hydrochloride

(MLN4924 (hydrochloride))

Cat. No.: HY-10484

Pevonedistat hydrochloride (MLN4924 hydrochloride) is a potent and selective NEDD8-activating enzyme (**NAE**) inhibitor, with an IC_{50} of 4.7 nM.



Purity: 98.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Pexidartinib

(PLX-3397)

Cat. No.: HY-16749

Pexidartinib (PLX-3397) is a potent, selective and ATP-competitive **CSF1R (cFMS)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively. Pexidartinib exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Anti-tumor activity.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Pexidartinib hydrochloride

(PLX-3397 hydrochloride)

Cat. No.: HY-16749A

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, selective and ATP-competitive **CSF1R (cFMS)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pexmetinib

(ARRY-614)

Cat. No.: HY-16782

Pexmetinib is a potent **Tie-2** and **p38 MAPK** dual inhibitor, with IC_{50}s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 is a potent, selective ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, 100-fold selectivity versus **Chk2** (K_i, 47 nM).



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-03814735

Cat. No.: HY-14574

PF-03814735 is a potent, orally available and reversible **aurora A** and **aurora B** inhibitor with IC_{50}s of 0.8 and 0.5 nM, respectively.



Purity: 99.77%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-04217903

Cat. No.: HY-12017

PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).



Purity: 99.59%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-04217903 methanesulfonate

Cat. No.: HY-12017A

PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).



Purity: 99.87%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-04418948

Cat. No.: HY-18966

PF-04418948 is an orally active, potent and selective **prostaglandin EP2 receptor** antagonist with an IC_{50} of 16 nM.



Purity: 99.60%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-04691502

Cat. No.: HY-15177

PF-04691502 is a potent and selective inhibitor of **PI3K** and **mTOR**. PF-04691502 binds to human PI3Kα, β, δ, γ and mTOR with K_is of 1.8, 2.1, 1.6, 1.9 and 16 nM, respectively.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-04957325

Cat. No.: HY-15426

PF-04957325 is a highly potent and selective **PDE8** inhibitor, with IC_{50}s of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PF-04979064

Cat. No.: HY-100398

PF-04979064 is a potent and selective **PI3K/mTOR** dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PF-06380101

Cat. No.: HY-12522

PF-06380101 is a novel cytotoxic Dolastatin 10 analogue; with excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

PF-06459988

Cat. No.: HY-19985

PF-06459988 is an irreversible inhibitor of T790M-Containing EGFR Mutants.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-06465469

Cat. No.: HY-108691

PF-06465469 is a covalent inhibitor of **ITK** with an IC_{50} of 2nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06726304

Cat. No.: HY-103682

PF-06726304 is a potent and selective **EZH2** inhibitor with a K_i of 0.7 nM.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PF-06821497

Cat. No.: HY-101571A

PF-06821497 (compound 23a) is a potent, selective and orally active **Enhancer of Zeste Homolog 2 (EZH2)** inhibitor, with a K_i value <0.1 nM against mutant Y641N EZH2. Exhibits robust tumor growth inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PF-06840003

(EOS200271)

Cat. No.: HY-101111

PF-06840003 is a highly selective orally bioavailable **IDO-1** inhibitor.



Purity: 99.80%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PF-06873600

Cat. No.: HY-114177

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase **(CDK)**, with K_i values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-2771

Cat. No.: HY-19530

PF-2771 is a potent and selective **centromere protein E (CENP-E)** inhibitor, inhibiting CENP-E motor activity with an IC_{50} of 16.1 nM; PF-2771 is used as an anticancer agent.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-3758309

Cat. No.: HY-13007

PF-3758309 is an inhbitor of **PAK** with IC_{50} of 1.3 nM for PAK4.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-431396

Cat. No.: HY-10460

PF-431396 is dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively), PF-431396 has a Kd value of 445 nM for BRD4.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

PF-4708671

Cat. No.: HY-15773

PF-4708671 is a potent cell-permeable **S6K1** inhibitor with a K_i of 20 nM and IC_{50} of 160 nM.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PF-4989216

Cat. No.: HY-13864

PF-4989216 is a potent and selective **PI3Kα** inhibitor with a K_i of 0.6 nM.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-5274857

Cat. No.: HY-13459

PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and can penetrate the blood–brain barrier.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-543

(Sphingosine Kinase 1 Inhibitor II)

Cat. No.: HY-15425

PF-543 is a novel cell-permeant inhibitor of **SPHK1** with a K_i of 4.3 nM and more than 100-fold selectivity for SPHK1 over SPHK2.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

PF-543 Citrate

(Sphingosine Kinase 1 Inhibitor II (Citrate))

Cat. No.: HY-15425A

PF-543 Citrate is a novel cell-permeant inhibitor of **SPHK1** with a K_i of 4.3 nM and more than 100-fold selectivity for SPHK1 over SPHK2.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-562271

Cat. No.: HY-10459

PF-562271 is a potent ATP-competitive, reversible inhibitor of **FAK** and **Pyk2** kinase, with an IC_{50} of 1.5 nM and 13 nM, respectively.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-562271 besylate

(PF562271 besylate; PF 562271 besylate)

Cat. No.: HY-10458

PF-562271 besylate is a potent ATP-competitive, reversible inhibitor of **FAK** and **Pyk2** kinase, with an IC_{50} of 1.5 nM and 13 nM, respectively.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-573228

Cat. No.: HY-10461

PF-573228 is a potent and selective **FAK** inhibitor with IC_{50} of 4 nM for purified recombinant catalytic fragment of FAK.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PF-670462

Cat. No.: HY-15490

PF-670462 is a potent and selective inhibitor of **casein kinase (CK1ε and CK1δ)**, with IC_{50}s of 7.7 nM and 14 nM, respectively.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PF-8380

Cat. No.: HY-13344

PF-8380 is a potent **autotaxin** inhibitor with an IC_{50} of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-8380 hydrochloride

Cat. No.: HY-13344A

PF-8380 hydrochloride is a potent **autotaxin** inhibitor with an IC_{50} of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-9366

Cat. No.: HY-107778

PF-9366 is a human methionine adenosyltransferase 2A (**Mat2A**) inhibitor, with an IC_{50} of 420 nM and a K_d of 170 nM.



Purity: 97.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-AKT400

(AKT protein kinase inhibitor)

Cat. No.: HY-10721

PF-AKT400 is a broadly selective, potent, ATP-competitive **Akt** inhibitor, displays 900-fold greater selectivity for **PKBα** (IC_{50}=0.5 nM) than **PKA** (IC_{50}=450 nM).



Purity: 95.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PFI-1

Cat. No.: HY-16586

PFI-1 is a selective **BET** (bromodomain-containing protein) inhibitor for BRD4 with IC_{50} of 0.22 μM in a cell-free assay.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PFI-2

((R)-PFI-2)

Cat. No.: HY-18627

PFI-2 is a a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC50 of 2 nM, 500 fold active than (S)-PFI-2.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

PFI-2 hydrochloride

((R)-PFI-2 hydrochloride)

Cat. No.: HY-18627A

PFI-2 hydrochloride is a a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC50 of 2 nM, 500 fold active than (S)-PFI-2.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PFI-3

Cat. No.: HY-12409

PFI-3 is a selective, potent and cell-permeable **SMARCA2/4** bromodomain inhibitor with a K_d of 89 nM.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PFI-4

Cat. No.: HY-18664

PFI-4 is a potent and selective and cell permeable BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of other bromodomains including BRPF2 (BRD1), BRPF3 and BRD4.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PFK-015

Cat. No.: HY-12204

PFK-015 is an effective inhibitor of PFKFB3 with IC50 of 110 nM (recombinant PFKFB3) and inhibits PFKFB3 activity in cancer cells with IC50 of 20 nM.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PFK-158

Cat. No.: HY-12203

PFK-158 is a potent and selective inhibitor of PFKFB3 that is currently being investigated in a phase I study in patients with advanced solid malignancies.



Purity: 98.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PGAM1-IN-1

Cat. No.: HY-128681

PGAM1-IN-1 is a **phosphoglycerate mutase 1** (**PGAM1**) inhibitor with an IC_{50} of 6.4 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PGAM1-IN-2

Cat. No.: HY-128682

PGAM1-IN-2 is a **phosphoglycerate mutase 1** (**PGAM1**) inhibitor with an IC_{50} of 2.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PGMI-004A

Cat. No.: HY-101143

PGMI-004A is a potent **phosphoglycerate mutase 1** (**PGAM1**) inhibitor with an IC_{50} of 13.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PHA-665752

Cat. No.: HY-11107

PHA-665752 is a potent, selective and ATP-competitive inhibitor of **c-Met Kinase**, with an IC_{50} of 9 nM. Has therapeutic potential of targeting c-Met in human cancers.



Purity: 96.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PHA-680632

Cat. No.: HY-10178

PHA-680632 is an **aurora** kinase inhibitor with IC_{50}s of 27, 135 and 120 nM for aurora A, B and C, respectively.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PHA-767491

(CAY10572)

Cat. No.: HY-13461

PHA-767491 is a dual **Cdc7/Cdk9** inhibitor, with IC_{50}s of 10 nM and 34 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

PHA-767491 hydrochloride

(CAY-10572 hydrochloride) Cat. No.: HY-13461A

PHA-767491 hydrochloride is a dual **Cdc7/Cdk9** inhibitor, with IC_{50}s of 10 nM and 34 nM, respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PHA-793887

Cat. No.: HY-11001

PHA-793887 is a potent, ATP-competitive **CDK** inhibitor, can inhibit Cdk2, Cdk1, Cdk4, and Cdk9 with IC_{50}s of 8 nM, 60 nM, 62 nM and 138 nM, respectively, and also inhibits glycogen synthase kinase 3β with an IC_{50} of 79 nM.



Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PHCCC

Cat. No.: HY-100409

PHCCC is a Group I metabotropic glutamate receptor antagonist with EC 50 of 6 uM and a positive allosteric modulator of mGluR4. Also as a potent to antagonism for mGluR2 and mGluR8.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Phen-DC3 Trifluoromethanesulfonate

(Phen-DC3 Triflate) Cat. No.: HY-15594A

Phen-DC3 Trifluoromethanesulfonate is a **G-quadruplex** (G4) specific ligand which can inhibit **FANCJ** and **DinG** helicases with IC_{50}s of 65±6 and 50±10 nM, respectively.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Phenformin hydrochloride

(Phenethylbiguanide hydrochloride) Cat. No.: HY-16397A

Phenformin (hydrochloride) is a hydrochloride salt of phenformin that is an anti-diabetic drug from the biguanide class, can activate **AMPK** activity.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 g, 5 g

Phenoxodiol

(Idronoxil; Dehydroequol; Haginin E) Cat. No.: HY-13721

Phenoxodiol, a synthetic analog of Genestein, activates the mitochondrial **caspase** system, inhibits XIAP (an apoptosis inhibitor), and sensitizes the cancer cells to Fas-mediated apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PhiKan 083

Cat. No.: HY-108637

PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes **Y220C** (a **p53** mutant), with a K_d of 167 μM, and a relative binding affinity (K_d) of 150 μM in Ln229 cells.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PhiKan 083 hydrochloride

Cat. No.: HY-108637A

PhiKan 083 hydrochloride is a carbazole derivative, which binds to the surface cavity and stabilizes **Y220C** (a **p53** mutant), with a K_d of 167 μM, and a relative binding affinity (K_d) of 150 μM in Ln229 cells.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Phorbol

(4β-Phorbol) Cat. No.: HY-N2147

Phorbol is a highly toxic diterpene, whose esters have important biological properties.



Purity: 96.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Phorbol 12,13-dibutyrate

(Phorbol dibutyrate; PDBu) Cat. No.: HY-18985

Phorbol 12,13-dibutyrate (Phorbol dibutyrate) is a **PKC** activator and a potent skin tumor promoter.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PHT-427

Cat. No.: HY-12063

PHT-247 is an inhibitor of the pleckstrin homology (PH) domain of **Akt**, and it is also an inhibitor of **PDPK1** with K_is of 2.7 μM and 5.2 μM and for Akt and PDPK1, respectively.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

PHT-7.3

Cat. No.: HY-128590

PHT-7.3 is a selective inhibitor of **connector enhancer of kinase suppressor of Ras 1 (Cnk1)** pleckstrin homology (PH) domain, which inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PHTPP

Cat. No.: HY-103456

PHTPP is a selective **ERβ** antagonist.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Physcion

(Parietin; Rheochrysidin)

Cat. No.: HY-N0108

Physcion (Parietin) is an anthraquinone isolated from traditional Chinese medicine Radix et Rhizoma Rhei, acts as an inhibitor of **6-phosphogluconate dehydrogenase**, with an IC_{50} and a K_d of 38.5 μM and 26.0 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PI-103

Cat. No.: HY-10115

PI-103 is a potent **PI3K** and **mTOR** inhibitor with IC_{50}s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 also inhibits **DNA-PK** with an **IC50** of 2 nM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI-103 Hydrochloride

Cat. No.: HY-10115A

PI-103 Hydrochloride is a dual **PI3K** and **mTOR** inhibitor with IC_{50}s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 also inhibits **DNA-PK** with an **IC50** of 2 nM.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI-1840

Cat. No.: HY-12286

PI-1840 is a potent and selective inhibitor for chymotrypsin-like (CT-L) (IC50 value = 27 ± 0.14 nM) over trypsin-like and peptidylglutamyl peptide hydrolyzing (IC50 values >100 μM) activities of the proteasome.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

PI3K-IN-1

Cat. No.: HY-12068

PI3K-IN-1 is a potent inhibitor of PI3K, more information can be found in patent WO2012103524 A2 and WO2013147649 A2.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PI3K-IN-6

Cat. No.: HY-101115

PI3K-IN-6 (compound 20a) is an oral active and highly selective **phosphoinositide 3-kinase (PI3K) β/δ** inhibitor, with IC_{50} values of 7.8 nM/5.3 nM for PI3K β/δ, respectively. PI3K-IN-6 (compound 20a) has potential top treat phosphatase and tensin homolog (PTEN) feficient tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PI3K/HDAC-IN-1

Cat. No.: HY-128582

PI3K/HDAC-IN-1 is a potent dual inhibitor of **PI3K/HDAC**, potently inhibits PI3Kδ and HDAC1 with IC_{50}s of 8.1 nM and 1.4 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PI3K/mTOR Inhibitor-1

Cat. No.: HY-112602

PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual **PI3K/mTOR** inhibitor with IC_{50}s of 20/376/204/46 nM and 186 nM for **PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ** and **mTOR**, respectively. Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PI3K/mTOR Inhibitor-2

Cat. No.: HY-111508

PI3K/mTOR Inhibitor-2 is a potent dual pan-**PI3K/mTOR** inhibitor with IC_{50}s of 3.4/34/16/1 nM for **PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ** and 4.7 nM for **mTOR**. Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PI3Kdelta inhibitor 1

Cat. No.: HY-112439

PI3Kdelta inhibitor 1 (Compound 5d) is a potent, selective and orally available **PI3Kδ** inhibitor with an IC_{50} of 1.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PI3Kα/mTOR-IN-1

Cat. No.: HY-U00326

PI3Kα/mTOR-IN-1 is a potent PI3Kα/mTOR dual inhibitor, with an IC_{50} of 7 nM for PI3Kα in a cell assay, and K_is of 10.6 nM and 12.5 nM for mTOR and PI3Kα in a cell free assay , respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

PI3Kγ inhibitor 1

Cat. No.: HY-10549

PI3Kγ inhibitor 1 is a **PI3Kδ** and **PI3Kγ** inhibitor extracted from patent WO2014004470A1, Compound 168 in Table 4, has IC_{50}s of <100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

PI3Kγ inhibitor 3

Cat. No.: HY-112443

PI3Kγ inhibitor 3 is a potent and remarkably selective **PI3Kγ** inhibitor with pIC_{50}s of 9.1, 5.1, <4.5, and 6.5 for **PI3Kγ**, **PI3Kα**, **PI3Kβ**, and **PI3Kδ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PI3kδ inhibitor 1

Cat. No.: HY-15288

PI3kδ inhibitor 1 is a potent and selective **PI3Kδ** inhibitor with an IC_{50} of 3.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

PI3Kδ-IN-2

Cat. No.: HY-102031

PI3Kδ-IN-2 is a potent and selective inhibitor of **PI3Kδ** extracted from patent WO 2015055071 A1, compound 10; has an IC_{50} of 6.4 nM.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PI4KIII beta inhibitor 3

Cat. No.: HY-15679

PI4KIII beta inhibitor 3 is a novel and high effective **PI4KIIIβ** inhibitor with IC_{50} of 5.7 nM.



Purity: 97.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

PI4KIIIbeta-IN-9

Cat. No.: HY-19798

PI4KIIIbeta-IN-9 is a potent **PI4KIIIβ** inhibitor with an IC_{50} of 7 nM. PI4KIIIbeta-IN-9 also inhibits **PI3Kδ** and **PI3Kγ** with IC_{50}s of 152 nM and 1046 nM, respectively.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Piceatannol

(Astringenin; trans-Piceatannol) Cat. No.: HY-13518

Piceatannol is a selective inhibitor of protein tyrosine kinase Syk. It could inhibit ICa,L, Ito, IKr, Ca2+ transients and Na+-Ca2+ exchange except IK1. Shows multiple biological activities such as anti-inflammatory, antiproliferative and immunomodulatory effects.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Picfeltarraenin IB

Cat. No.: HY-N2211

Picfeltarraenin IV, a triterpenoid obtained from Picriafel-terrae Lour (P.fel-terrae), is an acetylcholinesterase (**AChE**) inhibitor. Picfeltarraenin IV can be used for the treatment of herpes infections, cancer and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Picfeltarraenin IV

Cat. No.: HY-N5076

Picfeltarraenin IV, a triterpenoid obtained from Picriafel-terrae Lour (P.fel-terrae), is an acetylcholinesterase (**AChE**) inhibitor. Picfeltarraenin IV can be used for the treatment of herpes infections, cancer and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Piclidenoson

(IB-MECA; CF-101) Cat. No.: HY-13591

Piclidenoson (IB-MECA) is an agonist of the adenosine A3 receptor with EC50 values of 0.11 μM. IC50 value: 0.11 μM (EC50) Target: adenosine A3 receptor in vitro: Piclidenoson has been shown to play important roles in cell proliferation and apoptosis in a variety of cancer cell lines.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Pico145

(HC-608) Cat. No.: HY-101507

Pico145 is a remarkable inhibitor of **TRPC1/4/5** channels, inhibits (−)-englerin A-activated TRPC4/TRPC5 channels, with IC_{50}s of 0.349 and 1.3 nM in cells, and shows no effect on TRPC3, TRPC6, TRPV1, TRPV4, TRPA1, TRPM2, TRPM8.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Picropodophyllin

(AXL1717; Picropodophyllin; PPP) Cat. No.: HY-15494

Picropodophyllin (AXL1717) is a selective **insulin-like growth factor-1 receptor (IGF-1R)** inhibitor with an IC_{50} of 1 nM.



Purity: 99.85%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pictilisib

(GDC-0941) Cat. No.: HY-50094

Pictilisib (GDC-0941) is a potent inhibitor of **PI3Kα/δ** with an IC_{50} of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).



Purity: 99.62%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Pictilisib dimethanesulfonate

(GDC-0941 (dimethanesulfonate) ; GDC-0941 (2 MeSO3H salt)) Cat. No.: HY-20180

Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of **PI3Kα/δ** with IC_{50} of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Pifithrin-α hydrobromide

(Pifithrin hydrobromide; PFTα hydrobromide) Cat. No.: HY-15484

Pifithrin-α hydrobromide is a **p53** inhibitor which blocks its transcriptional activity and prevents cells from apoptosis. Pifithrin-α hydrobromide is also an **aryl hydrocarbon receptor (AhR)** agonist.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Pifithrin-β

(PFT β) Cat. No.: HY-16702

Pifithrin-β is a potent **p53** inhibitor with an IC_{50} of 23 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Pifithrin-β hydrobromide

(PFT β (hydrobromide))

Cat. No.: HY-16702A

Pifithrin-β hydrobromide is a potent **p53** inhibitor with an IC_{50} of 23 μM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pifithrin-μ

(PFTμ; 2-Phenylethynesulfonamide)

Cat. No.: HY-10940

Pifithrin-μ is an inhibitor of **p53** and **HSP70**, with antitumor and neuroprotective activity.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

PIK-294

Cat. No.: HY-10303

PIK-294 is a potent **p110δ**-selective inhibitor with an IC_{50} of 10 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PIK-75

(PIK-75 Hydrochloride)

Cat. No.: HY-13281

PIK-75 is a **DNA-PK** and **PI3K** inhibitor, which inhibits DNA-PK, **p110α** and p110γ with IC_{50}s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC_{50}=1.3 μM).



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PIK-90

Cat. No.: HY-12030

PIK-90 is a **DNA-PK** and **PI3K** inhibitor, which inhibits **p110α**, **p110γ** and **DNA-PK** with IC_{50}s of 11, 18 and 13 nM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PIK-93

Cat. No.: HY-12046

PIK-93 is the first potent, synthetic **PI4K (PI4KIIIβ)** inhibitor with IC_{50} of 19 nM, and also inhibits **PI3Kγ** and **PI3Kα** with IC_{50} of 16 nM and 39 nM, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pilaralisib

(XL-147; SAR245408)

Cat. No.: HY-16526

Pilaralisib (XL147; SAR245408) is a potent and highly selective class I **PI3K**s inhibitor with IC_{50}s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ.



Purity: 98.35%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pilaralisib analogue

(XL147 analogue)

Cat. No.: HY-11105

Pilaralisib analogue (XL147 analogue) is a representative and selective **PI3Kα** inhibitor extracted from patent WO2012006552A1, Compound 147 in Table 1.



Purity: 96.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PIM-447 dihydrochloride

(LGH447 dihydrochloride)

Cat. No.: HY-19322B

PIM447 is a **pan-PIM kinase** inhibitor with K_is of 6, 18, 9 nM for PIM1, PIM2 and PIM3, respectively.



Purity: 99.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PIM1-IN-1

Cat. No.: HY-111552

PIM1-IN-1 is a potent and highly selective **PIM1/3** inhibitor, with IC_{50}s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC_{50} of 262 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Pim1/AKK1-IN-1

(LKB1/AAK1 dual inhibitor) Cat. No.: HY-10371

Pim1/AKK1-IN-1 is a potent multi-kinase inhibitor with K_d values of 35 nM/53 nM/75 nM/380 nM for **Pim1/AKK1/MST2/LKB1** respectively, and also inhibits MPSK1 and TNIK.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PIM447

(LGH447) Cat. No.: HY-19322

PIM447 is novel pan-PIM kinase inhibitor, including Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Pimasertib

(AS703026; MSC1936369B) Cat. No.: HY-12042

Pimasertib (AS703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of **MEK1/2**, used for cancer treatment.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pimelic Diphenylamide 106

(RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII) Cat. No.: HY-19348

Pimelic Diphenylamide 106 is a slow, tight-binding inhibitor of class I HDAC (HDAC 1, 2, and 3, with IC50 values of 150 nM , 760nM, and 370 nM, respectively), demonstrating no activity against class II HDACs.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pimelic Diphenylamide 106 analog

(RGFA-8 analog; TC-H 106 analog) Cat. No.: HY-19430

Pimelic Diphenylamide 106 analog is an analog of Pimelic Diphenylamide 106 with unknown biological activity.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pimozide

(R6238) Cat. No.: HY-12987

Pimozide is a **dopamine receptor** antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at **α1-adrenoceptor**, with a K_i of 39 nM; Pimozide also inhibits **STAT3** and **STAT5**.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Pinometostat

(EPZ-5676) Cat. No.: HY-15593

Pinometostat (EPZ-5676) is a potent **DOT1L histone methyltransferase** inhibitor with a K_i of 80 pM.



Purity: 99.92%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pipendoxifene hydrochloride

Cat. No.: HY-13724B

Pipendoxifene hydrochloride is a selective **estrogen receptor** modulators (SERMs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Piperlongumine

(Piplartine) Cat. No.: HY-N2329

Piperlongumine is a natural alkaloid isolated from Piper longum Linn, possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Pipobroman

Cat. No.: HY-16398

Pipobroman is an anti-cancer drug that probably acts as an alkylating agent.



Purity: 97.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Pirarubicin

(THP) Cat. No.: HY-13725

Pirarubicin is an anthracycline antibiotics, acts as a **topoisomerase II** inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.



Purity: 99.02%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Pirarubicin Hydrochloride

(THP Hydrochloride) Cat. No.: HY-13725A

Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a **topoisomerase II** inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.



Purity: 96.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pixantrone

(BBR 2778) Cat. No.: HY-13727

Pixantrone is a **topoisomerase II** inhibitor and DNA intercalator, with anti-tumor activity.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Pixantrone dimaleate

(BBR 2778 dimaleate) Cat. No.: HY-13727A

Pixantrone dimaleate is a **topoisomerase II** inhibitor and DNA intercalator, with anti-tumor activity.



Purity: >95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PJ34

Cat. No.: HY-13688A

PJ34 is a potent specific inhibitor of **PARPI/2** with IC_{50} of 110 nM and 86 nM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PJ34 hydrochloride

Cat. No.: HY-13688

PJ34 hydrochloride is an inhibitor of **PARPI1/2** with IC_{50} of 110 nM and 86 nM, respectively.



Purity: 97.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PK11007

Cat. No.: HY-U00447

PK11007 is a **p53** targeting compound, has anti-tumor activities through activation of unstable **p53**.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PK68

Cat. No.: HY-128348

PK68 is a potent and selective type II inhibitor of **receptor-interacting kinase 1 (RIPK1)** with an IC_{50} of ~90nM, displays inhibition of RIPK1-dependent necroptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKC-iota inhibitor 1

Cat. No.: HY-126146

PKC-iota inhibitor 1 (compound 19) is a **protein kinase C-iota (PKC-ι)** inhibitor with an IC_{50} value of 0.34 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PKI-402

Cat. No.: HY-10683

PKI-402 is a selective, reversible, ATP-competitive inhibitor of **PI3K**, including PI3K-α mutants, and **mTOR** (IC_{50}=2, 3, 7,14 and 16 nM for PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ).



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PKM2-IN-1

Cat. No.: HY-103617

PKM2-IN-1 is a **pyruvate kinase M2** (**PKM2**) inhibitor with an **IC_{50}** of 2.95 μM.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

PKR-IN-2

Cat. No.: HY-19702

PKR-IN-2 is a pyruvate kinase (PKR) activator, extracted from patent WO2014139144A1, compound 160, has an IC50 of 100 nM for. PKR (R510Q), PKR (R532W), PKR (WT), and PKR (WT Cell Based).



Purity: 97.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Plicamycin

(Mithramycin A)

Cat. No.: HY-A0122

Plicamycin is a selective specificity protein 1 (**Sp1**) inhibitor. Plicamycin inhibits the growth of various cancers by decreasing Sp1 protein.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Plinabulin

(NPI-2358)

Cat. No.: HY-14444

Plinabulin (NPI-2358) is a vascular disrupting agents (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells.



Purity: 93.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Plumbagin

(2-Methyljuglone)

Cat. No.: HY-N1497

Plumbagin (2-Methyljuglone) is a naphthoquinone isolated from Plumbago zeylanica L, exhibits anticancer and antiproliferative activities.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Pluripotin

(SC1)

Cat. No.: HY-10579

Pluripotin is a dual inhibitor of **ERK1** and **RasGAP** with K_Ds of 98 nM and 212 nM, respectively. Pluripotin also inhibits **RSK1**, **RSK2**, **RSK3**, and **RSK4** with **IC_{50}**s of 0.5, 2.5, 3.3, and 10.0 μM, respectively.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PluriSIn 1

(NSC 14613)

Cat. No.: HY-15700

PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (**SCD**), and is a pluripotent cell-specific inhibitor.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PLX-4720

Cat. No.: HY-51424

PLX-4720 is a potent and selective inhibitor of **B-Raf^{V600E} with IC_{50} of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-Raf^{V600E} than wild-type B-Raf.**.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

PLX51107

Cat. No.: HY-111422

PLX51107 is a potent and selective **BET** inhibitor, with K_ds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (K_d, in the 100 nM range).



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PLX647

Cat. No.: HY-13838

PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PLX7904

Cat. No.: HY-18997

PLX7904 is a potent and selective **BRAF** inhibitor, with IC_{50} of appr 5 nM against $BRAF^{V600E}$ in mutant RAS expressing cells.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PLX8394

Cat. No.: HY-18972

PLX8394 is a potent and selective **BRaf** inhibitor, with an IC_{50} of appr 5 nM for $BRAF^{V600E}$.



Purity: 99.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PND-1186

(SR-2516; VS-4718)

Cat. No.: HY-13917

PND-1186 is a potent and reversible inhibitor of **FAK** with an IC_{50} of 1.5 nM in cell assay.



Purity: 99.71%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PNU-159682

Cat. No.: HY-16700

PNU-159682, a highly potent metabolite of the anthracycline nemorubicin with outstanding cytotoxicity, is a potent **ADCs cytotoxin**.



Purity: 96.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

PNU-248686A

Cat. No.: HY-19422

PNU-248686A is a novel matrix metalloproteinase (**MMP**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

PNU-74654

Cat. No.: HY-101130

PNU-74654 is an inhibitor of **Wnt/β-catenin** pathway with an IC_{50} of 129.8 μM in NCI-H295 cell.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

PNZ5

Cat. No.: HY-100696

PNZ5 is a potent and isoxazole-based **pan-BET** inhibitor with high selectivity and potency similar to the well-established (+)-JQ1, with a K_D of 5.43 nM for BRD4(1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Podocarpusflavone A

Cat. No.: HY-N2198

Podocarpusflavone A is a DNA topoisomerase I inhibitor, have moderated anti-proliferative activity induce cell apoptosis in MCF-7, is developing anti-tumor drugs target: DNA topoisomerase I In vitro: podocarpusflavone-A show significant inhibitions against DLD, KB,...



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Podofilox

(Podophyllotoxin)

Cat. No.: HY-15552

Podofilox (Podophyllotoxin) is a potent inhibitor of microtubule assembly and DNA topoisomerase II.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Poloxime

Cat. No.: HY-77195

Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive **Plk1** inhibitor, with moderate Plk1 inhibitory activity.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g

Poloxin

Cat. No.: HY-12134

Poloxin is a non-ATP competitive **Polo-like Kinase 1 (PLK1)** inhibitor that targets the polo-box domain, with an IC_{50} of appr 4.8 μM.



Purity: 96.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Polymyxin B nonapeptide

Cat. No.: HY-106783

Polymyxin B nonapeptide is a cyclic peptide obtained from Polymyxin B by proteolytic removal of its terminal amino acyl residue.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Polyoxyethylene stearate

(POES)

Cat. No.: HY-101530

Polyoxyethylene stearate (POES) is a non-ionic emulsifying agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg, 1 g, 5 g

Pomalidomide

(CC-4047)

Cat. No.: HY-10984

Pomalidomide is the third-generation immunomodulatory agent, functions through interacting with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Ponatinib

(AP24534)

Cat. No.: HY-12047

Ponatinib is a potent, orally available multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Porcn-IN-1

Cat. No.: HY-111472

Porcn-IN-1 is potent **porcupine** inhibitor with an IC_{50} of 0.5±0.2 nM.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Poziotinib

(HM781-36B; NOV120101)

Cat. No.: HY-15730

Poziotinib(NOV120101; HM781-36B) is an irreversible Pan-HER inhibitor with IC50s of 3/5/23 nM for HER1/HER2/HER4 respectively.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PP1

(AGL 1872; EI 275)

Cat. No.: HY-13804

PP1 is a potent, and **Src** family-selective tyrosine kinase inhibitor with IC_{50} of 5 and 6 nM for Lck and Fyn, respectively.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP121

Cat. No.: HY-10372

PP121 is a multi-targeted kinase inhibitor with IC_{50}s of 10, 60, 12, 14, 2 nM for **mTOR**, **DNK-PK**, **VEGFR2**, **Src**, **PDGFR**, respectively.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP2

(AGL 1879)

Cat. No.: HY-13805

PP2 is a reversible and ATP-competitive **Src** family kinases inhibitor with IC_{50}s of 4 and 5 nM for **Lck** and **Fyn**, respectively.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PP58

Cat. No.: HY-18622

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits **PDGFR**, **FGFR** and **Src** family activities with nanomolar IC_{50} values.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

PQ401

Cat. No.: HY-13686

PQ401, a selective insulin-like growth factor-1 receptor blocker, is a novel diarylurea compound that inhibits IGF1R autophosphorylation with IC50 < 1 uM.

Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PQR-530

Cat. No.: HY-107365

PQR-530 is a potent, oral and brain-penetrant dual pan-**PI3K/mTORC1/2** inhibitor, exhibiting antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PQR620

Cat. No.: HY-100026

PQR620 is a novel potent and selective brain penetrant inhibitor of **mTORC1/2**.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PR-619

Cat. No.: HY-13814

PR-619 is a broad-range **DUB** inhibitor with EC_{50} of 3.93, 4.9, 6.86, 7.2, and 8.61 μM for **USP4**, **USP8**, **USP7**, **USP2**, and **USP5**, respectively.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Pracinostat

(SB939)

Cat. No.: HY-13322

Pracinostat is a potent **histone deacetylase (HDAC)** inhibitor, with IC_{50}s of 40-140 nM, used for cancer research.



Purity: 99.07%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pralatrexate

Cat. No.: HY-10446

Pralatrexate(Folotyn) is an antifolate, and structurally a folate analog. Its IC50 is < 300 nM in some cell lines.



Purity: 99.23%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg

Pralsetinib

(Blu667)

Cat. No.: HY-112301

Pralsetinib (Blu667) is a highly potent and selective **RET** inhibitor with an IC_{50} of 0.4 nM for wild type RET kinase.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Prexasertib

(LY2606368)

Cat. No.: HY-18174

Prexasertib (LY2606368) is a potent, selective and ATP-competitive **checkpoint kinase 1 (Chk1)** inhibitor, with an IC_{50} and a K_i of <1 nM and 0.9 nM, respectively.



Purity: 97.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Prexasertib dihydrochloride

(LY2606368 (dihydrochloride))

Cat. No.: HY-18174A

Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a potent and selective ATP competitive inhibitor of the **Chk1** protein kinase, with IC_{50}s of <1 nM and 8 nM for CHK1 and CHK2, respectively, and a K_i of 0.9 nM against purified CHK1.



Purity: 99.41%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Prexasertib Mesylate Hydrate

(LY2606368 Mesylate Hydrate; LY2940930)

Cat. No.: HY-18174B

Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is a potent, selective, ATP competitive **CHK1** and **CHK2** inhibitor, with a K_i of 0.9 nM for CHK1 and IC_{50}s of <1 nM, 8 nM for CHK1 and CHK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PRIMA-1

(NSC-281668)

Cat. No.: HY-19980A

PRIMA-1 (NSC-281668) is a mutant **p53** reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

PRIMA-1Met

(APR-246)

Cat. No.: HY-19980

PRIMA-1Met restores wild-type conformation and function to mutant **p53**, and triggers apoptosis in tumor cells. PRIMA-1Met also targets the selenoprotein thioredoxin reductase 1 (**TrxR1**), a key regulator of cellular redox balance.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Prinaberel

(ERB-041)

Cat. No.: HY-14933

Prinaberel(ERB-041) is a potent and selective ERbeta agonist; being >200-fold selective for ERbeta.



Purity: 98.27%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg

Prinomastat

(AG3340; KB-R9896)

Cat. No.: HY-12170

Prinomastat is a broad spectrum **MMP** inhibitor with IC_{50}s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively.



Purity: 95.03%
Clinical Data: Phase 3
Size: 5 mg

Pristimerin

(Celastrol methyl ester)

Cat. No.: HY-N1937

Pristimerin is a potent and reversible monoacylglycerol lipase (**MGL**) inhibitor with an IC_{50} of 93 nM.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PRN1008

Cat. No.: HY-112166

PRN1008 is a reversible covalent, selective and oral active inhibitor of Bruton's Tyrosine Kinase (**BTK**), with an IC_{50} of 1.3 nM.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PRN1371

Cat. No.: HY-101768

PRN1371 is a highly selective and potent FGFR1-4 inhibitor with IC_{50} values of 0.6, 1.3, 4.1 and 19.3 nM, respectively.



Purity: 99.24%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Procarbazine Hydrochloride

Cat. No.: HY-13733

Procarbazine Hydrochloride is an **alkylating** agent, with anticancer activity.



Purity: >95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Procyanidin A2

Cat. No.: HY-N2343

Procyanidin A2 is a flavonoid found in cranberries and lingonberries, with anti-cancer, antioxidant, antimicrobial and anti-inflammation activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Procyanidin B2

(Proanthocyanidin B2) Cat. No.: HY-N0796

Procyanidin B2 is a natural flavonoid, with anti-cancer, antioxidant activities.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Prodigiosin

(Prodigiosine) Cat. No.: HY-100711

Prodigiosin (Prodigiosine) is a secondary metabolite of Symbiotic bacteria, with anti-fungal and anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 µg

Proglumide

Cat. No.: HY-B1330

Proglumide is a known **cholecystokinin** (**CCK**) antagonist.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Propyl pyrazole triol

(PPT) Cat. No.: HY-100689

Propyl pyrazole triol (PPT) is an **estrogen receptor alpha (ERα)** agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%).



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

PROTAC ABL binding moiety 1

Cat. No.: HY-111849

PROTAC ABL binding moiety 1, the Imatinib (ABL inhibitor) moiety, binds to IAP ligand via a linker to form SNIPER.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC ABL binding moiety 2

Cat. No.: HY-111852

PROTAC ABL binding moiety 2, the GNF5 (ABL inhibitor) moiety, binds to IAP ligand via a linker to form SNIPER.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC ABL binding moiety 3

Cat. No.: HY-111855

PROTAC ABL binding moiety 3, the HG-7-85-01 (ABL inhibitor) moiety, binds to IAP ligand via a linker to form SNIPER .



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC ABL binding moiety 4

Cat. No.: HY-111857

PROTAC ABL binding moiety 4, the Dasatinib (ABL inhibitor) moiety, binds to IAP ligand via a linker to form SNIPER .



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg

PROTAC AR Degrader-4

Cat. No.: HY-111848

PROTAC AR Degrader-4 comprises a **cIAP1** ligand binding group, a linker and an androgen receptor (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (**SNIPER**s).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PROTAC B-Raf degrader 1

Cat. No.: HY-111758

PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of **B-Raf**. With anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC Bcr-Abl-binding moiety 1

Cat. No.: HY-107447

PROTAC Bcr-Abl-binding moiety 1 is a compound binding to **BCR-ABL**, and used for inhibiting **BCR-ABL** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC BET Degrader-1

Cat. No.: HY-103633

PROTAC BET Degrader-1 is a potent **BET** degrader based on **PROTAC**, decreasing BRD2, BRD3, and BRD4 protein levels at low concentration.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PROTAC BET degrader-2

Cat. No.: HY-114228

PROTAC BET degrader-2 is a highly potent degrader of **Bromodomain and Extra-Terminal (BET)** proteins with an IC_{50} value of 9.6 nM in cell growth inhibition in the RS4;11 cells and capable of achieving tumor regression.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PROTAC BET degrader-3

Cat. No.: HY-114229

PROTAC BET Degrader-3 is a potent **BET** degrader based on **PROTAC**.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PROTAC BET-binding moiety 1

Cat. No.: HY-107451

PROTAC BET-binding moiety 1 is a key intermediate for the synthesis of high-affinity BET inhibitors.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PROTAC BET-binding moiety 2

Cat. No.: HY-43723

PROTAC BET-binding moiety 2 is an inhibitor of **BET bromodomain**.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PROTAC BRD4-binding moiety 2

Cat. No.: HY-107443

PROTAC BRD4-binding moiety 2 is a **BRD4(1)** inhibitor with an IC_{50} of 7.9 μM.



Purity: 96.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

PROTAC BRD4-binding moiety 3

Cat. No.: HY-111823

PROTAC BRD4-binding moiety 3 is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD9 Degrader-1

Cat. No.: HY-103632

PROTAC BRD9 Degrader-1 is a lead **PROTAC BRD9** chemical degrader (IC_{50}=13.5 nM), which can be used as a selective probe useful for the study of BAF complex biology.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PROTAC BRD9-binding moiety 1

Cat. No.: HY-107445

PROTAC BRD9-binding moiety 1 is a compound that binds to **BRD9**, and used for inhibiting **BRD9** activity, based on **PROTAC**.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC BRD9-binding moiety 1 hydrochloride

Cat. No.: HY-107445A

PROTAC BRD9-binding moiety 1 hydrochloride is a compound that binds to **BRD9**, and used for inhibiting **BRD9** activity, based on **PROTAC**.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC CDK9 Degrader-1

Cat. No.: HY-103628

PROTAC CDK9 Degrader-1 is a selective **CDK9** degrader.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PROTAC ER Degrader-2

Cat. No.: HY-128528

PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PROTAC ER Degrader-3

Cat. No.: HY-128527

PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PROTAC ERα Degrader-1

Cat. No.: HY-112098

PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an **estrogen receptor-alpha (ERα)** degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

PROTAC ERα Degrader-2

Cat. No.: HY-111846

PROTAC ERα Degrader-2 comprises a **cIAP1** ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PROTAC FAK degrader 1

Cat. No.: HY-119932

PROTAC FAK degrader 1 is a selective and potent **focal adhesion kinase (Fak)** degrader with an IC_{50} of 6.5 nM, DC_{50} of 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PROTAC FKBP12-binding moiety 1

Cat. No.: HY-107452

PROTAC FKBP12-binding moiety 1 is a synthetic ligand for **FKBP** (SLF), which is used in the synthesis of **PROTACs**.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC FLT-3 degrader 1

Cat. No.: HY-114323

PROTAC FLT-3 degrader 1 is an **FLT-3 internal tandem duplication (ITD)** degrader with an IC_{50} 0.6 nM. Anti-proliferative activity; apoptosis induction.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PROTAC IAP binding moiety 1

Cat. No.: HY-111850

PROTAC IAP binding moiety 1, the Bestatin (IAP ligand) moiety, binds to ABL inhibitor via a linker to form SNIPER.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC IAP binding moiety 2

Cat. No.: HY-111853

PROTAC IAP binding moiety 2, the MV-1 (IAP ligand) moiety, binds to ABL inhibitor via a linker to form SNIPER.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC IAP binding moiety 3

Cat. No.: HY-111856

PROTAC IAP binding moiety 3, the LCL161 derivative (IAP ligand) moiety, binds to ABL inhibitor via a linker to form SNIPER.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PROTAC Linker 1

Cat. No.: HY-108371

PROTAC Linker 1 is a **PROTAC** linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

PROTAC Linker 10

Cat. No.: HY-W017772

PROTAC Linker 10 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 10 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 11

Cat. No.: HY-W004896

PROTAC Linker 11 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 11 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 12

Cat. No.: HY-W025896

PROTAC Linker 12 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 12 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 13

Cat. No.: HY-W008474

PROTAC Linker 13 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 13 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 14

Cat. No.: HY-42637

PROTAC Linker 14 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 14 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 15

Cat. No.: HY-42776

PROTAC Linker 15 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 15 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 16

Cat. No.: HY-W004816

PROTAC Linker 16 is a polyethylene glycol (PEG)-based PROTAC linker. PROTAC Linker 16 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 17

Cat. No.: HY-W022240

PROTAC Linker 17 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 17 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 18

Cat. No.: HY-W018745

PROTAC Linker 18 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 18 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 2

Cat. No.: HY-108372

PROTAC Linker 2 is a **PROTAC** linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

PROTAC Linker 4

Cat. No.: HY-112496

PROTAC Linker 4 is a **PROTAC** linker can be used in the synthesis of chloroalkane-containing PROTACs (HaloPROTACs).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

PROTAC Linker 5

Cat. No.: HY-128801

PROTAC Linker 5 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 5 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 6

Cat. No.: HY-128802

PROTAC Linker 6 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 6 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 7

Cat. No.: HY-128803

PROTAC Linker 7 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 7 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 8

Cat. No.: HY-128804

PROTAC Linker 8 (Compound 15b) is a PROTAC linker can be used in the synthesis of a series of SNIPER(ER)s. SNIPER(ER)s contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Linker 9

Cat. No.: HY-128805

PROTAC Linker 9 is a PROTAC linker, which refers to the alkyl/ether composition. PROTAC Linker 9 can be used in the synthesis of a series of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC PARP1 degrader

Cat. No.: HY-114324

PROTAC PARP1 degrader is a **PARP1** degrader based on the **PROTAC** technology. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an $\mathbf{IC_{50}}$ of 6.12 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

PROTAC RAR Degrader-1

Cat. No.: HY-111844

PROTAC RAR Degrader-1 comprises a **cIAP1** ligand binding group, a linker and a RAR ligand binding group. PROTAC RAR Degrader-1 is an RAR degrader. Maximal RAR degradation at 30 μM concentration in HT1080 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

PROTAC Sirt2 Degrader-1

Cat. No.: HY-103636

PROTAC Sirt2 Degrader-1 is a SirReal-based **PROTAC**, acts as a **Sirt2** degrader, composed of a highly potent and isotype-selective **Sirt2** inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Protease-Activated Receptor-2, amide

Cat. No.: HY-P0283

Protease-Activated Receptor-2, amide (SLIGKV-NH_2) is a highly potent protease-activated receptor-2 (PAR2) activating peptide.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Proteasome-IN-1

Cat. No.: HY-100172

Proteasome-IN-1 is a **proteasome** inhibitor extracted from patent WO 2013142376 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Protein degrader 1 hydrochloride

Cat. No.: HY-101763A

Protein degrader 1 hydrochloride is a small molecule ligand for **VHL**, an **E3 ligase** which has been targeted in numerous **PROTAC**s.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 5 g

Protein degrader 1 TFA

Cat. No.: HY-110402

Protein degrader 1 TFA is a small molecule ligand for **VHL**, an **E3 ligase** which has been targeted in numerous **PROTAC**s.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Protein kinase inhibitors 1

Cat. No.: HY-U00439

Protein kinase inhibitors 1 is a novel inhibitor of **HIPK2** with an IC_{50} of 74 nM and K_d of 9.5 nM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Protein kinase inhibitors 1 hydrochloride

Cat. No.: HY-U00439A

Protein kinase inhibitors 1 hydrochloride is a potent **HIPK2** inhibitor, with IC_{50}s of 136 and 74 nM for HIPK1 and HIPK2, and a K_d of 9.5 nM for HIPK2.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Protocatechualdehyde

(Catechaldehyde; Protocatechuic aldehyde; Rancinamycin IV) Cat. No.: HY-N0295

Protocatechualdehyde (Catechaldehyde), a natural polyphenol compound isolated from the roots of radix Salviae Miltiorrhizae, is associated with a wide variety of biological activities and has been widely used in medicine as an antioxidant, anti-aging, an antibacterial and...



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Protodioscin

Cat. No.: HY-N0799

Protodioscin, a major steroidal saponin in dioscoreae rhizome, has been shown to exhibit multiple biological actions, such as anti-hyperlipidemia, anti-cancer, sexual effects and cardiovascular properties.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Protosappanin B

((-)-Protosappanin B) Cat. No.: HY-N0800

Protosappanin B is a phenolic compound extracted from Lignum Sappan. Anti-cancer activity. Protosappanin B induces apoptosis and causes G_1 cell cycle arrest in human bladder cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Proxalutamide

(GT0918) Cat. No.: HY-103184

Proxalutamide (GT0918) is a potent **androgen receptor (AR)** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PRT-060318

(PRT318) Cat. No.: HY-12974

PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinase **Syk** with an IC_{50} of 4 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PRT062607 Hydrochloride

(P505-15 Hydrochloride) Cat. No.: HY-15323

PRT062607 hydrochloride is a highly specific and potent inhibitor of purified **Syk** (IC_{50} 1-2 nM).



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PRT4165

(NSC600157) Cat. No.: HY-19817

PRT4165 is a potent inhibitor of **PRC1-mediated H2A ubiquitylation**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PS-1145

Cat. No.: HY-18008

PS-1145 is an IκB kinase (**IKK**) inhibitor with an IC_{50} of 88 nM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PSA1 141-150

Cat. No.: HY-P1813

PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.

FLTPKKLQCV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSB-12379

Cat. No.: HY-100747

PSB-12379 is a potent **Ecto-5'-Nucleotidase** (**CD73**) inhibitor with K_is of 9.03 nM (rat) and 2.21 nM (human).



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PSI-697

(P-Selectin Inhibitor) Cat. No.: HY-15526

PSI-697 is an oral **P-selectin** inhibitor with an IC_{50} of 125 μM.



Purity: 99.70%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PSI-7409

Cat. No.: HY-15745

PSI-7409 is the active 5'-triphosphate metabolite of Sofosbuvir (PSI-7977). Sofosbuvir (PSI-7977) is a selective and highly active nucleotide analog inhibitor of **HCV**.



Purity: 96.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Psoralen

(Ficusin; Furocoumarin)

Cat. No.: HY-N0053

Psoralen(Furocoumarin) is an active ingredient from Fructus Psoraleae; has anticancer activity.



Purity: 99.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Psoralidin

Cat. No.: HY-N0232

Psoralidin, a natural furanocoumarin, is isolated from Psoralea corylifolia L. possessing anti-cancer properties. IC50 value: Target: Anticancer natural compound in vitro: PSO dramatically decreased the cell viabilities in dose- and time-dependent manner.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PT-2385

Cat. No.: HY-12867

PT-2385 is a selective **HIF-2α** inhibitor with a K_i of less than 50 nM.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

PT2399

Cat. No.: HY-108697

PT2399 is a potent and selective **HIF-2α** antagonist, which directly binds to HIF-2α PAS B domain, with an IC_{50} of 6 nM. PT2399 displays potent antitumor activity in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PTACH

(NCH-51)

Cat. No.: HY-12954

PTACH (NCH-51) is a SAHA-based novel inhibitor of human HDAC. PTACH exerts potent growth inhibition against various human cancer cells, with EC50 values ranging from 1 to 10 μM.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PTC-028

Cat. No.: HY-103696

PTC-028 is an orally bioavailable inhibitor of stem cell factor **BMI-1** in ovarian cancer. PTC-028 selectively inhibits cancer cells whereas normal cells remain unaffected. Depletion of BMI-1 by PTC-028 induces caspase-mediated **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PTC-209

Cat. No.: HY-15888

PTC-209 is a specific **BMI-1** inhibitor with an IC_{50} of 0.5 μM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PTC-209 hydrobromide

Cat. No.: HY-15888A

PTC-209 hydrobromide is a specific **BMI-1** inhibitor with IC_{50} of 0.5 μM in both GEMS reporter and ELISA assays.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PTC299

Cat. No.: HY-124593

PTC299 is an orally bioavailable and potent **VEGF** inhibitor, acts through posttranscriptional regulation of VEGF mRNA under conditions of cellular stress. PTC299 has broad and potent activity against hematological cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

PTD-p65-P1 Peptide

Cat. No.: HY-P1832

PTD-p65-P1 Peptide is a nuclear transcription factor **NF-kappaB** inhibitor, composed of a membrane-translocating peptide sequence generated from antennapedia (PTD) conjugated with p65-P1, which selectively inhibits activation induced by various inflammatory stimuli.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pterostilbene

Cat. No.: HY-N0828

Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

PU-WS13

Cat. No.: HY-18680

PU-WS13 is a selective **Grp94** inhibitor, with an EC_{50} of 0.22 μM.



Purity: 95.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pulsatilla saponin D

(SB365; Hederacolchiside A)

Cat. No.: HY-N0834

Pulsatilla saponin D(SB365) isolated from the root of Pulsatilla koreana, has exhibited potential beneficial effects as a chemopreventive agent for critical health conditions including cancer.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

PUMA BH3

Cat. No.: HY-P1562

PUMA BH3 is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of **Bak**, with a K_d of 26 nM.

EEQWAREIGAQLRRMADDLNAQYER

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Puromycin aminonucleoside

(NSC 3056)

Cat. No.: HY-15695

Puromycin aminonucleoside (NSC 3056) is the aminonucleoside portion of the antibiotic puromycin, and used in nephrosis animal models.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g

Purvalanol A

(NG-60)

Cat. No.: HY-18299A

Purvalanol A is a potent **CDK** inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC_{50}s of 4, 70, 35, 850, 75 nM, resepctively.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Purvalanol B

(NG 95)

Cat. No.: HY-18299

Purvalanol B(NG-95) is a cyclin-dependent kinase inhibitor with IC50 values of 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PX-12

(IV-2)

Cat. No.: HY-13734

PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1 (**Trx-1**); inhibits the growth of MCF-7 and HT-29 cells with IC_{50} values of 1.9 and 2.9 μM, respectively.



Purity: 99.30%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

PX-478

Cat. No.: HY-10231

PX-478 is an antitumor inhibitor of hypoxia-inducible factor-1α (**HIF-1α**).



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PYR-41

Cat. No.: HY-13296

PYR-41 is a selective and cell permeable inhibitor of ubiquitin-activating enzyme **E1** with an IC_{50} of < 10 μM, with little activity at E2 and E3.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pyrazofurin

Cat. No.: HY-122502

Pyrazofurin, a pyrimidine nucleoside analogue with antineoplastic activity, inhibits cell proliferation and DNA synthesis in cells by inhibiting **uridine 5'-phosphate (UMP)** synthase.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Pyridoclax

(MR-29072)

Cat. No.: HY-12527

Pyridoclax is a potential **Mcl-1** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pyridone 6

(CMP 6; JAK Inhibitor)

Cat. No.: HY-14435

Pyridone 6 is a **pan-JAK** inhibitor, which potently inhibits the JAK kinase family, with IC_{50}s of 1 nM for **JAK2** and **TYK2**, 5 nM for **JAK3**, and 15 nM for **JAK1**, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Pyridostatin

(RR82)

Cat. No.: HY-15176

Pyridostatin is a **G-quadruplexe** stabilizer, with a K_d of 490 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Pyridostatin hydrochloride

(RR-82 hydrochloride)

Cat. No.: HY-15176A

Pyridostatin hydrochloride is a **G-quadruplexe** stabilizer, with a K_d of 490 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pyridoxal isonicotinoyl hydrazone

(PIH)

Cat. No.: HY-114758

Pyridoxal isonicotinoyl hydrazone (PIH) is a lipophilic, tridentate Fe-chelating agent that shows high Fe chelation efficacy.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Pyrotinib

(SHR-1258)

Cat. No.: HY-104065

Pyrotinib (SHR-1258) is a potent and selective **EGFR/HER2** dual inhibitor with IC_{50}s of 13 and 38 nM, respectively.



Purity: 98.84%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Pyrotinib dimaleate

(SHR-1258 dimaleate)

Cat. No.: HY-104065B

Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective **EGFR/HER2** dual inhibitor with IC_{50} s of 13 and 38 nM, respectively.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Pyrrolidinedithiocarbamate ammonium (Ammonium

pyrrolidinedithiocarbamate; APDC; ...)

Cat. No.: HY-18738

Pyrrolidinedithiocarbamate ammonium is a selective **NF-κB** inhibitor.



Purity: 99.86%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 100 mg

Pyrvinium pamoate

(Pyrvinium embonate)

Cat. No.: HY-A0293

Pyrvinium pamoate is an FDA-approved antihelmintic drug that inhibits **WNT** pathway signaling.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PYZD-4409

Cat. No.: HY-13297

PYZD-4409 is a novel small molecule inhibitor of Ubiquitin-activating enzyme UBA1/E1 enzyme with an IC50 of 20 uM (cell-free enzymatic assay).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pz-1

Cat. No.: HY-U00437

Pz-1 is a potent **RET** and **VEGFR2** inhibitor with IC_{50}s of less than 1 nM for both wild type kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Q-VD-OPh

(QVD-OPH; Quinoline-Val-Asp-Difluorophenoxymethylketone) Cat. No.: HY-12305

Q-VD-OPha is an irreversible **pan-caspase** inhibitor with potent antiapoptotic properties; inhibits caspase 7 with IC_{50} of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPha is able to cross the blood-brain barrier.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

QC6352

Cat. No.: HY-104048

QC6352 is a potent **KDM4C** inhibitor with an IC_{50} of 35 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

QCA570

Cat. No.: HY-112609

QCA570 is a potent BET degrader based on **PROTAC**, with an IC_{50} of 10 nM for **BRD4 BD1** Protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

QL47

Cat. No.: HY-80003

QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

QS11

Cat. No.: HY-12762

QS11 is a GTPase activating protein of ADP-ribosylation factor 1 (ARFGAP1) inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Quarfloxin

(CX 3543) Cat. No.: HY-14776

Quarfloxin (CX 3543), a fluoroquinolone derivative with antineoplastic activity, targets and inhibits **RNA pol I** activity, with IC_{50} values in the nanomolar range in neuroblastoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Quercetagetin

(6-Hydroxyquercetin) Cat. No.: HY-N4149

Quercetagetin (6-Hydroxyquercetin) is the major flavonoid isolated from Citrus unshiu (C. unshiu) peel. Quercetagetin is a moderately potent and selective, cell-permeable **pim-1** kinase inhibitor (IC_{50}, 0.34 μM). Anti-inflammatory and anticancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Quercetin

Cat. No.: HY-18085

Quercetin, a natural flavonoid, is a stimulator of recombinant **SIRT1** and also a **PI3K** inhibitor with IC_{50} of 2.4±0.6 μM, 3.0±0.0 μM and 5.4±0.3 μM for PI3K γ, PI3K δ and PI3K β, respectively.



Purity: >98.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 1 g, 5 g

Quinacrine dihydrochloride

(Mepacrine dihydrochloride; SN-390) Cat. No.: HY-13735A

Quinacrine is a fluorescent probe for the conformational transitions of the cholinergic receptor protein. Quinacrine shows activity in the low μM range with a mean IC50 of 2.30 μM In the patient AML cells.



Purity: 98.05%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 500 mg

Quisinostat

(JNJ-26481585) Cat. No.: HY-15433

Quisinostat (JNJ-26481585) is an orally available, potent **HDAC** inhibitor with an IC_{50} of 0.11 nM for HDAC1.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Quizartinib

(AC220) Cat. No.: HY-13001

Quizartinib (AC220) is a potent **Flt3** tyrosine kinase inhibitor with a K_d of 1.6±0.7 nM.



Purity: 99.34%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

QX77

Cat. No.: HY-112483

QX77 is a chaperone-mediated autophagy (**CMA**) activator.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

R-268712

Cat. No.: HY-12953

R-268712 is a potent and selective inhibitor of ALK5 with an IC50 of 2.5 nM.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

R-7050

(TNF-α Antagonist III) Cat. No.: HY-110203

R-7050 is a **tumor necrosis factor receptor** (**TNFR**) antagonist with greater selectivity toward **TNFα**.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

R-IMPP

Cat. No.: HY-101354

R-IMPP is an inhibitor of PCSK9 secretion.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

R1487 Hydrochloride

Cat. No.: HY-14975

R1487 (Hydrochloride) is highly potent and highly selective inhibitors of p38α. target: p38α; R1487 (Hydrochloride) potently inhibits cytokine production in a variety of in vitro and in vivo models.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

R1530

Cat. No.: HY-13737

R1530 is the multikinase inhibitor with potential antiangiogenesis and antineoplastic activities.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

R162

Cat. No.: HY-103096

R162 is a potent inhibitor of glutamate dehydrogenase 1 (**GDH1/GLUD1**), with anti-cancer properties.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

R547

Cat. No.: HY-10014

R547 is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

R916562

Cat. No.: HY-104075

R916562 is a potential and selective **Axl/VEGF-R2** dual inhibitor with IC_{50}s of 136 and 24 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

RA190

Cat. No.: HY-100739

RA190, a bis-benzylidine piperidon, inhibits proteasome function by covalently binding to cysteine 88 of ubiquitin receptor **RPN13**.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rabacfosadine

(GS-9219; VDC-1101)

Cat. No.: HY-13640

Rabacfosadine (GS-9219), a novel prodrug of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells.



Purity: >98%
Clinical Data: Phase 2
Size: 100 mg, 250 mg, 500 mg

Rabusertib

(LY2603618; IC-83)

Cat. No.: HY-14720

Rabusertib (LY2603618) is a potent and selective inhibitor of **Chk1** with an IC_{50} of 7 nM.



Purity: 99.69%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rac-Nedisertib

(Rac-M3814)

Cat. No.: HY-101570B

Rac-Nedisertib (Rac-M3814) is a racemate of Nedisertib, a potent **DNA-PK** inhibitor, with an IC_{50} of <3 nM.



Purity: 91.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RAD51 Inhibitor B02

(B02)

Cat. No.: HY-101462

RAD51 Inhibitor B02 (B02) is an inhibitor of human **RAD51** with an IC_{50} of 27.4 μM.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RAD51-IN-2

Cat. No.: HY-111887

RAD51-IN-2 (compound example 67A) is a **RAD51** inhibitor extracted from patent WO2019/051465A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

RAF265

(CHIR-265)

Cat. No.: HY-10248

RAF265 is a potent **RAF/VEGFR2** inhibitor.



Purity: 99.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RAF709

Cat. No.: HY-100510

RAF709 is a potent, selective, and efficacious **RAF** inhibitor with IC_{50}s of 0.4 nM and 0.5 nM for **BRAF** and **CRAF**, respectively. Antitumor efficacy.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ralimetinib
(LY2228820) Cat. No.: HY-13241A

Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of **p38 MAPK α/β**, with IC_{50}s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ralimetinib dimesylate
(LY2228820 dimesylate) Cat. No.: HY-13241

Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of **p38 MAPK α/β** with IC_{50}s of 5.3 and 3.2 nM, respectively.



Purity: 99.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Raltitrexed
(ZD1694; D1694; ICI-D1694) Cat. No.: HY-10821

Raltitrexed is an antimetabolite drug used in chemotherapy, acting by inhibiting **thymidylate synthase**.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ramucirumab
Cat. No.: HY-P9920

Ramucirumab is a human **VEGFR-2** antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.

Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg

Rapamycin
(Sirolimus; AY 22989) Cat. No.: HY-10219

Rapamycin (Sirolimus; AY 22989) is a potent and specific **mTOR** inhibitor with an IC_{50} of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of **mTORC1**. Rapamycin is an **autophagy** activator.



Purity: 99.93%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g, 5 g

RAR ligand 1
Cat. No.: HY-111843

RAR ligand 1 is a retinoic acid ligand, which targets **RAR**. RAR ligand 1 binds to **cIAP1** ligand Bestatin via a linker to form **PROTACs**.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

Ravoxertinib
(GDC-0994) Cat. No.: HY-15947

Ravoxertinib (GDC-0994) is an orally bioavailable **ERK** kinase inhibitor with an IC_{50} of 6.1 nM and 3.1 nM for **ERK1** and **ERK2**, respectively.



Purity: 99.79%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ravoxertinib hydrochloride
(GDC-0994 (hydrochloride)) Cat. No.: HY-15947A

Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for **ERK** kinase activity with IC_{50} of 6.1 nM and 3.1 nM for **ERK1** and **ERK2**, respectively.



Purity: 99.05%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RBC8
Cat. No.: HY-12873

RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.5 μM in H2122 cell and 3.4 μM in H358 cell.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RC-3095
Cat. No.: HY-P0107

RC-3095 is a **bombesin/gastrin** releasing peptide receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RCM-1

Cat. No.: HY-19979

RCM-1 is a **FOXM1** inhibitor.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ReACp53

Cat. No.: HY-P0121

ReACp53 could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.

H-RRRRRRRRRRPILTRITLE-OH

Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Rebastinib

(DCC-2036)

Cat. No.: HY-13024

Rebastinib (DCC-2036) is a conformational control **Bcr-Abl** inhibitor for **Abl1**^{WT} and **Abl1**^{T315I} with IC_{50} of 0.8 nM and 4 nM, also inhibits SRC, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit.



Purity: 99.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Recilisib

(Ex-RAD; ON 01210)

Cat. No.: HY-101625

Recilisib is a radioprotectant, which can activate **AKT**, **PI3K** activities in cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Refametinib

(BAY 869766; RDEA119)

Cat. No.: HY-14691

Refametinib is a potent, selective, allosteric **MEK1/MEK2** inhibitor with IC_{50}s of 19 nM and 47 nM, respectively.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Refametinib R enantiomer

(BAY 869766 R enantiomer; RDEA119 R enantiomer)

Cat. No.: HY-10216

Refametinib R enantiomer is a **MEK** inhibitor extracted from patent WO2007014011A2, compound 1022, has an EC_{50} of 2.0-15 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Regorafenib

(BAY 73-4506)

Cat. No.: HY-10331

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1**, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Regorafenib Hydrochloride

(BAY73-4506 hydrochloride)

Cat. No.: HY-13308

Regorafenib Hydrochloride is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Regorafenib monohydrate

(BAY 73-4506 monohydrate)

Cat. No.: HY-10331A

Regorafenib monohydrate is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Regorafénib N-oxyde M2

Cat. No.: HY-I0678

Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Relugolix

(TAK-385)

Cat. No.: HY-16474

Relugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Remetinostat

(SHP-141)

Cat. No.: HY-100365

Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of **histone deacetylase enzymes (HDAC)** which is under development for the treatment of cutaneous T-cell lymphoma.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Remodelin

Cat. No.: HY-16706

Remodelin is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Remodelin hydrobromide

Cat. No.: HY-16706A

Remodelin hydrobromide is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Repotrectinib

(TPX-0005)

Cat. No.: HY-103022

Repotrectinib (TPX-0005) is a potent **ALK/ROS1/TRK** inhibitor, with IC_{50} of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

RepSox

(E-616452; SJN 2511)

Cat. No.: HY-13012

RepSox is a potent and selective of the **TGFβR-1/ALK5** inhibitor which inhibits ALK5 autophosphorylation with IC_{50} of 4 nM.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Resibufogenin

(Bufogenin; Recibufogenin)

Cat. No.: HY-N0815

Resibufogenin, a component of huachansu, has been shown to exhibit the anti-proliferative effect against cancer cells, and this may be attributed to the degradation of cyclin D1 caused by the activation of GSK-3β.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Resminostat

(RAS2410; 4SC-201)

Cat. No.: HY-14718

Resminostat is a potent inhibitor of **HDAC1**, **HDAC3** and **HDAC6**, with mean IC_{50} values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC_{50} of 877 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Resminostat hydrochloride

(RAS2410 hydrochloride; 4SC-201 hydrochloride)

Cat. No.: HY-14718A

Resminostat hydrochloride is a potent inhibitor of **HDAC1**, **HDAC3** and **HDAC6**, with mean IC_{50} values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC_{50} of 877 nM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

RET-IN-1

Cat. No.: HY-112950

RET-IN-1 is a **RET kinase** inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC_{50s} of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Retaspimycin

Cat. No.: HY-15263

Retaspimycin is a potent and water-soluble inhibitor of **Hsp90**, with EC_{50}s of 119 nM for both Hsp90 and Grp9.



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 100 mg

Retaspimycin Hydrochloride

(IPI-504)

Cat. No.: HY-10210

Retaspimycin Hydrochloride is a potent and water-soluble inhibitor of **Hsp90** with EC_{50}s of 119 nM for both Hsp90 and Grp9.



Purity: >95.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Retinoic acid

(ATRA; Tretinoin; Vitamin A acid; all-trans-Retinoic acid)

Cat. No.: HY-14649

Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of **RAR** nuclear receptors, with IC_{50}s of 14 nM for RARα/β/γ. Retinoic acid bind to **PPARβ/δ** with K_d of 17 nM.



Purity: 98.36%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Retinyl acetate

(Retinol acetate; Vitamin A acetate)

Cat. No.: HY-N0679

Retinyl acetate is a natural form of vitamin A and has potential antineoplastic and chemo preventive activities.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

REV7/REV3L-IN-1

Cat. No.: HY-100468

REV7/REV3L-IN-1 is a **REV7/REV3L interaction** inhibitor with an IC_{50} of 78 μM, which directly binds to REV7 in nuclear magnetic resonance analyses, and inhibits the reactivation of a reporter plasmid containing an interstrand crosslink (ICL) in between the promoter...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reversan

(CBLC4H10)

Cat. No.: HY-107643

Reversan (CBLC4H10) is a potent and nontoxic **multidrug resistance-associated protein 1 (MRP1)** and **P-glycoprotein (Pgp)** inhibitor.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg

Reversine

Cat. No.: HY-14711

Reversine is a novel class of ATP-competitive **Aurora kinase** inhibitor with IC_{50}s of 400, 500 and 400 nM for **Aurora A**, **Aurora B** and **Aurora C**, respectively.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RG-12915

Cat. No.: HY-19110

RG-12915 is a selective **5-HT3** antagonist, with IC_{50} value of 0.16 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

RG108

(N-Phthalyl-L-tryptophan)

Cat. No.: HY-13642

RG108 is a non-nucleoside inhibitor of **DNA methyltransferase** with an IC_{50} of 115 nM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

RG13022

(Tyrphostin RG13022;)

Cat. No.: HY-101429

RG13022 is a **tyrosine kinase** inhibitor; inhibits the autophosphorylation reaction of the EGF receptor with an IC_{50} of 4 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RG14620

(Tyrphostin RG14620) Cat. No.: HY-101426

RG14620 is an **EGFR** inhibitor with an IC_{50} of 3 μM.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RG2833

(RGFP109) Cat. No.: HY-16425

RG2833 is a brain-penetrant **HDAC** inhibitor with IC_{50} of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RG7112

(RO5045337) Cat. No.: HY-10959

RG7112 is the first clinical and orally available **MDM-2/p53** inhibitor designed to occupy the p53-binding pocket of MDM2, with the K_d value of 11 nM.



Purity: 99.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RGB-286638

Cat. No.: HY-15504

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

RGB-286638 free base

Cat. No.: HY-15504A

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 99.55%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RGD

Cat. No.: HY-P0278

RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to **integrins**.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg

RGD Trifluoroacetate

Cat. No.: HY-P0278A

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to **integrins**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RGFP966

Cat. No.: HY-13909

RGFP966 is a highly selective **HDAC3** inhibitor with an IC_{50} of 80 nM and shows no inhibition to other HDACs at concentrations up to 15 μM.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

rGHRH(1-29)NH2

Cat. No.: HY-P1155

rGHRH(1-29)NH_2 is a synthetic peptide which can stimulate the **growth hormone** (**GH**) secretion.

Purity: 96.74%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

RGX-104 free Acid

Cat. No.: HY-111498A

RGX-104 free Acid is an orally bioavailable and potent liver-X nuclear hormone receptor **(LXR)** agonist that modulates innate immunity via transcriptional activation of the ApoE gene.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RH1

(NSC 697726)

Cat. No.: HY-13741

RH1 (NSC 697726) is a potent bioreductive agent with profound anti-cancer activity in vitro and in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Rhein

(Rheic Acid; Rhubarb yellow; Monorhein)

Cat. No.: HY-N0105

Rhein is a lipophilic anthraquinone extensively found in medicinal herbs, and has many pharmacological effects, including epatoprotective, nephroprotective, anti-inflammatory, antioxidant, anticancer, and antimicrobial activities.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Rho-Kinase-IN-1

Cat. No.: HY-100270

Rho-Kinase-IN-1 is a **rho kinase** inhibitor extracted from US 20090325960 A1, compound 1.008.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Rhosin

Cat. No.: HY-12646A

Rhosin is a specific Rho inhibitor; binds to WT RhoA with an affinity ~0.4 uM Kd; does not interfere with the binding of Cdc42 or Rac1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Rhosin hydrochloride

Cat. No.: HY-12646

Rhosin hydrochloride is a specific Rho inhibitor; binds to WT RhoA with an affinity ~0.4 uM Kd; does not interfere with the binding of Cdc42 or Rac1.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

RI-1

Cat. No.: HY-15317

RI-1 is a RAD51 inhibitor with IC50 ranging from 5 to 30 μM.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RI-2

Cat. No.: HY-16904

RI-2 is a reversible **RAD51** inhibitor, with an IC_{50} of 44.17 μM, and specifically inhibits homologous recombination repair in human cells.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ribociclib

(LEE011)

Cat. No.: HY-15777

Ribociclib (LEE01) is a highly specific **CDK4/6** inhibitor with IC_{50} values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ribociclib hydrochloride

(LEE011 (hydrochloride))

Cat. No.: HY-15777A

Ribociclib hydrochloride (LEE011 hydrochloride) is a highly specific **CDK4/6** inhibitor with IC_{50} values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ribociclib succinate

(LEE011 (succinate))

Cat. No.: HY-15777B

Ribociclib succinate (LEE011 succinate) is a highly specific **CDK4/6** inhibitor with IC_{50} values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ribociclib succinate hydrate

(LEE011 (succinate hydrate)) Cat. No.: HY-15777C

Ribociclib succinate hydrate (LEE011 succinate hydrate) is a highly specific **CDK4/6** inhibitor with **IC_{50}** values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 99.00%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ricolinostat

(ACY-1215; Rocilinostat) Cat. No.: HY-16026

Ricolinostat (ACY-1215) is a potent and selective **HDAC6** inhibitor, with an **IC_{50}** of 5 nM. ACY-1215 also inhibits **HDAC1**, **HDAC2**, and **HDAC3** with **IC_{50}**s of 58, 48, and 51 nM, respectively.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rigosertib

(ON-01910) Cat. No.: HY-12037A

Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the **PI3 kinase/Akt** pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle.



Purity: 98.09%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rigosertib sodium

(ON-01910 sodium) Cat. No.: HY-12037

Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the **PI3 kinase/Akt** pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle.



Purity: 99.49%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rimiducid

(AP1903) Cat. No.: HY-16046

Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the **FKBP** domains, initiating **Fas** signaling and hence **apoptosis**.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

RIP2 kinase inhibitor 1

Cat. No.: HY-19764

RIP2 kinase inhibitor 1 is a receptor interacting protein-2 (**RIP2**) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

RIP2 kinase inhibitor 2

Cat. No.: HY-19761

RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (**RIP2**) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

RIPGBM

Cat. No.: HY-122910

RIPGBM is a selective inducer of **apoptosis** in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an **EC_{50}** of ≤500 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

RIPK1-IN-7

Cat. No.: HY-119933

RIPK1-IN-7 is a potent and selective **RIPK1** inhibitor with a **K_d** of 4 nM and an enzymatic **IC_{50}** of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ripretinib

(DCC-2618) Cat. No.: HY-112306

Ripretinib (DCC-2618) is a pan-**KIT** and **PDGFRA** inhibitor, and has antitumor activity.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RITA

(NSC 652287)

Cat. No.: HY-13424

RITA is an inhibitor of **p53-HDM-2 interaction**, binds to p53dN, with a K_d of 1.5 nM, and also induces **DNA-DNA cross-links**.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Rituximab

(Anti-Human CD20 type I, Chimeric Antibody)

Cat. No.: HY-P9913

Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

Rituximab

Purity: 99.85%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg

Riviciclib

(P276-00 (free base))

Cat. No.: HY-16559A

Riviciclib (P276-00 free base) is a potent **cyclin-dependent kinase (CDK)** inhibitor, which inhibits **CDK9-cyclinT1**, **CDK4-cyclin D1**, and **CDK1-cyclinB** with IC_{50}s of 20 nM, 63 nM, and 79 nM, respectively. Riviciclib shows antitumor activity on cisplatin-resistant cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Riviciclib hydrochloride

(P276-00)

Cat. No.: HY-16559

Riviciclib hydrochloride (P276-00) is a potent **cyclin-dependent kinase (CDK)** inhibitor, which inhibits **CDK9-cyclinT1**, **CDK4-cyclin D1**, and **CDK1-cyclinB** with IC_{50}s of 20 nM, 63 nM, and 79 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

RK-287107

Cat. No.: HY-123892

RK-287107 is a potent and specific **tankyrase** inhibitor with IC_{50}s of 14.3 and 10.6 nM for **tankyrase-1** and **tankyrase-2**, respectively. RK-287107 blocks colorectal cancer cell growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

RKI-1447

Cat. No.: HY-15755

RKI-1447 is a potent small molecule inhibitor of **ROCK1** and **ROCK2** with IC_{50} values of 14.5 nM and 6.2 nM, respectively.



Purity: 97.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RMC-4550

Cat. No.: HY-116009

RMC-4550 is a potent, selective and allosteric inhibitor of **SHP2**, with an IC_{50} of 0.583 nM.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RMI 10874

Cat. No.: HY-100279

RMI 10874 is a tilorone analogue. Tilorone is a small-molecule, orally bioavailable antiviral agent. RMI 10874 completely abolishes lung colonization of an H-2 negative (GR9.B9) MCA-induced fibrosarcoma clone.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Ro 48-8071

Cat. No.: HY-18630

Ro 48-8071 is an inhibitor of **OSC (Oxidosqualene cyclase)** with IC_{50} of appr 6.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Ro 48-8071 fumarate

Cat. No.: HY-18630A

Ro 48-8071 fumarate is an inhibitor of **OSC (Oxidosqualene cyclase)** with IC_{50} of appr 6.5 nM.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ro 5126766

(CH5126766) Cat. No.: HY-18652

Ro 5126766 is a first-in-class dual **MEK/RAF** inhibitor that allosterically inhibits **$BRAF^{V600E}$**, **CRAF**, **MEK**, and **BRAF** (IC_{50}: 8.2, 56, 160 nM, and 190 nM, respectively).



Purity: 97.92%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ro 67-7476

Cat. No.: HY-100403

Ro 67-7476 is a positive allosteric modulator of mGlu1 receptors. Displays no activity at human mGlu1 receptors. Potentiates glutamate-induced calcium release with EC 50 of 60.1 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ro-3306

Cat. No.: HY-12529

Ro-3306 is a potent and selective inhibitor of **CDK1**, with K_is of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.



Purity: 96.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RO-5963

Cat. No.: HY-120086

RO-5963 is a dual **p53-MDM2** and **p53-MDMX** inhibitor with IC_{50}s of ~17 nM and ~24 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Ro3280

Cat. No.: HY-15161

Ro3280 is a potent, highly selective inhibitor of **PLK1** with an IC_{50} and a K_d of 3 nM and 0.09 nM, respectively, and nearly has no effect on PLK2 and PLK3.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

RO4987655

(CH4987655) Cat. No.: HY-14719

RO4987655 is an orally active and highly selective **MEK** inhibitor with an IC_{50} of 5.2 nM for inhibition of **MEK1/MEK2**.



Purity: 98.22%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

RO8994

Cat. No.: HY-16999

RO8994 is a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitor, with IC50 of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays).



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Roblitinib

(FGF-401) Cat. No.: HY-101568

Roblitinib (FGF-401) is an inhibitor of **FGFR4** extracted from patent WO2015059668A1, compound example 83; has an IC_{50} of 1.9 nM.



Purity: 98.08%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ROC-325

Cat. No.: HY-103706

ROC-325 is a novel inhibitor of **autophagy**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rociletinib

(CO-1686; AVL-301; CNX-419) Cat. No.: HY-15729

Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of **EGFR** including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.



Purity: 99.08%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Rociletinib hydrobromide (CO-1686 (hydrobromide); AVL-301 hydrobromide; CNX-419 hydrobromide)

Cat. No.: HY-15729A

Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of **EGFR** including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.



Purity: 97.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rogaratinib (BAY1163877)

Cat. No.: HY-100019

Rogaratinib is a potent and selective **fibroblast growth factor receptor** (**FGFR**) inhibitor.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Rolapitant (SCH619734)

Cat. No.: HY-14751

Rolapitant (SCH619734) is a potent, selective and orally active **neurokinin** NK1 receptor antagonist with a K_i of 0.66 nM.



Purity: 98.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Romidepsin (FK 228; FR 901228; NSC 630176)

Cat. No.: HY-15149

Romidepsin is a potent **HDAC1** and **HDAC2** inhibitor with IC_{50}s of 36 and 47 nM, respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Roniciclib (BAY 1000394)

Cat. No.: HY-13914

Roniciclib is an orally bioavailable pan-cyclin dependent kinase **(CDK)** inhibitor, with IC_{50}s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Ropidoxuridine (IPdR)

Cat. No.: HY-13742

Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Rosabulin (STA 5312)

Cat. No.: HY-14934

Rosabulin is a potent **microtubule** inhibitor, with anti-cancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Rosiptor (AQX-1125)

Cat. No.: HY-109011

Rosiptor is an activator of SH2-containing inositol-5'-phosphatase 1 (**SHIP1**).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Roxadustat (FG-4592)

Cat. No.: HY-13426

Roxadustat (FG-4592) is an oral **hypoxia-inducible factor prolyl-hydroxylase** inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.



Purity: 99.91%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Roy-Bz

Cat. No.: HY-111364

Roy-Bz is a selecive **PKCδ** activator. Roy-Bz potently inhibits the proliferation of colon cancer cells by inducing a PKCδ-dependent mitochondrial apoptotic pathway involving caspase-3 activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Rpn11-IN-1

Cat. No.: HY-101286

Rpn11-IN-1 is a potent and selective inhibitor of proteasome subunit **Rpn11** with an IC_{50} of 390 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

RQ-00203078

Cat. No.: HY-18662

RQ-00203078 is a highly selective, potent and orally available TRPM8 antagonist (IC50 values are 5.3 and 8.3 nM for rat and human channels respectively), exhibits >350-fold selectivity for TRPM8 over TRPV4, TRPV1 and TRPA1.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RR-11a

Cat. No.: HY-112205

RR-11a is a synthetic enzyme inhibitor of **Legumain**.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

RR6

Cat. No.: HY-18780

RR6 is a selective, reversible, and competitive vanin inhibitor.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

RS-1

Cat. No.: HY-19793

RS-1 is a **RAD51** activator, and also increases **CRISPR/Cas9**-mediated knock-in efficiencies.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RS-246204

Cat. No.: HY-112484

RS-246204 is a R-spondin-1 substitute compound that is able initiate small intestinal organoids without the use of the R-spondin-1 protein.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RTA-408

(Omaveloxolone)

Cat. No.: HY-12212

RTA-408 is an antioxidant inflammation modulator (AIM), which activates **Nrf2** and suppresses nitric oxide (NO).



Purity: 98.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RTS-V5

Cat. No.: HY-112908

RTS-V5 is a dual **HDAC/proteasome** inhibitor with IC_{50}s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

RU-SKI 43

Cat. No.: HY-18366

RU-SKI 43 is a small molecule inhibitor of Hhat(Hedgehog acyltransferase), the enzyme responsible for the attachment of palmitate onto Shh.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

RU-SKI 43 hydrochloride

Cat. No.: HY-18366A

RU-SKI 43 hydrochloride is a small molecule inhibitor of Hhat(Hedgehog acyltransferase), the enzyme responsible for the attachment of palmitate onto Shh.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Rubitecan

(RFS 2000; 9-Nitrocamptothecin) Cat. No.: HY-13744

Rubitecan (RFS 2000), a camptothecin derivative, is an orally active **topoisomerase I** inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rucaparib

(AG014699; PF-01367338) Cat. No.: HY-10617A

Rucaparib (AG014699) is an inhibitor of **PARP** with K_i of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP domains.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Rucaparib Camsylate

Cat. No.: HY-102003

Rucaparib Camsylate is an inhibitor of **PARP** with a K_i of 1.4 nM for PARP1, and also shows binding affinity to eight other PARP domains.



Purity: 99.92%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rucaparib phosphate

(AG-014699 phosphate; PF-01367338 phosphate) Cat. No.: HY-10617

Rucaparib phosphate (AG-014699 phosphate) is a potent and oral **PARP** inhibitor, with a K_i of 1.4 nM for PARP1 in cell-free assay, also showing binding affinity to eight other PARP domains.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ruxolitinib

(INCB018424) Cat. No.: HY-50856

Ruxolitinib is a potent and selective **JAK1/2** inhibitor with IC_{50}s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ruxolitinib phosphate

(INCB018424 phosphate) Cat. No.: HY-50858

Ruxolitinib phosphate is a potent **JAK1/2** inhibitor with IC_{50}s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ruxolitinib S enantiomer

(S-Ruxolitinib; INCB18424) Cat. No.: HY-50856A

Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective **JAK1/2** inhibitor to enter the clinic with IC_{50} of 3.3 nM/2.8 nM in cell-free assays.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Ruxolitinib sulfate

(INCB018424 sulfate) Cat. No.: HY-50859

Ruxolitinib sulfate is the first potent, selective **JAK1/2** inhibitor to enter the clinic with IC_{50}s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

RX-3117

(TV-1360; fluorocyclopentenylcytosine) Cat. No.: HY-15228

RX-3117(TV-1360; Fluorocyclopentenylcytosine) is novel a cytidine analog; shows anticancer activity in several cancer cell lines, including gemcitabine-resistant variants.



Purity: 97.45%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

S 2101

Cat. No.: HY-110277

S 2101 is a **lysine-specific demethylase 1** (**LSD1**) inhibitor with an IC_{50} of 0.99 μM, K_i of 0.61 μM and K_{inact}/K_i of 4560 M/s.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

S 3304

Cat. No.: HY-106992

S 3304 is a novel **matrix metalloproteinases (MMP)** inhibitor specific for **MMP-2** and **MMP-9**.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

S-Allyl-L-cysteine

Cat. No.: HY-W013573

S-Allyl-L-cysteine, one of the organosulfur compounds found in AGE, possess various biological effects including neurotrophic activity, anti-cancer activity, anti-inflammatory activity.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

S-Gboxin

Cat. No.: HY-111652

S-Gboxin, a functional analogue of Gboxin, inhibits growth of mouse and human glioblastoma (GBM) with an IC_{50} of 470 nM. Antitumour activity.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

S130

Cat. No.: HY-112818

S130 is a high affinity, selective inhibitor of **ATG4B** (a major cysteine protease) with an IC_{50} of 3.24 μM. S130 suppresses autophagy flux.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

S49076

Cat. No.: HY-12965

S49076 is a novel, potent inhibitor of **MET**, **AXL/MER**, and **FGFR1/2/3** with IC_{50} values below 20 nM.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

S55746

(BLC201)

Cat. No.: HY-117288

S55746 (BLC201) is a potent, orally active and selective **BCL-2** inhibitor, with a K_i of 1.3 nM and a K_d of 3.9 nM. S55746 (BLC201) has antitumor activity with low toxicity.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S55746 hydrochloride

(BLC201 (hydrochloride))

Cat. No.: HY-117288A

S55746 hydrochloride (BLC201 hydrochloride) is a potent, orally active and selective **BCL-2** inhibitor, with a K_i of 1.3 nM and a K_d of 3.9 nM. S55746 hydrochloride (BLC201 hydrochloride) has antitumor activity with low toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S63845

Cat. No.: HY-100741

S63845 is a potent and selective myeloid cell leukemia 1 (**MCL1**) inhibitor with a K_d of 0.19 nM for human MCL1.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sabutoclax

(BI-97C1)

Cat. No.: HY-15191

Sabutoclax is a potent and effective **Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1)** inhibitor with IC_{50}s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Saccharin 1-methylimidazole

Cat. No.: HY-112060

Saccharin 1-methylimidazole is an activator for **DNA/RNA Synthesis**.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SAFit2

Cat. No.: HY-102080

SAFit2 is a novel, selective **FK506-binding protein 51** (**FKBP51**) antagonist with a K_i of 6 nM and also enhances **AKT2**-AS160 binding.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

SAG

Cat. No.: HY-12848

SAG is a potent **Smo receptor** agonist which activates the Hedgehog signaling pathway with a K_d of 59 nM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SAG hydrochloride

Cat. No.: HY-12848B

SAG (hydrochloride) is a potent **Smo receptor** agonist, and activates the Hedgehog signaling pathway, with a K_d of 59 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SAHA chloroalkane T1

Cat. No.: HY-111595

SAHA chloroalkane T1 is a chloroalkane capture tag by tethering Vorinostat (SAHA) and a chloroalkane tag T1.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Saikosaponin D

Cat. No.: HY-N0250

Saikosaponin D is a triterpene saponin isolated from Bupleurum, with anti-inflammatory, anti-bacterial, anti-tumor, and anti-allergic activities; Saikosaponin D inhibits **selectin**, **STAT3** and **NF-kB** and activates **estrogen receptor-β**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sal003

Cat. No.: HY-15969

Sal003 is a potent, specific and cell-permeable inhibitor of the **eukaryotic translation initiation factor 2α (eIF2α) phosphatase**. Sal003 is a derivative of salubrinal.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Salermide

Cat. No.: HY-101073

Salermide is an inhibitor of **Sirt1** and **Sirt2**; can cause strong cancer-specific apoptotic cell death.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Salicin

(D-(−)-Salicin; Salicoside)

Cat. No.: HY-N0149

Salicin is a natural **COX** inhibitor.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Salinomycin

(Procoxacin)

Cat. No.: HY-15597

Salinomycin is an anticoccidial drug with potent **anti-bacterial** activity and an novel anticancer agent targeting human cancer stem cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Salinomycin sodium salt

(Salinomycin sodium; Sodium salinomycin)

Cat. No.: HY-17439

Salinomycin sodium salt is an anticoccidial drug with potent **anti-bacterial** activity and an novel anticancer agent targeting human cancer stem cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Salirasib (S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS)

Cat. No.: HY-14754

Salirasib is a **Ras** inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.



Purity: 98.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Salubrinal

Cat. No.: HY-15486

Salubrinal is a cell-permeable and selective inhibitor of **eIF2α dephosphorylation**. Salubrinal acts as a dual-specificity phosphatase 2 (**Dusp2**) inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Salvianolic acid C

Cat. No.: HY-N0319

Salvianolic acid C is a noncompetitive Cytochrome P4502C8 (**CYP2C8**) inhibitor and a moderate mixed inhibitor of Cytochrome P45022J2 (**CYP2J2**), with K_is of 4.82 μM and 5.75 μM for CYP2C8 and CYP2J2, respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

San78-130

Cat. No.: HY-101113

San78-130 is a selective and potent **ALK1** inhibitor with an IC_{50} of 62 nM. San78-130 also inhibits FLT4/VEGFR3, KDR/VEGFR2, MEK2, and FLT3 with IC_{50}s of 114, 162, 186.7, and 188 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Sanguinarine (Pseudochelerythrine; Sanguinarin)

Cat. No.: HY-N0052

Sanguinarine, a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate **apoptosis** via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sanguinarine chloride (Pseudochelerythrine chloride; Sanguinarium chloride)

Cat. No.: HY-N0052A

Sanguinarine chloride, a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate **apoptosis** via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SANT-1

Cat. No.: HY-100224

SANT-1 is a potent **Smo** antagonist, inhibits **Hedgehog** signaling, with IC_{50}s of 20 nM and 30 nM in Shh-LIGHT2 and SmoA1-LIGHT2 assay, respectively.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Sapacitabine (CS682; CYC682)

Cat. No.: HY-16445

Sapacitabine is an orally available **nucleoside analog** prodrug that is structurally related to cytarabine.



Purity: 98.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sapanisertib (INK-128; MLN0128)

Cat. No.: HY-13328

Sapanisertib (INK-128) is an orally available, ATP-dependent **mTOR1/2** inhibitor with an IC_{50} of 1 nM for mTOR kinase.



Purity: 99.06%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sapitinib (AZD-8931)

Cat. No.: HY-13050

Sapitinib (AZD-8931) is a reversible, ATP competitive **EGFR** inhibitor of with IC_{50}s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SAR-20347

Cat. No.: HY-100895

SAR-20347 is an inhibitor of **TYK2**, **JAK1**, **JAK2** and **JAK3** with IC_{50}s of 0.6, 23, 26 and 41 nM, respectively.



Purity: 97.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SAR-260301

Cat. No.: HY-15837

SAR-260301 is an orally available and selective **PI3Kβ** inhibitor with an IC_{50} of 23 nM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SAR125844

Cat. No.: HY-16446

SAR125844 is a potent, highly selective, reversible and ATP-competitive **MET receptor tyrosine kinase (RTK)** inhibitor, with an IC_{50} of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SAR131675

Cat. No.: HY-15458

SAR131675 is a potent and selective **VEGFR3** inhibitor with an IC_{50} of 23 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SAR405

Cat. No.: HY-12481

SAR405 is a **PIK3C3/Vps34** inhibitor with an IC_{50} of 1.2 nM. SAR405 prevents autophagy and synergizes with MTOR inhibition in tumor cells.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

SAR405 R enantiomer

Cat. No.: HY-12481A

SAR405 R enantiomer is the less active enantiomer of SAR405. SAR405 is a PIK3C3/Vps34 inhibitor.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

SAR405838

(MI-77301)

Cat. No.: HY-18986

SAR405838 is a highly potent and selective MDM2 inhibitor, binds to MDM2 with Ki= 0.88 nM and has high specificity over other proteins.



Purity: 95.14%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Saracatinib

(AZD0530)

Cat. No.: HY-10234

Saracatinib (AZD0530) is a potent **Src** family inhibitor with IC_{50}s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk and shows high selectivity over other tyrosine kinases.



Purity: 99.88%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Sardomozide

(CGP 48664; SAM-486A)

Cat. No.: HY-13746

Sardomozide is an S-adenosylmethionine decarboxylase (**SAMDC**) inhibitor with an IC_{50} of 5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sardomozide dihydrochloride

(CGP 48664A)

Cat. No.: HY-13746B

Sardomozide dihydrochloride is an S-adenosylmethionine decarboxylase (**SAMDC**) inhibitor with an IC_{50} of 5 nM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Saridegib

(IPI-926; Patidegib) Cat. No.: HY-16587

Saridegib is a potent and specific inhibitor of Smoothened **(Smo)**, a key signaling transmembrane protein in the Hedgehog (Hh) pathway.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sarsasapogenin

(Parigenin; Sarsagenin) Cat. No.: HY-N0073

Sarsasapogenin is a sapogenin from the Chinese medical herb Anemarrhena asphodeloides Bunge, with antidiabetic, anti-oxidative, anticancer and anti-inflamatory activities.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Satraplatin

(BMS182751; BMY45594; JM216) Cat. No.: HY-17576

Satraplatin is an **alkylating** agent, with potent antitumor effect.



Purity: 99.26%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Savolitinib

(Volitinib; HMPL-504; AZD-6094) Cat. No.: HY-15959

Savolitinib (AZD6094) ia highly potent and selective **c-Met** inhibitor with an IC_{50} of 5 nM.



Purity: 98.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SB 202190

Cat. No.: HY-10295

SB 202190 is a cell-permeable **p38 MAP kinase** inhibitor with IC_{50}s of 50 nM and 100 nM for p38 and p38β2, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

SB 242235

Cat. No.: HY-18306

SB-242235 is a potent and selective **p38 MAP kinase** inhibitor, with an IC_{50} of 1.0μM in primary human chondrocytes.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SB 525334

Cat. No.: HY-12043

SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC_{50} of 14.3 nM.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SB-366791

Cat. No.: HY-12245

SB-366791 is a potent , competitive and selective vanilloid receptor (VR1/TRPV1) antagonist with IC50 of 5.7±1.2 nM target: VR1/TRPV1 IC 50: 5.7±1.2 nM SB-366791 produced a concentration-dependent inhibition of the response to capsaicin with an apparent pKb of...



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB-3CT

Cat. No.: HY-12354

SB-3CT is a potent and competitive matrix metalloproteinase **MMP-2** and **MMP-9** inhibitor with K_i values of 13.9 and 600 nM, respectively. SB-3CT shows neuroprotective effects and blood-brain barrier permeability.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SB-431542

Cat. No.: HY-10431

SB-431542 is a potent and selective inhibitor of **ALK5/TGF-β type I Receptor** with an IC_{50} value of 94 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SB-505124

Cat. No.: HY-13521

SB-505124 is a selective inhibitor of **TGF-β Receptor type I receptor** (**ALK4**, **ALK5**, **ALK7**), with **IC_{50}**s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SB-505124 hydrochloride

Cat. No.: HY-13521A

SB-505124 hydrochloride is a selective inhibitor of **TGF-β Receptor type I receptor** (**ALK4**, **ALK5**, **ALK7**), with **IC_{50}**s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

SB-590885

Cat. No.: HY-10966

SB-590885 is a potent **B-Raf** inhibitor with **K_i** of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SB-743921

Cat. No.: HY-12069

SB-743921 is a potent inhibitor of the mitotic **kinesin KSP (Eg5)**, with a **K_i** of 0.1 nM.



Purity: 97.31%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SB1317

(TG02)

Cat. No.: HY-15166

SB1317 is a potent inhibitor of **CDK2**, **JAK2**, and **FLT3** for the treatment of cancer, with **IC_{50}** of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SBE13

Cat. No.: HY-15158A

SBE13 is a potent and selective **Plk1** inhibitor, with an **IC_{50}** of 200 pM; SBE13 poorly inhibits Plk2 (IC_{50}>66 μM) or Plk3 (IC_{50}=875 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

SBE13 Hydrochloride

Cat. No.: HY-15158

SBE13 Hydrochloride is a potent and selective **Plk1** inhibitor, with an **IC_{50}** of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC_{50}>66 μM) or Plk3 (IC_{50}=875 nM).



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SBI-0206965

Cat. No.: HY-16966

SBI-0206965 is a potent, selective and cell permeable autophagy kinase **ULK1** inhibitor with **IC_{50}**s of 108 nM for ULK1 kinase and 711 nM for the highly related kinase ULK2 .



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SBI-0640756

(SBI-756)

Cat. No.: HY-19560

SBI-0640756 (SBI-756) is a water soluble inhibitor of **eIF4G1** and disrupts the eIF4F complex.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

SC-514

(GK 01140)

Cat. No.: HY-13802

SC-514 is a selective **IKK-2** inhibitor (**IC_{50}**=11.2±4.7 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SC-560

Cat. No.: HY-59105

SC-560 is a potent and selective **COX-1** inhibitor with an IC_{50} of 9 nM.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC144

Cat. No.: HY-15614

SC144 is the first-in-class orally active small-molecule gp130 inhibitor; inhibits cell growth in a panel of human ovarian cancer cell lines with IC50 values in a submicromolar range.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SC144 hydrochloride

Cat. No.: HY-15614A

SC144 hydrochloride is the first-in-class orally active small-molecule gp130 inhibitor; inhibits cell growth in a panel of human ovarian cancer cell lines with IC50 values in a submicromolar range.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SC66

Cat. No.: HY-19832

SC66 is a novel **Akt** inhibitor, reduces cell viability in a dose- and time-dependent manner, inhibits colony formation and induces apoptosis in hepatocellular carcinoma (HCC) cells.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SC79

Cat. No.: HY-18749

SC79 is a selective and cell-permeable **Akt** activator which activates Akt phosphorylation and inhibits Akt membrane translocation.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Scabertopin

Cat. No.: HY-N1247

Scabertopin, isolated from the whole plant of Elephantopus scaber, is a sesquiterpene lactone. Scabertopin has been found to be prominent anticancer constituents.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

SCD1 inhibitor-1

Cat. No.: HY-112812

SCD1 inhibitor-1 is a potent and liver-selective **stearoyl-CoA desaturase-1 (SCD1)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SCH 58261

Cat. No.: HY-19533

SCH 58261 is a potent, selective and competitive antagonist of **adenosine A2A receptor** with an IC_{50} of 15 nM, and displays 323-, 53- and 100-fold more selective for A2A receptor than A1, A2B, and A3 receptors, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SCH-1473759

Cat. No.: HY-10482

SCH-1473759 is an **aurora** inhibitor with IC_{50}s of 4 and 13 nM for aurora A and B, respectively.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SCH-1473759 hydrochloride

Cat. No.: HY-10483

SCH-1473759 hydrochloride is an **aurora** inhibitor with IC_{50}s of 4 and 13 nM for aurora A and B, respectively.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SCH772984

Cat. No.: HY-50846

SCH772984 potently inhibits **ERK1** and **ERK2** activity with IC_{50}s of 4 and 1 nM, respectively.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SCH900776

(MK-8776)

Cat. No.: HY-15532

SCH900776 is a potent, selective and oral inhibitor of checkpoint kinase1 (**Chk1**) with an IC_{50} of 3 nM. It shows 50- and 500-fold selectivity over CDK2 andChk2, respectively.



Purity: 99.65%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SCH900776 S-isomer

(MK-8776 S-isomer)

Cat. No.: HY-15532B

SCH900776 S-isomer is the S-isomer of SCH900776. SCH900776 is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (**Chk1**) with IC_{50} of 3 nM.



Purity: 95.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Schisandrin C

(Schizandrin-C; Wuweizisu-C)

Cat. No.: HY-N0690

Schisandrin C is a phytochemical lignan isolated from Schizandra chinensis Baill; shows anticancer-effects in human leukemia U937 cells.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Schisandrol B

(Gomisin-A; TJN-101; Wuweizi alcohol-B)

Cat. No.: HY-N0692

Schisandrol B (Gomisin-A;TJN-101;Wuweizi alcohol-B) is one of its major active constituents of traditional hepato-protective Chinese medicine, Schisandra sphenanthera.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

SCR-1481B1

(c-Met inhibitor 2)

Cat. No.: HY-18711A

SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SCR7

Cat. No.: HY-12742

SCR7 is a **DNA Ligase IV** inhibitor with anticancer activity and is also a **CRISPR HDR** enhancer which increases the efficiency of Cas9-mediated HDR.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Scriptaid

(Scriptide; GCK1026)

Cat. No.: HY-15489

Scriptaid is a potent **histone deacetylase (HDAC)** inhibitor, used in cancer research.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Scutellarin

Cat. No.: HY-N0751

Scutellarin, an active flavone isolated from Scutellaria baicalensis, can down-regulates the **STAT3/Girdin/Akt** signaling in HCC cells, and inhibits RANKL-mediated **MAPK and NF-κB** signaling pathway in osteoclasts.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

SD-208

Cat. No.: HY-13227

SD-208 is a selective **TGF-βRI (ALK5)** inhibitor with IC_{50} of 48 nM, and > 100-fold selectivity over TGF-βRII.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SDZ281-977

(SDZ-LAP 977) Cat. No.: HY-101756

SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Seclidemstat

(SP-2577) Cat. No.: HY-103713

Seclidemstat (SP-2577) is a potent **LSD1** inhibitor, with a mean IC_{50} of 127 nM.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SEL120-34A

Cat. No.: HY-111388

SEL120-34A is a potent, selective, orally available, ATP-competitive **CDK8** inhibitor, with IC_{50}s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

SEL120-34A HCl

Cat. No.: HY-111388B

SEL120-34A HCl is a potent, selective, orally available, ATP-competitive **CDK8** inhibitor, with IC_{50}s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SEL120-34A monohydrochloride

Cat. No.: HY-111388A

SEL120-34A monohydrochloride is an ATP-competitive and selective **CDK8** inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC_{50}s of 4.4 nM and 10.4 nM, respectively, with a K_d of 3 nM for CDK8.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Seliciclib

(Roscovitine; CYC202; R-roscovitine) Cat. No.: HY-30237

Seliciclib (Roscovitine) is a potent and selective **CDKs** inhibitor with IC_{50}s of 0.2 μM, 0.65 μM, and 0.7 μM for **CDK5**, **Cdc2**, and **CDK2**, respectively.



Purity: 99.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Selisistat

(EX-527) Cat. No.: HY-15452

Selisistat (EX-527) is a potent and selective **SIRT1** inhibitor with IC_{50} of 98 nM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Selisistat R-enantiomer

(EX-527 (R-enantiomer)) Cat. No.: HY-15452B

Selisistat R-enantiomer (EX-527 R-enantiomer) is much less active R-enantiomer of Selisistat, with an IC_{50} of > 100 μM for SIRT1.



Purity: 97.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Selisistat S-enantiomer

(EX-527 (S-enantiomer)) Cat. No.: HY-15452A

Selisistat S-enantiomer (EX-527 S-enantiomer) is the S-enantiomer of Selisistat, with an IC_{50} of 123 nM for SIRT1. Selisistat S-enantiomer is much more potent than Selisistat R-enantiomer.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Selitrectinib

(LOXO-195) Cat. No.: HY-101977

Selitrectinib (LOXO-195) is a next-generation **TRK kinase** inhibitor (TKI), with IC_{50}s of 0.6 nM, <2.5 nM for TRKA and TRKC respectively.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Selonsertib

(GS-4997) Cat. No.: HY-18938

Selonsertib is an apoptosis signal-regulating kinase 1 (**ASK1**) inhibitor with a **pIC$_{50}$** of 8.3±0.07.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Selpercatinib

Cat. No.: HY-114370

Selpercatinib is a **RET kinase** inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an **IC$_{50}$** of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively. Antineoplastic activity.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Selumetinib

(AZD6244; ARRY-142886) Cat. No.: HY-50706

Selumetinib is a highly potent **MEK** inhibitor, with an **IC$_{50}$** of 14 nM against MEK1.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Semaxinib

(SU5416) Cat. No.: HY-10374

Semaxinib (SU5416) is a potent and selective inhibitor of **VEGFR** (**Flk-1/KDR**) with an **IC$_{50}$** of 1.23 μM.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Senexin A

Cat. No.: HY-15681

Senexin A is a **CDK8** inhibitor with an **IC$_{50}$** of 280 nM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Seocalcitol

(EB 1089) Cat. No.: HY-32341

Seocalcitol is a vitamin D analog, binds **vitamin D receptor** protein from human osteosarcoma MG-63 cells with **K$_d$** of 0.27 nM.



Purity: 98.85%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Serabelisib

(MLN1117; INK1117) Cat. No.: HY-12285

Serabelisib (MLN1117) is a selective **p110α** inhibitor with an **IC$_{50}$** of 15 nM.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Serdemetan

(JNJ-26854165) Cat. No.: HY-12025

Serdemetan(JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.



Purity: 98.32%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Sesamol

Cat. No.: HY-N1417

Sesamol is a constituent of sesame oil. Sesamol shows a free radical scavenging activity. Sesamol shows an IC$_{50}$=5.95±0.56 μg/mL in the DPPH assay. Anti-oxidant activities. Anticancer activities.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Seviteronel

(VT-464) Cat. No.: HY-15996

Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase IC$_{50}$=69 nM) that demonstrated both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition.



Purity: 99.11%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Seviteronel R enantiomer

(VT-464 (R enantiomer)) Cat. No.: HY-15996A

Seviteronel (VT-464) R enantiomer is the R enantiomer of Seviteronel (VT-464), which is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM); Seviteronel (VT-464) R enantiomer's activity is unknown.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Seviteronel racemate

(VT-464 (racemate)) Cat. No.: HY-15996B

Seviteronel (VT-464) racemate is the racemate form of Seviteronel (VT-464), which is a potent CYP17 lyase inhibitor(h-Lyase IC_{50}=nM)inhibition.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SF1670

(PTPase CD45 Inhibitor) Cat. No.: HY-15842

SF1670 is a potent and specific phosphatase and tensin homolog deleted on chromosome 10 (**PTEN**) inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SF2523

Cat. No.: HY-101146

SF2523 is a highly selective and potent inhibitor of **PI3K** with IC_{50}s of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for **PI3Kα**, **PI3Kγ**, **DNA-PK**, BRD4 and mTOR, respectively.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SGC-CBP30

Cat. No.: HY-15826

SGC-CBP30 is a potent CREBBP/EP300 bromodomain inhibitor with IC50 of 21-69 and 38 nM for CREBBP and EP300 bromodomains, respectively.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGC-GAK-1

Cat. No.: HY-122186

SGC-GAK-1 is a potent, selective cyclin G-associated kinase (**GAK**) inhibitor with a K_i of 3.1 nM. SGC-GAK-1 is a chemical probe for GAK.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SGC-iMLLT

Cat. No.: HY-112804

SGC-iMLLT is a potent and selective inhibitor of **MLLT1/3-histone** interactions, occupies the Kac/Kcr binding site of MLLT1 YD (ENL/YEATS1), with high binding activity at MLLT1 YD (IC_{50}, 0.26 μM; K_d, 0.129 μM) and MLLT3 YD (AF9/YEATS3) (K_d, 0.077 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGC0946

Cat. No.: HY-15650

SGC0946 is a highly potent and selective DOT1L methyltransferase inhibitor with IC50 of 0.3 nM; selectively kill mixed lineage leukaemia cells.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SGC2085

Cat. No.: HY-100565

SGC2085 is a potent and selective coactivator associated arginine methyltransferase 1 (**CARM1**) inhibitor with an IC_{50} of 50 nM.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SGC3027

Cat. No.: HY-112445

SGC3027 is a **histone methyltransferase** inhibitor. SGC3027 is the first potent, selective and cell active chemical probe for **PRMT7**.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

SGC707

Cat. No.: HY-19715

SGC707 is a first-in-class PRMT3 chemical probe which is a potent, selective, and cell-active allosteric inhibitor of PRMT3 with IC50 of 31 nM.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGI-1027

Cat. No.: HY-13962

SGI-1027 is a **DNA methyltransferase (DNMT)** inhibitor, with IC_{50}s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SGI-1776

Cat. No.: HY-13287

SGI-1776 is an inhibitor of **Pim** kinases, with IC_{50}s of 7 nM, 363 nM, and 69 nM for Pim-1, -2 and -3, respectively.



Purity: 99.94%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SGI-7079

Cat. No.: HY-12964

SGI-7079 is an Axl inhibitor, significantly inhibits the proliferation of SUM149 or KPL-4 cells with an IC50 of 0.43 or 0.16 μM, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGN-2FF

Cat. No.: HY-107366

SGN-2FF is an oral inhibitor of fucosylation, directly inhibits **fucosyltransferase** activity, and possesses antitumor activity.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SGX-523

Cat. No.: HY-12019

SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. IC50 value: 4 nM Target: Met in vitro: SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SH-4-54

Cat. No.: HY-16975

SH-4-54 is a **STAT** inhibitor that binds to STAT3 and STAT5 with K_Ds of 300, 464 nM, respectively.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SH5-07

Cat. No.: HY-100494

SH5-07 is a hydroxamic acid based **Stat3** inhibitor with an IC_{50} of 3.9 μM in in vitro assay.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Shepherdin 79-87

Cat. No.: HY-P1750

Shepherdin (79-87) is amino acids 79 to 87 fragment of Shepherdin. Shepherdin is a peptidomimetic antagonist of the complex between Hsp90 and Survivin. Anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Shikonin

(C.I. 75535; Isoarnebin 4)

Cat. No.: HY-N0822

Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin has shown various biological activities, including inhibition of **TNF-α**, **NF-κB**, **HIV-1**.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

SHIN1

Cat. No.: HY-112066

SHIN1 is a human serine hydroxymethyltransferse 1 and 2 (**SHMT1/2**) inhibitor with **IC_{50}**s of 5 and 13 nM, respectively, in an in vitro assay.

Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Shogaol

([6]-Shogaol; 6-Shogaol) Cat. No.: HY-14616

6-shogaol, an active compound isolated from Ginger (Zingiber officinale Rosc), exhibits a variety of biological activities including anticancer, anti-inflammation, and anti-oxidation.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

SHP099

Cat. No.: HY-100388

SHP099 is a potent, selective, orally available **SHP2** inhibitor with an **IC_{50}** of 70 nM.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SHP099 hydrochloride

Cat. No.: HY-100388A

SHP099 hydrochloride is a potent, selective and orally available **SHP2** inhibitor with an **IC_{50}** of 70 nM.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SHP394

Cat. No.: HY-114397

SHP394 is an orally efficacious protein tyrosine phosphatase **SHP2** inhibitor with an **IC_{50}** of 23 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SID 3712249

(MiR-544 Inhibitor 1) Cat. No.: HY-19731

SID 3712249 (MiR-544 Inhibitor 1) is an inhibitor of the biogenesis of microRNA-544 (miR-544).



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Silibinin

(Silybin; Silibinin A; Silymarin I) Cat. No.: HY-13748

Silibinin (Silybin), an effective anti-cancer and chemopreventive agent, has been shown to exert multiple effects on cancer cells, including inhibition of both cell proliferation and migration.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Silmitasertib

(CX-4945) Cat. No.: HY-50855

Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent **CK2** inhibitor, with **IC_{50}** values of 1 nM against CK2α and CK2α'.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Silmitasertib sodium salt

(CX-4945 (sodium salt)) Cat. No.: HY-50855B

Silmitasertib sodium salt is an orally bioavailable, highly selective and potent **CK2** inhibitor, with **IC_{50}** values of 1 nM against CK2α and CK2α'.



Purity: 99.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Silvestrol

((-)-Silvestrol) Cat. No.: HY-13251

Silvestrol is a eukaryotic translation initiation factor 4A (**eIF4A**) inhibitor isolated from the fruits and twigs of Aglaia foveolata.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 2 mg

Silvestrol aglycone

Cat. No.: HY-13250

Silvestrol aglycone is a Silvestrol analogue, inhibits protein translation initiation in cancer cells, with **EC_{50}**s of 10 and 200 nM for myc-LUC and tub-LUC luciferase reporter protein translation, respectively. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Simurosertib

(TAK-931)

Cat. No.: HY-100888

Simurosertib (TAK-931) is a selective cycle 7 **(CDC7)** kinase inhibitor, with an **IC_{50}**<0.3 nM.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Sinapine

Cat. No.: HY-N5077

Sinapine is an alkaloid from seeds of the cruciferous species which shows favorable biological activities such as antioxidant and radio-protective activities.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sinapine thiocyanate

Cat. No.: HY-N0450

Sinapine is an alkaloid from seeds of the cruciferous species which shows favorable biological activities such as antioxidant and radio-protective activities.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Sinapinic acid

(Sinapic acid)

Cat. No.: HY-W009732

Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of **HDAC**, with an **IC_{50}** of 2.27 mM, and also inhibits **ACE-I** activity.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Sincalide

(CCK-8; SQ19844; Cholecystokinin octapeptide)

Cat. No.: HY-P0093

Sincalide is a rapid-acting, synthetic analog of cholecystokinin for intravenous use in postevacuation cholecystography.



Purity: 99.60%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Sinomenine hydrochloride

(Cucoline hydrochloride)

Cat. No.: HY-15122A

Sinomenine hydrochloride is a blocker of the **NF-κB** activation and also an activator of **μ-opioid receptor**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Siramesine

(Lu 28-179)

Cat. No.: HY-14221

Siramesine(Lu 28-179) is a selective sigma-2 receptor agonist, which has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Siramesine hydrochloride

(Lu 28-179 hydrochloride)

Cat. No.: HY-14221A

Siramesine(Lu 28-179) Hcl is a selective sigma-2 receptor agonist, which has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Siremadlin

(NVP-HDM201; HDM201)

Cat. No.: HY-18658

Siremadlin (NVP-HDM201) is a potent and highly specific **MDM-2/p53** inhibitor.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Sirt2-IN-1

Cat. No.: HY-112427

Sirt2-IN-1 (Compound 9) is a **sirtuin 2** (**Sirt2**) inhibitor with an **IC_{50}** of 163 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Sirtinol

Cat. No.: HY-13515

Sirtinol is a **sirtuin** inhibitor, with **IC_{50}**s of 48 μM, 57.7 μM and 131 μM for ySir2, hSIRT2 and hSIRT2, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SIS3

Cat. No.: HY-13013

SIS3 is a cell-permeable and selective inhibitor of **Smad3**. It inhibits Smad3 phosphorylation with an **IC_{50}** of 3 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Sitravatinib

(MGCD516; MG516)

Cat. No.: HY-16961

Sitravatinib (MGCD516; MG516) is an orally bioavailable, **receptor tyrosine kinase (RTK)** inhibitor with **IC_{50}**s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT , FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SJ-172550

Cat. No.: HY-16664

SJ-172550 is a small molecule inhibitor of **MDMX**; competes for the wild type p53 peptide binding to MDMX with an **EC_{50}** of 5 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SJ000291942

Cat. No.: HY-112331

SJ000291942 is an activator of the canonical bone morphogenetic proteins (**BMP**) signaling pathway. BMPs are members of the transforming growth factor beta (**TGFβ**) family of secreted signaling molecules.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SJ572403

(SJ403)

Cat. No.: HY-114712

SJ572403 (SJ403) is an inhibitor of disordered protein p27(Kip1). p27(Kip1) is a regulator of the CDKs that control eukaryotic cell division.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SJB2-043

Cat. No.: HY-15757

SJB2-043 is an inhibitor of the native **USP1/UAF1** complex with **IC_{50}** of 544 nM.



Purity: 97.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SJB3-019A

Cat. No.: HY-80012

SJB3-019A is a potent and novel **USP1** inhibitor, 5 times more potent than SJB2-043 in promoting ID1 degradation and cytoxicity in K562 cells with **IC_{50}** of 0.0781 μM.



Purity: >99.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SJFα

Cat. No.: HY-114404

SJFα is a 13-atom linker **PROTAC**. SJFα degrades **p38α** with a **DC_{50}** of 7.16nM, but is far less effective at degrading p38δ (DC_{50}=299nM) and does not degrade the other p38 isoforms (β and γ) at concentrations up to 2.5μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

SJFδ

Cat. No.: HY-114405

SJFδ is a 10-atom linker **PROTAC**. SJFδ degrades **p38δ** with a **DC_{50}** of 46.17nM, but does not degrade p38α, p38β, or p38γ.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

SJG-136

(NSC-694501)

Cat. No.: HY-14573

SJG-136 is a **DNA cross-linking** agent, with an **XL_{50}** of 45 nM for pBR322 DNA; SJG-136 has potent antitumor activity.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

SK1-IN-1

Cat. No.: HY-101805

SK1-IN-1 is a potent sphingosine kinase 1 (**SPHK1**) inhibitor with an **IC_{50}** of 58 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SKF-96365 hydrochloride

Cat. No.: HY-100001

SKF-96365 hydrochloride is a non-selective **TRP Channel** blocker.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SKI II

Cat. No.: HY-13822

SKI-II is an oral active and synthetic inhibitor of **sphingosine kinase (SK)** activity, with **IC_{50}** values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

SKL2001

Cat. No.: HY-101085

SKL2001 is an agonist of the **Wnt/β-catenin** pathway, with anti-cancer activity.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

SKLB1002

Cat. No.: HY-13944

SKLB1002 is a potent **VEGFR2** inhibitor with an **IC_{50}** of 32 nM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SKLB4771

(FLT3-IN-1)

Cat. No.: HY-12960

SKLB4771 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM. IC50 value: 10 nM (in vitro) Target: in vitro: SKLB4771 inhibited FLT3 phosphorylation in a dose-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SKLB610

Cat. No.: HY-18199

SKLB610 is a **VEGFR** inhibitor with potent anti-tumor activity.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Skp2 Inhibitor C1

(SKPin C1)

Cat. No.: HY-16661

Skp2 Inhibitor C1(SKPin C1) is a specific small molecule inhibitor of Skp2-mediated p27 degradation, selectively inhibited Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts.



Purity: 96.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SL 0101-1

(SL0101)

Cat. No.: HY-15237

SL 0101-1 (SL0101), a kaempferol glycoside, isolated from the tropical plant F. refracta, is a cell-permeable, selective, reversible, ATP-competitive **p90 Ribosomal S6 Kinase (RSK)** inhibitor, with an IC_{50} of 89 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SL327

Cat. No.: HY-15437

SL327 inhibits **MEK1** and **MEK2**, with IC_{50} values of 180 nM and 220 nM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SLLK, Control Peptide for TSP1 Inhibitor

Cat. No.: HY-P0301

SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SLLK, Control Peptide for TSP1 Inhibitor(TFA)

Cat. No.: HY-P0301A

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for **LSKL**, which is a Thrombospondin (TSP-1) inhibitor.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SLLN-15

Cat. No.: HY-125465

SLLN-15 is an oral active, selective and potent enhancer of **autophagy** that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

SLV-2436

(SEL201-88; SEL-201)

Cat. No.: HY-112113

SLV-2436 is a highly potent and ATP-competitive inhibitor of **MNK1** and **MNK2** with IC_{50}s of 10.8 nM and 5.4 nM, respectively.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SLx-2119

(KD-025)

Cat. No.: HY-15307

SLx-2119 (KD-025) is a selective inhibitor of **ROCK2** with an IC_{50} of 105 nM.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SM 16

Cat. No.: HY-111482

SM 16 is a **ALK5/ALK4** kinase inhibitor with K_is of 10 and 1.5 nM, respectively.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SM-164

Cat. No.: HY-15989

SM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to **XIAP** protein containing both the BIR2 and BIR3 domains with an IC_{50} value of 1.39 nM and functions as an extremely potent antagonist of **XIAP**.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SM-164 Hydrochloride

Cat. No.: HY-15989A

SM-164 Hydrochloride is a cell-permeable Smac mimetic compound. SM-164 binds to **XIAP** protein containing both the BIR2 and BIR3 domains with an IC_{50} value of 1.39 nM and functions as an extremely potent antagonist of **XIAP**.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SMCC-DM1

(DM1-SMCC)

Cat. No.: HY-101070

SMCC-DM1 is DM1 with a reactive linker SMCC to make antibody drug conjugate. DM1 (mertansine), a thiol-containing maytansinoid, is a potent microtubule-disrupting agent.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SMER18

Cat. No.: HY-18672

SMER18 is a small molecule enhancer of rapamycin which act as a mTOR-independent autophagy inducer.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SMER28

Cat. No.: HY-100200

SMER28 is a positive regulator of **autophagy** acting via an mTOR-independent mechanism. SMER28 prevents the accumulation of amyloid beta peptide.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

SMI-16a

(PIM1/2 Kinase Inhibitor VI)

Cat. No.: HY-101947

SMI-16a is a selective **Pim** kinase inhibitor with IC_{50} values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

SMIP004

Cat. No.: HY-15694

SMIP004 is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells, it was found to downregulate SKP2 and to stabilize p27.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SMYD2-IN-1

Cat. No.: HY-111810

SMYD2-IN-1 is a **SMYD2** inhibitor extracted from patent WO2016166186A1, compound example 1.1, has an IC_{50} of 4.45 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SN-38

(NK012)

Cat. No.: HY-13704

SN-38 (NK012) is an active metabolite of the **Topoisomerase I** inhibitor Irinotecan. SN-38 (NK012) inhibits **DNA** and **RNA synthesis** with IC_{50}s of 0.077 and 1.3 μM, respectively.



Purity: 99.46%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

SNIPER(ABL)-013

Cat. No.: HY-111860

SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC_{50} of 20 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-015

Cat. No.: HY-111854

SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC_{50} of 5 μM .



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-019

Cat. No.: HY-111873

SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC_{50} of 0.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-020

Cat. No.: HY-111872

SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-024

Cat. No.: HY-111861

SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC_{50} of 5μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-033

Cat. No.: HY-111871

SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC_{50} of 0.3 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-039

Cat. No.: HY-111874

SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC_{50} of 10 nM. **IC_{50}**s are 0.54 nM, 10 nM, 12 nM, and 50 nM for **ABL**, cIAP1, cIAP2, XIAP, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-044

Cat. No.: HY-111862

SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC_{50} of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-047

Cat. No.: HY-111863

SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC_{50} of 2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-049

Cat. No.: HY-111851

SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC_{50} of 100 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-050

Cat. No.: HY-111858

SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-058

Cat. No.: HY-111859

SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ABL)-062

Cat. No.: HY-124847

SNIPER(ABL)-062, in which an ABL inhibitor is linked to a ligand of cIAP1 via a linker containing a variable polyethylene glycol (PEG) unit, shows a potent activity to degrade the **BCR-ABL** protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(AR)-51

(AR-51)

Cat. No.: HY-119391

SNIPER(AR)-51 (AR-51), consists of a cIAP1 ligand and an androgen ligand, connected by a linker. SNIPER(AR)-51 induces androgen receptor (AR) protein degradation.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(BRD)-1

Cat. No.: HY-111875

SNIPER(BRD)-1, consists of an IAP antagonist LCL-161 derivative and a BET inhibitor, (+)-JQ-1, connected by a linker. SNIPER(BRD)-1 induces the degradation of **BRD4** via the ubiquitin-proteasome pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(ER)-110

Cat. No.: HY-122825

SNIPER(ER)-110 consists of a cIAP1 ligand and an estrogen ligand, connected by a linker. SNIPER(ER)-51 induces **estrogen receptor** (ER) protein degradation with DC_{50}s of <3 nM and 7.7 nM after 4 h and 48 h, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(TACC3)-1

Cat. No.: HY-111876

SNIPER(TACC3)-1 targets the **TACC3** protein for degradation via the ubiquitin-proteasome pathway. SNIPER(TACC3)-1 induces cancer cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNIPER(TACC3)-2

Cat. No.: HY-111877

SNIPER(TACC3)-2 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway. SNIPER(TACC3)-2 induces cancer cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SNS-032

(BMS-387032)

Cat. No.: HY-10008

SNS-032 (BMS-387032) is a selective inhibitor of **CDK2**, **CDK7**, and **CDK9** with IC_{50}s of 38 nM, 62 nM and 4 nM, respectively.



Purity: 98.50%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SNS-314

(SNS-314 Mesylate)

Cat. No.: HY-12003

SNS-314 is a potent and selective **aurora** kinase inhibitor with IC_{50}s of 9, 31, and 6 nM for aurora A, B and C, respectively.



Purity: 99.81%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SNT-207707

Cat. No.: HY-11029

SNT-207707 is a selective, potent and orally active **melanocortin MC-4** receptor antagonist with an IC_{50} of 8 nM (binding) and 5 nM (function) on the MC-4 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

SNT-207858

Cat. No.: HY-11030

SNT-207858 is a selective and orally available **melanocortin MC-4** receptor antagonist with a 170-fold selectivity vs. MC-3 and a 40-fold selectivity versus MC-5. SNT-207858 has an IC_{50} of 8 nM (binding) and 5 nM (function) on the MC-4 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

SNX-5422 Mesylate

(PF-04929113 (Mesylate))

Cat. No.: HY-10213A

SNX-5422 Mesylate (PF-04929113 Mesylate), a prodrug of SNX-2112, is an orally active **Hsp90** inhibitor, with a K_d of 41 nM, and also induces Her-2 degradation, with an IC_{50} of 37nM.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

Soblidotin

(Auristatin PE; TZT-1027) Cat. No.: HY-14672

Soblidotin (Auristatin PE) is a novel synthetic Dolastatin 10 derivative and inhibitor of **tubulin** polymerization.



Purity: 99.76%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Sodium Butyrate

(Butanoic acid sodium salt) Cat. No.: HY-B0350A

Sodium Butyrate (Butanoic acid sodium salt) is a **histone deacetylase (HDAC)** inhibitor, with anti-tumor effects in several cancers.



Purity: >98.00%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 g, 5 g

Sodium orthovanadate

(Sodium vanadate) Cat. No.: HY-D0852

Sodium orthovanadate is an inhibitor of protein tyrosine phosphatases, alkaline phosphatases and a number of ATPases, most likely acting as a phosphate analogue.

Na_3VO_4

Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 g

Sodium phenylbutyrate

(Sodium 4-phenylbutyrate; TriButyrate) Cat. No.: HY-15654

Sodium phenylbutyrate is an inhibitor of **HDAC** and endoplasmic reticulum **(ER)** stress, used in cancer and infection research.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

Solamargine

(Solamargin; δ-Solanigrine) Cat. No.: HY-N0069

Solamargine is a major steroidal alkaloid glycoside extracted from a traditional Chinese medicinal herb, Solanum nigrum L. (SNL); has been shown to inhibit growth and induce apoptosis of various cancer cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Solasodine

(Purapuridine; Solancarpidine; Solasodin) Cat. No.: HY-N0068

Solasodine(Purapuridine) is a poisonous alkaloid chemical compound that occurs in plants of the Solanaceae family. Solasodine showed selective cytotoxicity against cervical cancer cell line (HeLa) and human myeloid leukemia cell line (U937).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 100 mg

Somatostatin

Cat. No.: HY-P0015

Somatostatin is a tetradecapeptide which can suppress the growth hormone (GH) secretion and control the pituitary hormone secretion in human CNS.

Somatostatin

Purity: 99.71%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Sonolisib

(PX-866) Cat. No.: HY-N6775

Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of **PI3K** (IC_{50}=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sophoflavescenol

Cat. No.: HY-N2284

Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with **IC_{50}** of 0.013 μM against **Phosphodiesterase 5 (PDE5)**, and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC_{50}s of 0.30 μM, 0.17 μM, 17.89 μg/mL, 10.98 μM, 8.37 μM and 8.21 μM, respectively.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sophoricoside

Cat. No.: HY-N0423

Sophoricoside is an isoflavone glycoside isolated from Sophora japonica and has anti-inflammatory, anti-cancer and immunosuppressive effects.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Sorafenib

(Bay 43-9006)

Cat. No.: HY-10201

Sorafenib (Bay 43-9006) is a potent multikinase inhibitor with **IC_{50}**s of 6 nM, 20 nM, and 22 nM for **Raf-1**, **B-Raf**, and **VEGFR-3**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sorafenib Tosylate

(Bay 43-9006 (Tosylate))

Cat. No.: HY-10201A

Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent multikinase inhibitor, with **IC_{50}**s of 6 nM, 20 nM, and 22 nM for **Raf-1**, **B-Raf**, and **VEGFR-3**, respectively.



Purity: 99.53%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sotetsuflavone

Cat. No.: HY-N2199

Sotetsuflavone is a potent inhibitor of DENV-NS5 RdRp (Dengue virus NS5 RNA-dependent RNA polymerase) with an IC50 of 0.16 uM, is the most active compound of this series .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SP-13786

Cat. No.: HY-100684

SP-13786 is a highly potent and selective inhibitor of fibroblast activation protein (**FAP**) with an **IC_{50}** of 3.2 nM; also inhibits prolyl oligopeptidase (**PREP**) with an **IC_{50}** of 1.8 μM.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SP2509

Cat. No.: HY-12635

SP2509 is a potent and selective antagonist of **lysine specific demethylase 1 (LSD1)** with **IC_{50}** of 13 nM.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SP600125

Cat. No.: HY-12041

SP600125 is a reversible and ATP-competitive **JNK** inhibitor with **IC_{50}**s of 40, 40 and 90 nM for **JNK1**, **JNK2** and **JNK3**, respectively.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Spautin-1

Cat. No.: HY-12990

Spautin-1 is a specific and potent **autophagy** inhibitor which inhibits ubiquitin-specific peptidases, USP10 and USP13 with **IC_{50}**s of 0.6-0.7 μM.



Purity: 97.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SPD304

Cat. No.: HY-111255

SPD304 is a selective inhibitor of tumor necrosis factor α **(TNFα)** and promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor, with an **IC_{50}** of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

SPDB-DM4

Cat. No.: HY-12460

SPDB-DM4 is a **drug-linker conjugate for ADC** by using the maytansinebased payload (DM4) via a SPDB linker, exhibiting potent anti-tumor activity.



Purity: 95.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Spebrutinib

(AVL-292; CC-292)

Cat. No.: HY-18012

Spebrutinib (AVL-292; CC-292) is a covalent, orally active, and highly selective with an **IC_{50}** of 0.5 nM.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Spebrutinib besylate

(AVL-292 (benzenesulfonate); CC-292 (besylate))

Cat. No.: HY-18012A

Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of **Btk** kinase activity (IC_{50}<0.5 nM, K_{inact}/K_i=7.69×10^4 M^{-1}s^{-1}) in biochemical assays.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

SPP-86

Cat. No.: HY-110193

SPP-86 is a potent and selective cell permeable inhibitor of **RET tyrosine kinase**, with an IC_{50} of 8 nM. SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg

SR-3029

Cat. No.: HY-100011

SR-3029 is a potent and ATP competitive **CK1δ** and **CK1ε** inhibitor, with IC_{50}s of 44 nM and 260 nM, respectively, and K_is of 97 nM for both kinases.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

SR-3677

Cat. No.: HY-13300

SR-3677 is a potent and selective **ROCK-II** inhibitor with an IC_{50} of ~3 nM.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SR-4370

Cat. No.: HY-111400

SR-4370 is an inhibitor of **HDAC**, with IC_{50}s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SR0987

Cat. No.: HY-101454

SR0987 is a **RORγt** agonist, with an EC_{50} of 800 nM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR1078

Cat. No.: HY-14422

SR1078 is an agonist of retinoic acid receptor-related orphan receptor α/γ (**RORα/RORγ**).



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SR9009

Cat. No.: HY-16989

SR9009 is a **REV-ERBα/β** agonist with IC_{50}s of 670 nM and 800 nM for REV-ERBα and REV-ERBβ, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR9011

Cat. No.: HY-16988

SR9011 is a **REV-ERBα/β** agonist with IC_{50}s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SR9011 hydrochloride

Cat. No.: HY-16988A

SR9011 hydrochloride is a **REV-ERBα/β** agonist with IC_{50}s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.



Purity: 97.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SR9243

Cat. No.: HY-16972

SR9243 is a **liver-X-receptor (LXR)** inverse agonist that induces LXR-corepressor interaction.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Src Inhibitor 1

(Src Kinase Inhibitor 1; Src-I1)

Cat. No.: HY-101053

Src Inhibitor 1 is a potent and selective dual site **Src** tyrosine kinase inhibitor with **IC_{50}** values of 44 nM for Src and 88nM for Lck.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

SRI 31215 TFA

Cat. No.: HY-114363A

SRI 31215 (TFA), a triplex inhibitor of **matriptase**, **hepsin** and **hepatocyte growth factor activator (HGFA)** with **IC_{50}**s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SRPIN340

(SRPK inhibitor)

Cat. No.: HY-13949

SRPIN340 is an ATP-competitive serine-arginine-rich protein kinase (**SRPK**) inhibitor, with a **K_i** of 0.89 μM for SRPK1.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SRPKIN-1

Cat. No.: HY-116856

SRPKIN-1 is a covalent and irreversible **SRPK1/2** inhibitor with **IC_{50}**s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

SRT 1460

Cat. No.: HY-124037

SRT 1460, a potent **Sirtuin-1 (SIRT1)** activator with an **$EC_{1.5}$** value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 μM), and is more potent than Resveratrol and the closest sirtuin homologues.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SRT 2183

Cat. No.: HY-19759

SRT 2183 is a selective **Sirtuin-1 (SIRT1)** activator with an **$EC_{1.5}$** value of 0.36 μM. SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SS28

Cat. No.: HY-100761

SS28, a SRT501 analog with oral bioavailability, inhibits **tubulin polymerization** to cause cell cycle arrest at G2/M phase. SS28 results in apoptosis rather than necrosis tubulin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SSE15206

Cat. No.: HY-111425

SSE15206 is a **microtubule** polymerization inhibitor (GI_{50} = 197 nM in HCT116 cells) that overcomes multidrug resistance. Causes aberrant mitosis resulting in G2/M arrest due to incomplete spindle formation in cancer cells.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SSR128129E

(SSR)

Cat. No.: HY-15599

SSR128129E is an orally available and allosteric **FGFR** inhibitor with an **IC_{50}** of 1.9 μM for FGFR1.



Purity: 99.65%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg

SSR128129E free acid

(SSR free acid)

Cat. No.: HY-15599A

SSR128129E free acid is an orally available and allosteric **FGFR** inhibitor with an IC_{50} of 1.9 μM for FGFR1.



Purity: >98%
Clinical Data: Phase 3
Size: 10 mg, 50 mg

ST8154AA1

Cat. No.: HY-112805

ST8154AA1 is a part of antibody drug conjugates (**ADCs**) charged with **HDAC** inhibitor by a linker, shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

ST8155AA1

Cat. No.: HY-112806

ST8155AA1 is a part of antibody drug conjugates (**ADCs**) charged with **HDAC** inhibitor by a linker, shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

STAT3-IN-1

Cat. No.: HY-100753

STAT3-IN-1 (compound 7d) is an excellent, selective and orally active **STAT3** inhibitor, with IC_{50} values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

STAT3-IN-3

Cat. No.: HY-128588

STAT3-IN-3 is a potent and selective inhibitor of **signal transducer and activator of transcription 3 (STAT3)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

STAT5-IN-1

Cat. No.: HY-101853

STAT5-IN-1 is a **STAT5** inhibitor with an IC_{50} of 47 μM for STAT5β isoform.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STAT5-IN-2

Cat. No.: HY-102048

STAT5-IN-2 is a **STAT5** inhibitor with EC_{50}s of 9 μM and 5 μM in K562 and KU812 cells, respectively. Potent antileukemic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Stattic

Cat. No.: HY-13818

Stattic is a potent inhibitor of **STAT3** activation and dimerization.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Stauprimide

Cat. No.: HY-N6747

Stauprimide is a staurosporine analog that promotes embryonic stem cell (ESC) differentiation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Staurosporine

(Antibiotic AM-2282; STS; AM-2282)

Cat. No.: HY-15141

Staurosporine is a potent and non-selective inhibitor of protein kinases with IC_{50}s of 6 nM, 15 nM, 2 nM, and 3 nM for **PKC**, **PKA**, **c-Fgr**, and **Phosphorylase kinase** respectively.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Stearic acid

Cat. No.: HY-B2219

Stearic acid is a long chain dietary saturated fatty acid which exists in many animal and vegetable fats and oils.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

StemRegenin 1

(SR1)

Cat. No.: HY-15001

StemRegenin 1 is a potent aryl hydrocarbon receptor (**AhR**) antagonist with **IC_{50}** of 127 nM.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Sterigmatocystine

Cat. No.: HY-N6725

Sterigmatocystine, a precursor of aflatoxins and a mycotoxin produced by common mold strains from Aspergillus versicolor, has developmental, teratogenic, and carcinogenic effects in animals.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STF-083010

Cat. No.: HY-15845

STF-083010 is a specific **IRE1α** inhibitor. STF-083010 inhibits Ire1 endonuclease activity, without affecting its kinase activity, after endoplasmic reticulum stress.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

STF-118804

Cat. No.: HY-12808

STF-118804 is a highly specific NAMPT inhibitor; reduces the viability of most B-ALL cell lines with IC50 <10 nM.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

STF-31

Cat. No.: HY-18728

STF-31 is an inhibitor of glucose transporter 1 (GLUT1, IC50 = 1 μM). IC50 value: 1 μM Target: GLUT1 in vitro: STF 31 is a glucose uptake inhibitor in RCC (renal cell carcinoma) 4 cells.



Purity: 96.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

STF-62247

(STF62247; STF 62247)

Cat. No.: HY-100746

STF-62247 is TGN inhibitor with IC50 of 0.625μM and 16μM in RCC4 and RCC4/VHL cells,respectively.It specifically induces autophagic cell death in cells that have lost VHL, an essential mutation in the development of RCC.



Purity: 97.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Stibogluconate sodium

(Sodium stibogluconate)

Cat. No.: HY-100595

Stibogluconate sodium is a potent inhibitor of **protein tyrosine phosphatase**. Stibogluconate sodium inhibits 99% of SHP-1, SHP-2 and PTP1B activity at 10, 100, 100 μg/mL, respectively.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Stilbamidine

(Ba 2652; Stilbamidin)

Cat. No.: HY-U00007

Stilbamidine is a diamidine compound derived from Stilbene and used chiefly in the form of its crystalline isethionate salt in treating various fungal infections.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

STING agonist-3

Cat. No.: HY-103665

STING agonist-3 is a selective small-molecule STING agonist. STING agonist-3 is a non-nucleotide STING agonist which has durable anti-tumor effect and tremendous potential to improve treatment of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STING agonist-4

Cat. No.: HY-123943

STING agonist-4 is an stimulator of Interferon Genes (STING) receptor agonist with an apparent inhibitory constant (IC_{50}) of 20 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STK16-IN-1

Cat. No.: HY-101270

STK16-IN-1 is a **STK16** kinase inhibitor with an IC_{50} of 295 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STL127705

Cat. No.: HY-122727

STL127705 (Compound L) is a **Ku 70/80 heterodimer protein** inhibitor, inhibits Ku70/80-DNA interaction, with an IC_{50} of 3.5 μM. STL127705 also inhibits Ku-dependent activation of DNA-PKCS kinase (IC_{50}, 2.5 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Streptonigrin

(Bruneomycin)

Cat. No.: HY-124586

Streptonigrin (Bruneomycin), a natural product produced by Streptomyces flocculus, possesses both anti-tumor and anti-bacterial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Streptozocin

(Streptozotocin; U 9889)

Cat. No.: HY-13753

Streptozocin is a potent **DNA-methylating antibiotic**. Streptozotocin causes methylation of liver and kidney and pancreatic DNA, but no methylation in brain DNA.



Purity: 99.58%
Clinical Data: Launched
Size: 100 mg, 500 mg

SU 5402

Cat. No.: HY-10407

SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC_{50} of 20 nM, 30 nM, and 510 nM for **VEGFR2**, **FGFR1**, and **PDGFRβ**, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SU11274

(PKI-SU11274)

Cat. No.: HY-12014

SU11274 is a selective **Met** inhibitor with IC_{50} of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SU14813

Cat. No.: HY-10501

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 95.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU14813 maleate

Cat. No.: HY-10501A

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU1498

(AG 1498; Tyrphostin SU 1498)

Cat. No.: HY-19326

SU1498 is a selective inhibitor of the **VEGFR2**; inhibits **Flk-1** with an IC_{50} of value of 700 nM.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SU6656

Cat. No.: HY-B0789

SU6656 is a **Src family kinases** inhibitor with IC_{50}s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively.



Purity: 97.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU9516

Cat. No.: HY-18629

SU9516 is a potent **CDK2** inhibitor, with an IC_{50} of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC_{50}s of 40, 200 nM, respectively.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Sucralose

(E955; Trichlorosucrose)

Cat. No.: HY-N0614

Sucralose is an intense organochlorine artificial sweetener.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sulfatinib

(HMPL-012)

Cat. No.: HY-12297

Sulfatinib (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against **VEGFR1/2/3**, **FGFR1** and **CSF1R** with IC_{50}s of in a range of 1 to 24 nM.



Purity: 96.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

sulfo-SPDB-DM4

Cat. No.: HY-101141

sulfo-SPDB-DM4 is a **drug-linker conjugate for ADC** by using the maytansinebased payload (DM4) via the sulfo-SPDB linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulforaphane

Cat. No.: HY-13755

Sulforaphane is an isothiocyanate present naturally in widely consumed vegetables; has shown anticancer and cardioprotective activities.



Purity: 99.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Sunitinib

(SU 11248)

Cat. No.: HY-10255A

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Sunitinib Malate

(SU 11248 (Malate))

Cat. No.: HY-10255

Sunitinib Malate (SU 11248 Malate) is a potent tyrosine kinase inhibitor targeting **VEGFR2** and **PDGFRβ** with IC_{50}s of 80 nM and 2 nM, respectively.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

SuO-Val-Cit-PAB-MMAE

Cat. No.: HY-100566

SuO-Val-Cit-PAB-MMAE is a **drug-linker conjugate for ADC** by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide SuO-Val-Cit-PAB.



Purity: 97.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Super-TDU (1-31) TFA

Cat. No.: HY-P1728A

Super-TDU (1-31) is a peptide of Super-TDU, which is an inhibitor of **YAP-TEADs**, shows potent anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Super-TDU 1-31

Cat. No.: HY-P1728

Super-TDU (1-31) is a peptide of Super-TDU, which is an inhibitor of **YAP-TEADs**, shows potent anti-tumor activity.

SVDDHFAKSLGDTWLQIGGSGNPKTANVPQT

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Suramin

Cat. No.: HY-B0879

Suramin is a polysulfonated naphthylurea with various biological activities. Suramin is a **DNA topoisomerase II** inhibitor with an IC_{50} of 5 μM.



Purity: >98%
Clinical Data: Launched
Size: 50 mg

Suramin sodium salt

(Suramin hexasodium salt; BAY-205; NF-060)

Cat. No.: HY-B0879A

Suramin sodium salt is a polysulfonated naphthylurea with various biological activities. Suramin sodium salt is a **DNA topoisomerase II** inhibitor with an IC_{50} of 5 μM.



Purity: 99.93%
Clinical Data: Launched
Size: 50 mg

SV40 T-Ag-derived NLS peptide

Cat. No.: HY-P1877

SV40 T-Ag-derived NLS peptide is a nuclear localization signal DNA tagged to this peptide efficiently translocates into the cell nucleus.

PKKKRKVEDPYC

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SW-163D-AcLysValCit-PABC-DMAE

Cat. No.: HY-114325

SW-163D-AcLysValCit-PABC-DMAE is a **Drug-Linker Conjugates for ADC** which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

SW044248

Cat. No.: HY-19637

SW044248 is a non-canonical **topoisomerase I** inhibitor, and selectively toxic for certain non-small cell lung cancer (NSCLC) cell lines.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SY-1365

Cat. No.: HY-128587

SY-1365 is a highly selective covalent inhibitor of **CDK7**. SY-1365 possesses therapeutic potential in both hematological and solid tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

SYP-5

Cat. No.: HY-100693

SYP-5 is a novel **HIF-1** inhibitor, suppresses tumor cells invasion and angiogenesis.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SZL P1-41

Cat. No.: HY-100237

SZL P1-41 is a specific **Skp2** inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

T-3775440 hydrochloride

Cat. No.: HY-103085

T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase **(LSD1)** inhibitor with an IC_{50} value of 2.1 nM.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

T0070907

Cat. No.: HY-13202

T0070907 is a potent **PPARγ** antagonist with a K_i of 1 nM.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

T025

Cat. No.: HY-112296

T025 is an orally available and highly potent **Cdc2-like kinase (CLK)** inhibitor with K_ds of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

T0901317

Cat. No.: HY-10626

T0901317 is a potent and selective agonist for **LXR** and **FXR**, with EC_{50}s of 50 nM and 5 μM, respectively.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

T338C Src-IN-1

Cat. No.: HY-16905

T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

T338C Src-IN-2

Cat. No.: HY-16906

T338C Src-IN-2 is a potent mutant c-Src T338C kinase inhibitor with IC50 of 317 nM; also inhibits T338C/V323A and T338C/V323S with IC50 of 57 nM/19 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

T56-LIMKi

(T5601640)

Cat. No.: HY-19352

T56-LIMKi is a selective inhibitor of **LIMK2**; inhibits the growth of Panc-1 cells with an IC_{50} of 35.2 μM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TA-02

Cat. No.: HY-100115

TA-02 is a p38 MAPK inhibitor with IC50 of 20 nM.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TAB29

Cat. No.: HY-128592

TAB29 is a potent inhibitor of **peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1)** with an IC_{50} of 874 nM, possesses therapeutic potential for human cancers.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Taccalonolide A

Cat. No.: HY-N2416

Taccalonolide A is a microtubule stabilizer, which is a steroid isolated from Tacca chantrieri, with cytotoxic and antimalarial activities. Taccalonolide A causes G_2-M accumulation, Bcl-2 phosphorylation and initiation of apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taccalonolide AJ

Cat. No.: HY-N4208

Taccalonolide AJ is a semi-synthesis compound with cellular microtubule stabilizing activity. Taccalonolide AJ exhibits high potency antiproliferative activity against cancer cells, with an IC_{50} of 4.2 nM for HeLa cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tacedinaline

(N-acetyldinaline; CI-994; Goe-5549) Cat. No.: HY-50934

Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (**HDAC**) with IC_{50}s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.



Purity: 99.32%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

TAK-243

(MLN7243; AOB87172) Cat. No.: HY-100487

TAK-243 is a potent and selective ubiquitin-like modifier activating enzyme 1 (**UBA1**) inhibitor.

Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

TAK-285

Cat. No.: HY-15196

TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.



Purity: 99.16%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TAK-448

(MVT-602) Cat. No.: HY-P0076

TAK-448 (MVT-602) is a potent and full **KISS1R** agonist with an IC_{50} of 460 pM and an EC_{50} of 632 pM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAK-448 acetate

(MVT-602 (acetate)) Cat. No.: HY-P0076A

TAK-448 acetate (MVT-602 acetate) is a potent and full **KISS1R** agonist with an IC_{50} of 460 pM and an EC_{50} of 632 pM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

TAK-580

(MLN 2480; BIIB-024) Cat. No.: HY-15246

TAK-580 (MLN 2480) is an orally active and selective inhibitor of **pan-Raf** kinase.



Purity: 99.89%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAK-593

Cat. No.: HY-15506

TAK-593 is a potent **VEGFR** and **PDGFR** family inhibitor with IC_{50}s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.



Purity: 99.62%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAK-632

Cat. No.: HY-15767

TAK-632 is a potent **pan-RAF** inhibitor with IC_{50} of 1.4, 2.4 and 8.3 nM for **CRAF**, **$BRAF^{V600E}$**, **$BRAF^{WT}$**, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAK-659

Cat. No.: HY-100867

TAK-659 is a highly potent, selective, reversible and orally available inhibitor of **spleen tyrosine kinase (SYK)** and **fms related tyrosine kinase 3 (FLT3)**, with an IC_{50} of 3.2 nM for SYK.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

TAK-659 hydrochloride

Cat. No.: HY-100867A

TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (**Syk**) inhibitor with an IC_{50} of 3.2 nM.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-733

Cat. No.: HY-13449

TAK-733 is a potent and selective **MEK** allosteric site inhibitor with an IC_{50} of 3.2 nM.



Purity: 99.81%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TAK-778

Cat. No.: HY-100167

TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

TAK-901

Cat. No.: HY-12201

TAK-901 is a multi-targeted **aurora** inhibitor with IC_{50}s of 21 and 15 nM for aurora A and B, respectively.



Purity: 99.80%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

TAK-960

Cat. No.: HY-15160

TAK-960 is an orally available, selective inhibitor of **polo-like kinase 1 (PLK1)**, with an IC_{50} of 0.8 nM at 10 μM ATP; TAK-960 also shows inhibitory activities against **PLK2** and **PLK3**, with IC_{50}s of 16.9 and 50.2 nM, respectively.



Purity: 97.59%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAK-960 dihydrochloride

Cat. No.: HY-15160B

TAK-960 dihydrochloride is an orally available, selective inhibitor of **polo-like kinase 1 (PLK1)**, with an IC_{50} of 0.8 nM at 10 μM ATP; TAK-960 dihydrochloride also shows inhibitory activities against **PLK2** and **PLK3**, with IC_{50}s of 16.9 and 50.2 nM, respectively.



Purity: 99.80%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAK-960 hydrochloride

Cat. No.: HY-15160A

TAK-960 hydrochloride is an orally available, selective inhibitor of **polo-like kinase 1 (PLK1)**, with an IC_{50} of 0.8 nM at 10 μM ATP; TAK-960 hydrochloride also shows inhibitory activities against **PLK2** and **PLK3**, with IC_{50}s of 16.9 and 50.2 nM, respectively.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

TAK-981

Cat. No.: HY-111789

TAK-981 is a first in class and selective inhibitor of the **SUMOylation** enzymatic cascade, with potential immune-activating and antineoplastic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TAK1/MAP4K2 inhibitor 1

Cat. No.: HY-77251

TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (**TAK1**) and mitogen-activated protein kinase kinase kinase kinase 2 (**MAP4K2**) inhibitor, with IC_{50}s of 41.1 nM and 18.2 nM, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Takinib

Cat. No.: HY-103490

Takinib is a potent and selective **TAK1** inhibitor with an IC_{50} of 9.5 nM.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Talabostat

(Val-boroPro; PT100)

Cat. No.: HY-13233

Talabostat (Val-boroPro) is an orally active and nonselective **dipeptidyl peptidase IV (DPP-IV)** inhibitor (IC_{50} < 4 nM; K_i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein **(FAP)** (IC_{50} = 560 nM), inhibits DPP8/9 (IC_{50} = 4/11 nM; K_i = 1.5/0.76 nM), quiescent...



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg

Talabostat mesylate

(Val-boroPro (mesylate); PT100 (mesylate)) Cat. No.: HY-13233A

Talabostat mesylate (Val-boroPro mesylate) is an orally active and nonselective **dipeptidyl peptidase IV (DPP-IV)** inhibitor (IC_{50} < 4 nM; K_i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein **(FAP)** (IC_{50} = 560 nM), inhibits DPP8/9 (IC_{50} = 4/11 nM; K_i =...



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Taladegib

(LY2940680) Cat. No.: HY-13242

Taladegib (LY2940680) is an antagonist of the **smoothened** receptor.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Talarozole R enantiomer

((R)-Talarozole) Cat. No.: HY-14802

Talarozole R enantiomer is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid for the treatment of psoriasis and acne.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Talazoparib

(BMN-673; LT-673) Cat. No.: HY-16106

Talazoparib (BMN-673) is a highly potent **PARP1/2** inhibitor with K_is of 1.2 nM and 0.87 nM, respectively.



Purity: 99.83%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Talazoparib 8R,9S

(BMN-673 (8R,9S); (8R,9S)-LT-673) Cat. No.: HY-16106A

Talazoparib 8R,9S (BMN-673 8R,9S) is an enantiomer of Talazoparib, less active than Talazoparib on the inhibition of **PARP1**, with an IC_{50} of 144 nM.



Purity: 95.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Talazoparib tosylate

(BMN 673ts) Cat. No.: HY-108413

Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available **PARP1/2** inhibitor with an IC_{50} of 0.57 nM for PARP1.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Talmapimod

(SCIO-469) Cat. No.: HY-10406

Talmapimod (SCIO-469) is a selective ATP-competitive p38 inhibitor with IC_{50} of 9 nM for p38α.



Purity: 98.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Taltobulin

(HTI-286; SPA-110) Cat. No.: HY-15584

Taltobulin (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin. IC50 value: Target: tubulin in vitro: HTI-286 significantly inhibited proliferation of all three hepatic tumor cell lines (mean IC50 = 2 nmol/L +/- 1 nmol/L) in vitro.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Taltobulin hydrochloride

(HTI-286 hydrochloride; SPA-110 hydrochloride) Cat. No.: HY-15584B

Taltobulin hydrochloride is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin. IC50 value: Target: tubulin in vitro: HTI-286 significantly inhibits proliferation of all three hepatic tumor cell lines (mean IC50 = 2 nmol/L +/- 1 nmol/L).



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Taltobulin trifluoroacetate

(HTI-286 trifluoroacetate; SPA-110 trifluoroacetate) Cat. No.: HY-15584A

Taltobulin trifluoroacetate (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

TAM-IN-2

Cat. No.: HY-126216

TAM-IN-2 is a TAM inhibitor extracted from patent US 20170275290 A1, pyrrolotriazine compound 0904.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAME

Cat. No.: HY-13255

TAME is a **serine protease** inhibitor and can be also utilized as a substrate for the serine proteases trypsin, plasmin, and thrombin. TAME is an inhibitor of **anaphase-promoting complex (APC)**, which binds to the APC and prevents its activation by Cdc20 and Cdh1.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

TAME hydrochloride

Cat. No.: HY-13255A

TAME hydrochloride is a **serine protease** inhibitor and can be also utilized as a substrate for the serine proteases trypsin, plasmin, and thrombin.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tamibarotene

(Am 80)

Cat. No.: HY-14652

Tamibarotene is a **retinoic acid receptor α/β (RARα/β)** agonist, showing high selectivity over RARγ.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tamoxifen

(ICI47699; Z-Tamoxifen; trans-Tamoxifen)

Cat. No.: HY-13757A

Tamoxifen is a selective estrogen receptor modulator (**SERM**) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Tamoxifen Citrate

(ICI 46474)

Cat. No.: HY-13757

Tamoxifen Citrate is a selective estrogen receptor modulator (**SERM**).



Purity: >99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Tandutinib

(MLN518; CT53518)

Cat. No.: HY-10202

Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tanespimycin

(17-AAG; NSC 330507; CP 127374)

Cat. No.: HY-10211

Tanespimycin (17-AAG) is a potent **HSP90** inhibitor with an IC_{50} of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90.



Purity: 99.03%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 25 mg, 100 mg, 200 mg

Tannic acid

Cat. No.: HY-B2136

Tannic acid is a novel **hERG channel** blocker with IC_{50} of 3.4 μM.



Purity: 81.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g, 5 g

TAPI-1

Cat. No.: HY-16657

TAPI-1 is a specific TACE(TNF-α-converting enzyme) inhibitor.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

TAPI-2

(TNF Protease Inhibitor 2)

Cat. No.: HY-100211

TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (**MMP**), tumour necrosis factorα-converting enzyme (**TACE**) and a disintegrin and metalloproteinase (**ADAM**), with an IC_{50} of 20±10 μM for MP.



Purity: 95.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Targapremir-210

Cat. No.: HY-15861

Targapremir-210 is a potent **miR-210** inhibitor with an IC_{50} of 200 nM in MDA-MB-231 cells. Targapremir-210 binds to the Dicer site of the miR-210 hairpin precursor. This interaction inhibits production of the mature miRNA.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Tariquidar

(XR9576)

Cat. No.: HY-10550

Tariquidar is a potent and specific inhibitor of **P-glycoprotein** (**P-gp**) with the high affinity (K_d=5.1±0.9 nM).



Purity: 98.57%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tariquidar methanesulfonate, hydrate

(XR9576 (methanesulfonate, hydrate))

Cat. No.: HY-10550A

Tariquidar methanesulfonate, hydrate is a potent and specific inhibitor of **P-glycoprotein** (**P-gp**) with a K_d of 5.1 nM.



Purity: 98.02%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

tarloxotinib bromide

(TH-4000; PR-610)

Cat. No.: HY-17632

Tarloxotinib bromide is an irreversible **EGFR/HER2** inhibitor.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAS-103

(BMS-247615)

Cat. No.: HY-13758

TAS-103 is a dual inhibitor of DNA **topoisomerase I/II**, used for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

TAS-103 dihydrochloride

(BMS-247615 dihydrochloride)

Cat. No.: HY-13758A

TAS-103 dihydrochloride is a dual inhibitor of DNA **topoisomerase I/II**, used for cancer research.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAS-114

Cat. No.: HY-124062

TAS-114 is a dual **dUTPase/dihydropyrimidine dehydrogenase (DPD)** inhibitor, can improving the therapeutic efficacy of fluoropyrimidine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAS-115

Cat. No.: HY-12423

TAS-115 is a potent **VEGFR** and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor with IC_{50}s of 30 and 32 nM for rVEGFR2 and rMET, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

TAS-115 mesylate

(TAS-115 methanesulfonate)

Cat. No.: HY-12423A

TAS-115 mesylate is a potent **VEGFR**and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor, with IC_{50}s of 30 and 32 nM for rVEGFR2 and rMET, respectively.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAS-116

Cat. No.: HY-15785

TAS-116 is an oral bioavailable, ATP-competitive, highly specific **HSP90α/HSP90β** inhibitor (K_is of 34.7 nM and 21.3 nM, respectively) without inhibiting other HSP90 family proteins such as GRP94. TAS-116 demonstrates less ocular toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TAS0728

Cat. No.: HY-111553

TAS0728 is a potent, selective, oral active, irreversible and covalent-binding **HER2** inhibitor, binds to HER2 at C805, inhibits its kinase activity, with an **IC_{50}** of 13 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TAS4464

Cat. No.: HY-128586

TAS4464 is a highly potent and selective inhibitor of **NEDD8 activating enzyme (NAE)**, with an **IC_{50}** of 0.955 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

TAS4464 hydrochloride

Cat. No.: HY-128586A

TAS4464 (hydrochloride) is a highly potent and selective inhibitor of **NEDD8 activating enzyme (NAE)**, with an **IC_{50}** of 0.955 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

TAS6417

Cat. No.: HY-112299

TAS6417 is an **EGFR** inhibitor and an efficacious drug candidate for patients with NSCLC, with **IC_{50}** values ranging from 1.1-8.0 nM.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Taselisib

(GDC-0032; RG-7604)

Cat. No.: HY-13898

Taselisib (GDC-0032) is a potent **PI3K** inhibitor targets PIK3CA mutations, with K_is of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.



Purity: 99.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tasidotin hydrochloride

(ILX651)

Cat. No.: HY-13760

Tasidotin hydrochloride is a peptide analog of the antimitotic depsipeptide dolastatin 15, as an inhibitor of microtubule assembly and microtubule dynamics.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Tasquinimod

(ABR-215050)

Cat. No.: HY-10528

Tasquinimod is an oral antiangiogenic agent in clinical trials for the treatment of castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn^{2+} binding domain of **HDAC4** with **K_d** of 10-30 nM.



Purity: 99.85%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tauroursodeoxycholate

(TUDCA; UR 906; Taurolite)

Cat. No.: HY-19696

Tauroursodeoxycholate (TUDCA; UR 906; Taurolite) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as **caspase-3** and **caspase-12**. Tauroursodeoxycholate also inhibits **ERK**.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Tauroursodeoxycholate dihydrate

(TUDCA dihydrate; UR 906 dihydrate; Taurolite dihydrate)

Cat. No.: HY-19696B

Tauroursodeoxycholate dihydrate (TUDCA dihydrate; UR 906 dihydrate; Taurolite dihydrate) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as **caspase-3** and **caspase-12**.



Purity: >97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Tauroursodeoxycholate Sodium (Sodium tauroursodeoxycholate; Tauroursodeoxycholic acid sodium salt)

Cat. No.: HY-19696A

Tauroursodeoxycholate Sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as **caspase-3** and **caspase-12**. Tauroursodeoxycholate also inhibits **ERK**.



Purity: 97.07%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Taxifolin ((+)-Dihydroquercetin; (+)-Taxifolin)

Cat. No.: HY-N0136

Taxifolin ((+)-Dihydroquercetin) exhibits important anti-**tyrosinase** activity. Taxifolin exhibits significant inhibitory activity against **collagenase** with an IC_{50} value of 193.3 μM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tazemetostat (EPZ-6438; E-7438)

Cat. No.: HY-13803

Tazemetostat (EPZ-6438) is a potent, selective and orally available **EZH2** inhibitor with K_i and IC_{50} of 2.5 and 11 nM, respectively.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

TBB (NSC 231634; Casein Kinase II Inhibitor I)

Cat. No.: HY-14394

TBB is a cell-permeable and ATP-competitive **CK2** inhibitor with an IC_{50} of 0.15 μM for rat liver CK2.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TBHQ (tert-Butylhydroquinone)

Cat. No.: HY-100489

TBHQ is an antioxidant that activates **Nrf2**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

tBID

Cat. No.: HY-100464

tBID is a selective inhibitor of homeodomain–interacting protein kinase 2 (**HIPK2**) with an IC_{50} of 0.33 μM.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TBK1/IKKε-IN-1

Cat. No.: HY-U00457

TBK1/IKKε-IN-1 is a dual **TBK1** and **IKKε** inhibitor extracted from patent US20160376283 A1, Compound 274 in Example 60, has IC_{50}s of <100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

TBK1/IKKε-IN-5

Cat. No.: HY-128679

TBK1/IKKε-IN-5 (compound 1) is a dual **TBK1** and **IKKε** inhibitor, with IC_{50} values of 1 nM and 5.6 nM for TBK1 and IKKε, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

TC HSD 21

Cat. No.: HY-103394

TC HSD 21 is a potent **17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3)** inhibitor with an IC_{50} of 14 nM. TC HSD 21 shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

TC-DAPK 6

Cat. No.: HY-15513

TC-DAPK 6 is a potent, ATP-competitive, and highly selective **DAPK** inhibitor (IC_{50}=69 and 225 nM against **DAPK1** and **DAPK3**, respectively, with 10 μM ATP).



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TC13172

Cat. No.: HY-101524

TC13172 is a mixed lineage kinase domain-like protein (**MLKL**) inhibitor with an EC_{50} value of 2 nM for HT-29 cells.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TCS 359

Cat. No.: HY-13907

TCS 359, a 2-acylaminothiophene-3-carboxamide, is a potent inhibitor of FLT3 with IC50 of 42 nM.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TCS JNK 5a

(JNK Inhibitor IX)

Cat. No.: HY-15881

TCS JNK 5a is a potent **JNK3** inhibitor with a pIC_{50} of 6.7. TCS JNK 5a also inhibits **JNK2** with a pIC_{50} of 6.5.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TCS PIM-1 1

(SC 204330)

Cat. No.: HY-18086

TCS PIM-1 1 (SC 204330) is a potent and selective ATP-competitive Pim-1 kianse inhibitor with IC50 of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2(IC50s >20,000 nM).



Purity: 97.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TCS-OX2-29

Cat. No.: HY-100452

TCS-OX2-29 is a potent and selective OX2 receptor antagonist with IC50 of 40 nM. Displays >250-fold selectivity for OX2 over OX1.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

TCS-PIM-1-4a

(SMI-4a)

Cat. No.: HY-16576

TCS-PIM-1-4a is a Pim inhibitor that blocks mTORC1 activity via activation of AMPK; kills a wide range of both myeloid and lymphoid cell lines (with IC50 values ranging from 0.8 to 40 μM).



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TCV-309 chloride

Cat. No.: HY-19121A

TCV-309 (chloride) is a platelet activating factor (PAF) antagonist.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TD-106

Cat. No.: HY-114406

TD-106 is a cereblon (**CRBN**) modulator, which can be used for targeted protein degradation. BRD4 **PROTAC**s with TD-106 induce BRD4 degradation.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TD-428

Cat. No.: HY-114407

TD-428 is a highly specific **BRD4** degrader with a DC_{50} of 0.32 nM. TD-428 is a **BET PROTAC**, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TDCPP

(Tris(1,3-dichloroisopropyl)phosphate)

Cat. No.: HY-108712

TDCPP is a chlorinated analog of tris(2,3-dibromopropyl)phosphate (Tris) which is one of the most detected organophosphorus flame retardants (OPFRs) in the environment.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

TDP1 Inhibitor-1

Cat. No.: HY-119372

TDP1 Inhibitor-1 is a potent **Tyrosyl-DNA Phosphodiesterase 1 (TDP1)** inhibitor with an IC_{50} of 7 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

TDZD-8

(GSK-3β Inhibitor I; NP 01139)

Cat. No.: HY-11012

TDZD-8 is an inhibitor of **GSK-3β**, with an IC_{50} of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclinB, CK-II, PKA, and PKC, with all IC_{50}s of >100 μM.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tectochrysin

(Techtochrysin; NSC 80687)

Cat. No.: HY-14592

Tectochrysin (Techtochrysin) is one of the major flavonoids of Alpinia oxyphylla Miquel. Tectochrysin (Techtochrysin) inhibits activity of **NF-κB**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tefinostat

(CHR-2845)

Cat. No.: HY-106409

Tefinostat (CHR-2845) is a monocyte/macrophage-targeted pan **HDAC** inhibitor, cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Anti-monocytoid lineage leukaemias activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Tegafur

(FT 207NSC 148958)

Cat. No.: HY-17400

Tegafur (FT 207; NSC 148958) is a chemotherapeutic 5-FU prodrug used in the treatment of cancers; is a component of tegafur-uracil.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Teijin compound 1

Cat. No.: HY-108323

Teijin compound 1 is a specific **CCR 2** antagonist with IC_{50}s of 24 and 180 nM in chemotaxis and binding assay, respectively.



Purity: 100.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Telaglenastat

(CB-839)

Cat. No.: HY-12248

Telaglenastat (CB-839) is a potent and selective inhibitor of glutaminase with an IC_{50} of less than 50 nM.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Telatinib

(Bay 57-9352)

Cat. No.: HY-10527

Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** with IC_{50}s of 6, 4, 15 and 1 nM, respectively.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Telomerase-IN-1

Cat. No.: HY-U00268

Telomerase-IN-1 is a **Telomerase** inhibitor with an IC_{50} of 0.19 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Telratolimod

(MEDI 9197; 3M 052)

Cat. No.: HY-109104

Telratolimod is a toll like receptors 7/8 (**TLR7/8**) agonist, with antitumor activity.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Teludipine hydrochloride

(GR53992B; GX1296B)

Cat. No.: HY-101621

Teludipine is a lipophilic **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Temoporfin

(m-THPC; KW2345)

Cat. No.: HY-16488

Temoporfin(KW 2345) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Temozolomide

(NSC 362856; CCRG 81045; TMZ)

Cat. No.: HY-17364

Temozolomide (NSC 362856; CCRG 81045) is an oral **DNA alkylating** agent used to treat some brain cancers.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Tempol

(4-Hydroxy-TEMPO)

Cat. No.: HY-100561

Tempol is a general superoxide dismutase (SOD)-mimetic drug that efficiently neutralizes reactive oxygen species (ROS).



Purity: 99.69%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 200 mg, 1 g

Temsirolimus

(CCI-779)

Cat. No.: HY-50910

Temsirolimus is an inhibitor of **mTOR** with an IC_{50} of 1.76 μM.



Purity: 99.25%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 100 mg

Tenacissoside H

(Tenacissimoside C)

Cat. No.: HY-N0670

Tenacissoside H is a Chinese medicine monomer extracted, isolated from Caulis Marsdeniae Tenacissimae. IC50 value: Target: In vitro: TDH significantly inhibited cells proliferation in a time-and-dose-dependent manner.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Tenalisib

(RP6530)

Cat. No.: HY-17645

Tenalisib (RP6530) is a novel, potent, and selective **PI3Kδ** and **PI3Kγ** inhibitor with IC_{50} values of 25 and 33 nM, respectively.



Purity: 99.09%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tenalisib R Enantiomer

(RP6530 R Enantiomer)

Cat. No.: HY-112172

Tenalisib R Enantiomer is an R enantiomer of Tenalisib.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Teniposide

(VM26)

Cat. No.: HY-13761

Teniposide is a podophyllotoxin derivative, acts as a **topoisomerase II** inhibitor, and used as a chemotherapeutic agent.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg, 200 mg

Tenofovir Disoproxil

(Bis(POC)-PMPA; GS 4331)

Cat. No.: HY-13782A

Tenofovir dsoproxil is a **nucleotide reverse transcriptase inhibitor** to treat HIV and chronic Hepatitis B.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tenovin-1

Cat. No.: HY-13423

Tenovin-1 is an inhibitor of **sirtuin 1** and **sirtuin 2**, an activator of **p53** and may have potential in the management of cancer.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tenovin-3

Cat. No.: HY-19339

Tenovin-3 is able to increase p53 levels, determined in MCF-7 cells treated for 6 hr at 10 μM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Tenovin-6

Cat. No.: HY-15510

Tenovin-6 is an inhibitor of **SIRT1** and **SIRT2**, slightly inhibits **HDAC8**, and is also a potent activator of **p53**, with IC_{50}s of 21 μM, 10 μM, and 67 μM for SirT1, SirT2, and SirT3, respectively.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tenovin-6 Hydrochloride

Cat. No.: HY-15510B

Tenovin-6 Hydrochloride is an inhibitor of **SIRT1** and **SIRT2**, slightly inhibits **HDAC8**, and is also a potent activator of **p53**, with IC_{50}s of 21 μM, 10 μM, and 67 μM for SirT1, SirT2, and SirT3, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tepotinib

(EMD-1214063)

Cat. No.: HY-14721

Tepotinib (EMD-1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.



Purity: 99.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TEPP-46

(ML-265)

Cat. No.: HY-18657

TEPP-46 is a potent and selective **pyruvate kinase M2 (PKM2)** activator with an AC_{50} of 92 nM, showing little or no effect on PKM1, PKL and PKR.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Teriparatide

(PTH 1-34; hPTH (1-34); Human parathyroid hormone-(1-34))

Cat. No.: HY-P0059

Teriparatide is a **PHT** agonist, with an IC_{50} of 2 nM in HEK293 cells.

Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Terrestrosin D

Cat. No.: HY-N5074

Terrestrosin D, a steroidal saponin from Tribulus terrestris L., induces cell cycle arrest and cancer cells apoptosis. Terrestrosin D has antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tesevatinib

(XL-647; EXEL-7647; KD-019)

Cat. No.: HY-13314

Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor; inhibits **EGFR**, **ErbB2**, **KDR**, **Flt4** and **EphB4** kinase with IC_{50}s of 0.3, 16, 1.5, 8.7, and 1.4 nM.



Purity: 99.21%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tetracosactide

(Tetracosactrin)

Cat. No.: HY-P0060

Tetracosactide (INN) is an analogue of adrenocorticotrophic hormone (ACTH), with the biological activity of stimulating production of corticosteroids in the adrenal cortex.

Purity: 99.54%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Tetrahydrocurcumin

(HZIV 81-2) Cat. No.: HY-N0893

Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit **CYP2C9** and **CYP3A4**.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tetrahydrouridine

(THU; NSC-112907) Cat. No.: HY-15345

Tetrahydrouridine is potent inhibitor of **cytidine deaminase** (**CDA**), which competitively blocks the enzyme's active site more effectively than intrinsic cytidine.



Purity: >85.0%
Clinical Data: Phase 2
Size: 100 mM * 50 μL , 100 mM * 20 μL ,

Tetrahydroxyquinone

(Tetrahydroxy-1,4-benzoquinone; Tetrahydroxybenzoquinone) Cat. No.: HY-B1106

Tetrahydroxyquinone is a molecule best known as a primitive anticataract drug, is also a highly redox active molecule that can take part in a redox cycle with semiquinone radicals, leading to the formation of reactive oxygen species (ROS).



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Tetramethylpyrazine

(Ligustrazine) Cat. No.: HY-N0264

Tetramethylpyrazine (Ligustrazine), an alkylpyrazine isolated from Ligusticum wallichii (Chuan Xiong), is present in french fries, bread, cooked meats, tea, cocoa, coffee, beer, spirits, peanuts, filberts, dairy products and soy products as fragrance and...



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Tetrandrine

(NSC-77037d-Tetrandrine) Cat. No.: HY-13764

Tetrandrine (NSC-77037) is a bis-benzyl-isoquinoline alkaloid, which inhibits voltage-gated **Ca^{2+} current** (ICa) and Ca^{2+}-activated **K^+ current**.



Purity: 99.90%
Clinical Data: Launched
Size: 100 mg, 250 mg

Tezacaftor

(VX-661) Cat. No.: HY-15448

Tezacaftor (VX-661) is a second **F508del CFTR** corrector and help CFTR protein reach the cell surface.



Purity: 99.92%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tezosentan

(RO 610612) Cat. No.: HY-17351

Tezosentan (RO 610612) is an **endothelin (ET)** receptor antagonist, with **pA_2s** of 9.5, 7.7 for ET_A and ET_B receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TG 100572

Cat. No.: HY-10184

TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has **IC_{50}**s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

TG 100801

Cat. No.: HY-10186

TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

TG 100801 Hydrochloride

Cat. No.: HY-10187

TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

TG003

Cat. No.: HY-15338

TG003 is a potent inhibitor of **Clk1/Sty**; inhibits Clk1 and Clk4 with IC_{50} values of 20 and 15 nM, respectively.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TG100-115

Cat. No.: HY-10111

TG100-115 is a selective **PI3Kγ/PI3Kδ** inhibitor with IC_{50}s of 83 and 235 nM, respectively.



Purity: 99.31%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TG101209

Cat. No.: HY-10410

TG101209 is a selective **JAK2** inhibitor with IC_{50} of 6 nM, less potent to **Flt3** and **RET** with IC_{50} of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TGFβRI-IN-1

Cat. No.: HY-114192

TGFβRI-IN-1 is an oral active and selective **TGFβ receptor type I (TGFβRI)** kinase inhibitor, with IC_{50} values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

TGX-221

Cat. No.: HY-10114

TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the **PI3K p110β** catalytic subunit, used for cancer treatment.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TH287

Cat. No.: HY-16965

TH287 is a potent inhibitor of MTH1 (NUDT1) with an IC50 value of 0.8 nM, less potent for MTH2, NUDT5, NUDT12, NUDT14, and NUDT16.



Purity: 97.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TH287 hydrochloride

Cat. No.: HY-16965A

TH287 hydrochloride is a potent inhibitor of MTH1 (NUDT1) with an IC50 value of 0.8 nM, less potent for MTH2, NUDT5, NUDT12, NUDT14, and NUDT16.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

TH34

Cat. No.: HY-111818

TH34, an **HDAC6/8/10** inhibitor with IC_{50}s of 4.6 μM, 1.9 μM, and 7.7 μM respectively, shows high selectivity over HDAC1/2/3.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TH588

Cat. No.: HY-12814

TH588 is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the **MTH1** (IC_{50}= 5 nM).



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 25 mg, 50 mg, 100 mg

TH588 hydrochloride

Cat. No.: HY-12814A

TH588 hydrochloride is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the **MTH1** (IC_{50}= 5 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 25 mg, 50 mg, 100 mg

THAL-SNS-032

Cat. No.: HY-123937

THAL-SNS-032 is a selective **CDK9** degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Thalidomide

Cat. No.: HY-14658

Thalidomide is initially promoted as a sedative, inhibits ereblon (CRBN), a part of the **cullin-4 E3 ubiquitin ligase** complex CUL4-RBX1-DDB1, with a K_d of 250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Thapsigargin

(Thapsigargin (TG))

Cat. No.: HY-13433

Thapsigargin is an inhibitor of microsomal **Ca^{2+}-ATPase**.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thiamet G

Cat. No.: HY-12588

Thiamet G is a potent and selective inhibitor of **O-GlcNAcase (OGA)**, which acts to remove O-GlcNAc from modified proteins, with K_i of 20 nM for human OGA.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Thiarabine

(OSI-7836)

Cat. No.: HY-16496

Thiarabine (OSI-7836) shows potent anti-tumor activity and inhibition of **DNA** synthesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Thiazovivin

Cat. No.: HY-13257

Thiazovivin is a potent **ROCK** inhibitor, which can protect human embryonic stem cells.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Thio-TEPA

Cat. No.: HY-17574

Thio-TEPA is a **DNA alkylating** agent, with antitumor activity.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Thiomyristoyl

Cat. No.: HY-101278

Thiomyristoyl is a potent and specific **SIRT2** inhibitor with an IC_{50} of 28 nM.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

THS-044

Cat. No.: HY-19621

THS-044 binding stabilizes the HIF2α PAS-B folded state, for regulating HIF2 activity in endogenous and clinical settings.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Thymine

Cat. No.: HY-W010450

Thymine is one of the four nucleobases in the nucleic acid of DNA and can be a target for actions of 5-fluorouracil (5-FU) in cancer treatment, with a K_m of 2.3 μM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

THZ1

Cat. No.: HY-80013

THZ1 is a selective and potent covalent **CDK7** inhibitor with an **IC_{50}** of 3.2 nM.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

THZ1 Hydrochloride

Cat. No.: HY-80013A

THZ1 Hydrochloride is a selective and potent **CDK7** inhibitor with an **IC_{50}** of 3.2 nM.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

THZ1-R

Cat. No.: HY-19988

THZ1-R is a non-cysteine reactive analog of THZ1 which displays diminished activity for **CDK7** inhibition. THZ1-R binds to **CDK7** with a **K_d** of 142 nM.



Purity: 97.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

THZ2

Cat. No.: HY-12280

THZ2 is a potent and selective **CDK7** inhibitor with an **IC_{50}** of 13.9 nM.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

THZ531

Cat. No.: HY-103618

THZ531 is a covalent inhibitor of both **CDK12** and **CDK13** with **IC_{50}**s of 158 nM and 69 nM, respectively.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

TIC10

(ONC-201)

Cat. No.: HY-15615A

TIC10 is a potent, orally active, and stable **TRAIL** inducer which acts by inhibiting Akt and ERK, consequently activating Foxo3a and significantly inducing cell surface TRAIL .



Purity: 99.68%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tigloylgomisin H

Cat. No.: HY-N6802

Tigloylgomisin H is a lignan isolated from the fruits of S. chinensis, can induce quinone reductase (QR) activity in Hepa1c1c7 mouse hepatocarcinoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tilfrinib

Cat. No.: HY-110244

Tilfrinib (compound 4f) is a potent and selective inhibitor of **breast tumor kinase (Brk)** with an **IC_{50}** of 3.15 nM, which displays anti-proliferative activity and acts as a promising antitumor agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Timonacic

(1,3-Thiazolidine-4-carboxylic acid)

Cat. No.: HY-B1169

Timonacic is used as an adjuvant in the treatment of acute and hepatic disorders. It has also been used for the treatment of some cases of cancer, through the induction of the reverse transformation.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Timosaponin BII

(Prototimosaponin A III)

Cat. No.: HY-N0812

Timosaponin BII is an antioxidant and an anti-inflammatory agent.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tipifarnib

(IND 58359; R115777)

Cat. No.: HY-10502

Tipifarnib is a nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits **farnesyltransferase (FTase)** with IC_{50} of 0.6 nM.



Purity: 99.89%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tipifarnib S enantiomer

((S)-(-)-R-115777; IND-58359 S enantiomer)

Cat. No.: HY-10502A

Tipifarnib S enantiomer is the S-enantiomer of Tipifarnib. Tipifarnib is a potent and specific **farnesyltransferase (FTase)** inhibitor with IC_{50} of 0.6 nM. Tipifarnib S enantiomer is the less active isomer.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tipiracil

Cat. No.: HY-A0063A

Tipiracil is a thymidine phosphorylase (**TPase**) inhibitor.



Purity: 97.83%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Tipiracil hydrochloride

Cat. No.: HY-A0063

Tipiracil (hydrochloride) is a thymidine phosphorylase inhibitor (TPI), used for cancer research.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tirabrutinib

(ONO-4059; GS-4059)

Cat. No.: HY-15771

Tirabrutinib (ONO-4059) is a highly selective, orally bioavailable **BTK** inhibitor with an IC_{50} of 2.2 nM.



Purity: 99.31%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tirabrutinib hydrochloride

(ONO-4059 (hydrochloride); GS-4059 (hydrochloride))

Cat. No.: HY-15771A

Tirabrutinib (ONO-4059) hydrochloride is a selective and novel inhibitor of BTK with IC_{50} 2.2 nm, Tirabrutinib binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.



Purity: 98.74%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tirapazamine

(SR259075; SR4233; Win59075)

Cat. No.: HY-13767

Tirapazamine is an anticancer agent that shows selective cytotoxicity for **hypoxic** cells in solid tumors, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death.



Purity: 98.37%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Tirbanibulin

(KX2-391; KX-01)

Cat. No.: HY-10340

Tirbanibulin (KX2-391) is an inhibitor of **Src** that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

Tirbanibulin dihydrochloride

(KX2-391 (dihydrochloride); KX-01 (dihydrochloride))

Cat. No.: HY-10340A

Tirbanibulin (dihydrochloride) (KX2-391 (dihydrochloride)) is an inhibitor of **Src** that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.



Purity: 96.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tirbanibulin Mesylate

(KX2-391 (Mesylate); KX01 (Mesylate))

Cat. No.: HY-10340B

Tirbanibulin (Mesylate) (KX2-391 (Mesylate)) is an inhibitor of **Src** that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.



Purity: 99.97%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tivantinib

(ARQ 197)

Cat. No.: HY-50686

Tivantinib is a novel and highly selective **c-Met** tyrosine kinase inhibitor with K_i of 355 nM.



Purity: 99.39%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tivozanib

(AV-951; KRN951)

Cat. No.: HY-10977

Tivozanib (AV-951; KRN951) is a highly potent and selective **VEGFR 1/2/3** inhibitor with IC_{50}s of 0.21, 0.16, and 0.24 nM in cell assay, respectively.



Purity: 99.52%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

TLK117

(TER117)

Cat. No.: HY-13634B

TLK117, the active metabolite of TLK199, selective inhibits **Glutathione S-transferase P1–1 (GSTP1-1)** with a K_i of 0.4 μM for GSTP. TLK117 also competitively inhibits **glyoxalase I** with a K_i of 0.56 μM.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

TM5275 sodium

Cat. No.: HY-100447

TM5275 sodium is a plasminogen activator inhibitor (**PAI-1**) with an IC_{50} of 6.95 μM.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TM5441

Cat. No.: HY-101761

TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (**PAI-1**), has IC_{50} values between 13.9 and 51.1 μM and induces intrinsic apoptosis in several human cancer cell lines.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TMP195

Cat. No.: HY-18361

TMP195 is a selective class IIa histone deacetylase (**HDAC**) inhibitor with K_is of 59, 60, 26, 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TMP269

Cat. No.: HY-18360

TMP269 is a novel and selective class IIa **histone deacetylase (HDAC)** inhibitor with IC_{50}s of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

TMPyP4 tosylate

(TMP 1363)

Cat. No.: HY-108477

TMPyP4 tosylate (TMP 1363) is a **quadruplex**-specific ligand, which inhibits the interaction between G-quadruplexes and IGF-1. TMPyP4 tosylate (TMP 1363) is a **telomerase** inhibitor with antitumor effects in osteosarcoma cell lines.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 100 mg

TMS

((E)-2,3',4,5'-tetramethoxystilbene)

Cat. No.: HY-19340

TMS is a selective inhibitor of **CYP1B1** activity.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TNF-α-IN-1

Cat. No.: HY-112275

TNF-α-IN-1 is a **TNF-α** inhibitor extracted from patent US20030096841A1, compound example I-7.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TNP

Cat. No.: HY-110079

TNP is a cell-permeable inhibitor of **IP6K1** and **IP3K**, with IC_{50} values of 0.55 μM and 10.2 μM for IP3K, respectively. TNP binds to the ATP-binding sites of both enzymes.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TNP-470

(AGM-1470)

Cat. No.: HY-101932

TNP-470 is a **methionine aminopeptidase-2** inhibitor and also an **angiogenesis** inhibitor.



Purity: >99.0%
Clinical Data: Phase 2
Size: 5 mg

Toceranib

(PHA 291639; SU11654)

Cat. No.: HY-10330

Toceranib is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor with K_is of 5 and 6 nM for **PDGFRβ** and **Flk-1/KDR**, respectively.



Purity: 96.50%
Clinical Data: Launched
Size: 10 mg, 50 mg

Toceranib phosphate

(PHA 291639 (phosphate); SU11654 (phosphate))

Cat. No.: HY-10330A

Toceranib phosphate is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor with K_is of 5 and 6 nM for **PDGFRβ** and **Flk-1/KDR**, respectively.



Purity: 98.43%
Clinical Data: Launched
Size: 10 mg, 50 mg

TOFA

(RMI14514; MDL14514)

Cat. No.: HY-101068

TOFA (RMI14514;MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (**ACCA**).



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tolrestat

(AY-27773)

Cat. No.: HY-16500

Tolrestat is a potent, orally active **aldose reductase** inhibitor with IC_{50} of 35 nM.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tomivosertib

(eFT508)

Cat. No.: HY-100022

Tomivosertib (eFT508) is a potent, highly selective, and orally bioavailable **MNK1** and **MNK2** inhibitor, with IC_{50}s of 1-2 nM against both isoforms.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Top1 inhibitor 1

Cat. No.: HY-126142

Top1 inhibitor 1 (compound 28) is a potent human **topoisomerase I (Top1)** inhibitor with an IC_{50} value of 29 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Topilutamide

(BP766; Fluridil)

Cat. No.: HY-19470

Topilutamide is a topical nonsteroidal antiandrogen (NSAA).



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Topotecan

(SKF 104864A; NSC 609669)

Cat. No.: HY-13768

Topotecan (SKF 104864A; NSC 609669) is a **Topoisomerase I** inhibitor. The IC_{50} values of Topotecan at 24 h are 2.73±0.25 μM of U251 cells, 2.95±0.23 μM of U87 cells, 5.46±0.41 μM of GSCs-U251 and 5.95±0.24 μM of GSCs-U87.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg

Topotecan Hydrochloride

(SKF 104864A (Hydrochloride); NSC 609669 (Hydrochloride)) Cat. No.: HY-13768A

Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a **Topoisomerase I** inhibitor with potent antineoplastic activities.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Toremifene

(GTx 006; Z-Toremifene) Cat. No.: HY-B0005A

Toremifene (NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg

Toremifene Citrate

(FC 1157a; NK 622) Cat. No.: HY-B0005

Toremifene Citrate(NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Torin 1

Cat. No.: HY-13003

Torin 1 is a potent inhibitor of **mTOR** with an IC_{50} of 3 nM. Torin 1 inhibits both **mTORC1/2** complexes with IC_{50} values between 2 and 10 nM.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Torin 2

Cat. No.: HY-13002

Torin 2 is an **mTOR** inhibitor with EC_{50} of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC_{50}: 200 nM). Torin 2 also inhibits **DNA-PK** with an IC_{50} of 0.5 nM in the cell free assay. Torin 2 can suppress both **mTORC1** and **mTORC2**.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Torkinib

(PP 242) Cat. No.: HY-10474

Torkinib (PP 242) is a selective and ATP-competitive **mTOR** inhibitor with an IC_{50} of 8 nM. PP242 inhibits both **mTORC1** and **mTORC2** with IC_{50}s of 30 nM and 58 nM, respectively.



Purity: 95.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tosedostat

(CHR-2797) Cat. No.: HY-14807

Tosedostat is an **aminopeptidase** inhibitor.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Toxoflavin

(Xanthothricin; Toxoflavine; PKF-118-310) Cat. No.: HY-100760

Toxoflavin (Xanthothricin) is an antagonist of **transcription factor 4 (TCF4)/β-catenin complex**, also acts as an inhibitor of **KDM4A**, with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Tozasertib

(VX 680; MK-0457) Cat. No.: HY-10161

Tozasertib (VX 680; MK-0457) is an inhibitor of **Aurora A/B/C kinases** with K_is of 0.6, 18, 4.6 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

TP-3654

Cat. No.: HY-101126

TP-3654 is a second-generation **Pim** kinase inhibitor with K_i values of 5 and 42 nM for Pim-1 and Pim-3, respectively.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TPEN

(TPEDA)

Cat. No.: HY-100202

TPEN is a specific cell-permeable heavy metal chelator.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

TPOP146

Cat. No.: HY-100697

TPOP146 is a selective **CBP/P300** benzoxazepine bromodomain inhibitor with K_d values of 134 nM and 5.02 μM for CBP and BRD4.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Trabectedin

(Ecteinascidin 743; ET-743)

Cat. No.: HY-50936

Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo.



Purity: 99.83%
Clinical Data: Launched
Size: 1 mg

Trametinib

(GSK1120212; JTP-74057)

Cat. No.: HY-10999

Trametinib is a potent **MEK** inhibitor that inhibits MEK1 and MEK2 with **IC_{50}**s of about 2 nM. Due to the poor solubility of Trametinib, **Trametinib DMSO solvate (Cat. No.: HY-10999A)** is recommeded.



Purity: 99.44%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Trametinib DMSO solvate

(GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate))

Cat. No.: HY-10999A

Trametinib DMSO solvate is a potent **MEK** inhibitor that specifically inhibits MEK1/2, with an **IC_{50}** value of about 2 nM.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tramiprosate

(Homotaurine; 3-Amino-1-propanesulfonic acid)

Cat. No.: HY-14602

Tramiprosate is a small, orally-administered compound that binds to soluble Aβ and reduces amyloid aggregation and subsequent deposition target: Aβ In vitro: Tramiprosate provides neuroprotection against Aβ-induced neurotoxicity in neuronal and mouse organotypic...



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 g, 5 g

Transcrocetin

(trans-Crocetin)

Cat. No.: HY-N2072

Transcrocetin (trans-Crocetin), extracted from saffron (Crocus sativus L.), acts as an **NMDA receptor** antagonist with high affinity.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Transcrocetin meglumine salt

(trans-Crocetin meglumine salt)

Cat. No.: HY-42937

Transcrocetin meglumine salt, extracted from saffron (Crocus sativus L.), acts as an **NMDA receptor** antagonist with high affinity.



Purity: 95.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Transcrocetinate disodium

(Disodium trans-crocetinate)

Cat. No.: HY-16502

Transcrocetinate disodium, extracted from saffron (Crocus sativus L.), acts as an **NMDA receptor** antagonist with high affinity.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Transportan

Cat. No.: HY-P1732

Transportan is a 27 amino acid-long peptide containing 12 functional amino acids from the amino terminus of the neuropeptide galanin and mastoparan in the carboxyl terminus, connected via a lysine. Transportan belongs to cell-penetrating peptides (CPPs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trastuzumab

(Anti-Human HER2, Humanized Antibody) Cat. No.: HY-P9907

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Trastuzumab

Purity: 99.70%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg

Treosulfan

(NSC 39069; Treosulphan) Cat. No.: HY-16503

Treosulfan (NSC 39069;Treosulphan) is an **alkylating** agent with activity in ovarian cancer and other solid tumor types.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TRi-1

Cat. No.: HY-125006

TRi-1 is a potent, **specific** and irreversible inhibitor of **cytosolic thioredoxin reductase 1 (TXNRD1)**, with an IC_{50} of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Triapine

(3-AP; PAN-811; OCX191; NSC663249) Cat. No.: HY-10082

Triapine is a novel inhibitor of the M2 subunit of **ribonucleotide reductase** (**RR**), and is a potent radiosensitizer.



Purity: 98.32%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Trichlormethine hydrochloride

(Tris(2-chloroethyl)amine hydrochloride) Cat. No.: HY-B1249A

Trichlormethine hydrochloride is a cytostatic agent in the treatment of cancer and arthritis; shows carcinogenic effects to humans.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg

Trichostatin A

(TSA) Cat. No.: HY-15144

Trichostatin A (TSA) is a potent and specific inhibitor of **HDAC class I/II**, with an IC_{50} value of 1.8 nM for HDAC.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Triciribine

(API-2; NSC 154020; TCN) Cat. No.: HY-15457

Triciribine is a **DNA synthesis** inhibitor, also inhibits **Akt** and **HIV-1/2** with IC_{50} of 130 nM, and 0.02-0.46 μM, respectively.



Purity: 99.20%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Trifluridine

(Trifluorothymidine; 5-Trifluorothymidine; TFT) Cat. No.: HY-A0061

Trifluridine (Trifluorothymidine; 5-Trifluorothymidine; TFT) is an irreversible **thymidylate synthase** inhibitor, and thereby suppresses **DNA synthesis**. Trifluridine is an antiviral drug for **herpes simplex virus (HSV)** infection.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Trifluridine/tipiracil hydrochloride mixture

(TAS-102) Cat. No.: HY-16478

Trifluridine-tipiracil hydrochloride mixture (TAS-102) is a novel oral combination drug that consists of an antineoplastic thymidine-based nucleoside analog, trifluorothymidine, and a potent **thymidine phosphorylase** inhibitor, tipiracil, in a 1:0.5 molar ratio.



Purity: 99.72%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Trilaciclib

(G1T28) Cat. No.: HY-101467

Trilaciclib is a **CDK4/6** inhibitor with IC_{50}s of 1 nM and 4 nM for CDK4 and CDK6, respectively.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Trilaciclib hydrochloride

(G1T28 hydrochloride) Cat. No.: HY-101467A

Trilaciclib hydrochloride is a **CDK4/6** inhibitor with IC_{50}s of 1 nM and 4 nM for CDK4 and CDK6, respectively.



Purity: 99.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Triphala

Cat. No.: HY-114335

Triphala, an Ayurvedic polyherbal formulation comprising of equiproportional fruit parts of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica. Triphala inhibits **NF-κB** activation. Triphala exerts **antifungal** action.

Triphala

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Triptolide

(PG490) Cat. No.: HY-32735

Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory and antiproliferative effects. Triptolide is a **NF-κB** activation inhibitor.



Purity: 99.78%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 100 mg

Troglitazone

(CS-045) Cat. No.: HY-50935

Troglitazone is a **PPARγ** agonist, with EC_{50}s of 550 nM and 780 nM for human and murinePPARγ receptor, respectively.



Purity: 99.53%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Trolox

Cat. No.: HY-101445

Trolox is a vitamin E analogue and is a powerful antioxidant.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Troxacitabine

(BCH 4556; L-OddC; SPD 758) Cat. No.: HY-13770

Troxacitabine is nucleoside analog with potent anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Troxerutin

(Trihydroxyethylrutin) Cat. No.: HY-N0139

Troxerutin, also known as vitamin P4, is a tri-hydroxyethylated derivative of natural bioflavonoid rutins which can inhibit the production of **reactive oxygen species** (**ROS**) and depress ER stress-mediated **NOD** activation.



Purity: 98.05%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 5 g

TRPM8 antagonist WS-3

Cat. No.: HY-W014325

TRPM8 antagonist WS-3 is an agonist of **TRPM8** with an EC_{50} of 3.7 μM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 g

TTNPB

(Ro 13-7410; Arotinoid acid; AGN191183) Cat. No.: HY-15682

TTNPB is a highly potent **RAR** agonist. Competitive binding assays using human RARs yield IC_{50}s of α=5.1 nM, β= 4.5 nM, and γ=9.3 nM, respectively.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TTP 22

Cat. No.: HY-15479

TTP 22 is a potent **CK2** inhibitor, with an IC_{50} of 100 nM and a K_i of 40 nM.



Purity: 97.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TTT-28

Cat. No.: HY-101511

TTT-28 is a synthesized thiazole-valine peptidomimetic, which reverses the ATP-binding cassette sub-family B member 1 (**ABCB1**)-mediated Multidrug resistance (MDR) by selectively blocking the efflux function of ABCB1.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Tubacin

Cat. No.: HY-13428

Tubacin is a potent and selective inhibitor of **HDAC6**, with an IC_{50} value of 4 nM and approximately 350-fold selectivity over HDAC1.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Tubastatin A Hydrochloride

(Tubastatin A HCl; TSA HCl)

Cat. No.: HY-13271

Tubastatin A (Hydrochloride) is a potent and selective **HDAC6** inhibitor with IC_{50} of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tubastatin-A

Cat. No.: HY-13271A

Tubastatin-A is a potent and selective **HDAC6** inhibitor with IC_{50} of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Tubeimoside I

(Tubeimoside-1; Lobatoside-H)

Cat. No.: HY-N0890

Tubeimoside I(Lobatoside-H) is an extract from Chinese herbal medicine Bolbostemma paniculatum (MAXIM.) FRANQUET (Cucurbitaceae) has been shown as a potent anti-tumor agent for a variety of human cancers.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tubeimoside II

(Tubeimoside-B)

Cat. No.: HY-N0891

Tubeimoside II(Tubeimoside-B) is a natural analogue of oleanane type of triterpenoid saponin; show anti-inflammatory, antitumor, and antitumor-promoting effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tubulin inhibitor 1

Cat. No.: HY-112607

Tubulin inhibitor 1 is a **tubulin** inhibitor, occupying the colchicine binding site, inhibits tubulin polymerization. Tubulin inhibitor 1 shows potent anti-tumor activity, casues cellular mitotic arrest in the G2/M phase, and induces cellular apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tubulysin A

(TubA)

Cat. No.: HY-15995

Tubulysin A(TubA) is a myxobacterial product that can function as an antiangiogenic agent in many in vitro assays; anti-microtubule, anti-mitotic, an apoptosis inducer, anticancer, anti-angiogenic, and antiproliferative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Tucatinib

(Irbinitinib; ARRY-380; ONT-380)

Cat. No.: HY-16069

Tucatinib (Irbinitinib; ARRY-380; ONT-380) is a potent and selective **HER2** inhibitor with an IC_{50} of 8 nM.



Purity: 98.53%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tucidinostat

(Chidamide; HBI-8000; CS 055)

Cat. No.: HY-109015

Tucidinostat is a potent and orally bioavailable **HDAC** enzymes class I (**HDAC1/2/3**) and class IIb (**HDAC10**) inhibitor, with IC_{50}s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC_{50}s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Turbinaric acid

Cat. No.: HY-111604

Turbinaric acid is a cytotoxic secosqualene carboxylic acid from the brown alga Turbinaria ornata.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TVB-3664

Cat. No.: HY-120062

TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable **fatty acid synthase (FASN)** inhibitor, with IC_{50} values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TW-37

Cat. No.: HY-12020

TW-37 is a potent **Bcl-2** inhibitor with K_i values of 260, 290 and 1110 nM for **Mcl-1**, **Bcl-2** and **Bcl-xL**, respectively.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TX1-85-1

Cat. No.: HY-100848

TX1-85-1 is an irreversible **Her3 (ErbB3)** inhibitor with an IC_{50} of 23 nM and is also the first selective **Her3 ligand**, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Tyrosine kinase inhibitor

Cat. No.: HY-10421

A Tyrosine kinase inhibitor.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Tyrphostin 23

(Tyrphostin A23; RG-50810; AG 18)

Cat. No.: HY-15644

Tyrphostin 23 (Tyrphostin A23) is an **EGFR** inhibitor with an IC_{50} and $K_i$of 35 and 11 μM, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tyrphostin A9

(AG 17; Tyrphostin 9)

Cat. No.: HY-15511

Tyrphostin A9(AG 17), a tyrosine kinase inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin A9 emerged as the most potent and selective of 51 tyrosine kinase inhibitors tested against the TNF-induced respiratory burst.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Tyrphostin AG 528

(Tyrphostin B66; AG 528)

Cat. No.: HY-100499

Tyrphostin AG 528 is an inhibitor of **EGFR** and **ErbB2** with IC_{50}s of 4.9 and 2.1 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG 879

(AG 879)

Cat. No.: HY-20878

TyrphostinAG879 is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation, but not TrKB and TrKC. also a ErbB2 kinase inhibitor, has at least 500-fold higher selectivity to ErbB2 (IC50 = 1 μmol/L) than EGFR (IC50 >500 μmol/L). target: TrKA , ErbB2 . IC 50: ErbB2 1 μmol/L .



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

TZ9

Cat. No.: HY-18643

TZ9 is a novel inhibitor of Rad6 ubiquitin conjugating enzyme(E2 enzyme); inhibits MDA-MB-231 cell proliferation with IC50 of ~6 uM.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

U-104

(NSC-213841; MST-104)

Cat. No.: HY-13513

U-104 is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki of 45.1 nM and 4.5 nM; low inhibition for CA I and CA II.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UAA crosslinker 1

Cat. No.: HY-111434

UAA crosslinker 1 hydrochloride is an amber codon used for non-canonical amino acids (ncAAs) incorporation. The ncAAs can be incorporated into proteins in vivo by making use of the promiscuous activity of certain wildtype and engineered aminoacyl-tRNA synthetases.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

UAMC-3203

Cat. No.: HY-112909

UAMC-3203 is a potent and selective **Ferroptosis** inhibitor with an IC_{50} of 12 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

UAMC-3203 hydrochloride

Cat. No.: HY-112909A

UAMC-3203 hydrochloride is a potent and selective **Ferroptosis** inhibitor with an IC_{50} of 12 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UAMC00039 dihydrochloride

Cat. No.: HY-101769

UAMC00039 dihydrochloride is a potent, reversible and competitive **dipeptidyl peptidase II** inhibitor with an IC_{50} of 0.48 nM.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UBCS039

Cat. No.: HY-115453

UBCS039 is the first synthetic, specific **Sirtuin 6 (SIRT6)** activator, inducing autophagy in human tumor cells, with an EC_{50} of 38 μM.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ubiquitin Isopeptidase Inhibitor I, G5

(NSC144303)

Cat. No.: HY-100738

Ubiquitin Isopeptidase Inhibitor I, G5 (NSC 144303) is an apoptosome-independent **caspase** and **apoptosis** activator with IC_{50} values of 1.76 and 1.6 μM in E1A and E1A/C9DN cells, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UC-112

Cat. No.: HY-12842

UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor; potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM).



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

UCN-02

(7-epi-Hydroxystaurosporine)

Cat. No.: HY-108262

UCN-02 (7-epi-Hydroxystaurosporine) is a selective **protein kinase C (PKC)** inhibitor produced by Streptomyces strain N-12, with IC_{50}s of 62 nM and 250 nM for PKC and protein kinase A (PKA), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UF010

Cat. No.: HY-18976

UF010 is a potent and selective HDAC inhibitor with IC50 ~0.06 μM, 0.1 μM, 0.5 μM and 1.5 μM for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

UK-5099

(PF-1005023)

Cat. No.: HY-15475

UK-5099 (PF-1005023) is a potent inhibitor of the mitochondrial pyruvate carrier (**MPC**). UK-5099 (PF-1005023) inhibits pyruvate-dependent O_2 consumption with an **IC_{50}** of 50 nM.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ulixertinib

(BVD-523; VRT752271)

Cat. No.: HY-15816

Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of **ERK1/2** kinases, with an **IC_{50}** of <0.3 nM against ERK2.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ulixertinib hydrochloride

(BVD-523 (hydrochloride); VRT752271 (hydrochloride))

Cat. No.: HY-15816A

Ulixertinib hydrochloride is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of **ERK1/2** kinases, with an **IC_{50}** of <0.3 nM against ERK2.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ULK-101

Cat. No.: HY-114490

ULK-101 is a potent and selective **ULK1** inhibitor, with **IC_{50}** values of 1.6 nM and 30 nM for ULK1 and ULK2, respectively. ULK-101 suppresses autophagy and sensitizes cancer cells to nutrient stress.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

UM-164

(DAS-DFGO-II)

Cat. No.: HY-112182

UM-164 (DAS-DFGO-II) is a highly potent inhibitor of **c-Src** with a **K_d** of 2.7 nM. UM-164 also potently inhibits **p38α** and **p38β**.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Umbralisib

(TGR-1202; RP5264)

Cat. No.: HY-12279

Umbralisib (TGR-1202) is a novel **PI3Kδ** inhibitor, with **IC_{50}** and **EC_{50}** of 22.2 nM and 24.3 nM, respectively; Umbralisib (TGR-1202) is also active against **CK1ε**, with an **EC_{50}** value of 6.0 μM.



Purity: 98.55%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Umbralisib hydrochloride

(TGR-1202 hydrochloride; RP5264 hydrochloride)

Cat. No.: HY-12279C

Umbralisib hydrochloride (TGR-1202 hydrochloride) is a novel **PI3Kδ** inhibitor, with **IC_{50}** and **EC_{50}** of 22.2 nM and 24.3 nM, respectively; Umbralisib hydrochloride (TGR-1202 hydrochloride) is also active against **CK1ε**, with an **EC_{50}** value of 6.0 μM.



Purity: 99.63%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Umbralisib R-enantiomer

(TGR-1202 R-enantiomer; RP5264 R-enantiomer)

Cat. No.: HY-12279F

Umbralisib R-enantiomer (TGR-1202 R-enantiomer) is a **PI3Kδ** inhibitor, which is the less active enantiomer of TGR-1202.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

UMI-77

Cat. No.: HY-18628

UMI-77 is a selective **Mcl-1** inhibitor, which shows high binding affinity to **Mcl-1** (**IC_{50}**=0.31 μM). UMI-77 binds to the BH3 binding groove of **Mcl-1** with **K_i** of 490 nM, showing selectivity over other members of anti-apoptotic Bcl-2 members.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UNBS5162

Cat. No.: HY-16509

UNBS5162 is a pan-antagonist of **CXCL chemokine** expression, with anti-tumor activity.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

UNC 0631

Cat. No.: HY-13808

UNC 0631 is a potent G9a inhibitor with IC50 value of 4 nM. IC50 value: 4 nM Target: G9a UNC 0631, which had high in vitro potency versus G9a and improved lipophilicity, was highly potent (IC50 < 0.06 μM) in reducing H3K9me2 levels in MDA-MB-231 cells and had low cell toxicity.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

UNC 669

Cat. No.: HY-15839

UNC 669 is a potent antagonist of L3MBTL1(IC50=4.2 uM) and L3MBTL3(IC50=3.1 uM).



Purity: 98.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

UNC-926

Cat. No.: HY-16510

UNC-926 is a methyl-lysine (**Kme**) reader domain inhibitor; inhibits L3MBTL1 with an IC_{50} of 3.9 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC0224

Cat. No.: HY-10929

UNC0224 is a potent and selective G9a inhibitor with IC50 of 15 nM in in the G9a Thioglo assay.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UNC0321

Cat. No.: HY-10930

UNC0321 is a potent and selective G9a inhibitor with Ki of 63 pM, UNC0321 is the first G9a inhibitor with picomolar potency and the most potent G9a inhibitor to date.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UNC0379

Cat. No.: HY-12335

UNC0379 is a selective, substrate-competitive inhibitor of **lysine methyltransferase SETD8** (**KMT5A**) with an IC_{50} of 7.3 μM; selective over 15 other methyltransferases.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC0379 TFA

Cat. No.: HY-12335A

UNC0379 TFA is a selective, substrate-competitive inhibitor of **lysine methyltransferase SETD8** (**KMT5A**) with an IC_{50} of 7.3 μM; selective over 15 other methyltransferases.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC0638

Cat. No.: HY-15273

UNC0638 selectively inhibits **G9a** and **GLP histone methyltransferase** activity with IC_{50}s of less than 15 nM and 19 nM, respectively.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC0642

Cat. No.: HY-13980

UNC0642 is a potent and selective **G9a/GLP** inhibitor, with an IC_{50} of less than 2.5 nM.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC0646

Cat. No.: HY-13807

UNC0646 is a potent and selective G9a inhibitor with IC50 of 6 nM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UNC1079

Cat. No.: HY-18373

UNC1079 is the piperidine analog of UNC1021, as a structurally similar but significantly less potent inhibitor for use as a negative control in cellular studies.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

UNC1215

Cat. No.: HY-15649

UNC1215 is a potent and selective chemical probe for the methyllysine (Kme) reading function of L3MBTL3 with Kd value of 120 nM.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UNC1999

Cat. No.: HY-15646

UNC1999 is a SAM-competitive, potent and selective inhibitor of **EZH1/2** with **IC_{50}**s of 10 nM and 45 nM, repectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC2025

Cat. No.: HY-12344

UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC2025 hydrochloride

Cat. No.: HY-12344A

UNC2025 hydrochloride is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC2250

Cat. No.: HY-15797

UNC2250 is a potent and selective **Mer** inhibitor with an **IC_{50}** of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC3866

Cat. No.: HY-100832

UNC3866 is a potent antagonist of the **CBX7**-H3 interaction as determined by AlphaScreen (**IC_{50}**=66±1.2 nM) and is more than 100-fold selective for CBX7 over the other nine members of this methyl-lysine (Kme) reader panel.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Upamostat

(WX-671)

Cat. No.: HY-16511

Upamostat is a **serine protease** inhibitor. Upamostat is the orally available prodrug of the WX-UK1, which is a urokinase plasminogen activator (uPA) inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

UPF 1069

Cat. No.: HY-14478

UPF 1069 is a **PARP** inhibitor, with **IC_{50}**s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Uprosertib

(GSK2141795)

Cat. No.: HY-15965

Uprosertib (GSK2141795) is a potent and selective **pan-Akt** inhibitor with **IC_{50}** values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Uprosertib hydrochloride

(GSK2141795 (hydrochloride))

Cat. No.: HY-15965A

Uprosertib hydrochloride (GSK2141795 hydrochloride) is a potent and selective **pan-Akt** inhibitor with IC_{50} values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Uramustine

(Uracil mustard)

Cat. No.: HY-13544

Uramustine is an oral **alkylating** agent, effective in the treatment of lymphosarcoma, chronic lymphatic leukaemia, and thrombocythemia.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

URB602

Cat. No.: HY-100792

URB602 is a selective monoacylglycerol lipase (**MGL**) inhibitor, which inhibits rat brain MGL with IC_{50} of 28±4 μM through a noncompetitive mechanism.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Urethane (Carbamic acid ethyl ester; Ethyl carbamate; Ethylurethane)

Cat. No.: HY-B1207

Urethane has been used as an antineoplastic agent and for other medicinal purposes.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 g

Uridine triphosphate

(UTP; Uridine 5'-triphosphate)

Cat. No.: HY-107372

Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a pyrimidine nucleoside triphosphate that participates in glycogen metabolism and synthesis of RNA during transcription.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Urolithin A

Cat. No.: HY-100599

Urolithin A is an intestinal metabolite of ellagic acid with antioxidant and antiproliferative effects; inhibits T24 and Caco-2 cell growth with IC_{50} values of 43.9 and 49 μM, respectively.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ursolic acid

(Prunol; Urson; Malol)

Cat. No.: HY-N0140

Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.



Purity: 99.27%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

USL311

Cat. No.: HY-114244

USL311 is a selective **CXCR4** antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

USP7-IN-1

Cat. No.: HY-16709

USP7-IN-1 is a selective and reversible inhibitor of **ubiquitin-specific protease 7 (USP7)**, with an IC_{50} of 77 μM, and can be used for the research of cancer.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

USP7-IN-3

Cat. No.: HY-112128

USP7-IN-3 (Compound 5) is a potent and selective allosteric ubiquitin-specific protease 7 (**USP7**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

USP7/USP47 inhibitor

Cat. No.: HY-13487

USP7/USP47 inhibitor is a selective **ubiquitin-specific protease 7/47 (USP7/USP47)** inhibitor, with **EC_{50}**s of 0.42 μM and 1.0 μM, respectively.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UT-155

Cat. No.: HY-112895

UT-155 is a selective and potent androgen receptor **(AR)** antagonist, with a **K_i** of 267 nM for UT-155 binding to AR-LBD.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

V-9302

Cat. No.: HY-112683

V-9302, a competitive antagonist of transmembrane glutamine flux, that selectively and potently targets the amino acid transporter **ASCT2 (SLC1A5)**. V-9302 inhibits ASCT2-mediated glutamine uptake (**IC_{50}**=9.6 μM) in HEK-293 cells.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Vactosertib

(EW-7197; TEW-7197)

Cat. No.: HY-19928

Vactosertib (EW-7197) is an ATP-competitive inhibitor of **ALK5** with an **IC_{50}** of 12.9 nM. It also inhibits ALK2 and ALK4 at nanomolar concentrations.



Purity: 99.58%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vactosertib Hydrochloride

(EW-7197 (Hydrochloride); TEW-7197 (Hydrochloride))

Cat. No.: HY-19928A

Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a small-molecule ATP-competitive inhibitor of **TGFβRI** (**ALK5**) with an **IC_{50}** of 12.9 nM.



Purity: 98.57%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vadimezan

(ASA-404; DMXAA)

Cat. No.: HY-10964

Vadimezan (ASA-404; DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the **stimulator of interferon genes** (**STING**) and also a potent inducer of **type I IFNs** and other cytokines.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VAL-083

(Dianhydrodulcitol; Dianhydrogalactitol)

Cat. No.: HY-16513

VAL-083 is an **alkylating** agent that creates N7 methylation on DNA, with antitumor activity.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Val-Cit-PAB-MMAE

Cat. No.: HY-100374

Val-Cit-PAB-MMAE is a **drug-linker conjugate for ADC** by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide Val-Cit-PAB.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Val-cit-PAB-OH

Cat. No.: HY-12362

Val-cit-PAB-OH is a peptide prodrug linker.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

Valecobulin

(CKD-516)

Cat. No.: HY-13598

Valecobulin (CKD516), a valine prodrug of (S516) and a vascular disrupting agent (VDA), is a potent **beta-tubulin polymerization** inhibitor with marked antitumor activity against murine and human solid tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Valemetostat

(DS-3201)

Cat. No.: HY-109108

Valemetostat (DS-3201) is an antineoplastic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Valorphin

Cat. No.: HY-P1599

Valorphin is an endogenous hemoglobin β-chain (33-39) fragment with opioid analgesic activity, binds to rat **mu-opioid receptor**, with an IC_{50} of 14 nM; Valorphin also shows anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Valproic acid

(VPA; 2-Propylpentanoic Acid)

Cat. No.: HY-10585

Valproic acid is an **HDAC** inhibitor, with IC_{50} in the range of 0.5 and 2 mM, also inhibits **HDAC1** (IC_{50}, 400 μM), and induces proteasomal degradation of **HDAC2**; Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.



Purity: 98.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g, 25 g

Valproic acid sodium salt

(Sodium Valproate)

Cat. No.: HY-10585A

Valproic acid sodium salt is an anticonvulsants used to treat epilepsy, bipolar disorder and migraines. Valproic acid inhibits **histone deacetylase 1 (HDAC1)** with an IC_{50} of 0.4 mM.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 g, 5 g, 25 g

Valrubicin

(AD-32)

Cat. No.: HY-13772

Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced **PKC** activation with IC_{50}s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Valspodar

(PSC 833)

Cat. No.: HY-17384

Valspodar is a selective **P-glycoprotein** inhibitor that has been used as an experimental cancer treatment and chemosensitizer.



Purity: 99.27%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Vandetanib

(ZD6474)

Cat. No.: HY-10260

Vandetanib is a potent inhibitor of **VEGFR2** with an IC_{50} of 40 nM.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg, 500 mg

Vandetanib hydrochloride

(ZD6474 hydrochloride)

Cat. No.: HY-10260B

Vandetanib hydrochloride is a potent inhibitor of **VEGFR2** with IC_{50} of 40 nM.



Purity: >98%
Clinical Data: Launched
Size: 25 mg, 100 mg, 200 mg

Vandetanib trifluoroacetate

(ZD6474 trifluoroacetate)

Cat. No.: HY-10260A

Vandetanib trifluoroacetate is a potent inhibitor of **VEGFR2** with IC_{50} of 40 nM.



Purity: >98%
Clinical Data: Launched
Size: 25 mg, 100 mg, 200 mg

Vapreotide

(RC160; BMY 41606)

Cat. No.: HY-P0061

Vapreotide is a **NK1R** antagonist, with an IC_{50} of 330 nM.

Purity: >98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Vapreotide acetate

(RC-160 acetate; BMY-41606 acetate) Cat. No.: HY-P0061A

Vapreotide acetate is a synthetic analog of somatostatin for the treatment of variceal bleeding; also exhibits antitumor activity. Sequence: Phe-Cys-Tyr-Trp-Lys-Val-Cys-Trp-NH2(Disulfide bridge: Cys2-Cys7).



Purity: 99.61%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Varlitinib

(ARRY-334543; ASLAN001) Cat. No.: HY-10530

Varlitinib (ARRY-334543; ASLAN001) is a potent, reversible, small molecule pan-**EGFR** inhibitor with IC_{50}s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vatalanib dihydrochloride (PTK787 dihydrochloride; CGP-797870 dihydrochloride; ZK-222584 dihydrochloride)

Cat. No.: HY-12018

Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of **VEGFR2/KDR** with IC_{50} of 37 nM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Vatalanib free base (PTK787 free base; PTK/ZK free base; CGP-79787 free base; ZK-222584 free base)

Cat. No.: HY-10203

Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of **VEGFR2/KDR** with IC_{50} of 37 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

VBY-825

Cat. No.: HY-15958

VBY-825 is a novel, reversible cathepsin inhibitor with high potency against cathepsins B, L, S and V.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Vc-MMAD

Cat. No.: HY-15742

Vc-MMAD consists the ADCs linker(Val-Cit) and potent tubulin inhibitor (MMAD), Vc-MMAD is an antibody drug conjugate. IC50 Valu: N/A Target: tubulin; ADCs Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload and antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

VcMMAE

(mc-vc-PAB-MMAE) Cat. No.: HY-15575

VcMMAE is a **drug-linker conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

VDR agonist 1

Cat. No.: HY-114310

VDR agonist 1 (compound 28) is a nonsteroidal **Vitamin D receptor (VDR)** agonist, with an IC_{50} of 690 nM in MCF-7 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

VE-821

Cat. No.: HY-14731

VE-821 is a potent ATP-competitive inhibitor of **ATR** with K_i/IC_{50} of 13 nM/26 nM.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vecabrutinib

(SNS-062) Cat. No.: HY-109078

Vecabrutinib is a potent, noncovalent **BTK** and **ITK** inhibitor, with K_d of 0.3 nM and 2.2 nM, respectively; Vecabrutinib shows an IC_{50} of 24 nM for ITK.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Veledimex

(INXN-1001; RG-115932) Cat. No.: HY-16785

Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for **CYP3A4/5**.



Purity: 99.09%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Veledimex racemate

(RG-115932 racemate; INXN-1001 racemate) Cat. No.: HY-16785A

Veledimex racemate is the racemate of veledimex. Veledimex is an orally available, small-molecule activator ligand for the RheoSwitch Therapeutic System.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Veliparib

(ABT-888) Cat. No.: HY-10129

Veliparib is a potent **PARP** inhibitor, inhibiting **PARP1** and **PARP2** with K_is of 5.2 and 2.9 nM, respectively.



Purity: >98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Veliparib dihydrochloride

(ABT-888 dihydrochloride) Cat. No.: HY-10130

Veliparib (dihydrochloride) is a potent inhibitor of **PARP1** a nd **PARP2** with K_is of 5.2 nM and 2.9 nM in cell-free assays, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Velpatasvir

(GS-5816) Cat. No.: HY-12530

Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Vemurafenib

(PLX4032; RG7204; RO5185426) Cat. No.: HY-12057

Vemurafenib (PLX4032; RG7204) is a novel and potent inhibitor of **B-RAF** kinase, with IC_{50}s of 31 and 48 nM for RAF^{V600E} and c-RAF-1, respectively.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Venetoclax

(ABT-199; GDC-0199) Cat. No.: HY-15531

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable **Bcl-2** inhibitor with a K_i of less than 0.01 nM.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

VER-246608

Cat. No.: HY-12492

VER-246608 is a potent and ATP-competitive inhibitor of **pyruvate dehydrogenase kinase** (**PDK**) with IC_{50}s of 35 nM, 40 nM, 84 nM, and 91 nM for **PDK-1**, **PDK-3**, **PDK-2**, and **PDK-4**, respectively.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

VER-49009

(CCT 129397) Cat. No.: HY-15986

VER-49009 is a **Hsp90** inhibitor, with an IC_{50} of 25 nM and a K_d of 78 nM.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

VER-50589

Cat. No.: HY-15984

VER-50589 is a **Hsp90** inhibitor, with an IC_{50} of 21 nM and a K_d of 4.5 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

VER-82576

(NVP-BEP800) Cat. No.: HY-10942

VER-82576 (NVP-BEP800) is a potent, orally available and selective **Hsp90** inhibitor, with an IC_{50} of 58 nM for Hsp90β; VER-82576 also slightly blocks Grp94 and Trap-1, with IC_{50}s of 4.1 and 5.5 μM, respectively.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Veratramine

(NSC17821; NSC23880) Cat. No.: HY-N0837

Veratramine(NSC17821; NSC23880) is useful as a signal transduction inhibitor for treating tumors.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Verbascoside

(Acteoside; Kusaginin; TJC160) Cat. No.: HY-N0021

Verbascoside is isolated from Lantana camara, acts as an ATP-competitive inhibitor of **PKC**, with an IC_{50} of 25 μM, and has antitumor, anti-inflammatory and antineuropathic pain activity.



Purity: 95.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

VERU-111

(ABI-231) Cat. No.: HY-120599

VERU-111 (ABI-231) is a potent and orally bioavailable **α and β tubulin** inhibitor, which displays strong antiproliferative activity, with an average IC_{50} of 5.2 nM against panels of melanoma and prostate cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VI 16832

Cat. No.: HY-18623

VI 16832 is a broad spectrum **Type I kinase** inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Vinblastine sulfate

(Vincaleukoblastine sulfate salt) Cat. No.: HY-13780

Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC_{50} of 8.9 μM.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vincristine sulfate

(Leurocristine sulfate; 22-Oxovincaleukoblastine sulfate) Cat. No.: HY-N0488

Vincristine sulfate is an antitumor vinca alkaloid which inhibits **microtubule** formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to **microtubule** with a K_i of 85 nM.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg

Vinflunine

Cat. No.: HY-B0628

Vinflunine is a new vinca alkaloid uniquely fluorinated with the properties of mitotic-arresting and tubulin-interacting activity.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Vinflunine Tartrate

Cat. No.: HY-B0628A

Vinflunine Tartrat is a new vinca alkaloid uniquely fluorinated with the properties of mitotic-arresting and tubulin-interacting activity.



Purity: 99.14%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Vinorelbine

(KW-2307 base) Cat. No.: HY-12053

Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC_{50} of 1.25 nM.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg

Vinorelbine ditartrate

(KW-2307; Nor-5'-anhydrovinblastine ditartrate) Cat. No.: HY-12053A

Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC_{50} of 1.25 nM.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Vipivotide tetraxetan

(PSMA-617) Cat. No.: HY-117410

Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen **(PSMA)** inhibitor, with a K_i of 0.37 nM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Vismodegib

(GDC-0449) Cat. No.: HY-10440

Vismodegib (GDC-0449) is an orally active **hedgehog** pathway inhibitor with an IC_{50} of 3 nM. It also inhibits P-gp, ABCG2 with IC_{50} values of 3.0 μM and 1.4 μM, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Vistusertib

(AZD2014) Cat. No.: HY-15247

Vistusertib (AZD2014) is an ATP competitive **mTOR** inhibitor with an IC_{50} of 2.81 nM. AZD2014 inhibits both **mTORC1** and **mTORC2** complexes.



Purity: 98.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Vitamin CK3

Cat. No.: HY-16516

Vitamin CK3 is the combination of Vitamin C and vitamin K3 and has been shown to inhibit tumor growth and lung metastasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Vitamin K4

(acetomenaphthone) Cat. No.: HY-B1508

Vitamin K4 is a chemically synthesized Vitamin K which plays an important role in the normal blood coagulation system.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg, 1 g

VL285

Cat. No.: HY-111663

VL285 is a potent **VHL** ligand.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VLX1570

Cat. No.: HY-12471

VLX1570 is a competitive inhibitor of proteasome deubiquitinases (**DUBs**) with an IC_{50} of approximate 10 μM.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

VO-Ohpic trihydrate

(VO-Ohpic) Cat. No.: HY-13074

VO-Ohpic trihydrate is a highly potent inhibitor of **PTEN** with an IC_{50} of 46±10 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Vofopitant dihydrochloride

(GR 205171A) Cat. No.: HY-12143

Vofopitant dihydrochloride (GR 205171A) is a potent, selective and orally available tachykinin neurokinin 1(NK1) receptor antagonist, inhibits [^{3}H]SP binding to the NK1 receptor with **pK_i** values of 9.5 and 10.6 in rat and human membranes respectively, acts as a potential...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Volasertib

(BI 6727) Cat. No.: HY-12137

Volasertib is a highly potent **Polo-like kinase 1 (PLK1)** inhibitor with an IC_{50} of 0.87 nM, as well as the two closely related kinases **PLK2** and **PLK3** with IC_{50}s of 5 and 56 nM, respectively.



Purity: 99.55%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vorasidenib

(AG-881) Cat. No.: HY-104042

Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual **mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2)** inhibitor, which exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG) with IC_{50} ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G,...



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Voreloxin

(SNS-595; Vosaroxin; AG 7352) Cat. No.: HY-10534

Voreloxin is a first-in-class **topoisomerase II** inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg

Voreloxin Hydrochloride (SNS-595 Hydrochloride; Vosaroxin Hydrochloride; AG 7352 Hydrochloride)

Cat. No.: HY-16518

Voreloxin Hydrochloride is a first-in-class **topoisomerase II** inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.



Purity: 99.70%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg

Vorinostat

(SAHA) Cat. No.: HY-10221

Vorinostat is a potent and orally available inhibitor of **HDAC1**, **HDAC2** and **HDAC3 (Class I)**, **HDAC7 (Class II)** and **HDAC11 (Class IV)**, with ID_{50} values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg, 500 mg, 1 g, 5 g

Voruciclib hydrochloride

Cat. No.: HY-12422A

Voruciclib hydrochloride is a clinical stage oral **CDK9** inhibitor. Voruciclib hydrochloride represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Voxtalisib

(XL765; SAR245409) Cat. No.: HY-15900

Voxtalisib (XL-765) is a potent **PI3K** inhibitor, which has a similar activity toward class I PI3K (IC_{50}s=39, 113, 9 and 43nM for **p110α**, **p110β**, **p110γ** and **p110δ**, respectively), also inhibits DNA-PK (IC_{50}=150nM) and mTOR (IC_{50}=157nM).



Purity: 98.93%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vps34-IN-1

Cat. No.: HY-12795

Vps34-IN-1 is an inhibitor of **Vps34** extracted from patent WO2012085815A1, compound example 16a, with an IC_{50} of 4 nM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vps34-IN-2

Cat. No.: HY-12473

Vps34-IN-2 is a novel, potent and selective inhibitor of **Vps34** with IC_{50}s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

VS-5584

(SB2343) Cat. No.: HY-16585

VS-5584 is a **pan-PI3K/mTOR** kinase inhibitor with IC_{50}s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks **mTORC2** as well as **mTORC1**.



Purity: 98.01%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

VU0661013

Cat. No.: HY-112859

VU661013 is a potent and selective **MCL-1** inhibitor.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VX-11e

Cat. No.: HY-14178

VX-11e is a potent, selective, and orally bioavailable inhibitor of **ERK** with K_i < 2 nM.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VX-984

(M9831)

Cat. No.: HY-19939S

VX-984 is a potent **DNA-PK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

VZ185

Cat. No.: HY-114322

VZ185 is a potent, fast, and selective dual **BRD7/9 PROTAC** degrader with DC_{50}s of 4.5 and 1.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

W146

(W-146; W 146)

Cat. No.: HY-101395

W146 is a selective antagonist of sphingosine-1-phosphate receptor 1 (**S1PR1**) with an EC_{50} value of 398 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

WAY 163909

Cat. No.: HY-15401

WAY 163909 is a potent and selective **5-HT(2C) receptor** agonist with a K_i of 10.5±1.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

WAY 316606

Cat. No.: HY-10858

WAY 316606 is an inhibitor of the secreted protein **sFRP-1**, an endogenous antagonist of the secreted glycoprotein **Wnt**. The affinity of WAY-316606 for sFRP-1 is determined using the FP binding assay with IC_{50} of 0.5 μM.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WAY-262611

Cat. No.: HY-11035

WAY-262611 is a wingless **β-Catenin** agonist that increases bone formation rate with an EC_{50} of 0.63 μM in TCF-Luciferase assay.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

WAY-600

Cat. No.: HY-15272

WAY-600 is a potent, ATP-competitive, and selective **mTOR** inhibitor with an IC_{50} of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (**mTORC1/2**) assemble and activation.



Purity: 95.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

WD2000-012547

Cat. No.: HY-U00223

WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pK_i of 8.221.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

WDR5-0103

(WD-Repeat Protein 5-0103) Cat. No.: HY-19347

WDR5-0103 is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with Kd of 450 nM.



Purity: 97.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WEHI-345

Cat. No.: HY-18937

WEHI-345 is a potent and selective inhibitor of RIPK2, with IC50 of 0.13 μM. IC50 value: 0.13 μM Target: RIPK2 in vitro: WEHI-345 is a selective RIPK2 kinase inhibitor, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WEHI-345 analog

Cat. No.: HY-100112

WEHI-345 analog is a Src inhibitor, extracted from patent WO/2012003544A1, compound example 71. Target:Src WEHI-345 (analog) is a protein kinase inhibitor.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

WEHI-539

Cat. No.: HY-15607

WEHI-539 is a selective inhibitor of **Bcl-X$_L$** with **IC$_{50}$** of 1.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

WEHI-539 hydrochloride

Cat. No.: HY-15607A

WEHI-539 hydrochloride is a selective inhibitor of **Bcl-X$_L$** with an **IC$_{50}$** of 1.1 nM.



Purity: 97.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

WH-4-023

(Dual LCK/SRC inhibitor) Cat. No.: HY-12299

WH-4-023 is a potent and selective dual **Lck/Src** inhibitor with **IC$_{50}$** of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WHI-P154

Cat. No.: HY-13895

WHI-P154 is a potent **EGFR** inhibitor, and also modestly blocks **JAK3**, with **IC$_{50}$**s of 4 nM and 1.8 μM, respectively.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

WHI-P180

(Janex 3) Cat. No.: HY-15769

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with **IC$_{50}$**s of 5 nM, 66 nM and 4 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

WHI-P180 hydrochloride

(Janex 3 hydrochloride;) Cat. No.: HY-15769A

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with **IC$_{50}$**s of 5 nM, 66 nM and 4 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 50 mg

WIKI4

Cat. No.: HY-16910

WIKI4 is a potent inhibitor of Wnt/β-catenin signaling (EC50 ~ 75 nM); inhibits auto-ADP-ribosylation of tankyrase 2 (TNKS2) (IC50 ~15 nM).



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

WIN site inhibitor 1

Cat. No.: HY-111753

WIN site inhibitor 1 is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (**WDR5**), with a K_d of 0.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Withaferin A

Cat. No.: HY-N2065

Withaferin A is a steroidal lactone isolated from Withania somnifera, inhibits **NF-kB** activation and targets **vimentin**, with potent antiinflammatory and anticancer activities.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

WM-1119

Cat. No.: HY-102058

WM-1119 is a highly potent and selective **KAT6A** inhibitor, with an IC_{50} of 0.25 μM for KAT6A in lymphoma cells, the binding K_D values of WM-1119 with KAT6A, KAT5 and KAT7 are 2 nM, 2.2 μM, 0.5 μM , respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WM-8014

Cat. No.: HY-102060

WM-8014 is an inhibitor of **MOZ**, a member of **histone acetyltransferases**, with an IC_{50} of 55 nM.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WNK463

Cat. No.: HY-100626

WNK463 is an orally bioavailable pan-**WNK**-kinase inhibitor with IC_{50}s of 5, 1, 6, and 9 nM for WNK1, WNK 2, WNK 3, and WNK 4, respectively.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Wnt-C59

(C59)

Cat. No.: HY-15659

Wnt-C59 (C59) is a highly potent and oral **porcupine (PORCN)** inhibitor with an IC_{50} of 74 pM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Wogonin

Cat. No.: HY-N0400

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of **CDK8** and **Wnt**, and exhibits anti-inflammatory and anti-tumor effects.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Wortmannin

(SL-2052; KY-12420)

Cat. No.: HY-10197

Wortmannin is a multi-target inhibitor. Wortmannin inhibits **PI3K**, **MLCK**, **DNA-PK**, **ATM**, **ATR**, and **Polo-like kinase 3** (**Plk3**) with IC_{50}s of 3 nM, 200 nM, 16 nM, 150 nM, 1.8 μM and 48 nM, respectively.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

WP1066

Cat. No.: HY-15312

WP1066 is an inhibitor of **JAK2** and **STAT3**, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.



Purity: 99.67%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

WR-1065 dihydrochloride

Cat. No.: HY-103640

WR-1065 dihydrochloride can protect normal tissues from the toxic effects of certain cancer drugs and activate **p53** through a JNK-dependent signaling pathway.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

WS-12

Cat. No.: HY-108449

WS-12 is an agonist of **TRPM8** with an EC_{50} of 39 nM.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

WS-383

Cat. No.: HY-126075A

WS-383 is a potent, selective and reversible inhibitor of **DCN1-UBC12** interaction, with an IC_{50} of 11 nM. WS-383 inhibits Cul3/1 neddylation, induces accumulation of p21, p27 and NRF2.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

WT-161

Cat. No.: HY-100871

WT-161 is a potent and selective **HDAC6** inhibitor with an IC_{50} of 0.40 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WY-135

Cat. No.: HY-111416

WY-135 is a **ALK** (IC_{50}=1.4 nM) and **ROS1** (IC_{50}=1.1 nM) dual inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

WYC-209

Cat. No.: HY-124136

WYC-209, a synthetic retinoid, is a **retinoic acid receptor (RAR)** agonist. WYC-209 induces apoptosis primarily via the **caspase 3** pathway (IC_{50} = 0.19μM for inmalignant murine melanoma TRCs), and has long-term effects with little toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WYE-132

(WYE-125132)

Cat. No.: HY-10044

WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific **mTOR** kinase inhibitor (IC_{50}: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits **mTORC1** and **mTORC2**.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

WYE-354

Cat. No.: HY-12034

WYE-354 is an ATP-competitive **mTOR** inhibitor with an IC_{50} of 5 nM. WYE-354 also inhibits **PI3Kα** and **PI3Kγ** with IC_{50}s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both **mTORC1** and **mTORC2**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

WYE-687

Cat. No.: HY-15271

WYE-687 is an ATP-competitive **mTOR** inhibitor with an IC_{50} of 7 nM. WYE-687 concurrently inhibits activation of **mTORC1** and **mTORC2**. WYE-687 also inhibits **PI3Kα** and **PI3Kγ** with IC_{50}s of 81 nM and 3.11 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

WZ-3146

Cat. No.: HY-12001

WZ3146 is a mutant selective **EGFR** inhibitor with IC_{50}s of 2, 2, 5, 14 and 66 nM for $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{E746\_A750}$, $EGFR^{E746\_A750/T790M}$ and EGFR, respectively.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

WZ4002

Cat. No.: HY-12026

WZ4002 is a mutant selective **EGFR** inhibitor with IC_{50}s of 2, 8, 3 and 2 nM for $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{E746\_A750}$ and $EGFR^{E746\_A750/T790M}$, respectively.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

WZ4003

Cat. No.: HY-15802

WZ4003 is the first potent and highly specific **NUAK kinase** inhibitor with IC_{50} of 20 nM/100 nM for NUAK1 (ARK5)/NUAK2, without significant inhibition on other 139 kinases.



Purity: 97.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 50 mg

WZ8040

Cat. No.: HY-12029

WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

WZ811

Cat. No.: HY-15478

WZ811 is a potent **CXCR4** antagonist, effectively inhibits TN14003 binding to **CXCR4**, with an EC_{50} of 0.3 nM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WZB117

Cat. No.: HY-19331

WZB117 is a **glucose transporter 1** (**Glut1**) inhibitor, which downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

X-376

Cat. No.: HY-16590

X-376 is a potent and dual **ALK**/**MET** inhibitor with IC_{50}s of 0.61 nM and 0.69 nM, respectively.



Purity: 98.36%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Xanthohumol

Cat. No.: HY-N1067

Xanthohumol is one of the principal flavonoids isolated from hops, the inhibitor of diacylglycerol acetyltransferase (**DGAT**), **COX-1** and COX-2, and shows anti-cancer and anti-angiogenic activities.



Purity: 99.68%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Xanthyletin

Cat. No.: HY-N4116

Xanthyletin is a coumarin isolated from Citrus, with anti-tumor and anti-bacterial activities. Xanthyletin also inhibits symbiotic fungus cultivated by leaf-cutting ants.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Xantocillin

Cat. No.: HY-122404

Xanthocillin is a marine agent extracted from Penicillium commune, induces **autophagy** through inhibition of the **MEK/ERK** pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

XAV-939

Cat. No.: HY-15147

XAV-939 is a **tankyrase** (**TNKS**) inhibitor and an indirect inhibitor of **Wnt/β-catenin signaling**, with IC_{50}s of 5 and 2 nM for TNKS1 and TNKS2, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

XCT790

Cat. No.: HY-10426

XCT-790 is a potent, selective and inverse agonist of estrogen-related receptor alpha(ERRα); induces cell death in chemotherapeutic resistant cancer cells.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

XL019

Cat. No.: HY-13775

XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1; shows good biochemical and cellular potency against JAK2 with good selectivity against the Janus Kinase family as well as a broad kinase panel.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL228

Cat. No.: HY-15749

XL228 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL388

Cat. No.: HY-13806

XL388 is a highly potent and ATP-competitive **mTOR** inhibitor with an IC_{50} of 9.9 nM. XL388 simultaneously inhibits both **mTORC1** and **mTORC2**.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL413

Cat. No.: HY-15260

XL413 is a potent, selective and ATP competitive inhibitor of **Cdc7**, with an IC_{50} of 3.4 nM, and also shows potent effect with IC_{50}s of 215, 42 nM on CK2, PIM1, respectively, and an EC_{50} of 118 nM on pMCM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

XL413 hydrochloride

Cat. No.: HY-15260A

XL413 hydrochloride is a potent, selective and ATP competitive inhibitor of **Cdc7**, with an IC_{50} of 3.4 nM, and also shows potent effect with IC_{50}s of 215, 42 nM on CK2, PIM1, respectively, and an EC_{50} of 118 nM on pMCM.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL888

Cat. No.: HY-13313

XL888 is a heat shock protein-90 (**HSP90**) inhibitor, with an IC_{50} of 24 nM.



Purity: 99.24%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

XMD16-5

Cat. No.: HY-101243

XMD16-5 is a potent **TNK2** inhibitor with IC_{50} values of 16 and 77 nM for the D163E and R806Q mutations, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XMD17-109

Cat. No.: HY-15665

XMD17-109 is a novel, specific **ERK-5** inhibitor, with an IC_{50} of 162 nM.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

XMD8-87

(ACK1-B19)

Cat. No.: HY-15811

XMD8-87 is a potent **TNK2** inhibitor with IC_{50} values of 38 and 113 nM for the D163E and R806Q mutations, respectively.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XMD8-92

Cat. No.: HY-14443

XMD8-92 is a highly selective **ERK5/BMK1** inhibitor with dissociation constant (K_d) value of 80 nM.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

XMU-MP-1

Cat. No.: HY-100526

XMU-MP-1 is a reversible and selective **MST1/2** inhibitor with **IC_{50}**s of 71.1 and 38.1 nM, respectively.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XY1

Cat. No.: HY-19714

XY1 is a very close analogue of SGC707 (a potent, selective, and non-competitive inhibitor of PRMT3 with IC50 of 31 nM), but XY1 is completely inactive.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

XY101

Cat. No.: HY-128604

XY101 is a potent, selective, metabolically stable and orally available **RORγ** inverse agonist with an **IC_{50}** of 30 nM and a **K_d** of 380 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Y-27632

Cat. No.: HY-10071

Y-27632 is an ATP-competitive inhibitor of **ROCK-I** and **ROCK-II**, with **K_i** of 220 nM and 300 nM for **ROCK-I** and **ROCK-II**, respectively, which primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal...



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Y-27632 dihydrochloride

Cat. No.: HY-10583

Y-27632 dihydrochloride is a cell-permeable, ATP-competitive inhibitor of **ROCK-I** and **ROCK-II**, with **K_i**s of 220 and 300 nM, respectively, which primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via...



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Y-33075

(Y 39983)

Cat. No.: HY-10067

Y-33075 is a selective **ROCK** inhibitor derived from Y-27632, and is more potent than Y-27632, with an **IC_{50}** of 3.6 nM.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Y-33075 dihydrochloride

Cat. No.: HY-10069

Y-33075 dihydrochloride is a selective **ROCK** inhibitor with an **IC_{50}** of 3.6 nM.



Purity: 97.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Y06036

Cat. No.: HY-111502

Y06036 is a potent and selective **BET** inhibitor, which binds to the **BRD4(1)** bromodomain with **K_d** value of 82 nM. Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Y06137

Cat. No.: HY-111503

Y06137 is a potent and selective **BET** inhibitor for treatment of castration-resistant prostate cancer (CRPC). Y06137 binds to the **BRD4(1)** bromodomain with a **K_d** of 81 nM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Y15

(FAK inhibitor Y15; FAK Inhibitor 14)

Cat. No.: HY-12444

Y15 is a potent and specific inhibitor of focal adhesion kinase (**FAK**) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth. .



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Y16

Cat. No.: HY-12649

Y16 is an inhibitor of G-protein–coupled Rho GEFs; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.



Purity: 97.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Yadanziolide A

Cat. No.: HY-N4210

Yadanziolide A, isolated from the cultivated dry seeds of Brucea javanica, has strong antiviral activities with IC_{50} of 5.5 μM against tobacco mosaic virus. Yadanziolide A shows significant antitumor effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Yadanzioside A

Cat. No.: HY-N4257

Yadanziolide A, a quassinoid glycoside from Brucea javanica, has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YAP/TAZ inhibitor-1

Cat. No.: HY-111429

YAP/TAZ inhibitor-1 is a **YAP**/**TAZ** inhibitor extracted from patent WO2017058716A1, Compound 1, has an IC_{50} of <0.100 μM in firefly luciferase assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

YF-2

Cat. No.: HY-16531

YF-2 is a highly selective, blood-brain-barrier permeable **histone acetyltransferase** activator, acetylates H3 in the hippocampus, with EC_{50}s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

YF-2 hydrochloride

Cat. No.: HY-16531A

YF-2 hydrochloride is a highly selective, blood-brain-barrier permeable **histone acetyltransferase** activator, acetylates H3 in the hippocampus, with EC_{50}s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

YH239-EE

Cat. No.: HY-12287

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

YHO-13177

Cat. No.: HY-12757

YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

YHO-13351

Cat. No.: HY-12758

YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

YHO-13351 free base

Cat. No.: HY-12758A

YHO-13351 (free base) is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

YK-4-279

Cat. No.: HY-14507

YK 4-279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. YK-4-279 inhibits Ewing's sarcoma family tumor (ESFT) cell growth; YK-4-279 induces apoptosis.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

YL-109

Cat. No.: HY-18619

YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

YLF-466D

(C24)

Cat. No.: HY-15840

YLF-466D is a newly developed **AMPK** activator, which inhibits platelet aggregation.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

YM-155

(Sepantronium bromide)

Cat. No.: HY-10194

YM-155 is a **survivin** inhibitor with an IC_{50} of 0.54 nM.



Purity: 98.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

YM-155 hydrochloride

Cat. No.: HY-10194A

YM-155 hydrochloride is a novel **survivin** suppressant with an IC_{50} of 0.54 nM for the inhibition of survivin promoter activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

YM-201636

Cat. No.: HY-13228

YM-201636 is a potent and selective **PIKfyve** inhibitor with an IC_{50} of 33 nM. YM-201636 also inhibits p110α with IC_{50} of 3.3 μM.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

YO-01027

(Dibenzazepine; DBZ)

Cat. No.: HY-13526

YO-01027 (Dibenzazepine;DBZ) is a potent **γ-secretase** inhibitor with IC_{50} values of 2.92±0.22 and 2.64±0.30 nM for **Notch** and **APPL** cleavage, respectively.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

YU238259

Cat. No.: HY-19977

YU238259 is an inhibitor of homology-dependent DNA repair (**HDR**), used for cancer research.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YW3-56

Cat. No.: HY-112903

YW3-56 is a potent peptidylarginine deiminase **(PAD)** inhibitor, with an IC_{50} of 1-5 μM for PAD4.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

YZ129

Cat. No.: HY-114413

YZ129 is an inhibitor of the HSP90-calcineurin-NFAT pathway against glioblastoma, directly binding to **heat shock protein 90 (HSP90)** with an IC_{50} of 820 nM on NFAT nuclear translocation.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Z-DEVD-FMK

Cat. No.: HY-12466

Z-DEVD-FMK is a specific and irreversible **caspase-3** inhibitor with IC_{50} of 18 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Z-IETD-FMK

(Z-IE(OMe)TD(OMe)-FMK)

Cat. No.: HY-101297

Z-IETD-FMK is a selective and cell permeable **caspase 8** inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Z-Ile-Leu-aldehyde

(Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII)

Cat. No.: HY-12465

Z-Ile-Leu-aldehyde(Z-IL-CHO; GSI-XII) is a potent gamma-Secretase inhibitor; Notch signaling inhibitor.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Z-VAD(OMe)-FMK

(Z-Val-Ala-Asp(OMe)-FMK)

Cat. No.: HY-16658

Z-VAD(OMe)-FMK is a cell-permeable and irreversible **pan-caspase** inhibitor.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Zamicastat

(BIA 5-1058)

Cat. No.: HY-106004

Zamicastat (BIA 5-1058) is a **dopamine β-hydroxylase (DBH)** inhibitor that could cross the blood-brain barrier (BBB) and cause central as well as peripheral effects.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Zanubrutinib

(BGB-3111)

Cat. No.: HY-101474A

Zanubrutinib is a selective **Bruton tyrosine kinase (BTK)** inhibitor.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

ZCL278

Cat. No.: HY-13963

ZCL278 is a selective **Cdc42** modulator that directly binds to Cdc42 and inhibits its functions with K_d of 11.4 μM for Cdc42-ZCL278 affinity in surface plasmon resonance (SPR) experiment.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ZD-4190

Cat. No.: HY-U00002

ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (**VEGFR2**) and of epidermal growth factor receptor (**EGFR**) signalling, used for the treatment of cancer.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ZD8321

Cat. No.: HY-U00256

ZD8321 is a potent inhibitor of human **Neutrophil elastase (NE)** with a K_i of 13±1.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Zebularine

(NSC309132; 4-Deoxyuridine)

Cat. No.: HY-13420

Zebularine (NSC309132; 4-Deoxyuridine) is a **DNA methyltransferase** inhibitor. Zebularine also inhibits **cytidine deaminase** with a K_i of 0.95 μM.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ZEN-3219

Cat. No.: HY-111977

ZEN-3219 is a **BET** inhibitor with IC_{50}s of 0.48, 0.16 and 0.47 μM for **BRD4(BD1)**, **BRD4(BD2)** and **BRD4(BD1BD2)**, respectively. ZEN-3219 can be used to form **PROTAC**s to induce degradation of BRD4.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

ZEN-3411

Cat. No.: HY-111979

ZEN-3411 is a **BET** inhibitor with IC_{50}s of 0.05, 0.05 and 0.06 μM for **BRD4(BD1)**, **BRD4(BD2)** and **BRD4(BD1BD2)**, respectively. ZEN-3411 can be used to form **PROTAC**s to induce degradation of BRD4.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

ZEN-3862

Cat. No.: HY-111978

ZEN-3862 is a **BET** inhibitor with IC_{50}s of 0.16 and 0.13 μM for **BRD4(BD1)** and **BRD4(BD2)** , respectively. ZEN-3862 can be used to form **PROTAC**s to induce degradation of BRD4.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Zibotentan

(ZD4054)

Cat. No.: HY-10088

Zibotentan (ZD4054) is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).



Purity: 98.13%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ZINC00881524

Cat. No.: HY-101244

ZINC00881524 is a **ROCK** inhibitor.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zingerone

(Vanillylacetone; Gingerone)

Cat. No.: HY-14621

Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor properties.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Ziyuglycoside II

Cat. No.: HY-N0332

Ziyuglycoside II is a triterpenoid saponin compound extracted from Sanguisorba officinalis L.. Ziyuglycoside II induces reactive oxygen species (**ROS**) production and **apoptosis**. Anti-inflammation and anti-cancer effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK756326 dihydrochloride

Cat. No.: HY-101038A

ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor **CCR8**.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZM 306416

(CB 676475)

Cat. No.: HY-13785

ZM-306416 (CB 676475) is a potent inhibitor of **VEGFR** with IC_{50}s of 0.1 and 2 μM for KDR and Flt, respectively. ZM-306416 is also a **EGFR** inhibitor with an IC_{50} of <10 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ZM 336372

Cat. No.: HY-13343

ZM 336372 is a potent inhibitor of the protein kinase **c-Raf**. The IC_{50} value is 0.07 μM in the standard assay, which contains 0.1 mM ATP.



Purity: 96.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ZM-447439

Cat. No.: HY-10128

ZM-447439 is an **aurora** kinase inhibitor with **IC_{50}**s of 110 and 130 nM for aurora A and B, respectively.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ZM223

Cat. No.: HY-101790

ZM223 is a non-sulfamide **NEDD8 activating enzyme** (**NAE**) inhibitor that inhibits HCT116 colon cancer cells with an **IC_{50}** value of 100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ZM323881

Cat. No.: HY-15467

ZM323881 is a potent and selective **VEGFR2** inhibitor with an **IC_{50}** of less than 2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

ZM323881 hydrochloride

Cat. No.: HY-15467A

ZM323881 hydrochloride is a potent and selective **VEGFR2** inhibitor with an **IC_{50}** of less than 2 nM.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ZM39923

Cat. No.: HY-12589A

ZM39923 is a **JAK3** inhibitor, with a **pIC_{50}** of 7.1; ZM39923 also potently inhibits tissue transglutaminase (**TGM2**) with an **IC_{50}** of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

ZM39923 hydrochloride

Cat. No.: HY-12589

ZM39923 hydrochloride is a **JAK3** inhibitor, with a **pIC_{50}** of 7.1; ZM39923 hydrochloride also potently inhibits tissue transglutaminase (**TGM2**) with an **IC_{50}** of 10 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Zoledronic Acid

(Zoledronate; CGP 42446; CGP42446A; ZOL 446)

Cat. No.: HY-13777

Zoledronic Acid is a third-generation, nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption, and also has antitumor activity.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Zoledronic acid monohydrate (Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ...)

Cat. No.: HY-13777A

Zoledronic acid monohydrate is a third-generation, nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption, and also has antitumor activity.



Purity: >99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Zosuquidar

(LY335979)

Cat. No.: HY-15255

Zosuquidar (LY335979) is a potent negative modulator of P-glycoprotein-mediated multi-drug resistance with Ki of 60 nM. IC50 value: 60 nM (Ki) Target: P-glycoprotein Zosuquidar (LY335979) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM.



Purity: 98.33%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Zosuquidar trihydrochloride (RS 33295-198 trihydrochloride; LY-335979 trihydrochloride)

Cat. No.: HY-50671

Zosuquidar trihydrochloride is an inhibitor of **P-glycoprotein** with a **K_i** value of 59 nM.



Purity: 98.75%
Clinical Data: Phase 3
Size: 10 mg, 50 mg, 100 mg

Zotarolimus

(ABT-578; A 179578) Cat. No.: HY-12424

Zotarolimus is a tetrazole-containing Rapamycin analog which is used as animmunomodulator, and is useful in the treatment of restenosis, immune, and autoimmune diseases.



Purity: 98.80%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 1 mg, 2 mg, 5 mg, 10 mg, 25 mg

ZSTK474

Cat. No.: HY-50847

ZSTK474 is an ATP-competitive pan-class I **PI3K** inhibitor with **IC_{50}**s of16 nM, 44 nM, 4.6 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.



Purity: 99.71%
Clinical Data: Phase 1
Size: 10 mg, 50 mg, 100 mg, 200 mg

ZXH-3-26

Cat. No.: HY-122826

ZXH-3-26 is a selective **BRD4** degrader with a **$DC_{50/5h}$** ($DC_{50/5h}$ referring to half-maximal degradation after 5 hours of treatment) of ~ 5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

[6]-Gingerol

((S)-(+)-[6]Gingerol; 6-Gingerol) Cat. No.: HY-14615

-Gingerol is an active compound isolated from Ginger (Zingiber officinale Rosc), exhibits a variety of biological activities including anticancer, anti-inflammation, and anti-oxidation.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

[Asp371]-Tyrosinase (369-377), human

Cat. No.: HY-P1919

Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy.

YMDGTMSQV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[D-Ala2]leucine-enkephalin

Cat. No.: HY-P0098

[D-Ala2]leucine-enkephalin, a **delta opioid** agonist, is a degradation resistant long-acting Leu-enkephalin.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

α-2,3-sialyltransferase-IN-1

Cat. No.: HY-112535

α-2,3-sialyltransferase-IN-1 is a noncompetitive **α-2,3-sialyltransferase** inhibitor with an **IC_{50}** of 6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

α-Hydroxytamoxifen

((E)-α-Hydroxy tamoxifen; α-OHTAM) Cat. No.: HY-118517

α-Hydroxytamoxifen is a metabolite of tamoxifen, reacts with DNA in the absence of metabolizing enzymes, and causes formation of DNA adducts.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

α-Lipoic Acid

((±)-α-Lipoic acid; DL-α-Lipoic acid; Thioctic acid) Cat. No.: HY-N0492

α-Lipoic Acid is an antioxidant, which is an essential cofactor of **mitochondrial** enzyme complexes. α-Lipoic Acid inhibits **NF-κB**-dependent **HIV-1** LTR activation.



Purity: 98.03%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

β-Caryophyllene ((−)-trans-Caryophyllene; (−)-β-caryophyllene; (-)-(E)-Caryophyllene)

Cat. No.: HY-N1415

β-Caryophyllene is a **CB2 receptor** agonist.



Purity: 94.40%
Clinical Data: No Development Reported
Size: 500 mg

β-Glycerol phosphate disodium salt pentahydrate

(β-Glycerophosphate disodium salt pentahydrate) **Cat. No.:** HY-D0886

β-Glycerol phosphate disodium salt pentahydrate (β-Glycerophosphate disodium salt pentahydrate) is a **phosphatase** inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 g, 5 g

β-Hydroxyisovalerylshikonin

Cat. No.: HY-N4201

Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of **protein tyrosine kinases (PTK)**, with IC_{50}s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Lapachone

(ARQ-501; NSC-26326) **Cat. No.:** HY-13555

β-Lapachone is a naturally occurring O-naphthoquinone, acts as a **topoisomerase I** inhibitor, and induces apoptosis by inhibiting cell cycle progression.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg